0000885725-20-000012.txt : 20200225 0000885725-20-000012.hdr.sgml : 20200225 20200225165801 ACCESSION NUMBER: 0000885725-20-000012 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 86 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200225 DATE AS OF CHANGE: 20200225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 20651744 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 10-K 1 a2019form10-k.htm 10-K Document
false--12-31FY201900008857250.01200000000016321480301642488911138458176013949226410000.010.01500000000000248000000247566270247566270 0000885725 2019-01-01 2019-12-31 0000885725 bsx:A2019AcquisitionsMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember 2019-01-01 2019-12-31 0000885725 bsx:A2017AcquisitionsMember 2019-01-01 2019-12-31 0000885725 bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 2019-06-28 0000885725 2020-01-31 0000885725 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000885725 bsx:SeniorNotedue2027Member 2019-01-01 2019-12-31 0000885725 2018-01-01 2018-12-31 0000885725 2017-01-01 2017-12-31 0000885725 2018-12-31 0000885725 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000885725 us-gaap:CommonStockMember 2018-12-31 0000885725 us-gaap:CommonStockMember 2017-12-31 0000885725 us-gaap:TreasuryStockMember 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000885725 us-gaap:RetainedEarningsMember 2017-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000885725 us-gaap:TreasuryStockMember 2017-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000885725 us-gaap:CommonStockMember 2016-12-31 0000885725 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2018-12-31 0000885725 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000885725 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000885725 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2018-12-31 0000885725 us-gaap:TreasuryStockMember 2019-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000885725 us-gaap:CommonStockMember 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2019-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000885725 us-gaap:NewAccountingPronouncementMember us-gaap:RetainedEarningsMember 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000885725 us-gaap:RetainedEarningsMember 2016-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000885725 us-gaap:TreasuryStockMember 2016-12-31 0000885725 2017-12-31 0000885725 2016-12-31 0000885725 bsx:OperatingleaserightofuseassetsotherlongtermassetsMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0000885725 us-gaap:ShippingAndHandlingMember 2019-01-01 2019-12-31 0000885725 us-gaap:ShippingAndHandlingMember 2017-01-01 2017-12-31 0000885725 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0000885725 us-gaap:AccountingStandardsUpdate201616Member 2018-03-31 0000885725 bsx:OperatingleaseliabilityotherlongtermliabilitiesMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0000885725 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-12-31 0000885725 us-gaap:NewAccountingPronouncementMember 2018-01-01 0000885725 bsx:BTGAcquisitionMember 2019-12-31 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000885725 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 us-gaap:FiniteLivedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2017AcquisitionsMember 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember 2019-12-31 0000885725 bsx:A2019AcquisitionsMember 2019-12-31 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 bsx:CryterionMember 2018-07-05 2018-07-05 0000885725 bsx:ProposedBTGAcquisitionMember 2019-08-19 2019-08-19 0000885725 bsx:NVisionMember 2018-04-16 0000885725 bsx:Other2018AcquisitionsMember 2018-01-01 2018-12-31 0000885725 bsx:ApamaMember 2017-10-10 2017-10-10 0000885725 bsx:MillipedeMember 2019-01-29 0000885725 bsx:NVisionMember 2018-04-16 2018-04-16 0000885725 bsx:DivestedbusinessduetoBTGacquisitionMember 2019-08-21 0000885725 bsx:VertiflexInc.Member 2019-06-11 0000885725 bsx:ClaretMember 2018-08-02 0000885725 bsx:Other2018AcquisitionsMember 2018-12-31 0000885725 bsx:BTGAcquisitionMember 2019-08-19 2019-08-19 0000885725 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-12-31 0000885725 bsx:CryterionMember 2018-07-05 0000885725 bsx:NxTheraMember 2018-04-30 2018-04-30 0000885725 bsx:ClaretMember 2018-08-02 2018-08-02 0000885725 bsx:ProposedBTGAcquisitionMember 2019-08-19 0000885725 bsx:ApamaMember 2017-10-10 0000885725 bsx:BTGAcquisitionMember bsx:CardiovascularMember 2019-01-01 2019-12-31 0000885725 bsx:VertiflexInc.Member 2019-06-11 2019-06-11 0000885725 bsx:AugmenixInc.Member 2018-10-16 0000885725 bsx:AugmenixInc.Member 2018-10-16 2018-10-16 0000885725 bsx:SymetisMember 2017-05-16 2017-05-16 0000885725 2019-08-21 2019-08-21 0000885725 bsx:NxTheraMember 2018-04-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 bsx:RevenuebasedpaymentsbyvaluationtechniqueMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 us-gaap:PatentsMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:PatentsMember 2019-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2018-12-31 0000885725 bsx:CardiovascularMember 2019-01-01 2019-12-31 0000885725 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-12-31 0000885725 bsx:RhythmandNeuroMember 2019-12-31 0000885725 us-gaap:AllOtherSegmentsMember 2019-12-31 0000885725 bsx:RhythmandNeuroMember 2018-01-01 2018-12-31 0000885725 bsx:CardiovascularMember 2018-01-01 2018-12-31 0000885725 bsx:RhythmandNeuroMember 2019-01-01 2019-12-31 0000885725 bsx:CardiovascularMember 2017-12-31 0000885725 us-gaap:AllOtherSegmentsMember 2018-12-31 0000885725 us-gaap:AllOtherSegmentsMember 2017-12-31 0000885725 bsx:MedsurgMember 2018-01-01 2018-12-31 0000885725 bsx:RhythmandNeuroMember 2017-12-31 0000885725 bsx:MedsurgMember 2017-12-31 0000885725 bsx:CardiovascularMember 2019-12-31 0000885725 bsx:MedsurgMember 2019-01-01 2019-12-31 0000885725 bsx:RhythmandNeuroMember 2018-12-31 0000885725 bsx:CardiovascularMember 2018-12-31 0000885725 bsx:MedsurgMember 2018-12-31 0000885725 bsx:MedsurgMember 2019-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885725 bsx:LicensingarrangementassetsMember 2019-01-01 2019-12-31 0000885725 bsx:LicensingarrangementassetsMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2019-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-12-31 0000885725 srt:MinimumMember bsx:LicensingarrangementassetsMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:LicensingarrangementassetsMember 2019-01-01 2019-12-31 0000885725 bsx:LicensingarrangementliabilitiesMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000885725 bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0000885725 us-gaap:LiabilityMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000885725 bsx:TenderOfferMember 2019-12-31 0000885725 bsx:ProposedBTGAcquisitionMember 2019-12-31 0000885725 us-gaap:NetInvestmentHedgingMember 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 bsx:December2027NotesMember 2019-12-31 0000885725 us-gaap:AccountsPayableMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherCurrentAssetsMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 currency:EUR us-gaap:NondesignatedMember 2019-01-01 2019-12-31 0000885725 bsx:EurodenominatedoutstandingdebtMember 2019-12-31 0000885725 us-gaap:AssetsMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 bsx:LicensingarrangementliabilitiesMember 2019-01-01 2019-12-31 0000885725 bsx:ActualCovenantMember 2019-12-31 0000885725 bsx:CurrentRequirementMember 2019-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2019-01-01 2019-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2018-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2019-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2019-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2018-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2018-01-01 2018-12-31 0000885725 bsx:January2020NotesMember 2019-12-31 0000885725 bsx:March2039NotesMember 2019-12-31 0000885725 bsx:August2022TermLoanMember 2018-12-31 0000885725 bsx:May2025NotesMember 2018-12-31 0000885725 bsx:November2035NotesMember 2018-12-31 0000885725 bsx:March2028NotesMember 2019-12-31 0000885725 bsx:December2027NotesMember 2018-12-31 0000885725 bsx:March2024NotesMember 2018-12-31 0000885725 bsx:March2039NotesMember 2018-12-31 0000885725 us-gaap:SeniorNotesMember 2019-12-31 0000885725 us-gaap:SeniorNotesMember 2018-12-31 0000885725 bsx:October2023NotesMember 2019-12-31 0000885725 bsx:March2026NotesMember 2019-12-31 0000885725 bsx:March2029NotesMember 2019-12-31 0000885725 bsx:May2025NotesMember 2019-12-31 0000885725 bsx:January2020NotesMember 2018-12-31 0000885725 bsx:November2035NotesMember 2019-12-31 0000885725 bsx:May2020NotesMember 2018-12-31 0000885725 bsx:March2029NotesMember 2018-12-31 0000885725 bsx:October2023NotesMember 2018-12-31 0000885725 bsx:March2028NotesMember 2018-12-31 0000885725 bsx:March2026NotesMember 2018-12-31 0000885725 bsx:March2024NotesMember 2019-12-31 0000885725 bsx:May2022NotesMember 2018-12-31 0000885725 bsx:May2022NotesMember 2019-12-31 0000885725 bsx:March2049NotesMember 2019-12-31 0000885725 bsx:January2040NotesMember 2019-12-31 0000885725 bsx:March2049NotesMember 2018-12-31 0000885725 us-gaap:InterestRateSwapMember 2019-12-31 0000885725 bsx:May2020NotesMember 2019-12-31 0000885725 bsx:January2040NotesMember 2018-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000885725 bsx:August2022TermLoanMember 2019-12-31 0000885725 us-gaap:InterestRateSwapMember 2018-12-31 0000885725 bsx:A2020TermLoanMember us-gaap:SubsequentEventMember 2020-01-09 2020-01-09 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember 2019-01-01 2019-12-31 0000885725 bsx:August2019TermLoanMember 2019-12-31 0000885725 bsx:RequirementfourthquarterfollowingqualifiedacquisitionMember 2019-12-31 0000885725 2019-11-27 2019-11-27 0000885725 bsx:March2028NotesMember 2019-01-01 2019-12-31 0000885725 bsx:February2019AggregateOfferingMember 2019-02-25 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2018-12-19 0000885725 bsx:January2020NotesMember 2019-01-01 2019-12-31 0000885725 bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember 2019-12-31 0000885725 bsx:The2018facilityMember 2019-01-01 2019-12-31 0000885725 bsx:October2018NotesMember 2018-01-01 2018-12-31 0000885725 bsx:May2020NotesMember 2019-01-01 2019-12-31 0000885725 bsx:August2019TermLoanMember 2019-01-01 2019-12-31 0000885725 bsx:May2025NotesMember 2019-01-01 2019-12-31 0000885725 bsx:October2023NotesMember 2019-01-01 2019-12-31 0000885725 bsx:RequirementsixthquarterandthereafterfollowingqualifiedacquisitionMember 2019-12-31 0000885725 bsx:CovenantRequirementDomain 2019-12-31 0000885725 bsx:The2017FacilityMember 2017-08-04 0000885725 us-gaap:CommercialPaperMember 2018-12-19 0000885725 bsx:RequirementthirdquarterfollowingqualifiedacquisitionMember 2019-12-31 0000885725 bsx:TwoYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2018-12-19 0000885725 bsx:RequirementfirsttwoquartersfollowingqualifiedacquisitionMember 2019-12-31 0000885725 bsx:TwoYearDelayedDrawTermLoanMember bsx:AggregateSeniorUnsecuredDelayedDrawTermLoanMember 2018-12-19 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2019-12-31 0000885725 bsx:A2020TermLoanMember 2019-12-05 0000885725 bsx:October2018NotesMember 2018-12-31 0000885725 2019-12-05 2019-12-05 0000885725 bsx:A2020TermLoanMember 2019-12-31 0000885725 us-gaap:BorrowingsMember 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2019-01-01 2019-12-31 0000885725 us-gaap:CommercialPaperMember 2019-12-31 0000885725 us-gaap:CommercialPaperMember 2018-01-01 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2019-12-31 0000885725 us-gaap:BorrowingsMember 2019-12-31 0000885725 srt:MaximumMember 2019-12-31 0000885725 srt:MaximumMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000885725 bsx:TransferCostsMember 2019-01-01 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 bsx:TransferCostsMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 bsx:TransferCostsMember bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember bsx:TransferCostsMember 2019-01-01 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember bsx:TransferCostsMember 2019-01-01 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2017-01-01 2017-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2017-01-01 2017-12-31 0000885725 us-gaap:EmployeeSeveranceMember 2017-01-01 2017-12-31 0000885725 bsx:TransferCostsMember 2017-01-01 2017-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2017-01-01 2017-12-31 0000885725 us-gaap:OtherRestructuringMember 2017-01-01 2017-12-31 0000885725 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember bsx:TransferCostsMember 2017-01-01 2017-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2017-01-01 2017-12-31 0000885725 us-gaap:CostOfSalesMember bsx:TransferCostsMember 2017-01-01 2017-12-31 0000885725 bsx:TransferCostsMember 2016-06-06 2019-12-31 0000885725 2016-06-06 2019-12-31 0000885725 bsx:A2019RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember 2016-06-06 2019-12-31 0000885725 bsx:A2016RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 bsx:TransferCostsMember bsx:A2019RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 bsx:A2016RestructuringPlanMember 2019-12-31 0000885725 us-gaap:OtherRestructuringMember 2016-06-06 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2019RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 bsx:TransferCostsMember bsx:A2016RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 bsx:RestructuringPlanMember srt:MinimumMember us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2019-12-31 0000885725 bsx:RestructuringPlanMember srt:MinimumMember us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2019-12-31 0000885725 bsx:RestructuringRelatedToPlanMember srt:MinimumMember us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2019-12-31 0000885725 srt:MinimumMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 bsx:RestructuringRelatedToPlanMember srt:MaximumMember us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 bsx:RestructuringPlanMember srt:MinimumMember us-gaap:EmployeeSeveranceMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 bsx:RestructuringRelatedToPlanMember srt:MinimumMember us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 srt:MinimumMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 srt:MaximumMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 bsx:RestructuringPlanMember srt:MaximumMember us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 bsx:RestructuringPlanMember srt:MaximumMember us-gaap:EmployeeSeveranceMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 bsx:RestructuringPlanMember srt:MinimumMember us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-12-31 0000885725 bsx:TransferCostsMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember bsx:TransferCostsMember 2018-01-01 2018-12-31 0000885725 us-gaap:EmployeeSeveranceMember 2018-01-01 2018-12-31 0000885725 us-gaap:OtherRestructuringMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember bsx:TransferCostsMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-12-31 0000885725 us-gaap:OtherAssetsMember 2019-12-31 0000885725 us-gaap:OtherAssetsMember 2018-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2019-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0000885725 us-gaap:SubsequentEventMember 2020-01-01 2020-12-31 0000885725 2018-06-30 0000885725 2018-10-01 2018-12-31 0000885725 2018-04-01 2018-06-30 0000885725 2019-07-01 2019-09-30 0000885725 2017-11-10 2017-11-10 0000885725 us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2020-01-29 0000885725 us-gaap:SubsequentEventMember 2020-01-29 0000885725 2019-01-01 2019-03-31 0000885725 2019-04-01 2019-06-30 0000885725 2019-10-01 2019-12-31 0000885725 2019-01-15 0000885725 2013-01-25 0000885725 srt:MaximumMember 2018-01-01 2018-12-31 0000885725 srt:MinimumMember 2017-01-01 2017-12-31 0000885725 srt:MinimumMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember 2018-01-01 2018-12-31 0000885725 srt:MaximumMember 2017-01-01 2017-12-31 0000885725 bsx:A2011LtipPlanMember 2011-05-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 2017-02-28 0000885725 2019-02-21 0000885725 2018-02-15 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2017-01-01 2017-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2019-01-01 2019-12-31 0000885725 bsx:BTGSpecPharmaMember 2019-01-01 2019-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2019-01-01 2019-12-31 0000885725 bsx:SpecialChargesMember 2017-01-01 2017-12-31 0000885725 bsx:SpecialChargesMember 2019-01-01 2019-12-31 0000885725 bsx:SpecialChargesMember 2018-01-01 2018-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2018-01-01 2018-12-31 0000885725 bsx:MedsurgMember 2017-01-01 2017-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2018-01-01 2018-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2017-01-01 2017-12-31 0000885725 bsx:CardiovascularMember 2017-01-01 2017-12-31 0000885725 bsx:RhythmandNeuroMember 2017-01-01 2017-12-31 0000885725 country:US 2017-12-31 0000885725 country:IE 2017-12-31 0000885725 country:US 2018-12-31 0000885725 bsx:OtherCountriesMember 2017-12-31 0000885725 bsx:OtherCountriesMember 2018-12-31 0000885725 bsx:OtherCountriesMember 2019-12-31 0000885725 country:IE 2019-12-31 0000885725 country:IE 2018-12-31 0000885725 country:US 2019-12-31 0000885725 bsx:BSXReportableSegmentsMember 2019-01-01 2019-12-31 0000885725 bsx:BSXReportableSegmentsMember 2018-01-01 2018-12-31 0000885725 bsx:BSXReportableSegmentsMember 2017-01-01 2017-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2018-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2018-12-31 0000885725 bsx:BTGSpecPharmaMember 2019-12-31 0000885725 bsx:BTGSpecPharmaMember 2018-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2019-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2019-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2017-01-01 2017-12-31 0000885725 country:US 2017-01-01 2017-12-31 0000885725 bsx:EmergingMarketsMember 2018-01-01 2018-12-31 0000885725 srt:AsiaPacificMember 2018-01-01 2018-12-31 0000885725 srt:AsiaPacificMember 2017-01-01 2017-12-31 0000885725 country:US 2018-01-01 2018-12-31 0000885725 country:US bsx:BSXReportableSegmentsMember 2019-01-01 2019-12-31 0000885725 bsx:EmergingMarketsMember 2017-01-01 2017-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2018-01-01 2018-12-31 0000885725 bsx:EmergingMarketsMember 2019-01-01 2019-12-31 0000885725 us-gaap:EMEAMember 2019-01-01 2019-12-31 0000885725 us-gaap:EMEAMember 2017-01-01 2017-12-31 0000885725 srt:AsiaPacificMember 2019-01-01 2019-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2019-01-01 2019-12-31 0000885725 bsx:BTGSpecPharmaMember country:US 2019-01-01 2019-12-31 0000885725 us-gaap:EMEAMember 2018-01-01 2018-12-31 0000885725 bsx:BTGSpecPharmaMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalCrmReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2018-01-01 2018-12-31 0000885725 us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalCrmReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalCrmReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:InternationalRetirementPlansMember 2019-12-31 0000885725 bsx:U.K.PlanMember 2019-12-31 0000885725 bsx:ExecutiveRetirementPlanMember 2019-12-31 0000885725 bsx:BTGAcquisitionDomain 2019-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-12-31 0000885725 bsx:U.K.PlanMember 2019-12-31 0000885725 bsx:OtherInternationalPlansMember 2019-12-31 0000885725 us-gaap:DomesticPlanMember 2019-12-31 0000885725 bsx:ExecutiveRetirementPlanMember 2018-12-31 0000885725 bsx:InternationalRetirementPlansMember 2018-12-31 0000885725 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000885725 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000885725 us-gaap:DefinedBenefitPlanCashMember 2019-12-31 0000885725 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000885725 us-gaap:FairValueInputsLevel1Member 2019-12-31 0000885725 us-gaap:OtherContractMember 2019-12-31 0000885725 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000885725 srt:MinimumMember us-gaap:DomesticPlanMember 2018-12-31 0000885725 srt:MinimumMember bsx:InternationalRetirementPlansMember 2018-12-31 0000885725 srt:MaximumMember bsx:InternationalRetirementPlansMember 2018-12-31 0000885725 srt:MaximumMember us-gaap:DomesticPlanMember 2018-12-31 0000885725 us-gaap:DomesticPlanMember 2018-12-31 iso4217:GBP xbrli:pure iso4217:USD iso4217:GBP xbrli:shares iso4217:USD xbrli:shares utreg:Rate xbrli:shares iso4217:EUR bsx:claims bsx:reportablesegments
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☑
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or
For the fiscal year ended December 31, 2019
☐
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
 
04-2695240
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)

300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
(Address of Principal Executive Offices)                         (Zip Code)

508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, $0.01 par value
 
BSX
 
New York Stock Exchange
0.625% Senior Notes due 2027
 
BSX27
 
New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act:
NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes: ☑ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes: ☐ No ☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes: ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorted period that the registrant was required to submit such files). Yes: ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
 
 
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes: ☐ No ☑
The aggregate market value of the registrant’s common stock held by non-affiliates was approximately $53.1 billion based on the last reported sale price of $42.98 of the registrant’s common stock on the New York Stock Exchange on June 28, 2019, the last business day of the registrant’s most recently completed second fiscal quarter. (For this computation, the registrant has excluded the market value of all shares of common stock of the registrant reported as beneficially owned by executive officers, and directors of the registrant; such exclusion shall not be deemed to constitute an admission that any such person is an affiliate of the registrant.)
The number of shares outstanding of Common Stock, $0.01 par value per share, as of January 31, 2020 was 1,396,195,349.

Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement to be filed within 120 days of December 31, 2019 with the Securities and Exchange Commission in connection with its 2020 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.



TABLE OF CONTENTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



2

PART I

ITEM 1. BUSINESS

Our Company

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for nearly 40 years, we advance science for life by providing a broad range of high performance solutions to address unmet patient needs and reduce the cost of healthcare. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

Our history began in the late 1960s when our co-founder, John Abele, acquired an equity interest in Medi-tech, Inc., a research and development company focused on developing alternatives to surgery. In 1969, Medi-tech introduced a family of steerable catheters used in some of the world's first less-invasive procedures. In 1979, John Abele joined with Pete Nicholas to form Boston Scientific Corporation, which indirectly acquired Medi-tech. This acquisition began a period of active and focused new product development, innovation, market development and organizational growth. Since then, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body.

Our net sales have increased substantially since our formation. Our growth has been fueled in part by strategic acquisitions designed to improve our ability to take advantage of growth opportunities in the medical device industry and to build depth of portfolio within our core businesses. These strategic acquisitions have helped us to add promising new technologies to our pipeline and to offer one of the broadest product portfolios in the world for use in less-invasive procedures in our core areas of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular. We believe that the depth and breadth of our product portfolio has also enabled us to compete more effectively in the current healthcare environment that seeks to improve outcomes and lower costs. Our strategy of category leadership also enables us to compete in a changing healthcare landscape and position our products with providers and payers, while also expanding internationally and managing the complexities of the global healthcare market.

Business Strategy

We operate pursuant to five strategic imperatives: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth and Develop Key Capabilities. We believe that our execution of these strategic imperatives will drive innovation, accelerate profitable revenue growth and increase stockholder value while strengthening our leadership position in the medical device industry.

We expect to continue to invest in our core franchises and pursue opportunities to diversify and further expand our presence in strategic growth adjacencies and new global markets. Our approach to innovation combines internally-developed products and technologies with those we may obtain externally through strategic acquisitions, alliances and other investments. Our research and development efforts are focused largely on the development of next-generation and novel technology offerings across multiple programs and all divisions. In the past several years, we have completed numerous acquisitions in support of our growth strategy, both strengthening our core franchises and expanding into high growth adjacent markets.

Our Enterprise Risk Management program analyzes the key risks inherent to achieving our strategic and organizational imperatives. Such risk assessment helps us to anticipate and adapt to potential challenges to preserve and grow stockholder value. Our Board of Directors oversees our risk management program and focuses on monitoring, and together with management, mitigating the most significant risks facing the Company, including strategic, operational, financial, legal and compliance risks.

Products

In 2019, our products were offered for sale by seven core businesses, with 26 percent of our revenue generated by our Interventional Cardiology business, 18 percent by our Cardiac Rhythm Management business, 18 percent by our Endoscopy business, 13 percent by our Urology and Pelvic Health business, 13 percent by our Peripheral Interventions business, eight percent by our Neuromodulation business, and three percent by our Electrophysiology business, with the remaining one percent generated by our recently acquired Specialty Pharmaceuticals business. Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG plc (BTG), which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We have presented our full year 2019 results to include BTG's Interventional

3

Medicine business within our Peripheral Interventions operating segment, following the close of the BTG acquisition. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. The following describes our principal product offerings by reportable segment, as well as our Specialty Pharmaceutical standalone operating segment.

MedSurg

Endoscopy

Gastroenterology and Pulmonary

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less invasive technologies. Our product offerings include the following:

•
our SpyGlass™ DS II Direct Visualization System, which brings digital imaging, a wider field of view and a simpler set-up (compared to our legacy SpyGlass System), thus enabling cholangioscopy to play a greater role in the diagnosis and treatment of pancreatico-biliary diseases,
•
our Resolution 360™ Clip, a hemostatic clipping technology designed to stop and help prevent bleeding during endoscopic procedures,
•
our Epic™ Biliary Endoscopic Stent System, indicated for the palliation of malignant strictures, is our first laser cut self-expanding metal stent and complements our braided metal stent portfolio,
•
our Acquire™ Endoscopic Ultrasound Fine Needle Biopsy Device, which is designed to obtain larger tissue specimens for histological assessment and is useful when diagnosing diseases such as pancreatic cancer, liver cancer and stomach lesions,
•
our AXIOS™ Stent and Electrocautery Enhanced Delivery System, the first, and currently only, stent in the U.S. indicated for endoscopic drainage of pancreatic pseudocysts,
•
our infection prevention portfolio, which includes a customizable Compliance EndoKit™ and single-use Orca™ Valves, designed to minimize the risk of infection transmission and improve operational efficiencies by streamlining manual cleaning or eliminating the need for cleaning and tracking, and
•
our endoluminal surgery portfolio with ORISE™ Tissue Retractor System, designed to enable tissue retraction and countertraction during en bloc colonic tissue resection procedures and ORISE™ Gel, designed to be used for submucosal lift of polyps, adenomas, early-stage cancers or other gastrointestinal mucosal lesions prior to excision with a snare or other endoscopic device.

In the fourth quarter of 2019, we received U.S. Food and Drug Administration (FDA) clearance for the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures. The EXALT Model D Duodenoscope is the first and only FDA-cleared single-use (disposable) duodenoscope on the market and was granted Breakthrough Device Designation from the FDA to ensure patients and healthcare providers have timely access to this device.

Urology and Pelvic Health

Our Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia (BPH), prostate cancer, erectile dysfunction, incontinence, pelvic floor disorders, abnormal uterine bleeding and uterine fibroids and polyps. Our product offerings include the following:

•
our comprehensive line of stone management products, including ureteral stents, catheters, baskets, guidewires, sheaths and balloons and stone laser devices,
•
our LithoVue™ Single-Use Digital Flexible Ureteroscope, which delivers detailed high-resolution digital images for high-quality visualization and seamless navigation,
•
our penile implants to treat erectile dysfunction and urinary control systems to treat male urinary incontinence, under our Prosthetic Urology portfolio,
•
our GreenLight XPS™ Laser System, our MoXy™ Fiber and Rezūm™ System, purchased as part of the NxThera, Inc. (NxThera) acquisition in the second quarter of 2018, under our BPH therapies,
•
our SpaceOAR™ Hydrogel System, purchased as part of the Augmenix, Inc. (Augmenix) acquisition in the fourth quarter of 2018, to help reduce side effects that men may experience after receiving radiotherapy to treat prostate cancer, and
•
our range of devices for the treatment of Women's Health conditions such as stress urinary incontinence, heavy menstrual bleeding (menorrhagia) and uterine fibroids and polyps.


4

Rhythm and Neuro

Cardiac Rhythm Management

Our Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Our product offerings include the following:

•
our implantable cardioverter defibrillators (ICD) and implantable cardiac resynchronization therapy defibrillators (CRT-D) as well as the world's first, and currently only, commercially available subcutaneous implantable cardiac defibrillators (S-ICD),
•
our pacemakers and implantable cardiac resynchronization therapy pacemakers (CRT-P), and
•
our LATITUDE™ Remote Patient Management System, which allows for more frequent monitoring and better guided treatment decisions by enabling physicians in most geographies to monitor implantable system performance remotely.

Our entire transvenous defibrillator portfolio leverages our EnduraLife™ Battery Technology, including our extended longevity (EL) ICD, our CRT-D’s and our MINI (smallest and thinnest) ICD.

Our most current generation of defibrillators, the RESONATE™ family of devices, is available in most major markets around the world. These devices include our proprietary HeartLogic™ Heart Failure (HF) Diagnostic, EnduraLife Battery Technology and SmartCRT™ with Multisite pacing in CRT-D. We have magnetic resonance imaging (MRI) conditional labeling across our defibrillator portfolio in most major markets around the world when used with our current generation of leads, including our current generation devices as well as our prior generation of DYNAGEN™ and INOGEN™ devices. Our implantable defibrillator portfolio is complemented by our suite of ACUITY™ X4 Quadripolar LV Leads, RELIANCE™ family of ICD Leads and INGEVITY™ Pacing Lead.

In addition to our transvenous defibrillator portfolio, we offer our EMBLEM™ MRI S-ICD System, which provides physicians the ability to treat patients who are at risk for sudden cardiac arrest without touching the heart or invading the vasculature. Our EMBLEM S-ICD devices have MRI conditional labeling and LATITUDE Remote Patient Management in most major markets.

We market our ACCOLADE™ family of pacemaker systems in nearly all major markets around the world. Approval of our ACCOLADE Pacemaker family in the U.S., Europe and Japan also included approval for use of these products in patients undergoing MRI scans. Much like our defibrillator portfolio, our pacemakers leverage our INGEVITY Pacing Leads and LATITUDE™ Remote Patient Management in nearly all major markets.

Electrophysiology

Our Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart, including a broad portfolio of therapeutic and diagnostic catheters and a variety of equipment used in the Electrophysiology lab. Our product offerings include the following:

•
our Rhythmia™ Mapping System, a next-generation, catheter-based, 3-D cardiac mapping and navigation solution designed to help diagnose and guide treatment of a variety of arrhythmias,
•
our Blazer™ Therapeutic Ablation Catheter line,
•
our broad portfolio of diagnostic catheters including Blazer™ Dx-20, Dynamic Tip™ and Viking™ Catheters,
•
our IntellaMap OrionTM Mapping Catheter, for use with our Rhythmia Mapping System to provide high-density, high-resolution maps of the heart,
•
our intracardiac ultrasound catheters, delivery sheaths and other accessories, and
•
our full offering of capital equipment used in Electrophysiology labs, such as recording systems, generators and pumps.

Our cooled ablation catheter portfolio includes our U.S. and CE Mark approved Blazer™ Open-Irrigated, IntellaNav™ Open-Irrigated, and IntellaNav MiFi™ Open-Irrigated ablation catheters with a unique Total Tip Cooling™ Design. We also offer our IntellaNav XP and IntellaNav MiFi XP solid tip catheters. Our IntellaTip™ MiFi XP, IntellaNav MiFi XP and IntellaNav MiFi Open-Irrigated Catheters include MicroFidelity (MiFi) sensor technology in the catheter tip. Additionally, the European and Japan markets have access to our DIRECTSENSE™ Software which leverages our proprietary MiFi electrode catheter design to capture and present local impedance. DIRECTSENSE Software provides meaningful information on tissue to catheter tip proximity, catheter stability, and other local tissue characteristics.


5

All of our IntellaNav Catheters are designed to allow magnetic tracking when used with our Rhythmia Mapping System. We also recently received CE Mark and U.S. IDE approval for our POLARx™ Cryoablation Single-shot Pulmonary Vein Isolation Technology, purchased as part of our acquisition of Cryterion in the third quarter of 2018.

Our capital equipment offerings include our Rhythmia Mapping System, LabSystem™ PRO Recording System, Maestro™ RF Generators and the MetriQ™ Pump.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Our product offerings include the following:

•
our Precision™, Precision Spectra™, Precision Montage™, Precision Novi™ and Spectra WaveWriter™ Spinal Cord Stimulator (SCS) Systems, designed to provide improved pain relief to a wide range of patients who suffer from chronic pain,
•
our Superion™ Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS) purchased as part of the acquisition of Vertiflex, Inc. in the second quarter of 2019, and
•
our Vercise™, Vercise™ PC and Vercise Gevia™ Deep Brain Stimulation (DBS) Systems for the treatment of Parkinson's disease, tremor, and intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions.

In January 2018, we announced FDA approval for the Spectra WaveWriter™ SCS System, the first and only system approved by the FDA to simultaneously provide paresthesia-based and sub-perception therapy. The Precision Spectra SCS System is the world's first and only SCS system with 32 contacts and 32 dedicated power sources. We believe that we continue to have a technological advantage due to our proprietary features such as Multiple Independent Current Control and our Illumina 3D™ Proprietary Programming Software, which together are intended to allow the physician to target specific areas of pain and customize stimulation of nerve fibers more precisely.

In 2018, we began commercializing our Vercise™ DBS System in the U.S. following FDA approval in late 2017. The Vercise DBS System is approved in the U.S. as an adjunctive therapy that aids in reducing some of the symptoms of moderate to advanced Parkinson’s disease. We also have regulatory approval for our Vercise DBS System in various international regions including Europe, Latin America and Asia Pacific. Our Vercise Gevia™ DBS System with the Cartesia™ Directional Lead is the first and only MRI conditional, rechargeable and directional system, using multi-directional stimulation designed for greater precision, intended to minimize side effects for patients. The Cartesia Directional Lead continues to expand our market access in Europe, Japan and various countries in Latin America. In the third quarter of 2018, we received CE mark approval in Europe for GUIDE™ XT System, the first DBS visualization system built for directionality that utilizes patient specific anatomy and stimulation field modeling. This technology provides physicians with 3-D image planning capability and when used in conjunction with the Vercise DBS Systems, enables physicians to personalize and optimize DBS treatment. In January 2019, the Vercise Gevia DBS System with the Cartesia Directional Lead was approved by the FDA and in August 2019 received ImageReady™ MRI labeling to be used in a full-body magnetic resonance imaging environment.

Cardiovascular

Interventional Cardiology

Our Interventional Cardiology business develops, manufactures and commercializes technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. Our broad, innovative product offerings have led to our leadership in the global interventional cardiology market.


6

Drug-Eluting Coronary Stent Systems

Our drug-eluting coronary stent product offerings are an important element of our global Interventional Cardiology market leadership. We believe we have enhanced the outcomes associated with the use of coronary stents, particularly the processes that lead to restenosis (the growth of neointimal tissue within an artery after angioplasty and stenting), through our scientific research and product development of drug-eluting stent systems. Our coronary stent offerings include the following:

•
our SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System, featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating,
•
our Promus ELITE™ Everolimus-Eluting Stent, and
•
our Promus PREMIER™ Everolimus-Eluting family of stents.

Complex PCI Product Offerings
 
Our product offerings to perform complex percutaneous coronary interventions (PCI) include a broad line of products used to treat patients with atherosclerosis, a principal cause of coronary artery obstructive disease. These include balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

PCI Guidance

Our PCI Guidance offerings include a family of intravascular catheter-directed ultrasound imaging catheters, complemented by our intravascular ultrasound (IVUS) imaging system and our fractional flow reserve (FFR) devices and systems for use in coronary arteries and heart chambers as well as certain peripheral vessels to assist in the diagnosis of coronary artery disease. Our PCI Guidance product offerings include the following:

•
our OptiCross™ IVUS Imaging catheter,
•
our COMET™ FFR Pressure Guidewire, and
•
our iLab™ Ultrasound Imaging System with Polaris Software, designed to enhance the diagnosis and treatment of blocked vessels and other heart disorders, which is compatible with our full line of imaging catheters and coronary physiology devices and continues to be our flagship console.

The iLab Ultrasound Imaging System has been placed in cardiology labs worldwide and provides an installed base through which we expect to continue to sell associated single-use products.

Structural Heart Therapies

Structural heart therapies are one of the fastest growing areas of the medical technology market and are highly synergistic with our Interventional Cardiology and Rhythm Management businesses. Our current structural heart product offerings include the following:

•
our WATCHMAN™ Left Atrial Appendage Closure (LAAC) Technology (WATCHMAN), and WATCHMAN FLX, designed to close the left atrial appendage in patients with non-valvular atrial fibrillation who are at risk for ischemic stroke,
•
our ACURATE TA™, ACURATE neo™, and ACURATE TF™ Aortic Valve Systems, which are based on a self-expanding architecture,
•
our LOTUS Edge™ Aortic Valve System, which is based on mechanical-expanding architecture, and
•
our Sentinel™ Cerebral Embolic Protection System, purchased as part of our acquisition of Claret Medical, Inc. (Claret) in the third quarter of 2018.

WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is marketed globally. The WATCHMAN Device has been commercially available internationally since 2009, received FDA approval in 2015 and is the leading device in percutaneous LAAC globally. In the first quarter of 2019, we received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ LAAC Device in Europe. We believe that the WATCHMAN device will be the only LAAC technology commercially available in the U.S. throughout 2020.


7

Our Transcatheter Aortic Valve Replacement (TAVR) portfolio is comprised of our dual valve offering including the LOTUS Edge™ Valve with mechanical-expanding architecture which is well suited for intra-annular cases and was launched commercially in the U.S. and Europe in the first half of 2019 and the ACURATE neo Valve based on self-expanding architecture for supra-annular cases. In addition to our dual valve offering, our TAVR portfolio includes the Sentinel Cerebral Embolic Protection System which is used to reduce the risk of stroke in TAVR procedures.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral vascular diseases, including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA), as well as products to diagnose, treat and ease various forms of cancer. Following the completion of the acquisition of BTG during the third quarter of 2019, we began to integrate BTG's Interventional Medicine (IM) portfolio into the Peripheral Interventions division, adding complementary technologies in the areas of venous disease and interventional oncology. Our combined broad peripheral portfolio includes products to treat arterial diseases (stents, balloon catheters, wires and atherectomy) and venous diseases (thrombectomy, acoustic pulse thrombolysis, wires and stents) and for use in interventional oncology techniques to treat various cancers (peripheral embolization devices, radioactive microspheres, radiofrequency and cryotherapy ablation systems, microcatheters and drainage catheters).

Our peripheral angioplasty balloon technologies include the following:

•
our Mustang™ PTA next-generation Balloon Catheter, a 0.035" balloon with superior crossing and tracking, powerful dilatation, longer lengths and smaller sheath sizes,
•
our Coyote™ Balloon Catheter, a highly deliverable and ultra-low profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures,
•
our Sterling™ Balloon Catheter, a 0.018" PTA balloon catheter designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries, and
•
our Ranger™ Drug-Coated Balloon, an innovative balloon built on the Sterling balloon platform, featuring a low-dose of paclitaxel.

Our peripheral stent technologies include the following:

•
our EPIC™ Vascular Self-Expanding Stent System, a nitinol stent designed to sustain vessel patency while providing enhanced visibility and accuracy during placement,
•
our Innova™ Self-Expanding Stent System, a laser-cut nitinol stent built for the superficial femoral artery (SFA, a large artery in the thigh) with flexibility, strength and fracture resistance, and
•
our Eluvia™ Drug Eluting Vascular Stent System, an innovative stent built on the Innova stent platform, designed to deliver a sustained dosage of paclitaxel during the time when restenosis is most likely to occur.

Our venous disease technologies include the following:

•
our AngioJet™ Thrombectomy System, used in endovascular procedures to remove blood clots from blocked arteries and veins,
•
our AngioJet Zelante DVT™ Thrombectomy Catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins, in the U.S. and Europe,
•
our VICI VENOUS STENT™ System to treat venous obstructive disease, purchased as part of the VENITI, Inc. acquisition in the third quarter of 2018, and
•
our EKOS™ Ultrasound Assisted Thrombolysis system used to treat deep vein thrombosis and pulmonary embolism, purchased as part of the BTG acquisition, which closed during the third quarter of 2019.

Our interventional oncology product offerings include the following:

•
our Therasphere™ Y-90 radioactive glass microspheres used in the treatment of hepatocellular carcinoma (HCC or the most common type of liver cancer) purchased as part of the BTG acquisition,
•
our Direxion™ Torqueable Microcatheter, and
•
our line of interventional oncology solutions, including the Renegade™ HI-FLO™ Fathom™ Microcatheter and Guidewire System and Interlock™ - 35 Fibered IDC™ and 18 Fibered IDC™ Occlusion System for peripheral embolization.


8

Specialty Pharmaceuticals

Following the closing of the BTG acquisition in the third quarter of 2019, Specialty Pharmaceuticals was added as an eighth operating segment. Our Specialty Pharmaceuticals business develops and manufactures acute care antidotes to treat overexposure to certain medications and toxins. These products are sold primarily in the U.S. through small, specialist sales teams and through commercial partners elsewhere, where approved or permitted, on a named patient basis. Our Specialty Pharmaceuticals product offerings include the following:

•
our CroFab®, the only FDA-approved product derived exclusively from U.S. snakes and approved to treat all North American pit viper envenomations in adult and pediatric patients,
•
our DigiFab® Digoxin Immune Fab (Ovine), a treatment for patients with life-threatening or potentially life-threatening digoxin toxicity or overdose that is clinically proven to effectively clear digoxin from the body, and
•
our Voraxaze®, a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than one micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than two standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function.

Research and Development

Our investment in research and development is critical to driving our future growth. Our investment in research and development supports the following:

•
internal research and development programs, regulatory design and clinical science, as well as other programs obtained through our strategic acquisitions and alliances, and
•
engineering efforts that incorporate customer feedback into continuous improvement efforts for currently marketed and next-generation products.

We have directed our development efforts toward innovative technologies designed to expand current markets or enter adjacent markets. We are transforming how we conduct research and development by identifying best practices, driving efficiencies and optimizing our cost structure, which we believe will enable increased development activity and faster concept-to-market timelines.

Focused, cross-functional teams take a formal approach to new product design and development, helping us to manufacture and offer innovative products consistently and efficiently. Involving cross-functional teams early in the process is the cornerstone of our product development cycle. We believe this collaboration allows our teams to concentrate resources on the most viable and clinically relevant new products and technologies and maximize cost and time savings as we bring them to market.

In addition to internal development, we work with hundreds of leading research institutions, universities and clinicians around the world to develop, evaluate and clinically test our products. We are expanding our collaborations to include research and development teams in emerging markets; these teams will focus on both global and local market requirements at a lower cost of development. We believe that these efforts will play a significant role in our future success.

9


Marketing and Sales

In 2019, we marketed our products and solutions to approximately 37,000 hospitals, clinics, outpatient facilities and medical offices in more than 120 countries worldwide, including the U.S. The majority of our net sales are derived from countries in which we have direct sales organizations. We also have a network of distributors and dealers who offer our products in certain countries and markets. We expect to continue to leverage our infrastructure in markets where commercially appropriate and use third party distributors in those markets where it is not economical or strategic to establish or maintain a direct presence.

No single institution accounted for more than ten percent of our net sales in 2019, 2018 or 2017; however, large group purchasing organizations, hospital networks and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales. We have a dedicated corporate accounts organization in the U.S. and Europe focused principally on selling to major buying groups and integrated healthcare networks. We consistently strive to understand and exceed the expectations of our customers. Each of our businesses maintains dedicated sales forces and marketing teams focused on physicians who specialize in the diagnosis and treatment of different medical conditions, as well as on key hospital service line administrators. We believe that this dual focus on disease state management and hospital administrators enables us to develop highly knowledgeable and dedicated sales representatives and to foster collaborative relationships with both physicians and key service line administrators. We believe that our strong working relationships with physicians, service line administrators and others in the medical industry enable us to gain a detailed understanding of new therapeutic and diagnostic alternatives and to respond quickly to our customers' changing needs.

International Operations

International net sales accounted for 42 percent of our net sales in 2019, 44 percent of our net sales in 2018 and 43 percent of our net sales in 2017. Maintaining and expanding our international presence is an important component of our long-term growth strategy. Through our international presence, we seek to increase net sales and market share, leverage our relationships with leading physicians and their clinical research programs, accelerate the time to bring new products to market and gain access to worldwide technological developments that we can implement across our product lines. In addition, we continue to invest in infrastructure in emerging markets to strengthen our sales and service capabilities and maximize our opportunities in these countries.

As of December 31, 2019, we had 9 principal international manufacturing facilities, in addition to our U.S. facilities, including three in Ireland, two in Costa Rica, one in Brazil, one in Malaysia, one in Puerto Rico and one in Switzerland. Approximately 52 percent of our products manufactured in 2019 were produced at these international facilities. We also maintain our primary research and development capabilities in China, Costa Rica, India, Ireland, Puerto Rico and the UK. Medical education is also a vital component of safe procedure adoption and collaboration with physicians. We continue to provide localized training programs through our 14 Institutes for Advancing Science in the Americas, Africa, Asia and Europe.

Manufacturing and Raw Materials

We are focused on continuously improving our supply chain effectiveness, strengthening our manufacturing processes and increasing operational efficiencies within our organization. We strive to improve the efficiency of our sourcing operations and to leverage the technical expertise of the broader market by partnering with strategic suppliers. In doing so, we seek to focus our internal resources on the development and commercial launch of new products and the enhancement of existing products. We continue to implement new systems designed to provide improved quality, reliability, service, greater efficiency and lower supply chain costs. We also drive continuous improvement in product quality through process controls and validations, supplier and distribution controls and then necessary training and tools for our operations team. In addition, we remain focused on examining our operations and general business activities to enhance our operational effectiveness by identifying cost-improvement opportunities.

We remain committed to maintaining appropriate investments in supply chain resiliency on an ongoing basis. Our products are designed and manufactured in technology centers around the world, either by us or third parties. We consistently monitor our inventory levels, manufacturing and distribution capabilities and maintain recovery plans to address potential disruptions that we may encounter. Supply chain resiliency also includes sterilization, which is performed and optimized through a combination of internal and third party locations and may also be subject to potential interruptions. Many components used in the manufacturing of our products are readily fabricated from commonly available raw materials or off-the-shelf items available from multiple supply sources; however, certain items are custom made to meet our specifications. We believe that in most cases, redundant capacity exists at our suppliers and that alternative sources of supply are available or could be developed within a reasonable period of time. We also have an ongoing program to identify single-source components and to develop alternative back-up supplies, and we regularly readdress the adequacy and abilities of our suppliers and sterilizers to meet our needs.

10


Quality Assurance

We are committed to providing high quality products to our customers. Our quality system starts with the initial product specification and continues through the design of the product, component specification process and the manufacturing, sale and servicing of the product. Our quality system is intended to build in quality and process control and to utilize continuous improvement concepts throughout the product life. These systems are designed to enable us to satisfy various international quality system regulations, including those of the FDA with respect to products sold in the U.S. All of our medical device manufacturing facilities and distribution centers are certified under the ISO 13485 quality system standard, established by the International Standards Organization (ISO) for medical devices, which includes requirements for an implemented quality system that applies to component quality, supplier control, product design and manufacturing operations. This certification can be obtained only after a complete audit of a company’s quality system by an independent outside auditor. Maintenance of the certification requires that these facilities undergo periodic re-examination.

Environmental Regulation and Management

We are subject to various environmental laws, directives and regulations both in the U.S. and abroad. Our operations involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. We believe that strong performance across relevant environmental, health and safety metrics enhances our competitive strength while benefiting our patients, customers, stockholders and employees. We are focused on continuous improvement in these areas by reducing pollution, depletion of natural resources and our overall environmental footprint. Specifically, we are working to optimize energy and resource usage, ultimately reducing greenhouse gas emissions and waste. We are listed on the FTSE4Good Corporate Social Responsibility Index, managed by the Financial Times and the London Stock Exchange, which measures the performance of companies that meet globally recognized standards of corporate responsibility. This listing recognizes our dedication to those standards and it places us in a select group of companies with a demonstrated commitment to responsible business practices and sound environmental policies. We also recognize the need to minimize the impact of the manufacturing of our products on the environment and have committed to carbon neutrality in our manufacturing and key distribution sites by 2030.

We have obtained ISO 14001:2015 certifications at our major manufacturing plants and Tier 1 distribution centers around the world, as well as our Corporate headquarters in Marlborough, Massachusetts. ISO 14001:2015 is a globally recognized standard for Environmental Management Systems, established by the International Standards Organization, which provides a voluntary framework to identify key environmental aspects associated with our business. Using this environmental management system and the specific attributes of our certified locations in the U.S., Ireland, Costa Rica and the Netherlands, we continue to improve our environmental performance and reduce our environmental footprint.

Competition

We encounter significant competition across our product lines and in each market in which we sell our products and solutions, some from companies that may have greater financial, sales and marketing resources than we do. Our primary competitors include Abbott Laboratories and Medtronic plc, as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. In certain countries, we face competition from domestic medical device companies that may benefit from their status as local suppliers. We also face competition from non-medical device companies, which may offer alternative therapies for disease states that could also be treated using our products, or from companies offering technologies that could augment or replace procedures using our products.

We believe that our products and solutions compete primarily on their ability to deliver both clinical and economic outcomes for our customers by enabling physicians to perform diagnostic and therapeutic procedures safely and effectively often in a less-invasive manner. We also compete on ease of use, comparative effectiveness, reliability and physician familiarity. In the current environment of managed care, with economically-motivated buyers, consolidation among healthcare providers, increasing prevalence and importance of regional and national tenders, increased competition and declining reimbursement rates, we have been increasingly required to compete on the basis of price, value, reliability and efficiency. We believe the current global economic conditions and healthcare reform measures could continue to put additional competitive pressure on us, including on our average selling prices, overall procedure rates and addressable market sizes. We recognize that our continued competitive success will depend upon our ability to:

•
offer products and solutions that provide differentiated clinical and economic outcomes,
•
create or acquire innovative, scientifically advanced technologies,
•
apply our technology and solutions cost-effectively and with superior quality across product lines and markets,
•
develop or acquire proprietary products and solutions,

11

•
attract and retain skilled personnel,
•
obtain patent or other protection for our products,
•
obtain required regulatory and reimbursement approvals,
•
compete in regional and national tenders for our products,
•
continually enhance our quality systems,
•
manufacture and market our products and solutions either directly or through third parties, and
•
supply sufficient inventory to meet customer demand.

Medical Device Regulatory Approvals

The medical devices that we manufacture and market are subject to regulation by numerous worldwide regulatory bodies, including the FDA and comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws and regulations governing development, testing, manufacturing, labeling, marketing and distribution. Medical devices are also generally subject to varying levels of regulatory control based on risk level of the device.

In the U.S., authorization to distribute a new device can generally be met in one of three ways. The first process requires that a premarket notification (510(k)) be made to the FDA to demonstrate that the device is as safe and effective as, or substantially equivalent to, a legally marketed device (the “predicate” device). Applicants must submit performance data to establish substantial equivalence. In some instances, data from human clinical trials must also be submitted in support of a 510(k) premarket notification. If so, these data must be collected in a manner that conforms to the applicable Investigational Device Exemption (IDE) regulations. The FDA must issue a decision finding substantial equivalence before commercial distribution can occur. Changes to cleared devices that could not significantly affect the safety or effectiveness of the device can generally be made without additional 510(k) premarket notifications; otherwise, a new 510(k) is required.

The second process requires the submission of a premarket approval (PMA) application to the FDA to demonstrate that the device is safe and effective for its intended use. This approval process applies to most Class III devices and generally requires clinical data to support the safety and effectiveness of the device, obtained in adherence with IDE requirements. The FDA will approve the PMA application if it finds that there is a reasonable assurance that the device is safe and effective for its intended purpose and that the proposed manufacturing is in compliance with the Quality System Regulation (QSR). For novel technologies, the FDA will generally seek input from an advisory panel of medical experts and seek their views on the safety, effectiveness and benefit-risk of the device. The PMA process is generally more detailed, lengthier and more expensive than the 510(k) process.

The third process requires that an application for a Humanitarian Device Exemption (HDE) be made to the FDA for the use of a Humanitarian Use Device (HUD). A HUD is intended to benefit patients by treating or diagnosing a disease or condition that affects, or is manifested in, not more than 8,000 individuals in the U.S. per year. The application submitted to the FDA for an HDE is similar in both form and content to a PMA application, but is exempt from the effectiveness requirements of a PMA. The HUD provision of the regulation provides an incentive for the development of devices for use in the treatment or diagnosis of diseases affecting smaller patient populations.

In the European Union (EU), we will be required to comply with the new Medical Device Regulation (MDR or EU MDR) effective May 2020 which will supersede the current Medical Device Directives. Medical devices which have a valid CE Certificate to the current Directives (issued before May 2020) can continue to be sold until May 2024 or until the CE Certificate expires, whichever comes first, providing there are no significant changes to the design or intended use. The MDR was published in May 2017 with a 3-year transition period. The CE Mark required to sell medical devices in the EU is affixed following conformity assessment and either approval from the appointed independent Notified Body or through self-certification by the manufacturer. The selected pathway to CE marking is based on product risk classification. CE Marking indicates conformity to the applicable Essential Requirements of the relevant Medical Devices Directive and in the future to the General Safety and Performance Requirements for the new MDR. The MDR will change multiple aspects of the existing regulatory framework for CE marking, such as increased clinical evidence requirements and other new requirements, including Unique Device Identification (UDI) as well as many other post-market obligations. MDR also significantly modifies and increases the compliance requirements for the industry and will require significant investment over the next few years to implement.

We are also required to comply with the regulations of every other country where we commercialize products before we can launch or maintain new products on the market, such as the requirements that we obtain approval from the Japanese Ministry of Health, Labor and Welfare (MHLW), the Japanese Pharmaceutical & Medical Device Agency (PMDA) and the China Food and Drug Administration (NMPA). Many countries that previously did not have medical device regulations, or had minimal regulations, are now introducing them. For example, India is in the process of expanding its current regulations to include all medical device categories while many countries in the Middle East and Southeast Asia are introducing new regulations.


12

The FDA and other worldwide regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through review and inspection of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the Food, Drug and Cosmetic Act and the Safe Medical Devices Act pertaining to medical devices or initiate action for criminal prosecution of such violations. Regulatory agencies and authorities in the countries where we do business can halt production in or distribution within their respective country or otherwise take action in accordance with local laws and regulations.

International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory requirements of each country to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries, medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing regulatory requirements; however, other countries, such as China, for example, require approval in the country of origin first. Most countries outside of the U.S. require that product approvals be recertified on a regular basis, generally every five years. The recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate testing to document continued compliance. Where recertification applications are required, they must be approved in order to continue selling our products in those countries.

Government Affairs

We maintain a global Government Affairs presence, headquartered in Washington, D.C., to actively monitor and advocate on myriad legislation and policies impacting us, both on a domestic and an international front. The Government Affairs office works closely with members of Congress and committee staff, the White House and Administration offices, state Governors, legislatures and regulatory agencies, embassies and global governments on issues affecting our business. Our proactive approach and depth of political and policy expertise are aimed at having our positions heard by federal, state and global decision-makers to improve patient care and to advance our business objectives by educating policymakers on our positions, key priorities and the value of our technologies. The Government Affairs office manages our political action committee and works closely with trade groups on issues affecting our industry and healthcare in general. The Government Affairs office also advocates for public policy that benefits our employees, and the patients we serve and supports the communities in which we live.
Healthcare Policies and Reimbursement
Political, economic and regulatory influences around the world continue to subject the healthcare industry to potential fundamental changes that could substantially affect our results of operations. Government and private sector initiatives related to limiting the growth of healthcare costs (including price regulation), coverage and payment policies, comparative effectiveness reviews of therapies, technology assessments and healthcare delivery structure reforms, are continuing in many countries where we do business. We believe that these changes are causing the marketplace to put increased emphasis on the delivery of treatments that can reduce costs, improve efficiencies and/or increase patient access. Although we believe our less-invasive products and technologies generate favorable clinical outcomes, value and cost efficiency, the resources necessary to demonstrate value to our customers, patients, payers and other stakeholders are significant and new therapies now take longer periods of time to gain widespread adoption.

The impact to our business of the U.S. Patient Protection and Affordable Care Act's (ACA) provisions related to coverage expansion, payment reforms and delivery system has been immaterial. The ACA and Health Care and Education Affordability Reconciliation Act were enacted into law in the U.S. in 2010. The legislation imposed on medical device manufacturers a 2.3 percent excise tax on U.S. sales of Class I, II and III medical devices beginning in January 2013. In December 2015, the Promise for Antibiotics and Therapeutics for Health Act, or PATH Act, was passed, which included legislation which temporarily suspended the 2.3 percent excise tax until December 31, 2017. In January 2018, another temporary two-year suspension of the 2.3 percent excise tax was passed, extending the suspension to December 31, 2019. On December 20, 2019, the President signed the 2020 spending bill, which included a provision to permanently repeal the excise tax.

The U.S. Federal government, as part of the ACA, and certain state governments have enacted laws aimed at increasing transparency, or "sunshine," in relationships between medical device, biologics and pharmaceutical companies and healthcare professionals (HCPs). As a result, we are required by law to report many types of payments and transfers of value provided to HCPs. Certain foreign jurisdictions have similar laws or are currently acting to implement similar laws. Failure to comply with sunshine laws and/or implement and adhere to adequate policies and practices to address changes to legal and regulatory requirements could

13

have a negative impact on our results of operations. Additional legislation at the state and federal levels may result in further changes to these laws.

As noted below, we expect certain trends to continue placing pressure on pricing and utilization in the U.S. The Tax Cuts and Jobs Acts (TCJA), enacted December 22, 2017 in the U.S., changed the tax treatment of healthcare expenses and repealed the “individual mandate” to purchase private insurance. These tax law changes have resulted in changes to insurance coverage and financing of insurance coverage in individual markets. Additional legislation may result in changes to government programs such as Medicare and Medicaid. In addition, the current U.S. Administration has enacted a number of administrative policy changes that will likely result in additional changes to insurance coverage, financing of insurance coverage and benefits offered through private insurance in both the employer-sponsored and individual markets. These changes and other similar changes being considered are likely to lead to an increase in the number of people without insurance. Other individual coverage policies will be less generous than those required under the ACA. The impact of these changes on coverage levels and patient cost-sharing could affect utilization of non-urgent, non-acute services in which our devices are used.

We expect that pricing of medical devices will remain under pressure as alternative payment reform, such as prospective payment systems for hospital care, preferential site of service payments, value-based purchasing and accountable care organizations (ACOs), continue to take shape globally. We also expect marketplace changes to place pressure on medical device pricing globally as hospitals consolidate and large group purchasing organizations, hospital networks and other groups continue to seek to aggregate purchasing power. Similarly, governments are increasing the use of tenders, placing pressure on medical device pricing. Some governments also seek to limit the growth of healthcare costs through price regulation. Implementation of cost containment initiatives and healthcare reforms in significant markets such as the U.S., Japan and Europe and other markets may limit the price of, or the level at which reimbursement is provided for, our products, which in turn may influence a hospital’s or physician's selection of products used to treat patients.

Our products are purchased principally by hospitals, physicians and other healthcare providers around the world that typically bill various third-party payers, including government programs (e.g., Medicare and Medicaid in the U.S.) and private insurance payers, for the services provided to their patients. Third-party payers and governments may approve or deny coverage for certain technologies and associated procedures based on independently determined assessment criteria. Coverage decisions by payers for these technologies and associated procedures are based on a wide range of methodologies that may reflect the assessed resource costs, clinical outcomes and economic value of the technologies and associated procedures.

Proprietary Rights and Patent Litigation

We rely on a combination of patents, trademarks, trade secrets and other forms of intellectual property to protect our proprietary rights. We generally file patent applications in the U.S. and foreign countries where patent protection for our technology is appropriate and available. As of December 31, 2019, we held more than 21,000 patents and had approximately 6,000 patent applications pending worldwide that cover various aspects of our technology. In addition, we hold exclusive and non-exclusive licenses to a variety of third-party technologies covered by patents and patent applications. In the aggregate, these intellectual property assets and licenses are of material importance to our business; however, we believe that no single patent, technology, trademark, intellectual property asset or license is material in relation to our business as a whole.

We rely on non-disclosure and non-competition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary technology. There has been substantial litigation regarding patent and other intellectual property rights in the medical device industry, particularly in the areas in which we compete. We continue to defend ourselves against claims and legal actions alleging infringement of the patent rights of others. Additionally, we may find it necessary to initiate litigation to enforce our patent rights, to protect our trade secrets or know-how and to determine the scope and validity of the proprietary rights of others. Accordingly, we may seek to settle some or all of our pending litigation, particularly to manage risk over time. Settlement may include cross licensing of the patents that are the subject of the litigation as well as our other intellectual property and may involve monetary payments to or from third parties.

We maintain insurance policies providing limited coverage against securities claims. We are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. See Note J – Commitments and Contingencies to our 2019 consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for a discussion of intellectual property, product liability and other litigation and proceedings in which we are involved.


14

Employees

As of December 31, 2019, we had approximately 36,000 employees, including approximately 14,000 in operations, 11,000 in selling, marketing and distribution, 7,000 in administration and 4,000 in clinical, regulatory and research and development. Of these employees, we employed approximately 19,000 outside the U.S., approximately 9,000 of whom are in the manufacturing operations function.

Community Outreach

We are united by a goal to make a difference in the lives of the over 30 million patients we serve annually. We seek to give our time and resources to make positive impacts upon those communities where we live, work, and serve. Guided by our core values, we seek to improve access to healthcare, to invest in educational programming for students with limited means and access to opportunities, and to support and embrace the spirit of volunteerism within our global workforce, while adhering to strong ethical standards.

In some parts of the world, access to health information, screening, care and services can be limited. Our collaborations with non-profit community organizations raise awareness of chronic disease and decrease these health disparities by improving health outcomes for underserved populations. We accomplish this through our focus on 3 P’s - Prevent, Provide and Prepare. We work to prevent chronic disease through education and awareness, provide access to healthcare through increasing the quantity and quality of healthcare workers and screenings, and preparing and empowering children at high risk of chronic disease to successfully navigate their health journey. Each year, our employees play a role in how we reach our health goals by participating in health awareness campaigns like Wear Red Day for heart health, No Shave November for men’s health, and in walks and runs for various health causes. For the last three years, Boston Scientific partnered with Project HOPE, a global health and humanitarian relief organization, to fund the United Dialogue and Action Against Non-Communicable Disorders (UDAAN) program to help reduce premature mortality in India. The program focuses on improving the health practices related to chronic disease treatment and care. Through the program, a chronic disease tool kit was developed to improve healthcare worker efficiencies and is now being scaled to other Health and Wellness centers in the area.

We are also passionate about inspiring young learners to see themselves in a Science, Technology, Engineering and Math (STEM) role in the future. Our employees work with underrepresented K-12 students around the world and share their passion for STEM by providing interactive product demos, development programs, and hands-on activities for young learners in their communities. A key effort of our STEM volunteers is to create resources that empower other employees to get involved. While each regional team focuses on what is needed most by students in their local communities, they also work together to share best practices that ensure we reach our overall goals. Resources like presentations, STEM kits, interactive displays, and an online activity database have been created to increase global collaboration and overall impact. In 2019, our employee volunteers participated in more than 160 STEM events and school programs. Through this outreach, we are helping to develop the diverse future talent that will enable Boston Scientific to create innovative health solutions for generations to come. Beyond the classroom, we empower our employees to participate in and influence the way we care for people in their local communities. We are proud of these efforts and the collective impact we have on advancing possibilities across the globe. In 2019 our employees volunteered more than 41,000 hours to make a positive impact at more than 600 global community events in 38 countries.

We also support the U.S. communities where we have significant business presences through the Boston Scientific Foundation. The mission of the foundation is simple: to help expand access to quality healthcare and educational opportunities for underserved populations. The Boston Scientific Foundation awarded approximately $1 million dollars in scholarships to children of employees and grant awards across the U.S. in 2019. The process involved more than 70 employee volunteers who evaluated proposals for the Boston Scientific Foundation Board review and approval, upon which the Boston Scientific Foundation was able to help fuel grassroots innovative solutions to improve access to quality healthcare and create new opportunities for students to learn and achieve.

Seasonality

Our net sales are influenced by many factors, including product launches, acquisitions, regulatory and reimbursement approvals, patient, physician and employee holiday schedules and other macro-economic conditions. While our consolidated net sales do not reflect any significant degree of seasonality, customer purchases of our medical devices have historically been lower in the first and third quarters of the year.


15

Available Information

Copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), are available free of charge on our website (www.bostonscientific.com) as soon as reasonably practicable after we electronically file the material with or furnish it to the U.S. Securities and Exchange Commission (SEC). Additionally, the SEC maintains an internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Printed copies of these posted materials are also available free of charge to stockholders who request them in writing from Investor Relations, 300 Boston Scientific Way, Marlborough, MA 01752-1234. Information on our website or linked to our website is not incorporated by reference into this Annual Report.

Safe Harbor for Forward-Looking Statements

Certain statements that we may make from time to time, including statements contained in this Annual Report and information incorporated by reference into this Annual Report, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aiming” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

The forward-looking statements in this Annual Report are based on certain risks and uncertainties, including the risk factors described in Item 1A under the heading “Risk Factors” and the specific risk factors discussed below and in connection with forward-looking statements throughout this Annual Report, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Annual Report. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions, new product introductions and the market acceptance of those products, markets for our products, expected pricing environment, expected procedural volumes, the closing and integration of acquisitions, clinical trial results, demographic trends, intellectual property rights, litigation, financial market conditions, the execution and effect of our restructuring program, the execution and effect of our business strategy, including our cost-savings and growth initiatives and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Item 1A. Risk Factors contained within this Annual Report on Form 10-K filed with the SEC, which we may update in Part II, Item 1A. Risk Factors in subsequent Quarterly Reports on Form 10-Q that we will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this Annual Report.

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, see Item 1A. Risk Factors.

Our Businesses
 
•
Our ability to increase net sales, expand the market, capture market share and adapt to market volatility,

•
The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

•
Competitive offerings and related declines in average selling prices for our products,

•
The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,

•
The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,

16

 
•
Variations in clinical results, reliability or product performance of our and our competitors' products,

•
Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

•
The effect of consolidation and competition in the markets in which we do business or plan to do business,

•
Disruption in the manufacture or supply of certain components, materials or products, or the failure to secure in a timely manner alternative manufacturing or additional or replacement components, materials or products,

•
Our ability to retain and attract key personnel, including those associated with recent acquisitions,

•
The impact of natural disasters, public health crises, and other catastrophic events,

•
The impact of enhanced requirements to obtain regulatory approval in the U.S. and around the world, including EU MDR and the associated timing and cost of product approval, and
 
•
The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies.

Regulatory Compliance, Litigation and Data Protection

•
The impact of healthcare policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other healthcare reform legislation,

•
Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

•
Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to our or our competitors' products,

•
The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,

•
Costs and risks associated with current and future asserted litigation,

•
The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provision and cash flows,
 
•
The impact of, diversion of management attention as a result of, and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

•
The possibility of failure to protect our intellectual property rights and the outcome of patent litigation, and

•
Our ability to operate properly our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that has a material adverse effect on our business, reputation or results of operations.

Innovation and Certain Growth Initiatives

•
The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,


17

•
Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

•
Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable revenue growth opportunities as well as to keep them in line with the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

•
Our ability to successfully develop, manufacture and market new products and technologies in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

•
Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development from our acquisitions, in our growth adjacencies or otherwise,

•
Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

•
The potential failure to successfully integrate and realize the expected benefits from the strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

International Markets

•
Our dependency on international net sales to achieve growth, including in emerging markets,

•
The impact of changes we may make in the future on our international structure and leadership,

•
The timing and collectability of customer payments,

•
Geopolitical and economic conditions (including the impact of the United Kingdom's exit from the EU, often referred to as "Brexit"),

•
Protection of our intellectual property,

•
Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA and similar laws in other jurisdictions

•
Our ability to comply with U.S. and foreign export control, trade embargo and custom laws,

•
The impact of changes in reimbursement practices and policies,

•
Our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in product diversification and emerging markets such as Brazil, Russia, India and China,

•
Our ability to execute and realize anticipated benefits from our investments in emerging markets, and

•
The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, expenses and resulting margins.

Liquidity

•
Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and covenant compliance,


18

•
Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

•
The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

•
The impact of examinations and assessments by domestic and international taxing authorities on our tax provision, financial condition or results of operations,

•
The possibility of counterparty default on our derivative financial instruments,

•
The impact of potential intangible asset impairment charges, including on our results of operations, and

•
Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

Cost Reduction and Optimization Initiatives

•
Risks associated with changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs and

•
Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.

19

ITEM 1A. RISK FACTORS
In addition to the other information contained in this Annual Report and the exhibits hereto, the following risk factors should be considered carefully in evaluating our business. Our business, financial condition, cash flows or results of operations could be materially adversely affected by any of these risks. This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements set forth at the end of Item 1. Business of this Annual Report. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business, financial condition, cash flows or results of operations.
Business and Operational Risks
We face intense competition and may not be able to keep pace with the rapid technological changes in the medical devices industry, which could have an adverse effect on our business, financial condition or results of operations.
The medical device markets in which we participate are highly competitive. We encounter significant competition across our product lines and in each market in which our products are sold from various medical device companies. Some of our competitors may have greater financial and marketing resources than we do, including as a result of consolidation among companies in our industry. Our primary competitors include Abbott Laboratories and Medtronic plc,, as well as a wide range of medical device companies that sell a single or limited number of competitive products or which participate in only a specific market segment or set of segments. We also face competition from non-medical device companies, including pharmaceutical companies, which may offer alternative therapies for disease states also amenable to treatment using our products. New direct or indirect competitors may emerge in the future, potentially including companies introducing new sales or distribution models to our industry or leveraging robotic, navigation, and/or other automation technologies into markets in which we compete.
In addition, the medical device markets in which we participate are characterized by extensive research and development and rapid technological change. Developments by other companies of products and/or services, processes or technologies may make our products or proposed products obsolete or less competitive and may negatively impact our net sales. It is necessary for us to devote continued efforts and financial resources to the development or acquisition of scientifically advanced technologies and products. In addition, we will need to apply our technologies cost-effectively across product lines and markets, obtain patent and other protection for our technologies and products, obtain required regulatory and reimbursement approvals and successfully manufacture and market our products consistent with our quality standards. If we fail to develop or acquire new products or enhance existing products, such failure could have a material adverse effect on our business, financial condition or results of operations. In addition, a delay in the timing of the launch of next-generation products and the overall performance of, and continued physician confidence in, those products may result in declines in our market share and have an adverse impact on our business, financial condition or results of operations.
We may experience declines in market size, average selling prices for our products, medical procedure volumes and our share of the markets in which we compete, which may materially adversely affect our results of operations and financial condition.
We continue to experience pressures across many of our businesses due to competitive activity, increased market power of our customers as the healthcare industry consolidates, economic pressures experienced by our customers, public perception of our products, and the impact of managed care organizations and other third-party payers. These and other factors may adversely impact market sizes, as well as our share of the markets in which we compete, the average selling prices for our products or medical procedure volumes. There can be no assurance that the size of the markets in which we compete will increase above existing levels, that we will be able to regain or gain market share or compete effectively on the basis of price or that the number of procedures in which our products are used will increase above existing levels. Decreases in market sizes or our market share and declines in average selling prices or procedural volumes could materially adversely affect our results of operations or financial condition.

Continued consolidation in the healthcare industry or additional governmental controls exerted over pricing in key markets could lead to increased demands for price concessions or limit or eliminate our ability to sell to certain of our significant market segments, which could have an adverse effect on our business, financial condition or results of operations.
Numerous initiatives and reforms by legislators, regulators and third-party payers to curb the rising cost of healthcare have catalyzed a consolidation of aggregate purchasing power within the markets in which we sell our products. Additionally, a growing number of countries have instituted or are contemplating introducing regional or national tender processes driven primarily by price. In some cases, such processes may favor local companies to multinational companies like Boston Scientific. As the healthcare industry consolidates, competition to provide products and services is expected to continue to intensify, resulting in pricing pressures, decreased average selling prices and the exclusion of certain suppliers from important market segments. We expect that market demand, government regulation, third-party coverage and reimbursement policies, government contracting requirements and

20

societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among our customers, which may increase competition, exert further downward pressure on the prices of our products and services and may adversely impact our business, financial condition or results of operations.

Healthcare cost containment pressures, government payment and delivery system reforms, changes in private payer policies, and marketplace consolidations could decrease the demand for our products, the prices which customers are willing to pay for those products and/or the number of procedures performed using our devices, which could have an adverse effect on our business, financial condition or results of operations.

Our products are purchased principally by hospitals, physicians and other healthcare providers around the world that typically bill various third-party payers, including government programs, authorities or agencies (e.g., Medicare and Medicaid in the U.S.) and private health plans, for the healthcare services provided to their patients. Governments and payers may also institute changes in healthcare delivery systems that may reduce funding for services or encourage greater scrutiny of healthcare costs. The ability of customers to obtain appropriate reimbursement for their products and services from private and governmental third-party payers is critical to the success of medical technology companies because it affects which products customers purchase and the prices they are willing to pay. Reimbursement and funding vary by country and can significantly impact the acceptance of new products and technologies and the use of established products and technologies. Even if we develop a promising new product, we may find limited demand for the product unless reimbursement approval is obtained from private and governmental third-party payers. Further legislative or administrative reforms to the reimbursement systems in the U.S., Japan, or other countries in a manner that significantly reduces reimbursement for procedures using our medical devices or denies coverage for those procedures, including price regulation, site of service requirements, competitive bidding and tendering, coverage and payment policies, comparative effectiveness of therapies, heightened clinical data requirements, technology assessments and managed-care arrangements, could have a material adverse effect on our business, financial condition or results of operations
We are subject to a number of market, business, financial, legal and regulatory risks and uncertainties with respect to our international operations that could have a material impact on our business, financial condition or results of operations.
International net sales accounted for 42 percent of our global net sales in 2019. An important part of our strategy is to continue pursuing growth opportunities in net sales and market share outside of the U.S. by expanding global presence, including in Emerging Markets. Our international operations are subject to a number of market, business and financial risks and uncertainties, including those related to our use of channel partners, geopolitical and economic instability, foreign currency exchange and interest rate fluctuations, competitive product offerings, local changes in healthcare financing and payment systems and healthcare delivery systems, local product preferences and requirements, including preferences for local manufacturers, workforce instability, weaker intellectual property protection in certain countries than exists in the U.S. and longer accounts receivable cycles. Such risks and uncertainties may adversely impact our ability to implement our growth strategy in these markets and, as a result, our sales growth, market share and operating profits from our international operations may be adversely affected.
Our international operations are subject to established and developing legal and regulatory requirements for medical devices in each country in which our products are marketed and sold. Most foreign countries have medical device regulations. Further, most countries outside of the U.S. require product approvals be renewed or recertified on a regular basis in order to continue to be marketed and sold there. In addition, several countries that previously did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded, or plan to expand, existing regulations, including requiring local clinical data in addition to global clinical data. These factors have caused or may cause us to experience more uncertainty, risk, expense and delay in commercializing products in certain foreign jurisdictions, which could affect our ability to obtain approvals for our products in those jurisdictions and adversely impact our net sales, market share and operating profits from our international operations.
Further, international markets are affected by economic pressure to contain healthcare costs, which can lead to more rigorous evidence requirements and lower reimbursement rates for either our products directly or procedures in which our products are used. Governments and payers may also institute changes in healthcare delivery systems that may reduce funding for services or encourage greater scrutiny of healthcare costs. In addition, certain international markets may also be affected by foreign government efforts to reference reimbursement rates in other countries. All of these types of changes may ultimately reduce selling prices of our products and/or reduce the number of procedures in which our products are used, which may adversely impact our net sales, market share and operating profits from our international operations.

In addition, our international operations are subject to other established and developing U.S. and foreign legal and regulatory requirements, including FCPA and/or similar laws in other countries and U.S. and foreign import and export controls and licensing requirements, trade protection and embargo measures and customs laws. Global businesses, including those in the medical device industry, are facing increasing scrutiny of, and heightened enforcement efforts with respect to, their international operations. Any

21

alleged or actual failure to comply with legal and regulatory requirements may subject us to government scrutiny, civil and/or criminal proceedings, sanctions and other liabilities, which may have a material adverse effect on our international operations, financial condition, results of operations and/or liquidity.
In a referendum on June 23, 2016, voters approved the exit of the United Kingdom (UK) from the European Union (EU). Following a formal notification by the UK to the EU that it intends to leave the EU, and after several extensions to the deadline for doing so agreed between the UK and the EU, the UK legally withdrew from the EU on January 31, 2020. Pursuant to the withdrawal agreement entered into on January 24, 2020, the UK will maintain access to the single EU market and to the global trade deals negotiated by the EU on behalf of its members and remain subject to EU for a transition period ending on December 31, 2020. Exit of the UK from the EU will have numerous consequences in all areas of our business, including, economic, regulatory and operational, and the actual impact is very difficult to assess at this time. Changes in industry regulations could have an effect on existing CE certificates being renewed and new certificates being issued which would impact the ability to trade; however, it is impossible to assess the full impact at this stage.
At this stage, the materiality to us of Brexit remains unknown and unquantifiable. However, we have implemented a Brexit Response Team and have put in place mitigation procedures to reduce any significant operational risks that have been identified to date.
Any significant changes in the political and economic, financial, competitive, legal and regulatory or reimbursement conditions where we conduct, or plan to expand, our international operations may have a material impact on our business, financial condition or results of operations.

If we are unable to manage our debt levels, maintain investment grade credit ratings at the three ratings agencies, or experience a disruption in our cash flows it could have an adverse effect on our cost of borrowing, financial condition or results of operations.
As part of our strategy to maximize stockholder value, we use financial leverage to manage our cost of capital. Our outstanding debt balance was $10.008 billion as of December 31, 2019 and $7.056 billion as of December 31, 2018. Although we currently have investment grade ratings at Moody's Investor Service, Standard & Poor's Rating Service and Fitch Ratings, our inability to maintain investment grade credit ratings could increase our cost of borrowing funds in the future and reduce our access to liquidity. Delays in our product development and new product launches could result in disruption in our cash flow or our ability to continue to effectively manage our debt levels could have an adverse effect on our cost of borrowing, financial condition or results of operations. In addition, our credit and security facilities contain covenants that require us to maintain specified financial ratios and place other limits on our business. If we are unable to satisfy these covenants, we may be required to obtain waivers from our lenders and no assurance can be made that our lenders would grant such waivers on favorable terms or at all and we could be required to repay any borrowings on demand.
We may record future intangible asset impairment charges related to one or more of our global reporting units, which could materially adversely impact our results of operations.
We test our goodwill balances during the second quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level and, in evaluating the potential for impairment of goodwill, we make assumptions regarding estimated revenue projections, growth rates, cash flows and discount rates. In the second quarter of 2019, we performed our annual goodwill impairment test for all of our reporting units existing at the time. In conjunction with our annual test, the fair value of each reporting unit exceeded its carrying value and none of our reporting units were at risk of impairment. Refer to Critical Accounting Policies and Estimates contained in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report for a discussion of key assumptions used in our testing.
On a quarterly basis, we monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill and other intangible assets. Relatively small declines in the future performance and cash flows of a reporting unit or asset group, changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses, or small changes in other key assumptions, may result in the recognition of significant asset impairment charges, which could have a material adverse impact on our results of operations.
Failure to integrate acquired businesses into our operations successfully could adversely affect our business, financial condition and operating results.
As part of our strategy to realign our business portfolio, we have completed multiple acquisitions over the past three years and may pursue additional acquisitions in the future. Our integration of acquired businesses requires significant efforts, including

22

corporate restructuring and the coordination of information technologies, research and development, sales and marketing, operations, regulatory, supply chain, manufacturing, quality systems and finance. These efforts result in additional expenses and involve significant management time. Some of the factors that could affect the success of our acquisitions include, among others, the effectiveness of our due diligence process, our ability to execute our business plan for the acquired companies, the strength of the acquired technology, results of clinical trials, regulatory approvals and reimbursement levels of the acquired products and related procedures, the continued performance of critical transition services, our ability to adequately fund acquired in-process research and development projects and retain key employees and our ability to achieve synergies with our acquired companies, such as increasing sales of our products, achieving cost savings and effectively combining technologies to develop new products. In addition, foreign acquisitions involve unique risks, including those related to integration of operations across different geographies, cultures and languages, currency risks and risks associated with the economic, political, legal and regulatory environment in specific countries. Our failure to manage successfully and coordinate the growth of the acquired companies could have an adverse impact on our business and our future growth. In addition, we cannot be certain that the businesses we acquire will become profitable or remain so, and if our acquisitions are not successful, we may record related asset impairment charges in the future or experience other negative consequences on our results.
We may not be successful in our strategy relating to future strategic acquisitions of, investments in, or alliances with, other companies and businesses, which have been a significant source of historical growth for us, and will be key to our diversification into new markets and technologies.
Our strategic acquisitions, investments and alliances are intended to further expand our ability to offer customers effective, high quality medical devices that satisfy their interventional needs. These acquisitions, investments and alliances have been a significant source of our growth. If we are unsuccessful in our acquisitions, investments and alliances, we may be unable to grow our business. The success of our strategy relating to future acquisitions, investments or alliances will depend on a number of factors, including:

•
our ability to identify suitable opportunities for acquisition, investment or alliance, if at all,
•
our ability to manage acquisition, investment or alliance opportunities within our capital capacity and prioritize those investments to execute on our strategy,
•
our ability to manage our due diligence process to uncover potential issues with targets,
•
our ability to finance any future acquisition, investment or alliance on terms acceptable to us, if at all,
•
our ability to complete acquisitions, investments or alliances in a timely manner on terms that are satisfactory to us, if at all,
•
our ability to successfully integrate and operate acquired businesses,
•
our ability to successfully identify and retain key target employees,
•
our ability to comply with applicable laws and regulations, including foreign laws and regulations, and
•
our ability to protect intellectual property and to prevail in litigation related to newly acquired technologies. 

Any potential future acquisitions we consummate may be dilutive to our earnings and may require additional debt or equity financing, depending on their size or nature.

We may not realize the expected benefits from our restructuring and optimization initiatives, our long-term expense reduction programs may result in an increase in short-term expenses and our efforts may lead to unintended consequences.

We monitor the dynamics of the economy, the healthcare industry and the markets in which we compete and assess opportunities for improved operational effectiveness and efficiency and to better align expenses with revenues, while preserving our ability to make investments in research and development projects, capital and our people that we believe are important to our long-term success. As a result of these assessments, we have undertaken restructuring and optimization initiatives in order to enhance our growth potential and position us for long-term success. In November 2018, we announced a restructuring initiative (the 2019 Restructuring Plan) intended to support our effort to improve operating performance and meet anticipated market demands by ensuring that we are appropriately structured and resourced to deliver sustainable value to patients and customers. Key activities under the 2019 Restructuring Plan include supply chain network optimization intended to maximize our global manufacturing and distribution network capacity and building functional capabilities that support business growth. These activities were initiated in 2019, with the majority of activity expected to be complete by the end of 2021. The 2019 Restructuring Plan is expected to result in total pre-tax charges of approximately $200 million to $300 million and reduce gross annual pre-tax operating expenses by approximately $100 million to $150 million by the end of 2022 as program benefits are realized. We expect a substantial portion of the savings to be reinvested in strategic growth initiatives. These measures could yield unintended consequences, such as distraction of our management and employees, business disruption, inability to attract or retain key personnel and reduced employee productivity, which could negatively affect our business, sales, financial condition and results of operations. Moreover, our restructuring and optimization initiatives result in charges and expenses some of which impact our operating results. We cannot

23

guarantee that the activities under our restructuring plans or other optimization initiatives will result in the desired efficiencies and estimated cost savings.

Current domestic and international economic conditions could adversely affect our cash flows and results of operations.

Uncertainty about global economic conditions, including those resulting from credit and sovereign debt issues, has caused and may continue to cause disruption in the financial markets, including diminished liquidity and credit availability. These conditions may adversely affect our suppliers, leading them to experience financial difficulties or be unable to borrow money to fund their operations, which could cause disruptions in our ability to produce our products. Our customers may experience financial difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability or decision to purchase our products, particularly capital equipment, or to pay for our products that they purchase on a timely basis, if at all. In addition, we have accounts receivable factoring programs in certain European and Asian countries. Continued deterioration of the global economy or increase in sovereign debt issues may impact our ability to transfer receivables to third parties in certain of those countries in the future. Third parties such as banks offering factoring programs in these countries are looking to reduce their exposure levels to government owned or supported debt. This could result in terminations of, or changes to the costs or credit limits of our existing factoring programs. Such terminations or changes could have a negative impact on our cash flow and days sales outstanding.

The strength and timing of economic recovery remains uncertain and there can be no assurance that there will not be further deterioration in the global economy. Accordingly, we cannot predict to what extent global economic conditions, including sovereign debt issues and increased focus on healthcare systems and costs in the U.S. and abroad, may continue to impact negatively our average selling prices, net sales and profit margins, procedural volumes and reimbursement rates from third party payers. In addition, conditions in the financial markets and other factors beyond our control may adversely affect our ability to borrow money in the credit markets, access the capital markets and to obtain financing for acquisitions or other general corporate and commercial purposes.
Our future growth is dependent upon the development of new products and enhancement of existing products, which requires significant research and development, clinical trials and regulatory approvals, all of which may be very expensive and time-consuming and may not result in commercially viable products.
In order to develop new products and enhance existing products, we focus our research and development programs largely on the development of next-generation and novel technology offerings across multiple programs and businesses. The development of new products and enhancement of existing products requires significant investment in research and development, clinical trials and regulatory approvals. The results of our product development efforts may be affected by a number of factors, including our ability to anticipate customer needs, innovate and develop new products, complete clinical trials, obtain regulatory approvals and reimbursement in the United States and abroad, manufacture products in a cost-effective manner, obtain appropriate intellectual property protection for our products and gain and maintain market approval of our products. There can be no assurance that any products now in development or that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance. If we are unable to develop and launch new products and enhanced products, our ability to maintain or expand our market position in the markets in which we participate may be materially adversely impacted. Further, we are continuing to investigate and have completed several acquisitions that involve opportunities to further expand our presence in and diversify into, priority growth areas by accessing new products and technologies. There can be no assurance that our investments will be successful or that we will be able to access new products and technologies on terms favorable to us, or that these products and technologies will achieve commercial feasibility, obtain regulatory approval or gain market acceptance. A delay in the development or approval of new products and technologies or our decision to reduce our investments may adversely impact the contribution of these technologies to our future growth.

Additionally, certain products or groups of products, in particular new products or enhancements of existing products, may have a disproportionate impact on our business, financial condition and results of operations. Failure to meet growth projections, poor clinical outcomes, increasing regulatory requirements, launch delays and inability to effectively scale manufacturing and achieve targeted margins with respect to any of these products or groups of products in particular may materially adversely impact on our business, financial condition and results of operations.

Natural disasters, public health crises, and other catastrophic events or other events outside of our control may affect sales of our products or disrupt our supply chain and have an adverse effect on our business, financial condition and results of operations.

If any of our facilities, or the facilities of our suppliers or customers, is affected by natural disasters, public health crises, such as pandemics and epidemics, or other events outside of our control, our business and operating results could suffer. These types of

24

events could negatively impact procedure volumes in the affected regions or depending upon the severity, globally, which could adversely impact our operating results. For example, we anticipate that the novel coronavirus may have a negative sales impact due to the potential effect on procedure volumes in China and supply chain disruption.
Interruption of our manufacturing operations could adversely affect our results of operations and financial condition.
Our products are designed and manufactured in technology centers around the world, either by us or third parties. In most cases, the manufacturing of any specific product is concentrated in one or a few locations. Factors such as a failure to follow specific internal protocols and procedures, equipment malfunction, environmental factors or damage to one or more of our facilities could adversely affect our ability to manufacture our products. In the event of an interruption in manufacturing, we may be unable to quickly move to alternate means of producing affected products or to meet customer demand. In the event of a significant interruption, for example, as a result of a failure to follow regulatory protocols and procedures, we may experience lengthy delays in resuming production of affected products due primarily to needs for regulatory approvals. As a result, we may experience loss of market share, which we may be unable to recapture and harm to our reputation, which could adversely affect our results of operations and financial condition.
Disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products by third-party vendors could adversely affect our results of operations and financial condition.
We purchase the majority of the materials and components used in manufacturing our products from third-party vendors. Certain of these materials and components are purchased from single sources due to quality considerations, expertise, costs or constraints resulting from regulatory requirements. In certain cases, we may not be able to establish additional or replacement vendors for such materials or components in a timely or cost effective manner, largely as a result of FDA regulations that require validation of materials and components prior to their use in our products and the complex nature of our and many of our vendors' manufacturing processes. A reduction or interruption in the supply of materials and components used in manufacturing our products, an inability to timely develop and validate alternative sources if required or a significant increase in the price of such materials or components could adversely affect our results of operations and financial condition.

In addition, many of our products require sterilization prior to sale and we utilize a mix of internal resources and contract sterilizers to perform this service. To the extent we or our contract sterilizers are unable to sterilize our products, whether due to capacity, availability of materials for sterilization, regulatory or other constraints, including federal and state regulations on the use of ethylene oxide, we may be unable to transition to other internal resources, contract sterilizers, sterilizer locations or sterilization methods in a timely or cost effective manner or at all, which could have a material impact on our results of operations and financial condition.
Our share price has been volatile and may fluctuate, and accordingly, the value of an investment in our common stock may also fluctuate.
Stock markets in general and our common stock in particular have experienced significant price and trading volume volatility over recent years. The market price and trading volume of our common stock may continue to be subject to significant fluctuations due to factors described under this Item 1A. Risk Factors, as well as economic and geopolitical conditions in general and to variability in the prevailing sentiment regarding our operations or business prospects, as well as, among other things, changing investment priorities of our stockholders. Because the market price of our common stock fluctuates significantly, stockholders may not be able sell their shares at attractive prices.
 
If we are unable to attract or retain key personnel, it could have an adverse effect on our business, financial condition and results from operations.
 
In our industry, there is substantial competition for key personnel in the regions in which we operate and we may face increased competition for such employees, particularly in emerging markets as the trend toward globalization continues. Our business depends to a significant extent on the continued service of senior management and other key personnel, the development of additional management personnel and the hiring of new qualified employees. There can be no assurance that we will be successful in retaining and developing existing personnel or recruiting new personnel. The loss of one or more key employees, our ability to attract or develop additional qualified employees or any delay in hiring key personnel could have material adverse effects on our business, financial condition or results of operations.


25

Legal and Regulatory Risk Factors

Healthcare policy changes, including healthcare reform legislation, may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Political, economic and policy influences are leading the healthcare industry to make substantial structural and financial changes that will continue affecting our results of operations. Government and private sector initiatives limiting the growth of healthcare costs (including price regulation), coverage and payment policies, comparative effectiveness of therapies, technology assessments and healthcare delivery structure reforms, are continuing in many countries where we do business. We believe that these changes are causing the marketplace to put increased emphasis on the delivery of more treatments that can reduce costs, improve efficiencies and/or increase patient access. Although we believe our less-invasive products and technologies generate favorable clinical outcomes, value and cost efficiency, the resources necessary and evidence necessary to demonstrate value to our customers, patients, payers and other stakeholders may be significant and it may take a longer period of time to gain widespread adoption. Moreover, there can be no assurance that our strategies will succeed for every product.

The Patient Protection and Affordable Care Act (ACA) and Health Care and Education Affordability Reconciliation Act of 2010 were enacted into law in the U.S. in March 2010. As a U.S. headquartered company with significant domestic sales, the medical device tax included in this law has materially affected us. The law imposed on medical device manufacturers a 2.3 percent excise tax on U.S. sales of Class I, II and III medical devices beginning in January 2013. In December 2015, this law was temporarily suspended until December 2019, when the law was permanently repealed as part of the 2020 fiscal spending bill. Under the current administration, there may be a permanent repeal or an alteration of other elements of the ACA, but at this time it is not definite that a change will be enacted or what new healthcare provisions may be implemented. While the implementation of the medical device tax has been repealed, other provisions of this law, including comparative effectiveness research, pilot programs to evaluate alternative payment methodologies and other changes to the payment systems, have started changing the way healthcare is delivered, reimbursed and funded. While the extent to which it has affected our business is not clear, these changes, over the long-term, may adversely affect our business and results of operations.

We cannot predict the specific healthcare programs and regulations that will be ultimately implemented by regional and national governments globally. However, any changes that lower reimbursements for either our products and/or procedures using our products reduce medical procedure volumes and/or increase cost containment pressures on us or others in the healthcare sector could adversely affect our business and results of operations.

We are subject to extensive and dynamic medical device regulation, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products.
Our products, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug and Cosmetic Act (FDC Act), by comparable agencies in foreign countries and by other regulatory agencies and governing bodies. Under the FDC Act, medical devices must receive FDA clearance or approval or an exemption from such clearance or approval before they can be commercially marketed in the U.S. In the European Union (EU), we will be required to comply with the new Medical Device Regulation (MDR or EU MDR) effective May 2020 which will supersede the current Medical Device Directives. Medical devices which have a valid CE Certificate to the current Directives (issued before May 2020) can continue to be sold until May 2024 or until the CE Certificate expires, whichever comes first, providing there are no significant changes to the design or intended use. The CE Mark is applied following approval from an independent notified body or declaration of conformity. The process of obtaining marketing approval or clearance from the FDA or by comparable agencies in foreign countries for new products, or with respect to enhancements or modifications to existing products, could:

•
take a significant period of time,
•
require the expenditure of substantial resources,
•
involve rigorous pre-clinical and clinical testing, as well as increased post-market surveillance,
•
require changes to products and
•
result in limitations on the indicated uses of products.
 
In addition, exported devices are subject to the regulatory requirements of each country to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries, medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing regulatory requirements; however, other countries, such as China for example, require approval in the country of origin or legal manufacturer first. Most countries outside of the U.S. require that product approvals be renewed or recertified on a regular basis, generally every

26

four to five years. The renewal or recertification process requires that we evaluate any device changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance. Where renewal or recertification applications are required, they may need to be renewed and/or approved in order to continue selling our products in those countries. There can be no assurance that we will receive the required approvals for new products or modifications to existing products on a timely basis or that any approval will not be subsequently withdrawn or conditioned upon extensive post-market study requirements.

Our global regulatory environment is becoming increasingly stringent and unpredictable, which could increase the time, cost and complexity of obtaining regulatory approvals for our products, as well as the clinical and regulatory costs of supporting those approvals. Several countries that did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded on existing regulations. Certain regulators are exhibiting less flexibility and are requiring local preclinical and clinical data in addition to global data. While harmonization of global regulations has been pursued, requirements continue to differ significantly among countries. We expect this global regulatory environment will continue to evolve, which could impact our ability to obtain future approvals for our products or could increase the cost and time to obtain such approvals in the future.
The FDA and other worldwide regulatory agencies actively monitor compliance with local laws and regulations through review and inspection of design and manufacturing practices, recordkeeping, reporting of adverse events, labeling and promotional practices. The FDA can ban certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial harm to the public health. The FDA can take action against a company that promotes "off-label" uses. The FDA may also enjoin and restrain a company for certain violations of the FDC Act and other amending Acts pertaining to medical devices, or initiate action for criminal prosecution of such violations. Any adverse regulatory action, depending on its magnitude, may restrict a company from effectively marketing and selling its products, may limit a company's ability to obtain future premarket clearances or approvals and could result in a substantial modification to our business practices and operations. International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance standards, are subject to FDA export requirements.
Regulations regarding the development, manufacture and sale of medical devices are evolving and subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition and results of operations. Later discovery of previously unknown problems with a product or manufacturer could result in fines, delays or suspensions of regulatory clearances or approvals, seizures or recalls of products, physician advisories or other field actions, operating restrictions and/or criminal prosecution. We may also initiate field actions as a result of a failure to strictly comply with our internal quality policies. The failure to receive product approval clearance on a timely basis, suspensions of regulatory clearances, seizures or recalls of products, physician advisories or other field actions, or the withdrawal of product approval by the FDA or by comparable agencies in foreign countries could have a material adverse effect on our business, financial condition or results of operations.
Our products are continually subject to clinical trials and other analyses conducted by us, our competitors or other third parties, the results of which may be unexpected, or perceived as unfavorable by the market, and could have a material adverse effect on our business, financial condition or results of operations.
As a part of the regulatory process of obtaining marketing clearance for new products and new indications for existing products, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations and trial endpoints. Unexpected or inconsistent clinical data from existing or future clinical trials or other analyses conducted by us, by our competitors or by third parties, including acquired businesses prior to acquisition by us, or the FDA's or the market's perception of this clinical data, may adversely impact our ability to obtain product approvals, our position in, and share of, the markets in which we participate and our business, financial condition, results of operations or future prospects.
The medical device industry and its customers continue to face scrutiny and regulation by governmental authorities and are often the subject of numerous investigations, often involving marketing and other business practices or product quality issues including device recalls or advisories. These investigations could result in the commencement of civil and criminal proceedings; imposition of substantial fines, penalties and administrative remedies, including corporate integrity agreements, stipulated judgments or exclusion; diversion of our employees' and management's attention; imposition of administrative costs and have an adverse effect on our financial condition, results of operations and liquidity; and may lead to greater governmental regulation in the future.
The medical devices we design, develop, manufacture and market are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. These authorities continue to closely scrutinize our industry. We have received and in the future may receive, subpoenas and other requests for information from Congress and state and federal

27

governmental agencies, including, among others, the U.S. Department of Justice (DOJ), the Office of Inspector General of the Department of Health and Human Services (HHS) and the Department of Defense, as well as from foreign governments and agencies. The requests and/or subpoenas we have received relate primarily to financial arrangements with healthcare providers, regulatory compliance and sale and/or product promotional practices. We have cooperated with these subpoenas and other requests for information and expect to continue to do so in the future. We cannot predict when a matter will be resolved, the outcome of the matter or its impact on us and cooperation may involve significant costs, including document production costs. An adverse outcome in any matter could include the commencement of an investigation, civil and criminal proceedings, substantial fines, penalties and administrative remedies, including exclusion from government reimbursement programs, entry into Corporate Integrity Agreements (CIAs) with governmental agencies and amendments to any existing CIAs. In addition, resolution of any matter could involve the imposition of additional and costly compliance obligations. Cooperation with requests and investigations from external agencies result in employee resource costs and diversion of employee focus. If any requests or investigations continue over a long period of time, they could divert the attention of management from the day-to-day operations of our business and impose significant additional administrative burdens on us. These potential consequences, as well as any adverse outcome from these requests or investigations, could have a material adverse effect on our financial condition, results of operations and liquidity.
In addition, certain foreign governments, state governments (including that of Massachusetts, where we are headquartered) and the U.S. federal government have enacted legislation aimed at increasing transparency of our interactions with healthcare providers. As an example, compliance with the U.S. Physician Payment Sunshine Act requires us by law to disclose payments and other transfers of value to all U.S. physicians and U.S. teaching hospitals at the U.S. federal level made after August 1, 2013. Any failure to comply with these legal and regulatory requirements could impact our business. In addition, we have and may continue to devote substantial additional time and financial resources to further develop and implement enhanced structure, policies, systems and processes to comply with enhanced legal and regulatory requirements, which may also impact our business.
We anticipate that governmental authorities will continue to scrutinize our industry closely and that additional regulation may increase compliance and legal cost and exposure to litigation and have additional adverse effects on our operations.
Changes in tax laws, unfavorable resolution of tax contingencies, or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.
We are subject to income taxes as well as non-income based taxes and tariffs, in both the U.S. and various foreign jurisdictions. We are subject to ongoing tax audits in various jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits to determine the appropriateness of our tax provision, and we have established contingency reserves for material, known tax exposures. However, the calculation of such tax exposures involves the application of complex tax laws and regulations in many jurisdictions, as well as interpretations as to the legality under European Union state aid rules of tax advantages granted in certain jurisdictions. Therefore, there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these disputes and other tax audits could have a material impact on our results of operations or financial condition.
Changes in tax laws and regulations, or their interpretation and application, in the jurisdictions where we are subject to tax could materially impact our effective tax rate. The U.S. enacted the Tax Cuts and Jobs Act (TCJA) on December 22, 2017 and we expect the U.S. Treasury to issue future notices and regulations under the TCJA. Certain provisions of the TCJA and the regulations issued thereunder could have a significant impact on our future results of operations as could interpretations made by the Company in the absence of regulatory guidance and judicial interpretations. The result of the upcoming U.S. presidential and congressional elections may result in additional U.S. tax law changes that could have a material impact on our future effective tax rate.
Additionally, the Organization for Economic Co-operation and Development (OECD), the European Commission (EC) and individual taxing jurisdictions where we and our affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual countries are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect our business.
Our operations in Puerto Rico and Costa Rica presently benefit from various tax incentives and grants. Unless these incentives and grants are extended, they will expire between 2023 and 2028. If we are unable to renew, extend, or obtain new incentive and grants, the expiration of the existing incentives and grants could have a material impact on our financial results in future periods.
Furthermore, changes in customs laws and regulations in the U.S. and various foreign jurisdictions could have a material impact on our results of operations or financial condition.

28

We may not effectively be able to protect our intellectual property or other sensitive data, which could have a material adverse effect on our business, financial condition or results of operations.

The medical device market in which we participate is largely technology driven. Physician customers have historically moved quickly to new products and new technologies. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. However, intellectual property litigation is inherently complex and unpredictable and appellate courts can overturn lower court decisions. Furthermore, as our business increasingly relies on technology systems and infrastructure, our intellectual property, other proprietary technology and other sensitive data are potentially vulnerable to loss, damage or misappropriation. Finally, our ability to protect novel business models is uncertain.

Competing parties in our industry frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These forces frequently drive settlement not only of individual cases, but also of a series of pending and potentially related and unrelated cases. In addition, although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

A number of third parties have asserted that our current and former product offerings infringe patents owned or licensed by them. We have similarly asserted that products sold by our competitors infringe patents owned or licensed by us. Adverse outcomes in one or more of the proceedings against us could limit our ability to sell certain products in certain jurisdictions, or reduce our operating margin on the sale of these products and could have a material adverse effect on our financial condition, results of operations or liquidity.

Patents and other proprietary rights are and will continue to be essential to our business and our ability to compete effectively with other companies will be dependent upon the proprietary nature of our technologies. We rely upon trade secrets, know-how, continuing technological innovations, strategic alliances and licensing opportunities to develop, maintain and strengthen our competitive position. We pursue a policy of generally obtaining patent protection in both the U.S. and abroad for patentable subject matter in our proprietary devices and attempt to review third-party patents and patent applications to the extent publicly available in order to develop an effective patent strategy, avoid infringement of third-party patents, identify licensing opportunities and monitor the patent claims of others. We currently own numerous U.S. and foreign patents and have numerous patent applications pending. We also are party to various license agreements pursuant to which patent rights have been obtained or granted in consideration for cash, cross-licensing rights or royalty payments. No assurance can be made that any pending or future patent applications will result in the issuance of patents, that any current or future patents issued to, or licensed by, us will not be challenged or circumvented by our competitors, or that our patents will not be found invalid. In addition, we may have to take legal action in the future to protect our patents, trade secrets or know-how or to assert them against claimed infringement by others. Any legal action of that type could be costly and time consuming and no assurances can be made that any lawsuit will be successful. We are generally involved as both a plaintiff and a defendant in a number of patent infringement and other intellectual property-related actions. The invalidation of key patents or proprietary rights that we own, or an unsuccessful outcome in lawsuits to protect our intellectual property, could have a material adverse effect on our business, financial condition or results of operations.

In addition, the laws of certain countries in which we market and plan on manufacturing some of our products in the near future, do not protect our intellectual property rights to the same extent as the laws of the U.S. If we are unable to protect our intellectual property in these countries, it could have a material adverse effect on our business, financial condition or results of operations.

Furthermore, our intellectual property, other proprietary technology and other sensitive data are potentially vulnerable to loss, damage or misappropriation from system malfunction, computer viruses and unauthorized access to our data or misappropriation or misuse thereof by those with permitted access and other events. While we have invested to protect our intellectual property, products and other data and continue to work diligently in this area, there can be no assurance that our precautionary measures will prevent breakdowns, breaches, cyber-attacks or other events. Such events could have a material adverse effect on our reputation, business, financial condition or results of operations.

We rely on the proper function, availability and security of information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations.

We rely on information technology systems, including technology from third party vendors, to process, transmit and store electronic information in our day-to-day operations. Similar to other large multi-national companies, the size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of

29

data privacy, or other significant disruption. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, the increasing need to protect patient and customer information and changing customer patterns. In addition, third parties may attempt to hack into our products to obtain data relating to patients or disrupt performance of our products or to access our proprietary information and the technology from third party vendors that we rely upon may have defects or vulnerabilities which, in turn, create vulnerabilities or disruptions in our system. Any failure by us to maintain or protect our information technology systems, products and data integrity, including from cyber-attacks, intrusions or other breaches, could result in the unauthorized access to patient data and personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations, or, in the worst case, could result in harm to patients. Such failure, or demonstration of vulnerability to such failure, may also result in additional regulatory scrutiny. We also grow our company through acquisitions and may face risks associated with defects and vulnerabilities in their systems as we work to integrate the acquisitions into our information technology system.

In the U.S., federal and state privacy and security laws require certain of our operations to protect the confidentiality of personal information including patient medical records and other health information, and to comply with other requirements with respect to personal data. In Europe, the Data Protection Directive requires us to manage individually identifiable information in the EU and, the new General Data Protection Regulation (GDPR) may impose fines of up to four percent of our global revenue in the event of violations after implementation of the requirements on May 25, 2018. Internationally, some countries have also passed laws that require individually identifiable data on their citizens to be maintained on local servers and that may restrict transfer or processing of that data. We believe that we meet the expectations of applicable regulations and that the ongoing costs and impacts of ensuring compliance with such rules are not material to our business. However, there is no guarantee that we will avoid enforcement actions by governmental bodies or civil actions based on this growing body of regulations. Enforcement actions could be costly and interrupt regular operations of our business. Any of these events, in turn, may cause us to lose existing customers, have difficulty preventing, detecting and controlling fraud, have disputes with customers, physicians and other healthcare professionals, be subject to legal claims and liability, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property, or suffer other adverse consequences, any of which could have a material adverse effect on our business, financial condition or results of operations.
Pending and future intellectual property litigation could be costly and disruptive to us.
We operate in an industry that is susceptible to significant intellectual property litigation and, in recent years, it has been common for companies in the medical device field to aggressively challenge the patent rights of other companies. We are currently the subject of various patent litigation proceedings and other proceedings described in more detail under Note J – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report. Intellectual property litigation is expensive, complex and lengthy and its outcome is difficult to predict. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial condition, results of operation or liquidity. Pending or future patent litigation may result in significant royalty or other payments or injunctions that can prevent the sale of products and may significantly divert the attention of our technical and management personnel. In the event that our right to market any of our products is successfully challenged, we may be required to obtain a license on terms which may not be favorable to us, if at all. If we fail to obtain a required license or are unable to design around a patent, our business, financial condition or results of operations could be materially adversely affected.

Pending and future product liability claims and other litigation, including private securities litigation, stockholder derivative suits and contract litigation, may adversely affect our financial condition and results of operations or liquidity.

The design, manufacturing and marketing of medical devices of the types that we produce entail an inherent risk of product liability claims. Many of the medical devices that we manufacture and sell are designed to be implanted in the human body for long periods of time or indefinitely. A number of factors could result in an unsafe condition or injury to, or death of, a patient with respect to these or other products that we manufacture or sell, including physician technique and experience in performing the surgical procedure, component failures, manufacturing flaws, design defects, off-label use or inadequate disclosure of product-related risks or product-related information. These factors could result in product liability claims, a recall of one or more of our products or a safety alert relating to one or more of our products. Product liability claims may be brought by individuals or by groups seeking to represent a class.


30

We are currently the subject of product liability litigation proceedings and other proceedings described in more detail under Note J – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report. The outcome of litigation, particularly class action lawsuits, is difficult to assess or quantify. Plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts, including not only actual damages, but also punitive damages. The magnitude of the potential losses relating to these lawsuits may remain unknown for substantial periods of time. In addition, the cost to defend against any future litigation may be significant. Product liability claims, securities and commercial litigation and other litigation in the future, regardless of the outcome, could have a material adverse effect on our financial condition, results of operations or liquidity. Additionally, we maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The fact that we do not maintain third-party insurance coverage for all categories of losses increases our exposure to unanticipated claims and adverse decisions and these losses could have a material adverse effect on our financial condition, results of operations or liquidity.
Any failure to meet regulatory quality standards applicable to our manufacturing and quality processes could have an adverse effect on our business, financial condition and results of operations.
As a medical device manufacturer, we are required to register our establishments and list our devices with the FDA and are subject to periodic inspection by the FDA for compliance with its Quality System Regulation requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. In addition, the Federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA which may result in observations on Form 483 and in some cases warning letters that require corrective action. In the European Community, we are required to maintain certain International Standards Organization (ISO) certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications. Many other countries in which we do business have requirements similar to those of the U.S. or the EU and other foreign governments or agencies may subject us to periodic inspections as well. If we, or our manufacturers, fail to adhere to quality system regulations or ISO requirements, this could delay production of our products and lead to fines, difficulties in obtaining regulatory clearances, recalls, enforcement actions, including injunctive relief or consent decrees, or other consequences, which could, in turn, have a material adverse effect on our financial condition or results of operations.

31


ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES
Our world headquarters is located in Marlborough, Massachusetts, with principal regional headquarters located in Singapore and Voisins-le-Bretonneux, France. As of December 31, 2019, our principal manufacturing and technology centers were located in Minnesota, California and Indiana within the U.S., as well as internationally in Ireland, Costa Rica, Puerto Rico, Malaysia, Brazil and Switzerland. Our products are distributed worldwide from primary customer fulfillment centers in Massachusetts, the Netherlands, and Japan. As of December 31, 2019, we maintained 16 principal manufacturing facilities, including seven in the U.S., three in Ireland, two in Costa Rica, one in Puerto Rico, one in Malaysia, one in Brazil and one in Switzerland, as well as various distribution and technology centers around the world. Many of these facilities produce and manufacture products for more than one of our divisions and include research facilities. The following is a summary of our facilities as of December 31, 2019 (in approximate square feet):
 
Owned (1)
 
Leased (2)
 
Total
U.S.
4,072,000

 
1,446,000

 
5,518,000

International
2,258,000

 
1,624,000

 
3,882,000

 
6,330,000

 
3,070,000

 
9,400,000

(1)
Includes our principal manufacturing facilities in Minnesota, Ireland, Puerto Rico and one facility in Costa Rica, our manufacturing facility in Malaysia, our primary customer fulfillment centers in Massachusetts, the Netherlands and Japan, and our global headquarters location in Marlborough, Massachusetts.
(2)
Includes our principal manufacturing facilities in California, Indiana, Brazil, Switzerland and one in Costa Rica, and our regional headquarters located in Singapore and Voisins-le-Bretonneux, France.

ITEM 3. LEGAL PROCEEDINGS
See Note J – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report and incorporated herein by reference.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.


32


PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock is traded on the New York Stock Exchange (NYSE) under the symbol “BSX.”
Holders of Record
As of January 31, 2020, there were 7,331 holders of record of our common stock.
Dividends
We did not pay a cash dividend in 2019, 2018 or 2017 and currently we do not intend to pay cash dividends. We may consider declaring and paying a cash dividend in the future; however, there can be no assurance that we will do so.
Securities Authorized for Issuance under Equity Compensation Plans
Please see Item 12. "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" under Part III of this Annual Report for information on where to find information required by Item 201(d) of Regulation S-K.
Purchases of Equity Securities by the Issuer and Affiliated Purchases
On January 25, 2013, our Board of Directors approved and on January 29, 2013, we announced a program authorizing the repurchase of up to $1.000 billion of our common stock. We made no share repurchases in 2019, 2018 or 2017 and as of December 31, 2019, we had approximately $535 million remaining available under the 2013 share repurchase program . Refer to Note K – Stockholders' Equity to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional information.

33

Stock Performance Graph
The graph below compares the five-year total return to stockholders on our common stock with the return of the Standard & Poor’s (S&P) 500 Stock Index and the S&P Healthcare Equipment Index. The graph assumes $100 was invested in our common stock and in each of the named indices on December 31, 2014 and that any dividends were reinvested.
totalreturngraph2019.jpg
Note: The stock price performance shown on the graph above is not indicative of future price performance. This graph shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.

34

ITEM 6. SELECTED FINANCIAL DATA
FIVE-YEAR SELECTED FINANCIAL DATA
(in millions, except per share data)
Operating Data
Year Ended December 31,
2019
 
2018
 
2017
 
2016
 
2015
Net sales
$
10,735

 
$
9,823

 
$
9,048

 
$
8,386

 
$
7,477

Gross profit
7,620

 
7,011

 
6,455

 
5,962

 
5,304

Total operating expenses
6,102

 
5,504

 
5,170

 
5,515

 
5,587

Operating income (loss)
1,518

 
1,506

 
1,285

 
447

 
(283
)
Income (loss) before income taxes
687

 
1,422

 
933

 
177

 
(650
)
Net income (loss)
4,700

 
1,671

 
104

 
347

 
(239
)
Net income (loss) per common share:
 
 
 
 
 
 
 
 
 
Basic
$
3.38

 
$
1.21

 
$
0.08

 
$
0.26

 
$
(0.18
)
Assuming dilution
$
3.33

 
$
1.19

 
$
0.08

 
$
0.25

 
$
(0.18
)
Balance Sheet Data
As of December 31,
2019
 
2018
 
2017
 
2016
 
2015
Cash, cash equivalents and marketable securities
$
217

 
$
146

 
$
188

 
$
196

 
$
319

Working capital (deficit)
(168
)
 
(1,257
)
 
(1,832
)
 
(348
)
 
1,041

Total assets
30,565

 
20,999

 
19,042

 
18,096

 
18,133

Borrowings (short-term)
1,416

 
2,253

 
1,801

 
64

 
3

Borrowings (long-term)
8,592

 
4,803

 
3,815

 
5,420

 
5,674

Stockholders’ equity
13,877

 
8,726

 
7,012

 
6,733

 
6,320

Book value per common share †
$
9.95

 
$
6.30

 
$
5.11

 
$
4.94

 
$
4.69

†
Book value per common share is calculated using shares outstanding as of December 31, for each year, respectively shown.

The data above should be read in conjunction with our consolidated financial statements, including the notes thereto, included in Item 8. Financial Statements and Supplementary Data of our Annual Report on Form 10-K.

35

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Boston Scientific Corporation and its subsidiaries. For a full understanding of our financial condition and results of operations, this discussion should be read in conjunction with our consolidated financial statements and accompanying notes included in Item 8. Financial Statements and Supplementary Data of this Annual Report.
For additional information on our financial condition and results of operations for 2017, refer to our Annual Report on Form 10-K for the year ended December 31, 2018.
During the third quarter of 2019, we completed the acquisition of BTG plc (BTG) which was composed of three key businesses, the largest of which was its interventional medicine (Interventional Medicine) that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. Following the closing of the acquisition, the Interventional Medicine business was integrated into our Peripheral Interventions division. For additional information, refer to Note B – Acquisitions and Strategic Investments.
Executive Summary
Financial Highlights and Trends

In 2019, we generated net sales of $10.735 billion, as compared to $9.823 billion in 2018. This increase of $912 million, or 9.3 percent, included operational growth of 11.1 percent and the negative impact of 180 basis points from foreign currency fluctuations. Operational net sales1 included $378 million in 2019 due to the acquisitions of NxThera, Inc. (NxThera) in the second quarter of 2018, Claret Medical, Inc. (Claret) in the third quarter of 2018, Augmenix, Inc. (Augmenix) in the fourth quarter of 2018, Vertiflex, Inc. (Vertiflex) in the second quarter of 2019, and BTG in the third quarter of 2019, each with less than a full year of prior period related net sales. Refer to the Business and Market Overview section for further discussion of our net sales by global business.  

Our reported net income in 2019 was $4.700 billion, or $3.33 per diluted share. Our reported results for 2019 included certain charges and/or credits totaling $2.466 billion (after-tax), or $1.75 per diluted share. These adjustments are excluded from results reviewed by management in order to analyze the underlying trends in our business, assess our performance period over period, and make operating decisions. Excluding these items, adjusted net income1 for 2019 was $2.234 billion, or $1.58 per diluted share.

Our reported net income in 2018 was $1.671 billion, or $1.19 per diluted share. Our reported results for 2018 included certain charges and/or credits totaling $389 million (after-tax), or $0.28 per diluted share. Excluding these items, adjusted net income for 2018 was $2.060 billion, or $1.47 per diluted share.









1 Operational net sales growth rates, which exclude the impact of foreign currency fluctuations and adjusted net income and adjusted net income per share, which exclude certain items required by generally accepted accounting principles in the United States (U.S. GAAP), are not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.

36

The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Results of Operations for a discussion of each reconciling item:
 
Year Ended December 31, 2019
(in millions, except per share data)
Net Income (Loss)
 
Impact per Share
GAAP net income (loss)
$
4,700

 
$
3.33

Non-GAAP adjustments:
 
 
 
Amortization expense
628

 
0.44

Intangible asset impairment charges
102

 
0.07

Acquisition/divestiture-related net charges (credits)
672

 
0.48

Restructuring and restructuring-related net charges (credits)
68

 
0.05

Litigation-related net charges (credits)
72

 
0.05

Investment impairment charges
3

 
0.00

EU MDR implementation charges
5

 
0.00

Debt extinguishment net charges (credits)
67

 
0.05

Deferred tax expenses (benefits)
(4,102
)
 
(2.91
)
Discrete tax items
18

 
0.01

Adjusted net income
$
2,234

 
$
1.58


 
Year Ended December 31, 2018
(in millions, except per share data)
Net Income (Loss)
 
Impact per Share
GAAP net income (loss)
$
1,671

 
$
1.19

Non-GAAP adjustments:
 
 
 
Amortization expense
520

 
0.37

Intangible asset impairment charges
31

 
0.02

Acquisition-related net charges (credits)
5

 
0.00

Restructuring and restructuring-related net charges (credits)
77

 
0.05

Litigation-related net charges (credits)
79

 
0.06

Investment impairment charges
6

 
0.00

Discrete tax items
(328
)
 
(0.23
)
Adjusted net income
$
2,060

 
$
1.47


Cash provided by operating activities was $1.836 billion in 2019. As of December 31, 2019, we had total debt of $10.008 billion, Cash and cash equivalents of $217 million and a working capital deficit of $168 million. Refer to Liquidity and Capital Resources for further information.

37

Business and Market Overview

The following section describes an overview of our product offerings and results of operations by business unit. For additional information on our businesses and their product offerings, see Item 1. Business of this Annual Report.

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG, which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less invasive technologies.

Our net sales of Endoscopy products of $1.894 billion represented 18 percent of our consolidated net sales in 2019. Our Endoscopy net sales increased $132 million, or 7.5 percent, in 2019, as compared to 2018. This increase included operational net sales growth of 9.2 percent and the negative impact of 170 basis points from foreign currency fluctuations, as compared to 2018. This year-over-year increase was primarily driven by growth in our pancreaticobiliary franchise with both our SpyGlass™ DS II Direct Visualization System, AXIOS™ Stent and Electrocautery Enhanced Delivery System, our core GI franchise featuring our Resolution 360™ Clip, disposable snares and Endoluminal Surgery products, and our infection prevention products.

Urology and Pelvic Health

Our Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies.

Our net sales of Urology and Pelvic Health products of $1.413 billion represented 13 percent of our consolidated net sales in 2019. Urology and Pelvic Health net sales increased $167 million, or 13.4 percent, in 2019, as compared to 2018. This increase included operational net sales growth of 14.7 percent and the negative impact of 130 basis points from foreign currency fluctuations, as compared to 2018. This year-over-year increase was primarily attributable to growth in sales of our prostate health product family, including the SpaceOAR™ Hydrogel System purchased as part of the acquisition of Augmenix in the fourth quarter of 2018 and the Rezûm™ System purchased as part of the acquisition of NxThera in the second quarter of 2018, as well as our stone franchise, including our LithoVue™ Digital Flexible Ureteroscope.

Rhythm and Neuro

Cardiac Rhythm Management

Our Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Our net sales of CRM products of $1.939 billion represented 18 percent of our consolidated net sales in 2019. Our net sales of CRM products decreased $12 million, or 0.6 percent, in 2019, as compared to 2018. This decrease included operational net sales growth of 1.2 percent and the negative impact of 180 basis points from foreign currency fluctuations, as compared to 2018. This year-over-year increase in operational net sales was driven by share gains in our high voltage franchise. Our high voltage performance was driven by the strength of our broad high voltage portfolio including the RESONATE™ family of cardiac resynchronization therapy defibrillator (CRT-D) and implantable cardiac defibrillator's (ICD) with HeartLogic™, our EMBLEM™ magnetic resonance imaging (MRI) subcutaneous implantable cardiac defibrillator (S-ICD), and high voltage replacement device growth. This strength in our high voltage pacemaker franchise was partially offset by declines in our low voltage pacemaker franchise primarily due to U.S. pacemaker share loss.

Electrophysiology

Our Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.


38

Our net sales of Electrophysiology products of $329 million represented three percent of our consolidated net sales in 2019. Our Electrophysiology net sales increased $17 million, or 5.5 percent, in 2019, as compared to 2018. This increase included operational net sales growth of 7.5 percent and the negative impact of 200 basis points from foreign currency fluctuations, as compared to 2018. This year-over-year increase was primarily driven by strong growth across our global Rhythmia™ Mapping and Navigation Products, partially offset by declines in our core diagnostic and therapeutic devices due to relatively slower end markets and share loss in select product categories. Our Rhythmia Mapping System and navigation portfolio growth was driven by the continued account expansion of our global system footprint and commercialization of our IntellaNav MiFi™ Open-Irrigated catheter and DIRECTSENSE™ Software in approved markets.

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain.

Our net sales of Neuromodulation products of $873 million represented eight percent of our consolidated net sales in 2019. Neuromodulation net sales increased $94 million, or 12.0 percent, in 2019, as compared to 2018. This increase included operational net sales growth of 13.1 percent and the negative impact of 110 basis points from foreign currency fluctuations, as compared to 2018. This year-over-year increase was primarily driven by strong performance of our deep brain stimulation (DBS) systems, sales of our Superion™ Indirect Decompression System following the acquisition of Vertiflex in the second quarter of 2019, and sales in international markets; partially offset by declines in our U.S. Spinal Cord Stimulator (SCS) Systems portfolio due to market contraction.

Cardiovascular

Interventional Cardiology

Our Interventional Cardiology business develops, manufactures and commercializes technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions.

Our net sales of Interventional Cardiology products of $2.816 billion represented 26 percent of our consolidated net sales in 2019. Our Interventional Cardiology net sales increased $226 million, or 8.7 percent, in 2019, as compared to 2018. This increase included operational net sales growth of 11.0 percent and the negative impact of 230 basis points from foreign currency fluctuations, as compared to 2018. This year-over-year increase was primarily related to growth in our structural heart therapies including our Watchman™ LAAC Device, our TAVR products including our ACURATE™ Neo Valve outside the U.S. and LOTUS™ Edge Valve as well as our Sentinel™ Cerebral Embolic Protection System. Our year-over-year sales increase was also attributable to our Complex PCI and PCI Guidance product offerings, partially offset by declines in sales of drug eluting stent product offerings.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer. In the third quarter of 2019, we completed the acquisition of BTG, and began integrating BTG's Interventional Medicine (IM) portfolio into the Peripheral Interventions division, adding complementary technologies in the areas of venous disease and interventional oncology.

Our net sales of Peripheral Interventions products of $1.392 billion represented 13 percent of our consolidated net sales in 2019, and included $144 million of sales from BTG products following the date of acquisition. Our Peripheral Interventions net sales increased $205 million, or 17.3 percent, in 2019, as compared to 2018, and $61 million or 5.1 percent excluding BTG. This increase included operational net sales growth of 19.1 percent (7.8 percent excluding BTG and the related divestiture of our drug-eluting and bland embolic microsphere portfolio) and the negative impact of 180 basis points from foreign currency fluctuations, as compared to 2018. This year-over-year increase was primarily driven by global growth of the Eluvia™ Drug Eluting Vascular Stent System, which was launched in the U.S. in the fourth quarter of 2018 and Japan in the first quarter of 2019.


39

Specialty Pharmaceuticals

Following the closing of the BTG acquisition in the third quarter of 2019, Specialty Pharmaceuticals was added as an eighth operating segment. Our Specialty Pharmaceuticals business develops and manufactures acute care antidotes to treat overexposure to certain medications and toxins. These products are sold primarily in the U.S. through small, specialist sales teams and through commercial partners elsewhere, where approved or permitted, on a named patient basis.

Our net sales of Specialty Pharmaceuticals products of $81 million following the date of acquisition represented less than one percent of our consolidated net sales in 2019.

Emerging Markets

As part of our strategic imperatives to drive global expansion, described in Item 1. Business of this Annual Report, we are seeking to grow net sales and market share by expanding our global presence, including in Emerging Markets. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. We have increased our investment in infrastructure in these countries in order to maximize opportunities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. The revision had an immaterial impact on prior year Emerging Markets sales. Our Emerging Markets net sales of Medical Devices represented 12 percent of our consolidated net sales in 2019 and 11 percent in 2018. In 2019, our Emerging Markets net sales grew 14.1 percent on a reported basis including operational net sales growth of 19.5 percent and the negative impact of 540 basis points from foreign currency fluctuations, as compared to 2018. Our future net sales in Emerging Markets may be negatively impacted by geopolitical and economic instability and a number of other factors, including the impact to our net sales in China from the evolving coronavirus situation.

40


Results of Operations
Net Sales
The following table provides our net sales by business and the relative change in growth on a reported basis:
 
Year Ended December 31,
 
2019 versus 2018
 
2018 versus 2017
(in millions)
2019
 
2018
 
2017
 
 
Endoscopy
$
1,894

 
$
1,762

 
$
1,619

 
7.5%
 
8.8%
Urology and Pelvic Health
1,413

 
1,245

 
1,124

 
13.4%
 
10.8%
MedSurg
3,307

 
3,007

 
2,742

 
10.0%
 
9.7%
Cardiac Rhythm Management
1,939

 
1,951

 
1,895

 
(0.6)%
 
2.9%
Electrophysiology
329

 
311

 
278

 
5.5%
 
12.1%
Neuromodulation
873

 
779

 
635

 
12.0%
 
22.7%
Rhythm and Neuro
3,140

 
3,041

 
2,808

 
3.3%
 
8.3%
Interventional Cardiology
2,816

 
2,590

 
2,419

 
8.7%
 
7.1%
Peripheral Interventions
1,392

 
1,187

 
1,081

 
17.3%
 
9.8%
Cardiovascular
4,208

 
3,777

 
3,500

 
11.4%
 
7.9%
Medical Devices(1)
10,654

 
9,823

 
9,048

 
8.5%
 
8.6%
Specialty Pharmaceuticals
81

 
n/a

 
n/a

 
n/a
 
n/a
Net Sales
$
10,735

 
$
9,823

 
$
9,048

 
9.3%
 
8.6%
(1)
We have three historical reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices). As part of our acquisition of BTG on August 19, 2019, we acquired an Interventional Medicine business, which is now included in our Peripheral Interventions operating segment's 2019 revenues from the date of acquisition.

Refer to Executive Summary for further discussion of our net sales and a comparison of our 2019 and 2018 net sales.

In 2018, we generated net sales of $9.823 billion, as compared to $9.048 billion in 2017. This increase of $775 million, or 8.6 percent, included operational growth of 8.0 percent and the positive impact of 60 basis points from foreign currency fluctuations. Operational net sales included approximately $78 million in 2018 due to the acquisitions of Symetis SA (Symetis) in the second quarter of 2017, NxThera, Inc. (NxThera) in the second quarter of 2018, Claret Medical, Inc. (Claret) in the third quarter of 2018 and Augmenix, Inc. (Augmenix) in the fourth quarter of 2018, each with no prior period related net sales.







41

Gross Profit
Our gross profit was $7.620 billion in 2019 and $7.011 billion in 2018. As a percentage of net sales, our gross profit decreased to 71.0 percent in 2019, as compared to 71.4 percent in 2018. The following is a rollforward of our gross profit margins and a description of the drivers of the change from period to period:
 
Gross Profit Margin
Year Ended December 31, 2017
71.3%
Manufacturing cost reductions
0.8%
Sales pricing and mix
(0.2)%
Inventory step-up due to acquisition accounting
(0.1)%
Net impact of foreign currency fluctuations
(0.8)%
All other, including other inventory charges and other period expense
0.4%
Year Ended December 31, 2018
71.4%
Manufacturing cost reductions
0.8%
Sales pricing and mix
(0.6)%
Inventory step-up due to acquisition accounting
(0.4)%
Net impact of foreign currency fluctuations
0.7%
All other, including other inventory charges and other period expense
(0.8)%
Year Ended December 31, 2019
71.0%

The primary factors contributing to the decrease in our gross profit margin for 2019 as compared to 2018 were the negative impacts of pricing declines related primarily to sales of our coronary drug-eluting stent products, as well as increased levels of scrap associated with recently launched products and excess and obsolete inventory. In addition, in connection with our recent acquisitions, we adjusted acquired inventory from manufacturing cost to fair value. The step-up in value is amortized through gross profit over an average estimated inventory turnover period. In 2019, we recorded increased cost of $46 million associated with these step-ups. This was partially offset by manufacturing cost reductions driven by our process improvement programs as well as favorable foreign currency fluctuations.

The primary factors contributing to the increase in our gross profit margin for 2018 as compared to 2017 were the positive impacts of cost reductions resulting from our process improvement programs and restructuring programs and favorable period expense, partially offset by negative impacts from foreign currency fluctuations.

EU MDR Implementation Charges

The European Union Medical Device Regulation (EU MDR) is a replacement of the existing European Medical Devices Directive (MDD) regulatory framework, and manufacturers of medical devices are required to comply with EU MDR beginning in May 2020 for new product registrations and by May 2024 for medical devices which have a valid CE Certificate to the current Directives (issued before May 2020).

We consider the adoption of EU MDR to be a significant change to a regulatory framework, and therefore, the incremental costs specific to complying with EU MDR for previously registered products are not considered to be ordinary course expenditures in connection with regulatory matters. As such, these medical device regulation charges are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance. We expect to incur expenditures of approximately $150 million over the next three years associated with the implementation of EU MDR, which will be recorded primarily within Cost of products sold.


42

Operating Expenses
The following table provides a summary of certain of our operating expenses:
 
Year Ended December 31,
 
2019
 
2018
 
2017
(in millions)
$
% of Net Sales
 
$
% of Net Sales
 
$
% of Net Sales
Selling, general and administrative expenses
$
3,941

36.7
%
 
$
3,569

36.3
%
 
$
3,294

36.4
%
Research and development expenses
1,174

10.9
%
 
1,113

11.3
%
 
997

11.0
%
Royalty expense
65

0.6
%
 
70

0.7
%
 
68

0.8
%

Selling, General and Administrative (SG&A) Expenses

In 2019, our SG&A expenses increased $371 million, or 10 percent, as compared to 2018 and were 40 basis points higher as a percentage of net sales. This increase in SG&A expenses as a percentage of net sales was primarily due to acquisition-related charges primarily associated with our acquisition and integration of BTG, partially offset by savings from ongoing cost optimization initiatives. These increased SG&A expenses were also partially offset by a $25 million net gain recorded in the first quarter primarily associated with a portion of the Edwards litigation settlement. For further details regarding the presentation of the Edwards litigation settlement see Litigation-related net charges (credits) below.

In 2018, our SG&A expenses increased $275 million, or eight percent, as compared to 2017 and were 10 basis points lower as a percentage of net sales. This decrease in SG&A expenses as a percentage of net sales was primarily due to leverage from increased sales, as well as the benefit of our targeted initiatives focused on reducing SG&A expenses such as end-to-end business process streamlining and automation, including functional expansion of global shared service and robotic process utilization.

Research and Development (R&D) Expenses

We remain committed to advancing medical technologies and investing in meaningful research and development projects across our businesses. In 2019, our R&D expenses increased $61 million, or six percent, as compared to 2018, and were 40 basis points lower as a percentage of net sales. In 2018, our R&D expenses increased $116 million, or 12 percent, as compared to 2017, and were 30 basis points higher as a percentage of sales. R&D expenses increased each year as a result of investments across our businesses in order to maintain a pipeline of new products that we believe will contribute to profitable sales growth.

Royalty Expense

In 2019, our Royalty expense decreased $5 million, or seven percent, as compared to 2018 and was 10 basis points lower as a percentage of net sales. The decrease in Royalty expense in 2019, as compared to 2018, relates primarily to contractual reductions in royalty rates associated with certain products.

In 2018, our Royalty expense increased $2 million, or three percent, as compared to 2017 and was 10 basis points lower as a percentage of net sales. The increase in Royalty expense in 2018 as compared to 2017 relates primarily to increased sales partially offset by expired royalties in certain countries.
The following table provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance, refer to Additional Information for a further description of certain operating expenses:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Amortization expense
$
699

 
$
599

 
$
565

Intangible asset impairment charges
105

 
35

 
4

Contingent consideration expense (benefit)
(35
)
 
(21
)
 
(80
)
Restructuring charges (credits)
38

 
36

 
37

Litigation-related net charges (credits)
115

 
103

 
285


43


Amortization Expense

In 2019, our Amortization expense increased $101 million, or 17 percent, as compared to 2018. In 2018, our Amortization expense increased $33 million, or six percent, as compared to 2017. The increases in each period were primarily due to an increase in the balance of amortizable intangible assets as a result of recent acquisitions.

Intangible Asset Impairment Charges

In 2019, our Intangible asset impairment charges were $105 million, primarily associated with technology-related amortizable intangible assets. Refer to Critical Accounting Estimates for a discussion of key assumptions used in our goodwill and intangible asset impairment testing and future events that could have a negative impact on the recoverability of our goodwill and intangible assets.

Contingent Consideration Expense (Benefit)

In 2019, 2018, and 2017, we recorded net benefits related to the change in fair value of our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional details related to our contingent consideration arrangements.

Restructuring Charges (Credits)

In June 2016, our Board of Directors approved, and we committed to a restructuring initiative (the 2016 Restructuring Plan), which was initiated in the second quarter of 2016 and substantially completed in 2019. The 2016 Restructuring Plan resulted in total pre-tax charges of $271 million and approximately $255 million in cash outlays.

In addition, in November 2018, our Board of Directors approved, and we committed to, a new global restructuring program (the 2019 Restructuring Plan). The 2019 Restructuring Plan is expected to result in total pre-tax charges of approximately $200 million to $300 million and approximately $180 million to $280 million of these charges are expected to result in cash outlays. A substantial portion of the savings are being reinvested in strategic growth initiatives. 

Restructuring charges pursuant to these programs were $38 million in 2019, $36 million in 2018, and $37 million in 2017. See Note G – Restructuring-related Activities to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional details on our restructuring plans.

Litigation-related Net Charges (Credits)

In 2019, our litigation-related net charges included a net charge of $223 million in the fourth quarter of 2019, primarily related to litigation with Channel Medsystems, Inc., net charges of $25 million in the third quarter of 2019 and $15 million in the second quarter of 2019, primarily related to transvaginal surgical mesh product liability litigation, and a gain of $148 million recorded in the first quarter of 2019, which represents a portion of the total $180 million one-time settlement payment received from Edwards Lifesciences Corporation (Edwards) in January 2019. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) in our consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within SG&A expenses. As such, a portion of the related gain from the Edwards settlement was recorded in SG&A expenses on our consolidated statements of operations.

In 2018 and 2017, our litigation-related net charges were primarily in connection with transvaginal surgical mesh product liability cases and claims.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants. Refer to Note J – Commitments and Contingencies to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional discussion of our material legal proceedings.

44

Interest Expense
The following table provides a summary of our Interest expense and average borrowing rate:
(in millions)
Year Ended December 31,
2019
 
2018
 
2017
Interest expense
$
(473
)
 
$
(241
)
 
$
(229
)
Weighted average borrowing rate
4.8
%
 
3.6
%
 
3.8
%
Interest expense increased in 2019, as compared to 2018, primarily due to the increase in our average debt balance following the February 2019 senior notes offering as well as the Euro bond offering in November 2019. A portion of the proceeds from the February 2019 senior notes offering were used to finance our acquisition of BTG. The net proceeds from our November 2019 senior notes offering were used to repay certain outstanding principal amounts of our senior notes and pay accrued and unpaid interest, premiums, and fees. In addition, Interest expense in 2019 included debt extinguishment charges following our 2019 senior notes offerings and subsequent repayment of existing senior notes and termination of the Bridge Facility.
Refer to Liquidity and Capital Resources in this Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations and Note D – Hedging Activities and Fair Value Measurements and Note E – Contractual Obligations and Commitments to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report for information regarding our debt obligations.
Other, net
The following are the components of Other, net:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Interest income
$
30

 
$
3

 
$
5

Net foreign currency gain (loss)
(358
)
 
11

 
(15
)
Net gains (losses) on investments
(30
)
 
155

 
(92
)
Other income (expense), net
(1
)
 
(14
)
 
(22
)
 
$
(358
)
 
$
156

 
$
(124
)

Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of our acquisition of BTG. In 2019, we settled all outstanding contracts, and we recognized a $323 million loss in Other, net due to changes in fair value of the contracts. These amounts are included in Acquisition/divestiture-related net charges (credits) presented in the reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Financial Summary for the reconciliation and Additional Information for a discussion of management's use of non-GAAP financial measures.

In 2018, we recorded gains of $184 million based on the difference between the book values and the fair values of our previously-held investments immediately prior to the acquisition dates, which aggregated to $251 million. We remeasured the fair value of each previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. Gains and losses recorded on previously-held investments are excluded by management for purposes of evaluating operating performance. Refer to Note B – Acquisitions and Strategic Investments to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report for information regarding our strategic investments.

45

Tax Rate
The following table provides a summary of our reported tax rate:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Reported tax rate
(584.0
)%
 
(17.5
)%
 
88.8
 %
Impact of certain receipts/charges (1)
594.2
 %
 
30.7
 %
 
(75.8
)%
 
10.2
 %
 
13.2
 %
 
13.0
 %
(1)
These receipts/charges are taxed at different rates than our effective tax rate.

The change in our reported tax rate for 2019, as compared to 2018, relates primarily to the deferred tax benefit of intra-entity transfers of intellectual property rights partially offset by increased current tax expense related to the U.S. taxation of current foreign earnings.

The change in our reported tax rate for 2018, as compared to 2017, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These receipts and charges included intangible asset impairment charges, acquisition-related items, restructuring and restructuring-related items, litigation-related items, as well as certain discrete tax items. Included in the discrete tax items were the effective settlement of our transfer pricing dispute with the Internal Revenue Service (IRS) for the 2001 through 2010 tax years, the conclusion of the IRS examinations of our 2011 through 2013 tax years, and the final impact of the Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017.
`
In the second quarter of 2018, a decision was entered by the U.S. Tax Court resolving all disputes for Guidant Corporation for its 2001 through 2006 tax years and our 2006 and 2007 tax years as well as the tax issues related to our 2006 transaction with Abbott Laboratories. Additionally, we resolved all issues with the IRS Office of Appeals for our 2008 through 2010 tax years. The final settlement calculation resulted in a final net tax payment of $303 million plus $307 million of estimated interest, which was remitted in the second quarter of 2018. Due to the final settlement of these disputes, we recorded a net tax benefit of $250 million in 2018 to remove a reserve related to these years.

In the fourth quarter of 2018, we received a Revenue Agent Report (RAR) from the IRS for our 2011 through 2013 tax years. We remitted $93 million to the IRS in the fourth quarter of 2018 reflecting the net balance of tax and interest due for these years after consideration of amounts owed to us by the IRS. Due to the resolution of these tax years, we recorded a net tax benefit of $90 million to remove a reserve related to these years.

See Note I – Income Taxes to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional details on our tax rate.

Liquidity and Capital Resources

Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, fund possible mergers and/or acquisitions and service and repay our existing debt. Please refer to Contractual Obligations and Commitments below for additional details on our future payment obligations and commitments.

As of December 31, 2019, we had $217 million of unrestricted Cash and cash equivalents on hand, comprised of $50 million invested in money market and government funds and $165 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn at market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer. We also have access to our $2.750 billion commercial paper program, which is backed by our 2018 revolving credit facility entered into on December 19, 2018. As of December 31, 2019, we had $711 million in commercial paper debt outstanding resulting in an additional $2.039 billion of available liquidity.

In the fourth quarter of 2019, we entered into a $700 million term loan credit agreement scheduled to mature on December 3, 2020 (2020 Term Loan). As of December 31, 2019, we had the full amount outstanding under the 2020 Term Loan, which is presented within Current debt obligations on our consolidated balance sheet. In the first quarter of 2020, we repaid $300 million of the outstanding balance of the 2020 Term Loan.


46

For the purpose of funding our acquisition of BTG, in the fourth quarter of 2018, we entered into a $1.000 billion two-year delayed draw term loan credit facility, maturing in two years from the date of the closing of our acquisition of BTG (Two-Year Delayed Draw Term Loan) and a $1.000 billion three-year delayed draw term loan credit facility, maturing in three years from the date of the closing of our acquisition of BTG (Three-Year Delayed Draw Term Loan). In 2019, we used the proceeds from the Two-Year and Three-Year Delayed Draw Term Loan facilities to refinance the Bridge Facility, as described below, and fund a portion of our acquisition of BTG. In the fourth quarter of 2019, we repaid $200 million of the Two-Year Delayed Draw Term Loan with proceeds from the sale of the Zytiga-related royalty interests obtained through the acquisition of BTG and extinguished the facility, and we repaid the remaining $800 million of the $1.000 billion with proceeds from the 2020 Term Loan and commercial paper and terminated the Two-Year Delayed Draw Term Loan. As of December 31, 2018, we had no amounts borrowed under the Two-Year Delayed Draw Term Loan or the Three-Year Delayed Draw Term Loan. As of December 31, 2019, we had $1.000 billion outstanding under the Three-Year Delayed Draw Term Loan, which is presented within Long-term debt on our condensed consolidated balance sheet.

In the fourth quarter of 2019, we completed an offering of €900 million in aggregate principal amount of 0.625% senior notes due in 2027. The Euro-denominated debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional entities. We used a portion of the net proceeds from our senior notes offering to repay certain outstanding principal amounts of our senior notes including $206 million of our $450 million 4.125% senior notes due 2023, $566 million of our $1.000 billion 4.000% senior notes due 2028 and $227 million of our $750 million 3.850% senior notes due 2025 and pay accrued and unpaid interest, premiums, fees and expenses in connection with the transaction.

In the first quarter of 2019, we completed an offering of $4.300 billion in aggregate principal amount of senior notes. We used a portion of the net proceeds from the offering to repay the $850 million plus accrued interest and premium of our 6.000% senior notes due in January 2020 (January 2020 Notes), the $600 million plus accrued interest and premium of our 2.850% senior notes due in May 2020 (May 2020 Notes) and the $1.000 billion plus accrued interest of our August 2019 Term Loan. In 2019, the remaining proceeds were used to finance a portion of our acquisition of BTG.

In the first quarter of 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described above, we terminated the Bridge Facility entered into on November 20, 2018. The termination was pursuant to the terms of the Bridge Facility, which required full termination upon the refinancing of the January 2020 Notes and May 2020 Notes discussed above. There were no amounts borrowed under the Bridge Facility as of December 31, 2018.

For additional information on our credit facilities, refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report.

47

The following provides a summary and description of our net cash inflows (outflows) and adjusted free cash flow:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Cash provided by (used for) operating activities
$
1,836

 
$
310

 
$
1,426

Cash provided by (used for) investing activities
(5,041
)
 
(1,921
)
 
(1,010
)
Cash provided by (used for) financing activities
2,973

 
1,432

 
110

 
 
 
 
 
 
Cash provided by (used for) operating activities
$
1,836


$
310


$
1,426

Less: Purchases of property, plant and equipment
461

 
316

 
319

Add: Proceed on disposals of property, plant and equipment
7

 
14

 
—

Free cash flow
1,382


8


1,107

Add: Restructuring and restructuring-related payments
66

 
89

 
72

Add: Acquisitions-related payments
266

 
205

 
95

Add: EU MDR payments
4

 
—

 
—

Add: Certain discrete tax payments (refunds/credits)
(42
)
 
977

 
(239
)
Add: Litigation-related settlements
330

 
791

 
694

Adjusted free cash flow2
$
2,007


$
2,070


$
1,729

Operating Activities
In 2019, cash provided by operating activities increased $1.526 billion, as compared to 2018. This increase was primarily due to the one-time settlement payment of $180 million that we received from Edwards Lifesciences Corporation in January 2019, comparatively fewer litigation payments in 2019 primarily associated with product liability cases or claims related to transvaginal surgical mesh products and the IRS final net tax settlement payments of $303 million plus $307 million of estimated interest that we remitted in the second quarter of 2018 and $93 million reflecting the net balance of tax and interest due in the fourth quarter of 2018.
In 2018, cash provided by operating activities decreased $1.116 billion, or 78 percent, as compared to 2017. This decrease was primarily due to the IRS tax settlement payments in 2018 described above.
Investing Activities
In 2019, cash used for investing activities primarily included Payments for acquisitions of businesses, net of cash acquired of $4.382 billion relating to our acquisitions of BTG, Vertiflex and Millipede, Inc. (Millipede), Purchases of property, plant and equipment of $461 million, Payments for investments and acquisitions of certain technologies of $149 million, partially offset by Proceeds from divestiture of certain businesses of $90 million relating to the sale of our drug-eluting and bland embolic microsphere portfolio to Varian Medical Systems, Inc. (Varian) in connection with our acquisition of BTG. Cash used for investing activities also included Payments for settlements of hedge contracts of $199 million, of which $95 million relates to the termination and settlement of our outstanding forward currency contracts designated as net investment hedges in our Euro-denominated entities and $294 million relates to the settlement of our non-designated forward currency contracts entered into for the purpose of managing our exposure to currency exchange rate risk related to the GBP-denominated purchase price of BTG. Refer to Note D – Hedging Activities and Fair Value Measurements consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for further information.
In 2018, cash used for investing activities primarily included Payments for acquisitions of businesses, net of cash acquired of $1.448 billion primarily relating to our acquisitions of Augmenix, NxThera, Cryterion Medical, Inc., Claret and nVision, Purchases of property, plant and equipment of $316 million and Payments for investments and acquisitions of certain technologies of $172 million, including our $90 million investment in Millipede in the first quarter of 2018.


2Adjusted free cash flow, which excludes certain items required by U.S. GAAP is not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of non-GAAP financial measures.

48

Financing Activities
Our cash flows provided by financing activities reflect issuances and repayments of debt, including our commercial paper program and cash used for new share settlement and stock issuances related to our equity incentive programs, as discussed in Note K – Stockholders' Equity to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report. In addition, our financing activities included Payments of contingent consideration and royalty rights established in purchase accounting of $135 million in 2019, $19 million in 2018 and $33 million in 2017. In connection with the acquisition of BTG, we acquired rights to future royalties associated with the Zytiga™ drug used to treat certain forms of prostate cancer. In the fourth quarter of 2019, we sold our rights to these royalties for $256 million in cash, included in Proceeds from royalty rights transfer.
Our liquidity plans are subject to a number of risks and uncertainties, including those described in Item 1A. Risk Factors of this Annual Report, some of which are outside our control. Macroeconomic conditions, adverse litigation outcomes and other risks and uncertainties could limit our ability to successfully execute our business plans and adversely affect our liquidity plans.

Debt

The following table presents the current and long-term portions of our total debt:
 
As of
(in millions)
December 31, 2019
 
December 31, 2018
Current debt obligations
$
1,416

 
$
2,253

Long-term debt
8,592

 
4,803

Total debt
$
10,008

 
$
7,056


The following table presents the portions of our total debt that are comprised of fixed and variable rate debt instruments, which are presented on an amortized cost basis:
 
As of
(in millions)
December 31, 2019
 
December 31, 2018
Fixed-rate debt instruments
$
7,587

 
$
4,797

Variable rate debt instruments
2,421

 
2,259

Total debt
$
10,008

 
$
7,056


As of and through December 31, 2019, we were in compliance with all the required covenants related to our debt obligations. For additional details related to our debt obligations, including our debt covenant requirements, refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report.

Equity
During 2019 we received $123 million in proceeds from stock issuances related to our stock option and employee stock purchase plans, as compared to $101 million in 2018. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of employees.
We did not repurchase any shares of our common stock during 2019 or 2018. As of December 31, 2019, we had remaining approximately $535 million authorized under our 2013 share repurchase program. There were approximately 248 million shares in treasury as of December 31, 2019 and December 31, 2018.
Stock-based compensation expense related to our stock ownership plans was $157 million in 2019 and $140 million in 2018. Stock-based compensation expense varies from period to period based upon, among other factors, the timing, number and fair value of awards granted during the period, forfeiture levels related to unvested awards and employee contributions to our employee stock purchase plan, as well as the retirement eligibility of stock award recipients.

49

Contractual Obligations and Commitments
The following table provides a summary of certain information concerning our obligations and commitments to make future payments and is based on conditions in existence as of December 31, 2019:
 (in millions)
2020
 
2021
 
2022
 
2023
 
2024
 
Thereafter
 
Total
Debt obligations (1)
$
1,411

 
$
—

 
$
1,500

 
$
244

 
$
850

 
$
6,068

 
$
10,072

Interest payments (2)
343

 
326

 
308

 
280

 
252

 
2,550

 
4,059

Lease obligations (2)
84

 
71

 
59

 
48

 
41

 
79

 
382

Purchase obligations (2)
334

 
20

 
7

 
3

 
1

 
1

 
366

Minimum royalty obligations (2)
3

 
3

 
2

 
2

 
2

 
2

 
15

License and software commitments (2)
4

 
5

 
5

 
3

 
3

 
—

 
20

Legal reserves
470

 
—

 
—

 
—

 
—

 
—

 
470

One-time transition tax
40

 
40

 
40

 
75

 
100

 
125

 
420

 
$
2,689

 
$
465

 
$
1,921

 
$
655

 
$
1,249

 
$
8,825

 
$
15,804

(1)
Debt obligations are comprised of our senior notes, term loan and commercial paper outstanding as of December 31, 2019. This does not include unamortized debt issuance discounts, deferred financing costs and gain on fair value hedges or capital lease obligations. Refer to Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional information. In January 2020, we repaid $300 million of the outstanding balance of the 2020 Term Loan with proceeds from our commercial paper program.
(2)
In accordance with U.S. GAAP, these obligations relate to expenses associated with future periods and are not reflected in our consolidated balance sheets. Interest payments included above are calculated based on rates and required fees applicable to our outstanding debt obligations as of December 31, 2019 described in Note E – Contractual Obligations and Commitments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report. Interest payments above do not include interest on variable rate debt instruments.

The amounts in the table above with respect to purchase obligations relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business. Royalty obligations reported above represent minimum contractual obligations under our current royalty agreements.

The table above does not include:

•
Our long-term liability for legal matters that are probable and estimable of $227 million due to the timing of payment being uncertain. Refer to Note J – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for more information,

•
Unrecognized tax benefits, accrued interest and penalties and other related items totaling $288 million because the timing of their future cash settlement is uncertain and tax payments and interest totaling $5 million related to state obligations of recently settled IRS tax years to be remitted in 2020. Refer to Note I – Income Taxes to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for more information, and

•
With certain of our acquisitions, we acquired IPR&D projects that require future funding to complete the projects. We estimate that the total remaining R&D cost to complete acquired IPR&D projects is between $200 million and $210 million. Net cash inflows from the projects currently in development are expected to commence in 2020 and will continue through 2037, following the respective launches of these technologies in the U.S., Europe and Japan. Certain of our acquisitions also involve the potential payment of contingent consideration, but the timing and amounts are uncertain. See Note B – Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for more information.

Legal Matters

For a discussion of our material legal proceedings see Note J – Commitments and Contingencies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report.


50

Critical Accounting Policies and Estimates
Our financial results are affected by the selection and application of accounting policies and methods. We have adopted accounting policies to prepare our consolidated financial statements in conformity with U.S. GAAP.
To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, including our contingent liabilities, as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting periods. Our actual results may differ from these estimates. We consider estimates to be critical (i) if we are required to make assumptions about material matters that are uncertain at the time of estimation or (ii) if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management’s judgment: Revenue Recognition, Bad Debt Reserves, Inventory Provisions, Valuation of Intangible Assets and Contingent Consideration Liability, Goodwill Valuation, Legal and Product Liability Accruals and Income Taxes.
See Note A – Significant Accounting Policies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional information related to our accounting policies and our consideration of these critical accounting areas. In addition, see Note B – Acquisitions and Strategic Investments and Note C – Goodwill and Other Intangible Assets for further discussion of the valuation of goodwill and intangible assets and contingent consideration, Note I – Income Taxes for further discussion of income tax related matters, Note J – Commitments and Contingencies for further discussion of legal and product liability matters and Note O – Revenue for further discussion of revenue recognition.
Revenue Recognition

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered.

Post Implant Services

We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. Since our modified retrospective adoption of FASB ASC Topic 606, Revenue from Contracts with Customers on January 1, 2018, because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses. We estimate the

51

amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost. Refer to Note A – Significant Accounting Policies and Note O – Revenue to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for further information on our adoption of FASB ASC Topic 606 and our revenue recognition accounting policies.
Inventory Provisions
We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory.
Valuation of Intangible Assets and Contingent Consideration Liability
We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. Further, for those arrangements that involve potential future contingent consideration, we record on the date of acquisition a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future. We re-measure this liability each reporting period and record changes in the fair value through a separate line item within our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, useful life or probability of achieving clinical, regulatory or revenue-based milestones could result in different purchase price allocations and recognized amortization expense and contingent consideration expense or benefit in current and future periods.
We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or adjustment to the remaining useful life. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset is determined not recoverable, we will write the carrying value down to fair value in the period identified. We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset using a risk-adjusted discount rate. The use of alternative assumptions, including estimated cash flows, discount rates and alternative estimated remaining useful lives could result in different calculations of impairment.
In addition, we test our indefinite-lived intangible assets at least annually for impairment and reassess their classification as indefinite-lived assets, or more frequently if indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other (FASB ASC Topic 350). If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to fair value. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows and discount rates could result in different fair value estimates.

Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances during the second quarter of each year for impairment, or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2019, 2018 and 2017 annual impairment assessments, we identified the following reporting units: Interventional Cardiology, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health and Neuromodulation. In addition, following the BTG acquisition in 2019, Specialty Pharmaceuticals was added as an additional reporting unit. We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based on the criteria prescribed in FASB ASC Topic 350.


52

Refer to Note A – Significant Accounting Policies to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional details related to our annual goodwill impairment assessments performed in 2019, 2018 and 2017.

Although we use consistent methodologies in developing the assumptions and estimates underlying the fair value calculations used in our impairment tests, these estimates are uncertain by nature and can vary from actual results. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows and discount rates could result in different fair value estimates.

Future events that could have a negative impact on the levels of excess fair value over carrying value of our reporting units include, but are not limited to, the following:

•
decreases in estimated market sizes or market growth rates due to greater-than-expected declines in procedural volumes, pricing pressures, reductions in reimbursement levels, product actions and/or competitive technology developments,

•
declines in our market share and penetration assumptions due to increased competition, an inability to develop or launch new and next-generation products and technology features in line with our commercialization strategies and market and/or regulatory conditions that may cause significant launch delays or product recalls,

•
decreases in our forecasted profitability due to an inability to implement successfully and achieve timely and sustainable cost improvement measures consistent with our expectations,

•
negative developments in intellectual property litigation that may impact our ability to market certain products or increase our costs to sell certain products,

•
the level of success of ongoing and future research and development efforts, including those related to recent acquisitions and increases in the research and development costs necessary to obtain regulatory approvals and launch new products,

•
the level of success in managing the growth of acquired companies, achieving sustained profitability consistent with our expectations, establishing government and third-party payer reimbursement, supplying the market and increases in the costs and time necessary to integrate acquired businesses into our operations successfully,

•
changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses and

•
increases in our market-participant risk-adjusted weighted average cost of capital (WACC) and increases in our market-participant tax rate and/or changes in tax laws or macroeconomic conditions.

Negative changes in one or more of these factors, among others, could result in future impairment charges.

Refer to Note C – Goodwill and Other Intangible Assets to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional details related to our annual goodwill balances.

Legal and Product Liability Accruals

In the normal course of business, we are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. Litigation and product liability matters are inherently uncertain, and the outcomes of individual matters are difficult to predict and quantify. As such, significant judgment is required in determining our legal and product liability accruals. Our estimates related to our legal and product liability accruals may change as additional information becomes available to us, including information related to the nature or existence of claims against us, trial court or appellate proceedings, and mediation, arbitration or settlement proceedings.


53

Income Taxes

We establish reserves when we believe that certain positions are likely to be challenged despite our belief that our tax return positions are fully supportable. The calculation of our tax liabilities involves significant judgment based on individual facts, circumstances and information available in addition to applying complex tax regulations in various jurisdictions across our global operations. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must determine it is more likely than not the position will be sustained, and the measurement of the benefit is calculated as the largest amount that is more than 50 percent likely to be realized upon resolution of the benefit. Although we believe that we have adequately provided for liabilities resulting from tax assessments by taxing authorities, positions taken by these tax authorities could have a material impact on our effective tax rate, results of operations, financial position and/or cash flows.

As part of the Tax Cut and Jobs Act of 2017, we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and will be reported as a part of continuing operations.

New Accounting Pronouncements
See Note A – Significant Accounting Policies to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional information on standards implemented since December 31, 2018 and Note Q – New Accounting Pronouncements to our consolidated financial statements included in Item 8. Financial Statements and Supplementary Data of this Annual Report for additional information on standards to be implemented.
Additional Information

Cybersecurity

We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues are analyzed by subject matter experts and a crisis committee for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of impact. Matters determined to present potential material impacts to the Company’s financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our escalation framework. In addition, we have established procedures to ensure that members of management responsible for overseeing the effectiveness of disclosure controls are informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made, as appropriate. 
Use of Non-GAAP Financial Measures

To supplement our consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (earnings) and adjusted net income (earnings) per share that exclude certain amounts, operational net sales growth that exclude the impact of foreign currency fluctuations and adjusted free cash flow that excludes certain amounts. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (earnings) and adjusted net income (earnings) per share we exclude certain charges (credits) from GAAP net income as detailed below. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB ASC section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." The GAAP financial measure most directly comparable to adjusted net income is GAAP net income (loss) and the GAAP financial measure most directly comparable to adjusted net income per share is GAAP net income (loss) per share.

To calculate operational net sales, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. The GAAP financial measure most directly comparable to operational growth rate percentages is growth rate percentages using net sales on a GAAP basis.


54

Adjusted free cash flow is a non-GAAP measure that excludes from free cash flow the cash component of certain charges (credits) that are also excluded from adjusted net income as well as any cash tax benefits of such charges, as detailed below. In addition, we exclude payments or refunds that relate to resolving tax disputes related to prior periods. Free cash flow is a non-GAAP measure that excludes net purchases of property, plant and equipment from cash provided by (used for) operating activities on a GAAP basis. The GAAP measure that is most directly comparable to adjusted free cash flow and free cash flow is cash provided by (used for) operating activities on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the relevant sections of this Annual Report.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income, adjusted net income per share that exclude certain amounts, operational net sales growth that exclude the impact of changes in foreign currency exchange rates, and adjusted free cash flow that excludes certain amounts, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

The following is an explanation of each of the adjustments that management excluded as part of these non-GAAP financial measures as well as reasons for excluding each of these individual items. In each case, management has excluded the item for purposes of calculating the relevant non-GAAP financial measure to facilitate an evaluation of our current operating performance and a comparison to our past operating performance:

Adjusted Net Income, Adjusted Net Income per Share and Adjusted Free Cash Flow

•
Amortization expense - We record intangible assets at historical cost and amortize them over their estimated useful lives. Amortization expense is excluded from management's assessment of operating performance and is also excluded from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Intangible asset impairment charges - This amount represents write-downs of certain intangible asset balances during each period. We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment and test our indefinite-lived intangible assets at least annually for impairment. If we determine the carrying value of the amortizable intangible asset is not recoverable or we conclude that it is more likely than not that the indefinite-lived asset is impaired, we will write the carrying value down to fair value in the period identified. Impairment charges are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Acquisition/divestiture-related net charges (credits) or payments - These adjustments may consist of (a) contingent consideration and Zytiga™ licensing arrangement fair value adjustments; (b) gains on previously held investments; (c) due diligence, deal fees and other fees and costs related to our acquisition and divestiture transactions; (d) inventory step-up amortization and accelerated compensation expense; (e) integration and exit costs; and (f) separation costs and gains primarily associated with the sale of a business or portion of a business. The contingent consideration and Zytiga licensing arrangement fair value adjustments represent accounting adjustments to state contingent consideration liabilities and Zytiga-related assets and liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration and Zytiga royalty payments. In addition, we have sold our rights to retain any future royalties related to Zytiga. Refer to Note D - Hedging Activities and Fair Value Measurements for further information on the Zytiga licensing arrangement. Gains on previously held investments, due diligence, deal fees and other fees and costs, inventory step-up amortization, accelerated compensation expense, and other expenses and gains associated with prior and potential future acquisitions and divestitures can be highly variable and not representative of ongoing operations. Integration and exit costs, include contract cancellations,

55

severance and other compensation-related charges and costs, project management fees and costs, and other direct costs associated with the integration of our acquisitions. Examples of integration and exit activities include the movement of business activities; the elimination or combination of redundant roles and business processes; the consolidation or closure of facilities and legal entities; and the transfer of product lines between manufacturing facilities. These integration and exit activities take place over a defined timeframe and have a distinct project timelines, are incremental to activities and costs that arise in the ordinary course of our business and are not considered part of our core, ongoing operations. In addition, our acquisition-related charges in 2019 included expenses for instruments entered into solely for the purpose of financing or hedging the BTG Acquisition, including net interest expense and hedging expenses. Subsequent to September 30, 2019, we did not incur and will not incur any hedging gains or losses related to the BTG Acquisition, and we are not classifying any interest expense subsequent to the BTG acquisition date as an acquisition/divestiture-related item. Acquisition/divestiture-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Restructuring and restructuring-related net charges (credits) or payments - These adjustments primarily represent compensation-related charges, fixed asset write-offs, contract cancellations, project management fees and other direct costs associated with our restructuring plans. These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing. Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals. Restructuring initiatives take place over a defined timeframe and have a distinct project timeline that begins subsequent to approval by our Board of Directors. In contrast to our ongoing cost reduction initiatives, restructuring initiatives typically result in duplicative cost and exit costs over this period of time, are one-time shut downs or transfers and are not considered part of our core, ongoing operations. These restructuring plans are incremental to the core activities that arise in the ordinary course of our business. Restructuring and restructuring-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Litigation-related net charges (credits) or payments - These adjustments include certain significant product liability and other litigation-related charges and credits. We record these charges and credits, which we consider to be unusual or infrequent and significant, within the litigation-related charges line in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within selling general and administrative expenses. Litigation-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
EU MDR implementation charges - These adjustments represent incremental costs or payments specific to complying with the new European Union Medical Device Regulation (EU MDR) for previously registered products. EU MDR is a replacement of the existing European Medical Devices Directive (MDD) regulatory framework, and manufacturers of medical devices are required to comply with EU MDR beginning in May 2020 for new product registrations and by May 2024 for medical devices which have a valid CE Certificate to the current Directives (issued before May 2020). We expect to incur significant expenditures in connection with the adoption of the EU MDR requirements and we consider the adoption of EU MDR to be a significant change to a regulatory framework, and therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters. As such, these medical device regulation charges are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Debt extinguishment net charges (credits) - These amounts relate to the early extinguishment of certain outstanding principal amounts of our senior notes in November 2019. Certain debt extinguishment net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Investment impairment charges - These amounts represent write-downs relating to our investment portfolio that are considered unusual or infrequent and significant. Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying

56

value and determine if the impairment is other-than-temporary. For other-than-temporary impairments, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. Certain investment impairment charges are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Deferred tax expenses (benefits) - This adjustment relates to a $4.1 billion non-cash tax benefit arising from an intra-entity asset transfer of intellectual property completed in the fourth quarter of 2019. The effects of this transfer were excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Discrete tax items - These items represent adjustments of certain tax positions including those which a) are related to the finalization of the enactment date impact of the TCJA, or b) are related to the tax consequences of a non-GAAP adjustment item booked in a prior period. These discrete tax items are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

Operational Net Sales Excluding the Impact of Foreign Currency Fluctuations

•
The impact of foreign currency fluctuations is highly variable and difficult to predict. Accordingly, management excludes the impact of foreign currency fluctuations for purposes of reviewing the net sales and growth rates to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

Rule 10b5-1 Trading Plans by Executive Officers

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 Trading Plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of deferred stock units. These plans are entered into at a time when the person is not in possession of material non-public information about our company. We disclose details regarding individual Rule 10b5-1 Trading Plans on the Investor Relations section of our website.


57

Management’s Annual Report on Internal Control over Financial Reporting
As the management of Boston Scientific Corporation, we are responsible for establishing and maintaining adequate internal control over financial reporting. We designed our internal control process to provide reasonable assurance to management and the Board of Directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
We assessed the effectiveness of our internal control over financial reporting as of December 31, 2019. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control–Integrated Framework (2013 framework). Based on our assessment, we believe that, as of December 31, 2019, our internal control over financial reporting is effective at a reasonable assurance level based on these criteria.
Ernst & Young LLP, an independent registered public accounting firm, has issued an audit report on the effectiveness of our internal control over financial reporting. This report, in which they expressed an unqualified opinion, is included below.
The BTG plc Acquisition

On August 19, 2019, we announced the closing of our acquisition of BTG plc (BTG). In accordance with the SEC Staff 's interpretive guidance for newly acquired businesses, we are permitted to omit an assessment of an acquired business's internal control over financial reporting from our assessment of internal control for up to one year from the acquisition date. As such, we have excluded BTG from our annual assessment of internal controls over financial reporting as of December 31, 2019, as the acquisition was completed on August 19, 2019. BTG represents less than 5% of total assets as of December 31, 2019 and less than 5% of revenues and net income, respectively, for the year then ended.

 
 
 
 
 
 
 
 
/s/ Michael F. Mahoney
 
/s/ Daniel J. Brennan
 
 
 
 
 
 
 
 
Michael F. Mahoney
 
 
Daniel J. Brennan
 
 
 
President and Chief Executive Officer
 
 
Executive Vice President and Chief
Financial Officer
 


58


Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Boston Scientific Corporation

Opinion on Internal Control over Financial Reporting

We have audited Boston Scientific Corporation’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Boston Scientific Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2019 consolidated financial statements of the Company and our report dated February 25, 2020 expressed an unqualified opinion thereon.

As indicated in the accompanying Management’s Annual Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of BTG plc, which is included in the 2019 consolidated financial statements of the Company and constituted less than 5% of total assets as of December 31, 2019 and less than 5% of revenues and net income, respectively, for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of BTG plc.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.


59

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP
Boston, Massachusetts
February 25, 2020

60


ITEM 7A.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.

Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $9.221 billion as of December 31, 2019 and $11.326 billion as of December 31, 2018. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $337 million as of December 31, 2019 as compared to $181 million as of December 31, 2018. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $412 million as of December 31, 2019 as compared to $222 million as of December 31, 2018. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impact on our consolidated statements of operations.

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had interest rate derivative instruments outstanding in the contract amount of $1.000 billion as of December 31, 2018 and none as of December 31, 2019. As of December 31, 2019, $7.661 billion of our outstanding debt obligations was at fixed interest rates, representing approximately 76 percent of our total debt. As of December 31, 2019, our outstanding debt obligations at fixed interest rates were comprised of senior notes.

See Note D – Hedging Activities and Fair Value Measurements to our consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data of this Annual Report for further information regarding our derivative financial instruments.

61


Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Boston Scientific Corporation

Opinion on the Financial Statements
    
We have audited the accompanying consolidated balance sheets of Boston Scientific Corporation (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), stockholders' equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 25, 2020 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters  

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.



62

 
Business Combinations
Description of the Matter
As disclosed in Note B to the consolidated financial statements, during 2019, the Company completed three acquisitions for total aggregate consideration of $4.38 billion, net of cash acquired. The most significant of these was the acquisition of all outstanding equity of BTG, plc. for consideration of approximately $3.62 billion, net of cash acquired. The transactions were accounted for as business combinations. In certain acquisitions, the Company has recognized a liability for acquisition consideration that is contingent upon achieving either research and development and commercialization milestones, or sales-based milestones. The Company determines the fair value of these arrangements, both as part of the initial purchase price allocation, and on an ongoing basis each reporting period until the arrangements are settled. As of December 31, 2019, the amount accrued for future estimated contingent consideration is $354 million.

Auditing the Company’s accounting for its acquisitions was complex due to the significant estimation required by management to determine the fair value of identified intangible assets, which totaled $2.2 billion and principally consisted of developed technology and assets related to currently marketed products, and to determine the fair value of contingent consideration arrangements. A significant emphasis is placed on the appropriateness of the estimate considerations used by management to determine the fair value of acquired intangible assets due to the sensitivity of the respective fair values to the underlying assumptions. The Company used an income approach to measure the technology-related intangible assets. The significant assumptions used to estimate the value of the intangible assets included discount rates and certain assumptions that form the basis of the forecasted results, including revenue growth rates, estimates of technological obsolescence, operating profit margin and market participant synergies. The significance of the estimations used by management to determine the fair value of contingent consideration was primarily due to the sensitivity of the respective fair values to the significant underlying assumptions. The significant assumptions include estimation of the probability and timing of payment, future sales forecasts, as well as the appropriate discount rate based on the estimated timing of payments. These significant assumptions are forward looking and could be affected by future economic and market conditions.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the Company’s accounting for acquisitions. For example, we tested controls over the identification and valuation of intangible assets, including the valuation models and underlying assumptions used to develop such estimates. We also tested controls over the valuation of the contingent consideration liability, including the valuation models and underlying assumptions used to develop such estimates.
For each of the Company's acquisitions, we read the purchase agreements, evaluated the significant assumptions and methods used in developing the fair value estimates, and tested the recognition of (1) the tangible assets acquired and liabilities assumed at fair value; (2) the identifiable intangible assets acquired at fair value; and (3) goodwill measured as a residual.
To test the estimated fair value of the intangible assets, we performed audit procedures that included, among others, evaluating the Company's use of the income approach and testing the significant assumptions used in the model, as described above. In testing the valuation of contingent consideration, we assessed, among other things, the terms of the arrangements and the conditions that must be met for the arrangements to become payable. We evaluated the completeness and accuracy of the underlying data used in the analyses. For example, we compared the significant assumptions to current industry, market and economic trends, to the assumptions used to value similar assets in other acquisitions, to the historical results of the acquired business and to other guideline companies within the same industry. We involved our valuation professionals to assist with our evaluation of the methodology used by the Company and significant assumptions included in the fair value estimates.
.


63

 
Income Taxes - Intra-entity transfer of a license for intellectual property
Description of the Matter
As discussed in Note I - Income Taxes, the Company completed intra-entity transfers of certain intellectual property rights among various wholly-owned subsidiaries. The Company determined that some of these transactions created a step-up in the tax deductible basis in the transferred intellectual property rights in certain jurisdictions and recognized a deferred tax asset and related income tax benefit of $4.1 billion based upon the tax basis step-up to the intellectual property’s current fair value.
Auditing management’s estimation of the intellectual property’s fair value was especially challenging because the estimates required significant and complex management judgments to establish assumptions about the intellectual property’s fair value, including revenue growth rates, projected profit margins, and discount rate. This also involved complex judgment to analyze, interpret and apply complex tax laws and regulations in the impacted jurisdictions.
How We Addressed the Matter in Our Audit
We tested the effectiveness of the Company’s controls over the accounting for the intra-entity transfers, including controls over the appropriateness of the valuation approach and method selected, assumptions and data used, and application of the technical tax guidance by management.
To test the estimated fair value of the intellectual property, we performed audit procedures that included, among others, evaluating the assumptions used by management related to revenue growth rates, projected profit margins, and the discount rate. We involved our valuation professionals to assist with the evaluation of the appropriateness of the valuation model used by management and the methodology used in determining the valuation of significant assumptions included in the fair value estimates. We also involved tax professionals to assess the technical merits of the Company’s tax positions related to the intra-entity transfers. To evaluate the reasonableness of management’s assumptions about revenue growth rates and projected profit margins, we compared these assumptions to historical revenue and profit margins for the business and to industry benchmarks. We also compared these assumptions to those used in the Company’s annual budget and forecasting process to determine whether they were consistent, where relevant. We recalculated the recognized deferred tax assets and assessed the adequacy of the related disclosures included in Note I - Income Taxes to the consolidated financial statements.


/s/ Ernst & Young LLP
We have served as the Company’s auditor since 1992.
Boston, Massachusetts
February 25, 2020


64


ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

 
Year Ended December 31,
(in millions, except per share data)
2019
 
2018
 
2017
Net sales
$
10,735

 
$
9,823

 
$
9,048

Cost of products sold
3,116

 
2,813

 
2,593

Gross profit
7,620

 
7,011

 
6,455

 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
Selling, general and administrative expenses
3,941

 
3,569

 
3,294

Research and development expenses
1,174

 
1,113

 
997

Royalty expense
65

 
70

 
68

Amortization expense
699

 
599

 
565

Intangible asset impairment charges
105

 
35

 
4

Contingent consideration expense (benefit)
(35
)
 
(21
)
 
(80
)
Restructuring charges (credits)
38

 
36

 
37

Litigation-related charges (credits)
115

 
103

 
285

 
6,102

 
5,504

 
5,170

Operating income (loss)
1,518

 
1,506

 
1,285

 
 
 
 
 
 
Other income (expense):
 
 
 
 
 
Interest expense
(473
)
 
(241
)
 
(229
)
Other, net
(358
)
 
156

 
(124
)
Income (loss) before income taxes
687

 
1,422

 
933

Income tax (benefit) expense
(4,013
)
 
(249
)
 
828

Net income (loss)
$
4,700

 
$
1,671

 
$
104

 
 
 
 
 
 
Net income (loss) per common share — basic
$
3.38

 
$
1.21

 
$
0.08

Net income (loss) per common share — assuming dilution
$
3.33

 
$
1.19

 
$
0.08

 
 
 
 
 
 
Weighted-average shares outstanding
 
 
 
 
 
Basic
1,391.5

 
1,381.0

 
1,370.1

Assuming dilution
1,410.6

 
1,401.4

 
1,392.7















See notes to the consolidated financial statements.

65

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Net income (loss)
$
4,700

 
$
1,671

 
$
104

Other comprehensive income (loss), net of tax:
 
 
 
 
 
Foreign currency translation adjustment
195

 
(21
)
 
48

Net change in derivative financial instruments
62

 
110

 
(106
)
Net change in available-for-sale securities
—

 
—

 
5

Net change in defined benefit pensions and other items
(20
)
 
2

 
(6
)
Total other comprehensive income (loss)
237

 
91

 
(59
)
Total comprehensive income (loss)
$
4,937

 
$
1,761

 
$
45





















































See notes to the consolidated financial statements.

66

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
 
As of December 31,
(in millions, except share and per share data)
2019
 
2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
217

 
$
146

Trade accounts receivable, net
1,828

 
1,608

Inventories
1,579

 
1,166

Prepaid income taxes
195

 
161

Other current assets
880

 
921

Total current assets
4,699

 
4,003

Property, plant and equipment, net
2,079

 
1,782

Goodwill
10,176

 
7,911

Other intangible assets, net
7,886

 
6,372

Deferred tax assets
4,196

 
87

Other long-term assets
1,529

 
845

TOTAL ASSETS
$
30,565

 
$
20,999

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Current debt obligations
$
1,416

 
$
2,253

Accounts payable
542

 
349

Accrued expenses
2,109

 
2,246

Other current liabilities
800

 
412

Total current liabilities
4,866

 
5,260

Long-term debt
8,592

 
4,803

Deferred tax liabilities
595

 
328

Other long-term liabilities
2,635

 
1,882

 
 
 
 
Commitments and contingencies

 

 
 
 
 
Stockholders’ equity:
 
 
 
Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding

 


Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,642,488,911 shares as of December 31, 2019 and 1,632,148,030 shares as of December 31, 2018
16

 
16

Treasury stock, at cost - 247,566,270 shares as of December 31, 2019 and December 31, 2018
(1,717
)
 
(1,717
)
Additional paid-in capital
17,561

 
17,346

Accumulated deficit
(2,253
)
 
(6,953
)
Accumulated other comprehensive income (loss), net of tax:
 
 
 
Foreign currency translation adjustment
142

 
(53
)
Unrealized gain (loss) on derivative financial instruments
173

 
111

Unrealized costs associated with defined benefit pensions and other items
(45
)
 
(25
)
Total stockholders’ equity
13,877

 
8,726

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
30,565

 
$
20,999


See notes to the consolidated financial statements.

67

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

 
 
 
 
 
Treasury Stock
 
Additional Paid-In Capital
 
Accumulated Deficit
 
Accumulated Other Comprehensive Income (Loss), Net of Tax
 
Common Stock
 
 
 
 
(in millions, except share data)
Shares Issued
 
Par Value
 
 
 
 
Balance as of December 31, 2016
1,609,670,817

 
$
16

 
$
(1,717
)
 
$
17,014

 
$
(8,581
)
 
$
1

Net income (loss)
 
 
 
 
 
 
 
 
104

 
 
Cumulative effect adjustment for ASU 2016-09
 
 
 
 
 
 
 
 
86

 
 
Changes in other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation adjustment
 
 
 
 
 
 
 
 
 
 
48

Derivative financial instruments
 
 
 
 
 
 
 
 
 
 
(106
)
Available-for-sale securities
 
 
 
 
 
 
 
 
 
 
5

Defined benefit pensions and other items
 
 
 
 
 
 
 
 
 
 
(6
)
Impact of stock-based compensation plans, net of tax
11,392,081

 
 
 
 
 
147

 
 
 
 
Balance as of December 31, 2017
1,621,062,898

 
$
16

 
$
(1,717
)
 
$
17,161

 
$
(8,390
)
 
$
(59
)
Net income (loss)
 

 
 

 
 
 
 

 
1,671

 
 

Cumulative effect adjustments for ASC Update Adoptions(1)
 
 
 
 
 
 
 
 
(233
)
 
 
Changes in other comprehensive income (loss), net of tax:
 

 
 

 
 
 
 

 
 
 
 

Foreign currency translation adjustment
 

 
 

 
 
 
 

 
 

 
(21
)
Derivative financial instruments
 

 
 

 
 
 
 

 
 

 
110

Defined benefit pensions and other items
 
 
 
 
 
 
 
 
 
 
2

Impact of stock-based compensation plans, net of tax
11,085,132

 


 


 
185

 
 

 
 

Balance as of December 31, 2018
1,632,148,030

 
$
16

 
$
(1,717
)
 
$
17,346

 
$
(6,953
)
 
$
33

Net income (loss)
 
 
 
 
 
 
 
 
4,700

 
 
Changes in other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
 
 
 
 
Foreign currency translation adjustment
 
 
 
 
 
 

 
 
 
195

Derivative financial instruments
 
 
 
 
 
 
 
 
 
 
62

Defined benefit pensions and other items
 
 
 
 
 
 
 
 
 
 
(20
)
Impact of stock-based compensation plans, net of tax
10,340,881

 


 
 
 
215

 
 

 
 

Balance as of December 31, 2019
1,642,488,911

 
$
16

 
$
(1,717
)
 
$
17,561

 
$
(2,253
)
 
$
270

(1) In 2018, we recorded cumulative effect adjustments to retained earnings to reflect the adoption of Accounting Standards Codification (ASC) Update No. 2014-09, Update No. 2016-16 and Update No. 2016-01. Please refer to Note A – Significant Accounting Policies for additional details.






See notes to the consolidated financial statements.

68


BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Net income (loss)
$
4,700

 
$
1,671

 
$
104

Adjustments to reconcile net income (loss) to cash provided by operating activities
 
 
 
 
 
Gain on sale of businesses
(8
)
 
—

 
—

Depreciation and amortization
1,011

 
894

 
844

Deferred and prepaid income taxes
(4,301
)
 
(87
)
 
245

Stock-based compensation expense
157

 
140

 
127

Intangible asset impairment charges
105

 
35

 
4

Net loss (gain) on investments and notes receivable
30

 
(155
)
 
92

Contingent consideration expense (benefit)
(35
)
 
(21
)
 
(80
)
Payment of contingent consideration in excess of amount recognized at acquisition
(6
)
 
(9
)
 
(14
)
Inventory step-up amortization
46

 
6

 
10

Exchange (gain) loss
358

 
(11
)
 
15

Other, net
63

 
8

 
13

Increase (decrease) in operating assets and liabilities, net of acquisitions:
 
 
 
 
 
Trade accounts receivable
(130
)
 
(110
)
 
(30
)
Inventories
(290
)
 
(83
)
 
(107
)
Other assets
45

 
(172
)
 
(20
)
Accounts payable and accrued expenses
111

 
(631
)
 
195

Other liabilities
(18
)
 
(1,164
)
 
28

Cash provided by (used for) operating activities
1,836

 
310

 
1,426

Purchases of property, plant and equipment
(461
)
 
(316
)
 
(319
)
Proceeds on disposals of property, plant and equipment
7

 
14

 
—

Payments for acquisitions of businesses, net of cash acquired
(4,382
)
 
(1,448
)
 
(560
)
Proceeds from divestiture of certain businesses
90

 
—

 
—

Proceeds from royalty rights
52

 
—

 
—

Payments for settlements of hedge contracts
(199
)
 
—

 
—

Payments for investments and acquisitions of certain technologies
(149
)
 
(172
)
 
(131
)
Cash provided by (used for) investing activities
(5,041
)
 
(1,921
)
 
(1,010
)
Payment of contingent consideration and royalty rights previously established in purchase accounting
(135
)
 
(19
)
 
(33
)
Proceeds from royalty rights transfer
256

 
—

 
—

Proceeds from short-term borrowings, net of debt issuance costs
700

 
999

 
—

Net increase (decrease) in commercial paper
(575
)
 
21

 
1,183

Proceeds from borrowings on credit facilities
—

 
569

 
2,156

Payments on borrowings from credit facilities
—

 
(569
)
 
(2,216
)
Payments on short-term borrowings
(1,000
)
 
—

 
—

Payments on long-term borrowings and debt extinguishment costs
(3,560
)
 
(602
)
 
(1,000
)
Proceeds from long-term borrowings, net of debt issuance costs
7,229

 
987

 
—

Cash used to net share settle employee equity awards
(65
)
 
(56
)
 
(65
)
Proceeds from issuances of shares of common stock
123

 
101

 
85

Cash provided by (used for) financing activities
2,973

 
1,432

 
110

Effect of foreign exchange rates on cash
10

 
(8
)
 
4

Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents
(222
)
 
(188
)
 
530

Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period
829

 
1,017

 
487

Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period
$
607

 
$
829

 
$
1,017

Supplemental Information
 
 
 
 
 
Cash (received) paid for income taxes, net
$
242

 
$
1,037

 
$
(42
)
Cash paid for interest
449

 
262

 
235

Fair value of contingent consideration recorded in purchase accounting
127

 
248

 
94

 
As of December 31,
Reconciliation to amounts within the consolidated balance sheets:
2019
 
2018
 
2017
Cash and cash equivalents
$
217

 
$
146

 
$
188

Restricted cash and restricted cash equivalents included in Other current assets
346

 
655

 
803

Restricted cash equivalents included in Other long-term assets
43

 
27

 
26

Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period
$
607

 
$
829

 
$
1,017

See notes to the consolidated financial statements.

69


NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE A – SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation

Our consolidated financial statements include the accounts of Boston Scientific Corporation and our wholly-owned subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest in a VIE. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs for 2019, 2018 and 2017.

Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

Reportable Segments

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG plc (BTG), which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note E – Contractual Obligations and Commitments and Note J – Commitments and Contingencies for further details.

Accounting Estimates

To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report for further discussion.

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider to be cash equivalents all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.


70

Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in the Other current assets caption on our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us as servicer of previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents

Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in the Other current assets caption on our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in the Other long-term assets caption on our consolidated balance sheets are related to deferred compensation plans.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral. We record our accounts receivable in our consolidated balance sheets at net realizable value. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses, based on historical information and management's best estimates. We write-off amounts determined to be uncollectible against this reserve. Write-offs of uncollectible accounts receivable were immaterial in 2019, 2018 and 2017. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2019, 2018 and 2017; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers in Southern Europe are subject to an increased number of days outstanding prior to payment relative to other countries. Historically, receivable balances with certain publicly-owned hospitals in these countries accumulated over a period of time and are then subsequently settled as large lump sum payments, sometimes at large discounts. While we believe our allowance for doubtful accounts in these countries is adequate as of December 31, 2019 and 2018, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts receivable may increase.
 
Revenue Recognition

In May 2014, the FASB issued FASB ASC Topic 606, Revenue from Contracts with Customers (Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, Revenue Recognition.

Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to retained earnings of $177 million on January 1, 2018, primarily related to the cost of providing non-contractual post-implant support to certain customers, which we historically deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within Selling, general and administrative expenses and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual.


71

The impact of adopting FASB ASC Topic 606 on our consolidated balance sheets resulted in an increase in Other current liabilities of $59 million and an increase in Other long-term liabilities of $205 million as of December 31, 2018, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in Other long-term assets of $12 million and a reduction in Deferred income taxes of $41 million as of December 31, 2018. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met:

•
We have a contract with a customer that creates enforceable rights and obligations,
•
Promised products or services are identified,
•
The transaction price, or the amount we expect to receive, is determinable and
•
We have transferred control of the promised items to the customer.

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.


72

Capitalized Contract Costs

We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our consolidated financial statements.

Post-Implant Services

We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. Following our modified retrospective adoption of FASB ASC Topic 606 on January 1, 2018, because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.

Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our Cardiac Rhythm Management business, which include implantable defibrillator and pacemaker systems. Our Cardiac Rhythm Management products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.

Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. Approximately 32 percent of our finished goods inventory as of December 31, 2019 and approximately 40 percent as of December 31, 2018 was at customer locations pursuant to consignment arrangements or held by sales representatives.

Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.

Leases

In February 2016, the FASB issued ASC Update No. 2016-02, Leases (FASB ASC Topic 842, Leases). We adopted the standard as of January 1, 2019, using the modified retrospective approach and the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, we applied the new leasing rules on the date of adoption and recognized the cumulative effect of initially applying the standard as an adjustment to our January 1, 2019 opening balance sheet, rather than at the earliest comparative period presented in the financial statements. Prior periods presented are in accordance with the previous lease guidance under FASB ASC Topic 840, Leases (FASB ASC Topic 840).


73

In addition, we applied the package of practical expedients permitted under FASB ASC Topic 842 transition guidance to our entire lease portfolio at January 1, 2019. As a result, we were not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases and (iii) the treatment of initial direct costs for any existing leases. Furthermore, we elected not to separate lease and non-lease components for the majority of our leases. Instead, for all applicable classes of underlying assets, we accounted for each separate lease component and the non-lease components associated with that lease component, as a single lease component.

As a result of adopting FASB ASC Topic 842 on January 1, 2019, we recognized right-of-use assets of $271 million and corresponding liabilities of $278 million for our existing operating lease portfolio on our consolidated balance sheet. Operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our consolidated balance sheets. Finance leases are immaterial to our consolidated financial statements. Refer to Note E – Contractual Obligations and Commitments for additional information. There was no material impact to our consolidated statements of operations or consolidated statements of cash flows as a result of adopting FASB ASC Topic 842. Please refer to Note F – Leases for information regarding our lease portfolio as of December 31, 2019 as accounted for under FASB ASC Topic 842.

To meet the reporting and disclosure requirements of FASB ASC Topic 842, we implemented a new lease administration and lease accounting system in 2018 that tracks all of our material leasing arrangements. In addition, we designed and implemented new processes and internal controls during the first quarter of 2019 to ensure the completeness and accuracy of the transition adjustment and subsequent financial reporting under FASB ASC Topic 842. We have also established monitoring controls to ensure we have appropriate mechanisms in place to identify material leases in a timely manner, particularly contracts that may contain embedded lease features.

Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In those circumstances where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.

Indefinite-lived Intangibles, including IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which is foundational to our ongoing operations within the Cardiovascular market and other markets within interventional medicine and IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.


74

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.

For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.

Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.

For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.

Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2019, 2018 and 2017 annual impairment assessment, we identified the following reporting units: Interventional Cardiology, Peripheral Interventions (including the Interventional Medicine business acquired with BTG), Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health and Neuromodulation. In addition, following the BTG acquisition in the third quarter of 2019, we added Specialty Pharmaceuticals as an additional reporting unit. We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based on the criteria prescribed in FASB ASC Topic 350.


75

In performing the goodwill impairment assessments for 2019, 2018 and 2017, we utilized both the optional qualitative assessment and the quantitative approach prescribed under FASB ASC Topic 350. The qualitative assessment was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent. All other reporting units were tested using the quantitative approach described below. The qualitative assessment requires an evaluation of whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount based on an assessment of relevant events including macroeconomic factors, industry and market conditions, cost factors, overall financial performance and other entity-specific factors. After assessing the totality of events, if it is determined that it is more likely than not that the fair value of the reporting unit exceeds its carrying value, no further steps are required. If it is determined that impairment is more likely than not, then we perform the quantitative impairment test.

When allocating goodwill from business combinations to our reporting units, we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition. In addition, for purposes of performing our goodwill impairment tests, assets and liabilities, including corporate assets, which relate to a reporting unit’s operations, and would be considered in determining its fair value, are allocated to the individual reporting units. We allocate assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.

For our 2019, 2018 and 2017 annual impairment assessments, for those reporting units for which a quantitative test was performed, we used only the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets. We have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technology-based assets within our reporting units for application of the cost approach. Therefore, we believe that the income approach represents the most appropriate valuation technique for which sufficient data are available to determine the fair value of our reporting units.

In applying the income approach to our accounting for goodwill, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk-adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows.

Refer to Note C – Goodwill and Other Intangible Assets to our consolidated financial statements for additional details related to our goodwill balances.

Investments in Publicly Traded and Privately Held Entities

In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to Other Comprehensive Income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to Other comprehensive income (loss) were reclassified to retained earnings, and all future fair value changes will be recorded to Net income (loss). For privately-held securities of investee companies over which we do not have the ability to exercise significant influence, we elected the measurement alternative approach for our existing investments, which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. 

In 2017, we accounted for our publicly traded investments as available-for-sale securities based on the quoted market price at the end of the reporting period. Unrealized holding gains or losses during the period, net of tax, were recorded to Accumulated other comprehensive income (loss), net of tax. We computed realized gains and losses on sales of available-for-sale securities at fair value, adjusted for any other-than-temporary declines in fair value. We accounted for investments in privately-held entities in which we had less than a 20 percent ownership interest under the cost method of accounting if we did not have the ability to exercise significant influence over the investee in accordance with FASB ASC Topic 325, Investments - Other.


76

We account for investments in entities over which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. If the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value if accounted for under measurement alternative. For our equity method investments, an impairment loss is recorded if we determine the impairment is other-than-temporary. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. For other-than-temporary impairments, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. Impairment losses on our investments are included in Other, net in our consolidated statements of operations.

Income Taxes

In February 2018, the FASB issued ASC Update No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The purpose of Update No. 2018-02 is to allow an entity to reclassify the income tax effects of the Tax Cut and Jobs Act of 2017 (TCJA) on items within Accumulated other comprehensive income (loss), net of tax (AOCI) to retained earnings. Update No. 2018-02 is effective for all entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We adopted Update No. 2018-02 in the first quarter of 2019 and have not elected to reclassify the income tax effects of the TCJA from AOCI to retained earnings.

In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to retained earnings of $55 million for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through Income tax expense (benefit).

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the TCJA, we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and will be reported as a part of continuing operations. See Note I – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.


77

Legal and Product Liability Costs

In the normal course of business, we are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue our best estimate of the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses. See Note J – Commitments and Contingencies for discussion of our individual material legal proceedings.

Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations. We record such costs into expense over the employee’s future service period, if any.

Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included in Restructuring charges (credits) in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities and are included within Costs of products sold and Selling, general and administrative expenses in our consolidated statements of operations. Impairment of right of use lease assets and lease terminations directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within Costs of products sold and Selling, general and administrative expenses in our consolidated statements of operations. See Note G – Restructuring-related Activities for further information and discussion of our restructuring plans.

Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate and translate revenues and expenses at the average exchange rates in effect during the year. We show the net effect of these translation adjustments in our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. For any significant foreign subsidiaries located in highly inflationary economies, we would re-measure their financial statements as if the functional currency were the U.S. dollar.

Foreign currency transaction gains and losses are included in Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.


78

Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.

Shipping and Handling Costs

We generally do not bill customers for shipping and handling of our products. We treat shipping and handling costs incurred after a customer obtains control of the good as a fulfillment cost and record in Selling, general and administrative expenses in our consolidated statements of operations. Shipping and handling costs were $144 million in 2019, $124 million in 2018 and $110 million in 2017.

Research and Development

We expense research and development costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles, including In-Process Research and Development above for our policy regarding IPR&D acquired in connection with our business combinations and asset purchases.

Net Income (Loss) per Common Share

We base Net income (loss) per common share upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options and stock awards whose effect would be anti-dilutive from the calculation.

NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS
Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. With the exception of the acquisition of BTG, which was completed on August 19, 2019, we have not presented supplemental pro forma financial information for acquisitions given their results are not material to our consolidated financial statements. Transaction costs for all acquisitions in 2019, 2018 and 2017 were immaterial to our consolidated financial statements and were expensed as incurred. In 2019, we recorded approximately $125 million of purchase price adjustments, of which $95 million related to BTG.


79

2019 Acquisitions

BTG plc

On August 19, 2019, we announced the closing of our acquisition of BTG, a public company organized under the laws of England and Wales. BTG had three key portfolios, the largest of which is its interventional medicine portfolio (Interventional Medicine) that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. Following the closing of the acquisition, we began to integrate BTG's Interventional Medicine business into our Peripheral Interventions division.

In addition to the Interventional Medicine product lines, the BTG portfolio also included a specialty pharmaceutical business (Specialty Pharmaceuticals) comprised of acute care antidotes to treat overexposure to certain medications and toxins and a licensing portfolio (Licensing arrangements) that generates net royalties related to BTG intellectual property and product license agreements. In connection with the acquisition, we acquired rights to future royalties associated with the Zytiga™ drug used to treat certain forms of prostate cancer. In the fourth quarter of 2019, we sold our rights to these royalties for $256 million in cash, included in Proceeds from royalty rights transfer. Refer to Note D – Hedging Activities and Fair Value Measurements for additional information.

The transaction price consisted of upfront cash in the aggregate amount of £3.312 billion (or $4.023 billion based on the exchange rate at closing on August 19, 2019) for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence (or $10.20 based on the exchange rate at closing) in cash for each BTG share. The transaction price included $404 million of cash and cash equivalents acquired. We implemented our acquisition of BTG by way of a court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.

Purchase Price Allocation

We accounted for our acquisition of BTG as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (FASB ASC Topic 805), we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed from the acquisition. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by FASB ASC Topic 805. As of December 31, 2019, the valuation studies necessary to determine the fair market value of the assets acquired and liabilities assumed are preliminary, including the projection of the underlying cash flows used to determine the fair value of the identified tangible, intangible and financial assets and liabilities.

We accounted for BTG as a business combination, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary purchase price of BTG, was comprised of the following components as of December 31, 2019:
(in millions)
 
Payment for acquisition, net of cash acquired
$
3,619



80

The following summarizes the preliminary purchase price allocation for our acquisition of BTG as of December 31, 2019:
(in millions)
 
Goodwill
$
1,644

Trade accounts receivable, net
108

Inventories
232

Other current assets
252

Other intangible assets, net
1,785

Other long-term assets
537

Accrued expenses and other current liabilities
(308
)
Other long-term liabilities
(274
)
Deferred tax liability
(358
)
 
$
3,619



As a result of our acquisition of BTG, we recognized goodwill of $1.644 billion, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of December 31, 2019, we have allocated $1.406 billion to our Peripheral Interventions reporting unit and $238 million to the Specialty Pharmaceuticals reporting unit.

We allocated a portion of the preliminary purchase price for our acquisition of BTG to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
1,709

 
10
-
18
 
11
%
-
12%
Other intangible assets
75

 
2
-
11
 
11%
 
$
1,785

 
 
 
 
 
 
 
 

Pro Forma Financial Information (unaudited)
BTG contributed $226 million to our Net sales and had an immaterial impact to our Net income (loss) for the period post acquisition through December 31, 2019.

The unaudited estimated pro forma results presented below include the effects of our acquisition of BTG as if it was consummated on January 1, 2018. In 2019, we incurred nonrecurring charges that we attributed to our acquisition of BTG, which are presented in our consolidated statements of operations for this period. These charges include acquisition-related costs, stock-based compensation expenses as a result of the change in control and retention bonuses and severance payments, adjusted for the related tax effects. We have reflected these nonrecurring charges as adjustments to the pro forma earnings presented below for 2019 and 2018.

Additionally, these pro forma amounts have been calculated after applying our accounting policies and adjusting the results of BTG to reflect the additional costs associated with fair value adjustments relating to inventories, property, plant, and equipment, and intangible assets as if the acquisition had occurred on January 1, 2018, with the consequential tax effects. Additionally, the pro forma amounts have been adjusted to reflect the amortization of deferred financing costs and interest expense associated with additional financing entered into as part of the acquisition. The pro forma results exclude BTG’s historical licensing revenue and related cost of sales, as these arrangements are accounted for as part of the acquisition as a financial asset and liability and are not accounted for within the scope of FASB ASC Topic 606.


81

The supplemental pro forma information presented below is for informational purposes only and should be read in conjunction with our historical financial statements. The pro forma results do not include any anticipated synergies or other expected benefits of the acquisition. Accordingly, the unaudited estimated pro forma financial information below is not necessarily indicative of what the actual results of operations of the combined companies would have been had the acquisition of BTG occurred as of January 1, 2018, nor are they indicative of future results of operations. We believe that the pro forma assumptions and adjustments are reasonable and appropriate under the circumstances and are factually supported based on information currently available.

 
Year Ended December 31,
(in millions, except per share data) (Unaudited)
2019
 
2018
Net sales
$
11,142

 
$
10,429

Net income (loss)
$
4,585

 
$
1,244

Net income (loss) per common share — basic
$
3.30

 
$
0.90

Net income (loss) per common share — assuming dilution
$
3.25

 
$
0.89



Transaction with Varian Medical Systems, Inc.

On August 21, 2019, we completed the sale of our drug-eluting and bland embolic microsphere portfolio to Varian Medical Systems, Inc. (Varian) in connection with our acquisition of BTG. The transaction price consisted of an upfront cash payment of $90 million, a portion of which is allocated to the fair value of the services to be rendered under the Transition Services Agreement and Transition Manufacturing Agreement entered into with Varian as part of this transaction. Additionally, we transferred certain contingent consideration arrangements arising from our initial acquisition of the portfolio to Varian and agreed to indemnify Varian for any payments ultimately arising under the terms of the contingent consideration arrangement. Accordingly, as part of the disposal, we recorded a liability of $16 million to recognize the fair value of this guarantee based on our potential obligation resulting from the indemnifications. The maximum amount payable under this guarantee is $200 million in accordance with FASB ASC Topic 460, Guarantees, which is consistent with the contingent consideration arrangement executed with our initial acquisition of the portfolio in accordance with FASB ASC Topic 805.

Vertiflex, Inc.

On June 11, 2019, we announced the closing of our acquisition of Vertiflex, Inc. (Vertiflex), a privately-held company which has developed and commercialized the Superion™ Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. We estimate the sales-based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn-out period. Following the closing of the acquisition, we have integrated the Vertiflex business into our Neuromodulation division.

Millipede, Inc.

On January 29, 2019, we announced the closing of our acquisition of Millipede, Inc. (Millipede), a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. We had previously been an investor in Millipede since the first quarter of 2018 as part of an investment and acquisition option agreement, whereby we purchased a portion of the outstanding shares of Millipede, along with newly issued shares of the company, for an upfront cash payment of $90 million. In the fourth quarter of 2018, upon the successful completion of a first-in-human clinical study, we exercised our option to acquire the remaining shares of Millipede. We held an interest of approximately 20 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. The transaction price for the remaining stake consisted of an upfront cash payment of $325 million and up to an additional $125 million of future payments upon achievement of a commercial milestone. Following the closing of the acquisition, we have integrated the Millipede business into our Interventional Cardiology division.


82

Purchase Price Allocation

We accounted for our 2019 acquisitions of Vertiflex and Millipede as business combinations, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of December 31, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
763

Fair value of contingent consideration
127

Fair value of prior interests
102

 
$
992



The preliminary purchase price allocations of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of December 31, 2019:
(in millions)
 
Goodwill
$
575

Amortizable intangible assets
220

Indefinite-lived intangible assets
240

Other assets acquired
24

Liabilities assumed
(12
)
Net deferred tax liabilities
(56
)
 
$
992



We allocated a portion of the preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, to the specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
Technology-related
$
210

 
12
 
15%
Other intangible assets
10

 
12
 
15%
Indefinite-lived intangible assets:
 
 
 
 
 
In-process research and development
240

 
n/a
 
19%
 
$
461

 
 
 
 


2018 Acquisitions

Augmenix, Inc.

On October 16, 2018, we announced the closing of our acquisition of Augmenix, Inc. (Augmenix), a privately-held company that developed and commercialized the SpaceOAR™ Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer. The transaction price consisted of an upfront cash payment of $500 million and up to $100 million in payments contingent upon achieving certain revenue-based milestones. Following the closing of the acquisition, we have integrated the Augmenix business into our Urology and Pelvic Health division.


83

Claret Medical, Inc.

On August 2, 2018, we announced the closing of our acquisition of Claret Medical, Inc. (Claret), a privately-held company that has developed and commercialized the Sentinel™ Cerebral Embolic Protection System. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter aortic valve replacement (TAVR). The transaction price consisted of an upfront cash payment of $220 million and an additional $50 million payment for achieving a reimbursement-based milestone that was achieved in the third quarter of 2018. Following the closing of the acquisition, we have integrated the Claret business into our Interventional Cardiology division.

Cryterion Medical, Inc.

On July 5, 2018, we announced the closing of our acquisition of Cryterion Medical, Inc. (Cryterion), a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation. We had been an investor in Cryterion since 2016 and held an interest of approximately 35 percent immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of $202 million. Following the closing of the acquisition, we have integrated the Cryterion business into our Electrophysiology division.

NxThera, Inc.

On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company that developed the Rezūm™ System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). We held a minority interest immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of approximately $240 million and up to approximately $85 million in future potential payments contingent upon achieving commercial milestones over the four years following the date of acquisition. Following the closing of the acquisition, we have integrated the NxThera business into our Urology and Pelvic Health division.

nVision Medical Corporation

On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction price consisted of an upfront cash payment of $150 million and up to an additional $125 million in future potential payments contingent upon achieving certain clinical and commercial milestones over the four years following the date of acquisition. Following the closing of the acquisition, we have integrated the nVision business into our Urology and Pelvic Health division.

Other Acquisitions

In addition, we completed other individually immaterial acquisitions in 2018 for total consideration of $158 million in cash at closing plus aggregate future potential contingent consideration of up to $62 million.

We recorded gains of $184 million in 2018 within Other, net on our consolidated statements of operations based on the difference between the book values and the fair values of our previously-held investments immediately prior to the acquisition dates. The aggregate fair value of our previously-held investments immediately prior to the acquisition dates was $251 million. We remeasured the fair value of each previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests.

Purchase Price Allocation

We accounted for these acquisitions as business combinations, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of December 31, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
1,449

Fair value of contingent consideration
248

Fair value of prior interests
251

 
$
1,948




84

The following summarizes the purchase price allocations for our 2018 acquisitions as of December 31, 2019:
(in millions)
 
Goodwill
$
939

Amortizable intangible assets
939

In-process research and development
213

Other assets acquired
38

Liabilities assumed
(19
)
Net deferred tax liabilities
(162
)
 
$
1,948



We allocated a portion of the purchase prices to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets
 
 
 
 
 
 
 
 
 
Technology-related
$
908

 
6
-
14
 
14
%
-
23%
Other intangible assets
31

 
6
-
13
 
13
%
-
15%
Indefinite-lived intangible assets
 
 
 
 
 
 
 
 
 
In-process research and development
213

 
n/a
 
15%
 
$
1,153

 
 
 
 
 
 
 
 


2017 Acquisitions

Apama Medical Inc.

On October 11, 2017, we announced the closing of our acquisition of Apama Medical Inc. (Apama), a privately-held company developing the Apama™ Radiofrequency single-shot Balloon Catheter System for the treatment of atrial fibrillation. The transaction price consisted of an upfront cash payment of approximately $175 million and up to approximately $125 million in future potential payments contingent upon achieving certain clinical and regulatory milestones. Following the closing of the acquisition, we have integrated the Apama business into our Electrophysiology division.

Symetis SA

On May 16, 2017, we announced the closing of our acquisition of Symetis SA (Symetis), a privately-held Swiss structural heart company focused on minimally-invasive TAVR devices, having developed the ACURATE neo™ Aortic Valve. The transaction price consisted of an upfront cash payment of approximately $430 million. Following the closing of the acquisition, we have integrated the Symetis business into our Interventional Cardiology division.

Purchase Price Allocation

We accounted for these acquisitions as business combinations and, in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices were as follows for our 2017 acquisitions:
(in millions)
 
Payment for acquisitions, net of cash acquired
$
560

Fair value of contingent consideration
72

 
$
632




85

The following summarizes the aggregate purchase price allocations for our 2017 acquisitions:
(in millions)
 
Goodwill
$
287

Amortizable intangible assets
278

Indefinite-lived intangible assets
186

Other assets acquired
44

Liabilities assumed
(61
)
Deferred tax liabilities
(102
)
 
$
632



We allocated a portion of the purchase prices to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
268

 
13
 
24%
Other intangible assets
10

 
2
-
13
 
24%
Indefinite-lived intangible assets
 
 
 
 
 
 
 
In-process research and development
$
186

 
n/a
 
15%
 
$
464

 
 
 
 
 
 


Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations as well as revenue and cash flow projections associated with future technologies and has been allocated to our reportable segments based on the relative expected benefit. Based on preliminary estimates updated for applicable regulatory changes, the goodwill recorded relating to our 2019, 2018 and 2017 acquisitions is not deductible for tax purposes.

Contingent Consideration

Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
 
Balance as of December 31, 2017
$
169

Amounts recorded related to current year acquisitions
248

Purchase price adjustments related to prior year acquisitions
(22
)
Contingent consideration expense (benefit)
(21
)
Contingent consideration payments
(28
)
Balance as of December 31, 2018
$
347

Amounts recorded related to current year acquisitions
127

Contingent consideration arrangements transferred to Varian
(16
)
Contingent consideration expense (benefit)
(35
)
Contingent consideration payments
(68
)
Balance as of December 31, 2019
$
354




86

As of December 31, 2019, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was $697 million, which includes our estimate of maximum contingent payments of $100 million associated with the Vertiflex acquisition described above. The maximum decreased $176 million compared to the amount as of December 31, 2018 due to the contingent consideration arrangement which is now accounted for as a guarantee in connection with our transaction with Varian as discussed in the BTG section above. In addition, the aggregated maximum decreased as a result of the expiration or full payment of certain contingent consideration arrangements in 2019, partially offset by the Millipede and Vertiflex arrangements entered into in 2019.
The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
Contingent Consideration Liability
Fair Value as of December 31, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
R&D, Regulatory and Commercialization-based Milestones
$198 million
Discounted Cash Flow
Discount Rate
2
%
-
3%
3%
Probability of Payment
40
%
-
90%
82%
Projected Year of Payment
2020

-
2027
2021
Revenue-based Payments
$156 million
Discounted Cash Flow
Discount Rate
11
%
-
15%
13%
Probability of Payment
60
%
-
100%
99%
Projected Year of Payment
2020

-
2026
2021

(1)
Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to some of our R&D, commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2019.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:
 
As of December 31,
(in millions)
2019
 
2018
Equity method investments
$
264

 
$
303

Measurement alternative investments(1)
171

 
94

Publicly-held securities(2)
1

 
—

Notes receivable
23

 
26

 
$
458

 
$
424

(1)
Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
(2)
Publicly-held equity securities are measured at fair value with changes in fair value recognized currently in Other, net on our accompanying consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

As of December 31, 2019, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $314 million, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities.

87


NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
 
As of December 31, 2019
 
As of December 31, 2018
(in millions)
Gross Carrying Amount
 
Accumulated
Amortization/Write-offs
 
Gross Carrying Amount
 
Accumulated
Amortization/Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
12,020

 
$
(5,706
)
 
$
10,197

 
$
(5,266
)
Patents
525

 
(408
)
 
520

 
(393
)
Other intangible assets
1,754

 
(1,081
)
 
1,666

 
(958
)
 
$
14,299

 
$
(7,195
)
 
$
12,383

 
$
(6,617
)
Indefinite-lived intangible assets
 
 
 
 
 
 
 
Goodwill
$
20,076

 
$
(9,900
)
 
$
17,811

 
$
(9,900
)
In-process research and development (IPR&D)
662

 
—

 
486

 
—

Technology-related
120

 
—

 
120

 
—

 
$
20,858

 
$
(9,900
)
 
$
18,417

 
$
(9,900
)


In the third quarter of 2019, we performed our annual impairment test of all IPR&D projects and our indefinite-lived core technology assets and determined that the assets were not impaired. In addition, we verified the classification as indefinite-lived assets continues to be appropriate.

Intangible asset impairment charges were $105 million in 2019, $35 million in 2018 and $4 million in 2017. Refer to Note A - Significant Accounting Policies for a discussion of key assumptions used in our goodwill and intangible asset impairment testing.

Effective January 1, 2018, we reclassified our Neuromodulation operating segment and associated goodwill balance from our MedSurg reportable segment to our Rhythm and Neuro reportable segment. This change did not impact our total goodwill carrying value.

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG, which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.


88

The following represents our goodwill balance by global reportable segment and our separately reported Specialty Pharmaceuticals operating segment:
(in millions)
MedSurg
 
Rhythm and Neuro
 
Cardiovascular
 
Specialty Pharmaceuticals
 
Total
Balance as of December 31, 2017
$
2,877

 
$
417

 
$
3,704

 
$
—

 
$
6,998

Reportable segment revisions
(1,379
)
 
1,379

 
—

 
—

 
—

Foreign currency fluctuations and other changes
(3
)
 
(22
)
 
(3
)
 
—

 
(29
)
Goodwill acquired
568

 
150

 
224

 
—

 
942

Balance as of December 31, 2018
$
2,063

 
$
1,924

 
$
3,925

 
$
—

 
$
7,911

Foreign currency fluctuations and other changes
(1
)
 
—

 
58

 
9

 
66

Goodwill acquired
—

 
268

 
1,712

 
238

 
2,218

Goodwill divested
—

 
—

 
(19
)
 
—

 
(19
)
Balance as of December 31, 2019
$
2,061

 
$
2,192

 
$
5,676

 
$
247

 
$
10,176



We did not have any goodwill impairments in 2019, 2018 or 2017.

Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of December 31, 2019 is as follows (in millions):
Fiscal Year
 
2020
$
787

2021
750

2022
722

2023
708

2024
672



NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.


89

Currency Hedging Instruments
Risk Management Strategy
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions, net investments in certain subsidiaries and the purchase price of any acquisition that is denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in Euro, Japanese yen, Chinese renminbi and British pound sterling. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) on our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within the Cost of products sold caption of our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within AOCI to earnings at that time.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro, Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. We elected to use the spot method to assess effectiveness for our derivatives that are designated as net investment hedges. Under the spot method, the change in fair value attributable to changes in the spot rate is recorded in the Foreign currency translation adjustment (CTA) component of OCI. We have elected to exclude the spot-forward difference from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. Amortization of the spot-forward difference is then reclassified from AOCI to current period earnings as a component of Interest expense on our consolidated statements of operations. In November 2019, we terminated and settled all of our outstanding forward currency contracts designated as net investment hedges in our entities with Euro-denominated functional currencies and recognized a gain of $95 million presented in the CTA component of OCI on our consolidated statements of comprehensive income (loss).

We also completed an offering of €900 million (approximately $1.000 billion) in aggregate principal amount of 0.625% senior notes due in 2027. The Euro-denominated debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional entities. As of December 31, 2019, the notional value of our outstanding net investment hedges was $1.950 billion, which includes our derivative and nonderivative instruments designated as net investment hedges.

We also use forward currency contracts that are not part of designated hedging relationships under FASB ASC Topic 815 as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within the Other, net caption of our consolidated statements of operations.

Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the GBP-denominated purchase price of BTG. In 2019, we settled all outstanding contracts, resulting in a cumulative loss on the contracts of $294 million that was recognized over time in earnings as we adjusted for changes in fair value until the final fair value was determined at maturity. As of December 31, 2018, the notional value of the contracts was $2.550 billion, and we entered into additional contracts in 2019. Upon settlement in 2019, we received £3.312 billion of cash to fund our acquisition of BTG, which translated into $4.303 billion based on hedged currency exchange rates. We recognized a $323 million loss in 2019 and a $29 million gain in 2018 within Other, net due to changes in fair value of the contracts.


90

Interest Rate Hedging Instruments
Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2019 and $1.000 billion outstanding as of December 31, 2018, which were intended to manage our earnings and cash flow exposure to changes in the benchmark interest rate in connection with the forecasted issuance of fixed-rate debt. For outstanding designated cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs, at which time we recognize the gain or loss within Interest expense over the same period that the hedged items affect earnings, so long as the hedge relationship remains effective. If we determine the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the amount of gains or losses from AOCI to earnings at that time.

During the fourth quarter of 2018, we entered into interest rate derivative contracts designated as cash flow hedges having a notional amount of $1.000 billion to hedge interest rate risk. In the first quarter of 2019, we terminated these instruments in connection with our senior notes issuance in the same period as discussed in Note E – Contractual Obligations and Commitments. We recognized an immaterial loss within OCI in 2019 and are reclassifying the amortization of the loss from AOCI into earnings as a component of Interest expense over the same period that the hedged item affects earnings, so long as the hedge relationship remains effective. We are also continuing to reclassify in a similar manner the amortization of the gains or losses of our other previously terminated interest rate derivative instruments that were designated as cash flow hedges. The balance of the deferred amounts on our terminated cash flow hedges within AOCI was a $34 million loss as of December 31, 2019 and a $7 million gain December 31, 2018. We recognized immaterial gains and losses in Interest expense relating to the amortization of our terminated cash flow hedges in the current and prior periods.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2019 and December 31, 2018. Prior to 2018, we terminated interest rate derivative instruments that were designated as fair value hedges and are continuing to recognize the amortization of the gains or losses originally recorded within the Long-term debt caption on our consolidated balance sheets into earnings as a component of Interest expense over the same period that the discount or premium associated with the hedged items affects earnings. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset. The balance of the deferred gains on our terminated fair value hedges within Long-term debt was immaterial as of December 31, 2019 and December 31, 2018. We recognized immaterial gains in Interest expense relating to the amortization of the terminated fair value hedges in the current and prior periods.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)
 
FASB ASC Topic 815 Designation
 
As of December 31,
 
2019
 
2018
Forward currency contracts
 
Cash flow hedge
 
$
3,891

 
$
3,962

Forward currency contracts
 
Net investment hedge
 
953

 
1,483

Foreign currency-denominated debt(1)
 
Net investment hedge
 
997

 
—

Forward currency contracts
 
Non-designated
 
4,377

 
5,880

Interest rate derivative contracts
 
Cash flow hedge
 
—

 
1,000

Total Notional Outstanding
 
 
 
$
10,218

 
$
12,326


(1)
The €900 million (approximately $1.000 billion) debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional subsidiaries.


91

The remaining time to maturity as of December 31, 2019 is within 60 months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts. The Euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 on our accompanying consolidated statements of operations. Refer to Note P – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within the consolidated statements of comprehensive income (loss).
 
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
 
Amount Recognized in OCI on Hedges
 
Consolidated Statements of Operations (1)
 
Amount Reclassified from AOCI into Earnings
 
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Location of Amount Reclassified
Total Amount of Line Item Presented
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss Net of Tax
Year Ended December 31, 2019
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
150

$
(34
)
$
117

 
Cost of products sold
$
3,116

 
$
(73
)
$
16

$
(56
)
Net investment hedges (2)
68

(15
)
53

 
Interest expense
473

 
(43
)
10

(33
)
Foreign currency-denominated debt
 
 
 
 
 
 
 
Net investment hedges
(14
)
3

(11
)
 
Interest expense
473

 
—

—

—

Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
473

 
3

(1
)
2

Year Ended December 31, 2018
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
167

$
(38
)
$
130

 
Cost of products sold
$
2,813

 
$
19

$
(4
)
$
15

Net investment hedges (2)
56

(13
)
43

 
Interest expense
241

 
(27
)
6

(21
)
Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
(44
)
10

(34
)
 
Interest expense
241

 
(1
)
—

(1
)
Year Ended December 31, 2017
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
(101
)
$
37

$
(65
)
 
Cost of products sold
$
2,593

 
$
(64
)
$
23

$
(41
)
Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
229

 
(1
)
—

(1
)
(1)
In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. All other amounts included in earnings related to hedging relationships were immaterial.
(2)
For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.


92

As of December 31, 2019, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging Instrument
 
FASB ASC Topic 815 Designation
 
Location on Consolidated Statements of Operations
 
Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contracts
 
Cash flow hedge
 
Cost of products sold
 
$
77

Forward currency contracts
 
Net investment hedge
 
Interest expense
 
24

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
 
(5
)


Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)
 
Location on Consolidated Statements of Operations
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(343
)
 
$
41

 
$
(25
)
Net gain (loss) on currency transaction exposures
 
Other, net
 
(15
)
 
(30
)
 
10

Net currency exchange gain (loss)
 
 
 
$
(358
)
 
$
11

 
$
(15
)


Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the GBP-denominated purchase price of BTG. In 2019, we settled all outstanding contracts. We recognized a $323 million loss in 2019 and a $29 million gain in 2018 within Net gain (loss) on currency hedge contracts due to changes in fair value of the contracts.
 

93

Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
 
Location on Consolidated Balance Sheets (1)
 
As of December 31,
 
2019
 
2018
Derivative and Nonderivative Assets:
 
 
 
 
 
 
Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
$
72

 
$
55

Forward currency contracts
 
Other long-term assets
 
216

 
183

 
 
 
 
288

 
237

Non-Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
33

 
67

Total Derivative and Nonderivative Assets
 
 
 
$
321

 
$
304

 
 
 
 
 
 
 
Derivative and Nonderivative Liabilities:
 
 
 
 
 
 
Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
$
3

 
$
2

Forward currency contracts
 
Other long-term liabilities
 
8

 
3

Foreign currency-denominated debt
 
Other long-term liabilities
 
998

 
—

Interest rate contracts
 
Other current liabilities
 
—

 
44

 
 
 
 
1,009

 
49

Non-Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
29

 
31

Total Derivative and Nonderivative Liabilities
 
$
1,037

 
$
80

(1)
We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

94

Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
December 31, 2019
 
December 31, 2018
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
50

 
$
—

 
$
—

 
$
50

 
$
13

 
$
—

 
$
—

 
$
13

Publicly-held securities
1

 
—

 
—

 
1

 
—

 
—

 
—

 
—

Hedging instruments
—

 
321

 
—

 
321

 
—

 
304

 
—

 
304

Licensing arrangements
—

 
—

 
518

 
518

 
—

 
—

 
—

 
—

 
$
51

 
$
321

 
$
518

 
$
890

 
$
14

 
$
304

 
$
—

 
$
318

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hedging instruments
$
—

 
$
1,037

 
$
—

 
$
1,037

 
$
—

 
$
80

 
$
—

 
$
80

Contingent consideration liability
—

 
—

 
354

 
354

 
—

 
—

 
347

 
347

Licensing arrangements
—

 
—

 
571

 
571

 
—

 
—

 
—

 
—

 
$
—

 
$
1,037

 
$
925

 
$
1,963

 
$
—

 
$
80

 
$
347

 
$
427



Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $50 million invested in money market and government funds as of December 31, 2019, we had $165 million in interest bearing and non-interest-bearing bank accounts. In addition to $13 million invested in money market and government funds as of December 31, 2018, we had $133 million in interest bearing and non-interest bearing bank accounts.

Our recurring fair value measurements using Level 3 inputs relates to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.

In addition, our recurring fair value measurements using Level 3 inputs relate to our licensing arrangements. In connection with our acquisition of BTG, we acquired intellectual property and related licensing arrangements, principally relating to Zytiga™, as a result of our acquisition of BTG that provides the contractual right to receive future royalty payments.

In the fourth quarter of 2019, we entered into a royalty purchase agreement with the Ontario Municipal Employees Retirement System (OMERS), whereby we sold to OMERS our remaining 50 percent of the future Zytiga™ royalty stream. The purchase price for these royalty interests consisted of an upfront cash payment of $256 million. Prior to our acquisition of BTG, BTG agreed to pay 50 percent of the Zytiga™ royalty stream, net of certain offsets, to the inventors associated with the intellectual property. As such, we do not expect to receive any future cash benefit from Zytiga™ royalties subsequent to our transaction with OMERS. In accordance with FASB ASC Topic 860, Transfers and Servicing, we are accounting for the transfer as a secured borrowing and continue to recognize the financial asset and financial liability in our consolidated balance sheets.

We have elected the fair value option to account for the licensing arrangements' financial asset and financial liability in accordance with FASB ASC Topic 825, Financial Instruments. As of December 31, 2019, we have recorded the fair values of the financial asset and financial liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations.

In connection with our preliminary purchase price allocation of BTG as of the acquisition date, the amount recognized for the financial asset was $567 million in aggregate, comprised of $195 million included in Other current assets and $373 million included in Other long-term assets. The amount recognized for the financial liability was $370 million, comprised of $54 million included in Accounts payable, $104 million included in Other current liabilities and $212 million included in Other long-term liabilities. The amounts above were valued using the fair value option with the exception of the Accounts payable, which was settled in the third quarter. During the fourth quarter, we also recorded the $256 million proceeds received from the sale of the Zytiga royalty stream as an increase in the fair value of the financial liability now accounted for as a secured borrowing, as discussed above. Refer to Note B – Acquisitions and Strategic Investments for further information on the preliminary purchase price allocation of BTG.



95

The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2019 include the following significant unobservable inputs:
Licensing Arrangements
Fair Value as of December 31, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
Financial Asset
$518 million
Discounted Cash Flow
Discount Rate
11
%
-
19%
19%
Projected Year of Payment
2020

-
2028
2024
Financial Liability
$571 million
Discounted Cash Flow
Discount Rate
19%
19%
Projected Year of Payment
2020

-
2027
2023
(1)
Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2019. However, increases or decreases in the financial asset would be substantially offset by increases or decreases in the financial liability, as such our earnings are not subject to material gains or losses from the licensing arrangement.

Changes in the fair value of our licensing arrangements' financial asset was as follows:
(in millions)
 
Balance as of December 31, 2018
$
—

Amounts recorded related to current year acquisition
567

Proceeds from royalty rights
(52
)
Fair value adjustment (expense) benefit
3

Balance as of December 31, 2019
$
518


Changes in the fair value of our licensing arrangements' financial liability was as follows:
(in millions)
 
Balance as of December 31, 2018
$
—

Amounts recorded related to current year acquisition
315

Proceeds from secured borrowings relating to royalty arrangements
256

Balance as of December 31, 2019
$
571



Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments.

Refer to Note C – Goodwill and Other Intangible Assets for a discussion of the fair values.

The fair value of our outstanding debt obligations as of December 31, 2019 was $11.020 billion, of which $1.004 billion relates to the Euro-denominated December 2027 Notes, and as of December 31, 2018 was $7.239 billion. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.

96


NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt of $10.008 billion as of December 31, 2019 and $7.056 billion as of December 31, 2018. The debt maturity schedule for our long-term debt obligations is presented below:
 
 
Issuance Date
 
Maturity Date
 
As of December 31,
 
Stated Interest Rate
(in millions, except interest rates)
 
 
 
2019
 
2018
 
January 2020 Notes
 
December 2009
 
January 2020
 
$
—

 
$
850

 
6.000%
May 2020 Notes
 
May 2015
 
May 2020
 
—

 
600

 
2.850%
May 2022 Notes
 
May 2015
 
May 2022
 
500

 
500

 
3.375%
August 2022 Term Loan
 
August 2019
 
August 2022
 
1,000

 
—

 
 
October 2023 Notes
 
August 2013
 
October 2023
 
244

 
450

 
4.125%
March 2024 Notes
 
February 2019
 
March 2024
 
850

 
—

 
3.450%
May 2025 Notes
 
May 2015
 
May 2025
 
523

 
750

 
3.850%
March 2026 Notes
 
February 2019
 
March 2026
 
850

 
—

 
3.750%
December 2027 Notes
 
November 2019
 
December 2027
 
1,011

 
—

 
0.625%
March 2028 Notes
 
February 2018
 
March 2028
 
434

 
1,000

 
4.000%
March 2029 Notes
 
February 2019
 
March 2029
 
850

 
—

 
4.000%
November 2035 Notes (1)
 
November 2005
 
November 2035
 
350

 
350

 
7.000%
March 2039 Notes
 
February 2019
 
March 2039
 
750

 
—

 
4.550%
January 2040 Notes
 
December 2009
 
January 2040
 
300

 
300

 
7.375%
March 2049 Notes
 
February 2019
 
March 2049
 
1,000

 
—

 
4.700%
Unamortized Debt Issuance Discount
and Deferred Financing Costs
 
 
 
2020 - 2049
 
(83
)
 
(29
)
 
 
Unamortized Gain on Fair Value Hedges
 
 
 
2020-2023
 
7

 
26

 
 
Finance Lease Obligation (2)
 
 
 
Various
 
6

 
6

 
 
Long-term debt
 
 
 
 
 
$
8,592

 
$
4,803

 
 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)
Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(2)
Effective January 1, 2019, we adopted FASB ASC Topic 842, which requires that we recognize finance lease obligations in our consolidated balance sheets. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with FASB ASC Topic 840. Please refer to Note A – Significant Accounting Policies for additional information.

Revolving Credit Facility

On December 19, 2018, we entered into a $2.750 billion revolving credit facility (the 2018 Facility) with a global syndicate of commercial banks and terminated our previous $2.250 billion revolving credit facility (the 2017 Facility), which was scheduled to mature in August 2022. The 2018 Facility will mature on December 19, 2023 with one-year extension options subject to certain conditions. Eurodollar and multicurrency loans bear interest at the Eurocurrency Rate determined for the interest period plus the applicable margin, based on our corporate credit ratings (1.02 percent as of December 31, 2019). ABR loans bear interest at ABR plus the applicable margin of up to 0.40 percent, based on our corporate credit ratings. Under the credit agreement for the 2018 Facility (the 2018 Credit Agreement), we are required to pay a facility fee (0.11 percent as of December 31, 2019) based on our credit ratings and the total amount of revolving credit commitment, regardless of usage of the 2018 Facility. This facility provides backing for the commercial paper program described below. The 2018 Credit Agreement for the 2018 Facility requires that we comply with certain covenants, including financial covenants as described below. There were no amounts borrowed under our current or prior revolving credit facilities as of December 31, 2019 or December 31, 2018.


97

Term Loans

On December 5, 2019, we entered into a $700 million term loan credit agreement scheduled to mature on December 3, 2020 (2020 Term Loan). The 2020 Term Loan bears interest at an annual rate of LIBOR plus a margin of 0.65%. In addition, we pay customary expenses. The credit agreement contains covenants, as described below, and also contains customary events of default, which may result in the acceleration of any outstanding commitments. As of December 31, 2019, we had $700 million outstanding under the 2020 Term Loan, which is presented within Current debt obligations on our consolidated balance sheet. We used the proceeds from the 2020 Term Loan to repay a portion of the Two-Year Delayed Draw Term Loan, described below. In January 2020, we repaid $300 million of the outstanding balance of the 2020 Term Loan with proceeds from our commercial paper program.

On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described below, we terminated the $1.000 billion Term Loan Credit Agreement, entered into on August 20, 2018 and amended on December 19, 2018 (August 2019 Term Loan). The August 2019 Term Loan was scheduled to mature on August 19, 2019. As of December 31, 2018, we had $1.000 billion outstanding under our August 2019 Term Loan, which is presented within Current debt obligations on our consolidated balance sheet.

On December 19, 2018, we entered into a $2.000 billion senior unsecured delayed-draw term loan facility consisting of a $1.000 billion two-year delayed draw term loan credit facility maturing in two years from the date of the closing of our acquisition of BTG (Two-Year Delayed Draw Term Loan) and a $1.000 billion three-year delayed draw term loan credit facility maturing in three years from the date of the closing of our acquisition of BTG (Three-Year Delayed Draw Term Loan). In 2019, we used the proceeds from the Two-Year and Three-Year Delayed Draw Term Loan facilities to refinance the Bridge Facility, as described below, and fund a portion of our acquisition of BTG. On November 27, 2019, we repaid $200 million of the Two-Year Delayed Draw Term Loan with proceeds from the sale of the Zytiga-related royalty interests obtained through the acquisition of BTG and extinguished the facility. On December 5, 2019, we repaid the remaining $800 million with proceeds from the 2020 Term Loan and commercial paper and terminated the Two-Year Delayed Draw Term Loan. Borrowings of the Three-Year Delayed Draw Term Loan are available in U.S. dollars and bear interest at LIBOR or a base rate in each case plus an applicable margin based on our public debt ratings (1.13 percent as of December 31, 2019). The facility contains customary events of default, which may result in the acceleration of any outstanding commitments. As of December 31, 2018, we had no amounts borrowed under the Two-Year Delayed Draw Term Loan or the Three-Year Delayed Draw Term Loan. As of December 31, 2019, we had $1.000 billion outstanding under the Three-Year Delayed Draw Term Loan.

Debt Covenants

As of and through December 31, 2019, we were in compliance with all the required covenants related to our debt obligations.

All existing credit arrangements described above require that we maintain certain financial covenants, as follows:
 
Covenant
Requirement as of December 31, 2019
 

Actual as of December 31, 2019
Maximum leverage ratio (1)
4.75 times
 
3.83 times
(1) Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters.

Our covenants require that we maintain a maximum leverage ratio of 3.75 times, provided, however, that for the two consecutive fiscal quarters ended immediately following the consummation of a Qualified Acquisition, as defined by each agreement, the maximum leverage ratio shall be 4.75 times, and then subject to a step-down for each succeeding fiscal quarter end to 4.50 times, 4.25 times, 4.00 times and then back to 3.75 times for each fiscal quarter end thereafter. On August 19, 2019, we announced the closing of our acquisition of BTG, a Qualified Acquisition, and our maximum leverage ratio was 4.75 times as of December 31, 2019. Refer to Note B – Acquisitions and Strategic Investments for more information.

Our covenants provide for an exclusion from the calculation of consolidated EBITDA, as defined by the agreements, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2019, we had $270 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments does not exceed $2.624 billion in the aggregate. As of December 31, 2019, we had $1.199 billion of the litigation exclusion remaining.

Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there

98

can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2018 Facility, as discussed above. Outstanding commercial paper directly reduces borrowing capacity under the 2018 Facility.
 
As of December 31,
(in millions, except maturity and yield)
2019
 
2018
Commercial paper outstanding
$
711

 
$
1,248

Maximum borrowing capacity
2,750

 
2,750

Borrowing capacity available
2,039

 
1,502

Weighted average maturity
55 days

 
27 days

Weighted average yield
2.21
%
 
3.04
%


Senior Notes

We had senior notes outstanding of $7.661 billion as of December 31, 2019 and $4.800 billion as of December 31, 2018.

In November 2019, we completed an offering of €900 million (approximately $1.000 billion) in aggregate principal amount of 0.625% senior notes due in 2027. The Euro-denominated debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional entities. Refer to Note D – Hedging Activities and Fair Value Measurements for additional information. We used a portion of the net proceeds from our November 2019 senior notes offering to repay certain outstanding principal amounts of our senior notes including $206 million of our $450 million 4.125% senior notes due 2023, $566 million of our $1.000 billion 4.000% senior notes due 2028 and $227 million of our $750 million 3.850% senior notes due 2025 and pay accrued and unpaid interest, premiums, fees and expenses in connection with the transaction. In 2019, we incurred associated debt extinguishment charges of $86 million presented in Other, net on our consolidated statements of operations.

In February 2019, we completed an offering of $4.300 billion in aggregate principal amount of senior notes comprised of $850 million of 3.450% senior notes due March 2024, $850 million of 3.750% senior notes due March 2026, $850 million of 4.000%
senior notes due March 2029, $750 million of 4.550% senior notes due March 2039 and $1.000 billion of 4.700% senior notes due March 2049. We used a portion of the net proceeds from the offering to repay the $850 million plus accrued interest and premium of our 6.000% senior notes due in January 2020, the $600 million plus accrued interest and premium of our 2.850% senior notes due in May 2020 and the $1.000 billion plus accrued interest of our August 2019 Term Loan. In 2019, the remaining proceeds were used to finance a portion of our acquisition of BTG.

In February 2018, we completed an offering of $1.000 billion in aggregate principal amount of 4.000% senior notes, due March 2028. We used a portion of the net proceeds from the offering to repay the $600 million plus accrued interest of our 2.650% senior notes due in October 2018, which were classified as short-term debt as of December 31, 2017. The remaining proceeds were used to repay a portion of our outstanding commercial paper.

Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below).

Our $7.311 billion of senior notes issued in 2009, 2013, 2015, 2018 and 2019 contain a change-in-control provision, which provides that each holder of the senior notes may require us to repurchase all or a portion of the notes at a price equal to 101 percent of the aggregate repurchased principal, plus accrued and unpaid interest, if a rating event, as defined in the indenture, occurs as a result of a change-in-control, as defined in the indenture. Any other credit rating changes may impact our borrowing cost, but do not require us to repay any borrowings.


99

Bridge Facility

On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described above, we terminated the Bridge Facility entered into on November 20, 2018. The termination was pursuant to the terms of the Bridge Facility, which required full termination upon the refinancing of the January 2020 Notes and May 2020 Notes discussed above. There were no amounts borrowed under the Bridge Facility as of December 31, 2018.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in the accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
 
As of December 31, 2019
 
As of December 31, 2018
Factoring Arrangements
Amount
De-recognized
 
Weighted Average Interest Rate
 
Amount
De-recognized
 
Weighted Average Interest Rate
Euro denominated
$
171

 
1.4
%
 
$
165

 
2.7
%
Yen denominated
226

 
0.6
%
 
195

 
0.9
%


BTG Revolving Credit Facility

After closing our acquisition of BTG, we terminated BTG's revolving credit facility with a borrowing capacity of £150 million (or approximately $184 million based on the exchange rate at termination on August 27, 2019), which contained an option to increase the facility by £150 million and was scheduled to expire in November 2020. The termination was effective on August 27, 2019, and there were no amounts outstanding at the time of close of the acquisition.
Other Contractual Obligations and Commitments

We had outstanding letters of credit of $105 million as of December 31, 2019 and $111 million as of December 31, 2018, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2019 and December 31, 2018, none of the beneficiaries had drawn upon the letters of credit or guarantees, accordingly, we have not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets as of December 31, 2019 and December 31, 2018.

Future minimum purchase obligations as of December 31, 2019 were as follows (in millions):
Fiscal Year
Unrecorded Purchase Obligations
2020
$
334

2021
20

2022
7

2023
3

2024
1

Thereafter
1

 
$
366



The amounts in the table above with respect to purchase obligations relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business.

100


NOTE F – LEASES

We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. Effective January 1, 2019, we adopted FASB ASC Topic 842 as discussed in Note A – Significant Accounting Policies. Beginning in 2019, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 60 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.

We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The following table presents supplemental balance sheet information related to our operating leases:
(in millions)
As of December 31, 2019
Assets
 
Operating lease right-of-use assets in Other long-term assets
$
336

Liabilities
 
Operating lease liabilities in Other current liabilities
67

Operating lease liabilities in Other long-term liabilities
276



The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
 
As of December 31, 2019
Weighted average remaining lease term
5.8 years
Weighted average discount rate
3.7%


Our operating lease cost under FASB ASC Topic 842 was $80 million in 2019. Rent expense under FASB ASC Topic 840 amounted to $92 million in 2018 and $88 million in 2017.

The following table presents supplemental cash flow information related to our operating leases:
 
Year Ended
(in millions)
December 31, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
 
Operating cash flows from operating leases
$
77



Right-of-use assets obtained in exchange for operating lease obligations were $137 million as of December 31, 2019.


101

The following table presents the maturities of our operating lease liabilities as of December 31, 2019 (in millions):
Fiscal year
Operating Leases
2020
$
84

2021
71

2022
59

2023
48

2024
41

Thereafter
79

Total future minimum operating lease payments
382

Less: imputed interest
39

Present value of operating lease liabilities
$
343



As of December 31, 2019, we have additional leases for office space and warehouse space, that have not yet commenced, of approximately $70 million. These leases will commence in 2020, with lease terms of up to 15 years.

Future minimum rental commitments as of December 31, 2018, under all noncancellable lease agreements, including capital leases, were as follows:
Fiscal year
Future Minimum Rental Commitments
2019
$
73

2020
61

2021
47

2022
39

2023
31

Thereafter
111

 
$
362



NOTE G – RESTRUCTURING-RELATED ACTIVITIES

2019 Restructuring Plan

On November 15, 2018, the Board of Directors approved, and we committed to a new global restructuring program (the 2019 Restructuring Plan). The 2019 Restructuring Plan is intended to support our effort to improve operating performance and meet anticipated market demands by ensuring that we are appropriately structured and resourced to deliver sustainable value to patients and customers. Key activities under the 2019 Restructuring Plan include supply chain network optimization intended to maximize our global manufacturing and distribution network capacity and building functional capabilities that support business growth. These activities were initiated in 2019, with the majority of activity expected to be complete by the end of 2021.

The following table provides a summary of our estimates of total pre-tax charges associated with the 2019 Restructuring Plan by major type of cost:
Type of Cost
Total Estimated Amount Expected to be Incurred
Restructuring charges:
 
 
 
Termination benefits

$75
 million
 to
$100 million
Other (1)

$25
 million
 to
$50 million
Restructuring-related expenses:
 
 
 
Other (2)

$100
 million
 to
$150 million
 

$200
 million
 to
$300 million
(1)
Consists primarily of consulting fees and costs associated with contractual cancellations.
(2)
Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.

102


Approximately $180 million to $280 million of these charges are expected to result in cash outlays.

2016 Restructuring Plan

On June 6, 2016, our Board of Directors approved, and we committed to a restructuring initiative (the 2016 Restructuring Plan). The 2016 Restructuring Plan was intended to develop global commercialization, technology and manufacturing capabilities in key growth markets, build on our Plant Network Optimization (PNO) strategy which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expand operational efficiencies in support of our operating income margin goals. Key activities under the 2016 Restructuring Plan included strengthening global infrastructure through evolving global real estate assets and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our PNO strategy. These activities were initiated in the second quarter of 2016 and substantially completed in 2019.

The following table provides a summary of total pre-tax charges associated with the 2016 Restructuring Plan by major type of cost:
Type of cost
Total Amount Incurred
Restructuring charges:
 
Termination benefits
$
86
 million
Other (1)
21
 million
Restructuring-related expenses:
 
Other (2)
164
 million
 
$
271
 million
(1)
Consists primarily of consulting fees and costs associated with contract cancellations.
(2)
Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities.

Approximately $255 million of these charges are expected to result in cash outlays; the majority of which were completed as of December 31, 2019.
The following presents the restructuring and restructuring-related charges (credits) by major type and line item within our accompanying consolidated statements of operations (in millions):
Year Ended December 31, 2019
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
38

 
$
—

 
$
—

 
$
38

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
32

 
—

 
32

Selling, general and administrative expenses
—

 
—

 
13

 
13

 
—

 
32

 
13

 
44

 
$
38

 
$
32

 
$
13

 
$
82



Year Ended December 31, 2018
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
32

 
$
—

 
$
4

 
$
36

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
47

 
—

 
47

Selling, general and administrative expenses
—

 
—

 
12

 
12

 
—

 
47

 
12

 
59

 
$
32

 
$
47

 
$
16

 
$
96



103

Year Ended December 31, 2017
Termination
Benefits
 
Transfer Costs
 
Other
 
Total
Restructuring charges
$
25

 
$
—

 
$
12

 
$
37

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
45

 
—

 
45

Selling, general and administrative expenses
—

 
—

 
13

 
13

 
—

 
45

 
13

 
58

 
$
25

 
$
45

 
$
25

 
$
95



The following table presents cumulative restructuring and restructuring-related charges incurred as of December 31, 2019, related to our Restructuring Plans by major type:
(in millions)
2016 Restructuring Plan
 
2019 Restructuring Plan
 
Total
Termination benefits
$
86

 
$
30

 
$
115

Other (1)
21

 
2

 
23

Total restructuring charges
106

 
32

 
138

Transfer costs
126

 
13

 
139

Other (2)
39

 
2

 
41

Restructuring-related charges
164

 
15

 
180

 
$
271

 
$
47

 
$
318

(1)
Consists primarily of consulting fees and costs associated with contract cancellations.
(2)
Comprised of other costs directly related to our Restructuring Plans, including program management, accelerated depreciation, and fixed asset write-offs.

Cash payments associated with our Restructuring Plans were made using cash generated from operations and are comprised of the following:
(in millions)
2016 Restructuring Plan
 
2019 Restructuring Plan
 
Total
Year Ended December 31, 2019
 
 
 
 
 
Termination benefits
$
13

 
$
6

 
$
18

Transfer costs
18

 
13

 
32

Other
10

 
4

 
14

 
$
41

 
$
23

 
$
64



NOTE H – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying consolidated balance sheets are as follows:
Trade accounts receivable, net
 
As of December 31,
(in millions)
2019
 
2018
Accounts receivable
$
1,902

 
$
1,676

Allowance for doubtful accounts
(74
)
 
(68
)
 
$
1,828

 
$
1,608



104


The following is a rollforward of our allowance for doubtful accounts:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Beginning balance
$
68

 
$
68

 
$
73

Net charges to expenses
23

 
19

 
14

Utilization of allowances
(17
)
 
(19
)
 
(18
)
Ending balance
$
74

 
$
68

 
$
68



Inventories
 
As of December 31,
(in millions)
2019
 
2018
Finished goods
$
971

 
$
760

Work-in-process
192

 
100

Raw materials
416

 
306

 
$
1,579

 
$
1,166



Other current assets
 
As of December 31,
(in millions)
2019
 
2018
Restricted cash and restricted cash equivalents
$
346

 
$
655

Derivative assets
105

 
122

Licensing arrangements
186

 
—

Taxes receivable
105

 
37

Other
138

 
107

 
$
880

 
$
921



Property, plant and equipment, net
 
As of December 31,
(in millions)
2019
 
2018
Land
$
117

 
$
97

Buildings and improvements
1,198

 
1,100

Equipment, furniture and fixtures
3,411

 
3,224

Capital in progress
442

 
319

 
5,169

 
4,740

Less: accumulated depreciation
3,089

 
2,958

 
$
2,079

 
$
1,782



Depreciation expense was $311 million in 2019, $296 million in 2018 and $279 million in 2017.


105

Other long-term assets
 
As of December 31,
(in millions)
2019
 
2018
Restricted cash equivalents
$
43

 
$
27

Operating lease right-of-use assets
336

 
—

Derivative assets
216

 
183

Investments
458

 
424

Licensing arrangements
332

 
—

Other
144

 
211

 
$
1,529

 
$
845



Accrued expenses
 
As of December 31,
(in millions)
2019
 
2018
Legal reserves
$
470

 
$
712

Payroll and related liabilities
708

 
630

Accrued contingent consideration
56

 
138

Rebates
298

 
229

Other
576

 
538

 
$
2,109

 
$
2,246



Other current liabilities
 
As of December 31,
(in millions)
2019
 
2018
Deferred revenue
$
144

 
$
115

Licensing arrangements
197

 
—

Taxes payable
265

 
125

Other
195

 
173

 
$
800

 
$
412



Other long-term liabilities
 
As of December 31,
(in millions)
2019
 
2018
Accrued income taxes
$
667

 
$
739

Legal reserves
227

 
217

Accrued contingent consideration
299

 
209

Licensing arrangements
374

 
—

Operating lease liabilities
276

 
—

Other
792

 
717

 
$
2,635

 
$
1,882



106


NOTE I – INCOME TAXES

Our Income (loss) before income taxes consisted of the following:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Domestic
$
(1,145
)
 
$
35

 
$
(408
)
Foreign
1,832

 
1,387

 
1,341

 
$
687

 
$
1,422

 
$
933



The related benefit for income taxes consisted of the following:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Current
 
 
 
 
 
  Federal
$
120

 
$
(221
)
 
$
320

  State
54

 
(27
)
 
9

  Foreign
101

 
160

 
255

 
275

 
(87
)
 
584

 
 
 
 
 
 
Deferred
 
 
 
 
 
  Federal
(146
)
 
(124
)
 
272

  State
(18
)
 
4

 
1

  Foreign
(4,124
)
 
(42
)
 
(28
)
 
(4,288
)
 
(162
)
 
244

 
$
(4,013
)
 
$
(249
)
 
$
828



The reconciliation of income taxes at the federal statutory rate to the actual benefit for income taxes is as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
(reclassified)(1)
U.S. federal statutory income tax rate
21.0
 %
 
21.0
 %
 
35.0
 %
State income taxes, net of federal benefit
6.7
 %
 
0.4
 %
 
(1.0
)%
Domestic taxes on foreign earnings
21.9
 %
 
0.5
 %
 
0.4
 %
Effect of foreign taxes
(47.6
)%
 
(8.3
)%
 
(38.9
)%
Acquisition-related
12.2
 %
 
2.1
 %
 
(1.7
)%
Research credit
(4.2
)%
 
(2.6
)%
 
(2.6
)%
Valuation allowance
1.1
 %
 
(5.2
)%
 
(4.1
)%
Compensation-related
(0.3
)%
 
(1.0
)%
 
(2.5
)%
Non-deductible expenses
3.3
 %
 
0.3
 %
 
2.2
 %
Uncertain tax positions
1.4
 %
 
(22.0
)%
 
10.7
 %
TCJA net impact
—
 %
 
(4.7
)%
 
91.4
 %
Intra-entity intangible asset transfers
(597.0
)%
 
—
 %
 
—
 %
Other, net
(2.5
)%
 
1.8
 %
 
(0.2
)%
 
(584.0
)%
 
(17.5
)%
 
88.8
 %

(1)
Due to the inclusion of new tax provisions in 2018 created by the TJCA, we have reclassified select items in prior years to align with the new categories established in 2018, domestic taxes on foreign earnings and uncertain tax positions.



107

Significant components of our deferred tax assets and liabilities are as follows:
 
As of December 31,
 (in millions)
2019
 
2018
 Deferred Tax Assets:
 
 
 
Inventory costs and related reserves
$
—

 
$
18

Tax benefit of net operating loss and credits
545

 
450

Reserves and accruals
258

 
258

Restructuring-related charges
20

 
12

Litigation and product liability reserves
168

 
221

Investment write-down
42

 
28

Compensation related
121

 
106

Federal benefit of uncertain tax positions
10

 
10

Intangible assets
3,447

 
—

Other
—

 
37

 
4,611

 
1,140

Less: valuation allowance
(915
)
 
(344
)
 
3,696

 
796

 Deferred Tax Liabilities:
 
 
 
Property, plant and equipment
16

 
25

Unrealized gains and losses on derivative financial instruments
52

 
44

Intangible assets
—

 
968

Inventory costs and related services
2

 
—

Other
25

 
—

 
95

 
1,037

 Net Deferred Tax Assets / (Liabilities)
3,601

 
(241
)
Prepaid on intercompany profit
195

 
161

 Net Deferred Tax Assets / (Liabilities) and Prepaid on Intercompany Profit
$
3,796

 
$
(80
)


Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit, are included in the following locations within our accompanying consolidated balance sheets (in millions):
 
Location on Consolidated Balance Sheets
As of December 31,
Component
2019
 
2018
Prepaid on intercompany profit
Prepaid income taxes
$
195

 
$
161

Non-current deferred tax asset
Deferred tax assets
4,196

 
87

Deferred Tax Assets and Prepaid on Intercompany Profit
 
4,391

 
249

 
 
 
 
 
Non-current deferred tax liability
Deferred income taxes
595

 
328

Deferred Tax Liabilities
 
595

 
328

 
 
 
 
 
Net Deferred Tax Assets (Liabilities) and Prepaid on Intercompany Profit
$
3,796

 
$
(80
)


As of December 31, 2019, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $449 million. As of December 31, 2018, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $416 million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $105 million as of December 31, 2019, as compared to $42 million as of December 31, 2018. These tax attributes expire periodically beginning in 2020.

During the fourth quarter of 2019, we completed intra-entity asset transfers of certain intellectual property rights among various wholly-owned subsidiaries. These transactions occurred to more closely align the global economic ownership of our intellectual property rights with our current and future business operations. These transactions did not result in a taxable gain in any jurisdiction,

108

however, some of the transactions did create a step-up in the tax-deductible basis in the transferred intellectual property rights in certain jurisdictions. As a result, we recorded deferred tax assets in the amount of $4.102 billion, which represents the book and tax basis differences measured at applicable statutory tax rates, net of a valuation allowance of $542 million.

After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we established a valuation allowance of $915 million as of December 31, 2019 and $344 million as of December 31, 2018, representing an increase of $571 million. The increase in the valuation allowance as of December 31, 2019, as compared to December 31, 2018, is primarily attributable to an intra-entity transfer of certain intellectual property. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $13 million in 2019, a charge of $37 million in 2018 and a benefit of $63 million in 2017.

We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100.0 percent exemption from income tax in the first eight years of operations and 50.0 percent exemption in the following four years. This tax incentive resulted in income tax savings of $173 million for 2019, $146 million for 2018 and $127 million for 2017. The tax incentive for 100.0 percent exemption from income tax was renewed during 2019 and is expected to expire in 2027. The impact on per share earnings was $0.12 for 2019 and $0.10 for 2018 and $0.09 for 2017. Additionally, we benefit from tax incentives in Puerto Rico. The income tax savings from Puerto Rico were immaterial for 2019, 2018 and 2017.

As of December 31, 2019, we had $455 million of gross unrecognized tax benefits, of which a net $355 million, if recognized, would affect our effective tax rate. As of December 31, 2018, we had $427 million of gross unrecognized tax benefits, of which a net $332 million, if recognized, would affect our effective tax rate. As of December 31, 2017, we had $1.238 billion of gross unrecognized tax benefits, of which a net $1.150 billion, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Beginning Balance
$
427

 
$
1,238

 
$
1,095

Additions based on positions related to the current year
30

 
79

 
134

Additions based on positions related to prior years
45

 
4

 
16

Reductions for tax positions of prior years
(34
)
 
(433
)
 
(3
)
Settlements with taxing authorities
(4
)
 
(459
)
 
(2
)
Statute of limitation expirations
(9
)
 
(3
)
 
(2
)
Ending Balance
$
455

 
$
427

 
$
1,238


We are subject to U.S. Federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2013, with the exception of select issues in 2011 and substantially all material state and local income tax matters through 2010. We have concluded all foreign income tax matters through 2013, with the exception of issues for Italy, which have concluded through 2002.

In the second quarter of 2018, a decision was entered by the U.S. Tax Court resolving all disputes for Guidant Corporation for its 2001 through 2006 tax years and our 2006 and 2007 tax years as well as the tax issues related to our 2006 transaction with Abbott Laboratories. Additionally, we resolved all issues with the IRS Office of Appeals for our 2008 through 2010 tax years. The final settlement calculation resulted in a final net tax payment of $303 million plus $307 million of estimated interest, which was remitted in the second quarter of 2018. Due to the final settlement of these disputes, we recorded a net tax benefit of $250 million in 2018 to remove a reserve related to these years.

In the fourth quarter of 2018, we received a Revenue Agent Report (RAR) from the IRS for our 2011 through 2013 tax years. We remitted $93 million to the IRS in the fourth quarter of 2018 reflecting the net balance of tax and interest due for these years after consideration of amounts owed to us by the IRS. Due to the resolution of these tax years, we recorded a net tax benefit of $90 million to remove a reserve related to these years.

We recognize interest and penalties related to income taxes as a component of income tax expense. We had $19 million accrued for gross interest and penalties as of December 31, 2019 and $11 million as of December 31, 2018. We recognized a benefit of $643 million of gross interest and penalties in our consolidated statements of operations in 2018 primarily related to reaching settlements with the taxing authorities. We recognized net tax benefit related to interest and penalties of $1 million in 2019, as compared to a net tax benefit of $498 million in 2018 and a net tax expense of $154 million in 2017. The decrease in our net tax benefit related to interest and penalties as of December 31, 2019, as compared to December 31, 2018, is related to reaching settlements with the taxing authorities.

109


It is reasonably possible that within the next 12 months we will resolve transactional- related issues with foreign and state taxing authorities, in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately $98 million.

During 2018, we completed our analysis and recording of all tax effects related to the Tax Cuts and Jobs Act, as required under SAB 118, and recorded a net benefit of $67 million, exclusive of the one-time transition tax adjustment described below.

For the year ended December 31, 2017, we were required under the Tax Cuts and Jobs Act (TCJA) to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&P) that we previously deferred from U.S. income taxes. As a result of settling our various tax audits, the revised amount of transition tax is approximately $856 million as of December 31, 2018 as compared to the preliminary amount recorded of approximately $1.044 billion as of December 31, 2017. We anticipate offsetting this liability against existing tax attributes reducing the required payment to approximately $499 million, which will be remitted over an eight-year period. We have begun remitting the required installment payments, with a balance remaining of $420 million as of December 31, 2019. In addition, we have provided for U.S. state income taxes of $18 million on all U.S. dollar-denominated E&P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.

We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.

NOTE J – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.


110

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Our accrual for legal matters that are probable and estimable was $697 million as of December 31, 2019 and $929 million as of December 31, 2018 and includes certain estimated costs of settlement, damages and defense. The decrease in our legal accrual was mainly due to settlement payments associated with product liability cases or claims related to transvaginal surgical mesh products. A portion of our legal accrual is already funded through our qualified settlement fund (QSF), which is included in our restricted cash and restricted cash equivalent balances in Other current assets of $346 million as of December 31, 2019 and $655 million as of December 31, 2018, as discussed in Note A – Significant Accounting Policies.

We recorded litigation-related net charges of $115 million in 2019, $103 million in 2018 and $285 million in 2017. These included litigation-related net charges included a net charge of $223 million in the fourth quarter of 2019, primarily related to litigation with Channel Medsystems, Inc., net charges of $25 million in the third quarter of 2019 and $15 million in the second quarter of 2019, primarily related to transvaginal surgical mesh product liability litigation, and a gain of $148 million recorded in the first quarter of 2019, which represents a portion of the total $180 million one-time settlement payment received from Edwards Lifesciences Corporation (Edwards) in January 2019. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) in our consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses. As such, a portion of the related gain from the Edwards settlement was recorded in Selling, general and administrative expenses on our consolidated statements of operations. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.

In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.

Patent Litigation

On October 28, 2015, BSC filed suit against Cook Group Limited and Cook Medical LLC (collectively, “Cook”) in the District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct Endoscopic Hemoclip. The case was transferred to the District Court for the S.D. Indiana. Cook filed seven Inter Partes Review (“IPR”) requests with the U.S. Patent and Trademark Office against the four asserted patents. All IPRs have concluded with claims confirmed in each patent. Cook and Boston Scientific have both appealed the Patent Office’s IPR decisions to the Federal Circuit Court of Appeals. The district court had stayed the case pending the appeals court decision on the IPRs. 

On November 29, 2016 Nevro Corp. (Nevro) filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Neuromodulation Corporation, in the U.S. District Court for the Northern District of California alleging that six U.S. patents (Alataris) owned by Nevro are infringed by our spinal cord stimulation systems. On June 29, 2017, Nevro amended the complaint to add an additional patent (Fang). On July 24, 2018, summary judgment was entered in favor of the Company and on July 31, 2018, we received final judgment and dismissal of the action. On July 31, 2018, Nevro filed an appeal.

On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro in U.S. District Court for the District of Delaware alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro’s Senza™ Spinal Cord Stimulation System.

On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen. Inc., served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas.

On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in U.S. District Court for the District of Delaware, and

111

amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro’s Senza™ I and Senza™ II Spinal Cord Stimulation Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our Spinal Cord Stimulation systems infringe 5 Nevro patents.

On April 30, 2019, Tissue Anchor Innovations filed a complaint for patent infringement in the United States District Court Central District of California against Fountain Valley Regional Hospital and Medical Center, Los Alamitos Medical Center and us. The complaint alleges that the Solyx™ Sling System infringes US Patent 6,506,190.

Product Liability Litigation

As of January 29, 2020, approximately 54,000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. As of January 29, 2020, we have entered into master settlement agreements in principle or are in the final stages of entering one with certain plaintiffs' counsel to resolve an aggregate of approximately 52,000 cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately 52,000 cases and claims, approximately 46,000 have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered that all manufacturers of surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse stop selling and distributing their products in the United States immediately, stemming from the FDA’s 2016 reclassification of these devices to class III (high risk) devices, and as a result, the Company ceased global sales and distribution of surgical mesh products indicated for transvaginal pelvic organ prolapse. The pending cases are in various federal and state courts in the U.S. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over 3,100 of the cases were specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the U.S. District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. On December 12, 2019 the Mississippi Attorney General filed suit against BSC in State Court alleging violations of the Mississippi Consumer Protection Act which the Company plans to vigorously defend. There were also fewer than 25 cases in Canada, inclusive of one certified class action and fewer than 25 claims in the United Kingdom. We have reached an agreement to settle the Canadian class action pending Court approval.

We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us, that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On May 5, 2014, we were served with a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General. The subpoena seeks information relating to the launch of the Cognis™ and Teligen™ line of devices in 2008, the performance of those devices from 2007 to 2009 and the operation of the Physician Guided Learning Program. We are cooperating with this request. On May 6, 2016, a qui tam lawsuit in this matter was unsealed in the U.S. District Court for the District of Minnesota. At the same time, we learned that the U.S. government and the State of California had earlier declined to intervene in that lawsuit on April 15, 2016. The complaint was served on us on July 21, 2016. On October 7, 2016, the plaintiff/relator served an amended complaint that dropped the allegations relating to the Physician Guided Learning Program. We filed a motion to dismiss the amended complaint on December 7, 2016 and the court heard our motion to dismiss on April 5, 2017. On August 29, 2017, the Court granted the motion to dismiss, without prejudice and on September 19, 2017, the relator filed a Second Amended Complaint. We filed a motion to dismiss the Second Amended Complaint on October 10, 2017 and the Court denied that motion on December 13, 2017. On July 31, 2018, the relator filed a motion seeking leave to file a Third Amended Complaint. The Court denied the motion on October 30, 2018.


112

On February 23, 2015, a judge for the Court of Modena (Italy) ordered a trial for Boston Scientific and three of its employees, as well as numerous other defendants charged in criminal proceedings. The charges arise from allegations that the defendants made improper donations to certain healthcare providers and other employees of the Hospital of Modena in order to induce them to conduct unauthorized clinical trials, as well as related government fraud in relation to the financing of such clinical trials. A trial began on February 24, 2016. On November 10, 2017, the Court issued a ruling that convicted one Boston Scientific employee but acquitted two others and levied a fine of €245 thousand against us and imposed joint and several civil damages of €620 thousand on all defendants. We continue to deny these allegations, timely appealed the decision on May 10, 2018 and intend to continue to defend ourselves vigorously.

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda., as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. We deny the allegations and intend to defend ourselves vigorously.

Other Proceedings

On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments are due pursuant a transaction agreement regarding Labcoat Limited.

On September 6, 2019, Boston Scientific Corporation, Boston Scientific Scimed, Inc., and Fortis Advisors, LLC, as a Securityholder Representative for the former Securityholders of nVision Medical Corp. filed a declaratory judgment action against BioCardia, Inc. in the United States District Court for the Northern District of California to address threats and allegations by BioCardia challenging inventorship and ownership of various patents that Boston Scientific Corporation acquired through an April 13, 2018 merger with nVision as well as related threats and allegations by BioCardia of trade secret misappropriation and unjust enrichment. On December 11, 2019, BioCardia filed an amended answer and counterclaims.

On April 18, 2019, Blue Cross & Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research & Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia. The complaint alleges that the defendants violated the Sherman Act and the antitrust and consumer protections laws of several states by pursuing patent litigation relating to ZYTIGA™ in order to delay generic entry. On June 21, 2019, the case was transferred to the United States District Court for the District of New Jersey and has been consolidated with similar complaints.

On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research & Development, LLC, and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant.

Refer to Note I – Income Taxes for information regarding our tax litigation.

Matters Concluded Since December 31, 2018

On January 15, 2019, we announced that we reached an agreement with Edwards Lifesciences Corporation (Edwards) to settle all outstanding patent disputes between us and Edwards in all venues around the world. All pending cases or appeals in courts and patent offices between the two companies will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices, and left atrial appendage closure devices. Any injunctions currently in place will be lifted. Under the terms of the agreement, Edwards made a one-time payment to us of $180 million. No further royalties will be owed by either party under the agreement. All other terms remain confidential. The previously disclosed matters that have been resolved as a result of this settlement include:

•
On October 30, 2015, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation and Edwards Lifesciences Services GmbH in Düsseldorf District Court in Germany for patent infringement. We allege that Edwards’

113

SAPIEN 3™ Heart Valve infringes our patent related to adaptive sealing technology. On February 25, 2016, we extended the action to allege infringement of a second patent related to adaptive sealing technology. The trial began on February 7, 2017. On March 9, 2017, the court found that Edwards infringed both patents and Edwards appealed.

•
On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.

•
On November 23, 2015, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '672) owned by Edwards is infringed by our Lotus™ Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we did not infringe the Spenser '672 patent. Edwards filed an appeal.

•
On November 23, 2015, Edwards Lifesciences Corporation filed a patent infringement action against us and Boston Scientific Medizintechnik GmbH in the District Court of Düsseldorf, Germany alleging an European patent (Bourang) owned by Edwards is infringed by our Lotus Valve System. The trial began on February 7, 2017. On March 28, 2017, the European Patent Office revoked the Bourang patent and on April 3, 2017, the court suspended the infringement action pending Edwards' appeal of the revocation of the patent at the European Patent Office.

•
On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation (Edwards) in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards’ SAPIEN 3™ Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus™ Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found our patent invalid. The Company filed an appeal before the United States Court of Appeals for the Federal Circuit on May 24, 2018.

•
On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the Central District of California for patent infringement. We allege that Edwards’ aortic valve delivery systems infringe eight of our catheter related patents. On October 13, 2016, Edwards filed a petition for inter partes review of one asserted patent with the USPTO, Patent Trial and Appeal Board. On April 21, 2017, the USPTO denied the petition. On April 19 and 20, 2017, Edwards filed multiple inter partes review petitions against the patents in suit. On September 8, 2017, the court granted a stay of the action pending an inter partes review of the patents in suit.

•
On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus™ Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

•
On October 27, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific, LTD, in the Federal Court of Canada alleging that three Canadian patents (Spenser) owned by Edwards are infringed by our Lotus Transcatheter Heart Valve System.

•
On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

•
On August 1, 2018, the Company filed a patent infringement action on the merits in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3™ Device and Sapien 3 Ultra Device infringed a patent owned by the Company.


114

•
On August 3, 2018, the Company filed a preliminary injunction request in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3 Ultra Device infringed a patent owned by the Company. On October 23, 2018, the court found that the Sapien 3 Ultra Device infringed the patent. Edwards had the right to appeal.

•
On August 22, 2018, Edwards Lifesciences LLC filed a patent infringement action against Boston Scientific Corporation, in the U. S. District Court of Delaware, alleging that two U.S. patents (Schweich) owned by them are infringed by our Watchman™ Left Atrial Appendage Closure Device, Watchman Delivery System and Watchman Access System.

On December 14, 2016, we learned that the Associacao Brasileira de Medicina de Grupo d/b/a ABRAMGE filed a complaint against us, Arthrex and Zimmer Biomet Holdings, in the U.S. District Court for the District of Delaware. This complaint, which ABRAMGE never served against us, alleges that the defendants or their agents paid kickbacks to health care providers in order to increase sales and prices and are liable under a variety of common law theories. On February 6, 2017, ABRAMGE filed and served an amended complaint on us and the other defendants. The amended complaint does not contain any material changes in the allegations against us. Subsequently, on March 2, 2017, ABRAMGE filed a motion to consolidate this lawsuit with two other similar suits that it had brought against Stryker and Abbott Laboratories, in a multidistrict litigation proceeding. On April 13, 2017, we filed a motion to dismiss the amended complaint, as well as a separate opposition to the multidistrict litigation motion and on May 31, 2017, the Joint Panel on Multi-District Litigation denied ABRAMGE’s motion for the multidistrict litigation. On September 1, 2017, ABRAMGE filed a motion for leave to file a Second Amended Complaint, while our motion to dismiss the Amended Complaint remained pending. On September 15, 2017, we filed an opposition to the motion seeking leave to amend. On November 8, 2018, the Court granted ABRAMGE’s motion for leave to file a Second Amended Complaint, while also granting us leave to renew our motion to dismiss. We filed our motion to dismiss the Second Amended Complaint on January 18, 2019. On February 28, 2019, ABRAMGE dismissed its Second Amended Complaint, concluding the lawsuit.

On or about January 12, 2016, Teresa L. Stevens filed a claim against us and three other defendants asserting, for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Southern District of West Virginia, before the same Court that is hearing the mesh MDL. The complaint, which alleges Racketeer Influenced and Corrupt Organizations Act (RICO) violations, fraud, misrepresentation, deceptive trade practices and unjust enrichment, seeks both equitable relief and damages under state and federal law. On January 26, 2016, the Court issued an order staying the case and directing the plaintiff to submit information to allow the FDA to issue a determination with respect to her allegations. In addition, we were in contact with the U.S. Attorney’s Office for the Southern District of West Virginia and responded voluntarily to their requests in connection with that office’s review of the allegations concerning the use of mesh resin in the complaint. We reached a settlement on this matter and this case was dismissed on May 13, 2019.

On February 27, 2017, Carolyn Turner filed a complaint against us and five other defendants asserting for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Middle District of Florida, Orlando Division and alleges violations of the RICO, negligence, strict liability, breach of an express or implied warranty, intentional and negligent misrepresentation, fraud and unjust enrichment. Ms. Turner served this complaint against us on April 7, 2017. As of April 27, 2017, this case was stayed, pending resolution of the transfer petition to the mesh multidistrict litigation. We reached a settlement on this matter and this case was dismissed on February 25, 2019.

On April 24, 2019, a class action complaint was filed in the U.S. District Court for the Southern District of New York against Boston Scientific Corporation, Michael F. Mahoney, our Chief Executive Officer, and Daniel J. Brennan, our Chief Financial Officer. The complaint alleges violations of federal securities laws based on false and/or misleading statements and failure to disclose facts related to the Company’s transvaginal surgical mesh products. On September 20, 2019, the case was dismissed with prejudice.

On March 10, 2017, Imran Niazi filed a patent infringement action against us in the U.S. District Court for the Western District of Wisconsin alleging that a U.S. patent owned by him is infringed by our Acuity™ Lead Delivery System. On June 30, 2017, we filed a motion to dismiss for improper venue and on November 7, 2017 the Wisconsin Court granted the motion to dismiss. On November 13, 2017 Niazi refiled the same action in the U.S. District of Minnesota. We reached a confidential settlement on this matter on February 3, 2020 pursuant to which we anticipate the court will dismiss the pending action.

On August 3, 2012, we were served with a qui tam complaint that had previously been filed under seal against Boston Scientific Neuromodulation Corporation in the U.S. District Court for the District of New Jersey on March 2, 2011. On August 8, 2012, we learned that the federal government had previously declined to intervene in this matter. The relators’ complaint, now unsealed, alleges that Boston Scientific Neuromodulation Corporation violated the federal and various states' false claims acts through

115

submission of fraudulent bills for implanted devices, under-reporting of certain adverse events and promotion of off-label uses. On September 10, 2012, the relators filed an amended complaint revising and restating certain of the claims in the original complaint. Our motion to dismiss, filed subsequently, was denied on May 31, 2013 and on June 28, 2013, we answered the amended complaint and brought certain counterclaims arising from relators’ unauthorized removal of documents from the business during their employments, which the relators moved to dismiss on July 22, 2013. The Court denied relators’ motion to dismiss the counterclaims on September 4, 2014. Following the completion of fact and expert discovery, we filed a motion for summary judgment against all claims on January 27, 2017, relators filed their own motion for summary judgment against our counterclaims that same date. On December 15, 2017, the Court denied both motions for summary judgment. The parties reached a settlement on May 2, 2019, and the Court subsequently ordered the case dismissed, except for any claim by relators to recover attorneys’ fees.

On November 1, 2017, we entered into a definitive agreement with Channel Medsystems, Inc. (Channel) pursuant to which we could have been obligated to pay $145 million in cash up-front and a maximum of $130 million in contingent payments to acquire Channel. The agreement contained a provision allowing Channel to sell the remaining equity interests of Channel to us upon achievement of a regulatory milestone and an option allowing us to acquire the remaining equity interests. We sent a notice of termination of that agreement to Channel in the second quarter of 2018. On September 12, 2018, Channel filed a complaint in Delaware Chancery Court against us for alleged breach of the agreement. Channel alleged that we breached the agreement by terminating it. We have answered the complaint, denied the claims by Channel and counterclaimed to recover part of our investment in Channel, alleging fraud in the inducement. On April 2, 2019, Channel announced its receipt of FDA approval of the Cerene™ Cryotherapy Device. Trial testimony was taken in April 2019, and the post-trial briefing and hearing have been completed. During the third quarter of 2019, Channel notified us that they were exercising their option to sell the remaining equity interests in Channel to us. We responded to the notification that we did not intend to purchase Channel since the previous agreement had been terminated. On December 18, 2019, the Chancery Court ruled that Boston Scientific was in breach of the agreement and granted Channel's request for specific performance to require the Company to complete the purchase. On January 10, 2020, we filed a Notice of Appeal of the Chancery Court’s decision to the Delaware Supreme Court. On February 4, 2020, the Company settled the dispute with Channel resulting in termination of the agreement, payment by the Company of an undisclosed sum and surrender of the Company's equity interest in Channel.

NOTE K – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. As of December 31, 2019 and 2018, we had no shares of preferred stock issued or outstanding.

Common Stock

We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs.

On January 25, 2013, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. Repurchased shares are available for reissuance under our equity incentive plans and for general corporate purposes, including acquisitions. We did not repurchase any shares of our common stock during 2019, 2018 or 2017. As of December 31, 2019, we had remaining $535 million authorized under our 2013 share repurchase program. There were approximately 248 million shares in treasury as of December 31, 2019 and December 31, 2018.

116


NOTE L – STOCK INCENTIVE AND OWNERSHIP PLANS

Employee and Director Stock Incentive Plans

In 2011, our Board of Directors and stockholders approved our 2011 Long-Term Incentive Plan (the 2011 LTIP), authorizing for issuance up to 146 million shares of our common stock. The 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, deferred stock units (DSU), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based DSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 124 million as of December 31, 2019. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee.

Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards and DSUs, issued to employees are generally granted with an exercise price of zero and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.

The following presents the impact of stock-based compensation on our consolidated statements of operations:
 
Year Ended December 31,
(in millions, except per share data)
2019
 
2018
 
2017
Cost of products sold
$
8

 
$
7

 
$
7

Selling, general and administrative expenses
120

 
109

 
98

Research and development expenses
28

 
24

 
23

 
157

 
140

 
127

Income tax (benefit) expense
(24
)
 
(21
)
 
(32
)
 
$
133

 
$
119

 
$
96

Net impact per common share - basic
$
0.10

 
$
0.09

 
$
0.07

Net impact per common share - assuming dilution
$
0.09

 
$
0.08

 
$
0.07



Stock Options

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Options granted (in thousands)
2,992
 
 
3,491
 
 
4,439
 
Weighted-average exercise price
$
40.20
 
 
$
27.26
 
 
$
24.70
 
Weighted-average grant-date fair value
$
11.76
 
 
$
8.55
 
 
$
7.16
 
Black-Scholes Assumptions
 
 
 
 
 
 
 
 
 
 
 
Expected volatility
24
%
 
26
%
 
25
%
Expected term (in years, weighted)
6.1
 
 
6.0
 
 
6.1
 
Risk-free interest rate
1.38
%
-
2.61%
 
2.61
%
-
3.01%
 
2.03
%
-
2.21%


Expected Volatility

We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.

117


Expected Term

We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.

Risk-Free Interest Rate

We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.

Expected Dividend Yield

We have not historically paid cash dividends to our stockholders and currently do not intend to pay cash dividends. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.

Information related to stock options under stock incentive plans are as follows:
 
Stock Options
(in thousands)
 
Weighted
Average
Exercise Price
 
Weighted Average
Remaining
Contractual Life 
(in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 2016
26,644

 
$
11

 
 
 
 
Granted
4,439

 
25

 
 
 
 
Exercised
(3,922
)
 
10

 
 
 
 
Cancelled/forfeited
(445
)
 
17

 
 
 
 
Outstanding as of December 31, 2017
26,716

 
$
13

 
 
 
 
Granted
3,491

 
27

 
 
 
 
Exercised
(4,385
)
 
11

 
 
 
 
Cancelled/forfeited
(519
)
 
22

 
 
 
 
Outstanding as of December 31, 2018
25,304

 
$
16

 
 
 
 
Granted
2,992

 
40

 
 
 
 
Exercised
(4,872
)
 
12

 
 
 
 
Cancelled/forfeited
(359
)
 
24

 
 
 
 
Outstanding as of December 31, 2019
23,065

 
$
19

 
5.5
 
$
594

Exercisable as of December 31, 2019
15,091

 
$
14

 
4.1
 
$
476

Expected to vest as of December 31, 2019
7,617

 
30

 
8.0
 
114

Total vested and expected to vest as of December 31, 2019
22,707

 
$
19

 
5.3
 
$
590


The total intrinsic value of stock options exercised was $140 million in 2019, $90 million in 2018 and $64 million in 2017.

118


Non-Vested Stock

We value restricted stock awards and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:
 
Non-Vested
Stock Award Units
(in thousands)
 
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 2016
18,797

 
$
14

Granted
4,798

 
24

Vested (1)
(7,663
)
 
11

Forfeited
(683
)
 
17

Balance as of December 31, 2017
15,250

 
$
18

Granted
4,375

 
28

Vested (1)
(6,194
)
 
16

Forfeited
(748
)
 
22

Balance as of December 31, 2018
12,683

 
$
22

Granted
3,656

 
39

Vested (1)
(4,811
)
 
20

Forfeited
(449
)
 
27

Balance as of December 31, 2019
11,079

 
$
29

(1)
The number of restricted stock units vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.

The total vesting date fair value of stock award units that vested was approximately $193 million in 2019, $170 million in 2018 and $190 million in 2017.

Market-based DSU Awards

During 2019, 2018 and 2017, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&P 500 Healthcare Index over a three-year performance period. The number of DSUs ultimately granted under this program range from 0 percent to 200 percent of the target number of performance-based DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based DSUs that satisfied the market performance criteria.

We determined the fair value of the market-based DSU awards to be approximately $10 million for 2019, $7 million for 2018 and $8 million for 2017. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 
2019
 
2018
 
2017
 
Awards
 
Awards
 
Awards
Stock price on date of grant
$
40.12

 
$
27.09

 
$
24.55

Measurement period (in years)
2.9

 
2.9

 
2.8

Risk-free rate
2.48
%
 
2.36
%
 
1.45
%

We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.

119


Free Cash Flow Performance-based DSU Awards

During 2019, 2018 and 2017, we granted free cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based DSUs is based on our adjusted free cash flow (AFCF) measured against our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st of each year and ending December 31st. The number of DSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based DSUs that satisfied the performance criteria.

The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2019:
 
2019 AFCF
 
2018 AFCF
 
2017 AFCF
Fair value, net of forfeitures to date (in millions)
$
8

 
$
11

 
$
6

Achievement of target payout
90
%
 
118
%
 
98
%
Year-end stock price used in determining fair value
$
45.22

 
$
35.34

 
$
24.79


We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.

Expense Attribution

We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.

We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, Compensation – Stock Compensation allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately six percent to all unvested stock-based awards as of December 31, 2019, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.

Unrecognized Compensation Cost

We expect to recognize the following future expense for awards outstanding as of December 31, 2019:
 
 Unrecognized
 Compensation Cost
(in millions) (1)
 
Weighted Average Remaining
Vesting Period
(in years)
Stock options
$
35

 
 
Non-vested stock awards
169

 
 
 
$
204

 
1.2
(1)
Amounts presented represent compensation cost, net of estimated forfeitures.

120


Employee Stock Purchase Plans

Our global employee stock purchase plan provides for the granting of options to purchase up to 50 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2019, there were approximately 8 million shares available for future issuance under the employee stock purchase plan.

Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Shares issued or to be issued (in thousands)
2,196
 
 
2,452
 
 
2,491
 
Range of purchase prices
$
29.29

-
$36.47
 
$
21.49

-
$27.91
 
$
18.60

-
$21.07
Expense recognized (in millions)
$
19
 
 
$
17
 
 
$
13
 


We use the Black-Scholes option-pricing model to calculate the grant-date fair value of shares issued under the employee stock purchase plan. We recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period.

NOTE M – WEIGHTED AVERAGE SHARES OUTSTANDING

 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Weighted average shares outstanding - basic
1,391.5

 
1,381.0

 
1,370.1

Net effect of common stock equivalents
19.0

 
20.4

 
22.6

Weighted average shares outstanding - assuming dilution
1,410.6

 
1,401.4

 
1,392.7



The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.

NOTE N – SEGMENT REPORTING

We have three reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices. We measure and evaluate our reportable segments based on net sales of reportable segments, operating income of reportable segments, excluding intersegment profits, and operating income of reportable segments as a percentage of net sales of reportable segments. Operating income of reportable segments as a percentage of net sales of reportable segments is defined as operating income of reportable segments divided by net sales of reportable segments. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition/divestitures-related items, restructuring and restructuring-related items, medical device regulation charges and litigation-related charges/(credits). Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes on the consolidated statements of operations and are included in the reconciliation below.

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG, which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.



121

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows (in millions, except percentages):
 
Year Ended December 31,
Net sales
2019
 
2018
 
2017
MedSurg
$
3,307

 
$
3,007

 
$
2,742

Rhythm and Neuro
3,140

 
3,041

 
2,808

Cardiovascular
4,208

 
3,777

 
3,500

Total net sales of reportable segments
10,654

 
9,823

 
9,048

All other (Specialty Pharmaceuticals)
81

 
n/a

 
n/a

Consolidated net sales
$
10,735

 
$
9,823

 
$
9,048



 
Year Ended December 31,
Depreciation expense
2019
 
2018
 
2017
MedSurg
$
75

 
$
72

 
$
68

Rhythm and Neuro
92

 
91

 
91

Cardiovascular
138

 
133

 
120

Total depreciation expense of reportable segments
306

 
296

 
279

All other (Specialty Pharmaceuticals)
6

 
n/a

 
n/a

Consolidated depreciation expense
$
311

 
$
296

 
$
279


 
Year Ended December 31,
Income (loss) before income taxes
2019
 
2018
 
2017
MedSurg
$
1,204

 
$
1,102

 
$
984

Rhythm and Neuro
666

 
655

 
537

Cardiovascular
1,137

 
1,117

 
988

Total operating income of reportable segments
3,007

 
2,875

 
2,509

All other (Specialty Pharmaceuticals)
56

 
n/a

 
n/a

Unallocated amounts:
 
 
 
 
 
Corporate expenses, including hedging activities
(264
)
 
(372
)
 
(252
)
Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and EU MDR implementation costs
(582
)
 
(398
)
 
(407
)
Amortization expense
(699
)
 
(599
)
 
(565
)
Operating income (loss)
1,518

 
1,506

 
1,285

Other expense, net
(831
)
 
(85
)
 
(353
)
Income (loss) before income taxes
$
687

 
$
1,422

 
$
933


Operating income of reportable segments as a percentage of net sales of reportable segments
Year Ended December 31,
2019
 
2018
 
2017
MedSurg
36.4
%
 
36.7
%
 
35.9
%
Rhythm and Neuro
21.2
%
 
21.5
%
 
19.1
%
Cardiovascular
27.0
%
 
29.6
%
 
28.2
%


122

 
As of December 31,
Total assets
2019
 
2018
MedSurg
$
1,803

 
$
1,846

Rhythm and Neuro
1,873

 
1,696

Cardiovascular
2,535

 
1,954

Total assets of reportable segments
6,211

 
5,497

All other (Specialty Pharmaceuticals)
211

 
—

Goodwill
10,176

 
7,911

Other intangible assets, net
7,886

 
6,372

All other corporate assets
6,082

 
1,219

 
$
30,565

 
$
20,999



 
As of December 31,
Long-lived assets
2019
 
2018
 
2017
U.S.
$
1,148

 
$
1,061

 
$
1,065

Ireland
327

 
242

 
210

Other countries
604

 
478

 
422

Property, plant and equipment, net
2,079

 
1,782

 
1,697

Goodwill
10,176

 
7,911

 
6,998

Other intangible assets, net
7,886

 
6,372

 
5,837

Operating lease right-of-use assets in Other long-term assets
336

 
—

 
—

 
$
20,477

 
$
16,064

 
$
14,531



NOTE O – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
 
Year Ended December 31,
 
2019
 
2018
 
2017
Businesses
U.S.
 
OUS
 
Total
 
U.S.
 
OUS
 
Total
 
U.S.
 
OUS
 
Total
Endoscopy
$
1,080

 
$
814

 
$
1,894

 
$
980

 
$
781

 
$
1,762

 
$
894

 
$
724

 
$
1,619

Urology and Pelvic Health
1,005

 
408

 
1,413

 
864

 
381

 
1,245

 
785

 
339

 
1,124

Cardiac Rhythm Management
1,135

 
804

 
1,939

 
1,159

 
792

 
1,951

 
1,135

 
760

 
1,895

Electrophysiology
148

 
180

 
329

 
150

 
161

 
311

 
136

 
142

 
278

Neuromodulation
695

 
178

 
873

 
624

 
155

 
779

 
517

 
118

 
635

Interventional Cardiology
1,293

 
1,522

 
2,816

 
1,154

 
1,436

 
2,590

 
1,122

 
1,297

 
2,419

Peripheral Interventions
741

 
651

 
1,392

 
608

 
579

 
1,187

 
575

 
506

 
1,081

Specialty Pharmaceuticals
70

 
11

 
81

 
n/a

 
n/a

 
n/a

 
n/a

 
n/a

 
n/a

Net Sales
$
6,167

 
$
4,569

 
$
10,735

 
$
5,538

 
$
4,286

 
$
9,823

 
$
5,162

 
$
3,885

 
$
9,048



123

 
Year Ended December 31,
Geographic Regions
2019
 
2018
 
2017
U.S.
$
6,097

 
$
5,538

 
$
5,162

EMEA (Europe, Middle East and Africa)
2,264

 
2,176

 
1,940

APAC (Asia-Pacific)
1,898

 
1,727

 
1,587

LACA (Latin America and Canada)
395

 
383

 
358

Medical Devices
10,654

 
9,823

 
9,048

U.S.
70

 
n/a

 
n/a

OUS
11

 
n/a

 
n/a

Specialty Pharmaceuticals
81

 
n/a

 
n/a

Net Sales
$
10,735

 
$
9,823

 
$
9,048

 
 
 
 
 
 
Emerging Markets (1)
$
1,252

 
$
1,097

 
$
931

(1)
We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our deferred revenue balance was $400 million as of December 31, 2019 and $373 million as of December 31, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of $143 million in 2019 that was included in the above December 31, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.

NOTE P – CHANGES IN OTHER COMPREHENSIVE INCOME

The following table provides the reclassifications out of Other comprehensive income, net of tax:
(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33

Other comprehensive income (loss) before reclassifications
228

 
116

 
—

 
(22
)
 
322

(Income) loss amounts reclassified from accumulated other comprehensive income
(33
)
 
(54
)
 
—

 
2

 
(86
)
Total other comprehensive income (loss)
195

 
62

 
—

 
(20
)
 
237

Balance as of December 31, 2019
$
142

 
$
173

 
$
—

 
$
(45
)
 
$
270




124

(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2017
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
—

 
96

 
—

 
(2
)
 
94

(Income) loss amounts reclassified from accumulated other comprehensive income
(21
)
 
14

 
1

 
4

 
(3
)
Total other comprehensive income (loss)
(21
)
 
110

 
—

 
2

 
91

Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33



Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.

As a result of adopting ASC Update No. 2016-01 in the first quarter of 2018, we recorded a cumulative effect adjustment to retained earnings to reclassify unrealized gains and losses from our equity investments previously recorded to Accumulated other comprehensive income (loss), net of tax. These equity investments were classified as available-for-sale securities under the former accounting guidance, and we now refer to these investments as publicly-held equity securities. Refer to Note A – Significant Accounting Policies for additional information.

The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from Accumulated other comprehensive income (loss), net of tax were reduced by immaterial income tax impacts in 2019 and in 2018.

NOTE Q – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements.

Standards to be Implemented

ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. We expect the adoption will have an immaterial impact on our financial position and results of operations.

ASC Update No. 2018-15

In August 2018, the FASB issued ASC Update No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.


125

ASC Update No. 2018-18

In November 2018, the FASB issued ASC Update No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying The Interaction Between Topic 808 and Topic 606. The purpose of Update No. 2018-18 is to clarify the interaction between FASB ASC Topic 808 and FASB ASC Topic 606 as FASB ASC Topic 808 did not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements was often based on an analogy to other accounting literature or an accounting policy election. Update No. 2018-18 is effective for annual periods beginning after December 15, 2019. We plan to adopt Update No. 2018-18 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.

No other new accounting pronouncements, issued or effective, during the period had, or is expected to have, a material impact on our consolidated financial statements.

NOTE R - EMPLOYEE RETIREMENT PLANS

Defined Benefit Pension Plans

Domestic Retirement Plans

Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan.

We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and division presidents. Participants may retire with benefits once retirement conditions have been satisfied.

U.K. Plan

As a result of our acquisition of BTG, we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom (U.K.) employees (U.K. Plan). The U.K. Plan was closed to new entrants as of June 1, 2004. Prior to the acquisition close date of August 19, 2019, the Trustees of the U.K. Plan executed buy-in arrangements (Buy-in Contracts), which effectively, as structured under the Buy-in Contracts, are intended to provide payments designed to equal all future designated contractual benefit payments to covered participants. The benefit obligation of the pension plan is not transferred to the insurers, and we remain responsible for paying pension benefits. We do not anticipate any additional material contributions or payments to the U.K. Plan or the insurer.

In connection with our preliminary purchase price allocation of BTG, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets as of the August 19, 2019 measurement date:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
U.K. Plan
0.4%
 
0.4%
 
3.4%

As of the measurement date of August 19, 2019, the funded status was as follows:
(in millions)
 
Fair value of plan assets
$
213

Benefit obligation
(216
)
Funded status
$
(3
)


Refer to Note B – Acquisitions and Strategic Investments for additional information on our acquisition of BTG.

Information about the U.K. Plan presented below is as of the December 31, 2019 measurement date.




126

Other International Retirement Plans

In addition, we maintain retirement plans covering certain international employees.

We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI. As of December 31, 2019 and 2018, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:
 
As of December 31, 2019
(in millions)
Accumulated Benefit Obligation (ABO)
 
Projected
Benefit
Obligation (PBO)
 
Fair value of Plan Assets
 
Unfunded/Underfunded
PBO Recognized
Domestic Retirement Plans
$
50

 
$
54

 
$
—

 
$
54

U.K. Plan
212

 
212

 
209

 
3

Other International Retirement Plans
204

 
223

 
123

 
100

 
$
466

 
$
488

 
$
332

 
$
156



 
As of December 31, 2018
(in millions)
Accumulated Benefit Obligation (ABO)
 
Projected
Benefit
Obligation (PBO)
 
Fair value of Plan Assets
 
Unfunded/Underfunded PBO Recognized
Domestic Retirement Plans
$
47

 
$
50

 
$
—

 
$
50

International Retirement Plans
166

 
182

 
107

 
75

 
$
213

 
$
232

 
$
107

 
$
125



A rollforward of the changes in the PBO for our retirement plans is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
Beginning obligations
$
232

 
$
207

Acquired and established plans(1)
216

 
23

Service costs
15

 
14

Interest costs
5

 
4

Actuarial (gain) loss
—

 
(1
)
Plan amendments and assumption changes
11

 
(2
)
Benefits paid
(10
)
 
(10
)
Impact of foreign currency fluctuations
19

 
(3
)
Ending obligation
$
488

 
$
232

(1)
Plans obtained through acquisition and other increases in connection with our international operations. Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

The critical assumptions associated with our employee retirement plans for 2019 are as follows:
 
Weighted Average Discount Rate
 
Weighted Average Expected Return on Plan
 
Weighted Average Rate of Compensation Increase(1)
 
 
 
Domestic Retirement Plans
2.94%
 
n/a
 
1.50%
U.K. Plan
0.60%
 
0.60%
 
3.00%
Other International Retirement Plans
0.75%
 
2.05%
 
2.65%
(1)
Rates of compensation increase were not weighted by the relative fair value of the instruments. As such, the amount represents the median of the inputs and is not a weighted average.


127

The critical assumptions associated with our employee retirement plans for 2018 are as follows:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
Domestic Retirement Plans
4.00
%
-
4.25%
 
n/a
 
3.00%
International Retirement Plans
0.50
%
-
2.34%
 
1.90
%
-
4.10%
 
1.50
%
-
6.78%


A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
Beginning fair value
$
107

 
$
87

Acquired and established plans(1)
213

 
16

Actual return on plan assets
7

 
(2
)
Employer contributions
13

 
14

Participant contributions
2

 
2

Actuarial gain (loss)
(20
)
 
—

Benefits paid
(10
)
 
(10
)
Impact of foreign currency fluctuations
19

 
—

Ending fair value
$
332

 
$
107

(1)
Plans obtained through acquisition and other increases in connection with our international operations. Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

For our defined benefit plans excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.

For our U.K. Plan, we utilize the insurance buy-in methodology and base our discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2019. We believe this is a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate is calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assume that all pension increases will continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which will be based on Consumer Price Inflation (CPI). We base our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy is to invest in fully matching assets. This has been achieved through the purchase of two buy-in policies (Buy-in contracts), which provide payments designed to equal all future benefit payments due from the fund. As of December 31, 2019, the Buy-in contracts represented 99% of the total plan assets, as compared to the target percentage of 100%, and are considered Level 3 investments.

The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value as of December 31, 2019:
 
As of
 
December 31, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Buy-in contracts
$
—

 
$
—

 
$
207

 
$
207

Cash
1

 
—

 
—

 
1

Total assets
$
1

 
$
—

 
$
207

 
$
209




128

Changes in the fair value of the U.K. Plan Level 3 assets were as follows:
(in millions)
Buy-in Contracts
Balance as of December 31, 2018
$
—

Acquired plans(1)
213

Actuarial gain (loss)
(20
)
Benefits paid
(4
)
Impact of foreign currency fluctuations
19

Balance as of December 31, 2019
$
209

(1)
Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

Defined Contribution Plan

We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $98 million in 2019, $87 million in 2018 and $79 million in 2017.

129

QUARTERLY RESULTS OF OPERATIONS
(in millions, except per share data)
(unaudited)

 
Three Months Ended
 
Mar 31,
 
June 30,
 
Sept 30,
 
Dec 31,
2019
 
 
 
 
 
 
 
Net sales
$
2,493

 
$
2,631

 
$
2,707

 
$
2,905

Gross profit
1,763

 
1,873

 
1,930

 
2,054

Operating income (loss)
541

 
384

 
383

 
210

Net income (loss)
424

 
154

 
126

 
3,996

Net income (loss) per common share - basic
$
0.31

 
$
0.11

 
$
0.09

 
$
2.87

Net income (loss) per common share - assuming dilution
$
0.30

 
$
0.11

 
$
0.09

 
$
2.83

 
 
 
 
 
 
 
 
2018
 
 
 
 
 
 
 
Net sales
$
2,379

 
$
2,490

 
$
2,393

 
$
2,561

Gross profit
1,707

 
1,751

 
1,720

 
1,832

Operating income (loss)
407

 
392

 
388

 
319

Net income (loss)
298

 
555

 
432

 
386

Net income (loss) per common share - basic
$
0.22

 
$
0.40

 
$
0.31

 
$
0.28

Net income (loss) per common share - assuming dilution
$
0.21

 
$
0.40

 
$
0.31

 
$
0.27


Our reported results for 2019 included EU MDR implementation charges, amortization expense, intangible asset impairment charges, acquisition/divestiture-related net charges, restructuring and restructuring-related net charges, litigation-related net charges, debt extinguishment charges, certain investment impairment charges, certain deferred tax benefits and certain discrete tax items (after tax) of: $66 million in charges in the first quarter, $396 million in charges in the second quarter, $424 million in charges in the third quarter and $3,353 million of credits in the fourth quarter. These after-tax net credits consisted primarily of: deferred tax benefits of $4,102 million arising from an intra-entity asset transfer of intellectual property, partially offset by $672 million of acquisition / divestiture-related net charges primarily related to the BTG acquisition and $628 million of amortization expense.

Our reported results for 2018 included amortization expense, intangible asset impairment charges, acquisition-related net charges, restructuring and restructuring-related net charges, litigation-related net charges, certain investment impairment charges and certain discrete tax items (after tax) of: $157 million in the first quarter, $13 million in the second quarter, $53 million in the third quarter and $166 million in the fourth quarter. These after-tax net charges consisted primarily of: $328 million credit related to certain discrete tax items and $520 million of amortization expense.
 



130


ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer (CEO) and Executive Vice President and Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2019 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and ensure that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that as of December 31, 2019, our disclosure controls and procedures were effective.
Management’s Annual Report on Internal Control over Financial Reporting
Management’s annual report on our internal control over financial reporting is contained in Item 7 of this Annual Report.
Report of Independent Registered Public Accounting Firm on Internal Control over Financial Reporting
The report of Ernst & Young LLP on our internal control over financial reporting is contained in Item 7 of this Annual Report.
Changes in Internal Control over Financial Reporting
During the quarter ended December 31, 2019, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION
None.


131


PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this Item is set forth in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2019 and is incorporated into this Annual Report by reference.

ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item is set forth in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2019 and is incorporated into this Annual Report by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this Item is set forth in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2019 and is incorporated into this Annual Report by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
The information required by this Item is set forth in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2019 and is incorporated into this Annual Report by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required by this Item is set forth in our Proxy Statement for the 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days of December 31, 2019 and is incorporated into this Annual Report by reference.


132

PART IV


ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a)(1) Financial Statements.
The response to this portion of Item 15 is set forth under Item 8.
(a)(2) Financial Statement Schedules.
The response to this portion of Item 15 (Schedule II) follows the signature page to this report. All other financial statement schedules are not required under the related instructions or are inapplicable and therefore have been omitted.
(a)(3) Exhibits (* documents filed or furnished with this report, ** certain schedules and exhibits omitted pursuant to Item 601(b)(2) of Regulation S-K. We agree to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request, # compensatory plans or arrangements)
 
 
 
EXHIBIT
NO.
 TITLE
 
 
 
 
 
 
2.1
 
 
 
 
3.1
 
 
 
 
3.2
 
 
 
 
4.1
 
Specimen Certificate for shares of the Company's Common Stock (incorporated herein by reference to Exhibit 4.1, Registration No. 33-46980).
 
 
 
4.2*
 
 
 
 
4.3
 
 
 
 
4.4
 
 
 
 
4.5
 
 
 
 
4.6
 
 
 
 
4.7
 

133

 
 
 
4.8
 
 
 
 
4.9
 
 
 
 
4.10
 
 
 
 
4.11
 
 
 
 
4.12
 
 
 
 
4.13
 
 
 
 
4.14
 
 
 
 
4.15
 
 
 
 
4.16
 
 
 
 
4.17
 
 
 
 
4.18
 
 
 
 
4.19
 
 
 
 
4.20
 
 
 
 
4.21
 
 
 
 
4.22
 
 
 
 
4.23
 
 
 
 

134

4.24
 
 
 
 
10.1
 
 
 
 
10.2
 
 
 
 
10.3
 
 
 
 
10.4
 
 
 
 
10.5
 
 
 
 
10.6
 
 
 
 
10.7
 
 
 
 
10.8
 
Transaction Agreement, dated as of January 8, 2006, as amended, between the Company and Abbott Laboratories (incorporated herein by reference to Exhibit 10.47, Exhibit 10.48, Exhibit 10.49 and Exhibit 10.50, Annual Report on Form 10-K for year ended December 31, 2005 and Exhibit 10.1, Current Report on Form 8-K dated April 7, 2006, File No. 1-11083).
 
 
 
10.9
 
 
 
 
10.10
 
 
 
 
10.11
 
 
 
 
10.12
 
 
 
 

135

10.13
 
Form of Boston Scientific Corporation Excess Benefit Plan, as amended (incorporated herein by reference to Exhibit 10.1, Current Report on Form 8-K dated June 29, 2005 and Exhibit 10.4, Current Report on Form 8-K dated December 16, 2008, File No. 1-11083).#
 
 
 
10.14
 
 
 
 
10.15
 
 
 
 
10.16
 
 
 
 
10.17
 
 
 
 
10.18
 
 
 
 
10.19
 
 
 
 
10.20
 
Boston Scientific Corporation 2000 Long-Term Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.20, Annual Report on Form 10-K for the year ended December 31, 1999, Exhibit 10.18, Annual Report on Form 10-K for the year ended December 31, 2001, Exhibit 10.1, Current Report on Form 8-K dated December 22, 2004, Exhibit 10.3, Current Report on Form 8-K dated May 9, 2005, and Exhibit 10.3, Current Report on Form 8-K dated December 16, 2008, File No. 1-11083).#
 
 
 
10.21
 
 
 
 
10.22
 
 
 
 
10.23
 
 
 
 
10.24
 

 
 
 
10.25
 
 
 
 
10.26
 
 
 
 
10.27
 

136

 
 
 
10.28
 
 
 
 
10.29
 
 
 
 
10.30
 
 
 
 
10.31
 
 
 
 
10.32
 
 
 
 
10.33
 
 
 
 
10.34
 
 
 
 
10.35
 
 
 
 
10.36
 
 
 
 
10.37
 
 
 
 
10.38
 
 
 
 
10.39
 
 
 
 
10.40
 
 
 
 
10.41
 
 
 
 

137

10.42
 
 
 
 
10.43
 
 
 
 
10.44
 
 
 
 
10.45
 
 
 
 
10.46
 
 
 
 
10.47
 
 
 
 
10.48
 
 
 
 
10.49
 
 
 
 
10.50
 
 
 
 
10.51
 
 
 
 
10.52
 
 
 
 
10.53
 
 
 
 
10.54
 
 
 
 
10.55
 
 
 
 

138

10.56
 
 
 
 
10.57
 
 
 
 
10.58
 
 
 
 
10.59
 
 
 
 
10.60
 
 
 
 
10.61
 
 
 
 
10.62
 
 
 
 
10.63
 
 
 
 
10.64
 
 
 
 
10.65
 
 
 
 
10.66
 
 
 
 
10.67
 
 
 
 
10.68
 
 
 
 
10.69
 
 
 
 

139

10.70
 
 
 
 
10.71
 
 
 
 
10.72
 
 
 
 
10.73
 
 
 
 
10.74
 
 
 
 
10.75
 
 
 
 
10.76
 
 
 
 
10.77
 
 
 
 
10.78
 
 
 
 
10.79
 
 
 
 
10.80
 
 
 
 
10.81
 
 
 
 
10.82
 
 
 
 
10.83
 
 
 
 

140

10.84
 
 
 
 
10.85
 
 
 
 
10.86
 
 
 
 
10.87
 
 
 
 
10.88
 
 
 
 
10.89
 
 
 
 
10.90
 
 
 
 
10.91
 
 
 
 
10.92
 
 
 
 
10.93
 
 
 
 
10.94
 
 
 
 
10.95
 
 
 
 
10.96
 
 
 
 

141

10.97
 
 
 
 
10.98
 
 
 
 
10.99
 
 
 
 
10.100
 
 
 
 
10.101
 
 
 
 
10.102
 
 
 
 
10.103
 
 
 
 
10.104
 
 
 
 
10.105
 
 
 
 
10.106
 
 
 
 
10.107
 
 
 
 
10.108
 
 
 
 
10.109
 
 
 
 
10.110
 
 
 
 

142

10.111
 
 
 
 
10.112
 
 
 
 
10.113
 
 
 
 
10.114
 
 
 
 
10.115
 
 
 
 
10.116
 
 
 
 
10.117
 
 
 
 
10.118
 
 
 
 
10.119
 
 
 
 
10.120
 
 
 
 
10.121
 
 
 
 
21*
 
 
 
 
23*
 
 
 
 
31.1*
 
 
 
 
31.2*
 
 
 
 
32.1*
 
 
 
 

143

32.2*
 
 
 
 
101.SCH*
 
XBRL Taxonomy Extension Schema Document.
 
 
 
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document.
 
 
 
101.DEF*
 
XBRL Taxonomy Extension Definition Linkbase Document.
 
 
 
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document.
 
 
 
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document.
 
 
 
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)
 
 
 






144

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
 
 
 
 
Dated: February 25, 2020
 
Boston Scientific Corporation
 
 
 
 
 
 
 
By:
 
 /s/ Daniel J. Brennan
 
 
 
 
 
 
 
 
 
Daniel J. Brennan
 
 
 
 
Executive Vice President and Chief Financial Officer
 
 
 
 
(duly authorized officer and principal financial officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
 /s/ Daniel J. Brennan
 
 
 
 
 
 
 
 
 
Daniel J. Brennan
 
 
 
 
Executive Vice President and Chief Financial Officer
 
 
 
 
(Principal Financial Officer)

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
/s/ Michael F. Mahoney
 
 
 
 
 
 
 
 
 
Michael F. Mahoney
 
 
 
 
Director, Chairman of the Board,
President and Chief Executive Officer
 
 
 
 
(Principal Executive Officer)

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
 /s/ Jonathan R. Monson
 
 
 
 
 
 
 
 
 
Jonathan R. Monson
 
 
 
 
Vice President, Global Controller and Chief Accounting Officer
 
 
 
 
(Principal Accounting Officer)


145

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
/s/ Nelda J. Connors
 
 
 
 
 
 
 
 
 
Nelda J. Connors
 
 
 
 
Director
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
/s/ Charles J. Dockendorff
 
 
 
 
 
 
 
 
 
Charles J. Dockendorff
 
 
 
 
Director
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
/s/ Yoshiaki Fujimori
 
 
 
 
 
 
 
 
 
Yoshiaki Fujimori
 
 
 
 
Director
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
/s/ Donna A. James
 
 
 
 
 
 
 
 
 
Donna A. James
 
 
 
 
Director
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
 /s/ Edward J. Ludwig
 
 
 
 
 
 
 
 
 
Edward J. Ludwig
 
 
 
 
Director
 
 
 
 
 


146

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
 /s/ Stephen P. MacMillan
 
 
 
 
 
 
 
 
 
Stephen P. MacMillan
 
 
 
 
Director
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
/s/ David J. Roux
 
 
 
 
 
 
 
 
 
David J. Roux
 
 
 
 
Director
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
/s/ John E. Sununu
 
 
 
 
 
 
 
 
 
John E. Sununu
 
 
 
 
Director
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
Dated: February 25, 2020
 
By:
 
/s/ Ellen M. Zane
 
 
 
 
 
 
 
 
 
Ellen M. Zane
 
 
 
 
Director
 
 
 
 
 


147


Schedule II
VALUATION AND QUALIFYING ACCOUNTS
(in millions)
Description
 
Balance at
Beginning of Year
 
Charges to
Costs and
Expenses (a)
 
Deductions to
Allowances for
Uncollectible
Accounts (b)
 
Charges to
(Deductions from)
Other Accounts (c)
 
Balance at
End of Year
Year Ended December 31, 2019:
 
 
 
 
 
 
 
 
 
 
Allowances for uncollectible accounts (d)
 
$
68

 
23

 
(17
)
 
—

 
$
74

Year Ended December 31, 2018:
 
 
 
 
 
 
 
 
 
 
Allowances for uncollectible accounts (d)
 
$
98

 
19

 
(19
)
 
(30
)
 
$
68

Year Ended December 31, 2017:
 
 
 
 
 
 
 
 
 
 
Allowances for uncollectible accounts and sales returns and allowances
 
$
119

 
14

 
(18
)
 
(17
)
 
$
98


(a) Represents allowances for uncollectible accounts established through selling, general and administrative expenses.
(b) Represents actual write-offs of uncollectible accounts.
(c) Represents net change in allowances for sales returns, recorded as contra-revenue.
(d) Following the adoption of FASB ASC Topic 606 as of January 1, 2018, the allowance for sales returns has been reclassified from Trade accounts receivable, net to Other current liabilities within the consolidated balance sheets and is not included in the ending balance for 2018 above. Prior period balances remain unchanged.


148
 EX-4.2 2 exhibit42-descriptiono.htm EXHIBIT 4.2 - DESCRIPTION OF REGISTERED SECURITIES FY2019 Exhibit


DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

As of the date of the Annual Report on Form 10-K of which this exhibit is a part, Boston Scientific Corporation (the “Company”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) our common stock, $.01 par value per share, and (2) our 0.625% Senior Notes due 2027. As used in this description, unless otherwise expressly stated or the context otherwise requires, all references to “we,” “us,” or “our” mean Boston Scientific Corporation excluding its subsidiaries.
Description of Common Stock
The following description of the terms of the common stock sets forth certain general provisions of the common stock as contained in our Charter and by-laws and is qualified in its entirety by reference to Delaware law and our Charter and by-laws in their entirety.
 
General
 
We are currently authorized to issue up to 2,000,000,000 shares of common stock, par value $0.01 per share. As of January 31, 2020, there were 1,396,195,349 shares of our common stock outstanding. All outstanding shares of our common stock are fully paid and nonassessable. Our common stock is listed on the NYSE under the symbol “BSX.”
 
Holders of our common stock have no preemptive, subscription, redemption or conversion rights and the common stock is not subject to redemption. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of holders of any series of preferred stock, whether currently outstanding or designated and issued in the future.
 
Dividends
 
Subject to the preferences of holders of preferred stock, if any, holders of common stock are entitled to dividends and other distributions when, as and if declared by our board of directors out of funds legally available therefor and shall share equally on a per share basis in all such dividends and other distributions.
 
Voting Rights
 
Except as otherwise provided by law or by the designation of the preferences, limitations and relative rights of any series of preferred stock, the voting power with respect to us is held by holders of our common stock. Each holder of common stock is entitled to one vote for each share held.
 
Liquidation and Dissolution
 
Except as otherwise provided by the certificate of designation and limitations and relative rights of any series of preferred stock, in the event of any of our liquidation, dissolution, or winding up, whether voluntary or involuntary, after payment of all our liabilities and obligations and after payment has been made to holders of each series of preferred stock of the full amount to which they are entitled, holders of




shares of common stock will be entitled to share, ratably according to the number of shares of common stock held by them, in all remaining assets available for distribution to holders of the common stock.
 
Certain Provisions of Delaware Law, the Charter and the By-laws
 
Business Combinations with Interested Stockholders. We are subject to the provisions of the Delaware General Corporate Law, or the DGCL. Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes mergers, consolidations, assets sales, and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an “interested stockholder” is a person who, together with affiliates owns, or within three years did own, 15% or more of the corporation’s voting stock.
 
Liability of Directors and Officers. As permitted by the DGCL, our Charter provides that our directors will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except in certain circumstances involving wrongful acts, such as the breach of a director’s duty of loyalty, acts or omissions which involve intentional misconduct or a knowing violation of law or for any transaction from which the director derives an improper personal benefit. Our directors are also subject to liability under Section 174 of the DGCL, which makes directors personally liable for unlawful dividends or unlawful stock repurchases or redemptions if the unlawful conduct is willful or results from negligence.
 
Under our Charter and by-laws (and in accordance with Section 145 of the DGCL), we will indemnify to the fullest extent permitted by the DGCL any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding. These include civil, criminal, administrative, investigative or other proceedings by reason of the fact that the person is or was one of our directors, officers or employees, or is or was serving in that capacity or as an agent at our request for another entity. Our indemnity covers expenses, judgments, fines and amounts paid or to be paid in settlement actually and reasonably incurred in connection with the defense or settlement of an action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal action or proceeding, had no reasonable cause to believe that their conduct was unlawful. We will indemnify a person in a derivative action under the same conditions, except that no indemnification is permitted without judicial approval if the person is adjudged to be liable to us in performance of his or her duty. Derivative actions are actions by us or in our right to procure a judgment in our favor. Our agents may be similarly indemnified at the discretion of our board of directors. In addition, we have entered into indemnification agreements with each of our directors and executive officers. These agreements provide rights of indemnification substantially similar to and, in certain respects, broader than those provided by the Charter and by-laws.
 
Election of Directors; Removal; Vacancies. Our Charter and by-laws provide that the directors shall be elected at each annual meeting or at any special meeting the notice of which specified the election of directors as an item of business for such meeting. Our by-laws provide that each nominee for director shall be elected to the board of directors by the affirmative vote of the majority of votes cast, in person or by proxy, by the holders of shares entitled to vote at a meeting at which a quorum is present; provided, however, that if the number of nominees exceeds the number of directors to be elected at any such meeting, the directors shall be elected by a plurality of the votes cast, in person or by proxy. Our Charter provides that vacancies on the board of directors may only be filled by a majority of the board of directors




then in office and further provides that directors may only be removed by the affirmative vote of holders of at least 80% of the voting power of all the then outstanding shares of stock entitled to vote generally in the election of directors. The provisions of our Charter and by-laws that govern the number, election, and terms of the board of directors may not be amended without the affirmative vote of at least 80% of the voting power of all the then outstanding shares of stock entitled to vote generally in the election of directors.
 
Meetings of Stockholders. Our Charter provides that stockholder action can only be taken at an annual or special meeting of stockholders and that the business permitted to be conducted at any special meeting of stockholders is limited to the business brought before the meeting by the Chairman of the board of directors or our President or at the request of a majority of the members of the board of directors. Our Charter and by-laws provide that special meetings of stockholders can be called only by the Chairman of the board of directors, the Chief Executive Officer (or if there is no Chief Executive Officer, the President), or pursuant to a resolution approved by a majority of the total number of directors which we would have if there were no vacancies on the board of directors. Stockholders are not permitted to call a special meeting or to require that the board of directors call a special meeting of stockholders.
 
Advance Notice Requirements for Stockholder Proposals and Director Nominees. Our by-laws provide that stockholders seeking to make nominations of candidates for election as directors, or to bring other business before an annual or special meeting of the stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder’s notice must be delivered to and received at our principal executive offices not less than 120 days prior to the anniversary date that our proxy statement was released to shareholders in connection with the previous year's annual meeting. However, in the event that the date of the annual meeting is more than 30 days before or after the first anniversary date of the preceding year’s annual meeting, or in the event of a special meeting of stockholders called for the purpose of electing directors, then the deadline is a reasonable time before the we begin to print and mail our proxy materials. Our by-laws also specify certain requirements as to the form and content of a stockholder’s notice. These provisions may restrict the ability of our stockholders to bring business before our annual meeting of stockholders or to make nominations for directors at our annual meeting or any special meeting of stockholders.
 
Proxy Access. Our by-laws permit an eligible stockholder or group of stockholders to include up to a specified number of director nominees in our proxy materials for an annual meeting of stockholders. To qualify, the stockholders (or group of up to twenty stockholders) must have continuously owned for at least three years 3% or more of our outstanding shares of common stock. The maximum number of stockholder nominees permitted under the proxy access provisions of our by-laws is the greater of (i) two or (ii) 20% of the total number of our directors in office as of the last day on which notice of a nomination may be delivered.
 
Notice of a nomination under our proxy access by-law provisions must generally be submitted to our principal executive offices not less than 120 days nor more than 150 days prior to the first anniversary of the date that we first mailed our proxy statement to stockholders for the immediately preceding annual meeting of stockholders. The notice must contain certain information specified in our by-laws.

Stock Repurchases; Change of Control. Our Charter prohibits us, with certain exceptions, from purchasing any shares of our stock from any person, entity or group that beneficially owns 5% or more of our voting stock at an above-market price, unless a majority of our disinterested stockholders approve the transaction. In addition, our Charter empowers the board of directors, when considering a tender offer or




merger or acquisition proposal, to take into account factors in addition to potential economic benefits to stockholders and to consider constituencies other than stockholders.
 
Amendment of Charter and By-Laws. The DGCL provides generally that the vote of a majority of shares entitled to vote is required to act on most matters and to amend a corporation’s certificate of incorporation. Our Charter and by-laws contain provisions requiring the affirmative vote of the holders of at least 80% of the voting stock, voting together as a single class, to amend certain provisions of the Charter and our by-laws, including certain of the foregoing provisions. Such a supermajority vote would be in addition to any separate class vote that might in the future be required with respect to shares of preferred stock then outstanding.
 
Miscellaneous. The foregoing and other provisions of Delaware law and the Charter and our by-laws could make it more difficult to acquire us by means of a tender offer, a proxy contest or otherwise. These provisions may have the effect of delaying, deferring or preventing a change in control of our company, may discourage bids for the common stock at a premium over the market price of the common stock and may adversely affect the market price of the common stock.
 
Transfer Agent
 
The transfer agent and registrar for our common stock is Computershare Shareowner Services.



Description of 0.625% Senior Notes due 2027
The following description of our 0.625% Senior Notes due 2027 (the “notes”) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the form of the notes and the indenture, dated as of May 29, 2013 (the “Indenture”), between us and U.S. Bank National Association, as trustee (the “trustee”), which are both incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part.
The notes are traded on The New York Stock Exchange under the bond trading symbol of “BSX27.” Currently, U.S. Bank National Association is acting as transfer agent and registrar for the notes and Elavon Financial Services DAC (UK Branch) is acting as paying agent.
Capitalized terms that are used but not otherwise defined herein have the meanings assigned to them in the Indenture, and those definitions are incorporated herein by reference. We encourage you to read the above referenced Indenture for additional information.
General
The notes offered were initially issued in an aggregate principal amount of €900,000,000 aggregate principal amount, which is the amount outstanding as of the date of the Annual Report on Form 10-K of which this exhibit is a part. The notes will mature on December 1, 2027. The notes will not be entitled to the benefit of a sinking fund.
The notes will bear interest from November 12, 2019, payable annually in arrears on December 1 of each year, beginning December 1, 2020, to the persons in whose names such notes are registered at the close of business on the business day (for this purpose, a day on which Clearstream and Euroclear are open for business) immediately preceding the relevant interest payment date. Interest on the notes will be




computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes (or November 12, 2019, if no interest has been paid on the notes), to, but excluding, the next scheduled interest payment date. This payment convention is referred to as ACTUAL/ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association.
Additional notes (the “Additional Notes”) in an unlimited amount may be issued in one or more series from time to time on the same terms and conditions, except for issue date, and in certain cases the issue price and the first interest payment, either of which may differ from the respective terms of the previously issued notes of the same series, and with the same CUSIP numbers as the notes (to the extent permissible under applicable law) without the consent of Holders of the notes.
Ranking
The notes are unsecured and rank on a parity with all of our other unsecured and unsubordinated indebtedness from time to time outstanding. The notes will rank senior to any existing and future unsecured and subordinated debt, effectively junior to our secured debt to the extent of the collateral securing such secured debt and effectively junior to liabilities of our subsidiaries, in each case as may be outstanding from time to time.
Issuance in Euro
We will pay the principal of, premium, if any, and interest on each note to the registered holder in euro in immediately available funds, provided that, if the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if the euro is no longer being used by the then member states of the European Economic and Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. In such circumstances, the amount payable on any date in euro will be converted by us into U.S. dollars at the rate mandated by the U.S. Federal Reserve Board as of the close of business on the second business day prior to the relevant payment date or, in the event the U.S. Federal Reserve Board has not mandated a rate of conversion, on the basis of the most recent U.S. dollar/euro exchange rate published in The Wall Street Journal on or prior to the second business day prior to the relevant payment date. Any payment in respect of the notes so made in U.S. dollars will not constitute an event of default under the notes or the indenture governing the notes.
Neither the trustee nor the paying agent shall have any responsibility for any calculation or conversion in connection with the foregoing.        
Limitation on Liens
We will not, and will not permit any of our Subsidiaries (as defined in the Indenture) to, directly or indirectly, create, incur, assume or suffer to exist any Lien (as defined in the Indenture) upon any of our property, assets or revenues, whether now owned or hereafter acquired, except for: (i) Liens for taxes not yet due or which are being contested in good faith by appropriate proceedings; provided that adequate reserves with respect thereto are maintained on our or our Subsidiaries’ books, as the case may be, in conformity with accounting principles generally accepted in the United States; (ii) carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business that are not overdue for a period of more than 60 days or which are being contested in good faith by appropriate proceedings; (iii) pledges or deposits in connection with workers’ compensation, unemployment insurance and other social security legislation and deposits securing liability to insurance




carriers under insurance or self-insurance arrangements; (iv) deposits to secure the performance of bids, trade contracts (other than for borrowed money), leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of business; (v) easements, rights-of-way, restrictions and other similar encumbrances incurred in the ordinary course of business which, in the aggregate, are not substantial in amount and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of our business or that of a Subsidiary; (vi) Liens in existence on the date of the first issuance by us of Securities (as defined in the Indenture) issued pursuant to the Indenture; provided that no such Lien is spread to cover any additional property after such date and that the amount of Debt (as defined in the Indenture) secured thereby is not increased; (vii) Liens securing our and our Subsidiaries’ Debt incurred to finance the acquisition of fixed or capital assets; provided that (A) such Liens will be created substantially simultaneously with the acquisition of such fixed or capital assets, (B) such Liens do not at any time encumber any property other than the property financed by such Debt and (C) the amount of Debt secured thereby is not increased; (viii) Liens on the property or assets of a corporation that becomes a Subsidiary after the date of the Indenture; provided that (A) such Liens existed at the time such corporation became a Subsidiary and were not created in anticipation thereof, (B) any such Lien is not spread to cover any property or assets of such corporation after the time such corporation becomes a Subsidiary, and (C) the amount of Debt secured thereby is not increased; (ix) Liens pursuant to any Receivables Transaction (as defined in the Indenture) in an aggregate principal amount not exceeding 20% of our Consolidated Tangible Assets (as defined in the Indenture); and (x) Liens (not otherwise permitted pursuant to the Indenture) (A) which secure obligations not exceeding (as to us and our Subsidiaries) the greater of (X) $250.0 million or (Y) 20% of our Consolidated Tangible Assets (as defined in the Indenture), in each case in an aggregate amount at any time outstanding, or (B) with respect to which we effectively provide that the Securities Outstanding (as defined in the Indenture) under the Indenture are secured equally and ratably with (or, at our option, prior to) the Debt secured by such Lien.
Optional Redemption
        Prior to the Par Call Date (as defined below), we may redeem the notes, in whole or in part, at our option, on at least 15 days, but no more than 60 days prior written notice mailed to the registered holders of the notes to be redeemed, at any time at a redemption price equal to the greater of:
•
100% of the principal amount of the notes being redeemed, or
•
as determined by a Quotation Agent (as defined below), the sum of the present values of the remaining scheduled payments of principal and interest thereon to the applicable Par Call Date (not including any portion of such payments of interest accrued to the date of redemption) discounted to the redemption date on an annual basis (ACTUAL/ACTUAL(ICMA)) at the Comparable Government Bond Rate (defined below), plus 20 basis points for the notes,
plus, in each case, accrued and unpaid interest on the notes to, but not including, the redemption date (subject to the right of holders as of the close of business on a regular record date to receive interest due on the related interest payment date).
At any time and from time to time on or after September 1, 2027 (the date that is three months prior to the maturity date of the notes) (the “Par Call Date”), we may redeem the notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the notes being redeemed plus accrued and unpaid interest to the redemption date.
“Comparable Government Bond Rate” means, for any redemption date, the rate per annum equal to the annual equivalent yield to maturity or interpolated yield to maturity (on a day count basis),




computed as the third business day immediately preceding that redemption date, of the Comparable Government Issue (as defined below), assuming a price for the Comparable Government Issue (expressed as a percentage of its principal amount) equal to the Comparable Price (as defined below) for such redemption date.
“Comparable Government Issue” means the euro-denominated security issued by the German federal government selected by a Quotation Agent as having an actual or interpolated maturity comparable to the remaining term of the notes to be redeemed that would be utilized (assuming that the notes matured on the applicable Par Call Date), at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of such notes.
“Comparable Price” means, with respect to any redemption date, (i) the average of the Reference Dealer Quotations (as defined below) for such redemption date, after excluding the highest and lowest such Reference Dealer Quotations, or (ii) if the trustee obtains fewer than three such Reference Dealer Quotations, the average of all such quotations.
“Quotation Agent” means the Reference Dealer appointed by the trustee after consultation with us.
“Reference Dealer” means (i) each of Barclays Bank PLC, Goldman Sachs & Co. LLC and Merrill Lynch International and their respective successors; provided, however, that, if any of the foregoing shall cease to be a broker or dealer of, and/or a market maker in, German government bonds (a “Primary Bond Dealer”), we shall substitute therefor another Primary Bond Dealer, and (ii) any other Primary Bond Dealers selected by the trustee after consultation with us.
“Reference Dealer Quotations” means, with respect to each Reference Dealer and any redemption date, the average, as determined by the trustee, of the bid and ask prices for the Comparable Government Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the trustee by such Reference Dealer at 5:00 p.m. London time, on the third business day preceding such redemption date.
If we redeem only some of the notes, the trustee shall determine by lot the notes to be redeemed or, in the case of notes held in global form, pursuant to applicable procedures of the depositary. Notice by the depositary to these participants and by participants to “street name” holders of indirect interests in the notes will be made according to arrangements among them and may be subject to statutory or regulatory requirements. Unless we default in payment of the redemption price, on and after the redemption date, interest will cease to accrue on the notes or portions of the notes called for redemption.
Repurchase at the Option of Holders Upon Change of Control Repurchase Event
If a Change of Control Repurchase Event occurs, unless we have exercised our option to redeem the notes as described under the heading “-Optional Redemption” above, each holder of the notes will have the right to require us to purchase all or a portion (equal to €100,000 and any integral multiples of €1,000 in excess thereof) of such holder’s notes pursuant to the offer described below (a “Change of Control Offer”) at a purchase price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest, if any, to, but not including, the date of repurchase (the “Change of Control Payment”), subject to the rights of holders of notes on the relevant record date to receive interest due on the relevant interest payment date.




We will be required to send a notice to each holder of the notes by first class mail, with a copy to the trustee, within 30 days following the date upon which any Change of Control Repurchase Event occurred, or at our option, prior to any Change of Control but after the public announcement of the pending Change of Control. The notice will govern the terms of the Change of Control Offer and will describe, among other things, the transaction that constitutes or may constitute the Change of Control Repurchase Event and the purchase date. The purchase date will be at least 30 days but no more than 60 days from the date such notice is mailed, other than as may be required by law (a “Change of Control Payment Date”). If the notice is mailed prior to the date of consummation of the Change of Control, the notice will state that the Change of Control Offer is conditioned on the Change of Control being consummated on or prior to the Change of Control Payment Date.
On the Change of Control Payment Date, we will, to the extent lawful:
•accept for payment all properly tendered notes or portions of notes not validly withdrawn;
•deposit with the paying agent the required payment for all properly tendered notes or portions of notes not validly withdrawn; and
•deliver or cause to be delivered to the trustee the repurchased notes, accompanied by an officers’ certificate stating, among other things, the aggregate principal amount of repurchased notes.
We will not be required to make a Change of Control Offer with respect to the notes upon the occurrence of a Change of Control Repurchase Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for such an offer made by us and the third party purchases all of the notes properly tendered and not withdrawn under its offer. In addition, we will not repurchase any notes if there has occurred and is continuing on the Change of Control Payment Date an Event of Default under the Indenture.
We will comply with the requirements of Rule 14e-1 under the Exchange Act, and any other securities laws and regulations thereunder, to the extent those laws and regulations are applicable, in connection with the repurchase of notes as a result of a Change of Control Repurchase Event. To the extent that the provisions of any such securities laws or regulations conflict with the Change of Control Offer provisions of the notes, we will comply with those securities laws and regulations and will not be deemed to have breached our obligations under the Change of Control Offer provisions of the notes by virtue of any such conflict.
The definition of Change of Control includes a phrase relating to the direct or indirect sale, lease, transfer, conveyance or other disposition of “all or substantially all” of our properties or assets and those of our subsidiaries taken as a whole. Although there is a limited body of case law interpreting the phrase “substantially all,” there is no precise established definition of the phrase under applicable law. Accordingly, the ability of a holder of notes to require us to repurchase the notes as a result of a sale, lease, transfer, conveyance or other disposition of less than all of our assets and the assets of our subsidiaries, taken as a whole, to another person or group may be uncertain.
For purposes of the foregoing discussion, the following definitions apply:
“Capital Stock” means the capital stock of every class whether now or hereafter authorized, regardless of whether such capital stock shall be limited to a fixed sum or percentage with respect to the




rights of the holders thereof to participate in dividends and in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of such corporation.
“Change of Control” means the occurrence of any of the following:
•the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all or substantially all of our assets and the assets of our subsidiaries, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act), other than us or one of our subsidiaries;
•the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any “person” (as that term is used in Section 13(d)(3) of the Exchange Act), other than us or one of our subsidiaries, becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of more than 50% of our then outstanding Voting Stock or other Voting Stock into which our Voting Stock is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares; or
•the adoption of a plan relating to our liquidation or dissolution.
Notwithstanding the foregoing, a transaction will not be considered to be a Change of Control if (a) we become a direct or indirect wholly-owned subsidiary of a holding company and (b)(x) immediately following that transaction, the direct or indirect holders of the Voting Stock of the holding company are substantially the same as the holders of our Voting Stock immediately prior to that transaction or (y) immediately following that transaction, no person is the beneficial owner, directly or indirectly, of more than 50% of the Voting Stock of such holding company.
“Change of Control Repurchase Event” means the occurrence of both a Change of Control and a Rating Event.
“Fitch” means Fitch, Inc. and its successors.
“Investment Grade” means a rating of Baa3 or better by Moody’s (or its equivalent under any successor rating categories of Moody’s), a rating of BBB- or better by S&P (or its equivalent under any successor rating categories of S&P) and a rating of BBB- or better by Fitch (or its equivalent under any successor rating categories of Fitch); provided, however, that we shall not be required to maintain a rating by more than two Rating Agencies at any time and if only two Rating Agencies provide a rating with respect to the notes, then “Investment Grade” shall mean the applicable rating described above of such two Rating Agencies.
“Moody’s” means Moody’s Investors Service, Inc., a subsidiary of Moody’s Corporation, and its successors.
“Rating Agencies” means each of Moody’s, S&P and Fitch, or if any of Moody’s, S&P or Fitch ceases to rate the notes or fails to make a rating of the notes publicly available, any “nationally recognized statistical rating organization” within the meaning of Section 3(a)(62) under the Exchange Act that is selected by us as a replacement agency for Moody’s, S&P or Fitch, or each of them, as the case may be; provided, however, that the Company shall not be required to maintain a rating by more than two Rating Agencies at any time.




“Rating Event” means, with respect to the notes, the rating of the notes shall be decreased by each of the Rating Agencies independently by one or more gradations during the Rating Period (as defined below). If the rating of the notes by each of the Rating Agencies is Investment Grade, then “Rating Event” will mean the rating of the notes shall be decreased by one or more gradations by each Rating Agency so that the ratings of the notes by all of the Rating Agencies fall below Investment Grade, on any date from the date of the public notice of an arrangement that could result in a Change of Control until the end of the 30-day period following public notice of the occurrence of the Change of Control (the “Rating Period”) (which 30-day period shall be extended by no more than 60 days from the date of the occurrence of the Change of Control if the rating of the notes is under publicly announced consideration for possible downgrade by any of the Rating Agencies and each other Rating Agency has either downgraded, or publicly announced that it is considering downgrading, the notes). A Rating Event otherwise arising by virtue of a particular reduction in rating will not be deemed to have occurred in respect of a particular Change of Control (and thus will not be deemed a Rating Event for purposes of the definition of “Change of Control Repurchase Event”) if each Rating Agency making the reduction in rating to which this definition would otherwise apply does not announce or publicly confirm or inform the trustee under the Indenture in writing at our request that the reduction was the result, in whole or in part, of any event or circumstance comprised of or arising as a result of, or in respect of, the applicable Change of Control (whether or not the applicable Change of Control has occurred at the time of the Rating Event).
“S&P” means S&P Global Ratings, a division of S&P Global Inc., and its successors.
“Voting Stock” means, with respect to any specified person as of any date, the Capital Stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person.
Redemption for Tax Reasons
Subject to a period of not less than fifteen (15) nor more than sixty (60) days’ prior written notice to the registered holders of the notes to be redeemed, we may redeem the notes at any time after the issue date and prior to the maturity date, in whole, but not in part, at a redemption price equal to 100% of the aggregate principal amount of notes being redeemed, plus accrued and unpaid interest, if any, to (but not including) the redemption date, on the date determined by us for early redemption, if:
(a) as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated thereunder) of a Relevant Taxing Jurisdiction (as defined below), or any change in, or amendment to, an official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after November 6, 2019, we have become or will become obligated to pay Additional Amounts (as defined below); or
(b) any act is taken by a taxing authority of a Relevant Taxing Jurisdiction on or after November 6, 2019, whether or not such act is taken with respect to us or any of our affiliates, that results in a substantial probability that we will be required to pay Additional Amounts on the notes; provided in each case that we determine, in our business judgment (determined in good faith), that the obligation to pay the Additional Amounts cannot be avoided by the use of reasonable measures available to us (including, for the avoidance of doubt, the appointment of a new paying agent where this would be reasonable and would not cause us to incur material additional out-of-pocket costs, but not including assignment of the obligation to make payment with respect to the notes).




No redemption above may be made unless (i) we shall have received an opinion of independent counsel to the effect that any such change, amendment or act described in paragraphs (a) or (b) above results in our requirement to pay (in the case of paragraph (a)) or a substantial probability that we will be required to pay (in the case of paragraph(b)) the Additional Amounts described herein and (ii) we shall have delivered to the paying agent a certificate, signed by a duly authorized officer, stating that based on such opinion, we are entitled to redeem the notes pursuant to their terms.
Additional Amounts
All payments of principal, premium, if any, and interest by or on behalf of us pursuant to the terms of the notes shall be made free and clear of, and without deduction or withholding for or on account of, any present or future taxes, duties, assessments or other governmental charges of whatsoever nature required to be deducted or withheld by the United States, any state thereof or the District of Columbia or any other jurisdiction through which payment on a note is made, or any political subdivision or taxing authority therein or thereof (a “Relevant Taxing Jurisdiction”), unless such withholding or deduction is required by law.
In the event any withholding or deduction on payments in respect of the notes for or on account of any present or future tax, assessment or other governmental charge is required to be deducted or withheld by a Relevant Taxing Jurisdiction, we shall remit the full amount required to be deducted or withheld to the relevant authority in accordance with applicable law and pay such additional amounts (the “Additional Amounts”) so that every net payment of the principal of, premium, if any, and interest on the notes will result in receipt by each holder of a note of such amounts (after all such withholding or deduction, including on any additional amounts) as would have been received had no such withholding or deduction been required. We will not be required, however, to make any payment of Additional Amounts for or on account of certain situations, as set forth in the form of notes.
Events of Default
The Indenture provides that the following will be “events of default” with respect to any series of debt securities:
(1) default in the payment of any interest on any debt security of that series, when it becomes due and payable, and continuance of such default for a period of 30 days;
(2) default in the payment of, the principal of, or premium, if any, on any debt security of that series when due at its maturity or upon acceleration;
(3) default in the deposit of any sinking fund payment, when and as due by the terms of the debt securities of that series and the Indenture;
(4) default in the performance, or breach, of any of our covenant or agreement in the Indenture which affects or is applicable to debt securities of such series (other than a default in the performance, or breach of a covenant or agreement that is specifically dealt with elsewhere in the Indenture), and the continuation of that default or breach for a period of 90 days after the trustee has given us, or after Holders of at least 25% in aggregate principal amount of all outstanding securities of that series have given us and the trustee, written notice thereof;
(5) certain events relating to our bankruptcy, insolvency or reorganization; or
(6) any other event of default provided with respect to debt securities of that series.




If an event of default specified in clauses (1), (2), (3), (4) or (6) therein with respect to the notes occurs and is continuing, either the trustee or the holders of at least 25% in aggregate principal amount of the outstanding notes may declare the principal amount, plus accrued interest, if any, on all the then outstanding notes to be due and payable immediately. If an event of default specified in clause (5) therein occurs and is continuing, then the principal amount, plus accrued interest, if any, of all the notes will be due and payable immediately, without any declaration or other act on the part of the trustee or any holder. In certain cases, holders of a majority in principal amount of the outstanding notes may, on behalf of holders of all the notes, rescind and annul a declaration of acceleration.
The Indenture provides that the trustee will not be liable for any action taken, suffered or omitted by it in good faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by the Indenture. The Indenture provides that no Holder may institute any proceedings, judicial or otherwise, to enforce the Indenture except in the case of failure of the trustee thereunder to act for 60 days after it has received a request to enforce the Indenture by Holders of at least 25% in aggregate principal amount of the then outstanding debt securities of that series (in the case of an event of default specified in clauses (1), (2), (3), (4) or (6) above) or a request to enforce the Indenture by Holders of at least 25% in aggregate principal amount of all of the debt securities then outstanding (in the case of an event of default specified in clause (5) above), and an offer of reasonable indemnity. This provision will not prevent any Holder from enforcing payment of principal thereof, and premium, if any, on and interest, if any, thereon at the respective due dates.
Holders of not less than a majority in aggregate principal amount of the debt securities of any series then outstanding may direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on it with respect to debt securities of that series. The trustee may, however, refuse to follow any direction that it determines may not lawfully be taken or would be illegal or in conflict with the Indenture or involve it in personal liability or which would be unjustly prejudicial to Holders not joining in that proceeding.
The Indenture provides that the trustee will, within 90 days after the occurrence of a default with respect to any series of debt securities, give to Holders of debt securities of that series notice of such default if that default has not been cured or waived. Except in the case of a default in the payment of principal of, or premium, if any, on or interest on, or in the payment of any sinking fund installment in respect of, any debt securities of that series, the trustee will be protected in withholding the notice if it determines in good faith that the withholding of the notice is in the interest of Holders of the debt securities of such series.
We will be required to deliver an officers' certificate to the trustee annually as to our compliance with all conditions and covenants under the terms of the Indenture.
Defeasance
The notes are subject to our defeasance option. At our option, the notes will be discharged from any and all obligations (except for certain obligations to register the transfer or exchange of notes, replace stolen, lost or mutilated notes, maintain paying agencies, and hold money for payment in trust), if we deposit with the trustee, in trust, money or Government Obligations (as defined in the Indenture) which through the payment of interest thereon and principal thereof in accordance with their terms will provide money in an amount sufficient to pay all the principal (including any mandatory sinking fund payments) of, and interest on, the notes on the dates such payments are due in accordance with the terms of the notes.




To exercise any such option, we are required to deliver to the trustee an opinion of counsel to the effect that the deposit and related defeasance would not cause the Holders of the notes to recognize income, gain or loss for federal income tax purposes and, in the case of a discharge pursuant to (1) above, such opinion of counsel must be based upon a ruling to such effect received by us from or published by the United States Internal Revenue Service or a change in applicable federal income tax law to such effect. We are required to deliver to the trustee an officer's certificate stating that no event of default with respect to the notes has occurred and is continuing.
Satisfaction and Discharge
As set forth in the Indenture, and upon the occurrence of certain events, the Indenture may be subject to satisfaction and discharge with respect to the notes.
Modification and Waiver
Modifications of and amendments to the Indenture may be made by us and the trustee with the consent of Holders of a majority in principal amount of the outstanding debt securities of each series issued under the Indenture that is affected by the modification or amendment; provided, however, that no such modification or amendment may, without the consent of the Holder of each outstanding debt security affected thereby make certain changes as set forth in the Indenture.
We may, with respect to any series of debt securities, omit to comply with certain restrictive provisions of the Indenture if Holders of at least a majority in principal amount of all outstanding debt securities affected waive compliance. No such waiver will extend to or affect any term, provision or condition except to the extent so expressly waived, and, until the waiver becomes effective, our obligations and the duties of the trustee to Holders of debt securities of that series in respect of the applicable term, provision or condition will remain in full force and effect.
Holders of a majority in principal amount of the outstanding debt securities of each series (in the case of an event of default specified in clauses (1), (2), (3), (4) and (6) under "Events of Default" above) or the Holders of a majority in principal amount of all of the debt securities then outstanding (in the case of an event of default specified in clause (5) under "Events of Default" above) may, on behalf of all those Holders, waive any past default under the Indenture with respect to debt securities of that series except a default in the payment of the principal of, or premium, if any, on or interest, if any, on any such debt security and except a default in respect of a covenant or provision the modification or amendment of which would require the consent of the Holder of each outstanding debt security affected.


 EX-21 3 exhibit21-listofsubsid.htm EXHIBIT 21 - FY2019 LIST OF SUBSIDIARIES DATED JAN 30, 2020 Exhibit
EXHIBIT 21
List of worldwide subsidiaries of Boston Scientific as of January 30, 2020
Structure of ownership and control:
Boston Scientific wholly owns or has a majority interest in all of the below mentioned entities.
 
Acurate Industria e Comercio Ltda. (Brazil)
American Medical Systems Europe B.V. (The Netherlands)
Apama Medical, Inc. (Delaware)
Augmenix K.K. (Japan)
Augmenix, Inc. (Delaware)
Biocompatibles International Limited (England)
Biocompatibles UK Limited (England)
Biocompatibles, Inc. (Delaware)
Boston Scientific (Malaysia) Sdn. Bhd. (Malaysia)
Boston Scientific (South Africa) Proprietary Limited (South Africa)
Boston Scientific (Thailand) Ltd. (Thailand)
Boston Scientific (UK) Limited (England)
Boston Scientific AG (Switzerland)
Boston Scientific Argentina S.A. (Argentina)
Boston Scientific Asia Pacific Pte. Ltd. (Singapore)
Boston Scientific Benelux NV (Belgium)
Boston Scientific Canada Limited (Canada)
Boston Scientific Ceska republika s.r.o. (Czech Republic)
Boston Scientific Chile SpA (Chile)
Boston Scientific Clonmel Limited, in liquidation (Ireland)


Boston Scientific Colombia Limitada (Colombia)
Boston Scientific Comercial de Costa Rica BSCR, S.R.L. (Costa Rica)
Boston Scientific Cork Limited, in liquidation (Ireland)
Boston Scientific de Costa Rica S.R.L. (Costa Rica)
Boston Scientific de Mexico, S.A. de C.V. (Mexico)
Boston Scientific del Caribe, Inc. (Puerto Rico)
Boston Scientific do Brasil Ltda. (Brazil)
Boston Scientific Far East B.V. (The Netherlands)
Boston Scientific Gesellschaft m.b.H. (Austria)
Boston Scientific Group plc (Ireland)
Boston Scientific Hellas S.A. (Greece)
Boston Scientific Hong Kong Limited (Hong Kong)
Boston Scientific Iberica, S.A. (Spain)
Boston Scientific India Private Limited (India)
Boston Scientific International B.V. (The Netherlands)
Boston Scientific International Finance Limited (Ireland)
Boston Scientific International S.A. (France)
Boston Scientific Ireland Limited, in liquidation (Ireland)
Boston Scientific Israel Ltd. (Israel)
Boston Scientific Japan K.K. (Japan)
Boston Scientific Korea Co., Ltd. (Korea)
Boston Scientific Lebanon SAL (Lebanon)
Boston Scientific Limited (England)
Boston Scientific Limited (Ireland)
Boston Scientific Ltd./Boston Scientifique Ltee. (Canada)
Boston Scientific Medical Device (Malaysia) Sdn. Bhd. (Malaysia)


Boston Scientific Medical Device Limited (Ireland)
Boston Scientific Medizintechnik GmbH (Germany)
Boston Scientific Middle East FZ-LLC (UAE)
Boston Scientific Middle East SAL (Offshore) (Lebanon)
Boston Scientific Nederland B.V. (The Netherlands)
Boston Scientific Neuromodulation Corporation (Delaware)
Boston Scientific New Zealand Limited (New Zealand)
Boston Scientific Nordic AB (Sweden)
Boston Scientific Peru S.A.C. (Peru)
Boston Scientific Philippines, Inc. (Philippines)
Boston Scientific Polska Sp. z o.o. (Poland)
Boston Scientific Portugal - Dispositivos Medicos, Lda (Portugal)
Boston Scientific Pty Ltd (Australia)
Boston Scientific Romania S.R.L. (Romania)
Boston Scientific S.A.S.(France)
Boston Scientific S.p.A. (Italy)
Boston Scientific Scimed, Inc. (Minnesota)
Boston Scientific Services Private Limited (India)
Boston Scientific Technology & Engineering Services Private Limited (India)
Boston Scientific TIP Gerecleri Limited Sirketi (Turkey)
Boston Scientific Uruguay S.A. (Uruguay)
Boston Scientific Vietnam Company Limited (Vietnam)
Bravo Bidco Limited (England)
BSC International Medical Trading (Shanghai) Co., Ltd. (China)
BSC Medical Device Technology (Shanghai) Co., Ltd. (China)
BTG Australasia Pty Ltd (Australia)


BTG Europe B.V. (The Netherlands)
BTG IM Holdings Ltd. (Israel)
BTG International (Holdings) Limited (England)
BTG International Asia Limited (Hong Kong)
BTG International Canada Inc. (Canada)
BTG International Germany GmbH (Germany)
BTG International Healthcare Inc. (Delaware)
BTG International Healthcare Limited (Delaware)
BTG International Healthcare LLC (Delaware)
BTG International Inc. (Delaware)
BTG International Limited (England)
BTG Limited (England)
BTG Management Services Limited (England)
BTG Medikal Limited Sirketi (Turkey)
Cardiac Pacemakers, Inc. (Minnesota)
CeloNova BioSciences Germany GmbH, in liquidation (Germany)
Claret Medical, Inc. (Delaware)
Cosman Medical, LLC (Massachusetts)
Cryterion Medical, Inc. (Delaware)
Cryterion Medical Ireland, Limited (Ireland)
EKOS LLC (Delaware)
Electron Acquisition Corporation (Delaware)
EMcision International Inc. (Canada)
EndoChoice GmbH, in liquidation (Germany)
EndoChoice Holdings, Inc. (Delaware)
EndoChoice, Inc. (Delaware)


EndoChoice Innovation Center Ltd. (Israel)
EndoChoice Israel Ltd. (Israel)
EP Technologies, Inc. (Delaware)
Galil Medical Inc. (Delaware)
Galil Medical Ltd. (Israel)
Galil Medical UK Limited (England)
Guidant Delaware Holding Corporation (Delaware)
Guidant Europe NV (Belgium)
Guidant Puerto Rico B.V. (The Netherlands)
Hong Kong Medtech Trading Limited (Hong Kong)
Millipede, Inc. (Delaware)
Notebook Merger Sub, Ltd. (Delaware)
Novate Medical Limited (Ireland)
nVision Medical Corporation (Delaware)
NXT Merger Corp. (Delaware)
NxThera, Inc. (Delaware)
PneumRx GmbH (Germany)
PneumRx Liimited (England)
PneumRx LLC (Delaware)
Protherics Medicines Development B.V. (Netherlands)
Protherics Medicines Development Limited (England)
Protherics UK Limited (England)
Provensis Limited (England)
PT Boston Scientific Indonesia (Indonesia)
RMI Acquisition Corp. (California)
Robert S. Smith, M.D., Inc. (Georgia)


Roxwood Medical, Inc. (Delaware)
Sadra Medical, Inc. (Delaware)
Securus Medical Group, Inc. (Delaware)
SNS Merger Corp (Delaware)
Special K Merger Corp. (Delaware)
StarMedTec GmbH, in liquidation (Germany)
Stream Enterprises LLC (Delaware)
Symetis SA (Switzerland)
Target Therapeutics, Inc. (Delaware)
Veniti, Inc. (Delaware)
Vertiflex, Inc. (Delaware)
Zuma Investment Pty Ltd (Australia)
34 Biomedical Merger Corp. (Delaware)
9357-1867 Quebec Inc. (Canada)


 EX-23 4 exhibit23-2019eyconsent.htm EXHIBIT 23 - E&Y CONSENT FY2019 Exhibit
EXHIBIT 23

Consent of Independent Registered Public Accounting Firm


We consent to the incorporation by reference in the following Registration Statements:
 
(1)
Registration Statement (Form S-3 Nos. 333-223095, 333-76346, 333-61994, and 333-64991) of Boston Scientific Corporation,

(2)
Registration Statement (Form S-4 Nos. 333-22581 and 333-131608) of Boston Scientific Corporation, and

(3)
Registration Statement (Form S-8 Nos. 333-25033, 333-25037, 333-36636, 333-61056, 333-61060, 333-76380, 333-98755, 333-111047, 333-131608, 333-133569, 333-134932, 333-151280, 333-174620, 333-174622, 333-188905, and 333-196672) pertaining to the Employees' Savings Plan of Boston Scientific Corporation;
 
of our reports dated February 25, 2020, with respect to the consolidated financial statements and schedule of Boston Scientific Corporation and the effectiveness of internal control over financial reporting of Boston Scientific Corporation included in this Annual Report (Form 10-K) of Boston Scientific Corporation for the year ended December 31, 2019.


/s/ Ernst & Young LLP
Boston, Massachusetts 
February 25, 2020



 EX-31.1 5 exhibit311-ceo30220191.htm EXHIBIT 31.1 CEO 302 CERT FY2019 Exhibit


EXHIBIT 31.1
 
CERTIFICATIONS
 
I, Michael F. Mahoney, certify that:


1
I have reviewed this Annual Report on Form 10-K of Boston Scientific Corporation;
 
 
2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 
3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
4
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
 
 
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
 
 
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
 
 
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
 
 
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
 
 
5
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
 
 
 
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
 
 
 
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 25, 2020
 
/s/ Michael F. Mahoney
 
 
 
Michael F. Mahoney
 
 
 
Chief Executive Officer
 



 EX-31.2 6 exhibit312-cfo30220191.htm EXHIBIT 31.2 CFO 302 CERT FY2019 Exhibit


EXHIBIT 31.2
 
CERTIFICATIONS
 
I, Daniel J. Brennan, certify that:


1
I have reviewed this Annual Report on Form 10-K of Boston Scientific Corporation;
 
 
2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 
3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
4
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
 
 
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
 
 
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
 
 
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
 
 
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
 
 
5
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
 
 
 
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
 
 
 
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 25, 2020
 
/s/ Daniel J. Brennan
 
 
 
Daniel J. Brennan
 
 
 
Executive Vice President and Chief Financial Officer
 



 EX-32.1 7 exhibit321-ceo90620191.htm EXHIBIT 32.1 CEO 906 CERT FY2019 Exhibit


EXHIBIT 32.1
 
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 
(1)   
the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
 
(2)   
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.


 
 
 
By:
/s/ Michael F. Mahoney
 
Michael F. Mahoney
 
 
Chief Executive Officer
 
 
 
 
 
February 25, 2020
 
 



 EX-32.2 8 exhibit322-cfo90620191.htm EXHIBIT 32.2 CFO 906 CERT FY2019 Exhibit


EXHIBIT 32.2
 
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Boston Scientific Corporation (the “Company”) for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 
(1)   
the Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
 
(2)   
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.


 
 
 
By:
/s/ Daniel J. Brennan
 
Daniel J. Brennan
 
 
 Executive Vice President and Chief Financial Officer
 
 
 
 
 
February 25, 2020
 



 EX-101.SCH 9 bsx-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2203200 - Disclosure - Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Acquisitions and Strategic Investments link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Acquisitions and Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Acquisitions and Strategic Investments Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Acquisitions and Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Borrowings and Credit Arrangements link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Borrowings and Credit Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Borrowings and Credit Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Changes in Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Changes in Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Changes in Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Consolidated Balance Sheet Paranthetical link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0002000 - Document - Cover Document Document link:presentationLink link:calculationLink link:definitionLink 2422403 - Disclosure - Employee Retirement Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2222201 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Employee Retirement Plans (Notes) link:presentationLink link:calculationLink link:definitionLink 2322302 - Disclosure - Employee Retirement Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Income Taxes (Details - Rate Table) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Income Taxes Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - New Accounting Pronouncements New Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2220201 - Disclosure - New Accounting Pronouncements New Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Restructuring Related Activities link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Restructuring Related Activities (Details in Narrative) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Restructuring Related Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Revenue Revenue link:presentationLink link:calculationLink link:definitionLink 2421402 - Disclosure - Revenue Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Revenue Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Schedule - Schedule II link:presentationLink link:calculationLink link:definitionLink 2423401 - Schedule - Schedule II (Details) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock Incentive and Ownership Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock Incentive and Ownership Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock Inventive and Ownership Plans link:presentationLink link:calculationLink link:definitionLink 2316302 - Disclosure - Stock Inventive and Ownership Plans Employee Stock Purchase Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Weighted Average Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Weighted Average Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bsx-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 bsx-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 bsx-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT New Accounting Pronouncements [Abstract] New Accounting Pronouncements [Abstract] Description of New Accounting Pronouncements Not yet Adopted [Text Block] Description of New Accounting Pronouncements Not yet Adopted [Text Block] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Statement [Line Items] Statement [Line Items] Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Treasury shares Treasury Stock, Shares Equity Method Investments and Joint Ventures [Abstract] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Equity Method Investments Equity Method Investments Cost Method Investments Cost Method Investments Available-for-sale Securities Available-for-sale Securities Notes Receivable From Portfolio Companies Notes Receivable From Portfolio Companies Notes Receivable From Portfolio Companies Investments Investments Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Earnings Per Share [Abstract] EARNINGS PER SHARE Earnings Per Share [Text Block] Fair Value Measurements [Abstract] Fair value measurements. FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Debt Disclosure [Abstract] BORROWINGS AND CREDIT ARRANGEMENTS Debt Disclosure [Text Block] Business Combinations [Abstract] ACQUISITIONS Business Combination Disclosure [Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] BSX Reportable Segments [Member] BSX Reportable Segments [Member] BSX Reportable Segments [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global CRM Reporting Unit [Member] Global CRM Reporting Unit [Member] Global CRM Reporting Unit [Member] Global Electrophysiology (EP) Reporting Unit [Member] Global Electrophysiology (EP) Reporting Unit [Member] Global Electrophysiology (EP) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Interventional Cardiology (IC) Reporting Unit [Member] Global Interventional Cardiology (IC) Reporting Unit [Member] Global Interventional Cardiology (IC) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] BTG Spec Pharma [Member] BTG Spec Pharma [Member] BTG Spec Pharma [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] EMEA [Member] EMEA [Member] UNITED STATES UNITED STATES Non-US [Member] Non-US [Member] Asia Pacific [Member] Asia Pacific [Member] Latin America and Canada [Member] Latin America and Canada [Member] Latin America and Canada [Member] Emerging Markets [Member] Emerging Markets [Member] Emerging Markets [Member] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Domain] Contract with Customer, Duration [Domain] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Contract with Customer, Liability Contract with Customer, Liability Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Retirement Benefits [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Retirement Plan Name [Axis] Retirement Plan Name [Axis] Retirement Plan Name [Domain] Retirement Plan Name [Domain] International retirement plans [Member] International retirement plans [Member] International retirement plans [Member] U.K. Plan [Member] U.K. Plan [Member] U.K. Plan [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] Statement of Comprehensive Income [Abstract] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net change in derivative financial instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Net change in available-for-sale securities Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Net change in derivative financial instruments Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Net change in defined benefit pensions and other items Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Statement, Scenario [Axis] Scenario, Unspecified [Domain] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Trade accounts receivable, net Accounts, Notes, Loans and Financing Receivable, Net, Current Inventories Inventory, Net Prepaid income taxes Deferred Tax Assets, Net of Valuation Allowance, Current Other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Deferred tax assets Deferred Tax Assets, Net, Current Other long-term assets Other Assets, Noncurrent TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Current debt obligations Debt, Current Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt Long-term Debt and Capital Lease Obligations Deferred tax liabilities Deferred Tax Liabilities, Net, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Commitments and contingencies Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding Preferred Stock, Value, Issued Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,642,488,911 shares as of December 31, 2019 and 1,632,148,030 shares as of December 31, 2018 Common Stock, Value, Issued Treasury stock, at cost - 247,566,270 shares as of December 31, 2019 and December 31, 2018 Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income (loss), net of tax: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustment Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Unrealized gain (loss) on derivative financial instruments Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax Unrealized costs associated with defined benefit pensions and other items Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Total stockholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Segment Reporting [Abstract] SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Income Tax Disclosure [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] Significant Accounting Policies [Abstract] Significant Accounting Policies [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Subsequent Events, Policy [Policy Text Block] Subsequent Events, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Concentration Risk Disclosure [Text Block] Concentration Risk Disclosure [Text Block] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Product Warranty Disclosure [Text Block] Product Warranty Disclosure [Text Block] Inventory, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Business Combinations Policy [Policy Text Block] Business Combinations Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Equity and Cost Method Investments, Policy [Policy Text Block] Equity and Cost Method Investments, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Legal Costs, Policy [Policy Text Block] Legal Costs, Policy [Policy Text Block] Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Shipping and Handling Cost, Policy [Policy Text Block] Shipping and Handling Cost, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Lessee, Leases [Policy Text Block] Leases [Abstract] Leases of Lessee Disclosure [Text Block] Leases of Lessee Disclosure [Text Block] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Lessee, leases not yet commenced, amount Lessee, leases not yet commenced, amount Lessee, leases not yet commenced, amount Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Two Operating Lease, Payments Operating Lease, Payments Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Rent Expense, Net Operating Leases, Rent Expense, Net Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments, Next Rolling Twelve Months Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Lessee, Operating and Finance Leases, Option to Extend Lessee, Operating and Finance Leases, Option to Extend Lessee, Operating and Finance Leases, Option to Extend Total leased assets Operating Lease, Liability, Current Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Discount Rate, Percent Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Lease, Liability Operating Lease, Liability Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments Due Operating Leases, Future Minimum Payments Due Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Statement of Cash Flows [Abstract] Adjustments to reconcile net income (loss) to cash provided by operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Gain on sale of businesses Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Depreciation and amortization Depreciation, Depletion and Amortization Deferred and prepaid income taxes Cash flow impact of deferred income tax expense (benefit) Cash flow impact of deferred income tax expense (benefit) Stock-based compensation expense Share-based Compensation Intangible asset impairment charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Net loss (gain) on investments and notes receivable Gain (Loss) on Investments Contingent consideration expense (benefit) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Payment of contingent consideration in excess of amount recognized at acquisition Payment for Contingent Consideration Liability, Operating Activities Inventory step-up amortization InventoryStepUpAmortization Inventory Step Up Amortization Exchange (gain) loss Net currency exchange gain (loss) Net currency exchange gain (loss) Other, net Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Increase (decrease) in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Trade accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Other liabilities Increase (Decrease) in Operating Liabilities Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Proceeds on disposals of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Payments for acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Proceeds from divestiture of certain businesses Proceeds from divestiture of businesses, net of costs Proceeds from divestiture of businesses, net of costs Proceeds from royalty rights Proceeds from Royalties Received Payments for settlements of hedge contracts Payments for Hedge, Investing Activities Payments for investments and acquisitions of certain technologies Payments to Acquire Investments Cash provided by (used for) investing activities Net Cash Provided by (Used in) Investing Activities Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Payment of contingent consideration and royalty rights previously established in purchase accounting Payments for (Proceeds from) Previous Acquisition Proceeds from royalty rights transfer Proceeds from secured borrowings relating to royalty arrangements Proceeds from secured borrowings relating to royalty arrangements Proceeds from short-term borrowings, net of debt issuance costs Proceeds from Short-term Debt Net increase (decrease) in commercial paper Proceeds from (Repayments of) Commercial Paper Proceeds from borrowings on credit facilities Proceeds from Long-term Lines of Credit Payments on borrowings from credit facilities Repayments of Long-term Lines of Credit Payments on short-term borrowings Repayments of Short-term Debt Payments on long-term borrowings and debt extinguishment costs Repayments of Long-term Debt Proceeds from long-term borrowings, net of debt issuance costs Proceeds from Issuance of Long-term Debt and Capital Securities, Net Cash used to net share settle employee equity awards Payment to net share settle employee equity awards Payment to net share settle employee equity awards Proceeds from issuances of shares of common stock Proceeds from Issuance of Common Stock Cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Supplemental Information Supplemental Cash Flow Information [Abstract] Cash (received) paid for income taxes, net Proceeds from Income Tax Refunds Income Taxes Paid Income Taxes Paid Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Fair value of contingent consideration recorded in purchase accounting Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Cash and cash equivalents Restricted cash and restricted cash equivalents included in Other current assets Restricted Cash and Cash Equivalents, Current Restricted cash equivalents included in Other long-term assets Restricted Cash Equivalents, Noncurrent Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information. Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Other Assets [Member] Other Assets [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Allowance, Credit Loss [Member] SEC Schedule, 12-09, Allowance, Credit Loss [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accounts Receivable, Net [Abstract] Accounts Receivable, Net [Abstract] Trade accounts receivable, net Accounts receivable Accounts Receivable, Gross, Current Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Beginning balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Net (credits) charges to expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Utilization of allowances SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Ending balance Inventory, Net [Abstract] Inventory, Net [Abstract] Finished goods Inventory, Finished Goods, Gross Work-in-process Inventory, Work in Process, Gross Raw materials Inventory, Raw Materials, Gross Inventory, Net Other Current Assets [Abstract] Other Current Assets [Abstract] Other Current Assets [Abstract] Restricted Cash and Cash Equivalents, Current Derivative Asset, Current Derivative Asset, Current Licensing arrangements, asset Licensing arrangements, asset Licensing arrangements, asset Income Taxes Receivable, Current Income Taxes Receivable, Current Other Assets, Miscellaneous, Current Other Assets, Miscellaneous, Current Other Assets, Current Other Assets, Current Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Land Land Buildings and improvements Buildings and Improvements, Gross Equipment, furniture and fixtures Equipment, furniture and fixtures Gross Equipment, furniture and fixtures Gross. Capital in progress Construction in Progress, Gross Property, plant and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Depreciation Depreciation Other Assets, Noncurrent [Abstract] Other Assets, Noncurrent [Abstract] Restricted Cash, Noncurrent Restricted Cash, Noncurrent Derivative Asset Derivative Asset Other Assets, Miscellaneous, Noncurrent Other Assets, Miscellaneous, Noncurrent Other Assets, Noncurrent Licensing arrangements Licensing arrangements Licensing arrangements Accrued Liabilities, Current [Abstract] Accrued Liabilities, Current [Abstract] Legal reserves Estimated Litigation Liability, Current Payroll and related liabilities Employee-related Liabilities, Current Accrued contingent consideration Business Combination, Contingent Consideration, Liability, Current Accrued Rebates, Current Accrued Rebates, Current Accrued Rebates, Current Other Accrued Liabilities, Current Other Accrued Liabilities, Current Accrued expenses Other Liabilities, Current [Abstract] Other Liabilities, Current [Abstract] Deferred Revenue, Current Deferred Revenue, Current Licensing arrangements, liability Accrued Royalties, Current Taxes Payable, Current Taxes Payable, Current Other Sundry Liabilities, Current Other Sundry Liabilities, Current Other Liabilities, Current Other Liabilities, Noncurrent [Abstract] Other Liabilities, Noncurrent [Abstract] Accrued income taxes Accrued Income Taxes, Noncurrent Legal reserves Estimated Litigation Liability, Noncurrent Accrued contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Other Liabilities Licensing arrangements, liability Licensing arrangements, liability Other Other Accrued Liabilities, Noncurrent Other long-term liabilities Compensation and Employee Benefit Plans [Text Block] Compensation and Employee Benefit Plans [Text Block] Commitments and Contingencies [Abstract] Commitments and Contingencies. COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] ASC Update No. 2016-13 [Policy Text Block] ASC Update No. 2016-13 [Policy Text Block] ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments [Policy Text Block] ASC Update No. 2018-15, Internal-Use Software [Policy Text Block] ASC Update No. 2018-15, Internal-Use Software [Policy Text Block] ASC Update No. 2018-15, Internal-Use Software [Policy Text Block] ASC Update No. 2016-02, Leases (Topic 842) [Policy Text Block] ASC Update No. 2018-18 [Policy Text Block] ASC Update No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying The Interaction Between Topic 808 and Topic 606 [Policy Text Block] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Statement of Stockholders' Equity [Abstract] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Adjustments for New Accounting Pronouncement [Member] Adjustments for New Accounting Pronouncement [Member] Accounting Standards Update 2016-09 [Member] Accounting Standards Update 2016-09 [Member] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Treasury Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Balance Net income (loss) Cumulative effect adjustment for ASU Adoptions(1) Cumulative Effect of New Accounting Principle in Period of Adoption Impact of stock-based compensation plans, net of tax Stock Granted, Value, Share-based Compensation, Net of Forfeitures Balance Stock Issued During Period, Value, New Issues Stock Issued During Period, Value, New Issues Balance (Shares) Impact of stock-based compensation plans, net of tax (Shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Balance (Shares) Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax [Abstract] Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Defined benefit pensions and other items Changes in Other Comprehensive Income [Abstract] Changes in Other Comprehensive Income [Abstract] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Income Taxes [Abstract] Income Taxes [Abstract] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Deferred Tax Liabilities, Net Deferred Tax Liabilities, Net One-time transaction tax post-1986 E&P One-time transaction tax post-1986 E&P One-time transaction tax post-1986 E&P Deferred tax assets, net of valuation allowance deferred tax assets and prepaid on intercompany profit deferred tax assets and prepaid on intercompany profit Income Tax Examination, Penalties and Interest Accrued Income Tax Examination, Penalties and Interest Accrued Unrecognized Tax Benefits Unrecognized Tax Benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Deferred Tax Assets, Operating Loss Carryforwards, Domestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic Deferred Tax Assets, Net, Current Deferred Tax Assets, Net, Noncurrent Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred Tax Assets, Inventory Deferred Tax Assets, Inventory Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Federal benefit of uncertain tax positions Federal benefit of uncertain tax positions Federal benefit of uncertain tax positions Deferred Tax Assets, Goodwill and Intangible Assets Deferred Tax Assets, Goodwill and Intangible Assets Deferred Tax Assets, Other Deferred Tax Assets, Other Deferred Tax Assets, Gross Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Valuation Allowance Change in Deferred Tax Assets, Valuation Allowance Change in Deferred Tax Assets, Valuation Allowance Change in Deferred Tax Assets, Valuation Allowance Deferred Tax Liabilities, Noncurrent Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Derivatives Deferred Tax Liabilities, Derivatives Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets Deferred Tax Liabilities, Intangible Assets Deferred Tax Liabilities, Inventory Deferred Tax Liabilities, Inventory Deferred Tax Liabilities, Other Deferred Tax Liabilities, Other Deferred Tax Liabilities, Gross Deferred Tax Liabilities, Gross Deferred Tax Liabilities Deferred tax liabilities, net Deferred tax liabilities, net Current Federal Tax Expense (Benefit) Current Federal Tax Expense (Benefit) Income (Loss) from Continuing Operations before Income Taxes, Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Income (Loss) from Continuing Operations before Income Taxes, Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Current State and Local Tax Expense (Benefit) Current State and Local Tax Expense (Benefit) Current Foreign Tax Expense (Benefit) Current Foreign Tax Expense (Benefit) Current Income Tax Expense (Benefit) Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Deferred Tax Assets, Operating Loss Carryforwards, Foreign Deferred Tax Assets, Operating Loss Carryforwards, Foreign Deferred Tax Asset, Intra-entity Transfer, Asset Other than Inventory Deferred Tax Asset, Intra-entity Transfer, Asset Other than Inventory deferred tax asset, Valuation allowance, intra-entity deferred tax asset, Valuation allowance, intra-entity deferred tax asset, Valuation allowance, intra-entity Cumulative Effect of New Accounting Principle in Period of Adoption Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Free Trade Zone Regime Tax Incentive Free Trade Zone Regime Tax Incentive Free Trade Zone Regime Tax Incentive Free Trade Zone Regime Tax Incentive Per Share Free Trade Zone Tax Incentive, Per Share Free Trade Zone Tax Incentive, Per Share Gross interest and penalties recognized in period Income Tax Examination, Increase (Decrease) in Liability from Prior Year Income Tax Examination, Penalties and Interest Expense Income Tax Examination, Penalties and Interest Expense Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters Potential reduction in unrecognized tax benefits over next 12 months as a result of concluding certain matters. Deferred Tax Assets, Prepaid on Intercompany Profit Deferred Tax Assets, Prepaid on Intercompany Profit Deferred Tax Assets, Prepaid on Intercompany Profit Net Deferred Tax Liabilities and Prepaid on Intercompany Profit Net Deferred Tax Liabilities and Prepaid on Intercompany Profit Net Deferred Tax Liabilities and Prepaid on Intercompany Profit Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent TCJA benefit recognized Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability One-time transaction tax post-1986 E&P - net payment One-time transaction tax post-1986 E&P - net payment One-time transaction tax post-1986 E&P - net payment Unrecognized Tax Benefits, Interest on Income Taxes Accrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued Tax Adjustments, Settlements, and Unusual Provisions Tax Adjustments, Settlements, and Unusual Provisions Net Settlement Payment to IRS Net Settlement Payment to IRS Net Settlement Payment to IRS transition tax payment remaining transition tax payment remaining transition tax payment remaining tax expense on state income taxes, USD E&P accumulated tax expense on state income taxes, USD E&P accumulated tax expense on state income taxes, USD E&P accumulated Income Tax Expense (Benefit) Income Tax Expense (Benefit) Revenue from Contract with Customer [Text Block] Revenue from Contract with Customer [Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment Tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Summary of Income Tax Contingencies [Table Text Block] Summary of Income Tax Contingencies [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] 2017 Acquisitions [Member] 2017 Acquisitions [Member] 2017 Acquisitions [Member] 2019 Acquisitions [Member] 2019 Acquisitions [Member] 2019 Acquisitions [Member] BTG Acquisition [Member] BTG Acquisition [Member] BTG Acquisition [Member] 2018 Acquisitions [Member] 2018 Acquisitions [Member] 2018 Acquisitions [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Business Acquisition, Pro Forma Information [Table Text Block] Business Acquisition, Pro Forma Information [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Business Combination, Components of Purchase Price [Table Text Block] Business Combination, Components of Purchase Price [Table Text Block] [Table Text Block] for The components of the purchase price for the acquisition. Business Combination, Purchase Price Allocation Schedule [Table Text Block] Business Combination, Purchase Price Allocation Schedule [Table Text Block] [Table Text Block] for Summary of the aggregate purchase price allocation for the acquisition. Business Acquisition, Purchase Price Allocation, Intangible Assets, Description Business Acquisition, Purchase Price Allocation, Intangible Assets, Description [Table Text Block] Business Acquisition, Purchase Price Allocation, Intangible Assets, Description [Table Text Block] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Investment [Table Text Block] Investment [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Stock Incentive and Ownership Plans [Abstract] Stock Incentive and Ownership Plans [Abstract] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain] Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain] [Domain] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items] [Line Items] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block] Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block] [Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block] Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block] Market-based awards, valuation assumptions [Table Text Block] Market-based awards, valuation assumptions [Table Text Block] Market-based awards, valuation assumptions [Table Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Significant Accounting Policies [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Indefinite-lived Intangible Assets [Axis] Indefinite Lived Intangible Assets Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In Process Research and Development [Member] In Process Research and Development [Member] Technology-Based Intangible Assets [Member] Technology-Based Intangible Assets [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents [Member] Patents [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Concentration Risk By Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Statement, Business Segments [Axis] Segments [Domain] Cardiovascular [Member] Cardiovascular [Member] Cardiovascular [Member] Other Segments [Member] Other Segments [Member] MedSurg [Member] MedSurg [Member] MedSurg [Member] Rhythm and Neuro [Member] Rhythm and Neuro [Member] Rhythm and Neuro [Member] Goodwill [Line Items] Goodwill [Line Items] Impairment of Intangible Assets (Excluding Goodwill) Impairment of Intangible Assets (Excluding Goodwill) Goodwill Goodwill, Period Increase (Decrease) Goodwill, Period Increase (Decrease) Goodwill, Translation and Purchase Accounting Adjustments Goodwill, Translation and Purchase Accounting Adjustments Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Goodwill (Textuals) [Abstract] Goodwill (Textuals) [Abstract] Goodwill (Textuals) [Abstract] Intangible Assets, Net (Excluding Goodwill) Goodwill, Acquired During Period Goodwill, Acquired During Period Other Intangible Assets (Textuals) [Abstract] Other Intangible Assets (Textuals) [Abstract] Other Intangible Assets (Textuals) [Abstract] Other intangible asset charges Goodwill, Written off Related to Sale of Business Unit Goodwill, Gross Goodwill, Gross Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived intangible assets, accumulated write-offs Indefinite-lived intangible assets, accumulated write-offs Indefinite-lived intangible assets, accumulated write-offs Indefinite-lived intangible assets, including goodwill Indefinite-lived intangible assets, including goodwill indefinite-lived intangible assets including goodwill Future Amortization Expense, Year One Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Future Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Future Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Future Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Future Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Information [Text Block] Supplemental information related to various balance sheet items. Weighted average shares outstanding Schedule of Weighted Average Number of Shares [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value by Liability Class [Axis] Liability Class [Axis] Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation, by Liability Class [Domain] Fair Value by Liability Class [Domain] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Classification of derivative assets and liabilities within level 2 Fair Value, by Balance Sheet Grouping [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Gains (losses) recognized in earnings for derivatives designed as hedging instruments Derivative Instruments, Gain (Loss) [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Net foreign currency gain (loss) [Table Text Block] Net foreign currency gain (loss) [Table Text Block] [Table Text Block] for Net foreign currency gain (loss) [Table] Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] Schedule of Changes in Projected Benefit Obligations [Table Text Block] Schedule of Changes in Projected Benefit Obligations [Table Text Block] Schedule of Defined Benefit Plans Disclosures [Table Text Block] Schedule of Defined Benefit Plans Disclosures [Table Text Block] Pension and Other Postretirement Plans, Policy [Policy Text Block] Pension and Other Postretirement Plans, Policy [Policy Text Block] Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Schedule of Changes in Fair Value of Plan Assets [Table Text Block] Schedule of Allocation of Plan Assets [Table Text Block] Schedule of Allocation of Plan Assets [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] ASC Topic 820, Fair Value Measurements and Disclosures Fair Value Measurement, Policy [Policy Text Block] ASC Topic 815, Derivatives and Hedging GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Cost of Sales [Member] Cost of Sales [Member] Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Axis] Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Axis] Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Axis] Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Domain] Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Domain] [Domain] for Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Axis] Restructuring Related To Plan [Member] Restructuring Related To Plan [Member] Restructuring Related To Plan [Member] Statement of Operations Caption [Axis] Statement of Operations Caption [Axis] Statement of Operations Caption [Axis] Statement of Operations Caption [Domain] Statement of Operations Caption [Domain] Statement of Operations Caption [Domain] Restructuring and Related Cost, by Type of Restructuring Charge Expected [Axis] Restructuring and Related Cost, by Type of Restructuring Charge Expected [Axis] Restructuring and Related Cost, by Type of Restructuring Three [Axis] Restructuring and Related Cost, by Type of Restructuring Charge [Domain] Restructuring and Related Cost, by Type of Restructuring Charge [Domain] Restructuring and Related Cost, by Type of Restructuring Three [Domain] Restructuring Plan [Member] Restructuring Plan [Member] Restructuring Plan [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance [Member] Other Restructuring [Member] Other Restructuring [Member] Transfer costs [Member] Transfer costs [Member] Transfer costs [Member]. Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] 2016 Restructuring Plan [Member] 2016 Restructuring Plan [Member] 2016 Restructuring Plan [Member] 2019 Restructuring Plan [Member] 2019 Restructuring Plan [Member] 2019 Restructuring Plan [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Severance Costs Severance Costs Restructuring and Related Cost, Incurred Cost Restructuring and Related Cost, Incurred Cost Restructuring Charges Incurred to Date Restructuring Charges Incurred to Date Restructuring Charges Incurred to Date Restructuring Charges Restructuring Charges Other Restructuring Costs Other Restructuring Costs Transfer Costs Transfer Costs Transfer Costs Restructuring plan estimated future cash outflow Restructuring plan estimated future cash outflow Restructuring plan estimated future cash outflow Payments for Restructuring Payments for Restructuring Restructuring and Related Cost, Cost Incurred to Date Restructuring and Related Cost, Cost Incurred to Date Restructuring and Related Cost, Expected Cost Restructuring and Related Cost, Expected Cost Restructuring-related Cost, Expected Cost Restructuring-related Cost, Expected Cost Restructuring-related Cost, Expected Cost Restructuring and Restructuring-related Cost, Expected Cost Restructuring and Restructuring-related Cost, Expected Cost Restructuring and Restructuring-related Cost, Expected Cost Restructuring-related Costs Incurred to Date Restructuring-related Costs Incurred to Date Restructuring-related Costs Incurred to Date Restructuring Related Expenses Restructuring Related Expenses Restructuring related expenses. Restructuring and Restructuring-Related Cost Restructuring and Restructuring-Related Cost Restructuring and Restructuring-related Cost Schedule Of Segment Reporting Information By Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Special Charges [Member] Special Charges [Member] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Total allocated to reportable segments [Member] Corporate Expenses including hedging activities [Member] Corporate Expenses including hedging activities [Member] Corporate Expenses including hedging activities [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries [Axis] United States [Member] IRELAND IRELAND Other countries [Member] Other countries [Member] Other countries [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Assets Property, Plant and Equipment, Net Net sales Amortization expense Amortization of Intangible Assets Operating income allocated to reportable segments Operating Income (Loss) Operating Income Unallocated to Segment Operating Income Unallocated to Segment Operating Income Unallocated to Segment Other expense, net Nonoperating Income (Expense) Income (loss) before income taxes Depreciation TOTAL ASSETS Segment operating income as percentage of net sales Segment operating income as percentage of net sales Long-Lived Assets Long-Lived Assets Segment Reporting (Textuals) [Abstract] Segment Reporting (Textuals) [Abstract] Segment Reporting. Number of reportable segments Number of Reportable Segments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Reconciliation of depreciation by reportable segment to total [Table Text Block] Reconciliation of depreciation by reportable segment to total [Table Text Block] Reconciliation of depreciation by reportable segment to total [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Segment operating income as percentage of net sales [Table Text Block] Segment operating income as percentage of net sales [Table Text Block] Segment operating income as percentage of net sales Reconciliation of Assets from Segment to Consolidated [Table Text Block] Reconciliation of Assets from Segment to Consolidated [Table Text Block] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Preferred Stock, Shares Authorized Common Stock, Shares Authorized Common Stock, Par or Stated Value Per Share Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Restructuring and Related Cost [Line Items] Impact of restructuring costs on the accompanying financial statements Restructuring and Related Costs [Table Text Block] Cumulative Restructuring Charges [Text Block] Cumulative Restructuring Charges [Text Block] Cumulative restructuring charges. Amount Of Cash Paid In Period To Fully Or Partially Settle Specified Type Of Restructuring Cost [Text Block] Amount Of Cash Paid In Period To Fully Or Partially Settle Specified Type Of Restructuring Cost [Text Block] Amount of cash paid in the period to fully or partially settle a specified type of restructuring cost. Income Statement [Abstract] Cost of products sold Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Selling, general and administrative expenses Selling, General and Administrative Expense Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Royalty expense Royalty Expense Amortization expense Intangible asset impairment charges Restructuring charges (credits) Litigation-related charges (credits) Litigation Settlement, Expense Operating expenses Operating Expenses Operating income (loss) Other income (expense): Other Nonoperating Income (Expense) [Abstract] Interest expense Interest Expense Other, net Other Nonoperating Income (Expense) Income tax (benefit) expense Net income (loss) Net income (loss) per common share — basic Earnings Per Share, Basic Net income (loss) per common share — assuming dilution Earnings Per Share, Diluted Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic Weighted Average Number of Shares Outstanding, Basic Assuming dilution Weighted Average Number of Shares Outstanding, Diluted Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Research and Development Expense [Member] Research and Development Expense [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2011 LTIP Plan [Member] 2011 LTIP Plan [Member] 2011 LTIP Plan [Member] High end of range [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Fair value of market based awards Fair value of market based awards Fair value of market based awards Share Price Share Price Unrecognized Compensation Cost - Stock Options Unrecognized Compensation Cost - Stock Options Unrecognized Compensation Cost - Stock Options Range of the target number of performance-based DSUs awarded Range of the target number of performance-based DSUs awarded Range of the target number of performance-based DSUs awarded Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock Issued During Period, Shares, Employee Stock Purchase Plans Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Measurement period - market based awards Measurement period - market based award Measurement period - market based awards Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Common Stock, Capital Shares Reserved for Future Issuance Common Stock, Capital Shares Reserved for Future Issuance Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Share-based compensation, net of tax benefit Share-based compensation, net of tax benefit Share-based compensation, net of tax benefit compensation expense, per share - basic compensation expense, per share - basic compensation expense, per share - basic compensation expense, per share - diluted compensation expense, per share - diluted compensation expense, per share - diluted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options expected to vest Options expected to vest Options expected to vest Options expected to vest, weighted average exercise price Options expected to vest, weighted average exercise price Options expected to vest, weighted average exercise price Options expected to vest, weighted average remaining contractual life Options expected to vest, weighted average remaining contractual life Options expected to vest, weighted average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Range of the target number of market-based DSUs awarded Range of the target number of market-based DSUs awarded Range of the target number of market-based DSUs awarded Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Amount of employees total compensation eligible for GESOP purchase Amount of employees total compensation eligible for GESOP purchase Amount of employees total compensation eligible for GESOP purchase Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Unrecognized Compensation Cost - Non-vested stock awards Unrecognized Compensation Cost - Non-vested stock awards Unrecognized Compensation Cost - Non-vested stock awards Unrecognized Compensation Cost Unrecognized Compensation Cost Unrecognized Compensation Cost weighted average remaining vesting period weighted average remaining vesting period weighted average remaining vesting period annualweightedaverageforfeiturerate annualweightedaverageforfeiturerate Annual Weighted Average Forfeiture Rate The weighted average of estimated forfeitures for grants based on historical trends voting power of all classes of stock voting power of all classes of stock voting power of all classes of stock Exercise price of the fair market value of our common stock on the date of grant Exercise price of the fair market value of our common stock on the date of grant Exercise price of the fair market value of our common stock on the date of grant Qualified options exercise price Non-vested stock awards exercise price Non-vested stock awards exercise price Fair value of the Free Cash Flow (FCF) performance awards Fair value of the Free Cash Flow (FCF) performance awards Fair value of the Free Cash Flow (FCF) performance awards Target payout of Free Cash Flows (FCF) performance awards Target payout of Free Cash Flows (FCF) performance awards Target payout of Free Cash Flows (FCF) performance awards Employee Stock Ownership Plan (ESOP), Compensation Expense Employee Stock Ownership Plan (ESOP), Compensation Expense Schedule of Other Assets [Table Text Block] Schedule of Other Assets [Table Text Block] Trade accounts receivable, net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Rollforward of allowances for doubtful accounts Rollforward Of Allowances For Doubtful Accounts [Text Block] An element designated to encapsulate the entire schedule of allowances for doubtful accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Inventories Inventory Disclosure [Text Block] Schedule of Other Current Assets [Table Text Block] Schedule of Other Current Assets [Table Text Block] Property, plant and equipment, net Property, Plant and Equipment [Table Text Block] Accrued expenses Schedule of Accrued Liabilities [Table Text Block] Other Current Liabilities [Table Text Block] Other Current Liabilities [Table Text Block] Other long-term liabilities Other Noncurrent Liabilities [Table Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] divested business due to BTG acquisition [Member] divested business due to BTG acquisition [Member] divested business due to BTG acquisition [Member] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Valuation Technique, Discounted Cash Flow [Member] Valuation Technique, Discounted Cash Flow [Member] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets [Member] Finite-Lived Intangible Assets [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] R&D, Regulatory and Commercialization-based Milestone [Member] R&D, Regulatory and Commercialization-based Milestone [Member] R&D, Regulatory and Commercialization-based Milestone [Member] Revenue-based payments by valuation technique [Member] Revenue-based payments by valuation technique [Member] Revenue-based payments by valuation technique [Member] revenue-based payments [Member] revenue-based payments [Member] revenue-based payments [Member] Business Acquisition [Axis] Vertiflex, Inc. [Member] Vertiflex, Inc. [Member] Vertiflex, Inc. Proposed BTG Acquisition [Member] Proposed BTG Acquisition [Member] Proposed BTG Acquisition [Member] Millipede [Member] Millipede [Member] Millipede [Member] Augmenix, Inc. [Member] Augmenix, Inc. [Member] Augmenix, Inc. [Member] Claret [Member] Claret [Member] Claret [Member] Cryterion [Member] Cryterion [Member] Cryterion [Member] NxThera [Member] NxThera [Member] NxThera [Member] nVision [Member] nVision [Member] nVision [Member] Other 2018 Acquisitions [Member] Other 2018 Acquisitions [Member] Other 2018 Acquisitions - immaterial in the aggregate [Member] Apama [Member] Apama [Member] Apama [Member] Symetis [Member] Symetis [Member] Symetis [Member] Minimum [Member] Weighted Average [Member] Weighted Average [Member] Proceeds from Divestiture of Businesses Proceeds from Divestiture of Businesses Business Acquisition, Pro Forma Revenue Business Acquisition, Pro Forma Revenue Goodwill, Purchase Accounting Adjustments Goodwill, Purchase Accounting Adjustments Proceeds from secured borrowings relating to royalty arrangements Total consideration for share purchase initial investment, cash paid initial investment, cash paid Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Employer Finite-lived Intangible Assets Acquired Finite-lived Intangible Assets Acquired Payments to Acquire Businesses, Net of Cash Acquired Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Other Significant Noncash Transaction, Value of Consideration Given Other Significant Noncash Transaction, Value of Consideration Given Business Acquisition, Share Price Business Acquisition, Share Price Cash Acquired from Acquisition Cash Acquired from Acquisition Business Combination, Contingent Consideration, Asset Business Combination, Contingent Consideration, Asset Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Maximum future contingent consideration for acquisitions completed after January 1, 2009 Maximum future contingent consideration for acquisitions Maximum future contingent consideration for acquisitions Potential payments based on acheiving certain milestones Potential payments based on acheiving certain milestones Potential payments based on acheiving certain milestones Fair value of contingent consideration Business Combination, Contingent Consideration, Liability Discount Rate, Fair Value Input Discount Rate, Fair Value Input Discount Rate, Fair Value Input Acquired Finite-lived Intangible Asset, Weighted Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Indefinite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Total Range of Risk Adjusted Discount Rates used in Purchase Price Allocation Range of Risk Adjusted Discount Rates used in Purchase Price Allocation Range of Risk Adjusted Discount Rates used in Purchase Price Allocation Additional Acquisitions (Textuals) [Abstract] Additional Acquisitions (Textuals) [Abstract] Additional Acquisitions Textuals Abstract. contingent consideration liability, probability of payment contingent consideration liability, probability of payment contingent consideration liability, probability of payment Acquisitions (Textuals) [Abstract] Acquisitions (Textuals) [Abstract] Acquisitions. Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Contingent payment related to business combination Contingent payment related to business combination Contingent payment related to business combination Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Notes receivable from portfolio companies Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Payments to Acquire Businesses, Gross Payments to Acquire Businesses, Gross Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Closing payment Closing payment Closing payment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Indefinite-lived Intangible Assets Acquired Indefinite-lived Intangible Assets Acquired Intangible Assets Acquired, Finite and Indefinite-lived Intangible Assets Acquired, Finite and Indefinite-lived Intangible Assets Acquired, Finite and Indefinite-lived change in maximum amount of future contingent consideration, increase (decrease) change in maximum amount of future contingent consideration, increase (decrease) change in maximum amount of future contingent consideration, increase (decrease) Accounts, Notes, Loans and Financing Receivable, Net, Current Prepaid Expense and Other Assets, Current Accrued Liabilities, Current Other Liabilities, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Diluted Business Acquisition, Pro Forma Earnings Per Share, Diluted Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table] Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Other International Plans [Member] Other International Plans [Member] Other International Plans [Member] Domestic Plan [Member] Domestic Plan [Member] BTG Acquisition [Member] BTG Acquisition [Domain] [Domain] for BTG Acquisition [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Other Contract [Member] Other Contract [Member] Defined Benefit Plan, Cash [Member] Defined Benefit Plan, Cash [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Executive retirement plan [Member] Executive retirement plan [Member] Executive retirement plan [Member] Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] Assets for Plan Benefits, Defined Benefit Plan Assets for Plan Benefits, Defined Benefit Plan Defined Benefit Plan, Accumulated Benefit Obligation Defined Benefit Plan, Accumulated Benefit Obligation Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Plan Assets, Amount Defined Benefit Plan, Plan Assets, Amount Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets Defined Benefit Plan, Acquired and Established Plan Changes, PBO Defined Benefit Plan, Acquired and Established Plan Changes, PBO Defined Benefit Plan, Service Cost Defined Benefit Plan, Service Cost Defined Benefit Plan, Interest Cost Defined Benefit Plan, Interest Cost Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment pension benefit obligation, benefits paid pension benefit obligation, benefits paid pension benefit obligation, benefits paid Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant defined benefit plan, plan assets, actuarial gain loss defined benefit plan, plan assets, actuarial gain loss defined benefit plan, plan assets, actuarial gain loss Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Executive Retirement Plan Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return Expense related to matching contributions Expense related to matching contributions Expense related to matching contributions Executive Retirement Plan Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Defined Benefit Plan, Funded (Unfunded) Status of Plan Defined Benefit Plan, Funded (Unfunded) Status of Plan Schedule of Short-term Debt [Table Text Block] Schedule of Short-term Debt [Table Text Block] Long-term Purchase Commitment [Table Text Block] Long-term Purchase Commitment [Table Text Block] Schedule of debt maturities Schedule of Long-term Debt Instruments [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants. Transfer of Financial Assets Accounted for as Sales [Table Text Block] Transfer of Financial Assets Accounted for as Sales [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Award Date [Axis] Award Date [Axis] Award Date [Domain] Award Date [Domain] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Other Comprehensive Income (Loss), Net of Tax Significant Accounting Policies Significant Accounting Policies [Table] Significant Accounting Policies [Table] Operating lease, Liability [Axis] Operating lease, Liability [Axis] Operating lease, Liability [Axis] Operating lease, Liability [Domain] Operating lease, Liability [Domain] [Domain] for Operating lease, Liability [Axis] Operating lease, liability, other long-term liabilities [Member] Operating lease, liability, other long-term liabilities [Member] Operating lease, liability, other long-term liabilities [Member] Operating lease, right-of-use asset [Axis] Operating lease, right-of-use asset [Axis] Operating lease, right-of-use asset [Axis] Operating lease, right-of-use asset [Domain] Operating lease, right-of-use asset [Domain] [Domain] for Operating lease, right-of-use asset [Axis] Operating lease, right-of-use assets, other long-term assets [Member] Operating lease, right-of-use assets, other long-term assets [Member] Operating lease, right-of-use assets, other long-term assets [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2016-16 [Member] Finite-Lived Intangible Assets by Major Class [Axis] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Shipping and Handling [Member] Shipping and Handling [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets Percent of finished goods at consignment Percent of finished goods at consignment Percent of finished goods at consignment Concentration Risk, Customer Concentration Risk, Customer Deferred Tax Liabilities, Noncurrent New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification Cover Document [Abstract] Cover Document [Abstract] Entities [Table] Entities [Table] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Public Float Entity Public Float Entity Listing, Par Value Per Share Entity Listing, Par Value Per Share Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Loss Contingencies [Table] Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Accrual for legal matters that are probable and estimable Loss Contingency Accrual Litigation Settlement Received, Gain Litigation Settlement Received, Gain Litigation Settlement Received, Gain Loss Contingency, Damages Paid, Value Loss Contingency, Damages Paid, Value Subsequent Event [Table] Subsequent Event [Table] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Settled Litigation [Member] Settled Litigation [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Product liability cases or claims related to mesh product assigned to one judge in state court in Massachusetts Product liability cases or claims related to mesh product assigned to one judge in state court in Massachusetts Product liability cases or claims related to mesh product assigned to one judge in state court in Massachusetts Product liability cases or claims related to mesh product Product liability cases or claims related to mesh product Product liability cases or claims asserted related to mesh products Product liability cases or claims in Canada, Mesh Product liability cases or claims related to mesh product - Canada Product liability cases or claims related to mesh product - Canada Certified class actions in Canada, Mesh Certified class actions in Canada, Mesh Certified class actions in Canada, Mesh Total Product liability cases and claims settled related to Mesh product Total Product liability cases and claims settled related to Mesh product Total Product liability cases and claims settled related to Mesh product Product liability cases or claims related to mesh product - United Kingdom Product liability cases or claims related to mesh product - United Kingdom Product liability cases or claims related to mesh product - United Kingdom Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2020 Term Loan [Member] 2020 Term Loan [Member] 2020 Term Loan [Member] Two-Year Delayed Draw Term Loan [Member] Two-Year Delayed Draw Term Loan [Member] Two-Year Delayed Draw Term Loan [Member] November 2035 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Yen Denominated Factoring Arrangements [Member] Yen Denominated Factoring Arrangements [Member] Yen denominated factoring arrangements. Three-Year Delayed Draw Term Loan [Member] Three-Year Delayed Draw Term Loan [Member] Three-Year Delayed Draw Term Loan [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Tender Offer [Member] Tender Offer [Member] Cash Tender Offer [Member] February2019AggregateOffering [Member] February2019AggregateOffering [Member] February2019AggregateOffering [Member] March 2039 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] Aggregate Senior Unsecured Delayed Draw Term Loan [Member] Aggregate Senior Unsecured Delayed Draw Term Loan [Member] Aggregate Senior Unsecured Delayed Draw Term Loan [Member] Debt Instrument, Redemption, Period Two [Member] Debt Instrument, Redemption, Period Two [Member] Debt Instrument, Redemption, Period Three [Member] Debt Instrument, Redemption, Period Three [Member] October 2018 Notes [Member] October 2018 Notes [Member] October 2018 Notes [Member] January 2020 Notes [Member] January 2020 Notes [Member] January 2020 Notes [Member] May 2020 Notes [Member] May 2020 Notes [Member] May 2020 Notes [Member] August 2019 Term Loan [Member] August 2019 Term Loan [Member] August 2019 Term Loan [Member] May 2022 Notes [Member] May 2022 Notes [Member] May 2022 Notes [Member] August 2022 Term Loan [Member] August 2022 Term Loan [Member] August 2022 Term Loan [Member] October 2023 Notes [Member] October 2023 Notes [Member] October 2023 Notes [Member] March 2024 Notes [Member] March 2024 Notes [Member] March 2024 Notes [Member] May 2025 Notes [Member] May 2025 Notes [Member] May 2025 Notes [Member] March 2026 Notes [Member] March 2026 Notes [Member] March 2026 Notes [Member] December 2027 Notes [Member] December 2027 Notes [Member] December 2027 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] March 2029 Notes [Member] March 2029 Notes [Member] March 2029 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] March 2049 Notes [Member] March 2049 Notes [Member] March 2049 Notes [Member] Interest Rate Swap [Member] Interest Rate Swap [Member] Capital Lease Obligations [Member] Capital Lease Obligations [Member] Senior Notes [Member] Senior Notes [Member] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Commercial Paper [Member] Commercial Paper [Member] the 2017 Facility [Member] the 2017 Facility [Member] the 2017 Facility [Member] the 2018 facility [Member] the 2018 facility [Member] the 2018 facility [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Covenant [Axis] Covenant [Axis] Covenant. Covenant [Domain] Covenant [Domain] Covenant. Covenant Requirement [Domain] Covenant Requirement [Domain] Covenant Requirement [Domain] Covenant Requirement [Member] Current Requirement [Member] Current Requirement. Actual, Covenant [Member] Actual, Covenant [Member] Actual Covenant. Requirement, first two quarters following qualified acquisition [Member] Requirement, first two quarters following qualified acquisition [Member] Requirement, first two quarters following qualified acquisition [Member] Requirement, third quarter following qualified acquisition [Member] Requirement, third quarter following qualified acquisition [Member] Requirement, third quarter following qualified acquisition [Member] Requirement, fourth quarter following qualified acquisition [Member] Requirement, fourth quarter following qualified acquisition [Member] Requirement, fourth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, sixth quarter and thereafter following qualified acquisition [Member] Requirement, sixth quarter and thereafter following qualified acquisition [Member] Requirement, sixth quarter and thereafter following qualified acquisition [Member] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Borrowings [Member] Borrowings [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Termination Loans Termination Loans Purchase Obligation, Due in Next Twelve Months Purchase Obligation, Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Next Twelve Months Purchase Obligation, Due after Fifth Year Recorded Unconditional Purchase Obligation Due in Second Year Purchase Obligation, Due in Second Year Purchase Obligation, Due in Third Year Purchase Obligation, Due in Third Year Purchase Obligation, Due in Fourth Year Purchase Obligation, Due in Fourth Year Purchase Obligation, Due in Fifth Year Purchase Obligation, Due in Fifth Year Repurchase Agreement Counterparty, Amount at Risk Repurchase Agreement Counterparty, Amount at Risk Senior notes issued Senior notes issued Senior notes issued Schedule of debt maturities Borrowings and Credit Arrangements [Abstract] Borrowings and Credit Arrangements. Payments due, Total Long-term Debt Long-term Debt and Capital Lease Obligations Summary of compliance with debt covenants Summary of compliance with debt covenants [Abstract] Summary of compliance with debt covenants [Abstract]. Maximum Leverage Ratio Maximum leverage ratio permitted by revolving credit facility agreement. Borrowings and Credit Arrangements (Textuals) [Abstract] Borrowings and Credit Arrangements (Textuals) [Abstract] Borrowings And Credit Arrangements Textuals Abstract. Total debt Debt and Capital Lease Obligations Debt, Current Short-term Debt Short-term Debt Revolving credit facility Line of Credit Facility, Remaining Borrowing Capacity Current interest rate on revolving credit facility Line of Credit Facility, Interest Rate During Period Line of Credit Facility, Description Debt Instrument, Interest Rate, Increase (Decrease) Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Amount of exclusions from EBITDA related to existing restructuring plans Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA. Amount of exclusions from EBITDA related to future litigation charges and payments Litigation and Debt Exclusion from EBITDA Exclusion of litigation payments and any debt Issued to fund tax deficiency payments Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net De-recognized receivables Continuing Involvement with Derecognized Transferred Financial Assets, Amount Outstanding Average interest rate of de-recognized receivables Receivable with Imputed Interest, Effective Yield (Interest Rate) Average discounted rates of notes receivables Average Discount Rate Of Notes Receivable Average discount rate of notes receivable. Debt Instrument, Interest Rate During Period Debt Instrument, Interest Rate During Period Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Repayments of Debt Repayments of Debt Commercial Paper Commercial Paper Weighted Average Maturity, Days Weighted Average Maturity, Days Weighted Average Maturity, Days Maximum Commercial Paper Outstanding with 2018 Facility Maximum Commercial Paper Outstanding with 2018 Facility Maximum Commercial Paper Outstanding with 2018 Facility Short-term Debt, Weighted Average Interest Rate, at Point in Time Short-term Debt, Weighted Average Interest Rate, at Point in Time Interest Expense Purchase Obligation Purchase Obligation Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Long-term Line of Credit Long-term Line of Credit Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Goodwill [Table Text Block] Schedule of Goodwill [Table Text Block] Schedule of Expected Amortization Expense [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Tax Rate [Axis] Tax Rate [Axis] Tax Rate [Axis] Tax Rate [Domain] Tax Rate [Domain] Tax Rate [Domain] Schedule of Income Tax Rate Reconciliation [Line Items] Schedule of Income Tax Rate Reconciliation [Line Items] [Line Items] for Schedule of Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent effective income tax reconciliation, compensation-related Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Effective Income Tax Rate Reconciliation, Tax Credits, Research Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions Effective Income Tax Rate Reconciliation, TCJA net impact Effective Income Tax Rate Reconciliation, TCJA net impact Effective Income Tax Rate Reconciliation, TCJA net impact Effective Income Tax Rate Reconciliation, intra entity intangible asset transfers Effective Income Tax Rate Reconciliation, intra entity intangible asset transfers Effective Income Tax Rate Reconciliation, intra entity intangible asset transfers Effective Income Tax Rate Reconciliation, Other Adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Reported tax rate Effective Income Tax Rate Reconciliation, Percent Fair Value Measurements [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Other Nonoperating Income (Expense) [Member] Interest Expense [Member] Interest Expense [Member] Hedging Relationship [Axis] Hedging Relationship [Domain] Net Investment Hedging [Member] Net Investment Hedging [Member] Cash Flow Hedging [Member] Hedging Designation [Axis] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Hedged Debt [Axis] Hedged Debt [Axis] Hedged Debt [Axis] Hedged Debt [Domain] Hedged Debt [Domain] [Domain] for Hedged Debt [Axis] Liability [Member] Liability [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Member Countries, Euro Euro Member Countries, Euro BTG Acquisition [Axis] BTG Acquisition [Axis] BTG Acquisition [Axis] BTG Acquisition [Domain] Licensing arrangement liabilities [Member] Licensing arrangement liabilities [Member] Licensing arrangement liabilities [Member] Licensing arrangement assets [Member] Licensing arrangement assets [Member] Licensing arrangement assets [Member] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Forward Contracts [Member] Forward Contracts [Member] Euro-denominated outstanding debt [Member] Euro-denominated outstanding debt [Member] Euro-denominated outstanding debt [Member] Interest Rate Contract [Member] Interest Rate Contract [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Accounts Payable [Member] Accounts Payable [Member] Assets [Member] Assets [Member] Other Current Assets [Member] Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] foreign currency denominated in debt [Member] foreign currency denominated in debt [Member] foreign currency denominated in debt [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt Instrument, Interest Rate, Stated Percentage Long-term Debt Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Foreign Currency Contract, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Weighted Average Discount Rate, Percent Weighted Average Discount Rate, Percent Assets, Fair Value Disclosure Assets, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure Foreign Currency Contracts, Liability, Fair Value Disclosure derivative, notional amount translated derivative, notional amount translated derivative, notional amount translated Accrued Contingent Consideration Accrued Contingent Consideration Estimated discounted potential payments under contingent consideration arrangements. Licensing arrangements, liability Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Notional Amount of Interest Rate Derivatives Derivative, Notional Amount Derivative, Loss on Derivative Derivative, Loss on Derivative Cash Cash Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Cost of Goods and Services Sold Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Net gain (loss) from foreign currency transaction exposures Net gain (loss) from foreign currency transaction exposures Net gain (loss) from foreign currency transaction exposures Foreign Currency Transaction Gain (Loss), Realized Foreign Currency Transaction Gain (Loss), Realized Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Liability Derivative Liability Fair Value of Assets Acquired Fair Value of Assets Acquired Proceeds from Royalties Received Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option Derivative, Notional Amount Weighted average shares outstanding Weighted average shares outstanding - basic Net effect of common stock equivalents Weighted Average Number Diluted Shares Outstanding Adjustment Weighted average shares outstanding - assuming dilution Maturities of Lease Liabilities [Table Text Block] Maturities of Lease Liabilities [Table Text Block] Maturities of Lease Liabilities [Table Text Block] Supplemental Cash Flow Information Related to Leases [Table Text Block] Supplemental Cash Flow Information Related to Leases [Table Text Block] Supplemental Cash Flow Information Related to Leases [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Lease, Cost [Table Text Block] Lease, Cost [Table Text Block] Operating Leases, Rent Expense, Minimum Rentals Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] EX-101.PRE 13 bsx-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 totalreturngraph2019.jpg begin 644 totalreturngraph2019.jpg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end XML 15 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Significant Accounting Policies Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2019
Significant Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Principles of Consolidation

Our consolidated financial statements include the accounts of Boston Scientific Corporation and our wholly-owned subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest in a VIE. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs for 2019, 2018 and 2017.

Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

Reportable Segments

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG plc (BTG), which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.
Subsequent Events, Policy [Policy Text Block]
Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note E – Contractual Obligations and Commitments and Note J – Commitments and Contingencies for further details.
Use of Estimates, Policy [Policy Text Block]
Accounting Estimates

To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report for further discussion.
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider to be cash equivalents all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.

Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in the Other current assets caption on our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us as servicer of previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents

Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in the Other current assets caption on our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in the Other long-term assets caption on our consolidated balance sheets are related to deferred compensation plans.
Concentration Risk Disclosure [Text Block]
Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral. We record our accounts receivable in our consolidated balance sheets at net realizable value. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses, based on historical information and management's best estimates. We write-off amounts determined to be uncollectible against this reserve. Write-offs of uncollectible accounts receivable were immaterial in 2019, 2018 and 2017. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2019, 2018 and 2017; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers in Southern Europe are subject to an increased number of days outstanding prior to payment relative to other countries. Historically, receivable balances with certain publicly-owned hospitals in these countries accumulated over a period of time and are then subsequently settled as large lump sum payments, sometimes at large discounts. While we believe our allowance for doubtful accounts in these countries is adequate as of December 31, 2019 and 2018, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts receivable may increase.
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition

In May 2014, the FASB issued FASB ASC Topic 606, Revenue from Contracts with Customers (Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, Revenue Recognition.

Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to retained earnings of $177 million on January 1, 2018, primarily related to the cost of providing non-contractual post-implant support to certain customers, which we historically deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within Selling, general and administrative expenses and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual.

The impact of adopting FASB ASC Topic 606 on our consolidated balance sheets resulted in an increase in Other current liabilities of $59 million and an increase in Other long-term liabilities of $205 million as of December 31, 2018, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in Other long-term assets of $12 million and a reduction in Deferred income taxes of $41 million as of December 31, 2018. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met:

•
We have a contract with a customer that creates enforceable rights and obligations,
•
Promised products or services are identified,
•
The transaction price, or the amount we expect to receive, is determinable and
•
We have transferred control of the promised items to the customer.

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

Capitalized Contract Costs

We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our consolidated financial statements.

Post-Implant Services

We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. Following our modified retrospective adoption of FASB ASC Topic 606 on January 1, 2018, because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.
Product Warranty Disclosure [Text Block]
Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our Cardiac Rhythm Management business, which include implantable defibrillator and pacemaker systems. Our Cardiac Rhythm Management products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.

Inventory, Policy [Policy Text Block]
Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. Approximately 32 percent of our finished goods inventory as of December 31, 2019 and approximately 40 percent as of December 31, 2018 was at customer locations pursuant to consignment arrangements or held by sales representatives.
Property, Plant and Equipment, Policy [Policy Text Block]
Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.
Business Combinations Policy [Policy Text Block]
Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In those circumstances where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.
In Process Research and Development, Policy [Policy Text Block]
Indefinite-lived Intangibles, including IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which is foundational to our ongoing operations within the Cardiovascular market and other markets within interventional medicine and IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.

For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.

For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2019, 2018 and 2017 annual impairment assessment, we identified the following reporting units: Interventional Cardiology, Peripheral Interventions (including the Interventional Medicine business acquired with BTG), Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health and Neuromodulation. In addition, following the BTG acquisition in the third quarter of 2019, we added Specialty Pharmaceuticals as an additional reporting unit. We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based on the criteria prescribed in FASB ASC Topic 350.

In performing the goodwill impairment assessments for 2019, 2018 and 2017, we utilized both the optional qualitative assessment and the quantitative approach prescribed under FASB ASC Topic 350. The qualitative assessment was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent. All other reporting units were tested using the quantitative approach described below. The qualitative assessment requires an evaluation of whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount based on an assessment of relevant events including macroeconomic factors, industry and market conditions, cost factors, overall financial performance and other entity-specific factors. After assessing the totality of events, if it is determined that it is more likely than not that the fair value of the reporting unit exceeds its carrying value, no further steps are required. If it is determined that impairment is more likely than not, then we perform the quantitative impairment test.

When allocating goodwill from business combinations to our reporting units, we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition. In addition, for purposes of performing our goodwill impairment tests, assets and liabilities, including corporate assets, which relate to a reporting unit’s operations, and would be considered in determining its fair value, are allocated to the individual reporting units. We allocate assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.

For our 2019, 2018 and 2017 annual impairment assessments, for those reporting units for which a quantitative test was performed, we used only the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets. We have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technology-based assets within our reporting units for application of the cost approach. Therefore, we believe that the income approach represents the most appropriate valuation technique for which sufficient data are available to determine the fair value of our reporting units.

In applying the income approach to our accounting for goodwill, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk-adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows.

Refer to Note C – Goodwill and Other Intangible Assets to our consolidated financial statements for additional details related to our goodwill balances.
Equity and Cost Method Investments, Policy [Policy Text Block]
Investments in Publicly Traded and Privately Held Entities

In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to Other Comprehensive Income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to Other comprehensive income (loss) were reclassified to retained earnings, and all future fair value changes will be recorded to Net income (loss). For privately-held securities of investee companies over which we do not have the ability to exercise significant influence, we elected the measurement alternative approach for our existing investments, which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. 

In 2017, we accounted for our publicly traded investments as available-for-sale securities based on the quoted market price at the end of the reporting period. Unrealized holding gains or losses during the period, net of tax, were recorded to Accumulated other comprehensive income (loss), net of tax. We computed realized gains and losses on sales of available-for-sale securities at fair value, adjusted for any other-than-temporary declines in fair value. We accounted for investments in privately-held entities in which we had less than a 20 percent ownership interest under the cost method of accounting if we did not have the ability to exercise significant influence over the investee in accordance with FASB ASC Topic 325, Investments - Other.

We account for investments in entities over which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. If the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value if accounted for under measurement alternative. For our equity method investments, an impairment loss is recorded if we determine the impairment is other-than-temporary. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. For other-than-temporary impairments, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. Impairment losses on our investments are included in Other, net in our consolidated statements of operations.
Income Tax, Policy [Policy Text Block]
Income Taxes

In February 2018, the FASB issued ASC Update No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The purpose of Update No. 2018-02 is to allow an entity to reclassify the income tax effects of the Tax Cut and Jobs Act of 2017 (TCJA) on items within Accumulated other comprehensive income (loss), net of tax (AOCI) to retained earnings. Update No. 2018-02 is effective for all entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We adopted Update No. 2018-02 in the first quarter of 2019 and have not elected to reclassify the income tax effects of the TCJA from AOCI to retained earnings.

In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to retained earnings of $55 million for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through Income tax expense (benefit).

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the TCJA, we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and will be reported as a part of continuing operations. See Note I – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA
Legal Costs, Policy [Policy Text Block]
Legal and Product Liability Costs

In the normal course of business, we are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue our best estimate of the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses. See Note J – Commitments and Contingencies for discussion of our individual material legal proceedings.
In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]
Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations. We record such costs into expense over the employee’s future service period, if any.

Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included in Restructuring charges (credits) in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities and are included within Costs of products sold and Selling, general and administrative expenses in our consolidated statements of operations. Impairment of right of use lease assets and lease terminations directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within Costs of products sold and Selling, general and administrative expenses in our consolidated statements of operations. See Note G – Restructuring-related Activities for further information and discussion of our restructuring plans.
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate and translate revenues and expenses at the average exchange rates in effect during the year. We show the net effect of these translation adjustments in our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. For any significant foreign subsidiaries located in highly inflationary economies, we would re-measure their financial statements as if the functional currency were the U.S. dollar.

Foreign currency transaction gains and losses are included in Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.

Derivatives, Policy [Policy Text Block]
Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.
Shipping and Handling Cost, Policy [Policy Text Block]
Shipping and Handling Costs

We generally do not bill customers for shipping and handling of our products. We treat shipping and handling costs incurred after a customer obtains control of the good as a fulfillment cost and record in Selling, general and administrative expenses in our consolidated statements of operations. Shipping and handling costs were $144 million in 2019, $124 million in 2018 and $110 million in 2017
Research and Development Expense, Policy [Policy Text Block]
Research and Development

We expense research and development costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles, including In-Process Research and Development above for our policy regarding IPR&D acquired in connection with our business combinations and asset purchases.
Earnings Per Share, Policy [Policy Text Block]
Net Income (Loss) per Common Share

We base Net income (loss) per common share upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options and stock awards whose effect would be anti-dilutive from the calculation.
Lessee, Leases [Policy Text Block]
Leases

In February 2016, the FASB issued ASC Update No. 2016-02, Leases (FASB ASC Topic 842, Leases). We adopted the standard as of January 1, 2019, using the modified retrospective approach and the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, we applied the new leasing rules on the date of adoption and recognized the cumulative effect of initially applying the standard as an adjustment to our January 1, 2019 opening balance sheet, rather than at the earliest comparative period presented in the financial statements. Prior periods presented are in accordance with the previous lease guidance under FASB ASC Topic 840, Leases (FASB ASC Topic 840).

In addition, we applied the package of practical expedients permitted under FASB ASC Topic 842 transition guidance to our entire lease portfolio at January 1, 2019. As a result, we were not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases and (iii) the treatment of initial direct costs for any existing leases. Furthermore, we elected not to separate lease and non-lease components for the majority of our leases. Instead, for all applicable classes of underlying assets, we accounted for each separate lease component and the non-lease components associated with that lease component, as a single lease component.

As a result of adopting FASB ASC Topic 842 on January 1, 2019, we recognized right-of-use assets of $271 million and corresponding liabilities of $278 million for our existing operating lease portfolio on our consolidated balance sheet. Operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our consolidated balance sheets. Finance leases are immaterial to our consolidated financial statements. Refer to Note E – Contractual Obligations and Commitments for additional information. There was no material impact to our consolidated statements of operations or consolidated statements of cash flows as a result of adopting FASB ASC Topic 842. Please refer to Note F – Leases for information regarding our lease portfolio as of December 31, 2019 as accounted for under FASB ASC Topic 842.

To meet the reporting and disclosure requirements of FASB ASC Topic 842, we implemented a new lease administration and lease accounting system in 2018 that tracks all of our material leasing arrangements. In addition, we designed and implemented new processes and internal controls during the first quarter of 2019 to ensure the completeness and accuracy of the transition adjustment and subsequent financial reporting under FASB ASC Topic 842. We have also established monitoring controls to ensure we have appropriate mechanisms in place to identify material leases in a timely manner, particularly contracts that may contain embedded lease features.
XML 16 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
New Accounting Pronouncements
 12 Months Ended
Dec. 31, 2019
New Accounting Pronouncements [Abstract]  
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
NOTE Q – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements.

Standards to be Implemented

ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. We expect the adoption will have an immaterial impact on our financial position and results of operations.

ASC Update No. 2018-15

In August 2018, the FASB issued ASC Update No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.

ASC Update No. 2018-18

In November 2018, the FASB issued ASC Update No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying The Interaction Between Topic 808 and Topic 606. The purpose of Update No. 2018-18 is to clarify the interaction between FASB ASC Topic 808 and FASB ASC Topic 606 as FASB ASC Topic 808 did not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements was often based on an analogy to other accounting literature or an accounting policy election. Update No. 2018-18 is effective for annual periods beginning after December 15, 2019. We plan to adopt Update No. 2018-18 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.

No other new accounting pronouncements, issued or effective, during the period had, or is expected to have, a material impact on our consolidated financial statements.
XML 17 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 18 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]
A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows (in millions, except percentages):
 
Year Ended December 31,
Net sales
2019
 
2018
 
2017
MedSurg
$
3,307

 
$
3,007

 
$
2,742

Rhythm and Neuro
3,140

 
3,041

 
2,808

Cardiovascular
4,208

 
3,777

 
3,500

Total net sales of reportable segments
10,654

 
9,823

 
9,048

All other (Specialty Pharmaceuticals)
81

 
n/a

 
n/a

Consolidated net sales
$
10,735

 
$
9,823

 
$
9,048
Reconciliation of depreciation by reportable segment to total [Table Text Block]
 
Year Ended December 31,
Depreciation expense
2019
 
2018
 
2017
MedSurg
$
75

 
$
72

 
$
68

Rhythm and Neuro
92

 
91

 
91

Cardiovascular
138

 
133

 
120

Total depreciation expense of reportable segments
306

 
296

 
279

All other (Specialty Pharmaceuticals)
6

 
n/a

 
n/a

Consolidated depreciation expense
$
311

 
$
296

 
$
279
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
 
Year Ended December 31,
Income (loss) before income taxes
2019
 
2018
 
2017
MedSurg
$
1,204

 
$
1,102

 
$
984

Rhythm and Neuro
666

 
655

 
537

Cardiovascular
1,137

 
1,117

 
988

Total operating income of reportable segments
3,007

 
2,875

 
2,509

All other (Specialty Pharmaceuticals)
56

 
n/a

 
n/a

Unallocated amounts:
 
 
 
 
 
Corporate expenses, including hedging activities
(264
)
 
(372
)
 
(252
)
Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and EU MDR implementation costs
(582
)
 
(398
)
 
(407
)
Amortization expense
(699
)
 
(599
)
 
(565
)
Operating income (loss)
1,518

 
1,506

 
1,285

Other expense, net
(831
)
 
(85
)
 
(353
)
Income (loss) before income taxes
$
687

 
$
1,422

 
$
933
Segment operating income as percentage of net sales [Table Text Block]
Operating income of reportable segments as a percentage of net sales of reportable segments
Year Ended December 31,
2019
 
2018
 
2017
MedSurg
36.4
%
 
36.7
%
 
35.9
%
Rhythm and Neuro
21.2
%
 
21.5
%
 
19.1
%
Cardiovascular
27.0
%
 
29.6
%
 
28.2
%
Reconciliation of Assets from Segment to Consolidated [Table Text Block]
 
As of December 31,
Total assets
2019
 
2018
MedSurg
$
1,803

 
$
1,846

Rhythm and Neuro
1,873

 
1,696

Cardiovascular
2,535

 
1,954

Total assets of reportable segments
6,211

 
5,497

All other (Specialty Pharmaceuticals)
211

 
—

Goodwill
10,176

 
7,911

Other intangible assets, net
7,886

 
6,372

All other corporate assets
6,082

 
1,219

 
$
30,565

 
$
20,999
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]
 
As of December 31,
Long-lived assets
2019
 
2018
 
2017
U.S.
$
1,148

 
$
1,061

 
$
1,065

Ireland
327

 
242

 
210

Other countries
604

 
478

 
422

Property, plant and equipment, net
2,079

 
1,782

 
1,697

Goodwill
10,176

 
7,911

 
6,998

Other intangible assets, net
7,886

 
6,372

 
5,837

Operating lease right-of-use assets in Other long-term assets
336

 
—

 
—

 
$
20,477

 
$
16,064

 
$
14,531
XML 19 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Significant Accounting Policies Significant Accounting Policies (Details) - USD ($)
$ in Millions
 12 Months Ended
Jan. 01, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2018
Jan. 01, 2018
Significant Accounting Policies [Line Items]            
Selling, general and administrative expenses   $ 3,941 $ 3,569 $ 3,294    
Percent of finished goods at consignment   32.00% 40.00%      
Concentration Risk, Customer   0 0 0    
Other Liabilities, Current   $ 800 $ 412      
Other Liabilities, Noncurrent   2,635 1,882      
Other Assets, Noncurrent   1,529 845      
Deferred Tax Liabilities, Noncurrent   595 328      
Shipping and Handling [Member]            
Significant Accounting Policies [Line Items]            
Selling, general and administrative expenses   $ 144 124 $ 110    
Adjustments for New Accounting Pronouncement [Member]            
Significant Accounting Policies [Line Items]            
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets           $ 177
Accounting Standards Update 2016-16 [Member]            
Significant Accounting Policies [Line Items]            
Cumulative Effect of New Accounting Principle in Period of Adoption         $ 55  
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]            
Significant Accounting Policies [Line Items]            
Other Liabilities, Current     59      
Other Liabilities, Noncurrent     205      
Other Assets, Noncurrent     12      
Deferred Tax Liabilities, Noncurrent     $ (41)      
Operating lease, right-of-use assets, other long-term assets [Member] | Accounting Standards Update 2016-02 [Member]            
Significant Accounting Policies [Line Items]            
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification $ 271          
Operating lease, liability, other long-term liabilities [Member] | Accounting Standards Update 2016-02 [Member]            
Significant Accounting Policies [Line Items]            
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification $ 278          
XML 20 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Schedule II (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]        
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount $ 74 $ 68 $ 98 $ 119
Net (credits) charges to expenses 23 19 14  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction (17) (19) (18)  
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment $ 0 $ (30) $ (17)  
XML 21 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
reportablesegments
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Segment Reporting Information [Line Items]      
Assets $ 30,565 $ 20,999  
Property, Plant and Equipment, Net 2,079 1,782 $ 1,697
Net sales 10,735 9,823 9,048
Amortization expense (699) (599) (565)
Operating income allocated to reportable segments 1,518 1,506 1,285
Other expense, net (831) (85) (353)
Income (loss) before income taxes 687 1,422 933
Depreciation (311) (296) (279)
Goodwill 10,176 7,911 6,998
Intangible Assets, Net (Excluding Goodwill) 7,886 6,372 5,837
Operating Lease, Right-of-Use Asset 336 0 0
Long-Lived Assets $ 20,477 16,064 14,531
Segment Reporting (Textuals) [Abstract]      
Number of reportable segments | reportablesegments 3    
United States [Member]      
Segment Reporting Information [Line Items]      
Property, Plant and Equipment, Net $ 1,148 1,061 1,065
Net sales 6,167 5,538 5,162
IRELAND      
Segment Reporting Information [Line Items]      
Property, Plant and Equipment, Net 327 242 210
Other countries [Member]      
Segment Reporting Information [Line Items]      
Property, Plant and Equipment, Net 604 478 422
Special Charges [Member]      
Segment Reporting Information [Line Items]      
Operating Income Unallocated to Segment (582) (398) (407)
Cardiovascular [Member]      
Segment Reporting Information [Line Items]      
Assets 2,535 1,954  
Net sales 4,208 3,777 3,500
Operating income allocated to reportable segments 1,137 1,117 988
Depreciation (138) (133) (120)
Goodwill $ 5,676 $ 3,925 $ 3,704
TOTAL ASSETS 27.00% 29.60% 28.20%
Other Segments [Member]      
Segment Reporting Information [Line Items]      
Net sales $ 81    
Goodwill 247 $ 0 $ 0
MedSurg [Member]      
Segment Reporting Information [Line Items]      
Assets 1,803 1,846  
Net sales 3,307 3,007 2,742
Operating income allocated to reportable segments 1,204 1,102 984
Depreciation (75) (72) (68)
Goodwill $ 2,061 $ 2,063 $ 2,877
TOTAL ASSETS 36.40% 36.70% 35.90%
Rhythm and Neuro [Member]      
Segment Reporting Information [Line Items]      
Assets $ 1,873 $ 1,696  
Net sales 3,140 3,041 $ 2,808
Operating income allocated to reportable segments 666 655 537
Depreciation (92) (91) (91)
Goodwill $ 2,192 $ 1,924 $ 417
TOTAL ASSETS 21.20% 21.50% 19.10%
Total allocated to reportable segments [Member]      
Segment Reporting Information [Line Items]      
Assets $ 6,211 $ 5,497  
Operating income allocated to reportable segments 3,007 2,875 $ 2,509
Corporate Expenses including hedging activities [Member]      
Segment Reporting Information [Line Items]      
Operating Income Unallocated to Segment (264) (372) (252)
Corporate, Non-Segment [Member]      
Segment Reporting Information [Line Items]      
Assets 6,082 1,219  
BSX Reportable Segments [Member]      
Segment Reporting Information [Line Items]      
Net sales 10,654 9,823 9,048
Depreciation (306) (296) $ (279)
BSX Reportable Segments [Member] | United States [Member]      
Segment Reporting Information [Line Items]      
Net sales 6,097    
BTG Spec Pharma [Member]      
Segment Reporting Information [Line Items]      
Assets 211 $ 0  
Net sales 81    
Operating income allocated to reportable segments 56    
Depreciation (6)    
BTG Spec Pharma [Member] | United States [Member]      
Segment Reporting Information [Line Items]      
Net sales $ 70    
XML 22 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies (Details)
€ in Thousands, $ in Millions
 3 Months Ended 12 Months Ended
Nov. 10, 2017
EUR (€)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jan. 29, 2020
claims
Jan. 15, 2019
USD ($)
Loss Contingencies [Line Items]                    
Contingent payment related to business combination | $           $ 68 $ 28      
Loss Contingency, Damages Awarded, Value | € € 245                  
Accrual for legal matters that are probable and estimable | $   $ 697       697 929      
Litigation Settlement Received, Gain | $                   $ 180
Restricted cash and restricted cash equivalents included in Other current assets | $   346       346 655 $ 803    
Litigation-related charges (credits) | $   $ 223 $ 25 $ 15 $ 148 $ 115 $ 103 $ 285    
Loss Contingency, Damages Paid, Value | € € 620                  
Subsequent Event [Member]                    
Subsequent Event [Line Items]                    
Product liability cases or claims related to mesh product assigned to one judge in state court in Massachusetts                 3,100  
Product liability cases or claims related to mesh product                 54,000  
Product liability cases or claims in Canada, Mesh                 25  
Certified class actions in Canada, Mesh                 1  
Product liability cases or claims related to mesh product - United Kingdom                 25  
Settled Litigation [Member] | Subsequent Event [Member]                    
Subsequent Event [Line Items]                    
Product liability cases or claims related to mesh product                 52,000  
Total Product liability cases and claims settled related to Mesh product                 46,000  
XML 23 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring Related Activities (Details in Narrative) - USD ($)
$ in Millions
 12 Months Ended 43 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Incurred Cost   $ 96 $ 95  
Restructuring Charges Incurred to Date       $ 138
Restructuring Charges $ 38 36 37  
Payments for Restructuring (64)      
Restructuring and Related Cost, Cost Incurred to Date 318     318
Restructuring-related Costs Incurred to Date       180
Restructuring Related Expenses 44 59 58  
Restructuring and Restructuring-Related Cost 82      
2016 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Charges Incurred to Date       106
Payments for Restructuring (41)      
Restructuring and Related Cost, Cost Incurred to Date 271     271
Restructuring-related Costs Incurred to Date       164
2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Charges Incurred to Date       32
Payments for Restructuring (23)      
Restructuring and Related Cost, Cost Incurred to Date 47     47
Restructuring-related Costs Incurred to Date       15
Employee Severance [Member]        
Restructuring Cost and Reserve [Line Items]        
Severance Costs 38 32 25  
Restructuring and Related Cost, Incurred Cost   32 25  
Restructuring Charges Incurred to Date       115
Payments for Restructuring (18)      
Restructuring Related Expenses 0 0 0  
Restructuring and Restructuring-Related Cost 38      
Employee Severance [Member] | 2016 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Charges Incurred to Date       86
Payments for Restructuring (13)      
Employee Severance [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Charges Incurred to Date       30
Payments for Restructuring (6)      
Other Restructuring [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Incurred Cost   16 25  
Restructuring Charges Incurred to Date       23
Other Restructuring Costs 0 4 12  
Payments for Restructuring (14)      
Restructuring-related Costs Incurred to Date       41
Restructuring Related Expenses 13 12 13  
Restructuring and Restructuring-Related Cost 13      
Other Restructuring [Member] | 2016 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Charges Incurred to Date       21
Payments for Restructuring (10)      
Restructuring-related Costs Incurred to Date       39
Other Restructuring [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Charges Incurred to Date       2
Payments for Restructuring (4)      
Restructuring-related Costs Incurred to Date       2
Transfer costs [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Incurred Cost   47 45  
Transfer Costs 0 0 0  
Payments for Restructuring (32)      
Restructuring-related Costs Incurred to Date       139
Restructuring Related Expenses 32 47 45  
Restructuring and Restructuring-Related Cost 32      
Transfer costs [Member] | 2016 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Payments for Restructuring (18)      
Restructuring-related Costs Incurred to Date       126
Transfer costs [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Payments for Restructuring (13)      
Restructuring-related Costs Incurred to Date       13
Maximum [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring plan estimated future cash outflow 280      
Restructuring and Restructuring-related Cost, Expected Cost 300     300
Minimum [Member] | 2016 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring plan estimated future cash outflow 255      
Minimum [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring plan estimated future cash outflow 180      
Restructuring and Restructuring-related Cost, Expected Cost 200     200
Restructuring Related To Plan [Member] | Maximum [Member] | Other Restructuring [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring-related Cost, Expected Cost 150     150
Restructuring Related To Plan [Member] | Minimum [Member] | Other Restructuring [Member] | 2016 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring-related Cost, Expected Cost 164     164
Restructuring Related To Plan [Member] | Minimum [Member] | Other Restructuring [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring-related Cost, Expected Cost 100     100
Restructuring Plan [Member] | Maximum [Member] | Employee Severance [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Expected Cost 100     100
Restructuring Plan [Member] | Maximum [Member] | Other Restructuring [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Expected Cost 50     50
Restructuring Plan [Member] | Minimum [Member] | Employee Severance [Member] | 2016 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Expected Cost 86     86
Restructuring Plan [Member] | Minimum [Member] | Employee Severance [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Expected Cost 75     75
Restructuring Plan [Member] | Minimum [Member] | Other Restructuring [Member] | 2016 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Expected Cost 21     21
Restructuring Plan [Member] | Minimum [Member] | Other Restructuring [Member] | 2019 Restructuring Plan [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Expected Cost 25     $ 25
Cost of Sales [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses     45  
Cost of Sales [Member] | Employee Severance [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses     0  
Cost of Sales [Member] | Other Restructuring [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses     0  
Cost of Sales [Member] | Transfer costs [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses     45  
Selling, General and Administrative Expenses [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses     13  
Selling, General and Administrative Expenses [Member] | Employee Severance [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses     0  
Selling, General and Administrative Expenses [Member] | Other Restructuring [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses     13  
Selling, General and Administrative Expenses [Member] | Transfer costs [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses     $ 0  
Selling, General and Administrative Expenses [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses 13 12    
Selling, General and Administrative Expenses [Member] | Employee Severance [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses 0 0    
Selling, General and Administrative Expenses [Member] | Other Restructuring [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses 13 12    
Selling, General and Administrative Expenses [Member] | Transfer costs [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses 0 0    
Cost of Sales [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses 32 47    
Cost of Sales [Member] | Employee Severance [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses 0 0    
Cost of Sales [Member] | Other Restructuring [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses 0 0    
Cost of Sales [Member] | Transfer costs [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Related Expenses $ 32 $ 47    
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheet Paranthetical - $ / shares
Dec. 31, 2019
Dec. 31, 2018
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 2,000,000,000.000 2,000,000,000
Common stock, shares issued 1,642,488,911 1,632,148,030
Common stock, shares outstanding 1,394,922,641 1,384,581,760
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 50,000,000 50,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Treasury shares 247,566,270 247,566,270
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Supplemental Balance Sheet Information
 12 Months Ended
Dec. 31, 2019
Supplemental Balance Sheet Information [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION
NOTE H – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying consolidated balance sheets are as follows:
Trade accounts receivable, net
 
As of December 31,
(in millions)
2019
 
2018
Accounts receivable
$
1,902

 
$
1,676

Allowance for doubtful accounts
(74
)
 
(68
)
 
$
1,828

 
$
1,608



The following is a rollforward of our allowance for doubtful accounts:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Beginning balance
$
68

 
$
68

 
$
73

Net charges to expenses
23

 
19

 
14

Utilization of allowances
(17
)
 
(19
)
 
(18
)
Ending balance
$
74

 
$
68

 
$
68



Inventories
 
As of December 31,
(in millions)
2019
 
2018
Finished goods
$
971

 
$
760

Work-in-process
192

 
100

Raw materials
416

 
306

 
$
1,579

 
$
1,166



Other current assets
 
As of December 31,
(in millions)
2019
 
2018
Restricted cash and restricted cash equivalents
$
346

 
$
655

Derivative assets
105

 
122

Licensing arrangements
186

 
—

Taxes receivable
105

 
37

Other
138

 
107

 
$
880

 
$
921



Property, plant and equipment, net
 
As of December 31,
(in millions)
2019
 
2018
Land
$
117

 
$
97

Buildings and improvements
1,198

 
1,100

Equipment, furniture and fixtures
3,411

 
3,224

Capital in progress
442

 
319

 
5,169

 
4,740

Less: accumulated depreciation
3,089

 
2,958

 
$
2,079

 
$
1,782



Depreciation expense was $311 million in 2019, $296 million in 2018 and $279 million in 2017.

Other long-term assets
 
As of December 31,
(in millions)
2019
 
2018
Restricted cash equivalents
$
43

 
$
27

Operating lease right-of-use assets
336

 
—

Derivative assets
216

 
183

Investments
458

 
424

Licensing arrangements
332

 
—

Other
144

 
211

 
$
1,529

 
$
845



Accrued expenses
 
As of December 31,
(in millions)
2019
 
2018
Legal reserves
$
470

 
$
712

Payroll and related liabilities
708

 
630

Accrued contingent consideration
56

 
138

Rebates
298

 
229

Other
576

 
538

 
$
2,109

 
$
2,246



Other current liabilities
 
As of December 31,
(in millions)
2019
 
2018
Deferred revenue
$
144

 
$
115

Licensing arrangements
197

 
—

Taxes payable
265

 
125

Other
195

 
173

 
$
800

 
$
412



Other long-term liabilities
 
As of December 31,
(in millions)
2019
 
2018
Accrued income taxes
$
667

 
$
739

Legal reserves
227

 
217

Accrued contingent consideration
299

 
209

Licensing arrangements
374

 
—

Operating lease liabilities
276

 
—

Other
792

 
717

 
$
2,635

 
$
1,882
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements
 12 Months Ended
Dec. 31, 2019
Fair Value Measurements [Abstract]  
FAIR VALUE MEASUREMENTS

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Hedging Instruments
Risk Management Strategy
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions, net investments in certain subsidiaries and the purchase price of any acquisition that is denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in Euro, Japanese yen, Chinese renminbi and British pound sterling. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Hedge Designations and Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) on our consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within the Cost of products sold caption of our consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within AOCI to earnings at that time.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro, Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. We elected to use the spot method to assess effectiveness for our derivatives that are designated as net investment hedges. Under the spot method, the change in fair value attributable to changes in the spot rate is recorded in the Foreign currency translation adjustment (CTA) component of OCI. We have elected to exclude the spot-forward difference from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. Amortization of the spot-forward difference is then reclassified from AOCI to current period earnings as a component of Interest expense on our consolidated statements of operations. In November 2019, we terminated and settled all of our outstanding forward currency contracts designated as net investment hedges in our entities with Euro-denominated functional currencies and recognized a gain of $95 million presented in the CTA component of OCI on our consolidated statements of comprehensive income (loss).

We also completed an offering of €900 million (approximately $1.000 billion) in aggregate principal amount of 0.625% senior notes due in 2027. The Euro-denominated debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional entities. As of December 31, 2019, the notional value of our outstanding net investment hedges was $1.950 billion, which includes our derivative and nonderivative instruments designated as net investment hedges.

We also use forward currency contracts that are not part of designated hedging relationships under FASB ASC Topic 815 as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within the Other, net caption of our consolidated statements of operations.

Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the GBP-denominated purchase price of BTG. In 2019, we settled all outstanding contracts, resulting in a cumulative loss on the contracts of $294 million that was recognized over time in earnings as we adjusted for changes in fair value until the final fair value was determined at maturity. As of December 31, 2018, the notional value of the contracts was $2.550 billion, and we entered into additional contracts in 2019. Upon settlement in 2019, we received £3.312 billion of cash to fund our acquisition of BTG, which translated into $4.303 billion based on hedged currency exchange rates. We recognized a $323 million loss in 2019 and a $29 million gain in 2018 within Other, net due to changes in fair value of the contracts.

Interest Rate Hedging Instruments
Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Hedge Designations and Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of December 31, 2019 and $1.000 billion outstanding as of December 31, 2018, which were intended to manage our earnings and cash flow exposure to changes in the benchmark interest rate in connection with the forecasted issuance of fixed-rate debt. For outstanding designated cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs, at which time we recognize the gain or loss within Interest expense over the same period that the hedged items affect earnings, so long as the hedge relationship remains effective. If we determine the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the amount of gains or losses from AOCI to earnings at that time.

During the fourth quarter of 2018, we entered into interest rate derivative contracts designated as cash flow hedges having a notional amount of $1.000 billion to hedge interest rate risk. In the first quarter of 2019, we terminated these instruments in connection with our senior notes issuance in the same period as discussed in Note E – Contractual Obligations and Commitments. We recognized an immaterial loss within OCI in 2019 and are reclassifying the amortization of the loss from AOCI into earnings as a component of Interest expense over the same period that the hedged item affects earnings, so long as the hedge relationship remains effective. We are also continuing to reclassify in a similar manner the amortization of the gains or losses of our other previously terminated interest rate derivative instruments that were designated as cash flow hedges. The balance of the deferred amounts on our terminated cash flow hedges within AOCI was a $34 million loss as of December 31, 2019 and a $7 million gain December 31, 2018. We recognized immaterial gains and losses in Interest expense relating to the amortization of our terminated cash flow hedges in the current and prior periods.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of December 31, 2019 and December 31, 2018. Prior to 2018, we terminated interest rate derivative instruments that were designated as fair value hedges and are continuing to recognize the amortization of the gains or losses originally recorded within the Long-term debt caption on our consolidated balance sheets into earnings as a component of Interest expense over the same period that the discount or premium associated with the hedged items affects earnings. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset. The balance of the deferred gains on our terminated fair value hedges within Long-term debt was immaterial as of December 31, 2019 and December 31, 2018. We recognized immaterial gains in Interest expense relating to the amortization of the terminated fair value hedges in the current and prior periods.

The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)
 
FASB ASC Topic 815 Designation
 
As of December 31,
 
2019
 
2018
Forward currency contracts
 
Cash flow hedge
 
$
3,891

 
$
3,962

Forward currency contracts
 
Net investment hedge
 
953

 
1,483

Foreign currency-denominated debt(1)
 
Net investment hedge
 
997

 
—

Forward currency contracts
 
Non-designated
 
4,377

 
5,880

Interest rate derivative contracts
 
Cash flow hedge
 
—

 
1,000

Total Notional Outstanding
 
 
 
$
10,218

 
$
12,326


(1)
The €900 million (approximately $1.000 billion) debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional subsidiaries.

The remaining time to maturity as of December 31, 2019 is within 60 months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts. The Euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.

The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 on our accompanying consolidated statements of operations. Refer to Note P – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within the consolidated statements of comprehensive income (loss).
 
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
 
Amount Recognized in OCI on Hedges
 
Consolidated Statements of Operations (1)
 
Amount Reclassified from AOCI into Earnings
 
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Location of Amount Reclassified
Total Amount of Line Item Presented
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss Net of Tax
Year Ended December 31, 2019
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
150

$
(34
)
$
117

 
Cost of products sold
$
3,116

 
$
(73
)
$
16

$
(56
)
Net investment hedges (2)
68

(15
)
53

 
Interest expense
473

 
(43
)
10

(33
)
Foreign currency-denominated debt
 
 
 
 
 
 
 
Net investment hedges
(14
)
3

(11
)
 
Interest expense
473

 
—

—

—

Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
473

 
3

(1
)
2

Year Ended December 31, 2018
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
167

$
(38
)
$
130

 
Cost of products sold
$
2,813

 
$
19

$
(4
)
$
15

Net investment hedges (2)
56

(13
)
43

 
Interest expense
241

 
(27
)
6

(21
)
Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
(44
)
10

(34
)
 
Interest expense
241

 
(1
)
—

(1
)
Year Ended December 31, 2017
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
(101
)
$
37

$
(65
)
 
Cost of products sold
$
2,593

 
$
(64
)
$
23

$
(41
)
Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
229

 
(1
)
—

(1
)
(1)
In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. All other amounts included in earnings related to hedging relationships were immaterial.
(2)
For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.

As of December 31, 2019, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging Instrument
 
FASB ASC Topic 815 Designation
 
Location on Consolidated Statements of Operations
 
Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contracts
 
Cash flow hedge
 
Cost of products sold
 
$
77

Forward currency contracts
 
Net investment hedge
 
Interest expense
 
24

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
 
(5
)


Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)
 
Location on Consolidated Statements of Operations
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(343
)
 
$
41

 
$
(25
)
Net gain (loss) on currency transaction exposures
 
Other, net
 
(15
)
 
(30
)
 
10

Net currency exchange gain (loss)
 
 
 
$
(358
)
 
$
11

 
$
(15
)


Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the GBP-denominated purchase price of BTG. In 2019, we settled all outstanding contracts. We recognized a $323 million loss in 2019 and a $29 million gain in 2018 within Net gain (loss) on currency hedge contracts due to changes in fair value of the contracts.
 
Fair Value Measurements

FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
 
Location on Consolidated Balance Sheets (1)
 
As of December 31,
 
2019
 
2018
Derivative and Nonderivative Assets:
 
 
 
 
 
 
Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
$
72

 
$
55

Forward currency contracts
 
Other long-term assets
 
216

 
183

 
 
 
 
288

 
237

Non-Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
33

 
67

Total Derivative and Nonderivative Assets
 
 
 
$
321

 
$
304

 
 
 
 
 
 
 
Derivative and Nonderivative Liabilities:
 
 
 
 
 
 
Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
$
3

 
$
2

Forward currency contracts
 
Other long-term liabilities
 
8

 
3

Foreign currency-denominated debt
 
Other long-term liabilities
 
998

 
—

Interest rate contracts
 
Other current liabilities
 
—

 
44

 
 
 
 
1,009

 
49

Non-Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
29

 
31

Total Derivative and Nonderivative Liabilities
 
$
1,037

 
$
80

(1)
We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.

Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
December 31, 2019
 
December 31, 2018
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
50

 
$
—

 
$
—

 
$
50

 
$
13

 
$
—

 
$
—

 
$
13

Publicly-held securities
1

 
—

 
—

 
1

 
—

 
—

 
—

 
—

Hedging instruments
—

 
321

 
—

 
321

 
—

 
304

 
—

 
304

Licensing arrangements
—

 
—

 
518

 
518

 
—

 
—

 
—

 
—

 
$
51

 
$
321

 
$
518

 
$
890

 
$
14

 
$
304

 
$
—

 
$
318

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hedging instruments
$
—

 
$
1,037

 
$
—

 
$
1,037

 
$
—

 
$
80

 
$
—

 
$
80

Contingent consideration liability
—

 
—

 
354

 
354

 
—

 
—

 
347

 
347

Licensing arrangements
—

 
—

 
571

 
571

 
—

 
—

 
—

 
—

 
$
—

 
$
1,037

 
$
925

 
$
1,963

 
$
—

 
$
80

 
$
347

 
$
427



Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $50 million invested in money market and government funds as of December 31, 2019, we had $165 million in interest bearing and non-interest-bearing bank accounts. In addition to $13 million invested in money market and government funds as of December 31, 2018, we had $133 million in interest bearing and non-interest bearing bank accounts.

Our recurring fair value measurements using Level 3 inputs relates to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.

In addition, our recurring fair value measurements using Level 3 inputs relate to our licensing arrangements. In connection with our acquisition of BTG, we acquired intellectual property and related licensing arrangements, principally relating to Zytiga™, as a result of our acquisition of BTG that provides the contractual right to receive future royalty payments.

In the fourth quarter of 2019, we entered into a royalty purchase agreement with the Ontario Municipal Employees Retirement System (OMERS), whereby we sold to OMERS our remaining 50 percent of the future Zytiga™ royalty stream. The purchase price for these royalty interests consisted of an upfront cash payment of $256 million. Prior to our acquisition of BTG, BTG agreed to pay 50 percent of the Zytiga™ royalty stream, net of certain offsets, to the inventors associated with the intellectual property. As such, we do not expect to receive any future cash benefit from Zytiga™ royalties subsequent to our transaction with OMERS. In accordance with FASB ASC Topic 860, Transfers and Servicing, we are accounting for the transfer as a secured borrowing and continue to recognize the financial asset and financial liability in our consolidated balance sheets.

We have elected the fair value option to account for the licensing arrangements' financial asset and financial liability in accordance with FASB ASC Topic 825, Financial Instruments. As of December 31, 2019, we have recorded the fair values of the financial asset and financial liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations.

In connection with our preliminary purchase price allocation of BTG as of the acquisition date, the amount recognized for the financial asset was $567 million in aggregate, comprised of $195 million included in Other current assets and $373 million included in Other long-term assets. The amount recognized for the financial liability was $370 million, comprised of $54 million included in Accounts payable, $104 million included in Other current liabilities and $212 million included in Other long-term liabilities. The amounts above were valued using the fair value option with the exception of the Accounts payable, which was settled in the third quarter. During the fourth quarter, we also recorded the $256 million proceeds received from the sale of the Zytiga royalty stream as an increase in the fair value of the financial liability now accounted for as a secured borrowing, as discussed above. Refer to Note B – Acquisitions and Strategic Investments for further information on the preliminary purchase price allocation of BTG.


The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2019 include the following significant unobservable inputs:
Licensing Arrangements
Fair Value as of December 31, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
Financial Asset
$518 million
Discounted Cash Flow
Discount Rate
11
%
-
19%
19%
Projected Year of Payment
2020

-
2028
2024
Financial Liability
$571 million
Discounted Cash Flow
Discount Rate
19%
19%
Projected Year of Payment
2020

-
2027
2023
(1)
Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of December 31, 2019. However, increases or decreases in the financial asset would be substantially offset by increases or decreases in the financial liability, as such our earnings are not subject to material gains or losses from the licensing arrangement.

Changes in the fair value of our licensing arrangements' financial asset was as follows:
(in millions)
 
Balance as of December 31, 2018
$
—

Amounts recorded related to current year acquisition
567

Proceeds from royalty rights
(52
)
Fair value adjustment (expense) benefit
3

Balance as of December 31, 2019
$
518


Changes in the fair value of our licensing arrangements' financial liability was as follows:
(in millions)
 
Balance as of December 31, 2018
$
—

Amounts recorded related to current year acquisition
315

Proceeds from secured borrowings relating to royalty arrangements
256

Balance as of December 31, 2019
$
571



Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments.

Refer to Note C – Goodwill and Other Intangible Assets for a discussion of the fair values.

The fair value of our outstanding debt obligations as of December 31, 2019 was $11.020 billion, of which $1.004 billion relates to the Euro-denominated December 2027 Notes, and as of December 31, 2018 was $7.239 billion. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to Note E – Contractual Obligations and Commitments for a discussion of our debt obligations.
XML 27 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Document Document - USD ($)
$ / shares in Units, $ in Billions
 12 Months Ended
Dec. 31, 2019
Jan. 31, 2020
Jun. 28, 2019
Entity Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2019    
Document Transition Report false    
Entity File Number 1-11083    
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-2695240    
Entity Address, Address Line One 300 Boston Scientific Way    
Entity Address, City or Town Marlborough    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01752-1234    
City Area Code 508    
Local Phone Number 683-4000    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 53.1
Entity Listing, Par Value Per Share $ 0.01    
Entity Common Stock, Shares Outstanding   1,396,195,349  
Entity Central Index Key 0000885725    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Amendment Flag false    
Common Stock [Member]      
Entity Information [Line Items]      
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol BSX    
Security Exchange Name NYSE    
Senior Note due 2027 [Member]      
Entity Information [Line Items]      
Title of 12(b) Security 0.625% Senior Notes due 2027    
Trading Symbol BSX27    
Security Exchange Name NYSE    
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions and Strategic Investments
 12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
ACQUISITIONS
NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS
Our consolidated financial statements include the operating results for acquired entities from the respective dates of acquisition. With the exception of the acquisition of BTG, which was completed on August 19, 2019, we have not presented supplemental pro forma financial information for acquisitions given their results are not material to our consolidated financial statements. Transaction costs for all acquisitions in 2019, 2018 and 2017 were immaterial to our consolidated financial statements and were expensed as incurred. In 2019, we recorded approximately $125 million of purchase price adjustments, of which $95 million related to BTG.

2019 Acquisitions

BTG plc

On August 19, 2019, we announced the closing of our acquisition of BTG, a public company organized under the laws of England and Wales. BTG had three key portfolios, the largest of which is its interventional medicine portfolio (Interventional Medicine) that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. Following the closing of the acquisition, we began to integrate BTG's Interventional Medicine business into our Peripheral Interventions division.

In addition to the Interventional Medicine product lines, the BTG portfolio also included a specialty pharmaceutical business (Specialty Pharmaceuticals) comprised of acute care antidotes to treat overexposure to certain medications and toxins and a licensing portfolio (Licensing arrangements) that generates net royalties related to BTG intellectual property and product license agreements. In connection with the acquisition, we acquired rights to future royalties associated with the Zytiga™ drug used to treat certain forms of prostate cancer. In the fourth quarter of 2019, we sold our rights to these royalties for $256 million in cash, included in Proceeds from royalty rights transfer. Refer to Note D – Hedging Activities and Fair Value Measurements for additional information.

The transaction price consisted of upfront cash in the aggregate amount of £3.312 billion (or $4.023 billion based on the exchange rate at closing on August 19, 2019) for the entire issued ordinary share capital of BTG, whereby BTG stockholders received 840 pence (or $10.20 based on the exchange rate at closing) in cash for each BTG share. The transaction price included $404 million of cash and cash equivalents acquired. We implemented our acquisition of BTG by way of a court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.

Purchase Price Allocation

We accounted for our acquisition of BTG as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (FASB ASC Topic 805), we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed from the acquisition. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by FASB ASC Topic 805. As of December 31, 2019, the valuation studies necessary to determine the fair market value of the assets acquired and liabilities assumed are preliminary, including the projection of the underlying cash flows used to determine the fair value of the identified tangible, intangible and financial assets and liabilities.

We accounted for BTG as a business combination, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary purchase price of BTG, was comprised of the following components as of December 31, 2019:
(in millions)
 
Payment for acquisition, net of cash acquired
$
3,619


The following summarizes the preliminary purchase price allocation for our acquisition of BTG as of December 31, 2019:
(in millions)
 
Goodwill
$
1,644

Trade accounts receivable, net
108

Inventories
232

Other current assets
252

Other intangible assets, net
1,785

Other long-term assets
537

Accrued expenses and other current liabilities
(308
)
Other long-term liabilities
(274
)
Deferred tax liability
(358
)
 
$
3,619



As a result of our acquisition of BTG, we recognized goodwill of $1.644 billion, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of December 31, 2019, we have allocated $1.406 billion to our Peripheral Interventions reporting unit and $238 million to the Specialty Pharmaceuticals reporting unit.

We allocated a portion of the preliminary purchase price for our acquisition of BTG to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
1,709

 
10
-
18
 
11
%
-
12%
Other intangible assets
75

 
2
-
11
 
11%
 
$
1,785

 
 
 
 
 
 
 
 

Pro Forma Financial Information (unaudited)
BTG contributed $226 million to our Net sales and had an immaterial impact to our Net income (loss) for the period post acquisition through December 31, 2019.

The unaudited estimated pro forma results presented below include the effects of our acquisition of BTG as if it was consummated on January 1, 2018. In 2019, we incurred nonrecurring charges that we attributed to our acquisition of BTG, which are presented in our consolidated statements of operations for this period. These charges include acquisition-related costs, stock-based compensation expenses as a result of the change in control and retention bonuses and severance payments, adjusted for the related tax effects. We have reflected these nonrecurring charges as adjustments to the pro forma earnings presented below for 2019 and 2018.

Additionally, these pro forma amounts have been calculated after applying our accounting policies and adjusting the results of BTG to reflect the additional costs associated with fair value adjustments relating to inventories, property, plant, and equipment, and intangible assets as if the acquisition had occurred on January 1, 2018, with the consequential tax effects. Additionally, the pro forma amounts have been adjusted to reflect the amortization of deferred financing costs and interest expense associated with additional financing entered into as part of the acquisition. The pro forma results exclude BTG’s historical licensing revenue and related cost of sales, as these arrangements are accounted for as part of the acquisition as a financial asset and liability and are not accounted for within the scope of FASB ASC Topic 606.

The supplemental pro forma information presented below is for informational purposes only and should be read in conjunction with our historical financial statements. The pro forma results do not include any anticipated synergies or other expected benefits of the acquisition. Accordingly, the unaudited estimated pro forma financial information below is not necessarily indicative of what the actual results of operations of the combined companies would have been had the acquisition of BTG occurred as of January 1, 2018, nor are they indicative of future results of operations. We believe that the pro forma assumptions and adjustments are reasonable and appropriate under the circumstances and are factually supported based on information currently available.

 
Year Ended December 31,
(in millions, except per share data) (Unaudited)
2019
 
2018
Net sales
$
11,142

 
$
10,429

Net income (loss)
$
4,585

 
$
1,244

Net income (loss) per common share — basic
$
3.30

 
$
0.90

Net income (loss) per common share — assuming dilution
$
3.25

 
$
0.89



Transaction with Varian Medical Systems, Inc.

On August 21, 2019, we completed the sale of our drug-eluting and bland embolic microsphere portfolio to Varian Medical Systems, Inc. (Varian) in connection with our acquisition of BTG. The transaction price consisted of an upfront cash payment of $90 million, a portion of which is allocated to the fair value of the services to be rendered under the Transition Services Agreement and Transition Manufacturing Agreement entered into with Varian as part of this transaction. Additionally, we transferred certain contingent consideration arrangements arising from our initial acquisition of the portfolio to Varian and agreed to indemnify Varian for any payments ultimately arising under the terms of the contingent consideration arrangement. Accordingly, as part of the disposal, we recorded a liability of $16 million to recognize the fair value of this guarantee based on our potential obligation resulting from the indemnifications. The maximum amount payable under this guarantee is $200 million in accordance with FASB ASC Topic 460, Guarantees, which is consistent with the contingent consideration arrangement executed with our initial acquisition of the portfolio in accordance with FASB ASC Topic 805.

Vertiflex, Inc.

On June 11, 2019, we announced the closing of our acquisition of Vertiflex, Inc. (Vertiflex), a privately-held company which has developed and commercialized the Superion™ Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. We estimate the sales-based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year earn-out period. Following the closing of the acquisition, we have integrated the Vertiflex business into our Neuromodulation division.

Millipede, Inc.

On January 29, 2019, we announced the closing of our acquisition of Millipede, Inc. (Millipede), a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. We had previously been an investor in Millipede since the first quarter of 2018 as part of an investment and acquisition option agreement, whereby we purchased a portion of the outstanding shares of Millipede, along with newly issued shares of the company, for an upfront cash payment of $90 million. In the fourth quarter of 2018, upon the successful completion of a first-in-human clinical study, we exercised our option to acquire the remaining shares of Millipede. We held an interest of approximately 20 percent immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. The transaction price for the remaining stake consisted of an upfront cash payment of $325 million and up to an additional $125 million of future payments upon achievement of a commercial milestone. Following the closing of the acquisition, we have integrated the Millipede business into our Interventional Cardiology division.

Purchase Price Allocation

We accounted for our 2019 acquisitions of Vertiflex and Millipede as business combinations, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of December 31, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
763

Fair value of contingent consideration
127

Fair value of prior interests
102

 
$
992



The preliminary purchase price allocations of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of December 31, 2019:
(in millions)
 
Goodwill
$
575

Amortizable intangible assets
220

Indefinite-lived intangible assets
240

Other assets acquired
24

Liabilities assumed
(12
)
Net deferred tax liabilities
(56
)
 
$
992



We allocated a portion of the preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, to the specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
Technology-related
$
210

 
12
 
15%
Other intangible assets
10

 
12
 
15%
Indefinite-lived intangible assets:
 
 
 
 
 
In-process research and development
240

 
n/a
 
19%
 
$
461

 
 
 
 


2018 Acquisitions

Augmenix, Inc.

On October 16, 2018, we announced the closing of our acquisition of Augmenix, Inc. (Augmenix), a privately-held company that developed and commercialized the SpaceOAR™ Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer. The transaction price consisted of an upfront cash payment of $500 million and up to $100 million in payments contingent upon achieving certain revenue-based milestones. Following the closing of the acquisition, we have integrated the Augmenix business into our Urology and Pelvic Health division.

Claret Medical, Inc.

On August 2, 2018, we announced the closing of our acquisition of Claret Medical, Inc. (Claret), a privately-held company that has developed and commercialized the Sentinel™ Cerebral Embolic Protection System. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter aortic valve replacement (TAVR). The transaction price consisted of an upfront cash payment of $220 million and an additional $50 million payment for achieving a reimbursement-based milestone that was achieved in the third quarter of 2018. Following the closing of the acquisition, we have integrated the Claret business into our Interventional Cardiology division.

Cryterion Medical, Inc.

On July 5, 2018, we announced the closing of our acquisition of Cryterion Medical, Inc. (Cryterion), a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation. We had been an investor in Cryterion since 2016 and held an interest of approximately 35 percent immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of $202 million. Following the closing of the acquisition, we have integrated the Cryterion business into our Electrophysiology division.

NxThera, Inc.

On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company that developed the Rezūm™ System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). We held a minority interest immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of approximately $240 million and up to approximately $85 million in future potential payments contingent upon achieving commercial milestones over the four years following the date of acquisition. Following the closing of the acquisition, we have integrated the NxThera business into our Urology and Pelvic Health division.

nVision Medical Corporation

On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction price consisted of an upfront cash payment of $150 million and up to an additional $125 million in future potential payments contingent upon achieving certain clinical and commercial milestones over the four years following the date of acquisition. Following the closing of the acquisition, we have integrated the nVision business into our Urology and Pelvic Health division.

Other Acquisitions

In addition, we completed other individually immaterial acquisitions in 2018 for total consideration of $158 million in cash at closing plus aggregate future potential contingent consideration of up to $62 million.

We recorded gains of $184 million in 2018 within Other, net on our consolidated statements of operations based on the difference between the book values and the fair values of our previously-held investments immediately prior to the acquisition dates. The aggregate fair value of our previously-held investments immediately prior to the acquisition dates was $251 million. We remeasured the fair value of each previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests.

Purchase Price Allocation

We accounted for these acquisitions as business combinations, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of December 31, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
1,449

Fair value of contingent consideration
248

Fair value of prior interests
251

 
$
1,948



The following summarizes the purchase price allocations for our 2018 acquisitions as of December 31, 2019:
(in millions)
 
Goodwill
$
939

Amortizable intangible assets
939

In-process research and development
213

Other assets acquired
38

Liabilities assumed
(19
)
Net deferred tax liabilities
(162
)
 
$
1,948



We allocated a portion of the purchase prices to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets
 
 
 
 
 
 
 
 
 
Technology-related
$
908

 
6
-
14
 
14
%
-
23%
Other intangible assets
31

 
6
-
13
 
13
%
-
15%
Indefinite-lived intangible assets
 
 
 
 
 
 
 
 
 
In-process research and development
213

 
n/a
 
15%
 
$
1,153

 
 
 
 
 
 
 
 


2017 Acquisitions

Apama Medical Inc.

On October 11, 2017, we announced the closing of our acquisition of Apama Medical Inc. (Apama), a privately-held company developing the Apama™ Radiofrequency single-shot Balloon Catheter System for the treatment of atrial fibrillation. The transaction price consisted of an upfront cash payment of approximately $175 million and up to approximately $125 million in future potential payments contingent upon achieving certain clinical and regulatory milestones. Following the closing of the acquisition, we have integrated the Apama business into our Electrophysiology division.

Symetis SA

On May 16, 2017, we announced the closing of our acquisition of Symetis SA (Symetis), a privately-held Swiss structural heart company focused on minimally-invasive TAVR devices, having developed the ACURATE neo™ Aortic Valve. The transaction price consisted of an upfront cash payment of approximately $430 million. Following the closing of the acquisition, we have integrated the Symetis business into our Interventional Cardiology division.

Purchase Price Allocation

We accounted for these acquisitions as business combinations and, in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices were as follows for our 2017 acquisitions:
(in millions)
 
Payment for acquisitions, net of cash acquired
$
560

Fair value of contingent consideration
72

 
$
632



The following summarizes the aggregate purchase price allocations for our 2017 acquisitions:
(in millions)
 
Goodwill
$
287

Amortizable intangible assets
278

Indefinite-lived intangible assets
186

Other assets acquired
44

Liabilities assumed
(61
)
Deferred tax liabilities
(102
)
 
$
632



We allocated a portion of the purchase prices to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
268

 
13
 
24%
Other intangible assets
10

 
2
-
13
 
24%
Indefinite-lived intangible assets
 
 
 
 
 
 
 
In-process research and development
$
186

 
n/a
 
15%
 
$
464

 
 
 
 
 
 


Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations as well as revenue and cash flow projections associated with future technologies and has been allocated to our reportable segments based on the relative expected benefit. Based on preliminary estimates updated for applicable regulatory changes, the goodwill recorded relating to our 2019, 2018 and 2017 acquisitions is not deductible for tax purposes.

Contingent Consideration

Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
 
Balance as of December 31, 2017
$
169

Amounts recorded related to current year acquisitions
248

Purchase price adjustments related to prior year acquisitions
(22
)
Contingent consideration expense (benefit)
(21
)
Contingent consideration payments
(28
)
Balance as of December 31, 2018
$
347

Amounts recorded related to current year acquisitions
127

Contingent consideration arrangements transferred to Varian
(16
)
Contingent consideration expense (benefit)
(35
)
Contingent consideration payments
(68
)
Balance as of December 31, 2019
$
354



As of December 31, 2019, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was $697 million, which includes our estimate of maximum contingent payments of $100 million associated with the Vertiflex acquisition described above. The maximum decreased $176 million compared to the amount as of December 31, 2018 due to the contingent consideration arrangement which is now accounted for as a guarantee in connection with our transaction with Varian as discussed in the BTG section above. In addition, the aggregated maximum decreased as a result of the expiration or full payment of certain contingent consideration arrangements in 2019, partially offset by the Millipede and Vertiflex arrangements entered into in 2019.
The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
Contingent Consideration Liability
Fair Value as of December 31, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
R&D, Regulatory and Commercialization-based Milestones
$198 million
Discounted Cash Flow
Discount Rate
2
%
-
3%
3%
Probability of Payment
40
%
-
90%
82%
Projected Year of Payment
2020

-
2027
2021
Revenue-based Payments
$156 million
Discounted Cash Flow
Discount Rate
11
%
-
15%
13%
Probability of Payment
60
%
-
100%
99%
Projected Year of Payment
2020

-
2026
2021

(1)
Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to some of our R&D, commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of December 31, 2019.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:
 
As of December 31,
(in millions)
2019
 
2018
Equity method investments
$
264

 
$
303

Measurement alternative investments(1)
171

 
94

Publicly-held securities(2)
1

 
—

Notes receivable
23

 
26

 
$
458

 
$
424

(1)
Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
(2)
Publicly-held equity securities are measured at fair value with changes in fair value recognized currently in Other, net on our accompanying consolidated statements of operations.

These investments are classified as Other long-term assets within our accompanying consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

As of December 31, 2019, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $314 million, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock Inventive and Ownership Plans
 12 Months Ended
Dec. 31, 2019
Stock Incentive and Ownership Plans [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
NOTE L – STOCK INCENTIVE AND OWNERSHIP PLANS

Employee and Director Stock Incentive Plans

In 2011, our Board of Directors and stockholders approved our 2011 Long-Term Incentive Plan (the 2011 LTIP), authorizing for issuance up to 146 million shares of our common stock. The 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, deferred stock units (DSU), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based DSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately 124 million as of December 31, 2019. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee.

Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a four-year service period and have a ten-year contractual life. In the case of qualified options, if the recipient owns more than ten percent of the voting power of all classes of stock, the option granted will be at an exercise price of 110 percent of the fair market value of our common stock on the date of grant and will expire over a period not to exceed five years. Non-vested stock awards, including restricted stock awards and DSUs, issued to employees are generally granted with an exercise price of zero and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.

The following presents the impact of stock-based compensation on our consolidated statements of operations:
 
Year Ended December 31,
(in millions, except per share data)
2019
 
2018
 
2017
Cost of products sold
$
8

 
$
7

 
$
7

Selling, general and administrative expenses
120

 
109

 
98

Research and development expenses
28

 
24

 
23

 
157

 
140

 
127

Income tax (benefit) expense
(24
)
 
(21
)
 
(32
)
 
$
133

 
$
119

 
$
96

Net impact per common share - basic
$
0.10

 
$
0.09

 
$
0.07

Net impact per common share - assuming dilution
$
0.09

 
$
0.08

 
$
0.07



Stock Options

We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Options granted (in thousands)
2,992
 
 
3,491
 
 
4,439
 
Weighted-average exercise price
$
40.20
 
 
$
27.26
 
 
$
24.70
 
Weighted-average grant-date fair value
$
11.76
 
 
$
8.55
 
 
$
7.16
 
Black-Scholes Assumptions
 
 
 
 
 
 
 
 
 
 
 
Expected volatility
24
%
 
26
%
 
25
%
Expected term (in years, weighted)
6.1
 
 
6.0
 
 
6.1
 
Risk-free interest rate
1.38
%
-
2.61%
 
2.61
%
-
3.01%
 
2.03
%
-
2.21%


Expected Volatility

We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.

Expected Term

We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.

Risk-Free Interest Rate

We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.

Expected Dividend Yield

We have not historically paid cash dividends to our stockholders and currently do not intend to pay cash dividends. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.

Information related to stock options under stock incentive plans are as follows:
 
Stock Options
(in thousands)
 
Weighted
Average
Exercise Price
 
Weighted Average
Remaining
Contractual Life 
(in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 2016
26,644

 
$
11

 
 
 
 
Granted
4,439

 
25

 
 
 
 
Exercised
(3,922
)
 
10

 
 
 
 
Cancelled/forfeited
(445
)
 
17

 
 
 
 
Outstanding as of December 31, 2017
26,716

 
$
13

 
 
 
 
Granted
3,491

 
27

 
 
 
 
Exercised
(4,385
)
 
11

 
 
 
 
Cancelled/forfeited
(519
)
 
22

 
 
 
 
Outstanding as of December 31, 2018
25,304

 
$
16

 
 
 
 
Granted
2,992

 
40

 
 
 
 
Exercised
(4,872
)
 
12

 
 
 
 
Cancelled/forfeited
(359
)
 
24

 
 
 
 
Outstanding as of December 31, 2019
23,065

 
$
19

 
5.5
 
$
594

Exercisable as of December 31, 2019
15,091

 
$
14

 
4.1
 
$
476

Expected to vest as of December 31, 2019
7,617

 
30

 
8.0
 
114

Total vested and expected to vest as of December 31, 2019
22,707

 
$
19

 
5.3
 
$
590


The total intrinsic value of stock options exercised was $140 million in 2019, $90 million in 2018 and $64 million in 2017.

Non-Vested Stock

We value restricted stock awards and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:
 
Non-Vested
Stock Award Units
(in thousands)
 
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 2016
18,797

 
$
14

Granted
4,798

 
24

Vested (1)
(7,663
)
 
11

Forfeited
(683
)
 
17

Balance as of December 31, 2017
15,250

 
$
18

Granted
4,375

 
28

Vested (1)
(6,194
)
 
16

Forfeited
(748
)
 
22

Balance as of December 31, 2018
12,683

 
$
22

Granted
3,656

 
39

Vested (1)
(4,811
)
 
20

Forfeited
(449
)
 
27

Balance as of December 31, 2019
11,079

 
$
29

(1)
The number of restricted stock units vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.

The total vesting date fair value of stock award units that vested was approximately $193 million in 2019, $170 million in 2018 and $190 million in 2017.

Market-based DSU Awards

During 2019, 2018 and 2017, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&P 500 Healthcare Index over a three-year performance period. The number of DSUs ultimately granted under this program range from 0 percent to 200 percent of the target number of performance-based DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based DSUs that satisfied the market performance criteria.

We determined the fair value of the market-based DSU awards to be approximately $10 million for 2019, $7 million for 2018 and $8 million for 2017. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 
2019
 
2018
 
2017
 
Awards
 
Awards
 
Awards
Stock price on date of grant
$
40.12

 
$
27.09

 
$
24.55

Measurement period (in years)
2.9

 
2.9

 
2.8

Risk-free rate
2.48
%
 
2.36
%
 
1.45
%

We recognize the expense on these awards in our consolidated statements of operations on a straight-line basis over the three-year measurement period.

Free Cash Flow Performance-based DSU Awards

During 2019, 2018 and 2017, we granted free cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based DSUs is based on our adjusted free cash flow (AFCF) measured against our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st of each year and ending December 31st. The number of DSUs ultimately granted under this program range from 0 percent to 150 percent of the target number of performance-based DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based DSUs that satisfied the performance criteria.

The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2019:
 
2019 AFCF
 
2018 AFCF
 
2017 AFCF
Fair value, net of forfeitures to date (in millions)
$
8

 
$
11

 
$
6

Achievement of target payout
90
%
 
118
%
 
98
%
Year-end stock price used in determining fair value
$
45.22

 
$
35.34

 
$
24.79


We recognize the expense on these awards in our consolidated statements of operations over the vesting period which is three years after the date of grant.

Expense Attribution

We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.

We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. FASB ASC Topic 718, Compensation – Stock Compensation allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately six percent to all unvested stock-based awards as of December 31, 2019, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.

Unrecognized Compensation Cost

We expect to recognize the following future expense for awards outstanding as of December 31, 2019:
 
 Unrecognized
 Compensation Cost
(in millions) (1)
 
Weighted Average Remaining
Vesting Period
(in years)
Stock options
$
35

 
 
Non-vested stock awards
169

 
 
 
$
204

 
1.2
(1)
Amounts presented represent compensation cost, net of estimated forfeitures.

Employee Stock Purchase Plans

Our global employee stock purchase plan provides for the granting of options to purchase up to 50 million shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than ten percent of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to 85 percent of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of December 31, 2019, there were approximately 8 million shares available for future issuance under the employee stock purchase plan.

Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Shares issued or to be issued (in thousands)
2,196
 
 
2,452
 
 
2,491
 
Range of purchase prices
$
29.29

-
$36.47
 
$
21.49

-
$27.91
 
$
18.60

-
$21.07
Expense recognized (in millions)
$
19
 
 
$
17
 
 
$
13
 


We use the Black-Scholes option-pricing model to calculate the grant-date fair value of shares issued under the employee stock purchase plan. We recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period.
XML 30 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]  
Schedule of Intangible Assets and Goodwill [Table Text Block]
 
As of December 31, 2019
 
As of December 31, 2018
(in millions)
Gross Carrying Amount
 
Accumulated
Amortization/Write-offs
 
Gross Carrying Amount
 
Accumulated
Amortization/Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
12,020

 
$
(5,706
)
 
$
10,197

 
$
(5,266
)
Patents
525

 
(408
)
 
520

 
(393
)
Other intangible assets
1,754

 
(1,081
)
 
1,666

 
(958
)
 
$
14,299

 
$
(7,195
)
 
$
12,383

 
$
(6,617
)
Indefinite-lived intangible assets
 
 
 
 
 
 
 
Goodwill
$
20,076

 
$
(9,900
)
 
$
17,811

 
$
(9,900
)
In-process research and development (IPR&D)
662

 
—

 
486

 
—

Technology-related
120

 
—

 
120

 
—

 
$
20,858

 
$
(9,900
)
 
$
18,417

 
$
(9,900
)
Schedule of Goodwill [Table Text Block]
The following represents our goodwill balance by global reportable segment and our separately reported Specialty Pharmaceuticals operating segment:
(in millions)
MedSurg
 
Rhythm and Neuro
 
Cardiovascular
 
Specialty Pharmaceuticals
 
Total
Balance as of December 31, 2017
$
2,877

 
$
417

 
$
3,704

 
$
—

 
$
6,998

Reportable segment revisions
(1,379
)
 
1,379

 
—

 
—

 
—

Foreign currency fluctuations and other changes
(3
)
 
(22
)
 
(3
)
 
—

 
(29
)
Goodwill acquired
568

 
150

 
224

 
—

 
942

Balance as of December 31, 2018
$
2,063

 
$
1,924

 
$
3,925

 
$
—

 
$
7,911

Foreign currency fluctuations and other changes
(1
)
 
—

 
58

 
9

 
66

Goodwill acquired
—

 
268

 
1,712

 
238

 
2,218

Goodwill divested
—

 
—

 
(19
)
 
—

 
(19
)
Balance as of December 31, 2019
$
2,061

 
$
2,192

 
$
5,676

 
$
247

 
$
10,176
Schedule of Expected Amortization Expense [Table Text Block]
Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of December 31, 2019 is as follows (in millions):
Fiscal Year
 
2020
$
787

2021
750

2022
722

2023
708

2024
672
XML 31 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring Related Activities (Tables)
 12 Months Ended
Dec. 31, 2019
Restructuring and Related Cost [Line Items]  
Impact of restructuring costs on the accompanying financial statements
The following presents the restructuring and restructuring-related charges (credits) by major type and line item within our accompanying consolidated statements of operations (in millions):
Year Ended December 31, 2019
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
38

 
$
—

 
$
—

 
$
38

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
32

 
—

 
32

Selling, general and administrative expenses
—

 
—

 
13

 
13

 
—

 
32

 
13

 
44

 
$
38

 
$
32

 
$
13

 
$
82



Year Ended December 31, 2018
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
32

 
$
—

 
$
4

 
$
36

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
47

 
—

 
47

Selling, general and administrative expenses
—

 
—

 
12

 
12

 
—

 
47

 
12

 
59

 
$
32

 
$
47

 
$
16

 
$
96


Year Ended December 31, 2017
Termination
Benefits
 
Transfer Costs
 
Other
 
Total
Restructuring charges
$
25

 
$
—

 
$
12

 
$
37

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
45

 
—

 
45

Selling, general and administrative expenses
—

 
—

 
13

 
13

 
—

 
45

 
13

 
58

 
$
25

 
$
45

 
$
25

 
$
95
Cumulative Restructuring Charges [Text Block]
The following table presents cumulative restructuring and restructuring-related charges incurred as of December 31, 2019, related to our Restructuring Plans by major type:
(in millions)
2016 Restructuring Plan
 
2019 Restructuring Plan
 
Total
Termination benefits
$
86

 
$
30

 
$
115

Other (1)
21

 
2

 
23

Total restructuring charges
106

 
32

 
138

Transfer costs
126

 
13

 
139

Other (2)
39

 
2

 
41

Restructuring-related charges
164

 
15

 
180

 
$
271

 
$
47

 
$
318

(1)
Consists primarily of consulting fees and costs associated with contract cancellations.
(2)
Comprised of other costs directly related to our Restructuring Plans, including program management, accelerated depreciation, and fixed asset write-offs.
Amount Of Cash Paid In Period To Fully Or Partially Settle Specified Type Of Restructuring Cost [Text Block]
Cash payments associated with our Restructuring Plans were made using cash generated from operations and are comprised of the following:
(in millions)
2016 Restructuring Plan
 
2019 Restructuring Plan
 
Total
Year Ended December 31, 2019
 
 
 
 
 
Termination benefits
$
13

 
$
6

 
$
18

Transfer costs
18

 
13

 
32

Other
10

 
4

 
14

 
$
41

 
$
23

 
$
64
2019 Restructuring Plan [Member]  
Restructuring and Related Cost [Line Items]  
Impact of restructuring costs on the accompanying financial statements
The following table provides a summary of our estimates of total pre-tax charges associated with the 2019 Restructuring Plan by major type of cost:
Type of Cost
Total Estimated Amount Expected to be Incurred
Restructuring charges:
 
 
 
Termination benefits

$75
 million
 to
$100 million
Other (1)

$25
 million
 to
$50 million
Restructuring-related expenses:
 
 
 
Other (2)

$100
 million
 to
$150 million
 

$200
 million
 to
$300 million
(1)
Consists primarily of consulting fees and costs associated with contractual cancellations.
(2)
Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.
2016 Restructuring Plan [Member]  
Restructuring and Related Cost [Line Items]  
Impact of restructuring costs on the accompanying financial statements
The following table provides a summary of total pre-tax charges associated with the 2016 Restructuring Plan by major type of cost:
Type of cost
Total Amount Incurred
Restructuring charges:
 
Termination benefits
$
86
 million
Other (1)
21
 million
Restructuring-related expenses:
 
Other (2)
164
 million
 
$
271
 million
(1)
Consists primarily of consulting fees and costs associated with contract cancellations.
(2)
Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities.
XML 32 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes Income Taxes (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Jun. 30, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating Loss Carryforwards [Line Items]              
Deferred Tax Liabilities, Net $ 241     $ 3,601 $ 241    
One-time transaction tax post-1986 E&P           $ 1,044  
Deferred tax assets, net of valuation allowance 249     4,391 249    
Income Tax Examination, Penalties and Interest Accrued 11     19 11    
Unrecognized Tax Benefits 427     455 427 1,238 $ 1,095
Unrecognized Tax Benefits that Would Impact Effective Tax Rate 332     355 332 1,150  
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions       30 79 134  
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions       45 4 16  
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions       (34) (433) (3)  
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities   $ (303)   (4) (459) (2)  
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations       (9) (3) (2)  
Deferred Tax Assets, Operating Loss Carryforwards, Domestic 416     449 416    
Deferred Tax Assets, Net, Current 161     195 161    
Deferred Tax Assets, Net, Noncurrent 87     4,196 87    
Deferred Tax Assets, Inventory 18     0 18    
Deferred Tax Assets, Operating Loss Carryforwards 450     545 450    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals 258     258 258    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges 12     20 12    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies 221     168 221    
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses 28     42 28    
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost 106     121 106    
Federal benefit of uncertain tax positions 10     10 10    
Deferred Tax Assets, Goodwill and Intangible Assets 0     3,447 0    
Deferred Tax Assets, Other 37     0 37    
Deferred Tax Assets, Gross 1,140     4,611 1,140    
Deferred Tax Assets, Valuation Allowance (344)     (915) (344)    
Change in Deferred Tax Assets, Valuation Allowance       571      
Deferred Tax Liabilities, Noncurrent (328)     (595) (328)    
Deferred Tax Liabilities, Property, Plant and Equipment 25     16 25    
Deferred Tax Liabilities, Derivatives 44     52 44    
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets 968     0 968    
Deferred Tax Liabilities, Inventory 0     2 0    
Deferred Tax Liabilities, Other 0     25 0    
Deferred Tax Liabilities, Gross 1,037     95 1,037    
Deferred Tax Liabilities 328     595 328    
Current Federal Tax Expense (Benefit)       120 (221) 320  
Income (Loss) from Continuing Operations before Income Taxes, Domestic       (1,145) 35 (408)  
Income (Loss) from Continuing Operations before Income Taxes, Foreign       1,832 1,387 1,341  
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest       687 1,422 933  
Current State and Local Tax Expense (Benefit)       54 (27) 9  
Current Foreign Tax Expense (Benefit)       101 160 255  
Current Income Tax Expense (Benefit)       275 (87) 584  
Deferred Federal Income Tax Expense (Benefit)       (146) (124) 272  
Deferred State and Local Income Tax Expense (Benefit)       (18) 4 1  
Deferred Foreign Income Tax Expense (Benefit)       (4,124) (42) (28)  
Deferred Income Tax Expense (Benefit)       (4,288) (162) 244  
Deferred Tax Assets, Operating Loss Carryforwards, Foreign $ 42     105 42    
Deferred Tax Asset, Intra-entity Transfer, Asset Other than Inventory       4,102      
deferred tax asset, Valuation allowance, intra-entity       542      
Other Comprehensive Income (Loss), Tax       13 37 63  
Free Trade Zone Regime Tax Incentive       $ 173 $ 146 $ 127  
Free Trade Zone Regime Tax Incentive Per Share $ 0.10     $ 0.12 $ 0.10 $ 0.09  
Gross interest and penalties recognized in period       $ (643)      
Income Tax Examination, Penalties and Interest Expense       1 $ 498 $ (154)  
Deferred Tax Assets, Prepaid on Intercompany Profit $ 161     195 161    
Net Deferred Tax Liabilities and Prepaid on Intercompany Profit (80)     3,796 (80)    
Deferred Tax Assets, Net of Valuation Allowance 796     $ 3,696 $ 796    
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent       21.00% 21.00% 35.00%  
TCJA benefit recognized         $ 67    
Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability         856    
One-time transaction tax post-1986 E&P - net payment       $ 499      
Unrecognized Tax Benefits, Interest on Income Taxes Accrued   $ 307          
Tax Adjustments, Settlements, and Unusual Provisions 90       250    
Net Settlement Payment to IRS $ 93       93    
transition tax payment remaining       420      
tax expense on state income taxes, USD E&P accumulated       18      
Income Tax Expense (Benefit)       $ (4,013) $ (249) $ 828  
Subsequent Event [Member]              
Operating Loss Carryforwards [Line Items]              
Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters     $ 98        
XML 33 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Operating Leased Assets [Line Items]      
Lessee, leases not yet commenced, amount $ 70    
Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months 84    
Lessee, Operating Lease, Liability, Payments, Due Year Two 71    
Operating Lease, Payments $ 77    
Operating Lease, Weighted Average Remaining Lease Term 5 years 9 months 18 days    
Operating Lease, Right-of-Use Asset $ 336 $ 0 $ 0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 137    
Rent Expense, Net 80 92 $ 88
Leases, Future Minimum Payments Due, Next Twelve Months 73    
Total leased assets $ 67    
Finance Lease, Weighted Average Remaining Lease Term 3.70%    
Lessee, Operating Lease, Liability, Payments, Due Year Three $ 59    
Lessee, Operating Lease, Liability, Payments, Due Year Four 48    
Lessee, Operating Lease, Liability, Payments, Due Year Five 41    
Lessee, Operating Lease, Liability, Payments, Due after Year Five 79    
Lessee, Operating Lease, Liability, Payments, Due 382    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 39    
Operating Lease, Liability 343    
Operating Leases, Future Minimum Payments, Due in Two Years 61    
Operating Leases, Future Minimum Payments, Due in Three Years 47    
Operating Leases, Future Minimum Payments, Due in Four Years 39    
Operating Leases, Future Minimum Payments, Due in Five Years 31    
Operating Leases, Future Minimum Payments, Due Thereafter 111    
Operating Leases, Future Minimum Payments Due 362    
Operating Lease, Liability, Noncurrent $ 276 $ 0  
Minimum [Member]      
Operating Leased Assets [Line Items]      
Lessee, Operating Lease, Term of Contract 1 year    
Maximum [Member]      
Operating Leased Assets [Line Items]      
Lessee, Operating Lease, Term of Contract 60 years    
Lessee, Operating and Finance Leases, Option to Extend 10 years    
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract 15 years    
JSON 34 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a2019form10-k.htm": { "axisCustom": 6, "axisStandard": 37, "contextCount": 568, "dts": { "calculationLink": { "local": [ "bsx-20191231_cal.xml" ] }, "definitionLink": { "local": [ "bsx-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "a2019form10-k.htm" ] }, "labelLink": { "local": [ "bsx-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "bsx-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-ref-2018-01-31.xml" ] }, "schema": { "local": [ "bsx-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 1078, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 19, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 24 }, "keyCustom": 128, "keyStandard": 618, "memberCustom": 90, "memberStandard": 69, "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0002000 - Document - Cover Document Document", "role": "http://www.bostonscientific.com/role/CoverDocumentDocument", "shortName": "Cover Document Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Fair Value Measurements", "role": "http://www.bostonscientific.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Borrowings and Credit Arrangements", "role": "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements", "shortName": "Borrowings and Credit Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Leases", "role": "http://www.bostonscientific.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Restructuring Related Activities", "role": "http://www.bostonscientific.com/role/RestructuringRelatedActivities", "shortName": "Restructuring Related Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:SupplementalBalanceSheetInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Supplemental Balance Sheet Information", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation", "shortName": "Supplemental Balance Sheet Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:SupplementalBalanceSheetInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Income Taxes", "role": "http://www.bostonscientific.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Commitments and Contingencies", "role": "http://www.bostonscientific.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Stockholders' Equity", "role": "http://www.bostonscientific.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Stock Inventive and Ownership Plans", "role": "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlans", "shortName": "Stock Inventive and Ownership Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Statements of Operations", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Weighted Average Shares Outstanding", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding", "shortName": "Weighted Average Shares Outstanding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Segment Reporting", "role": "http://www.bostonscientific.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Changes in Other Comprehensive Income", "role": "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome", "shortName": "Changes in Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - New Accounting Pronouncements", "role": "http://www.bostonscientific.com/role/NewAccountingPronouncements", "shortName": "New Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - Revenue Revenue", "role": "http://www.bostonscientific.com/role/RevenueRevenue", "shortName": "Revenue Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122100 - Disclosure - Employee Retirement Plans (Notes)", "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes", "shortName": "Employee Retirement Plans (Notes)", "subGroupType": "", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2123100 - Schedule - Schedule II", "role": "http://www.bostonscientific.com/role/ScheduleIi", "shortName": "Schedule II", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies)", "role": "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalCostsPolicyTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203200 - Disclosure - Accounting Policies (Policies)", "role": "http://www.bostonscientific.com/role/AccountingPoliciesPolicies", "shortName": "Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "lang": "en-US", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2220201 - Disclosure - New Accounting Pronouncements New Accounting Pronouncements (Policies)", "role": "http://www.bostonscientific.com/role/NewAccountingPronouncementsNewAccountingPronouncementsPolicies", "shortName": "New Accounting Pronouncements New Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "lang": "en-US", "name": "bsx:ASCUpdateNo.201613PolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2222201 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies)", "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies", "shortName": "Employee Retirement Plans Employee Retirement Plans (Policies)", "subGroupType": "policies", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Acquisitions and Strategic Investments (Tables)", "role": "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "shortName": "Acquisitions and Strategic Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)", "role": "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.bostonscientific.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Borrowings and Credit Arrangements (Tables)", "role": "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables", "shortName": "Borrowings and Credit Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:MaturitiesofLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Leases (Tables)", "role": "http://www.bostonscientific.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:MaturitiesofLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Restructuring Related Activities (Tables)", "role": "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables", "shortName": "Restructuring Related Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Supplemental Balance Sheet Information (Tables)", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables", "shortName": "Supplemental Balance Sheet Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Income Taxes (Tables)", "role": "http://www.bostonscientific.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Stock Incentive and Ownership Plans (Tables)", "role": "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables", "shortName": "Stock Incentive and Ownership Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Balance Sheets", "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:AssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316302 - Disclosure - Stock Inventive and Ownership Plans Employee Stock Purchase Plan (Tables)", "role": "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables", "shortName": "Stock Inventive and Ownership Plans Employee Stock Purchase Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - Weighted Average Shares Outstanding (Tables)", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables", "shortName": "Weighted Average Shares Outstanding (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - Segment Reporting (Tables)", "role": "http://www.bostonscientific.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Changes in Other Comprehensive Income (Tables)", "role": "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables", "shortName": "Changes in Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321301 - Disclosure - Revenue Revenue (Tables)", "role": "http://www.bostonscientific.com/role/RevenueRevenueTables", "shortName": "Revenue Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322302 - Disclosure - Employee Retirement Plans (Tables)", "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables", "shortName": "Employee Retirement Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details)", "role": "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "shortName": "Significant Accounting Policies Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "2", "lang": null, "name": "bsx:PercentOfFinishedGoodsAtConsignment", "reportCount": 1, "unique": true, "unitRef": "ratio", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "D2019Q3Varian", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Acquisitions and Strategic Investments (Details)", "role": "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "shortName": "Acquisitions and Strategic Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "D2019Q3Varian", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "invest:InvestmentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Acquisitions and Strategic Investments Strategic Investments (Details)", "role": "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails", "shortName": "Acquisitions and Strategic Investments Strategic Investments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Goodwill and Other Intangible Assets (Details)", "role": "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Consolidated Balance Sheet Paranthetical", "role": "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "shortName": "Consolidated Balance Sheet Paranthetical", "subGroupType": "", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Fair Value Measurements (Details)", "role": "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LongTermPurchaseCommitmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Borrowings and Credit Arrangements (Details)", "role": "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "shortName": "Borrowings and Credit Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LongTermPurchaseCommitmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "bsx:Lesseeleasesnotyetcommencedamount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Leases (Details)", "role": "http://www.bostonscientific.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "bsx:Lesseeleasesnotyetcommencedamount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Restructuring Related Activities (Details in Narrative)", "role": "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "shortName": "Restructuring Related Activities (Details in Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2018Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Supplemental Balance Sheet Information (Details)", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails", "shortName": "Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "bsx:SupplementalBalanceSheetInformationTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "ratio", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Income Taxes (Details - Rate Table)", "role": "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable", "shortName": "Income Taxes (Details - Rate Table)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "ratio", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - Income Taxes Income Taxes (Details)", "role": "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "shortName": "Income Taxes Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2017Q4YTD", "decimals": "-6", "lang": null, "name": "bsx:Onetimetransactiontaxpost1986EP", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "bsx:ContingentPaymentRelatedToBusinessCombination", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "D2017Q4Litigation", "decimals": "-3", "lang": null, "name": "us-gaap:LossContingencyDamagesAwardedValue", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Stockholders' Equity (Details)", "role": "http://www.bostonscientific.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "lang": null, "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "bsx:Fairvalueofmarketbasedawards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Stock Incentive and Ownership Plans (Details)", "role": "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails", "shortName": "Stock Incentive and Ownership Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "bsx:MarketBasedAwardsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "bsx:Fairvalueofmarketbasedawards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - Weighted Average Shares Outstanding (Details)", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "shortName": "Weighted Average Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - Segment Reporting (Details)", "role": "http://www.bostonscientific.com/role/SegmentReportingDetails", "shortName": "Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:NonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Changes in Other Comprehensive Income (Details)", "role": "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "shortName": "Changes in Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2017Q4", "decimals": "-6", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421402 - Disclosure - Revenue Revenue (Details)", "role": "http://www.bostonscientific.com/role/RevenueRevenueDetails", "shortName": "Revenue Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422403 - Disclosure - Employee Retirement Plans (Details)", "role": "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "shortName": "Employee Retirement Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2423401 - Schedule - Schedule II (Details)", "role": "http://www.bostonscientific.com/role/ScheduleIiDetails", "shortName": "Schedule II (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": "-6", "lang": null, "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Significant Accounting Policies", "role": "http://www.bostonscientific.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Acquisitions and Strategic Investments", "role": "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments", "shortName": "Acquisitions and Strategic Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2019form10-k.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 172, "tag": { "bsx_A2011LtipPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2011 LTIP Plan [Member]", "label": "2011 LTIP Plan [Member]", "terseLabel": "2011 LTIP Plan [Member]" } } }, "localname": "A2011LtipPlanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "domainItemType" }, "bsx_A2016RestructuringPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2016 Restructuring Plan [Member]", "label": "2016 Restructuring Plan [Member]", "terseLabel": "2016 Restructuring Plan [Member]" } } }, "localname": "A2016RestructuringPlanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "domainItemType" }, "bsx_A2017AcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 Acquisitions [Member]", "label": "2017 Acquisitions [Member]", "terseLabel": "2017 Acquisitions [Member]" } } }, "localname": "A2017AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "bsx_A2018AcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Acquisitions [Member]", "label": "2018 Acquisitions [Member]", "terseLabel": "2018 Acquisitions [Member]" } } }, "localname": "A2018AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "bsx_A2019AcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 Acquisitions [Member]", "label": "2019 Acquisitions [Member]", "terseLabel": "2019 Acquisitions [Member]" } } }, "localname": "A2019AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "bsx_A2019RestructuringPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 Restructuring Plan [Member]", "label": "2019 Restructuring Plan [Member]", "terseLabel": "2019 Restructuring Plan [Member]" } } }, "localname": "A2019RestructuringPlanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "domainItemType" }, "bsx_A2020TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2020 Term Loan [Member]", "label": "2020 Term Loan [Member]", "terseLabel": "2020 Term Loan [Member]" } } }, "localname": "A2020TermLoanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_ASCUpdateNo.201613PolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments [Policy Text Block]", "label": "ASC Update No. 2016-13 [Policy Text Block]", "terseLabel": "ASC Update No. 2016-13 [Policy Text Block]" } } }, "localname": "ASCUpdateNo.201613PolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsNewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo.201815InternalUseSoftwarePolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ASC Update No. 2018-15, Internal-Use Software [Policy Text Block]", "label": "ASC Update No. 2018-15, Internal-Use Software [Policy Text Block]", "terseLabel": "ASC Update No. 2018-15, Internal-Use Software [Policy Text Block]" } } }, "localname": "ASCUpdateNo.201815InternalUseSoftwarePolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsNewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo.201818PolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ASC Update No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying The Interaction Between Topic 808 and Topic 606 [Policy Text Block]", "label": "ASC Update No. 2018-18 [Policy Text Block]", "terseLabel": "ASC Update No. 2016-02, Leases (Topic 842) [Policy Text Block]" } } }, "localname": "ASCUpdateNo.201818PolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsNewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_AccruedContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Estimated discounted potential payments under contingent consideration arrangements.", "label": "Accrued Contingent Consideration", "terseLabel": "Accrued Contingent Consideration" } } }, "localname": "AccruedContingentConsideration", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_AccruedRebatesCurrent": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Rebates, Current", "label": "Accrued Rebates, Current", "terseLabel": "Accrued Rebates, Current" } } }, "localname": "AccruedRebatesCurrent", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_AccumulatedOtherComprehensiveIncomeLossSecuritiesAvailableforsaleAdjustmentafterTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "label": "Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossSecuritiesAvailableforsaleAdjustmentafterTax", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "bsx_AcquisitionsTextualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisitions.", "label": "Acquisitions (Textuals) [Abstract]", "verboseLabel": "Acquisitions (Textuals) [Abstract]" } } }, "localname": "AcquisitionsTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "bsx_ActualCovenantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Actual Covenant.", "label": "Actual, Covenant [Member]", "terseLabel": "Actual, Covenant [Member]" } } }, "localname": "ActualCovenantMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_AdditionalAcquisitionsTextualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Additional Acquisitions Textuals Abstract.", "label": "Additional Acquisitions (Textuals) [Abstract]", "terseLabel": "Additional Acquisitions (Textuals) [Abstract]" } } }, "localname": "AdditionalAcquisitionsTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "bsx_AggregateSeniorUnsecuredDelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate Senior Unsecured Delayed Draw Term Loan [Member]", "label": "Aggregate Senior Unsecured Delayed Draw Term Loan [Member]", "terseLabel": "Aggregate Senior Unsecured Delayed Draw Term Loan [Member]" } } }, "localname": "AggregateSeniorUnsecuredDelayedDrawTermLoanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_AmountOfCashPaidInPeriodToFullyOrPartiallySettleSpecifiedTypeOfRestructuringCostTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of cash paid in the period to fully or partially settle a specified type of restructuring cost.", "label": "Amount Of Cash Paid In Period To Fully Or Partially Settle Specified Type Of Restructuring Cost [Text Block]", "terseLabel": "Amount Of Cash Paid In Period To Fully Or Partially Settle Specified Type Of Restructuring Cost [Text Block]" } } }, "localname": "AmountOfCashPaidInPeriodToFullyOrPartiallySettleSpecifiedTypeOfRestructuringCostTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "textBlockItemType" }, "bsx_AmountOfEmployeesTotalCompensationEligibleForGesopPurchase": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of employees total compensation eligible for GESOP purchase", "label": "Amount of employees total compensation eligible for GESOP purchase", "terseLabel": "Amount of employees total compensation eligible for GESOP purchase" } } }, "localname": "AmountOfEmployeesTotalCompensationEligibleForGesopPurchase", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_Annualweightedaverageforfeiturerate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Annual Weighted Average Forfeiture Rate\nThe weighted average of estimated forfeitures for grants based on historical trends", "label": "annualweightedaverageforfeiturerate", "terseLabel": "annualweightedaverageforfeiturerate" } } }, "localname": "Annualweightedaverageforfeiturerate", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_ApamaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Apama [Member]", "label": "Apama [Member]", "terseLabel": "Apama [Member]" } } }, "localname": "ApamaMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_AugmenixInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Augmenix, Inc. [Member]", "label": "Augmenix, Inc. [Member]", "terseLabel": "Augmenix, Inc. [Member]" } } }, "localname": "AugmenixInc.Member", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_August2019TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "August 2019 Term Loan [Member]", "label": "August 2019 Term Loan [Member]", "terseLabel": "August 2019 Term Loan [Member]" } } }, "localname": "August2019TermLoanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_August2022TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "August 2022 Term Loan [Member]", "label": "August 2022 Term Loan [Member]", "terseLabel": "August 2022 Term Loan [Member]" } } }, "localname": "August2022TermLoanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_AverageDiscountRateOfNotesReceivable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average discount rate of notes receivable.", "label": "Average Discount Rate Of Notes Receivable", "verboseLabel": "Average discounted rates of notes receivables" } } }, "localname": "AverageDiscountRateOfNotesReceivable", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "bsx_BSXReportableSegmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BSX Reportable Segments [Member]", "label": "BSX Reportable Segments [Member]", "terseLabel": "BSX Reportable Segments [Member]" } } }, "localname": "BSXReportableSegmentsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_BTGAcquisitionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BTG Acquisition [Axis]", "label": "BTG Acquisition [Axis]", "terseLabel": "BTG Acquisition [Axis]" } } }, "localname": "BTGAcquisitionAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "bsx_BTGAcquisitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for BTG Acquisition [Axis]", "label": "BTG Acquisition [Domain]", "terseLabel": "BTG Acquisition [Member]", "verboseLabel": "BTG Acquisition [Domain]" } } }, "localname": "BTGAcquisitionDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_BTGAcquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BTG Acquisition [Member]", "label": "BTG Acquisition [Member]", "terseLabel": "BTG Acquisition [Member]" } } }, "localname": "BTGAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_BTGSpecPharmaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BTG Spec Pharma [Member]", "label": "BTG Spec Pharma [Member]", "terseLabel": "BTG Spec Pharma [Member]" } } }, "localname": "BTGSpecPharmaMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_BorrowingsAndCreditArrangementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Borrowings and Credit Arrangements.", "label": "Borrowings and Credit Arrangements [Abstract]", "verboseLabel": "Schedule of debt maturities" } } }, "localname": "BorrowingsAndCreditArrangementsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "bsx_BorrowingsAndCreditArrangementsTextualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Borrowings And Credit Arrangements Textuals Abstract.", "label": "Borrowings and Credit Arrangements (Textuals) [Abstract]", "terseLabel": "Borrowings and Credit Arrangements (Textuals) [Abstract]" } } }, "localname": "BorrowingsAndCreditArrangementsTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "bsx_BusinessAcquisitionPurchasePriceAllocationIntangibleAssetsDescriptionTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Purchase Price Allocation, Intangible Assets, Description [Table Text Block]", "label": "Business Acquisition, Purchase Price Allocation, Intangible Assets, Description [Table Text Block]", "terseLabel": "Business Acquisition, Purchase Price Allocation, Intangible Assets, Description" } } }, "localname": "BusinessAcquisitionPurchasePriceAllocationIntangibleAssetsDescriptionTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "bsx_BusinessCombinationComponentsofPurchasePriceTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for The components of the purchase price for the acquisition.", "label": "Business Combination, Components of Purchase Price [Table Text Block]", "terseLabel": "Business Combination, Components of Purchase Price [Table Text Block]" } } }, "localname": "BusinessCombinationComponentsofPurchasePriceTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "bsx_BusinessCombinationPurchasePriceAllocationScheduleTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Summary of the aggregate purchase price allocation for the acquisition.", "label": "Business Combination, Purchase Price Allocation Schedule [Table Text Block]", "terseLabel": "Business Combination, Purchase Price Allocation Schedule [Table Text Block]" } } }, "localname": "BusinessCombinationPurchasePriceAllocationScheduleTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "bsx_CardiovascularMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cardiovascular [Member]", "label": "Cardiovascular [Member]", "terseLabel": "Cardiovascular [Member]" } } }, "localname": "CardiovascularMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_CashFlowImpactOfDeferredIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash flow impact of deferred income tax expense (benefit)", "label": "Cash flow impact of deferred income tax expense (benefit)", "terseLabel": "Deferred and prepaid income taxes" } } }, "localname": "CashFlowImpactOfDeferredIncomeTaxExpenseBenefit", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_CertifiedclassactionsinCanadaMesh": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Certified class actions in Canada, Mesh", "label": "Certified class actions in Canada, Mesh", "terseLabel": "Certified class actions in Canada, Mesh" } } }, "localname": "CertifiedclassactionsinCanadaMesh", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_ChangeinDeferredTaxAssetsValuationAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Change in Deferred Tax Assets, Valuation Allowance", "label": "Change in Deferred Tax Assets, Valuation Allowance", "terseLabel": "Change in Deferred Tax Assets, Valuation Allowance" } } }, "localname": "ChangeinDeferredTaxAssetsValuationAllowance", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Changeinmaximumamountoffuturecontingentconsiderationincreasedecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "change in maximum amount of future contingent consideration, increase (decrease)", "label": "change in maximum amount of future contingent consideration, increase (decrease)", "terseLabel": "change in maximum amount of future contingent consideration, increase (decrease)" } } }, "localname": "Changeinmaximumamountoffuturecontingentconsiderationincreasedecrease", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ChangesInOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Changes in Other Comprehensive Income [Abstract]", "label": "Changes in Other Comprehensive Income [Abstract]" } } }, "localname": "ChangesInOtherComprehensiveIncomeAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_ClaretMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Claret [Member]", "label": "Claret [Member]", "terseLabel": "Claret [Member]" } } }, "localname": "ClaretMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_Closingpayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Closing payment", "label": "Closing payment", "terseLabel": "Closing payment" } } }, "localname": "Closingpayment", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_CommitmentsAndContingenciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and Contingencies.", "label": "Commitments and Contingencies [Abstract]" } } }, "localname": "CommitmentsAndContingenciesAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_CompensationExpensePerShareBasic": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "compensation expense, per share - basic", "label": "compensation expense, per share - basic", "terseLabel": "compensation expense, per share - basic" } } }, "localname": "CompensationExpensePerShareBasic", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "bsx_CompensationExpensePerShareDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "compensation expense, per share - diluted", "label": "compensation expense, per share - diluted", "terseLabel": "compensation expense, per share - diluted" } } }, "localname": "CompensationExpensePerShareDiluted", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "bsx_ContingentConsiderationLiabilityProbabilityOfPayment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "contingent consideration liability, probability of payment", "label": "contingent consideration liability, probability of payment", "terseLabel": "contingent consideration liability, probability of payment" } } }, "localname": "ContingentConsiderationLiabilityProbabilityOfPayment", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "percentItemType" }, "bsx_ContingentPaymentRelatedToBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent payment related to business combination", "label": "Contingent payment related to business combination", "terseLabel": "Contingent payment related to business combination" } } }, "localname": "ContingentPaymentRelatedToBusinessCombination", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_CorporateExpensesincludinghedgingactivitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate Expenses including hedging activities [Member]", "label": "Corporate Expenses including hedging activities [Member]", "terseLabel": "Corporate Expenses including hedging activities [Member]" } } }, "localname": "CorporateExpensesincludinghedgingactivitiesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_CovenantAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Covenant.", "label": "Covenant [Axis]", "terseLabel": "Covenant [Axis]" } } }, "localname": "CovenantAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "bsx_CovenantDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Covenant.", "label": "Covenant [Domain]", "terseLabel": "Covenant [Domain]" } } }, "localname": "CovenantDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_CovenantRequirementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Covenant Requirement [Domain]", "label": "Covenant Requirement [Domain]", "terseLabel": "Covenant Requirement [Domain]" } } }, "localname": "CovenantRequirementDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_CoverDocumentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover Document [Abstract]", "label": "Cover Document [Abstract]" } } }, "localname": "CoverDocumentAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_CryterionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cryterion [Member]", "label": "Cryterion [Member]", "terseLabel": "Cryterion [Member]" } } }, "localname": "CryterionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_CumulativeRestructuringChargesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cumulative restructuring charges.", "label": "Cumulative Restructuring Charges [Text Block]", "terseLabel": "Cumulative Restructuring Charges [Text Block]" } } }, "localname": "CumulativeRestructuringChargesTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "textBlockItemType" }, "bsx_CurrentRequirementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Current Requirement.", "label": "Current Requirement [Member]", "verboseLabel": "Covenant Requirement [Member]" } } }, "localname": "CurrentRequirementMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_December2027NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "December 2027 Notes [Member]", "label": "December 2027 Notes [Member]", "terseLabel": "December 2027 Notes [Member]" } } }, "localname": "December2027NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_DeferredTaxAssetsPrepaidonIntercompanyProfit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Prepaid on Intercompany Profit", "label": "Deferred Tax Assets, Prepaid on Intercompany Profit", "terseLabel": "Deferred Tax Assets, Prepaid on Intercompany Profit" } } }, "localname": "DeferredTaxAssetsPrepaidonIntercompanyProfit", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DeferredTaxLiabilitiesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred tax liabilities, net", "label": "Deferred tax liabilities, net", "terseLabel": "Deferred Tax Liabilities" } } }, "localname": "DeferredTaxLiabilitiesNet", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DeferredtaxassetValuationallowanceintraentity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "deferred tax asset, Valuation allowance, intra-entity", "label": "deferred tax asset, Valuation allowance, intra-entity", "terseLabel": "deferred tax asset, Valuation allowance, intra-entity" } } }, "localname": "DeferredtaxassetValuationallowanceintraentity", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Deferredtaxassetsandprepaidonintercompanyprofit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "deferred tax assets and prepaid on intercompany profit", "label": "deferred tax assets and prepaid on intercompany profit", "terseLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "Deferredtaxassetsandprepaidonintercompanyprofit", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Acquired and Established Plan Changes, PBO", "label": "Defined Benefit Plan, Acquired and Established Plan Changes, PBO", "terseLabel": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets" } } }, "localname": "DefinedBenefitPlanAcquiredandEstablishedPlanChangesPBO", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets", "label": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets", "terseLabel": "Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets" } } }, "localname": "DefinedBenefitPlanAcquiredandEstablishedPlanChangesPlanAssets", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return", "label": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return", "terseLabel": "Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return" } } }, "localname": "DefinedBenefitPlanPlanAssetsAssumptionsusedtoDetermineExpectedReturn", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_Definedbenefitplanplanassetsactuarialgainloss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "defined benefit plan, plan assets, actuarial gain loss", "label": "defined benefit plan, plan assets, actuarial gain loss", "terseLabel": "defined benefit plan, plan assets, actuarial gain loss" } } }, "localname": "Definedbenefitplanplanassetsactuarialgainloss", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "label": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "terseLabel": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]" } } }, "localname": "DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Derivativenotionalamounttranslated": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "derivative, notional amount translated", "label": "derivative, notional amount translated", "terseLabel": "derivative, notional amount translated" } } }, "localname": "Derivativenotionalamounttranslated", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DiscountRateFairValueInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Discount Rate, Fair Value Input", "label": "Discount Rate, Fair Value Input", "terseLabel": "Discount Rate, Fair Value Input" } } }, "localname": "DiscountRateFairValueInput", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "bsx_DivestedbusinessduetoBTGacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "divested business due to BTG acquisition [Member]", "label": "divested business due to BTG acquisition [Member]", "terseLabel": "divested business due to BTG acquisition [Member]" } } }, "localname": "DivestedbusinessduetoBTGacquisitionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_EffectiveIncomeTaxRateReconciliationTCJAnetimpact": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, TCJA net impact", "label": "Effective Income Tax Rate Reconciliation, TCJA net impact", "terseLabel": "Effective Income Tax Rate Reconciliation, TCJA net impact" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTCJAnetimpact", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "bsx_EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions", "label": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions", "terseLabel": "Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUncertainDomesticTaxPositions", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "bsx_EffectiveIncomeTaxRateReconciliationintraentityintangibleassettransfers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, intra entity intangible asset transfers", "label": "Effective Income Tax Rate Reconciliation, intra entity intangible asset transfers", "terseLabel": "Effective Income Tax Rate Reconciliation, intra entity intangible asset transfers" } } }, "localname": "EffectiveIncomeTaxRateReconciliationintraentityintangibleassettransfers", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "bsx_EmergingMarketsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Emerging Markets [Member]", "label": "Emerging Markets [Member]", "terseLabel": "Emerging Markets [Member]" } } }, "localname": "EmergingMarketsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_EquipmentFurnitureAndFixturesGross": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equipment, furniture and fixtures Gross.", "label": "Equipment, furniture and fixtures Gross", "terseLabel": "Equipment, furniture and fixtures" } } }, "localname": "EquipmentFurnitureAndFixturesGross", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_EuroDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Euro Denominated Factoring Arrangements [Member]", "label": "Euro Denominated Factoring Arrangements [Member]", "terseLabel": "Euro Denominated Factoring Arrangements [Member]" } } }, "localname": "EuroDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_EurodenominatedoutstandingdebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Euro-denominated outstanding debt [Member]", "label": "Euro-denominated outstanding debt [Member]", "terseLabel": "Euro-denominated outstanding debt [Member]" } } }, "localname": "EurodenominatedoutstandingdebtMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_ExclusionFromEbitdaForRestructuringCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exclusion from EBITDA for Restructuring Charges", "label": "Exclusion from EBITDA for Restructuring Charges", "verboseLabel": "Amount of exclusions from EBITDA related to existing restructuring plans" } } }, "localname": "ExclusionFromEbitdaForRestructuringCharges", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ExecutiveRetirementPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Executive retirement plan [Member]", "label": "Executive retirement plan [Member]", "terseLabel": "Executive retirement plan [Member]" } } }, "localname": "ExecutiveRetirementPlanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "bsx_Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise price of the fair market value of our common stock on the date of grant", "label": "Exercise price of the fair market value of our common stock on the date of grant", "terseLabel": "Exercise price of the fair market value of our common stock on the date of grant" } } }, "localname": "Exercisepriceofthefairmarketvalueofourcommonstockonthedateofgrant", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_ExpenseRelatedToMatchingContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expense related to matching contributions", "label": "Expense related to matching contributions", "terseLabel": "Expense related to matching contributions" } } }, "localname": "ExpenseRelatedToMatchingContributions", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_FairValueMeasurementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair value measurements.", "label": "Fair Value Measurements [Abstract]" } } }, "localname": "FairValueMeasurementsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_FairValueOfFreeCashFlowFcfPerformanceAwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of the Free Cash Flow (FCF) performance awards", "label": "Fair value of the Free Cash Flow (FCF) performance awards", "terseLabel": "Fair value of the Free Cash Flow (FCF) performance awards" } } }, "localname": "FairValueOfFreeCashFlowFcfPerformanceAwards", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Fairvalueofmarketbasedawards": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of market based awards", "label": "Fair value of market based awards", "terseLabel": "Fair value of market based awards" } } }, "localname": "Fairvalueofmarketbasedawards", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_February2019AggregateOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "February2019AggregateOffering [Member]", "label": "February2019AggregateOffering [Member]", "terseLabel": "February2019AggregateOffering [Member]" } } }, "localname": "February2019AggregateOfferingMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_FederalBenefitOfUncertainTaxPositions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Federal benefit of uncertain tax positions", "label": "Federal benefit of uncertain tax positions", "terseLabel": "Federal benefit of uncertain tax positions" } } }, "localname": "FederalBenefitOfUncertainTaxPositions", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ForeigncurrencydenominatedindebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "foreign currency denominated in debt [Member]", "label": "foreign currency denominated in debt [Member]", "terseLabel": "foreign currency denominated in debt [Member]" } } }, "localname": "ForeigncurrencydenominatedindebtMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "stringItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Axis]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumption [Domain]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "domainItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsLineItems", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "stringItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTable", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "stringItemType" }, "bsx_FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table]", "label": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]", "terseLabel": "Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]" } } }, "localname": "FreeCashFlowPerformancebasedDSUAwardsFairValueAssumptionsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "textBlockItemType" }, "bsx_FreeTradeZoneRegimeTaxIncentive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Free Trade Zone Regime Tax Incentive", "label": "Free Trade Zone Regime Tax Incentive", "terseLabel": "Free Trade Zone Regime Tax Incentive" } } }, "localname": "FreeTradeZoneRegimeTaxIncentive", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_FreeTradeZoneTaxIncentivePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Free Trade Zone Tax Incentive, Per Share", "label": "Free Trade Zone Tax Incentive, Per Share", "terseLabel": "Free Trade Zone Regime Tax Incentive Per Share" } } }, "localname": "FreeTradeZoneTaxIncentivePerShare", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "perShareItemType" }, "bsx_GlobalCrmReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global CRM Reporting Unit [Member]", "label": "Global CRM Reporting Unit [Member]", "terseLabel": "Global CRM Reporting Unit [Member]" } } }, "localname": "GlobalCrmReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalElectrophysiologyEpReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Electrophysiology (EP) Reporting Unit [Member]", "label": "Global Electrophysiology (EP) Reporting Unit [Member]", "terseLabel": "Global Electrophysiology (EP) Reporting Unit [Member]" } } }, "localname": "GlobalElectrophysiologyEpReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)", "label": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)", "terseLabel": "Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less)" } } }, "localname": "GlobalEmployeeStockPurchasePlanExerciseAmountequivalentto85ofFairMarketValueofCommonStockatbeginningorendofeachofferingperiodwhicheverisless", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_GlobalEndoscopyEndoReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Endoscopy (Endo) Reporting Unit [Member]", "label": "Global Endoscopy (Endo) Reporting Unit [Member]", "terseLabel": "Global Endoscopy (Endo) Reporting Unit [Member]" } } }, "localname": "GlobalEndoscopyEndoReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalInterventionalCardiologyIcReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Interventional Cardiology (IC) Reporting Unit [Member]", "label": "Global Interventional Cardiology (IC) Reporting Unit [Member]", "terseLabel": "Global Interventional Cardiology (IC) Reporting Unit [Member]" } } }, "localname": "GlobalInterventionalCardiologyIcReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalNeuromodulationNmReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Neuromodulation (NM) Reporting Unit [Member]", "label": "Global Neuromodulation (NM) Reporting Unit [Member]", "terseLabel": "Global Neuromodulation (NM) Reporting Unit [Member]" } } }, "localname": "GlobalNeuromodulationNmReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalPeripheralInterventionsPiReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "label": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "terseLabel": "Global Peripheral Interventions (PI) Reporting Unit [Member]" } } }, "localname": "GlobalPeripheralInterventionsPiReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalUrologyandPelvicHealthReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Urology and Pelvic Health Reporting Unit [Member]", "label": "Global Urology and Pelvic Health Reporting Unit [Member]", "terseLabel": "Global Urology and Pelvic Health Reporting Unit [Member]" } } }, "localname": "GlobalUrologyandPelvicHealthReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_GoodwillTextualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Goodwill (Textuals) [Abstract]", "label": "Goodwill (Textuals) [Abstract]", "terseLabel": "Goodwill (Textuals) [Abstract]" } } }, "localname": "GoodwillTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "bsx_HedgedDebtAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hedged Debt [Axis]", "label": "Hedged Debt [Axis]", "terseLabel": "Hedged Debt [Axis]" } } }, "localname": "HedgedDebtAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "bsx_HedgedDebtDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Hedged Debt [Axis]", "label": "Hedged Debt [Domain]", "terseLabel": "Hedged Debt [Domain]" } } }, "localname": "HedgedDebtDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_IncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Taxes [Abstract]", "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxesAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_IndefiniteLivedIntangibleAssetsAccumulatedWriteOffs": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Indefinite-lived intangible assets, accumulated write-offs", "label": "Indefinite-lived intangible assets, accumulated write-offs", "negatedTerseLabel": "Indefinite-lived intangible assets, accumulated write-offs" } } }, "localname": "IndefiniteLivedIntangibleAssetsAccumulatedWriteOffs", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_IndefiniteLivedIntangibleAssetsIncludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "indefinite-lived intangible assets including goodwill", "label": "Indefinite-lived intangible assets, including goodwill", "terseLabel": "Indefinite-lived intangible assets, including goodwill" } } }, "localname": "IndefiniteLivedIntangibleAssetsIncludingGoodwill", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Initialinvestmentcashpaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "initial investment, cash paid", "label": "initial investment, cash paid", "terseLabel": "Total consideration for share purchase" } } }, "localname": "Initialinvestmentcashpaid", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_IntangibleAssetsAcquiredFiniteandIndefinitelived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intangible Assets Acquired, Finite and Indefinite-lived", "label": "Intangible Assets Acquired, Finite and Indefinite-lived", "terseLabel": "Intangible Assets Acquired, Finite and Indefinite-lived" } } }, "localname": "IntangibleAssetsAcquiredFiniteandIndefinitelived", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_InternationalRetirementPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "International retirement plans [Member]", "label": "International retirement plans [Member]", "terseLabel": "International retirement plans [Member]" } } }, "localname": "InternationalRetirementPlansMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "domainItemType" }, "bsx_InventoryStepUpAmortization": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventory Step Up Amortization", "label": "InventoryStepUpAmortization", "terseLabel": "Inventory step-up amortization" } } }, "localname": "InventoryStepUpAmortization", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_January2020NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "January 2020 Notes [Member]", "label": "January 2020 Notes [Member]", "terseLabel": "January 2020 Notes [Member]" } } }, "localname": "January2020NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_January2040NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "January 2040 Notes [Member]", "label": "January 2040 Notes [Member]", "terseLabel": "January 2040 Notes [Member]" } } }, "localname": "January2040NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_LatinAmericaandCanadaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Latin America and Canada [Member]", "label": "Latin America and Canada [Member]", "terseLabel": "Latin America and Canada [Member]" } } }, "localname": "LatinAmericaandCanadaMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "label": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "verboseLabel": "Legal payments remaining to be excluded from calculation of consolidated EBITDA" } } }, "localname": "LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LesseeOperatingandFinanceLeasesOptiontoExtend": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating and Finance Leases, Option to Extend", "label": "Lessee, Operating and Finance Leases, Option to Extend", "terseLabel": "Lessee, Operating and Finance Leases, Option to Extend" } } }, "localname": "LesseeOperatingandFinanceLeasesOptiontoExtend", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "durationStringItemType" }, "bsx_LesseeSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "label": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "terseLabel": "Lessee Supplemental Balance Sheet Information [Table Text Block]" } } }, "localname": "LesseeSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_Lesseeleasesnotyetcommencedamount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessee, leases not yet commenced, amount", "label": "Lessee, leases not yet commenced, amount", "terseLabel": "Lessee, leases not yet commenced, amount" } } }, "localname": "Lesseeleasesnotyetcommencedamount", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LicensingarrangementassetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Licensing arrangement assets [Member]", "label": "Licensing arrangement assets [Member]", "terseLabel": "Licensing arrangement assets [Member]" } } }, "localname": "LicensingarrangementassetsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_LicensingarrangementliabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Licensing arrangement liabilities [Member]", "label": "Licensing arrangement liabilities [Member]", "verboseLabel": "Licensing arrangement liabilities [Member]" } } }, "localname": "LicensingarrangementliabilitiesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_Licensingarrangements": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Licensing arrangements", "label": "Licensing arrangements", "terseLabel": "Licensing arrangements" } } }, "localname": "Licensingarrangements", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Licensingarrangementsasset": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Licensing arrangements, asset", "label": "Licensing arrangements, asset", "terseLabel": "Licensing arrangements, asset" } } }, "localname": "Licensingarrangementsasset", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Licensingarrangementsliability": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Licensing arrangements, liability", "label": "Licensing arrangements, liability", "terseLabel": "Other Liabilities", "verboseLabel": "Licensing arrangements, liability" } } }, "localname": "Licensingarrangementsliability", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LitigationAndDebtExclusionFromEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exclusion of litigation payments and any debt Issued to fund tax deficiency payments", "label": "Litigation and Debt Exclusion from EBITDA", "verboseLabel": "Amount of exclusions from EBITDA related to future litigation charges and payments" } } }, "localname": "LitigationAndDebtExclusionFromEbitda", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LitigationSettlementReceivedGain": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Litigation Settlement Received, Gain", "label": "Litigation Settlement Received, Gain", "terseLabel": "Litigation Settlement Received, Gain" } } }, "localname": "LitigationSettlementReceivedGain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_March2024NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2024 Notes [Member]", "label": "March 2024 Notes [Member]", "terseLabel": "March 2024 Notes [Member]" } } }, "localname": "March2024NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2026NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2026 Notes [Member]", "label": "March 2026 Notes [Member]", "terseLabel": "March 2026 Notes [Member]" } } }, "localname": "March2026NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2028NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2028 Notes [Member]", "label": "March 2028 Notes [Member]", "terseLabel": "March 2028 Notes [Member]" } } }, "localname": "March2028NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2029NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2029 Notes [Member]", "label": "March 2029 Notes [Member]", "terseLabel": "March 2029 Notes [Member]" } } }, "localname": "March2029NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2039NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2039 Notes [Member]", "label": "March 2039 Notes [Member]", "terseLabel": "March 2039 Notes [Member]" } } }, "localname": "March2039NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2049NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2049 Notes [Member]", "label": "March 2049 Notes [Member]", "terseLabel": "March 2049 Notes [Member]" } } }, "localname": "March2049NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_MarketBasedAwardsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Market-based awards, valuation assumptions [Table Text Block]", "label": "Market-based awards, valuation assumptions [Table Text Block]", "terseLabel": "Market-based awards, valuation assumptions [Table Text Block]" } } }, "localname": "MarketBasedAwardsValuationAssumptionsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "textBlockItemType" }, "bsx_MaturitiesofLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maturities of Lease Liabilities [Table Text Block]", "label": "Maturities of Lease Liabilities [Table Text Block]", "terseLabel": "Maturities of Lease Liabilities [Table Text Block]" } } }, "localname": "MaturitiesofLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_MaximumCommercialPaperOutstandingwith2018Facility": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum Commercial Paper Outstanding with 2018 Facility", "label": "Maximum Commercial Paper Outstanding with 2018 Facility", "terseLabel": "Maximum Commercial Paper Outstanding with 2018 Facility" } } }, "localname": "MaximumCommercialPaperOutstandingwith2018Facility", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_MaximumLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum leverage ratio permitted by revolving credit facility agreement.", "label": "Maximum Leverage Ratio" } } }, "localname": "MaximumLeverageRatio", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "pureItemType" }, "bsx_Maximumfuturecontingentconsiderationforacquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum future contingent consideration for acquisitions", "label": "Maximum future contingent consideration for acquisitions", "terseLabel": "Maximum future contingent consideration for acquisitions completed after January 1, 2009" } } }, "localname": "Maximumfuturecontingentconsiderationforacquisitions", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_May2020NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May 2020 Notes [Member]", "label": "May 2020 Notes [Member]", "terseLabel": "May 2020 Notes [Member]" } } }, "localname": "May2020NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_May2022NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May 2022 Notes [Member]", "label": "May 2022 Notes [Member]", "terseLabel": "May 2022 Notes [Member]" } } }, "localname": "May2022NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_May2025NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May 2025 Notes [Member]", "label": "May 2025 Notes [Member]", "terseLabel": "May 2025 Notes [Member]" } } }, "localname": "May2025NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_Measurementperiodmarketbasedaward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement period - market based awards", "label": "Measurement period - market based award", "terseLabel": "Measurement period - market based awards" } } }, "localname": "Measurementperiodmarketbasedaward", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "durationItemType" }, "bsx_MedsurgMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MedSurg [Member]", "label": "MedSurg [Member]", "terseLabel": "MedSurg [Member]" } } }, "localname": "MedsurgMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_MillipedeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Millipede [Member]", "label": "Millipede [Member]", "terseLabel": "Millipede [Member]" } } }, "localname": "MillipedeMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_NVisionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "nVision [Member]", "label": "nVision [Member]", "terseLabel": "nVision [Member]" } } }, "localname": "NVisionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_NetDeferredTaxLiabilitiesandPrepaidonIntercompanyProfit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Deferred Tax Liabilities and Prepaid on Intercompany Profit", "label": "Net Deferred Tax Liabilities and Prepaid on Intercompany Profit", "terseLabel": "Net Deferred Tax Liabilities and Prepaid on Intercompany Profit" } } }, "localname": "NetDeferredTaxLiabilitiesandPrepaidonIntercompanyProfit", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_NetForeignCurrencyGainLossTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Table Text Block] for Net foreign currency gain (loss) [Table]", "label": "Net foreign currency gain (loss) [Table Text Block]", "terseLabel": "Net foreign currency gain (loss) [Table Text Block]" } } }, "localname": "NetForeignCurrencyGainLossTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "bsx_NetGainLossFromForeignCurrencyTransactionExposures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net gain (loss) from foreign currency transaction exposures", "label": "Net gain (loss) from foreign currency transaction exposures", "terseLabel": "Net gain (loss) from foreign currency transaction exposures" } } }, "localname": "NetGainLossFromForeignCurrencyTransactionExposures", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_NetSettlementPaymenttoIRS": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Settlement Payment to IRS", "label": "Net Settlement Payment to IRS", "terseLabel": "Net Settlement Payment to IRS" } } }, "localname": "NetSettlementPaymenttoIRS", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Netcurrencyexchangegainloss": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net currency exchange gain (loss)", "label": "Net currency exchange gain (loss)", "negatedTerseLabel": "Exchange (gain) loss" } } }, "localname": "Netcurrencyexchangegainloss", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_NewAccountingPronouncementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "New Accounting Pronouncements [Abstract]", "label": "New Accounting Pronouncements [Abstract]" } } }, "localname": "NewAccountingPronouncementsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_Nonvestedstockawardsexerciseprice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-vested stock awards exercise price", "label": "Non-vested stock awards exercise price", "terseLabel": "Qualified options exercise price" } } }, "localname": "Nonvestedstockawardsexerciseprice", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "bsx_NotesReceivableFromPortfolioCompanies": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Notes Receivable From Portfolio Companies", "label": "Notes Receivable From Portfolio Companies", "terseLabel": "Notes receivable from portfolio companies", "verboseLabel": "Notes Receivable From Portfolio Companies" } } }, "localname": "NotesReceivableFromPortfolioCompanies", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_November2035NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "November 2035 Notes [Member]", "label": "November 2035 Notes [Member]", "terseLabel": "November 2035 Notes [Member]" } } }, "localname": "November2035NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_NxTheraMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NxThera [Member]", "label": "NxThera [Member]", "terseLabel": "NxThera [Member]" } } }, "localname": "NxTheraMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_October2018NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "October 2018 Notes [Member]", "label": "October 2018 Notes [Member]", "terseLabel": "October 2018 Notes [Member]" } } }, "localname": "October2018NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_October2023NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "October 2023 Notes [Member]", "label": "October 2023 Notes [Member]", "terseLabel": "October 2023 Notes [Member]" } } }, "localname": "October2023NotesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_Onetimetransactiontaxpost1986EP": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "One-time transaction tax post-1986 E&P", "label": "One-time transaction tax post-1986 E&P", "terseLabel": "One-time transaction tax post-1986 E&P" } } }, "localname": "Onetimetransactiontaxpost1986EP", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Onetimetransactiontaxpost1986EPnetpayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "One-time transaction tax post-1986 E&P - net payment", "label": "One-time transaction tax post-1986 E&P - net payment", "terseLabel": "One-time transaction tax post-1986 E&P - net payment" } } }, "localname": "Onetimetransactiontaxpost1986EPnetpayment", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OperatingIncomeUnallocatedToSegment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Income Unallocated to Segment", "label": "Operating Income Unallocated to Segment", "terseLabel": "Operating Income Unallocated to Segment" } } }, "localname": "OperatingIncomeUnallocatedToSegment", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OperatingleaseLiabilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease, Liability [Axis]", "label": "Operating lease, Liability [Axis]", "terseLabel": "Operating lease, Liability [Axis]" } } }, "localname": "OperatingleaseLiabilityAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "bsx_OperatingleaseLiabilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Operating lease, Liability [Axis]", "label": "Operating lease, Liability [Domain]", "terseLabel": "Operating lease, Liability [Domain]" } } }, "localname": "OperatingleaseLiabilityDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bsx_OperatingleaseliabilityotherlongtermliabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease, liability, other long-term liabilities [Member]", "label": "Operating lease, liability, other long-term liabilities [Member]", "terseLabel": "Operating lease, liability, other long-term liabilities [Member]" } } }, "localname": "OperatingleaseliabilityotherlongtermliabilitiesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bsx_OperatingleaserightofuseassetAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease, right-of-use asset [Axis]", "label": "Operating lease, right-of-use asset [Axis]", "terseLabel": "Operating lease, right-of-use asset [Axis]" } } }, "localname": "OperatingleaserightofuseassetAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "bsx_OperatingleaserightofuseassetDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Operating lease, right-of-use asset [Axis]", "label": "Operating lease, right-of-use asset [Domain]", "terseLabel": "Operating lease, right-of-use asset [Domain]" } } }, "localname": "OperatingleaserightofuseassetDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bsx_OperatingleaserightofuseassetsotherlongtermassetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease, right-of-use assets, other long-term assets [Member]", "label": "Operating lease, right-of-use assets, other long-term assets [Member]", "terseLabel": "Operating lease, right-of-use assets, other long-term assets [Member]" } } }, "localname": "OperatingleaserightofuseassetsotherlongtermassetsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "bsx_OptionsExpectedToVest": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Options expected to vest", "label": "Options expected to vest", "terseLabel": "Options expected to vest" } } }, "localname": "OptionsExpectedToVest", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "bsx_OptionsExpectedToVestWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Options expected to vest, weighted average exercise price", "label": "Options expected to vest, weighted average exercise price", "terseLabel": "Options expected to vest, weighted average exercise price" } } }, "localname": "OptionsExpectedToVestWeightedAverageExercisePrice", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "bsx_OptionsExpectedToVestWeightedAverageRemainingContractualLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Options expected to vest, weighted average remaining contractual life", "label": "Options expected to vest, weighted average remaining contractual life", "terseLabel": "Options expected to vest, weighted average remaining contractual life" } } }, "localname": "OptionsExpectedToVestWeightedAverageRemainingContractualLife", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "durationItemType" }, "bsx_Other2018AcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other 2018 Acquisitions - immaterial in the aggregate [Member]", "label": "Other 2018 Acquisitions [Member]", "terseLabel": "Other 2018 Acquisitions [Member]" } } }, "localname": "Other2018AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OtherCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other countries [Member]", "label": "Other countries [Member]", "terseLabel": "Other countries [Member]" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_OtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Current Assets [Abstract]", "label": "Other Current Assets [Abstract]", "terseLabel": "Other Current Assets [Abstract]" } } }, "localname": "OtherCurrentAssetsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "bsx_OtherIntangibleAssetsTextualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Intangible Assets (Textuals) [Abstract]", "label": "Other Intangible Assets (Textuals) [Abstract]", "terseLabel": "Other Intangible Assets (Textuals) [Abstract]" } } }, "localname": "OtherIntangibleAssetsTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "bsx_OtherInternationalPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other International Plans [Member]", "label": "Other International Plans [Member]", "terseLabel": "Other International Plans [Member]" } } }, "localname": "OtherInternationalPlansMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "bsx_Paymenttonetsharesettleemployeeequityawards": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment to net share settle employee equity awards", "label": "Payment to net share settle employee equity awards", "negatedTerseLabel": "Cash used to net share settle employee equity awards" } } }, "localname": "Paymenttonetsharesettleemployeeequityawards", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_Pensionbenefitobligationbenefitspaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "pension benefit obligation, benefits paid", "label": "pension benefit obligation, benefits paid", "negatedTerseLabel": "pension benefit obligation, benefits paid" } } }, "localname": "Pensionbenefitobligationbenefitspaid", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_PercentOfFinishedGoodsAtConsignment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percent of finished goods at consignment", "label": "Percent of finished goods at consignment", "terseLabel": "Percent of finished goods at consignment" } } }, "localname": "PercentOfFinishedGoodsAtConsignment", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "bsx_PotentialPaymentsBasedOnAcheivingCertainMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Potential payments based on acheiving certain milestones", "label": "Potential payments based on acheiving certain milestones", "terseLabel": "Potential payments based on acheiving certain milestones" } } }, "localname": "PotentialPaymentsBasedOnAcheivingCertainMilestones", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_PotentialReductionInUnrecognizedTaxBenefitsOverNextTwelveMonthsAsResultOfConcludingCertainMatters": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Potential reduction in unrecognized tax benefits over next 12 months as a result of concluding certain matters.", "label": "Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters", "terseLabel": "Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters" } } }, "localname": "PotentialReductionInUnrecognizedTaxBenefitsOverNextTwelveMonthsAsResultOfConcludingCertainMatters", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ProceedsFromDivestitureOfBusinessesNetOfCosts": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from divestiture of businesses, net of costs", "label": "Proceeds from divestiture of businesses, net of costs", "terseLabel": "Proceeds from divestiture of certain businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinessesNetOfCosts", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bsx_Proceedsfromsecuredborrowingsrelatingtoroyaltyarrangements": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from secured borrowings relating to royalty arrangements", "label": "Proceeds from secured borrowings relating to royalty arrangements", "terseLabel": "Proceeds from secured borrowings relating to royalty arrangements", "verboseLabel": "Proceeds from royalty rights transfer" } } }, "localname": "Proceedsfromsecuredborrowingsrelatingtoroyaltyarrangements", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Productliabilitycasesorclaimsrelatedtomeshproduct": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product liability cases or claims asserted related to mesh products", "label": "Product liability cases or claims related to mesh product", "terseLabel": "Product liability cases or claims related to mesh product" } } }, "localname": "Productliabilitycasesorclaimsrelatedtomeshproduct", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_ProductliabilitycasesorclaimsrelatedtomeshproductCanada": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product liability cases or claims related to mesh product - Canada", "label": "Product liability cases or claims related to mesh product - Canada", "terseLabel": "Product liability cases or claims in Canada, Mesh" } } }, "localname": "ProductliabilitycasesorclaimsrelatedtomeshproductCanada", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_ProductliabilitycasesorclaimsrelatedtomeshproductUnitedKingdom": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product liability cases or claims related to mesh product - United Kingdom", "label": "Product liability cases or claims related to mesh product - United Kingdom", "terseLabel": "Product liability cases or claims related to mesh product - United Kingdom" } } }, "localname": "ProductliabilitycasesorclaimsrelatedtomeshproductUnitedKingdom", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_ProductliabilitycasesorclaimsrelatedtomeshproductassignedtoonejudgeinstatecourtinMassachusetts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product liability cases or claims related to mesh product assigned to one judge in state court in Massachusetts", "label": "Product liability cases or claims related to mesh product assigned to one judge in state court in Massachusetts", "terseLabel": "Product liability cases or claims related to mesh product assigned to one judge in state court in Massachusetts" } } }, "localname": "ProductliabilitycasesorclaimsrelatedtomeshproductassignedtoonejudgeinstatecourtinMassachusetts", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_ProposedBTGAcquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Proposed BTG Acquisition [Member]", "label": "Proposed BTG Acquisition [Member]", "terseLabel": "Proposed BTG Acquisition [Member]" } } }, "localname": "ProposedBTGAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RDRegulatoryandCommercializationbasedMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "R&D, Regulatory and Commercialization-based Milestone [Member]", "label": "R&D, Regulatory and Commercialization-based Milestone [Member]", "terseLabel": "R&D, Regulatory and Commercialization-based Milestone [Member]" } } }, "localname": "RDRegulatoryandCommercializationbasedMilestoneMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RangeofRiskAdjustedDiscountRatesusedinPurchasePriceAllocation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Risk Adjusted Discount Rates used in Purchase Price Allocation", "label": "Range of Risk Adjusted Discount Rates used in Purchase Price Allocation", "terseLabel": "Range of Risk Adjusted Discount Rates used in Purchase Price Allocation" } } }, "localname": "RangeofRiskAdjustedDiscountRatesusedinPurchasePriceAllocation", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "percentItemType" }, "bsx_RangeofthetargetnumberofmarketbasedDSUsawarded": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of the target number of market-based DSUs awarded", "label": "Range of the target number of market-based DSUs awarded", "terseLabel": "Range of the target number of market-based DSUs awarded" } } }, "localname": "RangeofthetargetnumberofmarketbasedDSUsawarded", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_RangeofthetargetnumberofperformancebasedDSUsawarded": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of the target number of performance-based DSUs awarded", "label": "Range of the target number of performance-based DSUs awarded", "terseLabel": "Range of the target number of performance-based DSUs awarded" } } }, "localname": "RangeofthetargetnumberofperformancebasedDSUsawarded", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_ReconciliationOfDepreciationByReportableSegmentToTotalTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of depreciation by reportable segment to total [Table Text Block]", "label": "Reconciliation of depreciation by reportable segment to total [Table Text Block]", "terseLabel": "Reconciliation of depreciation by reportable segment to total [Table Text Block]" } } }, "localname": "ReconciliationOfDepreciationByReportableSegmentToTotalTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, fifth quarter following qualified acquisition [Member]", "label": "Requirement, fifth quarter following qualified acquisition [Member]", "terseLabel": "Requirement, fifth quarter following qualified acquisition [Member]" } } }, "localname": "RequirementfifthquarterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementfirsttwoquartersfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, first two quarters following qualified acquisition [Member]", "label": "Requirement, first two quarters following qualified acquisition [Member]", "terseLabel": "Requirement, first two quarters following qualified acquisition [Member]" } } }, "localname": "RequirementfirsttwoquartersfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementfourthquarterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, fourth quarter following qualified acquisition [Member]", "label": "Requirement, fourth quarter following qualified acquisition [Member]", "terseLabel": "Requirement, fourth quarter following qualified acquisition [Member]" } } }, "localname": "RequirementfourthquarterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementsixthquarterandthereafterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, sixth quarter and thereafter following qualified acquisition [Member]", "label": "Requirement, sixth quarter and thereafter following qualified acquisition [Member]", "terseLabel": "Requirement, sixth quarter and thereafter following qualified acquisition [Member]" } } }, "localname": "RequirementsixthquarterandthereafterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementthirdquarterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, third quarter following qualified acquisition [Member]", "label": "Requirement, third quarter following qualified acquisition [Member]", "terseLabel": "Requirement, third quarter following qualified acquisition [Member]" } } }, "localname": "RequirementthirdquarterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RestructuringAndRelatedCostByTypeOfRestructuringChargeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and Related Cost, by Type of Restructuring Three [Domain]", "label": "Restructuring and Related Cost, by Type of Restructuring Charge [Domain]", "terseLabel": "Restructuring and Related Cost, by Type of Restructuring Charge [Domain]" } } }, "localname": "RestructuringAndRelatedCostByTypeOfRestructuringChargeDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "domainItemType" }, "bsx_RestructuringAndRelatedCostByTypeOfRestructuringChargeExpectedAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and Related Cost, by Type of Restructuring Three [Axis]", "label": "Restructuring and Related Cost, by Type of Restructuring Charge Expected [Axis]", "terseLabel": "Restructuring and Related Cost, by Type of Restructuring Charge Expected [Axis]" } } }, "localname": "RestructuringAndRelatedCostByTypeOfRestructuringChargeExpectedAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "stringItemType" }, "bsx_RestructuringChargesIncurredToDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring Charges Incurred to Date", "label": "Restructuring Charges Incurred to Date", "terseLabel": "Restructuring Charges Incurred to Date" } } }, "localname": "RestructuringChargesIncurredToDate", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA.", "label": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "verboseLabel": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA" } } }, "localname": "RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_RestructuringPlanEstimatedFutureCashOutflow": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Restructuring plan estimated future cash outflow", "label": "Restructuring plan estimated future cash outflow", "terseLabel": "Restructuring plan estimated future cash outflow" } } }, "localname": "RestructuringPlanEstimatedFutureCashOutflow", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "bsx_RestructuringPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring Plan [Member]", "label": "Restructuring Plan [Member]", "terseLabel": "Restructuring Plan [Member]" } } }, "localname": "RestructuringPlanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "domainItemType" }, "bsx_RestructuringRelatedCostsIncurredToDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring-related Costs Incurred to Date", "label": "Restructuring-related Costs Incurred to Date", "terseLabel": "Restructuring-related Costs Incurred to Date" } } }, "localname": "RestructuringRelatedCostsIncurredToDate", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "bsx_RestructuringRelatedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring related expenses.", "label": "Restructuring Related Expenses", "terseLabel": "Restructuring Related Expenses" } } }, "localname": "RestructuringRelatedExpenses", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "bsx_RestructuringRelatedToPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring Related To Plan [Member]", "label": "Restructuring Related To Plan [Member]", "terseLabel": "Restructuring Related To Plan [Member]" } } }, "localname": "RestructuringRelatedToPlanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "domainItemType" }, "bsx_RestructuringandRelatedCostbyTypeofRestructuringChargeIncurredAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Axis]", "label": "Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Axis]", "terseLabel": "Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Axis]" } } }, "localname": "RestructuringandRelatedCostbyTypeofRestructuringChargeIncurredAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "stringItemType" }, "bsx_RestructuringandRelatedCostbyTypeofRestructuringChargeIncurredDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Axis]", "label": "Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Domain]", "terseLabel": "Restructuring and Related Cost, by Type of Restructuring Charge Incurred [Domain]" } } }, "localname": "RestructuringandRelatedCostbyTypeofRestructuringChargeIncurredDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "domainItemType" }, "bsx_RestructuringandRestructuringRelatedCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Restructuring and Restructuring-related Cost", "label": "Restructuring and Restructuring-Related Cost", "terseLabel": "Restructuring and Restructuring-Related Cost" } } }, "localname": "RestructuringandRestructuringRelatedCost", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "bsx_RestructuringandRestructuringrelatedCostExpectedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring and Restructuring-related Cost, Expected Cost", "label": "Restructuring and Restructuring-related Cost, Expected Cost", "terseLabel": "Restructuring and Restructuring-related Cost, Expected Cost" } } }, "localname": "RestructuringandRestructuringrelatedCostExpectedCost", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "bsx_RestructuringrelatedCostExpectedCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring-related Cost, Expected Cost", "label": "Restructuring-related Cost, Expected Cost", "terseLabel": "Restructuring-related Cost, Expected Cost" } } }, "localname": "RestructuringrelatedCostExpectedCost", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "bsx_RevenueBasedPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "revenue-based payments [Member]", "label": "revenue-based payments [Member]", "terseLabel": "revenue-based payments [Member]" } } }, "localname": "RevenueBasedPaymentsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RevenuebasedpaymentsbyvaluationtechniqueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue-based payments by valuation technique [Member]", "label": "Revenue-based payments by valuation technique [Member]", "terseLabel": "Revenue-based payments by valuation technique [Member]" } } }, "localname": "RevenuebasedpaymentsbyvaluationtechniqueMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_RhythmandNeuroMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rhythm and Neuro [Member]", "label": "Rhythm and Neuro [Member]", "terseLabel": "Rhythm and Neuro [Member]" } } }, "localname": "RhythmandNeuroMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_RollforwardOfAllowancesForDoubtfulAccountsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An element designated to encapsulate the entire schedule of allowances for doubtful accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period).", "label": "Rollforward Of Allowances For Doubtful Accounts [Text Block]", "verboseLabel": "Rollforward of allowances for doubtful accounts" } } }, "localname": "RollforwardOfAllowancesForDoubtfulAccountsTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "bsx_ScheduleofIncomeTaxRateReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Income Tax Rate Reconciliation [Table]", "label": "Schedule of Income Tax Rate Reconciliation [Line Items]", "terseLabel": "Schedule of Income Tax Rate Reconciliation [Line Items]" } } }, "localname": "ScheduleofIncomeTaxRateReconciliationLineItems", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "stringItemType" }, "bsx_ScheduleofIncomeTaxRateReconciliationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Income Tax Rate Reconciliation [Table]", "label": "Schedule of Income Tax Rate Reconciliation [Table]", "terseLabel": "Schedule of Income Tax Rate Reconciliation [Table]" } } }, "localname": "ScheduleofIncomeTaxRateReconciliationTable", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "stringItemType" }, "bsx_SegmentReportingTextualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Segment Reporting.", "label": "Segment Reporting (Textuals) [Abstract]", "verboseLabel": "Segment Reporting (Textuals) [Abstract]" } } }, "localname": "SegmentReportingTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "bsx_Segmentoperatingincomeaspercentageofnetsales": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales", "terseLabel": "TOTAL ASSETS" } } }, "localname": "Segmentoperatingincomeaspercentageofnetsales", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "percentItemType" }, "bsx_SegmentoperatingincomeaspercentageofnetsalesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Segment operating income as percentage of net sales", "label": "Segment operating income as percentage of net sales [Table Text Block]", "terseLabel": "Segment operating income as percentage of net sales [Table Text Block]" } } }, "localname": "SegmentoperatingincomeaspercentageofnetsalesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "bsx_SeniorNotedue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Note due 2027 [Member]", "label": "Senior Note due 2027 [Member]", "terseLabel": "Senior Note due 2027 [Member]" } } }, "localname": "SeniorNotedue2027Member", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "domainItemType" }, "bsx_Seniornotesissued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Senior notes issued", "label": "Senior notes issued", "terseLabel": "Senior notes issued" } } }, "localname": "Seniornotesissued", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ShareBasedCompensationNetOfTaxBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based compensation, net of tax benefit", "label": "Share-based compensation, net of tax benefit", "terseLabel": "Share-based compensation, net of tax benefit" } } }, "localname": "ShareBasedCompensationNetOfTaxBenefit", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingAggregateIntrinsicValue", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_SignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant Accounting Policies [Abstract]", "label": "Significant Accounting Policies [Abstract]" } } }, "localname": "SignificantAccountingPoliciesAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "bsx_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant Accounting Policies [Table]", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "bsx_SpecialChargesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Special Charges [Member]", "label": "Special Charges [Member]" } } }, "localname": "SpecialChargesMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_StatementOfOperationsCaptionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statement of Operations Caption [Axis]", "label": "Statement of Operations Caption [Axis]", "terseLabel": "Statement of Operations Caption [Axis]" } } }, "localname": "StatementOfOperationsCaptionAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "stringItemType" }, "bsx_StatementOfOperationsCaptionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statement of Operations Caption [Domain]", "label": "Statement of Operations Caption [Domain]", "terseLabel": "Statement of Operations Caption [Domain]" } } }, "localname": "StatementOfOperationsCaptionDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "domainItemType" }, "bsx_StockIncentiveandOwnershipPlansAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Incentive and Ownership Plans [Abstract]", "label": "Stock Incentive and Ownership Plans [Abstract]" } } }, "localname": "StockIncentiveandOwnershipPlansAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_SummaryOfComplianceWithDebtCovenantsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of compliance with debt covenants [Abstract].", "label": "Summary of compliance with debt covenants [Abstract]", "verboseLabel": "Summary of compliance with debt covenants" } } }, "localname": "SummaryOfComplianceWithDebtCovenantsAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of term loan and revolving credit facility agreement compliance with debt covenants.", "label": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]", "verboseLabel": "Summary of term loan and revolving credit facility agreement compliance with debt covenants" } } }, "localname": "SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "bsx_SupplementalBalanceSheetInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental Balance Sheet Information.", "label": "Supplemental Balance Sheet Information [Abstract]" } } }, "localname": "SupplementalBalanceSheetInformationAbstract", "nsuri": "http://www.bostonscientific.com/20191231", "xbrltype": "stringItemType" }, "bsx_SupplementalBalanceSheetInformationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental information related to various balance sheet items.", "label": "Supplemental Balance Sheet Information [Text Block]", "verboseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION" } } }, "localname": "SupplementalBalanceSheetInformationTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "bsx_SupplementalCashFlowInformationRelatedtoLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental Cash Flow Information Related to Leases [Table Text Block]", "label": "Supplemental Cash Flow Information Related to Leases [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information Related to Leases [Table Text Block]" } } }, "localname": "SupplementalCashFlowInformationRelatedtoLeasesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_SymetisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Symetis [Member]", "label": "Symetis [Member]", "terseLabel": "Symetis [Member]" } } }, "localname": "SymetisMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_TargetPayoutOfFreeCashFlowsFcfPerformanceAwards": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Target payout of Free Cash Flows (FCF) performance awards", "label": "Target payout of Free Cash Flows (FCF) performance awards", "terseLabel": "Target payout of Free Cash Flows (FCF) performance awards" } } }, "localname": "TargetPayoutOfFreeCashFlowsFcfPerformanceAwards", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_TaxCutsandJobsActIncompleteAccountingTransitionTaxforAccumulatedForeignEarningsProvisionalLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability", "terseLabel": "Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability" } } }, "localname": "TaxCutsandJobsActIncompleteAccountingTransitionTaxforAccumulatedForeignEarningsProvisionalLiability", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_TaxCutsandJobsActMeasurementPeriodAdjustmentIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)", "terseLabel": "TCJA benefit recognized" } } }, "localname": "TaxCutsandJobsActMeasurementPeriodAdjustmentIncomeTaxExpenseBenefit", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_TaxRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Rate [Axis]", "label": "Tax Rate [Axis]", "terseLabel": "Tax Rate [Axis]" } } }, "localname": "TaxRateAxis", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "stringItemType" }, "bsx_TaxRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Rate [Domain]", "label": "Tax Rate [Domain]", "terseLabel": "Tax Rate [Domain]" } } }, "localname": "TaxRateDomain", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "domainItemType" }, "bsx_TaxexpenseonstateincometaxesUSDEPaccumulated": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "tax expense on state income taxes, USD E&P accumulated", "label": "tax expense on state income taxes, USD E&P accumulated", "terseLabel": "tax expense on state income taxes, USD E&P accumulated" } } }, "localname": "TaxexpenseonstateincometaxesUSDEPaccumulated", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_TenderOfferMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Tender Offer [Member]", "label": "Tender Offer [Member]", "terseLabel": "Tender Offer [Member]" } } }, "localname": "TenderOfferMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_The2017FacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "the 2017 Facility [Member]", "label": "the 2017 Facility [Member]", "terseLabel": "the 2017 Facility [Member]" } } }, "localname": "The2017FacilityMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_The2018facilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "the 2018 facility [Member]", "label": "the 2018 facility [Member]", "terseLabel": "the 2018 facility [Member]" } } }, "localname": "The2018facilityMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_ThreeYearDelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three-Year Delayed Draw Term Loan [Member]", "label": "Three-Year Delayed Draw Term Loan [Member]", "terseLabel": "Three-Year Delayed Draw Term Loan [Member]" } } }, "localname": "ThreeYearDelayedDrawTermLoanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_TotalAllocatedToReportableSegmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total allocated to reportable segments [Member]", "label": "Total allocated to reportable segments [Member]", "terseLabel": "Total allocated to reportable segments [Member]" } } }, "localname": "TotalAllocatedToReportableSegmentsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_TotalProductliabilitycasesandclaimssettledrelatedtoMeshproduct": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Product liability cases and claims settled related to Mesh product", "label": "Total Product liability cases and claims settled related to Mesh product", "terseLabel": "Total Product liability cases and claims settled related to Mesh product" } } }, "localname": "TotalProductliabilitycasesandclaimssettledrelatedtoMeshproduct", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_TransferCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Transfer Costs", "label": "Transfer Costs", "terseLabel": "Transfer Costs" } } }, "localname": "TransferCosts", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "bsx_TransferCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transfer costs [Member].", "label": "Transfer costs [Member]", "terseLabel": "Transfer costs [Member]" } } }, "localname": "TransferCostsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "domainItemType" }, "bsx_Transitiontaxpaymentremaining": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "transition tax payment remaining", "label": "transition tax payment remaining", "terseLabel": "transition tax payment remaining" } } }, "localname": "Transitiontaxpaymentremaining", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_TwoYearDelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-Year Delayed Draw Term Loan [Member]", "label": "Two-Year Delayed Draw Term Loan [Member]", "terseLabel": "Two-Year Delayed Draw Term Loan [Member]" } } }, "localname": "TwoYearDelayedDrawTermLoanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_U.K.PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "U.K. Plan [Member]", "label": "U.K. Plan [Member]", "terseLabel": "U.K. Plan [Member]" } } }, "localname": "U.K.PlanMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "domainItemType" }, "bsx_UnrecognizedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Compensation Cost", "label": "Unrecognized Compensation Cost", "terseLabel": "Unrecognized Compensation Cost" } } }, "localname": "UnrecognizedCompensationCost", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_UnrecognizedCompensationCostNonVestedStockAwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Compensation Cost - Non-vested stock awards", "label": "Unrecognized Compensation Cost - Non-vested stock awards", "terseLabel": "Unrecognized Compensation Cost - Non-vested stock awards" } } }, "localname": "UnrecognizedCompensationCostNonVestedStockAwards", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_UnrecognizedCompensationCostStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Compensation Cost - Stock Options", "label": "Unrecognized Compensation Cost - Stock Options", "terseLabel": "Unrecognized Compensation Cost - Stock Options" } } }, "localname": "UnrecognizedCompensationCostStockOptions", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "bsx_VertiflexInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vertiflex, Inc.", "label": "Vertiflex, Inc. [Member]", "terseLabel": "Vertiflex, Inc. [Member]" } } }, "localname": "VertiflexInc.Member", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "bsx_Votingpowerofallclassesofstock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "voting power of all classes of stock", "label": "voting power of all classes of stock", "terseLabel": "voting power of all classes of stock" } } }, "localname": "Votingpowerofallclassesofstock", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "bsx_WeightedAverageMaturityDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Maturity, Days", "label": "Weighted Average Maturity, Days", "terseLabel": "Weighted Average Maturity, Days" } } }, "localname": "WeightedAverageMaturityDays", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "durationStringItemType" }, "bsx_WeightedAverageRemainingVestingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "weighted average remaining vesting period", "label": "weighted average remaining vesting period", "terseLabel": "weighted average remaining vesting period" } } }, "localname": "WeightedAverageRemainingVestingPeriod", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "durationItemType" }, "bsx_YenDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Yen denominated factoring arrangements.", "label": "Yen Denominated Factoring Arrangements [Member]", "terseLabel": "Yen Denominated Factoring Arrangements [Member]" } } }, "localname": "YenDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20191231", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "country_IE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "IRELAND", "terseLabel": "IRELAND" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]", "verboseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro Member Countries, Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2017-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r635" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r634" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r636" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r636" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r636" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r637" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingParValuePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.", "label": "Entity Listing, Par Value Per Share", "terseLabel": "Entity Listing, Par Value Per Share" } } }, "localname": "EntityListingParValuePerShare", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "perShareItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r636" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r636" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r636" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r636" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r632" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r633" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "tradingSymbolItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r638" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount", "verboseLabel": "Notional Amount of Interest Rate Derivatives" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "invest_InvestmentTableTextBlock": { "auth_ref": [ "r639" ], "lang": { "en-US": { "role": { "documentation": "A table of investments, shown as a text block.", "label": "Investment [Table Text Block]", "terseLabel": "Investment [Table Text Block]" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region of Asia Pacific.", "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r184", "r196" ], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by currency.", "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of investment, including named security. Excludes consolidated entity.", "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r202", "r303", "r308" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]", "verboseLabel": "High end of range [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r199", "r303", "r306", "r625" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by range, including, but not limited to, upper and lower bounds.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extent of variation, for example, but not limited to, upper and lower bounds.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables", "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Information by name of investment, including named security. Excludes consolidated entity.", "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r145", "r642" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIi" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r201", "r303", "r307", "r628", "r631", "r640", "r641" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Entity-Wide Disclosure on Geographic Areas, Revenue from External Customers Attributed to Individual Foreign Countries [Axis]", "verboseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2018-01-31", "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average of a range of values, calculated with consideration of proportional relevance.", "label": "Weighted Average [Member]", "terseLabel": "Weighted Average [Member]" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r565" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201609Member": { "auth_ref": [ "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.", "label": "Accounting Standards Update 2016-09 [Member]", "terseLabel": "Accounting Standards Update 2016-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201609Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201616Member": { "auth_ref": [ "r450", "r451" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.", "label": "Accounting Standards Update 2016-16 [Member]", "terseLabel": "Accounting Standards Update 2016-16 [Member]" } } }, "localname": "AccountingStandardsUpdate201616Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate of amounts due from customers or clients, within one year of the balance sheet date (or one operating cycle, if longer), for goods or services that have been delivered or sold in the normal course of business and an amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date within one year of the balance sheet, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection and net of any write-downs taken for collection uncertainty on the part of the holder, respectively.", "label": "Accounts, Notes, Loans and Financing Receivable, Net, Current", "terseLabel": "Accounts, Notes, Loans and Financing Receivable, Net, Current", "totalLabel": "Trade accounts receivable, net", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]", "terseLabel": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r31", "r610" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.", "label": "Accounts Receivable, Gross, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounts Receivable, Net [Abstract]", "terseLabel": "Accounts Receivable, Net [Abstract]" } } }, "localname": "AccountsReceivableNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r25", "r596", "r613" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "negatedTerseLabel": "Accrued Liabilities, Current", "totalLabel": "Accrued expenses", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r10", "r12", "r49" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Licensing arrangements, liability" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r246" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax": { "auth_ref": [ "r72", "r77", "r79" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax", "terseLabel": "Unrealized gain (loss) on derivative financial instruments" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r75", "r80" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedLabel": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedTerseLabel": "Unrealized costs associated with defined benefit pensions and other items" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r70", "r77", "r79", "r80", "r550", "r553" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r77", "r79", "r80" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Accumulated other comprehensive income (loss), net of tax:" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r76", "r80", "r83", "r489" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Acquired Finite-lived Intangible Asset, Weighted Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r32" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of adjustments to net income or loss necessary to remove the effects of all items whose cash effects are investing or financing cash flows. The aggregate amount also includes all noncash expenses and income items which reduce or increase net income and are thus added back or deducted when calculating cash provided by or used in operating activities.", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "terseLabel": "Other, net" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to cash provided by operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r182" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "Other Segments [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r60", "r205" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "negatedLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r122", "r227", "r237" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization expense", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "terseLabel": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r188", "r593", "r612" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r67" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r532" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Member]", "terseLabel": "Assets [Member]" } } }, "localname": "AssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r368", "r395" ], "lang": { "en-US": { "role": { "documentation": "Information by date or year of grant, pertaining to equity-based compensation arrangements.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r368", "r395" ], "lang": { "en-US": { "role": { "documentation": "Date or year of grant of equity-based compensation.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r368", "r395" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r501", "r507" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BorrowingsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Obligations to pay to another in accordance with an expressed or implied agreement.", "label": "Borrowings [Member]", "terseLabel": "Borrowings [Member]" } } }, "localname": "BorrowingsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r8", "r245" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r466", "r467" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]", "verboseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r464", "r465" ], "lang": { "en-US": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Business Acquisition, Pro Forma Earnings Per Share, Basic" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r464", "r465" ], "lang": { "en-US": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Business Acquisition, Pro Forma Earnings Per Share, Diluted" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r464", "r465" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business Acquisition, Pro Forma Information [Table Text Block]" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Business Acquisition, Share Price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r464", "r465" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r464", "r465" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Business Acquisition, Pro Forma Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "auth_ref": [ "r461", "r478" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination", "terseLabel": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination", "verboseLabel": "Total" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r121", "r482" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration expense (benefit)" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r481" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r481" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationAsset": { "auth_ref": [ "r475", "r476", "r480" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Asset", "terseLabel": "Business Combination, Contingent Consideration, Asset" } } }, "localname": "BusinessCombinationContingentConsiderationAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r474", "r476", "r480" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r474", "r477" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Accrued contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r474", "r477" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Accrued contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r483" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "verboseLabel": "ACQUISITIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "auth_ref": [ "r471" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r421", "r469" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r469" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "verboseLabel": "Indefinite-lived intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r468", "r469" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r469" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r469" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r462" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r463" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r133", "r459" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations Policy [Policy Text Block]" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r563" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]", "terseLabel": "Capital Lease Obligations [Member]" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash Acquired from Acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r37", "r124" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r16", "r126", "r133", "r204", "r591" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r115", "r124", "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r115", "r549" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r497" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/CoverDocumentDocument", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r20", "r594", "r615" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "Commercial Paper", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r266", "r602", "r619" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r265", "r277" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.bostonscientific.com/role/CoverDocumentDocument" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance (Shares)", "periodStartLabel": "Balance (Shares)", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r30", "r289" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r30" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,642,488,911 shares as of December 31, 2019 and 1,632,148,030 shares as of December 31, 2018" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r319", "r322", "r364", "r410" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r86", "r88", "r486", "r492" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Comprehensive Income (Loss) Note [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r171", "r172", "r544", "r545", "r627" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk By Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCustomer": { "auth_ref": [ "r169", "r170", "r172" ], "lang": { "en-US": { "role": { "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures).", "label": "Concentration Risk, Customer", "terseLabel": "Concentration Risk, Customer" } } }, "localname": "ConcentrationRiskCustomer", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration Risk Disclosure [Text Block]" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r171", "r172", "r544", "r545" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r245" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Capital in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "auth_ref": [ "r303", "r309" ], "lang": { "en-US": { "role": { "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.", "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing [Axis]" } } }, "localname": "ContractWithCustomerBasisOfPricingAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.", "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing [Domain]" } } }, "localname": "ContractWithCustomerBasisOfPricingDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerDurationAxis": { "auth_ref": [ "r303", "r310" ], "lang": { "en-US": { "role": { "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Axis]", "terseLabel": "Contract with Customer, Duration [Axis]" } } }, "localname": "ContractWithCustomerDurationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerDurationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Domain]", "terseLabel": "Contract with Customer, Duration [Domain]" } } }, "localname": "ContractWithCustomerDurationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r299", "r300", "r304" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract with Customer, Liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r305" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r303", "r312" ], "lang": { "en-US": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostMethodInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments.", "label": "Cost Method Investments", "terseLabel": "Cost Method Investments" } } }, "localname": "CostMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r94" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold", "verboseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "auth_ref": [ "r133", "r257", "r258", "r263" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.", "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "terseLabel": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative Effect of New Accounting Principle in Period of Adoption", "verboseLabel": "Cumulative effect adjustment for ASU Adoptions(1)" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease": { "auth_ref": [ "r551" ], "lang": { "en-US": { "role": { "documentation": "The increase (decrease) in cumulative translation adjustment before transfers included in determining net income.", "label": "Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)", "terseLabel": "Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)" } } }, "localname": "CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r135", "r447", "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Current Federal Tax Expense (Benefit)" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r139", "r449" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Current Foreign Tax Expense (Benefit)" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r447", "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "terseLabel": "Current Income Tax Expense (Benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r135", "r447", "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "Current State and Local Tax Expense (Benefit)" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r601", "r621" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.", "label": "Debt and Capital Lease Obligations", "terseLabel": "Total debt" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Debt, Current", "verboseLabel": "Current debt obligations" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "BORROWINGS AND CREDIT ARRANGEMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r23", "r24", "r595", "r598", "r609" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r51", "r556" ], "lang": { "en-US": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "terseLabel": "Line of Credit Facility, Description" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "negatedTerseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r606" ], "lang": { "en-US": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Debt Instrument, Redemption, Period Three [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r606" ], "lang": { "en-US": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Debt Instrument, Redemption, Period Two [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r136", "r290", "r291", "r292", "r293", "r555", "r556", "r558", "r607" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r284", "r557" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]", "terseLabel": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r448", "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Deferred Federal Income Tax Expense (Benefit)" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r448", "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Deferred Foreign Income Tax Expense (Benefit)" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r122", "r135", "r448", "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r26", "r27", "r438", "r597", "r608" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "terseLabel": "Deferred Tax Liabilities, Gross" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r11" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue, Current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r448", "r453" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Deferred State and Local Income Tax Expense (Benefit)" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory": { "auth_ref": [ "r445" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from intra-entity transfer of asset within consolidated group. Excludes intra-entity transfer of inventory.", "label": "Deferred Tax Asset, Intra-entity Transfer, Asset Other than Inventory", "terseLabel": "Deferred Tax Asset, Intra-entity Transfer, Asset Other than Inventory" } } }, "localname": "DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Deferred Tax Assets, Goodwill and Intangible Assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r416", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Deferred Tax Assets, Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent": { "auth_ref": [ "r421", "r423", "r442" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, netted by jurisdiction and classified as current.", "label": "Deferred Tax Assets, Net, Current", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r440" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetCurrent": { "auth_ref": [ "r421", "r422", "r423", "r424", "r439" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as current.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Current", "terseLabel": "Deferred Tax Assets, Net, Current", "verboseLabel": "Prepaid income taxes" } } }, "localname": "DeferredTaxAssetsNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetNoncurrent": { "auth_ref": [ "r421", "r422", "r423", "r424", "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Noncurrent", "terseLabel": "Deferred Tax Assets, Net, Noncurrent" } } }, "localname": "DeferredTaxAssetsNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r414", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r414", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r414", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r416", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Deferred Tax Assets, Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r414", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r415", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r414", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": { "auth_ref": [ "r414", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": { "auth_ref": [ "r414", "r445", "r446" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges", "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r441" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r423", "r442" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Deferred Tax Liabilities, Net" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "auth_ref": [ "r415", "r445", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.", "label": "Deferred Tax Liabilities, Inventory", "terseLabel": "Deferred Tax Liabilities, Inventory" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDerivatives": { "auth_ref": [ "r445", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from derivatives.", "label": "Deferred Tax Liabilities, Derivatives", "terseLabel": "Deferred Tax Liabilities, Derivatives" } } }, "localname": "DeferredTaxLiabilitiesDerivatives", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r416", "r445", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "terseLabel": "Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r421", "r423", "r424" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "negatedLabel": "Deferred Tax Liabilities, Noncurrent", "negatedTerseLabel": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred tax liabilities", "verboseLabel": "Deferred Tax Liabilities, Noncurrent" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r416", "r445", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Deferred Tax Liabilities, Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r416", "r445", "r446" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Deferred Tax Liabilities, Property, Plant and Equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Defined Benefit Plan, Accumulated Benefit Obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r333", "r358" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r328" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": { "auth_ref": [ "r323", "r338" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position", "terseLabel": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r19", "r323", "r324", "r338", "r592", "r611" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Assets for Plan Benefits, Defined Benefit Plan" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r346" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Executive Retirement Plan Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Executive Retirement Plan Rate of Compensation Increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r330", "r361" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r340", "r341", "r349", "r358" ], "lang": { "en-US": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCashMember": { "auth_ref": [ "r340", "r341", "r358" ], "lang": { "en-US": { "role": { "documentation": "Cash in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash [Member]", "terseLabel": "Defined Benefit Plan, Cash [Member]" } } }, "localname": "DefinedBenefitPlanCashMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r335", "r340", "r341", "r357", "r358" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r332", "r340", "r341", "r358" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "terseLabel": "Defined Benefit Plan, Plan Assets, Amount" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r329" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "verboseLabel": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r323", "r338" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Defined Benefit Plan, Funded (Unfunded) Status of Plan" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r327", "r344", "r356", "r358" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Defined Benefit Plan, Interest Cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r331" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r337", "r361" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Benefits Paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r334" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r326", "r343", "r355", "r358" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Defined Benefit Plan, Service Cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r350", "r351", "r353", "r354", "r358" ], "lang": { "en-US": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r122", "r244" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "negatedTerseLabel": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r122", "r186" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding": { "auth_ref": [ "r585" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transferred financial assets in which the transferor has continuing involvement with the assets underlying the transaction that have been derecognized. Continuing involvement includes, but is not limited to, servicing, recourse, and restrictions on transferor's interests in transferred financial assets.", "label": "Continuing Involvement with Derecognized Transferred Financial Assets, Amount Outstanding", "verboseLabel": "De-recognized receivables" } } }, "localname": "DerecognizedAssetsSecuritizedOrAssetbackedFinancingArrangementAssetsAndAnyOtherFinancialAssetsManagedTogetherPrincipalAmountOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r68", "r69", "r542" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative Asset, Current" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "verboseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r502", "r505", "r514", "r523" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "verboseLabel": "Derivative Instrument Risk [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r499", "r502", "r514" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value" } } }, "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value" } } }, "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "auth_ref": [ "r506" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r513", "r515" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "auth_ref": [ "r506" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r68", "r69", "r542" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "verboseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r503" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Loss on Derivative", "terseLabel": "Derivative, Loss on Derivative" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r133", "r142", "r494", "r495", "r499", "r500", "r526" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives, Policy [Policy Text Block]", "verboseLabel": "ASC Topic 815, Derivatives and Hedging" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AccountingPoliciesPolicies", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted": { "auth_ref": [ "r152" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.", "label": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]", "terseLabel": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]" } } }, "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncements", "http://www.bostonscientific.com/role/NewAccountingPronouncementsNewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r499" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.", "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]", "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]" } } }, "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueTables" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r297", "r410" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r122", "r243", "r248" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedTerseLabel": "Gain on sale of businesses" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan [Member]" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r92", "r149", "r155", "r156", "r157", "r158", "r162", "r604", "r623" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net income (loss) per common share \u2014 basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r92", "r149", "r155", "r156", "r157", "r158", "r162", "r604", "r623" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net income (loss) per common share \u2014 assuming dilution" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r133", "r159", "r160", "r161" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r549" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r138", "r425", "r426" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Reported tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Other Adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to excess tax benefit for share-based compensation cost.", "label": "Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Percent", "terseLabel": "effective income tax reconciliation, compensation-related" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r425", "r426", "r452" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Tax Credits, Research" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r393" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.", "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "negatedTerseLabel": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": { "auth_ref": [ "r409" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of plan compensation cost recognized during the period.", "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense", "terseLabel": "Employee Stock Ownership Plan (ESOP), Compensation Expense" } } }, "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan.", "label": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased", "terseLabel": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased" } } }, "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityAndCostMethodInvestmentsPolicy": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated domestic subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. Additionally, this element describes the entity's application of the cost method to equity investments or other interests that are not consolidated or accounted for under the equity method of accounting. The disclosure provided may include how equity method or cost investments are assessed for impairment.", "label": "Equity and Cost Method Investments, Policy [Policy Text Block]", "terseLabel": "Equity and Cost Method Investments, Policy [Policy Text Block]" } } }, "localname": "EquityAndCostMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [ "r209" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r38", "r189", "r207" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r531", "r532", "r533", "r534", "r539", "r540" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r536", "r540" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r532", "r540" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r532", "r543" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "verboseLabel": "Classification of derivative assets and liabilities within level 2" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r340", "r341", "r358", "r533", "r581" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r538", "r540" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Fair Value by Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r541" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r340", "r341", "r358", "r533", "r582" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r340", "r341", "r358", "r533", "r583" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r340", "r341", "r358", "r533", "r584" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r536", "r540" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation, by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r536", "r540" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r531", "r538" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "verboseLabel": "ASC Topic 820, Fair Value Measurements and Disclosures" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r537" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "terseLabel": "Fair value of contingent consideration recorded in purchase accounting", "verboseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r531", "r538" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r128", "r129", "r130" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Fair Value of Assets Acquired", "terseLabel": "Fair Value of Assets Acquired" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r575", "r578" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r236" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Future Amortization Expense, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Future Amortization Expense, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Future Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Future Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Future Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r228", "r232", "r236", "r240", "r589" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r236", "r589" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r228", "r235" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-Lived Intangible Assets [Member]", "terseLabel": "Finite-Lived Intangible Assets [Member]" } } }, "localname": "FiniteLivedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r229" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r530" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "verboseLabel": "Foreign Currency Contract, Asset, Fair Value Disclosure" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Foreign Currency Contracts, Liability, Fair Value Disclosure" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r546", "r547", "r548" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Realized", "terseLabel": "Foreign Currency Transaction Gain (Loss), Realized" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r133", "r548", "r553" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r340", "r520" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "verboseLabel": "Foreign Exchange Contract [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r518" ], "lang": { "en-US": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts [Member]" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet": { "auth_ref": [ "r512" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness.", "label": "Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net", "terseLabel": "Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net" } } }, "localname": "GainLossOnCashFlowHedgeIneffectivenessNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r502", "r513" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r97", "r122", "r206" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedTerseLabel": "Net loss (gain) on investments and notes receivable" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r122", "r286", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Gain (Loss) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r216", "r217" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 2.0, "parentTag": "us-gaap_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r133", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r133", "r233" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r218", "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill, Gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r218", "r223" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Goodwill, Period Increase (Decrease)" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r222", "r460" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r221", "r222", "r460" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "terseLabel": "Goodwill, Translation and Purchase Accounting Adjustments" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r220" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedLabel": "Other intangible asset charges" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r93" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r499", "r524" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r499" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r499" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r122", "r241" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Intangible asset impairment charges", "verboseLabel": "Impairment of Intangible Assets (Excluding Goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r122", "r241" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Intangible asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r42", "r133", "r412" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "In Process Research and Development, Policy [Policy Text Block]" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r137" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r91", "r149", "r590", "r603", "r624" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r137" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]", "verboseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]", "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear": { "auth_ref": [ "r435" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount the liability recorded for the income tax examination increased or decreased in the current year/accounting period.", "label": "Income Tax Examination, Increase (Decrease) in Liability from Prior Year", "terseLabel": "Gross interest and penalties recognized in period" } } }, "localname": "IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Income Tax Examination, Penalties and Interest Accrued" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.", "label": "Income Tax Examination, Penalties and Interest Expense", "negatedTerseLabel": "Income Tax Examination, Penalties and Interest Expense" } } }, "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r187", "r455" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Income Tax Expense (Benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r133", "r419", "r420", "r436", "r437", "r443", "r457", "r630" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r118", "r127" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "negatedTerseLabel": "Income Taxes Paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r58", "r600", "r622" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income Taxes Receivable, Current" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r121" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r121" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).", "label": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option", "terseLabel": "Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option" } } }, "localname": "IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r121" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Increase (decrease) in operating assets and liabilities, net of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilities": { "auth_ref": [ "r121" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.", "label": "Increase (Decrease) in Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r121" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r231", "r239" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r231", "r239" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite Lived Intangible Assets Major Class Name [Domain]", "verboseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived Intangible Assets Acquired" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "Information about effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Axis]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effect of transition method for cumulative effect in initial period of application.", "label": "Initial Application Period Cumulative Effect Transition [Domain]", "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]" } } }, "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r226", "r234" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 3.0, "parentTag": "us-gaap_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r90", "r185", "r554", "r557", "r605" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r522" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r111", "r117", "r127" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r530" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r340", "r519" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract [Member]" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r519" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r64", "r212" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, Net", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory, Net [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r65", "r133", "r164", "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r620" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r7", "r40" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r576" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r564", "r579" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases of Lessee Disclosure [Text Block]" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r132", "r133", "r276" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs, Policy [Policy Text Block]" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AccountingPoliciesPolicies", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r569" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r571" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r577" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r570" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of Credit Outstanding, Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r34", "r599", "r617" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "verboseLabel": "Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liability [Member]", "terseLabel": "Liability [Member]" } } }, "localname": "LiabilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r24", "r598", "r609" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r46", "r136" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "auth_ref": [ "r46" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate during the reporting period.", "label": "Line of Credit Facility, Interest Rate During Period", "terseLabel": "Current interest rate on revolving credit facility" } } }, "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r46" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "verboseLabel": "Revolving credit facility" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r54", "r266", "r275" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Estimated Litigation Liability, Current", "terseLabel": "Legal reserves" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveNoncurrent": { "auth_ref": [ "r54", "r266" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.", "label": "Estimated Litigation Liability, Noncurrent", "terseLabel": "Legal reserves" } } }, "localname": "LitigationReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation-related charges (credits)" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r24", "r285", "r598", "r615" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "negatedLabel": "Payments due, Total", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r24" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Long-term Debt and Capital Lease Obligations", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table Text Block]", "terseLabel": "Long-term Purchase Commitment [Table Text Block]" } } }, "localname": "LongTermPurchaseCommitmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r283" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r266", "r267", "r268", "r270", "r271", "r272", "r274", "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r266", "r267", "r268", "r270", "r271", "r272", "r274", "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "verboseLabel": "Accrual for legal matters that are probable and estimable" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r266", "r269", "r273" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesPaidValue": { "auth_ref": [ "r266", "r269", "r273" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of damages paid to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Paid, Value", "terseLabel": "Loss Contingency, Damages Paid, Value" } } }, "localname": "LossContingencyDamagesPaidValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r266", "r267", "r268", "r270", "r271", "r272", "r274", "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money Market Funds, at Carrying Value" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r115" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash provided by (used for) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r115" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash provided by (used for) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r115", "r119", "r123" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash provided by (used for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r498" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging [Member]" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement [Member]" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1": { "auth_ref": [ "r147", "r150", "r151" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.", "label": "New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets", "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.", "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification", "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r200" ], "calculation": { "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "totalLabel": "Long-Lived Assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r499" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "verboseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)", "verboseLabel": "Operating income allocated to reportable segments" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r567" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r567" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Total leased assets" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r567" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r568", "r572" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r566" ], "calculation": { "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 4.0, "parentTag": "us-gaap_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r574", "r578" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r559", "r561" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Operating Leases, Future Minimum Payments Due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r559", "r561" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r559", "r561" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r559", "r561" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r559", "r561" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r559", "r561" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Next Rolling Twelve Months", "terseLabel": "Leases, Future Minimum Payments Due, Next Twelve Months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r560" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Rent Expense, Net" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r493" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r12", "r13", "r49" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other Accrued Liabilities, Current" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 6.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other Assets, Current" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r501", "r528" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets [Member]" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Current", "terseLabel": "Other Assets, Miscellaneous, Current" } } }, "localname": "OtherAssetsMiscellaneousCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Noncurrent", "terseLabel": "Other Assets, Miscellaneous, Noncurrent" } } }, "localname": "OtherAssetsMiscellaneousNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other Assets, Noncurrent", "verboseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other Assets, Noncurrent [Abstract]" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": { "auth_ref": [ "r77", "r81", "r82", "r345" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r74" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Net change in available-for-sale securities", "verboseLabel": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r80", "r89" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r72", "r77" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Net change in derivative financial instruments" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r72", "r77" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r72", "r77", "r504", "r509", "r529" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r77", "r81" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r77", "r81", "r511" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "auth_ref": [ "r73", "r77", "r510", "r529" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax": { "auth_ref": [ "r73", "r77", "r510", "r529" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": { "auth_ref": [ "r72" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax", "verboseLabel": "Net change in derivative financial instruments" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r70", "r552" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r516" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r517" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r85", "r88", "r89", "r289" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other Comprehensive Income (Loss), Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r75", "r77" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r75", "r77" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Net change in defined benefit pensions and other items", "terseLabel": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax", "verboseLabel": "Defined benefit pensions and other items" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax": { "auth_ref": [ "r77", "r81", "r82" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities.", "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax", "terseLabel": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r78", "r454", "r456" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "terseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r74", "r77" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherContractMember": { "auth_ref": [ "r340", "r521" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is classified as other.", "label": "Other Contract [Member]", "terseLabel": "Other Contract [Member]" } } }, "localname": "OtherContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r501", "r528" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Other Current Liabilities [Table Text Block]" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r49" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other Liabilities, Current [Abstract]" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Liabilities, Noncurrent", "totalLabel": "Other long-term liabilities", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "terseLabel": "Other Liabilities, Noncurrent [Abstract]" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r99" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r122", "r251", "r258", "r261" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other Restructuring Costs" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other Restructuring [Member]" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": { "auth_ref": [ "r128", "r129", "r130" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Value of Consideration Given", "terseLabel": "Other Significant Noncash Transaction, Value of Consideration Given" } } }, "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r49", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other Sundry Liabilities, Current" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r473" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r112" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedTerseLabel": "Payment of contingent consideration in excess of amount recognized at acquisition" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForHedgeInvestingActivities": { "auth_ref": [ "r106", "r120" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Payments for Hedge, Investing Activities", "negatedTerseLabel": "Payments for settlements of hedge contracts" } } }, "localname": "PaymentsForHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromPreviousAcquisition": { "auth_ref": [ "r143" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.", "label": "Payments for (Proceeds from) Previous Acquisition", "negatedTerseLabel": "Payment of contingent consideration and royalty rights previously established in purchase accounting" } } }, "localname": "PaymentsForProceedsFromPreviousAcquisition", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r113", "r253" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r104", "r479" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r104" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Payments for acquisitions of businesses, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r106" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payments for investments and acquisitions of certain technologies" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r105" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": { "auth_ref": [ "r133", "r350", "r359", "r362", "r363" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]", "terseLabel": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]" } } }, "localname": "PensionAndOtherPostretirementPlansPensionsPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies", "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "auth_ref": [ "r133", "r350", "r359", "r360", "r362", "r363" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "terseLabel": "Pension and Other Postretirement Plans, Policy [Policy Text Block]" } } }, "localname": "PensionAndOtherPostretirementPlansPolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r368", "r395" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r35", "r36" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from Divestiture of Businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "auth_ref": [ "r119", "r127" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.", "label": "Proceeds from Income Tax Refunds", "terseLabel": "Cash (received) paid for income taxes, net" } } }, "localname": "ProceedsFromIncomeTaxRefunds", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r107" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuances of shares of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": { "auth_ref": [ "r108" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with security instrument that either represents a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes proceeds from (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).", "label": "Proceeds from Issuance of Long-term Debt and Capital Securities, Net", "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r109" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from borrowings on credit facilities" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "auth_ref": [ "r109", "r110", "r125" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.", "label": "Proceeds from (Repayments of) Commercial Paper", "terseLabel": "Net increase (decrease) in commercial paper" } } }, "localname": "ProceedsFromRepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRoyaltiesReceived": { "auth_ref": [ "r116" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received for royalties during the current period.", "label": "Proceeds from Royalties Received", "terseLabel": "Proceeds from royalty rights", "verboseLabel": "Proceeds from Royalties Received" } } }, "localname": "ProceedsFromRoyaltiesReceived", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r103" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds on disposals of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r109" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-term Debt", "verboseLabel": "Proceeds from short-term borrowings, net of debt issuance costs" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "terseLabel": "Product Warranty Disclosure [Text Block]" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r84", "r87", "r114", "r188", "r197", "r486", "r487", "r488", "r491", "r492" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r247" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r245" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r247", "r618" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 1.0, "parentTag": "us-gaap_NoncurrentAssets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r39", "r133", "r247" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r247" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r245" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase Obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueAfterFifthYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing after the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due after Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months" } } }, "localname": "PurchaseObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInFifthYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due in Fifth Year", "terseLabel": "Purchase Obligation, Due in Fifth Year" } } }, "localname": "PurchaseObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInFourthYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the fourth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due in Fourth Year", "terseLabel": "Purchase Obligation, Due in Fourth Year" } } }, "localname": "PurchaseObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the next fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due in Next Twelve Months", "terseLabel": "Purchase Obligation, Due in Next Twelve Months" } } }, "localname": "PurchaseObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due in Second Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Second Year" } } }, "localname": "PurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligationDueInThirdYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.", "label": "Purchase Obligation, Due in Third Year", "terseLabel": "Purchase Obligation, Due in Third Year" } } }, "localname": "PurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r556" ], "lang": { "en-US": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "verboseLabel": "Average interest rate of de-recognized receivables" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r80", "r83", "r89" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r193", "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r192", "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r191", "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r110" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings and debt extinguishment costs" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r110" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Payments on borrowings from credit facilities" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r110" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "negatedTerseLabel": "Payments on short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepurchaseAgreementCounterpartyAmountAtRisk": { "auth_ref": [ "r140" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount at risk under repurchase agreements is defined as the excess of carrying amount (or market value, if higher than the carrying amount or if there is no carrying amount) of the securities or other assets sold under agreement to repurchase, including accrued interest plus any cash or other assets on deposit to secure the repurchase obligation, over the amount of the repurchase liability (adjusted for accrued interest).", "label": "Repurchase Agreement Counterparty, Amount at Risk", "terseLabel": "Repurchase Agreement Counterparty, Amount at Risk" } } }, "localname": "RepurchaseAgreementCounterpartyAmountAtRisk", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r411" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r133", "r411" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r16", "r124", "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted Cash and Cash Equivalents, Current", "verboseLabel": "Restricted cash and restricted cash equivalents included in Other current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashEquivalentsNoncurrent": { "auth_ref": [ "r6", "r19", "r131", "r629" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash equivalents included in Other long-term assets" } } }, "localname": "RestrictedCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r6", "r19", "r131", "r629" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted Cash, Noncurrent" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r252", "r254", "r260", "r262" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Restructuring and Related Cost, Cost Incurred to Date" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r252", "r254", "r260", "r262" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and Related Cost, Expected Cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r252", "r254", "r260", "r262" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring and Related Cost, Incurred Cost" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r122", "r251", "r258", "r261" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges", "verboseLabel": "Restructuring charges (credits)" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]", "verboseLabel": "Restructuring and Related Cost [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r33", "r294", "r616" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails", "http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r320", "r321", "r350", "r351", "r362" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r320", "r321", "r350", "r351", "r362" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r301", "r302", "r303" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r146", "r315" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r132", "r133", "r134" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition, Policy [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r573", "r578" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]", "verboseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of accumulated benefit obligations and fair values of plan assets of pension plans and/or other employee benefit plans where the accumulated benefit obligation exceeds the fair value of plan assets.", "label": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Allocation of Plan Assets [Table Text Block]" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r466", "r467" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r466", "r467" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.", "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]" } } }, "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation of pension plans and/or other employee benefit plans from the beginning to the end of the period, showing separately, if applicable, the effects of the following: service cost, interest cost, contributions by plan participants, actuarial gains and losses, foreign currency exchange rate changes, benefits paid, plan amendments, business combinations, divestitures, curtailments, settlements, and special and contractual termination benefits.", "label": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]", "terseLabel": "Schedule of Changes in Projected Benefit Obligations [Table Text Block]" } } }, "localname": "ScheduleOfChangesInProjectedBenefitObligationsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r52", "r136", "r290", "r291", "r292", "r293", "r555", "r556", "r558", "r607" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of debt maturities" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable": { "auth_ref": [ "r316", "r317", "r318" ], "lang": { "en-US": { "role": { "documentation": "Schedule, table or text reflecting pension and other postretirement benefit arrangements with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]", "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Postretirement Benefits [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualPostretirementBenefitsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "auth_ref": [ "r350", "r351", "r353", "r354", "r358" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/EmployeeRetirementPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r502", "r514", "r524" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "verboseLabel": "Gains (losses) recognized in earnings for derivatives designed as hedging instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r141", "r494", "r495", "r496", "r499", "r500", "r508", "r514", "r525", "r527" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r367", "r392", "r407" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "terseLabel": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r228", "r235" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r562" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Operating Leases, Rent Expense, Minimum Rentals" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r224", "r225" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r224", "r225" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Schedule of Other Assets [Table Text Block]" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of Other Current Assets [Table Text Block]" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r255", "r256", "r259" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r255", "r256", "r259" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "verboseLabel": "Impact of restructuring costs on the accompanying financial statements" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r183", "r188", "r190", "r194", "r224" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r368", "r395" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r371", "r382", "r385" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Share-based Compensation, Stock Options, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table Text Block]", "terseLabel": "Schedule of Short-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which it is expected to be recognized.", "label": "Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]", "terseLabel": "Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "verboseLabel": "Weighted average shares outstanding" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Expected Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "verboseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables", "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT REPORTING" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r96", "r211" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r100" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes [Member]" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation [Member]" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r122", "r251", "r258", "r261" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance Costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r121" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r378" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r378" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r389" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r383" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r395" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r373", "r395" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r366", "r370" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r388", "r406" ], "lang": { "en-US": { "role": { "documentation": "Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r395" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "auth_ref": [ "r132", "r133" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping and Handling Cost, Policy [Policy Text Block]", "terseLabel": "Shipping and Handling Cost, Policy [Policy Text Block]" } } }, "localname": "ShippingAndHandlingCostPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]", "terseLabel": "Shipping and Handling [Member]" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r21", "r595", "r614" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term Debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.", "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Short-term Debt, Weighted Average Interest Rate, at Point in Time" } } }, "localname": "ShortTermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r188", "r224", "r250", "r254", "r262", "r625" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Statement, Business Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables", "http://www.bostonscientific.com/role/RevenueRevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r28", "r29", "r30", "r289" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/CoverDocumentDocument", "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r57", "r289" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Statement, Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r365", "r408" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Stock Granted, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Impact of stock-based compensation plans, net of tax" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r29", "r30", "r289", "r294" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r29", "r30", "r289", "r294" ], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Impact of stock-based compensation plans, net of tax (Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r29", "r30", "r289", "r294", "r375" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r29", "r30", "r289", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r484", "r485", "r490" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets", "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r580" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r580" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r580" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails", "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events, Policy [Policy Text Block]", "terseLabel": "Subsequent Events, Policy [Policy Text Block]" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r428", "r435", "r437" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Summary of Income Tax Contingencies [Table Text Block]" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r413", "r417" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "terseLabel": "Tax Adjustments, Settlements, and Unusual Provisions" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Taxes Payable, Current" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r472" ], "lang": { "en-US": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TerminationLoans": { "auth_ref": [ "r588" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Definite liabilities to third parties under a termination loan agreement, whether or not guaranteed in whole or in part by the government.", "label": "Termination Loans", "terseLabel": "Termination Loans" } } }, "localname": "TerminationLoans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r303", "r311" ], "lang": { "en-US": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]", "terseLabel": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": { "auth_ref": [ "r586" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.", "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]", "terseLabel": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r587" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax": { "auth_ref": [ "r71", "r517" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification from accumulated other comprehensive income (AOCI) of gain (loss) from increase (decrease) in fair value of net investment hedge.", "label": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax", "terseLabel": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax" } } }, "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r56", "r295" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r56", "r295" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical", "http://www.bostonscientific.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r56", "r295", "r296" ], "calculation": { "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost - 247,566,270 shares as of December 31, 2019 and December 31, 2018" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r418", "r429" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r430" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r431" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense accrued for an underpayment of income taxes.", "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued", "terseLabel": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued" } } }, "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r433" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r434" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r165", "r166", "r167", "r168", "r173", "r174", "r175" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesAdjustments": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment" } } }, "localname": "ValuationAllowancesAndReservesAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIiDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIiDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Net (credits) charges to expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIiDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r145" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Utilization of allowances", "negatedTerseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ScheduleIiDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Valuation Technique, Discounted Cash Flow [Member]" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule for share-based compensation.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r395" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule for share-based compensation.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageDiscountRatePercent": { "auth_ref": [ "r626" ], "lang": { "en-US": { "role": { "documentation": "The average discount rate applied to insurance contracts to determine future policy benefits to be paid to or on behalf of policyholders.", "label": "Weighted Average Discount Rate, Percent", "terseLabel": "Weighted Average Discount Rate, Percent" } } }, "localname": "WeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r158" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "verboseLabel": "Net effect of common stock equivalents" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r154", "r158" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average shares outstanding - assuming dilution", "verboseLabel": "Assuming dilution" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding", "verboseLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r153", "r158" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding - basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3581-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3098-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(m)(1)(i)(B)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27405-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3,4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=6396582&loc=d3e15243-108350" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r315": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2410-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2417-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2417-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2439-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947" }, "r364": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109243414&loc=d3e3913-113898" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79507997-165333" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79507997-165333" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508013-165333" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508013-165333" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508029-165333" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508029-165333" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508043-165333" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508043-165333" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508057-165333" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109253770&loc=SL79508057-165333" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28511-109314" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928272&loc=d3e28446-109314" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31928-109318" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31958-109318" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928189&loc=SL96870463-158277" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=115928189&loc=SL96870463-158277" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e961-128460" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=SL65897772-128472" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5227-128473" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r483": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686" }, "r493": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r541": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32022-110900" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b),(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r564": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r579": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107314-111719" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=68073528&loc=d3e56288-109415" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.5(c))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=d3e14881-158438" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "305", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r632": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r633": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r634": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r635": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r636": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r637": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r638": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r639": { "Article": "6", "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(c)", "Publisher": "SEC", "Section": "10", "Subparagraph": "(1)" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r640": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r641": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r642": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" } }, "version": "2.1" } XML 35 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity
 12 Months Ended
Dec. 31, 2019
Stockholders' Equity Attributable to Parent [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
NOTE K – STOCKHOLDERS' EQUITY

Preferred Stock

We are authorized to issue 50 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. As of December 31, 2019 and 2018, we had no shares of preferred stock issued or outstanding.

Common Stock

We are authorized to issue 2.000 billion shares of common stock, $0.01 par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs.

On January 25, 2013, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to $1.000 billion of our common stock. Repurchased shares are available for reissuance under our equity incentive plans and for general corporate purposes, including acquisitions. We did not repurchase any shares of our common stock during 2019, 2018 or 2017. As of December 31, 2019, we had remaining $535 million authorized under our 2013 share repurchase program. There were approximately 248 million shares in treasury as of December 31, 2019 and December 31, 2018.
XML 36 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]
NOTE A – SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation

Our consolidated financial statements include the accounts of Boston Scientific Corporation and our wholly-owned subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest in a VIE. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs for 2019, 2018 and 2017.

Basis of Presentation

The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

Reportable Segments

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG plc (BTG), which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

Subsequent Events

We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our consolidated financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying consolidated financial statements (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the consolidated financial statements have been disclosed accordingly. Refer to Note E – Contractual Obligations and Commitments and Note J – Commitments and Contingencies for further details.

Accounting Estimates

To prepare our consolidated financial statements in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our consolidated financial statements and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to Critical Accounting Estimates included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report for further discussion.

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents

Cash and Cash Equivalents

We record Cash and cash equivalents in our consolidated balance sheets at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider to be cash equivalents all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.

Restricted Cash

Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in the Other current assets caption on our consolidated balance sheets. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us as servicer of previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee.

Restricted Cash Equivalents

Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in the Other current assets caption on our consolidated balance sheets. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in the Other long-term assets caption on our consolidated balance sheets are related to deferred compensation plans.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral. We record our accounts receivable in our consolidated balance sheets at net realizable value. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses, based on historical information and management's best estimates. We write-off amounts determined to be uncollectible against this reserve. Write-offs of uncollectible accounts receivable were immaterial in 2019, 2018 and 2017. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in 2019, 2018 and 2017; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales.

We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers in Southern Europe are subject to an increased number of days outstanding prior to payment relative to other countries. Historically, receivable balances with certain publicly-owned hospitals in these countries accumulated over a period of time and are then subsequently settled as large lump sum payments, sometimes at large discounts. While we believe our allowance for doubtful accounts in these countries is adequate as of December 31, 2019 and 2018, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts receivable may increase.
 
Revenue Recognition

In May 2014, the FASB issued FASB ASC Topic 606, Revenue from Contracts with Customers (Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied FASB ASC Topic 606 to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with FASB ASC Topic 606. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in FASB ASC Topic 605, Revenue Recognition.

Due to the adoption of FASB ASC Topic 606, we recorded a net reduction to retained earnings of $177 million on January 1, 2018, primarily related to the cost of providing non-contractual post-implant support to certain customers, which we historically deemed immaterial in the context of the arrangement. Upon the adoption of FASB ASC Topic 606, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within Selling, general and administrative expenses and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual.

The impact of adopting FASB ASC Topic 606 on our consolidated balance sheets resulted in an increase in Other current liabilities of $59 million and an increase in Other long-term liabilities of $205 million as of December 31, 2018, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in an increase in Other long-term assets of $12 million and a reduction in Deferred income taxes of $41 million as of December 31, 2018. The remaining impact of adopting FASB ASC Topic 606 was not material to our financial position or results of operations.

We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met:

•
We have a contract with a customer that creates enforceable rights and obligations,
•
Promised products or services are identified,
•
The transaction price, or the amount we expect to receive, is determinable and
•
We have transferred control of the promised items to the customer.

Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.

Deferred Revenue

We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.

Capitalized Contract Costs

We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our consolidated financial statements.

Post-Implant Services

We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. Following our modified retrospective adoption of FASB ASC Topic 606 on January 1, 2018, because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to Selling, general and administrative expenses. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.

Warranty Obligations

We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our Cardiac Rhythm Management business, which include implantable defibrillator and pacemaker systems. Our Cardiac Rhythm Management products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary.

Inventories

We state inventories at the lower of first-in, first-out cost or net realizable value. We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. Approximately 32 percent of our finished goods inventory as of December 31, 2019 and approximately 40 percent as of December 31, 2018 was at customer locations pursuant to consignment arrangements or held by sales representatives.

Property, Plant and Equipment

We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of 40 years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a three to seven year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.

Leases

In February 2016, the FASB issued ASC Update No. 2016-02, Leases (FASB ASC Topic 842, Leases). We adopted the standard as of January 1, 2019, using the modified retrospective approach and the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, we applied the new leasing rules on the date of adoption and recognized the cumulative effect of initially applying the standard as an adjustment to our January 1, 2019 opening balance sheet, rather than at the earliest comparative period presented in the financial statements. Prior periods presented are in accordance with the previous lease guidance under FASB ASC Topic 840, Leases (FASB ASC Topic 840).

In addition, we applied the package of practical expedients permitted under FASB ASC Topic 842 transition guidance to our entire lease portfolio at January 1, 2019. As a result, we were not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases and (iii) the treatment of initial direct costs for any existing leases. Furthermore, we elected not to separate lease and non-lease components for the majority of our leases. Instead, for all applicable classes of underlying assets, we accounted for each separate lease component and the non-lease components associated with that lease component, as a single lease component.

As a result of adopting FASB ASC Topic 842 on January 1, 2019, we recognized right-of-use assets of $271 million and corresponding liabilities of $278 million for our existing operating lease portfolio on our consolidated balance sheet. Operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our consolidated balance sheets. Finance leases are immaterial to our consolidated financial statements. Refer to Note E – Contractual Obligations and Commitments for additional information. There was no material impact to our consolidated statements of operations or consolidated statements of cash flows as a result of adopting FASB ASC Topic 842. Please refer to Note F – Leases for information regarding our lease portfolio as of December 31, 2019 as accounted for under FASB ASC Topic 842.

To meet the reporting and disclosure requirements of FASB ASC Topic 842, we implemented a new lease administration and lease accounting system in 2018 that tracks all of our material leasing arrangements. In addition, we designed and implemented new processes and internal controls during the first quarter of 2019 to ensure the completeness and accuracy of the transition adjustment and subsequent financial reporting under FASB ASC Topic 842. We have also established monitoring controls to ensure we have appropriate mechanisms in place to identify material leases in a timely manner, particularly contracts that may contain embedded lease features.

Valuation of Business Combinations

We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through Selling, general and administrative expenses.

In those circumstances where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through Contingent consideration expense (benefit) on our consolidated statements of operations. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.

Indefinite-lived Intangibles, including IPR&D

Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which is foundational to our ongoing operations within the Cardiovascular market and other markets within interventional medicine and IPR&D intangible assets acquired in a business combination. Our IPR&D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&D intangible asset.

We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other. If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.

We use the income approach to determine the fair values of our IPR&D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See Note C – Goodwill and Other Intangible Assets for more information related to indefinite-lived intangibles, including IPR&D.

For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date.

Amortization and Impairment of Intangible Assets

We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, two to 20 years; amortizable technology-related and customer relationships, five to 25 years; other intangible assets, various.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See Note C – Goodwill and Other Intangible Assets for more information related to impairments of intangible assets.

For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent.

Goodwill Valuation

We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2019, 2018 and 2017 annual impairment assessment, we identified the following reporting units: Interventional Cardiology, Peripheral Interventions (including the Interventional Medicine business acquired with BTG), Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health and Neuromodulation. In addition, following the BTG acquisition in the third quarter of 2019, we added Specialty Pharmaceuticals as an additional reporting unit. We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based on the criteria prescribed in FASB ASC Topic 350.

In performing the goodwill impairment assessments for 2019, 2018 and 2017, we utilized both the optional qualitative assessment and the quantitative approach prescribed under FASB ASC Topic 350. The qualitative assessment was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent. All other reporting units were tested using the quantitative approach described below. The qualitative assessment requires an evaluation of whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount based on an assessment of relevant events including macroeconomic factors, industry and market conditions, cost factors, overall financial performance and other entity-specific factors. After assessing the totality of events, if it is determined that it is more likely than not that the fair value of the reporting unit exceeds its carrying value, no further steps are required. If it is determined that impairment is more likely than not, then we perform the quantitative impairment test.

When allocating goodwill from business combinations to our reporting units, we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition. In addition, for purposes of performing our goodwill impairment tests, assets and liabilities, including corporate assets, which relate to a reporting unit’s operations, and would be considered in determining its fair value, are allocated to the individual reporting units. We allocate assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.

For our 2019, 2018 and 2017 annual impairment assessments, for those reporting units for which a quantitative test was performed, we used only the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets. We have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technology-based assets within our reporting units for application of the cost approach. Therefore, we believe that the income approach represents the most appropriate valuation technique for which sufficient data are available to determine the fair value of our reporting units.

In applying the income approach to our accounting for goodwill, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk-adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows.

Refer to Note C – Goodwill and Other Intangible Assets to our consolidated financial statements for additional details related to our goodwill balances.

Investments in Publicly Traded and Privately Held Entities

In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to Other Comprehensive Income. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to Other comprehensive income (loss) were reclassified to retained earnings, and all future fair value changes will be recorded to Net income (loss). For privately-held securities of investee companies over which we do not have the ability to exercise significant influence, we elected the measurement alternative approach for our existing investments, which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. 

In 2017, we accounted for our publicly traded investments as available-for-sale securities based on the quoted market price at the end of the reporting period. Unrealized holding gains or losses during the period, net of tax, were recorded to Accumulated other comprehensive income (loss), net of tax. We computed realized gains and losses on sales of available-for-sale securities at fair value, adjusted for any other-than-temporary declines in fair value. We accounted for investments in privately-held entities in which we had less than a 20 percent ownership interest under the cost method of accounting if we did not have the ability to exercise significant influence over the investee in accordance with FASB ASC Topic 325, Investments - Other.

We account for investments in entities over which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing consolidated financial statements. Lastly, we have notes receivable from certain companies that we account for in accordance with FASB ASC Topic 320, Investments - Debt and Equity Securities. Refer to Note B – Acquisitions and Strategic Investments for additional details on our investment balances.

Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. If the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value if accounted for under measurement alternative. For our equity method investments, an impairment loss is recorded if we determine the impairment is other-than-temporary. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. For other-than-temporary impairments, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. Impairment losses on our investments are included in Other, net in our consolidated statements of operations.

Income Taxes

In February 2018, the FASB issued ASC Update No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The purpose of Update No. 2018-02 is to allow an entity to reclassify the income tax effects of the Tax Cut and Jobs Act of 2017 (TCJA) on items within Accumulated other comprehensive income (loss), net of tax (AOCI) to retained earnings. Update No. 2018-02 is effective for all entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We adopted Update No. 2018-02 in the first quarter of 2019 and have not elected to reclassify the income tax effects of the TCJA from AOCI to retained earnings.

In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to retained earnings of $55 million for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through Income tax expense (benefit).

We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the TCJA, we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and will be reported as a part of continuing operations. See Note I – Income Taxes for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.

Legal and Product Liability Costs

In the normal course of business, we are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue our best estimate of the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses. See Note J – Commitments and Contingencies for discussion of our individual material legal proceedings.

Costs Associated with Exit Activities

We record employee termination costs in accordance with FASB ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with FASB ASC Topic 420, Exit or Disposal Cost Obligations. We record such costs into expense over the employee’s future service period, if any.

Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with FASB ASC Topic 420 and are included in Restructuring charges (credits) in our consolidated statements of operations. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities and are included within Costs of products sold and Selling, general and administrative expenses in our consolidated statements of operations. Impairment of right of use lease assets and lease terminations directly related to our active restructuring initiatives are expensed in accordance with FASB ASC Topic 842 and included within Costs of products sold and Selling, general and administrative expenses in our consolidated statements of operations. See Note G – Restructuring-related Activities for further information and discussion of our restructuring plans.

Translation of Foreign Currency

We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate and translate revenues and expenses at the average exchange rates in effect during the year. We show the net effect of these translation adjustments in our consolidated financial statements as a component of Accumulated other comprehensive income (loss), net of tax. For any significant foreign subsidiaries located in highly inflationary economies, we would re-measure their financial statements as if the functional currency were the U.S. dollar.

Foreign currency transaction gains and losses are included in Other, net in our consolidated statements of operations, net of losses and gains from any related derivative financial instruments.

Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.

Shipping and Handling Costs

We generally do not bill customers for shipping and handling of our products. We treat shipping and handling costs incurred after a customer obtains control of the good as a fulfillment cost and record in Selling, general and administrative expenses in our consolidated statements of operations. Shipping and handling costs were $144 million in 2019, $124 million in 2018 and $110 million in 2017.

Research and Development

We expense research and development costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to Indefinite-lived Intangibles, including In-Process Research and Development above for our policy regarding IPR&D acquired in connection with our business combinations and asset purchases.

Net Income (Loss) per Common Share

We base Net income (loss) per common share upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options and stock awards whose effect would be anti-dilutive from the calculation.
XML 37 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring Related Activities
 12 Months Ended
Dec. 31, 2019
Restructuring and Related Activities [Abstract]  
Restructuring and Related Activities Disclosure [Text Block]
NOTE G – RESTRUCTURING-RELATED ACTIVITIES

2019 Restructuring Plan

On November 15, 2018, the Board of Directors approved, and we committed to a new global restructuring program (the 2019 Restructuring Plan). The 2019 Restructuring Plan is intended to support our effort to improve operating performance and meet anticipated market demands by ensuring that we are appropriately structured and resourced to deliver sustainable value to patients and customers. Key activities under the 2019 Restructuring Plan include supply chain network optimization intended to maximize our global manufacturing and distribution network capacity and building functional capabilities that support business growth. These activities were initiated in 2019, with the majority of activity expected to be complete by the end of 2021.

The following table provides a summary of our estimates of total pre-tax charges associated with the 2019 Restructuring Plan by major type of cost:
Type of Cost
Total Estimated Amount Expected to be Incurred
Restructuring charges:
 
 
 
Termination benefits

$75
 million
 to
$100 million
Other (1)

$25
 million
 to
$50 million
Restructuring-related expenses:
 
 
 
Other (2)

$100
 million
 to
$150 million
 

$200
 million
 to
$300 million
(1)
Consists primarily of consulting fees and costs associated with contractual cancellations.
(2)
Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.

Approximately $180 million to $280 million of these charges are expected to result in cash outlays.

2016 Restructuring Plan

On June 6, 2016, our Board of Directors approved, and we committed to a restructuring initiative (the 2016 Restructuring Plan). The 2016 Restructuring Plan was intended to develop global commercialization, technology and manufacturing capabilities in key growth markets, build on our Plant Network Optimization (PNO) strategy which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expand operational efficiencies in support of our operating income margin goals. Key activities under the 2016 Restructuring Plan included strengthening global infrastructure through evolving global real estate assets and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our PNO strategy. These activities were initiated in the second quarter of 2016 and substantially completed in 2019.

The following table provides a summary of total pre-tax charges associated with the 2016 Restructuring Plan by major type of cost:
Type of cost
Total Amount Incurred
Restructuring charges:
 
Termination benefits
$
86
 million
Other (1)
21
 million
Restructuring-related expenses:
 
Other (2)
164
 million
 
$
271
 million
(1)
Consists primarily of consulting fees and costs associated with contract cancellations.
(2)
Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities.

Approximately $255 million of these charges are expected to result in cash outlays; the majority of which were completed as of December 31, 2019.
The following presents the restructuring and restructuring-related charges (credits) by major type and line item within our accompanying consolidated statements of operations (in millions):
Year Ended December 31, 2019
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
38

 
$
—

 
$
—

 
$
38

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
32

 
—

 
32

Selling, general and administrative expenses
—

 
—

 
13

 
13

 
—

 
32

 
13

 
44

 
$
38

 
$
32

 
$
13

 
$
82



Year Ended December 31, 2018
Termination
Benefits
 
Transfer
Costs
 
Other
 
Total
Restructuring charges
$
32

 
$
—

 
$
4

 
$
36

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
47

 
—

 
47

Selling, general and administrative expenses
—

 
—

 
12

 
12

 
—

 
47

 
12

 
59

 
$
32

 
$
47

 
$
16

 
$
96


Year Ended December 31, 2017
Termination
Benefits
 
Transfer Costs
 
Other
 
Total
Restructuring charges
$
25

 
$
—

 
$
12

 
$
37

Restructuring-related expenses:
 
 
 
 
 
 
 
Cost of products sold
—

 
45

 
—

 
45

Selling, general and administrative expenses
—

 
—

 
13

 
13

 
—

 
45

 
13

 
58

 
$
25

 
$
45

 
$
25

 
$
95



The following table presents cumulative restructuring and restructuring-related charges incurred as of December 31, 2019, related to our Restructuring Plans by major type:
(in millions)
2016 Restructuring Plan
 
2019 Restructuring Plan
 
Total
Termination benefits
$
86

 
$
30

 
$
115

Other (1)
21

 
2

 
23

Total restructuring charges
106

 
32

 
138

Transfer costs
126

 
13

 
139

Other (2)
39

 
2

 
41

Restructuring-related charges
164

 
15

 
180

 
$
271

 
$
47

 
$
318

(1)
Consists primarily of consulting fees and costs associated with contract cancellations.
(2)
Comprised of other costs directly related to our Restructuring Plans, including program management, accelerated depreciation, and fixed asset write-offs.

Cash payments associated with our Restructuring Plans were made using cash generated from operations and are comprised of the following:
(in millions)
2016 Restructuring Plan
 
2019 Restructuring Plan
 
Total
Year Ended December 31, 2019
 
 
 
 
 
Termination benefits
$
13

 
$
6

 
$
18

Transfer costs
18

 
13

 
32

Other
10

 
4

 
14

 
$
41

 
$
23

 
$
64
XML 38 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 217 $ 146
Trade accounts receivable, net 1,828 1,608
Inventories 1,579 1,166
Prepaid income taxes 195 161
Other current assets 880 921
Total current assets 4,699 4,003
Property, plant and equipment, net 2,079 1,782
Goodwill 10,176 7,911
Other intangible assets, net 7,886 6,372
Deferred tax assets 4,196 87
Other long-term assets 1,529 845
TOTAL ASSETS 30,565 20,999
Current liabilities:    
Current debt obligations 1,416 2,253
Accounts payable 542 349
Accrued expenses 2,109 2,246
Other current liabilities 800 412
Total current liabilities 4,866 5,260
Long-term debt 8,592 4,803
Deferred tax liabilities 595 328
Other long-term liabilities 2,635 1,882
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding
Common stock, $0.01 par value - authorized 2,000,000,000 shares; issued 1,642,488,911 shares as of December 31, 2019 and 1,632,148,030 shares as of December 31, 2018 16 16
Treasury stock, at cost - 247,566,270 shares as of December 31, 2019 and December 31, 2018 (1,717) (1,717)
Additional paid-in capital 17,561 17,346
Accumulated deficit (2,253) (6,953)
Accumulated other comprehensive income (loss), net of tax:    
Foreign currency translation adjustment 142 (53)
Unrealized gain (loss) on derivative financial instruments 173 111
Unrealized costs associated with defined benefit pensions and other items (45) (25)
Total stockholders’ equity 13,877 8,726
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 30,565 $ 20,999
XML 39 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Other Intangible Assets
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
 
As of December 31, 2019
 
As of December 31, 2018
(in millions)
Gross Carrying Amount
 
Accumulated
Amortization/Write-offs
 
Gross Carrying Amount
 
Accumulated
Amortization/Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
12,020

 
$
(5,706
)
 
$
10,197

 
$
(5,266
)
Patents
525

 
(408
)
 
520

 
(393
)
Other intangible assets
1,754

 
(1,081
)
 
1,666

 
(958
)
 
$
14,299

 
$
(7,195
)
 
$
12,383

 
$
(6,617
)
Indefinite-lived intangible assets
 
 
 
 
 
 
 
Goodwill
$
20,076

 
$
(9,900
)
 
$
17,811

 
$
(9,900
)
In-process research and development (IPR&D)
662

 
—

 
486

 
—

Technology-related
120

 
—

 
120

 
—

 
$
20,858

 
$
(9,900
)
 
$
18,417

 
$
(9,900
)


In the third quarter of 2019, we performed our annual impairment test of all IPR&D projects and our indefinite-lived core technology assets and determined that the assets were not impaired. In addition, we verified the classification as indefinite-lived assets continues to be appropriate.

Intangible asset impairment charges were $105 million in 2019, $35 million in 2018 and $4 million in 2017. Refer to Note A - Significant Accounting Policies for a discussion of key assumptions used in our goodwill and intangible asset impairment testing.

Effective January 1, 2018, we reclassified our Neuromodulation operating segment and associated goodwill balance from our MedSurg reportable segment to our Rhythm and Neuro reportable segment. This change did not impact our total goodwill carrying value.

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG, which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.

The following represents our goodwill balance by global reportable segment and our separately reported Specialty Pharmaceuticals operating segment:
(in millions)
MedSurg
 
Rhythm and Neuro
 
Cardiovascular
 
Specialty Pharmaceuticals
 
Total
Balance as of December 31, 2017
$
2,877

 
$
417

 
$
3,704

 
$
—

 
$
6,998

Reportable segment revisions
(1,379
)
 
1,379

 
—

 
—

 
—

Foreign currency fluctuations and other changes
(3
)
 
(22
)
 
(3
)
 
—

 
(29
)
Goodwill acquired
568

 
150

 
224

 
—

 
942

Balance as of December 31, 2018
$
2,063

 
$
1,924

 
$
3,925

 
$
—

 
$
7,911

Foreign currency fluctuations and other changes
(1
)
 
—

 
58

 
9

 
66

Goodwill acquired
—

 
268

 
1,712

 
238

 
2,218

Goodwill divested
—

 
—

 
(19
)
 
—

 
(19
)
Balance as of December 31, 2019
$
2,061

 
$
2,192

 
$
5,676

 
$
247

 
$
10,176



We did not have any goodwill impairments in 2019, 2018 or 2017.

Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of December 31, 2019 is as follows (in millions):
Fiscal Year
 
2020
$
787

2021
750

2022
722

2023
708

2024
672
XML 40 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Assets and liabilities measured at fair value on a recurring basis
Changes in the fair value of our licensing arrangements' financial asset was as follows:
(in millions)
 
Balance as of December 31, 2018
$
—

Amounts recorded related to current year acquisition
567

Proceeds from royalty rights
(52
)
Fair value adjustment (expense) benefit
3

Balance as of December 31, 2019
$
518


Changes in the fair value of our licensing arrangements' financial liability was as follows:
(in millions)
 
Balance as of December 31, 2018
$
—

Amounts recorded related to current year acquisition
315

Proceeds from secured borrowings relating to royalty arrangements
256

Balance as of December 31, 2019
$
571


The recurring Level 3 fair value measurements of our licensing arrangements recognized in our consolidated balance sheets as of December 31, 2019 include the following significant unobservable inputs:
Licensing Arrangements
Fair Value as of December 31, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
Financial Asset
$518 million
Discounted Cash Flow
Discount Rate
11
%
-
19%
19%
Projected Year of Payment
2020

-
2028
2024
Financial Liability
$571 million
Discounted Cash Flow
Discount Rate
19%
19%
Projected Year of Payment
2020

-
2027
2023
(1)
Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
December 31, 2019
 
December 31, 2018
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
50

 
$
—

 
$
—

 
$
50

 
$
13

 
$
—

 
$
—

 
$
13

Publicly-held securities
1

 
—

 
—

 
1

 
—

 
—

 
—

 
—

Hedging instruments
—

 
321

 
—

 
321

 
—

 
304

 
—

 
304

Licensing arrangements
—

 
—

 
518

 
518

 
—

 
—

 
—

 
—

 
$
51

 
$
321

 
$
518

 
$
890

 
$
14

 
$
304

 
$
—

 
$
318

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hedging instruments
$
—

 
$
1,037

 
$
—

 
$
1,037

 
$
—

 
$
80

 
$
—

 
$
80

Contingent consideration liability
—

 
—

 
354

 
354

 
—

 
—

 
347

 
347

Licensing arrangements
—

 
—

 
571

 
571

 
—

 
—

 
—

 
—

 
$
—

 
$
1,037

 
$
925

 
$
1,963

 
$
—

 
$
80

 
$
347

 
$
427
Classification of derivative assets and liabilities within level 2 The following are the balances of our derivative and nonderivative assets and liabilities:
(in millions)
 
Location on Consolidated Balance Sheets (1)
 
As of December 31,
 
2019
 
2018
Derivative and Nonderivative Assets:
 
 
 
 
 
 
Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
$
72

 
$
55

Forward currency contracts
 
Other long-term assets
 
216

 
183

 
 
 
 
288

 
237

Non-Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
33

 
67

Total Derivative and Nonderivative Assets
 
 
 
$
321

 
$
304

 
 
 
 
 
 
 
Derivative and Nonderivative Liabilities:
 
 
 
 
 
 
Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
$
3

 
$
2

Forward currency contracts
 
Other long-term liabilities
 
8

 
3

Foreign currency-denominated debt
 
Other long-term liabilities
 
998

 
—

Interest rate contracts
 
Other current liabilities
 
—

 
44

 
 
 
 
1,009

 
49

Non-Designated Hedging Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
29

 
31

Total Derivative and Nonderivative Liabilities
 
$
1,037

 
$
80

(1)
We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.
Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]
As of December 31, 2019, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Hedging Instrument
 
FASB ASC Topic 815 Designation
 
Location on Consolidated Statements of Operations
 
Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contracts
 
Cash flow hedge
 
Cost of products sold
 
$
77

Forward currency contracts
 
Net investment hedge
 
Interest expense
 
24

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
 
(5
)
Gains (losses) recognized in earnings for derivatives designed as hedging instruments
The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 on our accompanying consolidated statements of operations. Refer to Note P – Changes in Other Comprehensive Income for the total amounts relating to derivative and nonderivative instruments presented within the consolidated statements of comprehensive income (loss).
 
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
 
Amount Recognized in OCI on Hedges
 
Consolidated Statements of Operations (1)
 
Amount Reclassified from AOCI into Earnings
 
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Location of Amount Reclassified
Total Amount of Line Item Presented
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss Net of Tax
Year Ended December 31, 2019
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
150

$
(34
)
$
117

 
Cost of products sold
$
3,116

 
$
(73
)
$
16

$
(56
)
Net investment hedges (2)
68

(15
)
53

 
Interest expense
473

 
(43
)
10

(33
)
Foreign currency-denominated debt
 
 
 
 
 
 
 
Net investment hedges
(14
)
3

(11
)
 
Interest expense
473

 
—

—

—

Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
473

 
3

(1
)
2

Year Ended December 31, 2018
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
167

$
(38
)
$
130

 
Cost of products sold
$
2,813

 
$
19

$
(4
)
$
15

Net investment hedges (2)
56

(13
)
43

 
Interest expense
241

 
(27
)
6

(21
)
Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
(44
)
10

(34
)
 
Interest expense
241

 
(1
)
—

(1
)
Year Ended December 31, 2017
Forward currency contracts
 
 
 
 
 
 
 
Cash flow hedges
$
(101
)
$
37

$
(65
)
 
Cost of products sold
$
2,593

 
$
(64
)
$
23

$
(41
)
Interest rate derivative contracts
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
229

 
(1
)
—

(1
)
(1)
In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. All other amounts included in earnings related to hedging relationships were immaterial.
(2)
For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.
Schedule of Derivative Instruments [Table Text Block]
The following table presents the contractual amounts of our hedging instruments outstanding:
(in millions)
 
FASB ASC Topic 815 Designation
 
As of December 31,
 
2019
 
2018
Forward currency contracts
 
Cash flow hedge
 
$
3,891

 
$
3,962

Forward currency contracts
 
Net investment hedge
 
953

 
1,483

Foreign currency-denominated debt(1)
 
Net investment hedge
 
997

 
—

Forward currency contracts
 
Non-designated
 
4,377

 
5,880

Interest rate derivative contracts
 
Cash flow hedge
 
—

 
1,000

Total Notional Outstanding
 
 
 
$
10,218

 
$
12,326


(1)
The €900 million (approximately $1.000 billion) debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional subsidiaries.
Net foreign currency gain (loss) [Table Text Block]
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
(in millions)
 
Location on Consolidated Statements of Operations
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(343
)
 
$
41

 
$
(25
)
Net gain (loss) on currency transaction exposures
 
Other, net
 
(15
)
 
(30
)
 
10

Net currency exchange gain (loss)
 
 
 
$
(358
)
 
$
11

 
$
(15
)
ZIP 41 0000885725-20-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-20-000012-xbrl.zip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�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

?LE1=6V/JA^/$EZV60],RQ!5S^"#)M# 8+P?:/&1@*FO;? MSU_PW,(9#%.P&32K)./14WD&TAL!'\,5MT_FHM_??]$?R MH*+76$G1="[>)J-95G4L7);,-8&\1 )'R5(5-:QX20DE2&!)_,##")0T8Z6: MUJ;6,=5T6*2IMH!FQ"'/&4XMSUHA5/_0D=*>KE3L6W=@A63'D("D(GP:8F6[ M 4<\Y#8%NI>DR+=$3-B.:N[\]3/P0)2!#-"L\#-,=:VP;$+8279086=TF(Z[ MP]\[/FC9)BDLCRMK'$]W'YV6H& 8[OP +8QUJ:PQ/DVU2&Y :S=Z4@BU;/?A MY1E)29YUU!]J?]X4L-S&TT>=Q&"2)I/D3YW/.-/-:\=%Q"$:IN5W12ADDH(! MG\RR,J:1)S_DH]WZ."/+HP$U135_4;/O,6E7A^9L6GF>5/) 25>W5,:8V1(, MG+)B!EQ0N8WGN25GA[!B1I7.*S,CP0K@M$JNFH1A\S1>( MZ#E+#,&H'L)'4S( %)7%Q8-,;N<*;7*^\!7K/H.< L1;Y:EG\W-D#@3>/6/0JL9)=&6(> MED2J@[+Y(?;.3!@Z7US+^>)97Y/)L&=)Q'=^E/%MYS:9$>4&=:,\WQ!?V]2_H>Z#%/W99_JL_VZVHJR%3&?4@DMX'@?1(Y6D"(K_9>' M23+62BT9/$-!^JIKY765C@L,\.>[%34_BDH[D#Z32MH<(8>XA)5%.V")X>M: M6I;'PE#ZPE,V=V00^(*[A58B#A7HQ>*@C>\!!12#0ICH\JMT%K_[2:OVWGQB M\^6?*_OG(A2V*-7;7<3T\C0+;0$8 +%YDQ*[L=O\S= LT^9[?/QSWX5[S MN?Z"L38X1L\ ,##*P2T,OH0YS2I^_?_>:=+6IUN3J%=^7K&87X(C2N^$X'UXTFR;E%SFRAOGF<=B?WL/5,/D" 4>6OD.(O/Y87+?Z&7_B);'7;]L"QI^TARULE2,!_*Q=U=-B<.V$3K>) M0-J*2K=E\86-:\982#!1G 0!6&-V&'J,!F7*(\7\-2F/O\73CP,/2*\YU.4# M'8-<,;:,9WD 1.1VPL]=5DL,15K6G2GM";Q^QOCJ=BW6SSQ7QP%=C3"I M9$"HC\L,9T\%8H]#KE\*;_AI3YS< T7_V/+)Y^X,WW[6/7<;YSE/YU'U>;AR MWQX*&PSA2^RQ8#/>G0IL>2K0%![M*RBK_0+EW+W##JF[0^I^%5*W;5=.DL2> M1YF2R'-<5X*4= .GM)IL#XGMK*;*5OJJ\\X'<9IJK/_>:*87;)T,_4<\ZG_2 M^N]K4GM<:P4JOE*-FEIG"O%]((CA5APTK@CEGR$H'FL;*)[8#Q3/?K?8!_CX MYX=K.J=\Z=W'_=EHBU/$P'&"Z@#M( M. CN*T%%J4N96#P&?)'$&J"HKZ8DH$SRSV8/#U$*/V?FM'$A3:/*X=CF?''' MH[>#G>2]1A)U!V[=@5M;HPS=@5MWX+;5"OR<)/U'((KN)*T[27ON).KTDWDA MD>0!MZG' Y81TO= MX=_NN9BL81 J0B4FH72Q&W!!F$8>+)F7*F_I&'R%\_,Y[B5W8QA$_T9;KL/! M,%IJU^:,^[]46:-.GC1:]79;+!Z\1%G0?JX^=W.EZT*^DS2H=69TJ!0(>10A M@6SJ*X0<54H#7VR%2+J'-'BQ%VPK)03!]*(;C%^:09"C&RS4-+QA0T!5K,\X M#SX)<>ASW;2L &T".6 C?QLTR9WE0.V;5G+_BF;P M!]#VRWRR#RDUQ4JK@L*79A[\%FLTXSP_P9I&W^N5C@?.O3MK\5&KO&=881(H M2H3G8P(.A%1^*3XX"))*$L]I5:Q+.%H.F?ISU MTJ'IF[$Y!TTJAK@22 F?24X<1!VWS$$+L._7"O2H'[7 8+?FZ:'02:Z)/ G/HH.6\M$SC!&G8$K U>TLGA64[DCR(4.)C M=&EAAT\+PW1C7A@_:%[8*WYZ81POO&NWT?.=[MIN&*U.A3NR(=[JC+=MI,K^ M!J7SH&&N+% G\*+%Z.D11O/Z-,6C!Z(ZHCP!49J\'J/1/^EV>ZT@3(.)_]:I MDK4I$'I &OP\S/Z\=OK:8@4#TQ]F!@]P/9[DD49ET%9-5QL@R"U1'%L<>3M& M4&F?+,&-,OC-ABF[B7<3[R;>3?Q,)WZ:A)"6+4(W\3_=CTR/L.HU'.A)\).>LE35I+?F DF)159?Y''$D5("YSPFE$KE.45WF M(1E\LAA3ACG]X;KD]C=IU^C?R6I-P+GPCROO*>B5%5JZR.RU/O1!*!W'I3S@CA=XCDL<7$"> M4Y_QD"\R>\G1+[#<'\;7C_L.K&1T%_^>Q8/9Z)?A(%XO!+)T^G^F79EA4?WI M5WC^P^QA@=%;*B1J['^=Q;T/_5FJ(Y/O?A+K(/M?08 /0/RC^%QBQ^]^NFX? M=S4F'+=A+EDQEPJ1#(C@3#HRP+:C,8]+YB(\7-*D1V.NZ/L%,!=F#7!7I[Y: M;YJJBJ%"KFS05,H&XB8,,RP8*1E*V2RLY_ 8DD\&^M2@/#0HSPQ,S%Z'[(?K MTGK6I#"?N9Z:&[,F<[!NSI*Y-7M-7D[)6^YTN#_7M2M+^B^==CY_[;Q.FI!: M/V8F?>HP(@1UN?2XR[6&SJ6))RBF)Y FYZ28&Y F9+F8^R_KQ4G#!Z8M#J-] M+%J<-PN@63,@K)A1V2$-&J>),!,(+<,ALP:3$+'2H(Y9J ME]]6@&PW)JP DO8/BW7J\)),Y=H9KZ3("3V-X;.CH)==3ERM,P/.W@Q8*X[L"L/$H[HOJ+3#T/<<1S@NP[*,ZSN!<-YJ M).[@XH@?)/YV%F2ZHBZA L2\-E&AQHL3+MULZN;7S:^;7S>_8Y0!7,!SFEDA_*^BW]#>:T/,B$.991(CS%/4-L.'5:>3 82D<4X9V6(OG@Z>=C# MR0WP\&N=EIOQIYQ:/A?$XHS[?D4J'11\=U;9(.3&V0>(QG^/NLW?$=GB*&JC MN:W>3F\H-M<;Q'$#%7J!BWU%I1/XG@IRO>%ZPN/NH>-BYZ1&EJ)@-[^%%Q@' M:Y,)WW6R[SK9/Y-=C%0VKRNI"$A(I,\\SP,!ANUPGHT7>K(NN]89N'G,''R- M!8.XO8"UF#=JE)YG2_JW+A>[^77SZ^;7A8F[O>SF]Y8PVH\]"/-,,+Z2O!/" MAQE8B:E^,SP+;#S;JAMYIQUJ*]8K_Z@O+V%47UI!9Q(]1-:O<5\SI74S[KWO MEA#N^#BV/O:F"3@,%L97EJ:S*^LQMJ+Q.)F->[J/U7UL]48)."!W&OT^F:5Y MY\N<$/57RTMK_6"^^]N51LY/A]\B\'2>8#8CK>H>8(Q/Y7&+?JI^@[G^K_\E MF20_6I^C_C 9I/&_9_&X]V3I5X_BZ^P^F5JN!N6'UWH1W#6%47]YRJ;Q@W9C MS'.F:1Q-=41%#RR:ID,8T6!XFPY'(T,3[ZVOYJIHG!5.GT'PUQY8-C10K/J^ ML36;#%)8*ZL79??6)'J:/W(R29/OX!_I&,G?WW)@=454EE?D"EY!X. MB><[.!1>Z.-YRP0W4(N'+I_R,6=?D\+]+'W(./LMGGX<>#"QU2P>9\3WLYB%4B=R]XH*]>?'/<-YOHI@U'W4Z.JI3E4)?JH #YV$?( M1C(,4-DF,1"TVDX=3_B43'4?LVA4[JDI9/TX=GH@'[X!"&#L?68#:=I;$U*=>J9-K,+ 4LDF;@V01V)>K=#V.];%8O M7S<0;\.QD5V:,-+X;@:R(DF?]/"*!7UOA:9M1RFN:@)1?ZP)1",][Z-O!@LX MODM-_Y"YA+-NBP77OR9&F :Z?TJ:3.Z?LJ$I4[9 "\##0%:=6CFT0$.]3LE_ M@2V?#C/KB],M7:[+"QV5.S5&&MI #<.Q]^B; A<\M7YYV=M#.@V.E>:,"[P$+/6":?-SFF39*G.&%/3[6B58W-:8&F04'4P- M-J"D2HY?5E.F_=XWK5N3,;"X%Z7]W=75\07L 131NY^V[(_0KI4X7+NTGCF> M!THJG+'L&)9 M7\'#[%D2\9T?95@EU>9&O^"1O'8BGYIN]*R-QM%RHWCP/O7EPU2G&4YTCSQ@ MMT$$G[]%HUG>"VZ9,ZV^SFYX;S7<(=#>KD/@LZZ<#V L:S&;#)ZE66S1"# ( M/"*Q $#DCVLA&@LFU2:P08AB[''G5=GSB<^MC#M&P?&E!ETW>%]3Z+ M^\[TU>_!BWT$M8+LS2XRCF0NO_$26%N%JZ*%<%WV7EGCV#@PQJ$IU?*1#N=.EVB]4RK7'JW* M6U*(P)6H :CZV V(H Q)X6,6JD 5":7F,VUMP/)Q;(#>4EU I=5 ME@VNR-SB-R*JBD7WZFWO3Y 6TA)^%C4(4ZDD\CT2"DR9I-A3A!:0AR[PM2,7 M^=D "GR!,>N^V]%X^ELRUCK@:Q4"^Z=>>&#L^EK_#([8>#T48@,\:I-+:)+1 M3L.B3=D\A\D87[>:;R&5?!\#Y2QSS 6MS!FDP)9Q/.S;Q'&9C9CT-3_E Z3 M]&M2>UP#@+&'L8($;5+$[DZ6[#+8;+M MXVJ-&4:6Y N3,O^]3ZOHW%U\?9O&T9_7T0 &^2$:/49/F0X9W:?+\]L<7@Q# M'DI?NL+&(:?4I\*A97B14PSXI7C;>+6 M2!+?'Y()0_"@)&B!%XA)CS;7PP\'_H, M2 >V!_/#OVSV\!"E\'/V8GS;BN:+]')H>P@S]TM:J=C M> #[ZN?Q_2NS$,HG^C3@[X_XO52Z/DZ?R5 7]63O9 MW;Z(KLQOQJ[8&YGW+2+0V8S5#GX='%+@)A8BHMP0!;Y;"@/L4+H>@6XE:D_P MO8B.MEJI8RDZI7Y&2CUO>[>0+?J&E;FH^-=74F"'A\+UI$,\VW7+Q T'.8(O M9?PWJ-9D=]KVL_6Y:_5?EG/ WZ(:_V&3')"LUC&+ MOW(!5L(FT2#1!7@'H@)VPMLCR.&%!>$".;A+*.L2RKJ$LMT2RB3%74)9EU!V%@EE.\*^-0AAOCRF MDV0QU:Y:D\6T&++TXZR7#B>&*SF*:FNBS\ERE-_*#I3:_XZ85QO/"N'4?/SB0# MJ[7M4DZ;C=:4'EIAZCD/&DK# ED/+UJ,(QYA-*_/CCMZ2*8CRA,0I?S+=6=5-K%>-W$^\FWDV\FW@W\3.:^&X'W"WNM/PU[MV/#4;H=1J/ M= 3O2$9Z*^ME6G0.O^$(2:FJ+,8AOD#*#4.&F"VQ1"&>9^IACXG%(Z1P\-=^C.65&J@=9?O*^Y1'UQ$8GZ;\"QWMK).!,G>H'UR_.MYYS/$*ZA M# ;_3(< MQ)LEP@&YNL:OUUG<^]"?I3JD].ZGJB/[$JKK6V2)"V2#-1J0(5KQ@6 ,A=SQ M?6*[GG(Y4S@H^4"&MMV6KM6GUHE+':O)MOVJR7*>>Q/]JK=S%%IL/^<%)%UM MV!;\6JL-R14/J"^!ZC#N8EOPIG66^=I\5J:.-@=BJ^;(S1-QMB:-7$ M#RXMUAFYHE+N&B68@-GKVS:RF9(\].:(HP$)\'&,W"R=_I\Q'0R+ZT^_ZD9) MLX=#"XJUIB]IP/)] 'H>Q2>CJ>9,QNLSXJ3&1.IHO-HC!1]/RDC->E#=FKI;$7(=E:LK/B)$^0@'%)"P)2EKB"( MSN%.$/'\2_4ZM[-K6^=KGH547Y%^L3<2R2G"HVT23=W\NOEU\^OFU\WO*%BA M+8[6WHRO)VG2T\TMTS@#X[]W;UI#%KV,=>.A#D?T(G%$&>:H@R;K L:7Z9FW M,]WZ(%[Z^.]1M_DMG?CIPC*X!E@5($H#XC**N1]@QW/ ARS!L B#G8,IP6!P;^J&Q21&T[5(@X M 7.0C:3C,#S'SO;\ R7Q[B)G7KBG.5A-T22NYF:HEU8BNKQU>=G-KYM?-[]N M?GO%-5N#B'78EHO''\3'66I-EZK'E@\G\R;:V=3@0>GK-:%911@VSJ[T'?%( MPV#-\N\G0(Q/)BP[',-HIS.M_>$G\&'C-(.G:P*S'H?3>QW$G<"-&E,*;NS/ M>AK%'6Z)_TK*S(648F;-1SWD@=8Q F\)^K=7^F'PP* MV65^'CSK6:Z_V6HS]*0BF'*4U_3KE81[]83@]=DTC3397&L2LFXCV#9+,ZR^ M9&A@\@W2C17#MCR8%\Q,PH^ES=#L_:DILA5L4<: K<P0&TO^F)[VAV3O#004'S&EG M6!#^/3SM-H['-60W&)P>0AIK@#<#!I'%=SJRD&E2@0LT P =&N+39#J?UBUP MR& (+.&6UTW@HN'#I/M< MV/0%+HUZ3QW0P>F<"UO7L= ML &AH5]T5RYU&O>T =\O7JUI.A]K20ROWD7M*>U\\]5>[Y4[WVPV;I]7VWN\ MNA;+LD!LC),I2"LM'XWTT3NJ,;0GLW229.0;D><7@K%V0KF,W%N$39RO?C8$7\,W.?:I^J>3]'L'T))A-) MA(0(A&U+SW&8;3.%2IA,&1"O!I/I4]=1G+J*Z>8E=AB$C)V.906NI56OHH->?4'FR/-/(.BU[MX3&;-DHV?V_2KTR^5)U]ZP\>X38V=V M;7^[MK^M6*0S3N5I-9D\#[B[T2@:]XQP!''JQST3BK8HOK+JELV%IO4T=1+3 MXCR?70]9F"WF)H$7.-3W'4Q=ZB$>8NJ$!5**_C]WFP:E:XP6<_ZQXD#8_E_6 M1.Z.4!>=NW-9.?PE-'"VX)CF/G31T\Y HCYSFRZXJ= F%E55/PRAJ,2!4ECZ MTB.!#3Q:6.V"2&Z3I7-0,*/_J:WH7^,HFZ6Q#DC\,9S>_SY.;K,X_::MRYOQ M9#;-=!>R<0_LZ+(G&6P$K(>KPUQE.Z*G,M5CL2N1=GADX?#L#S'$+@)BZ(T8 M&^]^^O2LA8$5F4RA//)58^R)[J32.%N?)13$AB9BC..*X3E2+E/<55R$GN<* M['-7,$6%'2!/^$O]!'>F&[UYFXT;;T73=_]K& M]K6XW/-XC YLCT$<_% $MC=YI>>LNC>R,B65[O8P\EV,!+598%.E&"UZ67D< MVVHI5O@*\SI-=?#,\'8>1[L9YT;6Q\&:6^8J?54:U &$09.M0"^0Y\_=!E@K M#";1DR'+3L^O$ Z\5BW/?/2V[6NQ/^>I^SLVL MK\D*D7%02[U)0[U3\2WCZE>'$>4NNWZ D//%)7VO7Y9+R_GF=@VXF?N^S7SN M@#!D+%3"+6$KI>2.MQ3KV#\<*1L)1U)F'RP[>WDGVYF<_68,GU/$,AM=LY.* MB6VE@JKJUVQ.2."$V,&('@'E0CAB":;KB!%0U91=A4FC$N0,._5> MC!'U@FL4U;QV:UHUIM:BXY]1.HQ6]=EZ*X$3@2N6YSCDA(?"<14)N,M]^%$P MQ814 @3!$B#!"D/@4YI\ ^FK,Z5OQCGGF9;$((^C414CO=%9Q9-1/(VK:.FZ M_N%["X!MXB:X252""W2DSMU\.%H0]2(#*(+RRBZ0/B(><@BC(?:P#%R[A._T M7!2J]D17FY<2=+GBO(O#O 43HJ'HZEG+ "YJ)RP(,\=%S.%<<@6..''+B(%P M[4:#J(T9^XTV5+I 'CUO%?_J(*K:.T;4%'1&&]W&@X175T$>[)'J>9:!5U%# M;A:">H(B))R *!2 ]\6<4HQ2B9? -O8/O*IF J_\N+ 8;620#7&5YNN]6U&< MM@10#Y_S>J%9E).!N2R_<7'8R[A<&ZJ=#F'L6!I_\-F4S'_OTZJ@Z"Z^ODWC MZ,_K: "#_!"-'J.G3!?"W*?+\UM8@!6U8F'(0^E+5]C X)3Z5#BTK!6C7-!K MN?TR-+B[CM&*.Y=:ENHTKP%9U*FO?EQ>2ON0MV#09>'@]>GQ%87!:VO2?@"I M4""EQ?V_Y8,IB^WAVY&N^K72.$_<:7F TZ\=97E9>E&#KC2])H;;SI1.V%]UNNWTU9\=6CB34]0// MQ8P1)U!",.&[KJU"N@S3NEO PT ?AQ\G$TUWD)F3E+^ 3+@^>[FFTO^J17I M8!1_KQZ\%=[?_+Z;<>]]@RW EGN -44G2T@!6DS,IU$_[(.19[UT> L71K?) MM_B]];4F46"P(-)UV?^A*8=4I;^>1T*;A0I+1I%#"7986);^"AN19VZR"7@- MQ\6 CI WMLGZ," J!+3>X$+^1P=047O@&A2 M&7J :_51[:RIE' :A> 1*+504CFL1&9%UMTL@HNGL<& @<>,,0 OQ;I],B_[5=/2!&C9X$?46+S^%&,VYH@R2?G(!1"'G> "YH?7!73A MN%]&EH=Q5AQH]S]69]5PP6_).'UV=*WO+Y #-+S0OV=Q]E4[ 2\"";B,>SYV ME,=9X#B2$\3\TCC$'@YK0 )N$#@"!2 [?!1*0BC&Q8$\\AWAXET_C?"UO_&=X)%> $5X26 D=:LURY?X#);4! S.FS[/9JW+_K)6T6#6^@%O.FI-D\>8RS:3*.UV1H M;+T;E[_:VP:R9*TXWE6<(18$F'HT5$)ZH11ESI-[N(="YN;>AB\F:V]VG MKT^3>![?_.Q7] +DLD0MAECFM++0[&39?W_6;V#Y9W]^\.!%V7T(3FAS(56U MG*RR)MK6?D)OIYA_]U.U?Y;>0$OOX)OL;50NA*6;#9UZ!0XA.X];12-)#>K+ M=H2O&)8\Q';@.J$0Y=D?H8@\._NKMWR:!R2-L?RJ-O;#\8HV]F),H91A# NE#5N?@L/PAQMJ71ICF0_I9R:#*RB M..-8 ,4O,GM;['B[RN'SG8#ZR@Y]QD5(?1?9 2E4&/+"$*VN>%D=ZJBM_,=! ML>YKPA^=>;^N,^-RRMFE%?/L8JF?C?39Q>8^BFG=$NM9VG/10V40(@\IQW>9 M(CZA=N"7UC-&.#R>Z.F,:BUZU++HV<.J;H'QW!K[6-5RYGTB7>XZA'HJA"M" MJEQC'_O@2CI('(WHWX;9O#7QR^6X6A-6\_G'T#_EW>WBOO7_- K57A;U1BBR MX\7;#V^*$T30,=?H9'6!)XZRMM2H.RJMM\\:!.K?I2E0.U:MM>8&K"J^I/R< MDZ3@Y$U&6<#!Y4,!5KI-E"2285:FWW!% MEZ 83Y9^DY.,H9BR6//VZ5MIH4Y+"[7-B3=\ZS*WC@5.G7GSEI9JU]R;MYLUTZ3&%@+(K\TY*[/@\8"[BB-J4@+RRRP"_M /6LO28LQ-0RZ"=YQVO M/S7?;T?@-9PSZ0H>NLKS0=\ZMN,Y*/!U,-_7*"J^:[5DA![OF-&"#Y/2 MX+/T793E:1JM.%R^$[AU!'VJ'GA($( U[$!(+0)NP\ M8H9-]6:^Z8/'_*U)A%J.[6+4YKC8.7 M,F":QZ9O#+?06G[;*@Q!)G/F+ AB:YT)6_Q\[9> 'ZOW*WC],UJA!4CC]@NF MS Q68P6]-,8?-PQR/;.IUY)+?L/ORV"9UF."I/4FLPU^5.AR8M4D:LZ]&\:3](XRSLV:ACGN*^!;XM7%2/4@$ & M77=J1=5(H]RH?+^)^EO93^'X@ZH,JV6D]6(SLGJOW2QYB$N@UCE*4V\-+)/> MH?19'MG#'*C)BH"^*NQ^2WMSUR[NJ?31@9@H5L/ M23\>O;>^U+!?2USL3,,6EPC'!H*X(KYB6-F5_NYVCO7[C![+]UDZ)F\>I@\#HOZ8LDEQ[^>HZZ#T$K3)R/*YOU- MM!C-YI0SK"C'-"G1N/CI4,O-0O/-L:X[+.O#8UG+=^L-R_P5]DM8UB_\] *Z M](Y/W/ME)P4X2.!56IE_N ?O/E[:\ETX+]=Z&U!F[4W-? _@2YXBE]]9 H9N M?\CQP/&%_*.^_,-P"@_N:4\-;+4BUSO;U =Z;9KW*<(0[0%N;0/>^#:K<2J) MTY'-.K*1+4Y1.GBL,_CW3&7F7(DJYRPWF=W26);*9Q-%K.4+XD M27)2)[J!>?U:CSZ/P-@;YZ<]*PR2'8AY-GGAR.N%DSA[,BU/T6:3-80R-[#) M 1K'M(73154SA+$M$:.^ZU(6()\$C/#29@@%62H)]Y)L>CR+ =M-%@6VUC"X M /W_)OBF!J;G>;Y"+'!IX'(4(!GZO,#Q))+8/-B5;YK1CZI)0[O]6O"HAG43 M9^6SV]&P-WH"/37JZVZ[L]0<&I],)Y)F=&*C^] 2IJ>URB0D'1]^"'R?V\#U MF#NJ9'J&/;S4#=CY%@U'^O@J3-(OP+9?YCM].(UYT79QJP1!6S7L17(AJ4Q6 MQ[.19&$8NHHAY 1$,J_D0INJ_;AP1_W[GSA-^E%VK[=0$DQ^O&@V; N(?5/S M_"W1:5EIW(N')G7Q[9JXM(86IIAPA6!$"D2!MUS/(;+D,^)R6B_S,2OX>;Z M89H\?$K2Z2 9#1,O>8 W'U+ID2:C0:U5;F])AYTS"PF[7BF' HIME_@"^Q(< M2(5++]$/B=T$"S7C,9)EN+HS9*%V>HQM.HIYGA= )]^M?C+3"79[%:VM6\U3 M BBMR [8Z61GTX+M<_1S4@B\%0NTG8"KP>M3I1S)%"5$"=?!MD"M3HGU.4>(H)[NA4?YV5A M!&$^LQ^'T/IGIHM*H#R\$%H2'/0S'ACZJXCM=:AI-S2.+,KR^%>EJUFQJ MC>(LLX;@S0W3O#9P.+"B\=.5-1G-3&4@/ [^Z-UKH).LJ/[3I3X#\ >M6G4M M#+87SZ\;CBW#4S"H:1J-LYRY,RT,\DI7776CMT&_0I<1PH)%:6T%RL*@#(22 M-E:=%>GKLORT16J-$6^V@\^#I M6;Q'$I_AJ&$C5%D\\1E9WD:C: SJ,;N/]QGEE2FZA^&E??,X(P9^?__EO?6S MXWPRJ 3E!&8&\\":P!!Z($RZ(G=]A],JX(&K EXDFQ=,SRNJY^I@N7#&BK^# MT]*/\ZW.[C67%;927K5OR+:X'<@%Q'3!'!KK9(^,GLGFYCZ>/L;QV"MJS1U3:NZ,^[_/9YT_ MX6!Q/(J7O=4U+71VH(7'^V'OO@X/$STD8.G\IX"NF8*N'^H_\[V\LFX^S5%* M[I*D_PCC, *@'\-Z:8MA&GV?0]0L2X!E36:^SKETD3V7:^6VMY4:.^RRY&)# M.?/?^[1\RB2ZBZ]OP1?Z\SH:P" _1*/'Z"G3!OE]6LPO,A2;^8Z/I**.ZPG! M9:B9?!K\H_7SQX_^'S>__&(YO_G6QZ__"#Y; M-[]]=7[[^<;]);"<+U^"KU_VL7>>O]PZM>ILA?[6J"-W:9)EJQ!'GDG!Q)B' M2V+3_#;'^])&::\W>Y@5?Q<"UR@V':A8OCV;W6J8)0WG].QJ_=CZHQYA^/%U M,AADST>6ZB<58"?9!ZL!EO[2NX_[LU'\<;#(T<#D);]O1MCQ,*&A+_Q <$<0 M\(==,>$8A+0P@M6+Q;'STJ M@DV7 ]%RN2^[M,3$#GSF1? 9ZZ0H(>W(I'O;N[\?V$>'/]06()E34-3/QK(M MXQM6'N!XX]+D[5*#4[D3:]VN(XVDYNG\_8^Y9]-1YANES$Y.==1PWG*JG6GY MQ\BK=%XZ5-B7QL]ZL?;)U+W@%.5N][O=[W:_)1/O=O_(N[];_!:W=Z:F)2!L MT=W3=7$$=B3#_> SVZ5BY R*>(40F,>*U;$0L8/LT M<#RD?,5\1D9^_*<9Q MN(3T% ['8 K_,OP6+QWZ&T]N37?+LIOD"[>[3[]&_TI23^?X/>M 65&9:6.Y M>-]2\\F=P67(E6D/>/Z%PF_ 5^Y$RI%%R@\;9(JHSO253U6 ;8\AQ\&,N,H+ MW4*F. 0I^0J94HL'U!WR,Y8R_ I6HD$AL\R7;2#V5U5-=5*IDTJ',71D)90\ M)D/&N0A#;BOD!*%;)A JY@55+_L]#!UY)B((HRNL[,[0Z41*)U)>;>A@A&J6 MCAN"\T0H)=+V?8VQA22A[6/JA,I%,A0>*R,=W U)*R,=3;,Z0XTBDFVBF?:K M_TXV7*ILV"0:>"4:%,%*!+["G&/7M67H^*H0#=+#:*GUS GB#C\B\OM M^+BZYOD-(I^7,D!5#CUR"??!J[>99SN^3WU"<>G0>R%;ZB!Y H?>[-_ACA"N M;'X17;C>P G"13#G)@V-,:^UT!$8.ZX*@U K:V!5'YI? MD6RR>=;Y*.:.P<^#P3?Q=RWJ)@@-L"M"["!'^:[OV$5W2M"^#+NOB;H=RK4^ M-#>+1D_6.NW;,>=^VK<6^'(#!MK79KX2W$<$O&2_C(F[#K/;>29^6'Y5C?;L M.!_=^T8J([NV'%LLDOG8M>5HL"U'*7ME58JJ:5P(HD"0ESA2T)X($.B)"I% M9N ?KEBE 2%J7V'5:);5WI3R*I.T9;S597)T4KB3PL>S6PFIA#!1CF,CXONV M3URE',KF5C1=V>W=A*SDYB=Q-S*;F65R QEX(8()&40 MTL"VB8WL>4V!C3QZJ#!K T)47 G<9/EA9[Q,$>N'&V9NNWVLMO+;B^[O6P_GMO9E_F6K7^.1-"G*_W8R5'9PP]I M27859;267<65PH%-L2UMGWI,H7EV%?+94O9D21N'/3 DZ K93>8\=>5%;=(9 MG0AIO0C9%)R@@E1=W3!%-!2N$J%/L6L[3A"4\5R?D254R5*&W#Q,HF$:]VL1 MB?PKW;SUET/*%W6ET%&J%\\G>ZN31YT\:K$\VB2.9"6.&&>VC87T F0[2 F& M6 E(*6VRG)*ZR:1IZ"S)OI*XR:*,SJ3I1$@G0AHT:1BJ9(@D! 5(8H1M9H,, M0#JUO<1S0&+IO&4?DZ89^=*9- V=B[0X,',SOIZD22_.,BN-LSA*>_>F?70_ M_A:/DHFF,>N'FT^?_QH]3'[T-W5+/.<2E4VLC.6(7EP4)&PI KY#,N!>6A M+TJ@+M?WB3J -I!GI V8["J-.\;MM,$JHGH[!\#;=OJZ;)BX35JECA!%,;49 M]JG+780)IY[T"JVB4.@NG:*VQ,0YS!-EBK9T;6]>U7*;?=_$_[7HH>E%_7$PV 0:=R(1@.82 #V7 /^)TZ0? M9?6TQ7CXS:(EKV1D!G0SH M9, ^,H"S6FFK=!V/,XM9UOM?@"G32;9.LKVB2)\K5?4*L5$HE<(0(6*S%NR,YCZ,J A$BB@W"$R+ T_P=5K M1-OV4;_.\&N/X6="?W^?1C#7\OM&1&^^,[_-'N"6WK.9CH;C^/H^'Q@FZ"\_ MUJ;^KUDV'0Z>#J0/CC^(F[$UO8_A?\.T;_U[%J73.+62P7-A_NJG:O=IYYNO MK,?8FH!^ N:*^U8R2ZUH/)Y%(VLX+_>QIG$VA7%:T6ADS:LRK$F:_"ON33-3 MN:%O'"ZB6_62%&8[C\D7$%=%I0?,_0&6O0_+$4W-NA0_/\9PUSB9%B.(^^\M M6#C-3IJKS8"!:X>#H;DWMGKZ& ^]@S\&SQE>2#%D[7T&8YG<69-$^L67CB! M.4S2(0BI]Z>FC980Z',XLCH1].ZC]"XNMF=G>LMUTG]OTDEV5<'&D;)QX""% M)'.ILH4?Y'%6A<'Z=OG2:?1\R!\'KSV*]O-0Q/_[ZC=A#9V 8R5L;OM.:(>B[$;M<9OBY9*G/?=>-K7W MM+U;+W=_LQ;X+!MMD159_F/5F8"4 P8$=\V=L;)'9PT1O3F;-,@/% M:8R8NX(^#+$OPG,N&D4PQ/?6J95V*RR'8# 6Q",+>M_(C ?TR<+7UE:VAA[ M+8U+(ZVP,7^+9VGRD/2U@V@V!4S0R.QX%M^9Y=7+#[P3LF26H\E_DS@%;U%9_OGZ;W#^:)YKTK+GUO?;T?9MK& M&=_%0"W]N0':FYIG3!,@V6H4O2A-G_1POT6C6?P:&KB4#?\(BY+%W^)Q;N7? MSC)X+_ (F/?P,4GOHC%<;5@H 3,]C>,5RYY]*+?O:FF7KLR?7I3VA\FW"-AW M%*7O=Q=^83(:)8]ZRXR/T_OW;)@-IX5 <+_^#'1Z/^S=@S>1:&G0GZ7ZVE7N MFB9K9*JO$T/Z_G*K*3I/\"UT_7UP KUP7V9@***1M,GZQ/8 M] ]1+YZ9&$A6#0^K'>@X5PS$L\U5B.GB7EP@3,?^_3\BF3Z"Z^ODWCZ,_K: "#_!"- M'J.G#-[U]_MT>7XP_<+AC>:6UE<8]Y=X%!NKY-KUO5#8B FL H<0+J2;A_N4 M%())]QJ_*P]&BE5<[RX]-\6^].YC$.[QQT%I;^DWNZ.D]^>[%0/A+F,!#XG M\$Q%L$.14P[$4QZ^KC4^Q0='X%;AS,!C!#ZMTF!E:"6+)Q$P8#QZ*JX" M>;.>C9>X]4/#VJ+V@&?G!6CR/7^ CL",\\_U-XRUS3QZ%BO%*#\OR>?=BT>C MXE>3A*D_P\A[Y><5V_!U^ !*Y[?XT?J)O+_U$=[NM>UGK7[9]H>VS M\X;EPX&S2+1=Y=_] ,9*X?IFFV!\-N%NGWB1"L/@$"DB) -)J>^%KI\' MBQP>.,[2^?$+:;AVK3SURS2:QCJNXA;QTB]%S-,4H]YFW_\/+/H,+/K&:L[) ME;0;S=YM7=%IJP18FS)V.[%T&6))X2JER<<<^:XO'.K#OR3P4('DZS /.4O1 M],;$4NYH@I]IW,SFP!:;K2SH9%,GFSK9=$39I'!UOD8=%C+A^LA&?N"$"MF> M*DTFA10YF&QZ'OMH3#;1*QLMYV-UTJF33J^33BTKWCBVZ&IG;=,FN48KN>9+ MW=I-!=*7G"/F"^'8@DOJV9(C)0[C"I97.:/1QRE,K?QQ=^EV$B2B\RSE[.1> M9Y6=M57&JL),&2JB. ]=1S(G4(@PAJI EH=>)[V:Z+9RI52C.$*M,ZM.BH+6 MP+P^+V>3I?&WH]P5@>\C*5W'I8(KW2?- MHUSA=5RE,W:3_LVXE\91%OMQ_N_:>J)#QXTS6$;X[N5BM"MJJP;Y=:<"Z(/S M\AO%LKD(QMW$M[+B6^DBSU',5KX'-GSH>7;H%GR+W-!?&S\]'-\>*+#:-->V MUE;OF/#43'B&?6PZHNJ(JB.JCJC:3U3M3--J8,)ADL8P?*LW2]-XW'NR!J-9 M;YH7G!7 ,#KN6136[NMWGB7H_@:'%/ZM=>M6 18>N*AAX(=VX/'0EV5B@$WY MVF[=7]-HG.6EU,ZX_VF6PGIG<55'[_1U+9Z$ @@%60F% MP%&!#'P?$\1"Y=L4^4$A%)1RPK6QWR,+A7UEY)+97A!R'0XK#X8D079+A,,^R3V=X=#)ADXV_/_LO?ESXT:6/_BO M(&JFO^N.4%7GCCME?)B 2*F%,D6J +%G]UV]F B# M0^(%2B"9/1Y;)''D\=[G'?F.K;SDVB[!X 02Q @''D:)*0L@EHUPQRH0, M_)4.\6\ #6<2']-;9Y7C\U/E\XTZ &EE.87*QZ&D%" )N B(4O.078;9476 M3C7\+H^ZSD"*GWH$RL_S4HJFVEJ>#L_2';V=7&:-7,81BAE0!$/)HB@6.$"U M/0\P(\_:\[):Q M$G8C!KMHJT:Z/'-UT5<]*Y*U7&Y\]\YXW918ZV7>Z9K5/+ROY.HL+BTG&R%& MYS@H0XF@BB /"8J M#E2/":JMR%2ET51;^I' 40ACR:"* GL*$4(*.5AI[-L)J)[6<8/#58>K#E<= MKF[&U58@L.]+0'T$@: A\0&.H2*ELJJ8T)/8#5<[T#;]*P&A0\5S+3'WNMG_ M?3[\W12NCZG?=+#U@PAB'!(!8Q(J[D=JGK*G]-_'"=<7O4GR[Q(03B>8WX5Q MG 8G;V)DWV^%=]%5CBU[RY:" MS=DR#!02' 2 2J0H#;@B<_DJA7^D(CH[L^61'+S4)=\XMNP+6Q+8L"4#F$(B MM$&(PXAJXU2:6""N?$1!'*LCI:/OQ);=NPB7 RH=;SK>[ MOXB80CS ?8H(0 M"B!!+,0TPD%=8HH+]6Q \V44S G8.?-7/,.4.)MQU'OA)%G38Q(VTX4:? MQH21(%98D!@) J3^IJH"J11[UJ[<,CW@=3Q!KBA++]BWKX+S+'G8;X(QH=9V M,5T#3W5.G'IL7T<$_5$:([C\^ ^S?8V33? MWLJ)BQ('CB@=43JB?+W@3RJ:TC]2^HJB "I$ 4PA$0 1OV 8Q@%',KG=)5_ MZ/=/T_&7V]O?TY$V*8;7DZ]:Y?AR6]L5?]?:R5L[%[:*_NRTR/.65./"0QT6 M],)L8;"IQ2,"@A"ZH#8+ZS"^[N( P(GF@]HP7%CY0'$P M56!-%LR2$YK7U-6V6TB0S&L<0HAAQ0124#4(5Q/,^C M@?C9>* #@#/# !%$R8;40$0$I*)@.$ M1:82= 6 ^CN^2\62W0#P6-F75\SO,AG% : #0 > 9P: /FP $,!0QCB*3*12 M3 4)_,"6PO-]!D,JV%$ \/AAA\1W(.A T(&@ \%G01 W(=D$FD(=4& ."26" MQ)&HZM:% %"QHQG>LGXR?M61Y]F M]P])EEN1[&5CKQ[KSB]I']+L?//50>_E>]_L3?*#WNSO??.'MR:*-92YP"W/ MG_TNXN/7P5TZG(W2R6V<:2A,?\F^I\-/XVDR_I9I=I9%D4Z+>#:=Y:F\GVB\ M^IIQ<'W*/)CCH@4$5) 11B& MH,1KP9D?A.I]*R@!Q0(HA01! D11E0?+(A13]VU]5+RX7=GR6TJ/+29'!GCF&UPN[=Z@WU MBID1$4;>Z\]&K'E/:9(7WDU2Z+G,'O2+)[/<2ZJ1&&F3S6G 2PP1> _ZM]O) M*)M49[Q[#[$^'"X5P^43XMUGG!5F1'IH6F\MO!\T"NH;1J:NZ%\_[L6F XVF M:;Z&7EKW+^B>0"M/]OYLK)7F\G/[!6.C/HP65# (2H7+"DUOD(Y&U:__\0Z\ MLY_UP ?UYS7K<9W=IX7W.7WT?I_<)RN:^GV2?\O&Y?"2V712?U$J_O:;QVPX MO=-7Z\E7.H=6)T;)0Y%^K/_X<5F)>#]G./S>,MK6'N-^$P,?;#T ^YY&$0*4J +ZNRLCZEBJ]TQWA!QUNCW7W6 M4[Q^3$??TU_U2.^6ZW)U9T/KX;I/D^/Q'06N&MYIB77D$OQ7&%*T,F4"$04$(2Y! M#*0("%<"U@P9AF2EF-8>#'F7I^GQ6!*==UV=,Q2%^')%H< -Y]%8"15IEM," MT0^E5DOK^!R?!92LI*ONSGGQ9)8?C_' 651#OR192)PL7.5(VG D#! 3/@/: M/ PB/PXXC' M"T&H5@)&]N!(?>W1.)+Y%R *CW]J:CZ;'@X_?SE6GF1 M9W.,X8_>?ZKHYT^??_9D>/WIOSY=?U)?/?DY\F+YZ7?OO^0O?U?>KTI^_?OO MZE?U^?KK]N,\CW/HU9.K-2L:Z3N_:RK[GGJ?QL4TGY4'TZ:]VW^FPV_F_$EJ M1OZ>3;/E'F][G5[&29;_5S*:I5%6#$:38I:GQ8O'D3&.-2C"B+* ,<40 TC5 MQY$01+QU'$DH\F/?][$OPT@(;=?C,M5,0*1-_:C$/;3^[KSG\FBN%VN5E@^F?YJYJ>Q_=M=^;S[9)Q\LS&-WD,^^98G]X7W>)<-[O1=@]%LF-J3T5F1 MFG/,84.SYKF:"%O?W&;C9#S(DI&^T-J=)+\86*O7QG@1/-25DUJ.+%A'O;\T<;.=F MKF:,5^90U2S3MT0_PD1::/[2+_"TSE'.N7E)X7U+QWHY1J,GO:*WYK2XOCBO M[L_3P>3;6)/"L'J =Z8/ M23Y]\@9Y.LPJSKEY\D;9?68::'B)5F@>JO/DYGI#6G9O_U?OQ2(Y9]-924R/ MV=2PAJEC9VE2D[+FD?H]B7EZ<=6\R.Q>8<=67I;^^6#QU[PL&^O5RX8S M_9ZED1@BUV,V5/P]U=1R/]%:XL345%P_Q_+=]K;%M[9?L3@ RYU:TYQXZ?W# M:*+?D12&G<;IM%RF/#=04G+$]"Z9EA.SS[=KNKS>&A'>/R1/=F7T=B2>G8Q- M!O$TJ4]')2,/+1I,['/TNRS=E\]_G,Q&PS)VRS8Y?33LVRI6;(8Q.(OF3W1PRG,KV7D2(EJTU*@:5R)9[D9_)59#PN! M)LG3.%992 M[7J:IP]3;80,JRTQ(UFB&+N@)E)NX7M/6)WW$FS7!CO5ERX-<#579/ABJ M,VO4X\M%'>R_[_(F0N9;^OXF3Y,_WB>W>I ?D]%C\E08@^(N7YW?DI6RC^X& M#U/)T!N$E-EG:HMW4F+]QYE1/LR;];/"6ONI5>>62KT] 2\$'>$Z4.GHQL&[ MGWXW /1KH^A\-?(L_?;4LZ&_^\DH3&O5T.?43XNSA8:YASS3:FQFM1XCRM)I MDC^5X7*ES!IER4TVLM;.E=5J!UH6E:JK07.#3Z5HR_+A^Q*BVUK>E14DC6 N M1Y7F%A4UOFJTS_3[TT9 /E1]M(BLWQE$333NF ZGE0RQ#PU M:69;XK.^KM33_O[AZP<-R1K!*4"VDPVJZ2B1ZR;QBE6MP;4:#1 M>#9(*U%76%ES5Y&WU@NFR1\6I8??M4PR;S%BQBJ4I>+16AL[EDK"OZC"M^32 M56O']&X\)OFPF8>!#N-FTEQ,[_.#<1UZ1I/4 M*_.MXH0G&Z^K.="4/IIIW5KKA=F#?=OJMB\;4I6NJ)?53,ZJMX.I46B3TD7R M9-DTN[W5=JZ](&EF^4$+ V-*6YZ^V@:T\K)0F'FK@839N+*_%I;+S,AD%"P; MAXO4WD?UZ>W=8>]^,G(Z]:+4Z-5)N:!FX6R)-O/I+GO807"?[=)IS:828D_Q?)KX,FOH7<]><@&'H?TV1#SI7V\ M\J*6:Z/EO-P_1OV'O6_=81H;*]9=V5E;5<&A?O@F M!]_^^VRT.JT'ECZ*#L=O_*G]\.7 M\--?]Y]$95'O_8 %S:^HT\N+TAOQ[ SV'Z]I(#LJ7;K6?'HJG51K=6IO,M!P M8[1'/8C=[K&NEKD?<^X;G1.__G,N,(T2V#T5AY7&K#E6:Z=Z1?4R#P\@UN2A M=C >:[]++[E!B_U3[8RJ8Q6E[[6>5%L,>4NR&@ 93_1.:![7FHO6FJR/\:YQOM+EI:05.L_O4Z7+UN93Q&,^%U-S*?MY,-&)LT3ROE1&]UJ5, M2VS27(O%7C#GJROTU]9=4)J1M[.Q)4;CY2X'8'Y:,MT-^97FS-?'K#"N3RW1 MEFV;]6:,OF4RT^_Y?S4#Z"5[-/);_WR=9(_Z8\OHMUZT4ETPQV;FE<7#9.K= MI].[26E4&+(O&L8SE43L*=6BFWC!A=O6"-8NY0?O[^/:H=UZWU7I/YC+\]LD MJ]659#K-LYM9>0QB7,^-931_B'54K.H;'?*J%R^?8$Z;]N?:;JM;G7L_A-?R M ,EW-'7C *BQ]&(/.UI$HXW1^;FKV8/W-5_5]JW&Y/D92$E*]]6T2E9:I*M: MC:T25BO97=3G0T6J97AB3DJN2FMA9,])#:&5 L2>U=BSW[FM=E4JKUH'3 S: MO#?(8_)C]5--BIJ]37/-?2TZYCL[1X@:&#YX"QF]U?7/S3JSIZSC1IYD]7%0 MGV1'.=NI9YP=FM\;46)5^2-1X:?ZB/_@I.@C:K1=:3B?-979DMDFV,5J&(;: M*I0W]%X>->J_1Z-:6&CLUH,9EWG=SPNJ+8#60."J^#%2Y7U;VJR71V9TK?/] MI%*+#T@1+RWX?W\NUI%3B'#JTR98)\#(%S9@#8* *\(5ADSX@$(!N/#Q"XG,.XMBZ_W%XG?V[NI-$X%IK# M''-0LE!K2S_NTWR#*M=#9_6V!%T)JJSSY9>"*W=G,[V:11GO<@3;YUKV4D[N M3^0G9F:[ XL%4Z&.QC#@;,ZH4AO$4= LH '@F. M24B$XC30T(=%)'F,Z4K+\5^T,7NM14N4WBRW"%DN#6@NG5:77C\]I/.2J-?& M>9A_,;-> :;4)&GL TQ@-1FQ,V3Z(7G0UON?MGC+Z.G8@JE5MIN04&(,9,A) M"**0Q1PQLSM8JC@*T4I$Z[%WYWFQ(5XN<_8!K-N?FV[VYP 3R)Q=?_N6I]^, M2O^@F= 8-(X8!8]#4IV.(2A^&(06""15&* *A\,GR5IM] M:[2 6MG]7<_#EN0<_I;F)KPG^?9,BL5F0J@K[2" _,^3:;I:M=.JKFV"H'-Z M>(]>) CP04]SA2#^^\[KRK"SHP$.] MRBU",U;GLQ$'*Z<>ZY3O[9U#9BQM';S6U@]8&]E-+:>51C\[/ZGTZ>AM+ZG6/#.JB*;L1A4!&E(A?+<;D%\L!I2^&\FSE/7QK7;%7"JOQ MV[[@))B[94TDL3D":_O']"*O.W-9=^[^5H?;);[6 S>D5%0!AV7XNPU:LRZ. M5J#Z2T%LK8"9#:%]E0.DO'QM')(]*B]2&TK>6M/G?8AUI4]ODF=ZV34@FL.: M*DFCC)NNHA -N5MG3>L\:]'K7,%9/>_BJI6M,3+>5!M99(*Z35' )D; 9N@, MWT\G[ZM7(MI;;?>Y*;Y\S'><0]$L5A9Y.S_[D\ZVAHQ?XM10LM,1"+R#: MH]:GRU0JZY#2E&F.HZHH69,L9:-V#3!8RWT_:#"/^SGX;4%#7 W"#:Y_/D!' M^S1NG,(+7N"66C2?]@'BN$S_,$^K H+OZ^RR.KBG#-NM%_CH'EZ._$;G8D"% M(882P) 22@.B0JUSB2!FE%&R4OB[T9Z,3_?+N/G\O)>VR*?_4[M]K995$\'_ MJ+__/E>Y*BVK%>>WJ)$9E:6FS^[:) AR/.](F:64+&;IV4,O(W3:<2V)8:OJ M +/DOF<$0A.3- M+XDSPGE Q23,*(8A2(J*ZP(!)@*_9H%M.G?(O]Z#J5'I#Z'3H<;K(^Z&XAL M<@?F?H7?\HG!SZ&&M=;/G9D=Z ,]JMEA%)S')=%0QU+;E,5Z>[,2>-^"+/]N M:C*WL@NSE@R89PT>[&J&#&_P-'/2-* A+$"8 VWWDHC1@$(5<0W!$BD-SCQ> MZ< 5FA;N^U/9.NK:S3BN3O)4)<'#:F.7'G40GG^[>=B+QO$'#%?+FW1%X_8, MR 383JV_:%A6]VYE 94Z26V!-Z!0,L.1(8WP.4DA @D@E$$D!(U\"#A01JI3 M#'DLP4H!TTL@J7UADWS !^/I,I:\7HWEXW,Y_*:]O%4+(01')D,:0O9"A6VTIK@Z14*Y>"!=;14/%Y,HWFVRV+BCA:%VR. M&]B;J'>GQ/EO943$O#W8+Y/!ZOW6&-* MI_6Y+H-8KOS_YG49T&%U&7#/ZC+,PU+-4?W%%F%2ZUQUCKLMT'SYH1N\;W/G'V:8R M:;]5 M]=J(8Y?+V>>UL^P*>WE MZ(;O;3.KN=]N.2#(KG.3Y;-)B<'8#I4VI.BW3ZLZZB!W>-21W?GC&GD"-'Z&,%), M4$:8CPD3BBB J^X$G(M !/L'#O%= X?:\8;/>+'66I*UW1D\59I/FV\6WF!\ M=;$F@(6HI&VMPA>MU1.):CTFR>_?-+5V^MKC\78=B':,S%HEXCF=P8CT&RV) M[TR5R!SHZ5U/%F,_FL'SRP! MS#P]/Q^VTD/G UPU8MM)J=VG:Q^4<;>VHL%JP9YY80)S?%MZ\LV![G6F9:%AL$XV+'/5%RO&:LJT":%S2KWRBC)/ORY;6X;6+E0(R--[FZ4_ MSR7]X'VZM?4SZ]/HOE87:*+9E^L,]"Y3U%49>![#9WE=/O=V8JJI>O^<::M) M[[W>V#+H8/E8^EG%Z[GLSA6UZR[Y;L5/8Q-UEAJQ2?'!P"D^EZGXS"M@K+I1 MYN5<;K-ZR9_QU+Q91$TYIE[?EYN1\<7,+W34,U=]_,"[4<2 MY =A__Y#,N7V+10?W(U%;;5U2I5K3A45S.) M#/D\^]:>)]A]GK2U)1NY6F1Z[$EN+)IQ-GUAZ+NS0]I'#Q&9H@QLPO/5U6 MF[_/9O\FR4?KE=ZZ5_L?LK#FD0,9,UJ: ( ME 1(176H:8RP:'5_C:$*" P8TO](;4@*1?RZ^VOD W^G]JW':YUS.QF-;,BA M5U8\KBHP%@M1VK/YH<_Z:OUY&^,WIF_M_T-'XKT8_W' M2F]J,^)\L3L]A._:C<"KGZL1E^_ _"\_UAL_/01/OSI657:^S=@__?C GDB36IMVFM_KI[0_JHD M$532YS%;RJ^313]H"5"YBYH:GZUF\[LLTC$6P:CJQ@WR\2X;:E[O O],^C+X M\<"YOC%!/ N9^Y#$8B_VU4CB=LSK^F4[=[*8@Z__!F3Q%D2P6MUBS<*LD3_G M3P&X%\!0O<5J-BNO> N":=N!%XH-CC*>HPR^%WC)(,_ON6F_8S1 MER?YQW\;#-+T]O8T="XM3Y^M-+8'O[SJ8KPR(_5GXD=@C'<_A8LG>GU?@SYM M_C[S>W:Q]@/(KM#@WX^Q[R\MPUZS[2RKO S!>#D" T(AYOXS(3' .(28TQ S M*$GH^U7 ;R@")E^Q1/)V)7O.(>9W0\#1%1=P)3IB4U[B9[,]ZV\9,.?2J( :\(/PO,N*03%T.^0Z\] 0ZF5YRO%O@\00Z^&&_WI^>*A[@\@[Y/W.49]%?J;M,2"<Z7";;LN?4V)6[,.VRD??J-\<$ H"IGP M41AB0!4.<#SW+Z(('60P=2&,P14RE3B.)(W7['H_,\<"_WZ14@CY4NW7S!A9U!&[V]-8"8A8,,@ MGR<8L2N]E#=<[]7!H/4RXVO$C/RX 3)HRU$< G)[UG2R7]:]E"X.'/!L/LH=D9)KVFKZGX[6=&):: M)>@+UZ1WU/6R%W\KNU!JF+!]E+>S\:#RH!2SFR(;9DF>I@Q>2J,Y+K+5^>WM !K*LK'. X0@Q%E 6.* M(0:0JBO*0Q#Q]_A=W>DF'3[5>QX\KR90/&S%26-SW%;7_XZ4Q?_M2C MOA/9H=TZWOW$P-ZWEJ;;O?[ZKC"@YR6C41M5;I^-&K8-&IK^):.TL"V43&^@ MU'M*DWS^N/%"C.H+CRR[GQ@46DF3;"'B5IAW5[7_:;H'S+>^74S8[A[R^]BP M[!B=)>H3G4_CKU.]@.:[+[>Q7F:]M,GHMS2W8F\\2%]L0<%1 #@6DF'I1UQQ MXC->1):-[X&]ZV"QT+NB[+Q8 M"]>6 #><\YQ(?[X9NKUK#:T791^D_>%CMVLRN9$R-E8Q8>/89]N^E!MJ_-0VTFQ977VS#W5!/.D_O MTG%A-O736"_" 1UU#'[:KCGV7*ON?M+NL[,U355TV4E_N1?W9;"P IE= >\' MT^_NK_MOE.ODLJF3BQ ?&!#8IX?UC.>55W.Z!%]G^ 9$+Z0"BYHI4%1_DM2.1;$=$.1C,[F6("R&<\@1(4TO33E&K:N$G0S&V/?J%YK[."6$3@IQ(IL&:K0_;.NK7!1WU MR]QV\'8\1SE#"K@\*!@E19'=9L83E4_N/6GPP+:.5E6_9"?K^.OG3,\XT[X=?VJ:M6\B=XG7U(@;I.+W-IMX/JNP_[)9RKZ5LT:)G2KQI M*:=7]PAA[6> ;SV8?^_HYY?)8-ZH>XVD=$RY%[Y9OVVUG'IA?\G&VA#5BJCW M6^V.[2V%.@VDQX15:R _&-C_JV=@WRWDOAK(#Y4*\E>O4D'<4NZSE"U:?%D# M:9M2[8,'MZIK5O6_31R%&@^UL?ILR,FFM87@-:M(]B$1T+4Y/;GR([W5,,YX M$2YVXF[WW2*X1>B!9_L(64I+):=>ZX#OZ//:)XWPD'&_:N44A$A3'!&B&! E M0N#',4-,_Q4'9=@GP2%N*J?4,:_VN'_AM+\\[#>F2+LP23JO9Y+>3O*T\6^5 MKB\Y'FJ#Y=USD;8][%IT[*HKK0(R9CWGAZBULW!Q,)-B^N7V:S)*B^YJMM"S M*/_H\.;U\>:'38##FFH)F$<^( "J4(9*D%D7-93%C@4BJHC 8Y#FS= &S,, M_=W+[8Q)AZBSJ@+U@;M?*^K%P=1A:I'?I,^J2'*M%P62<8U7D"'.48E22($( M^,=2BTR.H8.JGBE&T%6V/P';^FRZC!@:-B#=+BJ][[ M9Z5!!^"&KR#LLJR.@[<3@C?'[8?9M1@UR=<,!2 TS45XZ L8!TQS?,7N$8BI M/%AC7-852PW2*8L]M6O]+EN'.[O6P=3^2@FF38F( (<0!I"S&$)"-3A16GG? ML-#F;NUO-> MY^E6:<.7* Y(ZS R#@F*A*86%$@910I1447U0Q1)O.)_6P*<8P8@,=FY"#DJ9Q4XA@Z$,5^0CX **8(E$?G<7(!S5RW!1_[HD:MI'- MB9_3GQEHO-B]]=S5I?-F_8U: VNT!AIP(6"H(<"/!0.8@A#7O"^9J4"^J#5< MY\FX*#FD\<%H_EOE_67'C;[BRZWC^9[R/';ZP;,'Z=M76CJ)PW/[<:6@DF&F M>4&EE?9<+OK]'.>W=764,YCKN<_ODO;2S?4,YWK9H6O.3EFU4QCDS?$"9SA& M+ HB%"-$)?5-!)N,H1!12-1.V?%O$K=FNE57:E:M9;64+-.2[L89+P?'JW19 MV>,,K)BSAY!-"()Q$_D* DY!% E$PA '!/D$6P2)%:2 T-.)>G-0;%0I6G4(0V#T">2#$+" 1#C E!M 0#R,0KQ;P9T>!+ Y5'@-!0,Z!<.% MGO1MXB[^[8W42Q^[^+=>:#7]X447_];)7O^??^,(HDZ1UVG=;IO<-IW\-EW6 MR?Q<"\NUW:.%?VVP'=3RZ SDWKG/[V*._=Q>NKFZN?9[KA=S-+]=AQK'^:;-^?XR=/KEDW-GV!0"_0,B=;3L0 MZH5_[2+YC[3Z.L4,.M=634S/'?;.F_LW M!2H+VE3:%((#C&*)<$B*@K.R$5'-Z_V/E93HCQ703R92'%)J#P&ST! MP5CK!X1$" =4JDC%DM1N61"PE?Z/K@?*2:/%"R"!SEH[6!L"AN@F[I_DPS2O M61@^_&FZW&9#[]^ _5]'%E/U%G//ZBN.[MI8$T'VWVF2>VH\3(=>E XL@7D8 M7GF:1WEGX76G??"_9M4T%#TF^7!>$>>@>+MS-M(O=N);1_^<\R)<[,3=[KM% M<(NP8WC@22@#VT8!=C[3H\_KQ+N!OFP(8T2;^*1(^4A&O@*^I!P1)'E85S3F M$<7A:P!X0B7'( M7C4@TJ'-F[HA3!E(## MSP=V#N!T4/5FBA'NLLO#62E&?;*MW]BD[B[DTM"P-[GU'O+)<#:8%N9D9.A$ MR"F($ P:13<*><5AEP%2#MY."-X$)OKL$GCI=\&PU&'-,7QHF#0=A,-8!B&)%(>(!""4(<&LKB8@!3S< MA^:\9SV F:V:E3KGF<.G7NA"M-&%5"04\"GV \%B!C5*!744OHH0V:F_\J'! MM0ZCWDP5HN>@"EU,0:>UO9:\'Y#+)%@#=JU, C]60:#_"?T@1$I_$E%5V0E% M0:BP"Z"XW!X(E)UUPEU.LR \;9;/T'BTU809L*_B;NF\@H]$6@,$)1"*5?^W=\QKL_ MU'(HT5.4<$[=D^;YC0J"WR@(D8@58C$&G'#$>*2OB>O#'>S#5RT3Y3B_/RX: MY$K+/7M*[CH-NDZ#YSF_B^EBYO;2S=7-M=]SO9C M*X[#6ZH;7F6-@U#3<4? MIFA ?:(8XY#A&/H1)BR&*HH1"X X5J#*Z06L]2I"]_BGSEVF$AS,9/TW>2X> M_J M.:+&1DV%-D5X!,'(9Y+"6 (5AV$4!T$)&U@2I;@+DSM#[-BJ9IC353K-ESSG M:)?^3/PD0N[.4>9L$CD^O\"0O%-4G?K#R[T-V3M'_MVH,[8Z;W.(:"A#A4)? M$BF98MKN-#JCDC[CT>$ZXUF$]%V6NM@+W#PI;?&R\68#W/@0M4I=2*@8)%B# M3B @#$7 2A.5X-@/#\_^=CZMG@!-&U_^E>:3H9Z9$=H<0?1C'P#&^;3ZJI_X MJ-%/(&5:7X'ZQT (%C"L)*Q\6H ALM(@_B(C"L\'-9QZ\CJQAJZEY?I0Q1=: M6OH7'\?9:>?*,_ RG/O\+B8VS.VEFZN;:[_GZN(WCXM7;V,F]]_, M)0"(5L07U9\9HL0G0,9$@)#/2\!R*E\[R-1WINY;EZJ&P"7-.=0[.=3;!'JH MR196'$G(8X(B'(#X##% 5*LI1C"17&KRJ3F488Q$?WKMHYSA;!UYOKJZQ+LOW7X"V=L[A9_V9 M^-DUW'22[[45=M8H[#'"$9$^5$2%,)91B%1=WH>$X6K]OYU:=/K=M>BDPI4$ MODAL=8C2!T39J$OS)KN>A+'@F$ 6,RH"1 /.: 4I(HX4>=7X8Z=&O[T:W6FJ MVOFKT0[Q^H!XFP!/M#*F((82"]/?'" 8,03J7A:8!X315XJ =E#W5NY.=-FZ MJ0.L/@#6)A4-PD9%"QBC2JJ(A-+'&$.%HZA"K# .\*L6=76P]>8:VNMTNC@= M#>VR8H!=+=?+G-_%Q!FZO71S=7/M]UQ=+/">V:2GF"VZP5)!M$D6#>,HI"(, M0Q7Z2LHXDM"OHVACQ(]6 ,U%T9Y_FGD?'2V7S?@^;)RJ0"BF!/(#C",DN8AC M63(^P6' H(LD=5SON/XLN)XW_6 #I1A4/E8QCH#0O\N8UD-3%?"T6>-F'DV.#7&TX,WDBX;SY*Y,+[6M/PU':467M]S% ". MA618^A%7G/BLJB3&61@I\1Z6PE(_0@N1Z/KY%GM. G/TG!(]4E-UP&R@1ION!OF<#W[G <^!L; KK;6SQ!#(>T,L M!NPT:?XKJ<=OL?//"OBTOO8P&9NMTA/5Y#N8E>"7E!@[-"'7^IYAHQQ^\*[O M,@.=V52#G_<]&[T^9JO?=I45@ZT?>7<*Y5W+'^T@!R M,AA,\F$R'J3>8S:]VW/=-3W+KX$GOX;>]>0A&W@R] MTA+!&V9#;SR9&J*>?!OK>[QD_&3IO:@)/K7RR-Y?+\^B"%I=%,L_JTLSEVE; M@=2",-H.2#LU6E=&9;\N+[1_OGC6M3W\=6:&>@(M3<'^^RZOG_*0?$O?W^1I M\L?[Q-B#'Y/18_)4&!E[EZ_.;[,4B'$<( 8CR@+&%$,,(%5+ 0@B_IZ\*$(W MWD[?U5ZT2@M9M5Y%=1Y5VLLWQ9\?7[0ZIW?)]#YYNFG%*J1#P]H&>:<355&H MX=QL?/V8CKZGO^I7WA77A@[-\(/19/#'NS6+ 0,,).* Q7' &>4Q/Y\-B2" M[YMC.0!IB $6L60*A0&4 8!5^"40%&B+,=7&XX,AK'R6;D]*_SLKIMGM4Q?$ M)(O]A$9U^W)/ +'WDZ[F!D MB=O(=%M)_59^3=;L>DO*7YF;]).^9Y-9,7I: M^,7*D#I^6*L.Z]4!;>OKM^R_)%T >LWIAHP]3<=:1G6BCS1)3)TH)/-AMC22 MDJ4JE>I/+:W^F-WMF7VT--K[)-?67#F\9#:=U%^4 M/AS[36DP"?&!0&)J(_^E[A&.&>3\80^RO"SILVQHS6F-MAUUR2F.G3<3..=JP M/Q,_3A'9Q=36OJ^!V_P^5A"^6!+89WZNBM8KQT)2TOA&N8I5+)7/"45Q!!2. MJEPU+F,&U4K/@"H4*:RDY-IHJ.M)L.#PC6:Y7HC/>KH0E>[=I;BH3Z5G^>2" MHMZJ5)]_WIU)MM8Y+U&U=!*D)[K"YS6G%CV9K]O/H^4ZGOM>;ATTWN?8\$WZ M#V_T'TDB1D$<(*B5GQ#R.$1EZP@>4!%$P?JC[K\7J9Z;1H!/_^9:?P,=345$)^P('B*I3/XYUS:!VCBC6?+?D99[S[,:H8(E0J( &U! M%9O4?C!/E(G\"+2B@GE@@":*?!H%D?Z9!'45 *BA)8 ]B K^/ _!-6&R37; MW)%81OXW:38FMV QU:9.3FN'Z4YN;PO]Y)NG5HQOZP4VJ'7^"OWD<5'ALQ;2 MDV*F@6)= .D.(:,G'2!:Q2T"<%C8)Z0;XSX)VB_8'($411%C'&$E:0B!!3574.D('BE7=0Q,)F?+":_ M>4?XMV4NUP_% >M% >LF;5> !EEC012C 80T)DK&$8Z%K)$51P2_!K+Z)XNL MVVB[J+^!7?U3=L\MK_$E/]S:L*'+/#Q[RZWNB6_M#'9Q^U#L(QQ*]$:X8M)J M:D\$QSZ! (64\0#@&%;"5821#)=".FLI&>>3^Z7PSNL&*U0-%1?G-X*=2M(M M:;#_D=(.62X$66B#+")6&(<<1Q*'$ /,(U$[J47,<=PYLIRN]V,KCS1PR.*0 MY6R191.P^$T2F2 1"4(FL0\952%"G-0JB_0)5YT#R^D:_R]I*J^))RX?_]7+ M4!NS?F['IU5EB;:A[]S-;N)NXMLA&M:(-IS,3"K:(<*TER<0:[!CKR.)30MV MLF<6:Q9H*VN( M@H+5$D(N1'BO(@AICR" M6*RV219LJ-+8TE:9;K9[EO]+A MQ?E8].H=3779AVY/YCQC#2$[+<#)!"<3.I0)FT0";D0"D=1GR.=^K']BD:"^ MF+O> \)9IR+A=)UC+]FPG88&[4VL+G;(P7@OB]K"<8Y"&:J($ADC MR8, R7E\$@3^2N3G03A^NK[(-SX^=9K]3WTH6'4<@??Z19U"37*VP?FM;:6J MI_^^5;+IA1[JCVF>>C:>QS:"GDYL.U;3X?-AEC],"MM@^SX9)[;@DWEV'7AE M>CRM>G1M_=4\*_[P\K3LYZTO,X_[.?A-#VD\N<_*,>G'ZUL*4_$I&]BW!-<_ MS[M*[[P IC^V<378CMA%.IV.3*FJT6BAE_Q*!N?.K_FP?^_8?Z1-AVX]M/T? M5(J$?]\D$CAL1 *.PXB@,!2<,N+'',0Q$[XTOAZMW:_4.:R!_\MX23CL%\NZ MV244S(K,=!B7@W_.LB*; _]-\>?_:+)H?;TD-!R/3X/\\FCP MI:!K<3S*L\=\)>7Q_9]2=9_NL#/V'CG_NP][."M%I96/E@%ODRSWOB>CF15[ M1CC.7_/AK16)M6:LI@LSPFP\2THEV'Y=ZCW+XUR-$WZW]3PZ"^+P!%Z:@OWW M75X_Y2'YEKZ_R=/DC_?)K1[DQV3TF#P5^EU_N\M7Y[>T &MJA,8X#A"#$64! M8XHA!I"J:X1"$/'WM$0@_0@-4-.=;V?;KV)GU+#*,FL4^]@0\W]98OXU38QB M:/'VD+J=O5#!=ZHP.[>E]6+8M6@MQ6_:\AH\E?]^L1AB1:LRLX@'!+Y,:YO>LUJE=N<=6>TUO3^ MYJF6O+8^K%;G6ZT=C HS-L)U_DV['JV&W)M%C7MJH%83:P._A2EFFV9&P.J_ MM-50>-KX&67)33;2DKZLBVOP^289)6-MI11W:3K]X/W#M)C0J*%MF=3^OHCH MQDK:>IQ&Z_A6/B37M/0XR?^P17 '>79CJN ^+0B\E85%X.IYB;@D[IYA53O M*"L&HZ6$FB4[>G>VW (V-]/B3U=V@/I!16;6L%JM5#/N?5F0N&Q1K.V^Q\EL M-#1[GII5UEOYD#Q9^]/XM&Y3:]<6B\M?4H6^YV&2&^7*,Q4GK:JAORL>]# ; M.W==!).Q=XLK8SDW_4?T9RO4M4F=3?6&&K5%*Y:-L)^9JQ^2?/IDK>W9.*\\ M;*4VHNUKJV>6.V.H:?(X7GW, HK8O'T[,QV#"Y*=+\NRW]7$VB=I+8I[8?^F17IKK*KDXY-KW( M#QJ_GFPA["MSQV"2YY.;26YI^.;IJOV6_#)7Q'S'(N9;+](9''J?"D&\14'S2L)Z5L06>[BTQ/H7_@ O M/2G)[U-2TA%)2UKEQ55+=_5]735Q1S:O7DU\,[+>7R!8MVHJ?%VQ% M:6W%CWOPV>6%/YX%@;AV^V_WSV_VMQ>/B1'E/9VH?.$P'D[+OUL>9 MD7G&!6CEX3S,L J$\5IA-Y=IC;KYG?;\M@:P4\!'TLA\I_*4)$F/KX5%;(V M4/VW/'U(LF$5F%[(\= R:!FW/RU?MUOH_(LA_9U%OOOH-Q]7.V M&+]V4WMORXPF9FAI?K^_-7,&.[IUA>%.@W5>6:ZQ1JX!AN*0^(%4H4(LB 6/ MR]+DPH<"D.UZM1U-K:_S3P=]%V0(L@XE66_U=,HEIQE3Q<*:WVNHKKR3 XY%UVP>V_1GJVQ^/.)=&S'>].CW5[?HB\VQ1D MVNDB]:+SY@8I2B%K*LB$,?0E18)2Z6,,@.15RIN6K3'PCZHF]T( (GZ\4M,[ M$)LK,.H YFP IE4!&0"*D2_]*$0^A2!6PJ]ZIC,2!*LEJCI5T_L!,-AW ',A MGN27@CJU-?C>!7:>JZ_9A0->0#B@V\OSV4L7VND"^R[+C>1".SNT^;I284GA+O]#& L+6GNMUM.2:0L,=F(2XRS.7 M_H4'.02Y5 0AK6Z((N2(Q1'S8QK*.% NVL>SE M68]#/8=Z#O5:J.<#,D<]WZ#B?A1T(] M0!SJ;5TO]$V](G45<[VLEQNQZ!;!+<*K+T(_"[LYJG!4T9\%.7MWX(N.P%\6 M.J0XL\JY T]O!R\FK,CMY?GLY:6$B+UJ*=IS/OQW$[^TB?=33^^3P'.[?\Z[ M?V;Y.ZX2U'F:7HNASZV6HVY3CUL?YBTK-1XR[M>-FQ2 SP\""0&$"8@QC%&L M"%5A2.N$63_$N]6C;;F.NJY>585$MMZP%!<9UVVPFW$M/*5"VK#&USY6QSF+ MVC@.T!R@O3:@(7\.:,@/0H"4C' 8"!@3AB2L*_$%--RMPNS6@+9[M:Z+ +0N MRW+W.*3B//QR+G73I6ZV[9>FDNUA%LPY$\)%YU\)VHA=A9E4@C$013Y$/(JP MBNN 0AP$HB]V1%,D\WG)VPO1V6F9L-YE7#G,N%3,\)NL;R$!#H$O..< H(@* M&.(J9S, .([ZHJJ?#&:<=Y[W.3K_4_V\N;K]7H//Y#XKC[^'Z5=._0R@ M*QWZ#+;U BK&,P";BO%1%+"8 :PSR(DA&0X\CG@01Q#3$/2JY80/1=L0G2I M#O=6ZW5:3X9) M<6=(BB.(?CP')K\<=_$GHRNEQ=3+-64X7_$E^XJ[B74Y9S+H9WWWODA4UA3D MH-(/HP!+&8'8EX& OA_6GF0*(>J+)_G@ ]P:/G_7Z%F?XIZ]6-Z;NGNKM#O0 MNE30XDT]#<1C%5 4*0P5IDA $==5A*!";&:ZV_U+WOUS#$UT M=0G.S@?CZA("NZ!/H81]7W,(9)" E#KQ0I$+QU*MOCWF,>.N-/VG'O30C\/ M,1Q*.I1T*'DQ%WB =C2H:_H]W6OZ9S_JI@_KSFD%=9_=I MX7U.'[W?)_?)^$=O=72+#O3';#B]^TAXB:'5OFSM;]I)8+W@')(:!@CJ$U8KNDT9*2D6LXXY^(]*DE2/T(;J-.=;\>+FVH.E=_7 M?6P0^$MKCX1>A$7$)>74M]]F8=?Q!_C7I3U>V<67J=Q$KW2S>)MF_SR-BUU) MO+SA'YHV1TE19+=/WG#1LAHO6%:)3;6T/[3\X/KKN7O\\2X=>].[U-,73D>I M\49X0Y/H-KFU7])-QZCVE2>Y-VV7*;_G153/;DC MH<%K#^*EP(O?4[,3)M;".'X\Z_GQ?DV38I:G:^(N7AIZ6_S:[E''6= O8R_Q M\OFP;Y(B*ZZ\Q]2[+T>M83*?)MG8NZV#[-MDV'RY0)!3[]9,_[N=OGYD.O1F M#YH;_SF;F'B4^R3_(YUZ#WDV2(L/WC_TT-*UOQG2G-CSG\E-D>;?+8YGXX>9 M>;V^9SR9>LGW)!N9'^RHDX>'T9-]<O)0S;P. )[/\J,3,\A*^[,\FE6S=-4 ^KW=-2:RUV6 MYDD^N'LR.H,WS(K!:&*W2#-W:[WO6^3VP;LV7*^G_&V2/YD+D^6--&N;\A@&&J!ZZ'H"'P=C+2[U]N_[63Z%]@.:/?OKDN ML)T4MN\_4 S/#3..$-O),JLD[^O+@E\LG4'/)OS!'[U/)3!4M-60['TZO9L, MM4K[K22:M4AC6"K3UJV=60UQ1C(VN+8L(%?$H2.V_1]EJ>3VZ,0J*?4[[ $>O%$RO>F5AGXU4]JY3Q MYN)DG'RSLMH^UO]1_V;$_5RIJB5^,2?EQ"Q'ID>OOWND:>%7]LI/I5J\9>6%H5RSKY M:CS3]KO9V1FW)\C2I.R_[_*&-[^E[V_R-/GC?7*K!_DQ&3TF3X7AK+M\=7Z; M+>08QP%B,*(L8$PQQ !2M84,0<2-_^H%]\+&V_VM[/284Q(B05FH5$R#B)%( MUH\)$8'OP8;-6&![LN0)MB!V'.:3ZZWTBIB'2];19(W]9597_V=:Z[RE:JM_ M_KB]^;@ZD=;5"TL#ZI7(QD;_L9_;CQL;!^5H%2_DJ)/[2$D6+O\'G?V)[W;7? M3^Y=[EVG\Z[-:MP9!MEAV*"(N_[*F3/S78?T#79] MOS.Y(Y)$E YL/*&'X95GXD0N/.#64<4ZJN"'@,8Q5NQM8BKMY1^SJ7[PP!Q^ M:HM8WS,RQNSR,>C.Z6IONTA'I*7*W7OAN'+I^X_<_E_T_F.W_Q>Z_S;UP.W^ MA>Z^D_YN_YWTO_3]=]+_4O?_.>F_O??@O%(Q7XI"+4\@7=T;5_7HV=T_LS:> MW6_VF^6U./)TX-23B5_H[K]MOILCC1Z3AMM]I[4XK<61IP,GM_MN]\\TZNO7 MR3A]JG,83!CW-T-28YN&<*NW[[4JCQY]HOO4$^F%X-RFSHP%<;G'6/+*53A[GZ3]GIM3Q^N>U$\_GF>F=E?VC758G MZ:WB<@82R@%3SX!)H*9Q;*RA"?B0 "(8 B+&,"B!"80$X:!WP(1Z"$QGV9+= M 9,#IE<&)@CA')@D$SX)11B%%(9(18KAJ (F0CGV>P=,V &3 R8'3.<)3+@! M)J:(%#[S.8[C",7"#[&H@4D$X'C Y.PNAR(.14X912AHU!L> 19 &DKD^P'G M',/*(0298%%T.(KPBW,(0>R R0&3 Z;=@,J$MPW-2%]XL>L8G-. M"5[1/V3=%R">Y%\U%WV=+[2+WC&@T65K(1>.W"-=Y;(1@S2Q-01C;;,@I% 4 M:HT@4@RA6C&( %R)K7E+Q+@T+XJ## <9?8$,UAPN*],&4% ,"(DA! 1"ZM=* M!I>\5TK&I?DW'&0XR.@+9/ &,GR,)>!"2:K_ZTL5*%3'HX!0P)63Y"X@PQD1 MCKT=>Q^-O3%HSF,C% 'AHR" @ (<^9#X]7DL#A!E!['W!<2(.(W 0<8E0 9L M3DI1( &5/I"*4Z8X4T35D,$#$8 ^08;S.SC(<)#Q-I"!&\@@(HX40%+X!(_%A$,>(1I$SB"((A\OB[W,KJ/*?Z?";?J67C8MI/K,T<2!SGS(/^PT/1X#Z <)^I&F:Q50% MD-4GE!R%\0H/:]9-]8A#S4Z&]4(] /,66^]WSGI15@Q&$\-]EQGHX&(LSURR MGS+S"[\1X"!&0(0(,W\??0=+!Q08=7E$X;C?R>55U0@&-^Q_QOQ_P^:<*!0T0AHSZ,8@,!O@A5'=N' L!4[YG_%$QT M0!SW.^[O"_>+-O>#,. 1XY!S%88@"/F\!"8((>P]]SL3W3&_8_[MF9_")MV8 M\QA"0F,D)2$L$K%4L&9^+L#KZ?U.3K_-V?JIEQGX)1NDX\(6"QAQ]._IV]'U*]+V=5N>WDC6C4% D2:#9 M(L32CP),F0@P$"2(?(9KK>ZF^//C7("VY6=B]+G+/%Q=+D,.>9=!F YO'-Z< M"=Z(!F\$C8$0ON*(A3Q42NJ/!F]B%O$88=XUWCAP<.#@P,$IVXZ^'7T[^G;T M[>C;T;>C;T??ET;?YY9!N7=M^L6MPWKKAI/9S2B=[]T^"U ]U%RQ2@Q'7@O[ M\3&U2W\S&0U_W*_4_=;KTODR=,3/:]9A*^\$$ZV2VIR'C,944:I() ( 43 _ MXY;12GB;/$(08X;YB M"J(H!A1%=:.2$$"PDO#[AG!["G'#G:8,.;QU>.OP]@SP%K!CY5 MI.X0&OL$'P%O^P*.7 'C@X<'3@Z<&R#8ZNO>Q12%,,@(C@@"@BH=5/)1$ % M%Y*&_FH?@1W \0(J!BPW'NDR%\G!K8-;![=G +>B@5N?.OPUN'MI>,M!TT#"RE$!"0#/@^%U/^*8*1*O U$A!GM M$=[VT==ZU/KV#FX=W#JX/7VX14WC 8AYD#)(((Q][EB83CO2JAUWF.HM[W1 M1=TYU [QK:==Q62%5>P;-"E,\L1L_$<]KS0?9>/T1U/P)+G)1K:CS8; ;_R: MK8-.*EKX$L+^W>[W8>)N]]WNN]UWN^]VW^V^VWVW^V[WW>Z[W>]\$9T7M M\7EZDYC]/H9)N>KJIRFH'%KU#*UP$TH$"(EH*#4V^8$DH00(Q/-.C41$IX%6 M)Q!E!*_T$CO 4!1I%_&H!U:6$Z M#JT<6ET,6K$&K40L(<.4!3*,E/)]PJ-YHQT)R2L;@TX741]"?P*K2+(Y4J%L'ZBU0FXFGB7Y1H<6CFTNABT0OX P\+&H42" =*$AGQP,\EDZ;-8\;"^Y"S#J/%&]=VU$>@4GO6V3 M*Y^2/D%&'_T?RR4?:*?EQQQF.,SH"6:@!C-8%!"" M$0UQS$3@LSB@<\M$$G(4S' ,[AC<,?@Q&1PW@6X!13R(68!#X%.A61WZ="N*(*A)@9KKU$:;5(LR:^OI&(YI+I+9 FL?CN0-KV>^ MP@'%*P.%WP %@93R&&'NQR$+90@BZ!N@\+$TD:;@&$#AN-IQM>-JIY,ZHG1$ MZ8C2$:4C2D>4CBA/BB@O)F&Q9^TOGUO-2^B+N9&4SJQA)B=^<\1) BI\$"O, M XP@%C)&=5A$1+&(E[._6\T$77'Y7C0I[B/KNK@*A^L.UU\=UP5KA:X(/XB) MSPF*,=!_!"JH:Q 1&+&^X7H?HV2/7'K60;N#=@?M#MJW@78*:;M+E%2< @Q" M@96@V ]!#>TPC%;ZKKPUM)_ .;Q U &[ W8'[ [87QO8<0/L@L:$J9!$2#(? M^PQC5K?_(XS1E8X/70%[7U 87@F&'0X[''8X['#XM7&8DB:[6&O2"E$@!($( M,8X)K L21 "IX& <=D4)'*X[7'>X[G#]^+CN-[@>*@Y#K05+X@NM9!,.JNIS M6K^.E%KI>?36N'X"/O%.RV0[7'>X[G#=X?I6N"YPXS=A! K"D6E%+@GG N-Y M ;$(JI4.!F^-ZR?@$.\X^]\!NP-V!^P.V+< =@:;IA1<1KYD*%8D)B+ <>A' M=7 BD$JLM/WK"MC[@L($.13>$"O^MVFBIU!_W\FS]8(;0LG&LZ1<\=;T1MDX M?7]74C5$X"\_MN;[O[-BFMT^'6G*KS^(+[/E= MZMUJ]O&^&_[Q[FK5R;M)!\FL2,T%3_8Q]H*A-[-%;?XYFTSUA^K5#WDV2(L/ MWO5=JN]H#W+I_4GAUH5=VEZP"BOS-Z;X>5# M^S@S:._O'[Y^\'Z6\C>[(O4$9K;\E?>@AS#(S!9]TG=JR62A?CK9?UZE\/CW M3=*C55<8*8$4DXAR/U" $Q@"64H/!#"2:%EZ_&J(^U=+8+&A93D-DSPWNV&A M_C)CVY=3VU?]/9[>MY'^8TDP[CAK%D>'32)DW61H1B%/D1%4&," PDYI"4I V90&REPZ@!KO7TV\6Q/5L- MGNJ0*/0_TS37E*$E1&*(V=*#?MG[^H?W]0\WR?B/&H5>'WHH:M4GC@ +( TE M\OV /^AAS7M.&).8OTM"R0-0X5" MJ"*_)FV"%-P2>G@WT(./2A2;H<=;#SUOK;KWQG[(:QAHZ_SW+9RHU/O20,!Z MP0TDZ=M&6G\M#&H;Q;(TQU[J[OG!TW2D6>HEF%]2YC]K@\(+/!N> '_TY$"K M\X45%H7=YJ]3_9+T6S;0C?&:0F]UK8JK:DY M09K]"ZY_MG!OO\ZMJ)JFHY&^:Y:,M$$\>4CSZ9.EW/*UPV=>>&6LY_$@>TA& MHZ?R6G.)'N3_]S3-OB6:(0A'/UX9,9?HWXO9:%H3T.J8-*4EQAZ??-?45)1D M."D[0IMQ66>B>;9>P33[KHER-M5KYN63IV2DA_N0/)6K\-9;WA>ZLXRKEUH3 MP3]G2:ZEC%EHHZO;W4^MW+&;/S&[4R_C3*MZ2:&IXUN>VFTNZ<@\[\9A)$$(J& QXE00U"ZI]UL^&:3IL-"#OB\,>*7#FTF>3Q[UGA4U MST\GU;S;\+"DJT6EF?C?UU$'ZAJB[&CJV@?O-TWE>0VVZ]#3P)5E$$O->A-[ M0;TOD>V5-TXMF0TTN"?&3WA[6Z0&P_4$S,W&<-%0D!NCI)@,,HO[<]9?*R(^ M>++PBMG@S@+*<*+UV:F7_OF@+VL#=3)^JAG+TOQ-.DYO,VT":8I:.^8L-8^] M*:R).*WW04N"<9&T1)L%D=(V7W(HME?RIUA^#3SY-?2N)P]:!>,,7&VMV5V; M=VIML-+CTOR[!K[QM\/,+.-8;CDX*^PHYVHO+TX2T6M[) MM[%^>(EO,C>;[^9:F5=YB'OE%'8BV]SQ#V. :W9)#9L98%E2 MO!]J[U-%.W/"6:^<_5^[D,1.#(3H]@P4S]_W::R!:-:UZ?-A?TJ6/7/[ZJTW M+)T/5_:^F*LG6^YH:4*4AITAE;0Z9S+!'5[RH/$[&=S-#3>KLQN=)I_<5$^H MCMOU?268TWJF]33-J"Q_0P:/-G'K%.7%@W(Q:DTP]8JP&0^JM(" MJ V0MB5@383"6M?69"B]:A;6YNK4C>9.:Y 6#85<-+H\8QH^Z 7.[O5>Y$_+ M.JTVZB:#I&V@)7-";.M$1A16UR:"Z;A'**6"?=Q_]/4;?5='S=A?90' MW"<01;&*"0N44B0T'8 51#*FP4KTQ]P/_>56FO$6LC*5GU5IYR[LH!2)7XU$ M_*5:OP4?=_G )2=Y8#@V+8J6Z\C>I!7P_]$KW_JZN_,WMAH1TJ7#,_FF]>-O MEC;,872>%:4%=/1M;\ZV L!\15G$$2!^0'VHM-E@MQW&012O1',><]N_:#;( MPUF>:WCJ"PE <=3CML%H-BP/0CH4^'8=O4&YD"6:'! S803HL0F2_/_L?7MS MXS:6[U=A]>[L3:K:'KP( IG:5 $@.-M[DW2VN[-3<__9HB6ZS8DL:42I'>^G MOP!(BM3+DB52IFRF=GLLB0\\SCDXS]^IRK(AAA%&0(=&'MF\,X*H+ A2D$B< MGR!_F8P'W:))'+0:AVF1)D<3FT.9S.Y/I M,J!\C09-M4 M2"L80NH#1:BB&@4X9#0PVKP5.4+0 !FU;@->]ES*7"U3_.6I$8(SD>/'!NEQ M1:,;5L4=2*( M+DY8KNMV-?IL1,'+O/AF\BWQ'I+U//7M_M]E1";Y8Y!,2^^,_:*;)\3#73JX M<^JI(?3Y*-\?%^ZX2V?#,C)][86+I1]R-6B=ATRL9W#%.]HV>[.@CY8>QGC3 M8LIEO&^8!_;L)F5F;*O!R37OL(MUV>2X@?GDZB^VY!OMLGG&UID]*!W<+I5I M:^3,Y9\4.4ZVD,/R6\>SO,RRVOG<6D9(;.U,OKF.V\>%L_YPQ^TEQ=<"8[5U J /:4!5I")(F.WB:.2IE"S"Z J\6T:WAV+^[-OAX9O1 M($U]<2&J,J.OS-G;E=E7I+YMC]?6/3U=#-)WITRF5/4*9<%(.Y2E2*'\X2@@6G+Y)*K7[5RK1P?2/_/YT/#3WNL_U%XRM M(!^MU%Q#D%?BN_I3;Y",1L6O__[.,H7Y; 8^*#]O6:DOZ;VQEGY)'KQ/D_MX MHV[_/IY]3TN'\SEQM)E]4Z [,NL;3+/FA_*.^*JX> M]]VRO=*R.19_5R^H76V^E+_"+F]YT?IOD#WQVQ/W(;S[M^")1S[QQ-T_/37& MVA,/[C[5#(Y#L6GN(9MUU<<57>\D_6,,C-7R_66;7D_4).#)A>C-=%L[^)(.[LB>OHQ'P<6\*K[_9 5MMUG[8M;R;V5ZG#!K9BPN[SOX_2Y3:1>7L)LD>ZB;D[$J24ZK4"!?0N(# M#4+,C:V-:(04#D.B$0[J;LZE E>W8%W:P]F:P#01N[4%TX>Y17M"/)80PRH' MV8'>1,92!T J?U(&=&E :"<*I_715>Y#7875L7+[NAK-IO_CU.?G'"RGWY.Q^G] MXGX=ZZ(\Q:IBAV5,=9O(C&M)=S5YYDJIZQ(-+07:%7HZ_@^;0'D[E. J]FD- M0K IY+<_O33#[93J+R:8K[H'1]K*4=88>. A4HG#2J$BG(81!0%%F&L>*D8) MRJ62X#)0J@6I%/_12:G$-Z32GUH42QVDP:;U^KU46)V-TM=_)YS MHW72,"3-7MWB-$A(2N9%.8*#3;])LX[@GEA?SE%\Y1=4 XSG%D%^@X)YAH&(0$!"Y6/F6:L<"I'VO?#4]TWQQK+ MH_62GMY'TS%)=@BI<0!8#80]T-3G+) 8^]I\$LY'@[EM- #Y!@C[2_AHND!V M!SMJ7HV]VSMR>D?.JR3LWI'S!$D'KVYQ&G7DX%U'PVH+KUTU7HW567B;T]E6 M\T!8SE+%-AY\EIF-:::T"IY66H7VE%95J\#-(JS0&2Y*6P[?9>[6<3.=N80E.9TGFZN/LM_?),(W'U3/=<.S0T\P-**Z&%.>Z M\?5!=+0B/3I=']O>(#[7ZN?*@NS,,SMEE/7B0SJN;5L-";38C_7:[O&P(0S/ M]TLD4V_FNGF4D,E&('L61GFTO,L0PGT\3+R'R6(T+%%5;>.!O*PRKI<)CAX] M,WR+BS_S[LSRFK^VEVZ6$WP.TFX-UK0KA9/7WG^8Z7ZSF J[-W@K7*=;S)O$ MH7+/S.I0(T9CQ<07=QU#K\.%[VRY)QEF9?K$RS9Y8<30:_O]MR F(6!#(@BC , MF(8!\=T)J ,2^H*%]*KJV*3#"$G)J=!2$2%5%!"+P:2Y#\T9J.AI>H91NI)L M$$^MYCA;) =K'4=OD=K7Y>90?K?P)N;_\EKD(RN-=Y/>!94:-U1'3/;6$3-Z M5&$O?**R]YCJW1D(BPO\FL\G0]K7\T>%* MH;\T4;^QCW9>.(]^A^O[S) 9K<]3%/A^2]BZT@XV1DV)=NE<'[5F"GM.VIU9 M)B>L3#?*N3@D57LR+ ,9 WG<52Y=^*A];8XS^YWML'5.$N^+]L2GLK/+1B[73FB&:KRA+4, M6$@"KAE7(20H@MP=T5(1A+6_SM4?"@=Q6/B&/XPK;^9R,[*/XVVN364.XM1Z M%)>W_#8V:UR=^@X&^6Q5:4A(K[2!")(%)8!*'$MAL:!IS(,*"X8_@^ MVQ[Y<6Y#R+V0<3GJ[VTZKGJ4R4@HSKDF$H%@/ % MHA%F4"&ML40G532W$TCLE.K;1RA?K4>TCU ^Q_V)6)4(R4&D&2.8^2K &@I* MN:(105 18'XCYX]0/E6>>;3'$F[V!^_#E-WEY]4PY48?M*(.Q%JCAL'+*&:\ MMP/'ZXYE[N%Z#, K;P38PO'=?5:_"(Z^X"C#*S":#EV7UV8\85093QIIK(@( MH2^CT-=$8BHHEX1& < TW!\S.#\<5*>,IP-PIMJ,&W37BEH-#S3R[)7JJHY4 M?)U[$.Z90VO.N<+)'Q8V4<*^^2^V?^WX:DG27JT+6)WF.U@U=_Y!_"WQ[HS M] :&[6);-.I,MI6J3MN>WA6NVHK%HE)TZ)G/]1B0+3VJ&69>7&G$O;DLO4W-3T9LNKZD,V]01;(&Z6RPN+=EGH-RDO?Q8UY* MNU(^Z\5#(YBRQ#,JGRW6G.QJWER-[C+:+L=EM^BBA;*-Y&7+UU2SR:Z]LX8; M.\$3X4,Z&KG-^^C:6W\8&V+[FMJC*_>.--C*_OBZZVV4L$K? M61>+C,\_B$U!91EF8O0RLZU6)3:JTLU*/7]W2N)=U/WHNP_"5^4XJ%P(%/E0 M]I('/M$+76P5!O MMH*A/GO!WMMM?[A+!W?M+WH%:LN@5 &" @BI(QC @(4V6=58,CP*0G3:HA^4 M7JH7LXDY=B?WYAIS)M=XP[+&,^R+/;MW#0!I;?.*\$!FA;\5A'925[59-<#/ M%OO*LP?&\2?X>W>P-"Q@6+<%#*NR_ 12/D :*2I#'&H*1<@* 2,#S<'QM,X: M$3#!-<*;F(]-D>BU9W3W86(48T.3AB)KQ]+-H[=PF5C_7$PLL=['L]^3N38Z[,DG%J?AY;LGSO#4;&',C59[.SSO/@ M0>\AG=]M9H'=E1Z,G"AOXT%2_&+?-YC<&UO598%-XZE%9;'C]D:3N%!M!^;M MJ34I!GF&6,V37Y,@Q^K4>JF2J4D%S/.Q?DJ;,2@SR+0MI7I=+]@+UN2^SG6> M=65G$VQN#X!(&R$%C].U*;A_[V95[MW7Y.IFEL2_7SG3[X=X]! _9C9G[&Y6 MS"]V_)T)KHR:@+!/./4Y9Y)QS51(M*:","+L/7%M(78MS)DLD:/ ;:STL>BU MHXDU:Y^$J0DD@@1(RH$B0(L(D5)S8A03QFHP-4@PX.,0:!4$@M* \)#DER*M MB/\THMO>]\!GP=0R)7T+SV\\_?_CRL_[ER^=3+*C5]W?:Q&W&2;XB';<%72JYZT1B+I;%SL#I M&[4#K=LLMLDC9B$+T7Z""K9/]0$! DEK%8UCK74C$K( ">819+ G'$)#L-@ M(R?#RAXQ'JIX:G?^)UN55CO\VK.P@%'2M_0=;DI);TCSS1-53[>O+<.T3 -^ MA1CBAX!C&B@-)?*USZAM8>UH #.*!#J9!II2@L&60'RG2>!X"RCW9#MY8-9C M,;.:;%: VBWU[M'$1E*M^KOA*THSK\ MQOCZFH[SX<6+^:3\(D^M<-\T5 4"_;UE(/BP>HZ-G\A9;WOBIR-OZ\C+ M^!$E,Y=>[?$&YK>_-58WRI]:['GW("5T\%/Y=*S]NE@N5I M''0)/:7%/1>;Z9EO<^=[_O_Q\]P%QS[8%R39SL9]?;EPO5SXO9?\,4BFMA-! ML6P.^']'%?%KYZ)^?I<]O\:KW#MVW!U9>M#O["7L[+DJ\+NTLV^F9/ _X_$B MGCW:Q!NPFGC3)+[ I9)!IR;>3COI*O,*'%4]UF_]I6Y]G?6[O@!=VOE&T65: M%_#GQHMY\;)M%Q-FO *@!B#0V%<28\"P4I'$2+LX'!, ^$BN!P9_FHR_?DEF M]S8LN"?EUUXZ+R[]\CA-EOF^!6]9UG*'ZH7!K[Q8;6 O='JA<[%"A\-*Z#", M(50@"GWS6X D Q#GP7^@,:8;R4A[A X[K]!92U=A_F9%2"]UWH#4N7PE]R"^ MK0$>L @JH8U^$&BF(A7Z$2M2ARG1&HFGRR=*'[]U\>=N_U^3F9U,_'5?]=#Q M7.U*O>M\_>&7:,G8MGWU$YQ-KP'8Y.T_[6;NUP6P8H.S)_H^7KL(N!A.SW?2 M(I9U8H[]'I[ C1V9XTO%$EXEB&)^U-8:0_F1$+Y5D4-STDHB?17DN=I,(QB& M41MVN2&PCMODG56">P:[" :K@92:SZ'A*9^%".@ 2$!ID:M.(:.R%1NT&09; MUU*WZ*@]AW61PUZ'&G((HT%0 P:%(*#,)Q#"D(6802(CE'.:KWW#=^>W&I_D MPPV+T3_47D37VWQ!3=B+EQY(+U17U ?1.SWQKIF>_:Y?^*XCU/7)=U7)?EUH MX852@*M:9"2-(@"-GH"YCGP9&<,V*M1O)/6S0T#/./91L^JWWZCZW8=_>F[M M"K?Z5>!'D @'DJ& ,0 YHSEGMN[;FUUZ@.9]J@8EJ. M0Z@"287@$C-"_0@%Q1&+"> O9G?O8.E3(K7X&@>;W7C>4*16++XNLGEN8UO! MZ_TTB7=TH^J];)? []7S>S,AR8^#^:0 U<=] M6++3$V_9P,)=GW^_\4UN?)WQN[X 7=4@7V.\ [(J.LD1)2*D82 Y#$(DHPCG M*4N,*>++YZJ6!UEQ!5U:LFPVYH'(9M>;/N;1<^S%;"#<4(9U&T8@ZUQ+.E+2E\MQW9GXB\7I42UFE(_$H@(3#&@RE:"^R$M M4PMH*.D+U)3N9>OC,X3)-41O.D[YLVWX955OTM>47GIL*TIN9@5&4A^DO.2- MK)BR([/LJA)]R;IRK;:42X:)5CB"&D=2<7/BAI2'$: 8"IP.[FWAL8LB749 M?*6S"G'/9)?!9/7ZTB#BTFBRG%%AFRPB'N5,%D).-'QN ?>!*;/-,%D?F;Q, M'GL=ZLA!K(9K!:9"($TCP4E(0D8BQE&$+:M!;(XVJK?V56T[T?5)1CPMU76; M=Z@O,EV6G/E]-+?3$^^+3/M=;[;(M-_U/BA4*0:U(M,( HH5E]CW&69^J",! M2A EFSG87I&IWW#9FDU5Z -"/;>^.FZM%YD&6" <2,VDE$H+J#0LDBX8E_RY MJ?//*#)MF%N#/GS[:KFU.Q-_0=N[5F0:44U"&2 8J8 AAB- HK(R7!CC^Z6* M3'>P]/&A6]P:N-/%F-=%E(CVH=M+=['UH=M7LI$54W9DEEU5GB]81R:U\E(M M H:!))1%0BL>:J PY1KZ0(4L%*V4EY;.;-J';GLF>[5,5BLL90+X0F%?"4*C M2#*,0NB8C$%-S:G,ED?NKU,'GL=ZLAAK.97K(:$S[$/A(\Q\R7B4 +N M6$TS&"'Z(AA%3S+B::';;9ZA/G2[TF@5!7W\MM,3;T5P_&*6LR" HPS2?NLO M=NM7>+_K*]!5S?LUQH9(K2#7!T#+"'(AE5":A5%(K4HN;+]:$$F_#;NW)$Q+ ME\V:OO ]@+ /$?5,^_J8UJ_5Y/K2?,3 IQ(K"@3BQ&CT7"O,J6)!V$J+G0:9 MMF\N_58XMCL3?SFKW*_5Y"I)*200:8I\$4"E?&>5JQ"%0/%@@W';M\KWL_7Q MD5UP3?NB7!=$8GUD]](]^;M8P? UN$G"JLQIQSV27P62LALXMB/ C302D MD*I(82$*E"@!+)NU&=EMF,EZ9.[+8;/7H9$WN5TYCX^U/-K M5_C5I[4272C-,BFE$/"ISPDB@>77$($0ZJB5B&Y3_-J'<]\*NW9GXB]HAP%0S:-(<20_ M[XAGJDNBX&(XOK:EX!BPHWXCN[>1^(UNY%L(.06PBNM"'3(I0QW",(I\/_29 M)"6J#?5E*R9N26:6RIJU% M FH#!+8)T[3GLY[/7H=B H $D42: RJA\GF@15BD*TEDCKCSVY3[ MF?$4LS+HP[M[HCRX#^]V>^)]>+??^C;"N[C?]SY<5"D)K KO[3%=>WY]E?S*0!4H"I#T0ZD915$$(H8@8Y'C M5QF"0#+98GCW9'[MP[MOA5V[,_&7,\49JKA68AU@2A4)F:+4'%2:VO NYU!& M6JB7P]#:Q=.GA7?]MPW#_)_QN+"W".C+=2_=[U8#/P(]$/,%;V2=+3LRSZYJ MT9>L+-<*=E&D!"!"FN]P$&G*9:B+6D*B9+31N+X)X[:@,DMD#<>;^EK"GLVZ MPV:UDEV$E 04A0'A!&$91&I9%T\%A*V ,?=L]N;9['5H)0=Q&Z^5[+)(0L"T M+P@.A$*$ 4GS+ K* 0\VLI7:MR7W\N)I45TF&8#PQQS M)U?BL?WY-IG-S'51.C97F,%Y:I+-^X!R/[]^?B]T B" @'=UK&W]"K;Q5<2W MOGOZ"#=G:15'EE1HHV '6LL@\K&".))E@;!F:"/ M7J$U\1]*=]_G27WZ>)> MC(?NTD+\.\G^2W*4=5W^^#D9IY/9$'?;D7^-T[!G1%\7IS/OO>+1(O/](AE_[R&\_\7[B'9EX:U;IE?D' M=WWV7=5L7V'TR/POKRI]@R 0.(!<:()\%JE(@V66)E'/;:QRL$6ZXL%^B*?- MU?OV(:2>9U\?ST+ *BL5!%PPA*'A6*HH\R429<Z9] MI4S[-B?>J?AE$RFC+LZ8>#\E<99X'V_,PV,GI;Y#O1^EGU\_OQGVZ3RUUD=[RWQV\UD-DQFY4S@] \OFXS2H?GY]12I.)RVLPVQ,V%7;RWU\2-SK;B:C MH7F$%0Y75CH8YKZ9]V9W/_%^XIV8^#F8_S)6HE,DL**"8*."#">+FU%RDCJZ MYZ@UA?XYQ/&2G-''9GJQV8O- MLXO-FO,2TQ!" BFC7!%&M<] DV4-O=A\*V+SM4[< M.5S^/(\-T2Z_=__6QC-*Q\G572XH( )_VI+J7+V0/W>$?+LHLB40/Y0#?M[3 MWOWH?;E+/#/!:#%,C"BITJC-7XOQ//-FRO$^3^WC\%V^3 E9]9 _I<'[W V$Y*144 M?;!+S9#JNZ2[']5D-IWD!#!+ MAJDC!C-O+[V?SFQSL\02S7W\: @G6XPL;7FQ/95F+IW"?)H;*HR'_UADEEY6 M2>9.9)^,87SOR M7WE?MO["7"#4WOJ0CD;>3>)-S>DZ3B;ESQA!Y66Q>MN$NFM^W+; MR,RX,LLJRUO-BF2NMLFRH7F?&7F2FN]GGG #%]C^>V>V,YE=[Q-4/6<]Q5G/ M2]YY"<[2M[>)T;T,W98XW?"]PZU[[SU8EIE,+;9%#-7),/ZF46"L +,<= M^VYSZ#BMT+'?33QR;\GNDJ0"A'CN(Z\]803!K;=$NZ21A98 2' MF6*!1F'XUYUU3E7?/L]X,##ZK!OA@V'JYG8.'#_57_.1NFG8.>Q\TJH6XG[Y MP4XU'11JB"<\AV,$_^)]-CR0WAKN,9)9#%PMJ!7#OYJ-&J3)T1MC;1;/\KY= M4;/(Z3@W8LRGO;+P,.G2J*F0VT^_+.[-+8.#18<]!]/;QX8,U[5]^I1\FXR^ MV;U0^3%DS--TE,X?O=6QGWNL6Q?P_(/X.*Z8WDK9G.F-(',Y:[EV8MC\",9= M2;/XUSVN TPJ:&,52J%#'+$H$IA3Q66 \SP+C"4@K'0=W&1__/!S_$=ZO[A7 MDWM# "/H2@XH%+';D@.^LTJ:78(E4WR?B^G8 M^SJ:F*/%RQ[-*@Z<7GIK5JZ9E,4VR<8 M?TDP!"/."0JDHI$/":)0%(ERF/E2;6!A_V18Z^-M+@[*B1>$)">SV>3!K)6* MK;ZXC5Z"_\+E357^SI8G+H&VC,YM;UN^J3FR02]+-D%%-J4^]& 4@FQ@C-[% M*%<0S. 7,V?SB,57([;,?0CE=L@*X>5F1G'U9$,H(9P3YL0(Q<G *+*V MIL77YR9M>>7LPFP\EH9.ZU9'MO[+)TL#!Z MS'CP: R5V#SAQCYX:1W%5XWJ8Q82"=#;SI: M9+F1-YV:8\@9)??Q[&LZ?F]8)[.\DNN @^V69.9]=R+_[&6?JB0P,F1$M$]\ M%3+D!X$44I?RUER_V;AA"['72X7"QW$FL.VS"/<_W]2_@ TV V5V VVZ]LG<$SM]^NC[2_+/K?%"&^='/^Y[H^#+3[O(W/ZTFV+M M/!;3)Q7E9DC2K_6CQ01@GT'L<4;1UI&T4;T8#=:XH=Q[G4)"^_+ MN0F2'$J.X)IL$>8-D>.!4N?:^VT\3'*15OP2?YTESJ&UE'6K8KM2(0KU6I0W M?)^;[,Y@=$:R.P^F\:/1+I9'R6V2M"[JZJV@4, 9"E'D*P@"7Z"0HE+4,:X/ M$G56"TSG=H91DNR$X>R2I /7$+X92;=&Z6NN1ZNPV@C Q'HL^'?V&KC-8 M;O)[\^/7>#8<)9F;Z"(SFVW_V. %J]6D647;UA><#A,C<./![_;9)0?5].BI M-23LE5]GL M9^^+H(<;6XXL:H:T_-GN[+81&8YV?J#Q9!D@N7%JL[EJX>2'6WFG,\VM[W8Z ML][=7?IDFF0=HR$[YF;'PHY^W/5+.P@.<_.4EZT/]7\:T9Y _QZ"%^S*Q?_VZV.3\S?2OKT_$B7AXX7\RX M/R>CQ G7JT B2("D'"@"M(@0@6%^SC"*"6-7,#\NS".2H9@_^W9T^"JVZERS MKA+O)Z=5=I!.7]:;YM<"%V=VIM7P7B2F4HI($F[TFS *0>A'5& 5^(R$&FT@ M'"X]8$M/2+;I C&*C;W$;KP%'%IJ.*MJ^%*W$?:B\H;F@%^V0(Q[]PTY/URY MA367-O7@;>Z-NL,".W\%\+YS_RXYY/OKXT>3JP'UISDC+ENQXLR7\=B(I%$1 M1[[U?OH@/Q:675PSYEI6MWGEF M"R:C1M!D!C'$@48 0%03[.&(^Y*PUT/NC M"/$4VXWN;T[W_*/?^S!>QGZ<&+'&T\!(J\F]C8PF?TR3<99DN9JX0:=V@8RZ ME]7UO4V-[KW3BB MN2$>/QH]<.F'KVG49L!'KXGHE*+H-N4N/B8@_2R!3D"-I[!6BOLL] ,(*><1 M5L#P%)&!Y)1'&^U?]@KT9ICG3%+\QQ6:6BR]%:O2L:128XU-#97:TW?H;*!T MO'.GUC0;3Q7VBZVYJT>UUT93.E1VA>1/D/I_2XRQF>0&J[$0!TDR--;E;'*_ M9<;V+)HEN7-E:M/7$3M5EW0$ MWN=Y#=,X;9_08>4#-)I*H$+-((>2 JZ8Y$9S(7[$$?,)H.N$_LE.W\F7C[>; M)=>AG9,;G-Y=I*RDW0YM7?6VU/W)CN4]!-G=%* MDEZZ/59HSWD75BDT9XKM;HXNFK0O8BI4C3F7ML)B.LF/T\%HDMF5-RMNUW(E M0VYR>YO,7)*?T0^^?K7^J;D5$>EXD$Y7_%IMLRNJ&AP9HX-H7_+ ATRS,&+, MZ'X"L0"IT/?Y,]J2Y><1M#_L[V)4KJ&]1Y1K\;%8H,9"K>1Z*\=VD=)K_UM]V1N*KUQ=/YT\D_YU)O<6D)[[3CNP-I=@>&EL)XQC=^/F.P8/4 MYV?.\6!5>_^1_HJ4B"YD[Q%2J>T*!! +J .&&%8IP>P_7:I ML6^L>5-8-]:XV:&L[]0AEGI#WF/EMW&6#(RH'.Y\9"/)6ZT*A$)?7)13,4-T M<[D:6N.O\FXN@Y66K=)L7JB<[5.,7^5[8J$PPU(8I5$%.%0!#$DI\J&/5<4Y=02/>&HVLI_\Y1:(P/\R]WJ-S12\= M$\/"^[S%BHD'_URD65IZ)^27OWK?[7%/?)\K1^W38^5A4PPIR(&2E!/H&TFV MI$>DL=9/(CX<1X]W1E-LGR+M6RZ&)NU@CZ=*>_>I=.E&\!1E7N=>Y _C*L[W MA+]N2>>6GO<^O)X*?F$-P^VVO/*!)5 MQ6%0BUR>R>_G5Q%+@C04BK$(8Z45TMIV30XY5KXO_4AL*!![_7Y6^[]-9]F\ MN*X) /LS^-_V",9M7C=[6V:&7S[B_SW.C=Y]598OSR:/\>_$LN3=OLCS7-BG1 M"K%31@0&4".*0*!5I/S0#PPI$41#12#<2",]B)1&<9.4Q-JDI!TDLN:^M9N[ MX:M=*^TX@"!/B'14MON2^/<*2)M8&G^+TY%+539"_[?KS]=>GN&?)_IMY#GG M\7!;4.>2!(M2Y;&7Q,8>'MAO\ECY>$L2]$I6X71A#-I!;MN>*6&?!)6#+I) M(0XDIBH@PL=$*-N\ARL5( 3Y1F1D=UC]>:GZ1ZLOC039X37<1&AYK5FLN6>O M;IV]R=#\\7F32]_E[BS50P[9(LMVKS@Z0?AU:L$O(!>"5^>[#L,0P4#[+ IY M1/P(,F4$(1.,^2"2FXCE/M -_S01QS0EK42WM=.^#ZW>9SMS3E MJ3+9JU^DI8C,JSYR Z=3XM*54;B*C'NC;U8H&?%H5!A-1>%459-1@Z*RFNAZ M>*6!W%OEZ.-M*9/%>+@$@%BKO"K#LVJY^'\S:V^9 M:,E#7ZP%8%/SY6@R^/W=ED1_7RL:Z@A38?1O$FD=A'Z9J:\YA%>5UHXX#["B M4&H=!9! 7PI0NKD))68>B1'G4ULT,5LD+Y#@;]C%T%WR1Q$&*!-*9[-X_+7 MM*J\3#FX5$&@RW(C:^/G-49%K=&6LB+GKKHU=MKD(?OA-*I;044"T]7&VF"Z MK:UV[0U[[ZX/86S/U]$*B!\$.0Q38YA3:Z/-$:8@,',O0"$'UKJ=9LD/Y1\; M $P53-6R>PLIX:FVH%+EKT#\3S4,J]7?L+_[-WC8;8>W;FBAC\P+-,]K"(+W M[/-OJDV9^[B*V5A*U)WO/NQ@-_Q1HF9G"VP=MXJ[P@LT)97XCAXY@9I^!!GL1]4 M^3@HX&&@(AD"0*52D(0JRH&X(ZP0PEO0M'XJ-N%3[JO=ZB>QSI!2JB^](T72 M5TW,[O?_HJ47 ^Q)P0TV:ZR\N56AUEP8745O[H1,[UFD8!%6L4@H?<8%E80H M OR0(TY@R2((T&V S2"[_RZ^;8P]\S;9$1_:PQ^D8WZ0TFYXPS)K 7>P MT)Y;;1ME MR114&28^!^:C3Q7&POR'% P(%0CKD @01J31(['XHG8FAA.['LTP_:%GXA'^ MR0*^9OC>NYL\V.F_S_>SY!F;^O<$HWAY.4-Z?V\8RW#FZ+%P^E@NRU%PQIEU MURVCDMY_&QHT-'#-G"JB\%BE&=!BT)MH];1VLUJ[X( \XPI&$0<1@P M)3'/MY]@9M2+EK9_?I?.AL6DS[;UV[!'&]KZEC<,5;GG4 4!EI&@)- (\HB' M$)0;)LUO;?&KT3+F=^?>,=0>L[:]8[7L;.J'2(0(2:D#P!E$O(3P"_R0M;9C MZ>WY-VQ;V+Z1#:N$J[4%SR C:^6E2 4T(B%2G%#-:! $%=RLA'Y;&YB9%2XW MT,S>-AA)'-C7F7:S15VM.@JWG7_+B;H\W;PF,/<;E 6@.5#G>#Q9C =%KN?> M!/GW3^AKXQP*?(=69@M3VZ8V\H;=7Y>>^WCM?=K?F6,U\\7UXI#+7APU:LPS M@3_/;:KOUW3@?1A_2[(\U?'H >;SM#QW/W'Y&[M:"506-"*!5OS;VRCM4UF[\V4B M$T>@PV1HZ5-5G/OQ5M7X-B?V77VVCTIKT6M8SK:'T6:GC)(XMWLN3 M\KRRJ,C[;IS,2]&T?I'U0*?3>?;]/F%G"U^28A.:%**EOR_W\KE2,J.\%:-= MOM#.8.?\ELTTS>7)47W:GDGCE5EH6[.'A#!J"-^BFZ*(J)+&-8U69.Q/RZ&+ M\= F_&T1NB?0[K["?XI(>]G89,B45N7Y MJX%:R2#]R:S:J$"&>PG!MR^5'W+>8BI_T;:S8NUM N^E]UWF/DZ^3N8V7Y#&69':? ME4;X>L7[9);?]Q"GWY*RTGW/V]][-Q/;1NFV*!8K![-L4UNU&KPIBS+-19FM M#(NLSS(/ ]F\]SK5^#R0?G--XEY8+(2 MTAPN$O<@HP+9\2V9Q'H&&D<\_6Y_TD>=-D7I$;AF\ ML9F1;[AT90EF5^#U?;Q=!:E[J@(%4&ST&$*M:X'3, B47E:@1%""6@5*!#!E MF@:^;R1(P(- 0K_4D7V$X!DJ4-8<=U5'3<^UU&P2@:Z#1/%2OK@=4B+-6Q-5 MYN!*,Z'<7DRSP2++RH*?:^_C4V)B:#2:0=X??K@8)%E=ARCZ::Y@=M>;)QVU M4CN3!B^HS"<'F,B'%R_FD_*+/*'2?=-0)1#;6PE$GRCI>>JGX+C;VGS9P55' M;:3Z&E:9W8XF#S_2M2\49I8]QD\3\Y<>+F)6E?X:D;CF7AEYQ(>1RQ-K_5NAR MS74MVM)0MX4JM)>EZ6V=/SM75'?FXZ^79V]8GN&JVXWOXU!R(05$4!,N":"B ME&?:MZZTY\HS]I+R#+Y'A+U=B?:BOH(6J^DWW6][E'JT1ZEOU#]P9NZM=1Q0 MH10ZQ!&+(H$Y55P&>)F"#LBV@M\U!JZY06V8U?)OZ>TMC_(W> M!UO*=8[G[\[J'J] Q7@3S%A#,Z8TC )*0@@H()@)[A?9.8Q1&*IM&?K',N,S M#]J>&YLZ-R_=\2$WXUA+[/$3N;C1I>D*>_.*O4$0!-#WB<0!09PI*#4H-66! MHPVP\CI&;\G%RSR\Y3ZH8AOV. :V/>Q,+ [P9J)>"PIU9T_BU^P%>-/,S>M( M&@&!4$!?"40#' (!5%A4UVF$V(89?#)SLRXP-WSO _2JF?NU&<1_^?X$,+C.'J5OZ<2\8(XB MK%)ZM>1$!2Q02E((=!@B5"J] &#_>(YB+7(4"EX+1[T9PW3C8'/Y/+W6NJFU MTHH[:1#XR-?>\ ;U%YLGZ4IQ<57-U M[UF^,&.W,/6BN],A4;FHXC57%=PL>RV7MMTTHJ )/"*@B9GEM!(=%H:\C M%,@2(=,70CZ34-A+$@JYWMINN +;O & A9Y@HPC7S)>4!YJ%@$?9YTV+8]3!U M-?D?[;0W."M9S(X*B? V,<.^BZ?3V>0/\R97<]^V\"-5HA@A2F ,A&)$@5#1 MB"%JMP<+'84*;11PM[T]W6P!^_WQ6VLA1TJH(F]JV'"03FU[)(?)T'I7 +/7 M%2LJ:8XY I&FR#>&H5(^X)1K%:(0*!YLE"CL[JK^>6ZA@'[-.Y,;Z_!82B@/ M! 10L/T@W# '_4/-07!-M\!!_^ED7EU1;RU0A-EA._Z7:)!M6ZCKQ6QR-4S& MDQSV8Y@W#:DH+O[]_L_!)=FN\Z616 M JQ89 &[%>;$L!AT!2R27?X5/6#-#BMU (>-,HT?JZVK66CK\FF)S+3R+'/- M:.&N;_N@JL'?:\UI%K=&[*M^T-3>]/RF1]4R+Q^)! 1F)J-4D@RX(^'?S)+2'VLE:MQZ$1>I'MVQ%1$8H@X%AR'###9!1# M31EH4?K]',\&=V;"K%G^\NGERSZ&*CM*$.$;N2<@A51%"@M1R#X!= 2?:^8> M)/N.WIF7-*7:EGVL5L*H?&F,6Z@0%$Q'.A!^49*MS%\J.+_LV[-C&Y+OPR_1 MX;)OVZZU(_O865RTM11[ 2/.:: X0R",* AX"*SR%QJ#5H5R(Y+9J/A[-#/V M&U;\JD2DBQ5^O/*@BP +A .IF912:0&5+MJ+,L8E5^T(OQ;V95O5TJ4H?;P* M_$=4DU &"$8J8(CA")"B)8R.!*4;BO@Y!-\3NW6\PH>OV98=:T?H^24BJ$5K MG2V<:]U"J4[C=&A,XGS-+,A\M(ZQ/)YL,TLHM9';.V.V+-+MS[IVR-47[D5D(:J8\ M"Q )%8;(:*Y:^T"8PS@$$N+ 7(Q9 M:NJ/=O\SB\]D:>)@G]7'''9ZG,Q7'V8=/J>(\I4F"9GEY=QS9X^(:>+X;GR\ MSZN/OQ7QMRBYF2WBV6/[\;>];(8JTQ\S3K0O>>!#IED8,289%<@PGPI]GS\C MKIV+>6A_V"_JR\6P]X@R\O&Q6((& ]VX32-E;]2F?D(<_QI+)K/4>GC/01J5 MIXY+AHE6.((:1U+QD,J0\C "% !,!6XCZE?:/J19E6V; M"D*MVNU@9QQ:]" M($TCP4E(0D8BQE&$[:9 ;/:'ZHU0[/G,U1U;=HJYBJ^W.5A;T-S<'*S^1EIW MV,%:VH,6 <- $LHBH0V#::#,9FKH Q6R4#S7)'K6=M&>PVJ;4DMV0,+GV*B; M/L;,EXA#Z0+@T-<,1HAN5.J?C\-V;-EI'+;-FFV3PVC['$8J[QYES'8B]T'( M!14<:[4IL0XPI0K\(&R3RQ% M Y=G8+,:8@7&2$;2*#((@8 (%K# ;@LQPB]2[ 5R-?=LVFEL%IPG=EFR&>'G M2L041@*J5#$, LUA#04$"L14$FB%H.G_QF/D,4]'BVP9Y"DC.WGT)P_N-!1BW;>'K-*K6025T#H* LU4I$(_*HO9*-$: MO4 :U]ZM/44@T',E,Z1CKYB(56_!T4]^?Q:FKN6V:$D@0TH2B0+M"^XS"0Q3 M8S] 1B%3;3)U'LMMF*%IF^4U76'H6D8+! %E/H$0ABS$#!(9%1WK?>V;K7RI M$/VAS'QPB!Z=*T1O6-E,X30V=C1Q#D[FM(;2$!@ZX.;$!D8OER%A&!M.MC9N MZ.O-:'B#G"P67Q?9W-Y@-?J?)O'X4G3Q[1Q=<'$^K;P(PD[,LS.[KA(D[ 8O MFWU7&MM#,BLT.Z.I+;O'UI4\UV-V\,]%FJ7E5_++7U]76]<7#Z"S)P/HJ\ O M+;&G^:-/[#TB9IYOSDN6.R)8I61'@HRYF4Y[!=ZGA<*<3#49QEJ6W:5XCG%EXKRN[ M'GE*:;S9J=8\(;CVOAR@9N4"8$/)FCS1@[O/.K1W?%PORG7+FF99SJ/>='$S M2@=+86MD=SRSVS%,S([8-M_F;)ZXNNJ59KGV(O,\+UO<_",9S.WO63K^W>[# M[<+\/DN,]EO42MM6Z6N#L+M M!M30, (A( XX P3Y""L9 )DWN.-("^VO=.7)H9H<)>8LMMW)T@C2%][2>;/) M&-9J*?]28" N)/]FDY&5[=^, M33P9E\>&^V)HGC^_B^:(> HHHAF-I-9EC0JB@1*4VB9&9$X/Q1."-)S#^EV>_/)3!TJ%H!P1;RFN:J M4!/D9?>FL@"KC1Q6UN#[58UR:QE->FLVUJI/YN1)OIFQO;>*QC"Y-;+(T:M] M3SH>FE_,6?/>FPS,F9/E&";F"8N14U"W$.N3S[GVQ/@Q/WZ\@6N[48XA?TY. MJ^G]U"R<.VEJ_0NB)F-)PZY4.E[$.8"J M^SJ_<'V8FSW)WQT\C<9@<3V^WL7>_7LW*Y\R-1K^UMY<>3?;G-_: CC^_V+&_3D9Y85;5X%$D !).5 $:!$A O.>,)Q13!B[PHLG5,KV8X-:/N;LR/.7/P+::37!8,1I.LJ-79 +Y9NB[:!O7: MJ\?4$GCZ,I_CSRNCH@QFZ8T]A&XFWQ+G>;:S+0P62P_K/.3D7.X'F5CCI8:Y ME*M,)X0#K,5.U-L7OR>E0?MVN!*]:LX>H;&9C/:4_V) M2S*?)7F$HR!U^U4]$%[ &MNCN0RJ%5\-TVRPR+)RR9R59DXY9WZ.)TO/ERUCLRXV(QFS@G-6"H(C\5EZ MXK/RODRFZS;ZGE_N.K?[URT<=6O;6+67%:I7[H(9&7*79/"]/?N^^F]A8;&9,R#QZ MNVV;<]>5-S('EGGPLGFIB<96&ED-W>V6(Z'SQ>>VM- MD':6EJ\>J^7R?KR- MJ+/)4,R?_1[XSC-G9#RUVKZQUM[]* H!/TRNS.)/OHX-20QS],-R4^R&Y7Q0 M;4]Y-#D_WA^.;89Y3&BCG<"?EV;X'CW\D,&?,G?4C,PVE#'<2K*NX/]X5;&@ M8?M@8Y".'T\"9%Q!"KB)1R[Y(;M+DA/:DHF^<^NOVP:IQ71RQU8!7C MP6/N#_6^,S,K8E?9]S]4!]R&:7JHP7;03A]X:!6&[N:95;M_I7\,F/Z1WY][ M&=SG^@O&5OL=K?00@2#O&.(Z=YB3:C0J?OWW=Y:=S>?,]@\M/F_9DB_IO>&^ M7Y('[]/D/M[HN',?S[ZFXWQX\6(^*;_(.YJX;Q[2X?S.7&TF;SWXRR90L>2-[M;EB6OP/!/_VEO&C]MZ=^"HZ[[8F?6.-/ M[.#P7[3QZ4MU@J+[.D'E)%[,!$[_\)PP]/X%N/^:;0BU4X(<<]8\Y$+DQJA& MYA%B:RQVW3_VUCIRONW=9UM6Y_#ND2TLS=F;2&Y9JFAI=VT+Y.Z@(]Q"9]=G M+$:;E..4>F?)AW6]_HT+CC9:^79CPY==58OV?EZ9'N79_*@WONW[^/R%A6(O M!WHY\&)RH"M]IPL>=-;R!@.VWFS3]3FI>3#.Q!\[U_1E5^-?CYC^7O)X:AF. MFNU9^_!B4L.&%T0B0CED/$1<,0H0R;MQ)W'0S%^=.&B-7_TS_'8,/KPR^1K8G_]M8Q>Y[+_8Y5Y MNZ>0<#6]>AD7MJP15IRQ5+3K>G9C:>\P.$O?[Y=EKVU9.F^]Q_?Y)GX1PJ96 M3BH4#57$0S_0 %,6,8"7PH:+3:2 3\MPQ-_2^=V'^^G"<&VI!>@RX_KO:3(: M/M$#?$O5:9/R8:.. A^<[GC=W9[@+RM6MC4,[T5*KZV]16W-KY4'&NT,2!BA MD(>1KR52&-%2@#(:;H$P[*JVQKJFK='-YER]MO;61>N;T]9\7%60Z! S'JF( M0"H"S8@@(2J%C0SU%O"/IK0UUD5M#5UO]D7JM;5=VMJ+AO);F./?D_%^IUJK M3MFN2(A:F2(3H=)(ATPCBH!/,:6ZE! 1#K94O7=5'3G >60HX&S:"$*;G7V. MES6=U2M>N_IPR6Q.*ZO#8@KAP.+4( FUI@'S*T5 :5BO1BYB-6&19/[)%=ZX MZHQ*/3@?_QU_VH/K)CGPJ$.]DUZ65\"R;^*49I4>KY@?*8@(8>:H5IS24(4E M^Q)$-HKPNGM*'^ T..>R.045FV, J(^ 0$R+4/HLU'JI MC WD-KN#+ M7[U/R;?)Z)M-S%4Y_D99+OS2%:8=6+-W/PJ+7U%!%&R%HUTO8C=?_1];=5:N M:X%KD. ?KV9'J? M-FI MX#M;=CF=SB9_F)?-+2Y:R\ 3M-9$-)(! F&HB!\@&5(!-8NH0)PB"*2&&[[K M\^W5T*'$HEC501K,_Y40UD%>P/-]63Y; MH' 5L,A3=_E\8@O19XE%R[+/7G+VS"M_,G/Y>)N+^E+2_QP;:E[=9!>VN1MAT)@P0 &=\EP M,BMTR!(OL:*H7($OR>I]B7>_!<"C#L%IZ=,^/[VW M\+WN_$F66%_5NCX#M&.EVA67%;*MZQA;,J!S1 TUR;/0\B)4-@_E\S):6T-!#A4%"E@P9H@#5# ]L /KM, ^SHQ]74EBS-YCD( MY'T\,S>5J"O>UT4\B\U"%\ [#EW ;(P1Q!94Y&$R^]WLTO]Q#2&2<59 /(RS MQ2SOSU%S>EQ[XA5Q0.-;8>AM>6K?)./D-AT4$,E6G ]G\4,-'VR+1)_5MNJ] M@QVQR,Y?1X_.XBR0@"SNY1(5QD)QCIP16H(T/RZ1CYX^/HR"8R]Z I7D54F[ MAO>ZB^AI1X$JE5B%OQ8@LI4J]B1Z$E L I&"D0Z-/>K*;LC4XGZ-(LP?=>0[HSG[,G> XJ!N[*TU"S+Q:=(G4 M*H+>WY-XUI>:[UBCW\9649A9&+A2NMC:JW,'RI&I575X;2D6AR M@$GE0-> 1(!%OFWO#20@" *C>W FE-0<;#C02SZIV"1<)!_&OYBY?'E(1M^2 MG\V0[G;XU1LP7#$^2RW=BR5IO+9\:B-'X-M-SPI(+51%5$BP82P?"\X0\AG0 MEM-"+C BFZT =W#:9W-BC8?V6&^-Q]!F1.$"TYW>TE&-3F2Q1I>@*[Q'>:W$ M*8H(HM8.#Z2B!,@ .=Z3FDK*-AJH[N"]+W?IK%W6.TOI4?=9\G(X#[_APXU5 M#"9]*;EA+:)#)E44@D@Z-3+4 39ZI3Z0P:+)8C:_:Y7#<'^V7=;91OJS;8/U M&*A8+S0'6\0HM!YD 'P6RI!8UM,@C 36&VG_NU@OO6V9\\X"D]1]EKP0SG,M M=5ROLE/Y[YS(QF=FPUHF(E484JK"2(=(2*@ !MRQ(:8< KX1^M_*ABZW]L(X M<<_V=I\A+_V,/![U8F7KL-FZX61A T^GL.9+2>8M[OVCW+O[UJ3+_M\M:W"8 M'/,KA[#"@6:*,,T@Y4K),+)=?1"26BJE#Y%C[:GNM,E:W>-W^F5%6COE0/7F M1Z<&Q,^84MJ@MK/,.BZ[AN4=O6R#P;P^999DTZ(?_=84B#S/J)9=-K=->,=7 M YLQ-,H;@:5CV^W+-FD;5!F]>U* M*@*E[3UQ;25VK=HDAF:>3(GB6LAE- *1S+2 M0#"S(KCL0<64KVHY20H%&% - 0LD\9$.",RQ()B(@"#JR:YF>]^ST=&MA?RP MU7/PEX]?M!=Y__8O#$'X%^\G+3[KST?F%VUY?-\!G5JA>>SF'%*6%-ETWG=LFFK9 Q8I. MB+Q[%ZJV2:7F,9EK%/&?9RUU9SY+KEQ18MX;T=Q,KE,S.0A_5'V\:3\=QFNMJQVFJKR=@< M*X_+Z;OJ'-LMU+SGN^QN,IM?N?GF2_^]:Y>YS(W-O\T/G,S5Y\2>[7AIJ>3* M4HPM%TO-^GPKFN?FU[L'VDW<>/YR=,ON\W;Y[(-=F_KZXEU['VZ+HA_SAKAH M;5^FW-HUR;+[HB_FVJL=1<292^S-%J/Y^Z*7\+U9@#R1=WFI(7)SEF9FHV=) MWN:SVG77]]&5P=G6GOE;IK/D6VKHS*SH,,DKF6S>\/*!;IO,_++%368HS8QO M9/L%FJ-\^VX4R_&0CD;5OCR'*JJI5UU%[UWFL?UE:/LG+\MNXXT-<9QAE[?L M_IFWR#1J1>H*CMQ(2DXUOZPPJKNYED>]C06NO27BMRL)4(D_%2>U]7,Q*+G!N%* (*E\3J!E101 0*:DO(F.P!A2H#;3Q7&7Z6%*^.R=L@O?' MV[(";T>59S:;_\\G*Z=<3:?]]'.>$ET6<]9LUZLL&?PP7,P>K1^O 0T EC*(/)Y$%%? NSSR(_H1HE\DTN> M5^;N77(*MJYY=NJBO_>R25Z"FI<5W<>/RQ[$Y)86BXF/I[7=_%]58-L5BJ=V##(-V>AWSP6DM3P&*=&)W/M M[ NC()T-%O>VPLO8$E:YR^RCBD)RLRO5F;>F9YOC;JD7Y2\J:\?29'G@IG8\ M,^L4FN059,X9]+EHS>SJS1^GU@6Z-&SB85K34X#QSUKBS!MRDQD7+Y4K'M5MM MBN3DWLC&9/PMG4W&^9ZJ@N7CH27>_+;B89M;Y^3ZC=T\8U'."M4YG2?W^1I9 MQ:JT*(?F]\'[ZHRG&;K%\V M][K&3Q#<^;+ 7[(ZL@-),'MS7IR?)*!5;U1-((B843H%BI@ 88B0H(Q*0 A' MRD?KWJQ5/]8G.^R/M[]EB9,W+58^OHI>$6_W./JI\B'T9](;/9/J?J0VSB+G M;AG/Z^]YBP5*3L0S4/D/F$6'!83[2&B@(61< B?BJ6+;,'U717S)N8\J7][6 M9#QMLO[OM8CXGKVWJ)K-,?CKJH_*.1]5RIWRHX@A" G"OI:RE"I@$&DL-:! MB#9@.7=P_B^3\:!EYD=!H^G-??;RI;C55W(ZU22;[W>=AYQ'$2>"PU!@*J$4 M@%-?0Z!4A *B:ZYSGP4!AP KA12G40 I1O921(G/)3I'*N9)KG,;G\D5:8OF MF#\2SV/>@?XF_$XV$2* Z1D M&Y!G':>>@Q*G6%"UV )ID#N3H_QK=E!VU"NN1]\@[I63_DP^]YJM)_JMT6Z]<=ROR6QPB/DS<[W>CVCRAK9%"-S+Z;7^9UIH[Y&S%:_T](@B!3YBM;4,18(AK:.VH M2&*I KEAS:T>"MDGPSLZ+[7Y92-*5+<)3_8CL!8; AWOU+)8/B<@>E][=@&7 MQ4I-4R$X?DGRY,310N_YFG#),.3'(I]CO9;SM&^).=TL0M. MXI\;PV_+TED5):^EW.Z+O)R-%>YOCL;HT^X>W,)=TM-K<#Z M6%?*^C3M"\CD@<9*K\Q@( 2,L(*(,3\ D90AIHQ&@B@5\&@#Z7C5#/ZU*!5M MT_46O)[\O=ZSWM(@/FTI2YGJ]A9K^+K\31M M[6+[V'>QW;U&ET?=D5.'?#V^-F>V8/0RW'APDD%#*J M"^4<:86@U)BR 41" D+-]J8;<,U7!HQI<,A7"2V/>XG<^Z8:\[2)9>=I4GN MR]+R6VG$]%8[Z.;<"6%E75#"(FJ,((PA\35BB!-@N!-*B3@&=*.+YZ'<:8-] M7QXF[37U;++?4O?YZM++*/I^NMLY$=S)&F-%WW^^FML7]?A]R8[[!8LYUL M2*2&0&*^41[X+%9,O[5W^)&^!>\E'7Y]"]X#^)*#&HZ?QEC3*% 08<.D.J*! M]=X0S@"/Y-%\Z;KRMLZ<0:.::=^5MVNAC"\36S]PN["=';W[O'',1FBQQ+-_ M2R?PEK4ZB/51S35$E(J,44H%1$8G9I#Z+'2L+S0W&LU!/8"VL7Y[:)YLLRZN M/XN[RL[O?K0$\X-MLK&8NS2MO/7&VS5-46C%16_BC"'(:.A#$,<04&5%)!@%V$F(2 ,0'8@ M'&5[TI#@ULR0Y]!"AV/+?69\2X,0G]1G7>D M=G@0&UVJ7?]?]P3;<^TQL3W"[HUE,4B&[UW'WB9[=^[+Y$>U]IW:B!W!=1A" M$@'EAX13&T@W%W(5\:KA0=7O*Y^WF8:9Q7(2<;N*6= >CHUKH+?L;IMW@"RG M=2+0!#H>2J;HR+O64+?]GJ'&9JZJ/&"(A>1:!#KR-1,^@HA:VO"U9"(XT(EF M__EE,O][,E]T!@7=*_U"_I?ZA+RT5FT(7_CRX2X:+4?+Q-G(^J*)W M\2>':U&Z/#9*<@ZH#XB$Q,I7MG&*Q9WCMBS(D$N ?$0$\W&M/@!&(:"1EB!D M0C$.A9;N4L+]**04=: ^(%IUT,T*V ]#QFG1,[*-E/_CH8C>%UA8L1%AAB@& M%LIO-')I]44?]Z^SQ)5(9^^+ NJ\.G9JJ_D+"?@^+R:+LZ(T(OOAN%Z5.[.< M+ZATX#Z>?4W'^?#BQ7Q2?I';N.Z;/$^?\VL*. [\UFL,@N-J#)[XK:\QZ&L, MGK5&N50LS@PO/S0\54G%#KND7KKH8"ON1U]T\*:+#C"!-2A'S(#6'%*%! @X M Z&F3! 1 HP!W8,VG:UH=^Z"@Z!1KU$WZ?BMA+IVETF]A< 6]BO<34XI MCP*E(+==R:G" 2.&,YE/D))0!<=P9KA(/HR_/$QL/DE[_$C[DH/+"6HU4N-S M42D?A_)B4.-%'" )%(** @8B&?F*!T&D ZUH%,J-#(_#>='6&[3+C:1)6* ^ MU^,""H NF>DXK64Z,\H9HDQ'*F**&JASVL\ 4D-!=[WH5%#*6$2X\B'$0E):)@QI*$(@I"2XYDQ_=;R 8C[ MPH-+.@ ;*SRX9,[#%>'BK"C/HXYSJS*V88\V>_YQP- MPE>EU2\?OVCOK]Z__0M#$/[%^Z0_?_GTF_KRVZ'+!_WYR-29+2\^+NGE=:7AYA_MY56[#TOLW@IA>[^.XG&_6N:.CV/O%Z,( M.KAGZ.?)7.\=D*R.3-5I;;W/9U%M][W]D'[]B.[UU6ZZY?O?2$9IFVWLTVP[&CM.VP)K.Y M0\8U1Y[]TWR;WKN9U8IOS!_NP!X7Z='W23(W?YCC-IVZ9EGW\>QW\]4P,=<, M,^_FT4O&63Y@ESEMEB>V26EVS::S-,^2+J=E&P&;AYI5,N,8Y",;)J/4'.AF MA)F%&G?Y87E5D/G1O#/-T_?,;0-SQ<2(]>SZZ"4Y?C'_;_+HQV)? MR[8G>2.R1V]P9R9G2&7^,)G];A9\GMZG_UL 2M?VZ=XFSIK7NHTJB,JL].(V M+A]N5V*8FM>E-PMW>_E,(^WC03I_=%?<+-*12QF\78P'11J\O6 )@>PVJZ2* MFT5F^"[+/*,>/="M=9%OGD,__F,SL?&U2 M?G[?HVLU.B@X\\9QZG24S!-+I_8>L\[V_'&SV4>]Z[<0U\Z#N1\\BT=6LARPZSW M1O@^EOCF9LE=$8K+:YX[F(+I++F:QW]863/[ZF#.L\D@9Y\EU^P25X9!'$-Y M\\>I*\BT?:./PR)_:_G$ &%R+ZYV)R&NO)ZKMBK)[=N?3!BU! M%KLH4D-2=JE__29 @H $4;P!) AD=Y2L"PD0F?D\><[)OLX90>7P9!:SR%JI)(&["X)-3G=?C-$LP9:N#R!UU,V_>,M='J3LS$"_$: M#Q7.5-^)P]![DF9>KYA)(<0JXC47R4QEO8'N,!,$.ZMI],]]>O/OGQ;A#X,_ MPPW-[&M'>_MR&)NLR&R+D572"C:$&FJQ02Z-^5)%)6$YE5D/*Z5=%TEE1QE9 M&22>O+@M7(;JM+*VKNMNF5_G(NI6V&67ODOMQ'("% 8;9M@1@R3&!J35 U*( M-5!;">EQ67+T"#YSKJL +65Y72U#<7%59!N(\*RCCC# CH:>-!ASC3P MEMB<")$#:B,1#C/6.)08#S+*3AJ\KM>6VG6I[653M:R\^V@+K EJJ@[L8:/6 M8/;L,79;FX>LL86V&\F5]+$8A,&L\YP98AC@'.F\DL0HACP_'!^%M;'++QT618TF3^,LUK1FR19 M%6:F=5Z5:J,4!.DR>LA*#Y<-#M(U-?]IZRIZ)E%P62OIF9["(55O\+AB-G2& M]5P)"E=D)79:X34,WK:G;P H=P$B\R0K+9UF,?(E(JZS$O* F_S$:S'-:O!> MK!(O]_G("\?#FAU^R]J O!T,K\*"3\NTPW6ND_MPY5$V1&\'-Z,_TL+J^3Q9 M#'Z$#YB\F][=S:H?>RQY+NFY*!.THYM:41*1 K]?P,\EMIH M*@@VT$N.Q*H<60=:@AN-R-1D6]?&+267S'!^^^EAD9Y7OME8N]UZ'QF*YEJ_ MU=!,;>O)LF M9:(_X6NJI7" Z,]3&VZE4S+ZGJS%?EZ:@D+LY\4)^C&L1^UG&4*Z3KXGX^E] MKB*3=3M8)%>WD^EX^FVI&?-49^:)6DR WN_)XTH>9J4!%"S, M3&5F$+@T'<3T$1;!V5JJT7PJ*]S\^=>/G_X2GB:U7L/-?MR.KFY3::,G"D6C MN_MQF.3L6D\_RGUVY;6(4";FLC)GEQ\UN!*INL[*M$WO^+)UFSUF8);TGY7F M4::,DZ1=84?)Y&KUK&NUI*741B&/%$STZ5TJ/9.*00R^30.+MDV,Z,65M1(C M2IVO63+Y%EXZ2?^V6AJCRTH MW1>"XSC/.K[F$S]+OJ6!A97'D]G1V6REXC^I][1I'JHI#1DT^[LY 1!*#QEJB'*1@A&ENB[B-%=+5=BJB_ M/5&7XD0K2:*H0;2M6"-J$$5%FLXHTAS2<:!%B?NO!S AP+P0%Z=, T2=5TXP MJZ2TC"ZM0J:-0*X3)81G5*/9[$@<'6H5K/=J-#W9>[<*6/2SB5I.9Q2OZ0QP M8"3!! .BB 9$(L-S.G-,51J;](_.CDS/;Y#/T$FZR'6I#;_>Y.JSR54VB$L3#<,LR5P>?+GG)0X' M];:N(9G16D]<6/2<*@$P-H)XFI,\4AR4DAD=X4Y)C@5RTG/BN>,L;]/(('J] M3>/6^^R7S/@DSP[GN7D-9S>&C6">M:RM5GJN>M^^$!'/U_*?KX+'-EK,__(L MC3%]9_IX@["9W&7&W&B9=!\VH;!VAY/'+%W::2')3G*PYH[QGOM?:_>YXG^5S*<#5Q6 M=Y/O5X/G6U5'\D8/RAHMLN(V$N8I/H<^;49>FPY+XS(,RW#E-)YU#6;F M8ER O5R V>EKG/M>SGU6.='?+)9MV4VY#W=N;?R6'58==!Q\A(K^11X#8U+2 MHB;< F48)U)*I@3B=B4LPYE3"%7".WD">[8O/S_GW58BNW^&?!U"@^(4B3(7 M*D/I+TGM"<*44& N6""$4V U1@; MA9',:<\;3I_;?M5DZ)I(<%NV=63#R(:1#2,;ULZ&!!1L:"3'G'L#"&$\S0&0 M>34,1,RHUXO8E_4JFZDPNK%',5BL7.QUY6*,]W?J6;O^?'$NN_-\O9G+FL_5 M8%LWWV5&09JDN$J%GZ=&SDN:;'TO%:>@J!8,1C"7BA)N% U&LG*(TE6H0$F, M-_Q G2&?QT\SD8S?-Z]9@N)M 0 M8PGGW MZR0:HR+HG ?O.$2 AP9H:8# F.1M87@0.V\X&-1Z^/'?6462!R (= M9 $LB^,#)!304!IMB=%*"X!1?GP \"O=>UO& ITY?8AT$.G@Q'1 "SH@UG@A M*-/2.4R1 8SRW"@ T+DSTT'C MR2CKR)+V3\I#[,>"NX$L[+9@G)>V?$6<\E!!G39#50!Y:'*,$R@V*\8U@O'5 M_/YM.;MA5U=/YC:_6<=#!%M67FN-@E[M_1VF!UEH4S@#'1'0."F!1-8Y#E5. M#T@JT 5ZN)2$S4@+D1;.2 L,%NTA B%0326V$%MAO3?>Z)P6A!>F"[301!#A MN>(KCOP0^:$K_%!J'X/2,P2&(-4<@T *DF._+K_PO,W\$&%==W#ALLMV3P3\ MBXHE'IJ53D*@E08^9BWT($D2$B0UPJ0W!8,(10S# AE3%> V ]!%RMPP\0'Q]^ MJ '8I-9F3Q<'[&[5_\663O57+O>UI1,G)3%TPW5P>[ V3B(#I&=F'23!QFTV M=8:9H5(AMA=Z^K4C8-)H9?2VE=3."ND>')M$8HS$N )&!HDB(D1 C(5XD(?(B44]RR)"U4'*AM!$$<[J.ED,B MQ'DMQ__]"!^(ZKEUZF!VZDYW^CJ57/V&LV ^MLMPOL&]85^\5^Z%M[H&"S,U%;LS/67P;K5K'3ML!=;'86 M@_E=?M:N/U^VWV>]C)(/Q;U-$:QQ1%$F858X0Q '-! &&< M5.@(00 1FYWMOZQB+.&<>T$?V0""HGC4>LX08Q"6*SLT@' MD0[VHP-2T($'&F(!K<#!32 !P\Z /(>" "O/3 =Q4V\FR-YB1S\V.ZL%XZS M.*7:*,HL!MIPJH%2J-CRP5&Z@ =@/#8[:W-[@SX%A_M,#Z+4DD A9*WWQ#(- M "*,(;>.$AJR653J@NCA4O(U(RU$6C@C+2!0-") 2!"*'<98$*"9D)ROPH62 M("..Z8K>&EHXA5#3*7L=1'Z(_- H/Z""'[P(A@(3QD#KB+-(,X7SR(&'J,W\ M$&%==W#ALFMR8T."PQF!%(S ) <&"$ \RAM<4;INAZ+ G%,AY+SUY[&WF;Q M[*#/?'!@LGZP&(J:=(>A-()2Z9%CWDGE(5A7+N&B)KUY@KB4'()(#)$8NDH, M@I2J>+2A2&&$#-,<6>(TS2T' 94^O>70E8A 9(C($)?*$!@4#*$X9X))HY2P M5$.L@#1Y--)S>;QO40.PJ>PUL+M5[MPX,SG6HNH?)E,.*7Z[!98DQ&D6D5E(HM%%HLL=D(6*^7>8F>=XPRDBLQ> M6"TM9;D?";&JG<5J(!_9#_)YH1?7N;IIK8;[X\-=>,O5\N=T?D>3A^%R_+.7 M+=_X_#-6)?W?O/X,3:22#"# SYXI^WH[RR]S/_R6O/LZ2X:_OQO>A$_Y?CC^ M,7R58;#D6M=@; M"691*$I9G%Q9**@VF$AG!'9J%9)7U"!']V\YQMN6_(!H?^7<6T62;8K31Q+L M.PGB(J+O-6-66ZN89T0(RKA9:>XJP@5A^S0EVY/^+D7DHHU+/])>I+U(>WO2 M'BVIA0C ,%7"0(^ QHH2N:0]"1PWMI)+MGM3L@-MP(LIX&DC(B(;1C:,;+@G M&_*"#0V3BD/@*?22>$JP-DOM)(F %ZC2HG''KF2\MJYD)]%$;2>#=:M,:5ML M+W8EB_'^+C]KUY\OSF5WGJ\WI)3ITC#40:."T-< @+JX !Q&Q MF@1C 0A$(5\6HTO"=2"&BZ&!V)@L\D'D@\/X !=\( R#&'!%J:8842T9R/,H MI&..G9L/XK;>3*"]Q M$(7\)O56*^F!8]PI#!TSF.;! N"$Z 0OG"*3$4>"B 31$8(0H" ([0,_<(*A ME AYZ$R/(\>$(E/?:AP\NYDOW'+H2(X@,$1GB M8AFBK.L,*6?*",ZAXL!1;8A:?TE%P M4HKS$F458-A#ZX#R &B2]U=56A#)ZI.9/W_DHU'%KM;*U??@C".26 ])K)P1 M&N@+0HX0D]PYHAB!?.5U864I.!N)761T)I)7)*](7LV2%RTRV:3D*#"64YYK M@KG$CJ,\9 2)DV>WP!J,($43++)89+&+9;%2/JXS%.-@?@G)C23!$O-KA6?M MF:ZQ8VQM42[9#_)YH5U9'=FWK 2K^S)PW1JHM'KA9/ M$6,U#W!J/V>'.<&D7OM<[PV%T4%>S=(0/>-MA?VKC MS7K8L"U[^?O1(ESX*ESCSZ/)(+QGG&;E_J5CK7'J,P(#0;(7>*V?#DY<#^EZ MD'$]Q/5PXN99+:[[+[6Q''P];2O)EFHK]TH0?+G/ZSQ]/PR,K!_>U7R.HZ9G_Y.BGKK\^W5&HF M5/Y<6XA8U-I4OIV@B1F&D3 C898(L]0UBQ,-I'-:"0^)L51 @IFTE!CG&>:; M:[%:39BR.<+$(!)F),Q(F+TBS%*_+>@#?1+.7* 92J#Q::O!0)@"*"H%ARTC MS#KJ4&"/>Z]V3DLO2S<9_!ENB\O6JF>QZWBT!>^\R. FB"B()+20 D]0*HEK MUQXE=YOE<1O&^Z:TH?.[E CV00.C3S'87G.!+!*A%<;4.8@U!=8!;Y3D,G.6 MO$/<6W2A7-"@MU1KP\Y(!9$*SDD%")8$,BU%CDNN)482:4N05)D;$%P"YC1I M&Q74@>6H;=4=;:M-YXW/$LA6:6)MDLR_Q!ZU&)7*J3P!3'IJB$16*J X 3KW M*!!]12*O#NHXI2, 03Q<:@=]M-9:B,10*E7BCE/FL!;42JT0,1:XU*:@F!"& ML#TM,31YAE*K6Q!Y(?)"]WB!E31UM8>0 B$D$@SX8"@XG?D:G$N!?%V\4(MD M5:W2-I>%[,X=%>2E]6'!S#:HNDM-QD MUC95#D"U52FNA4!NT&2O58PRXCCB^#@BDV+ A9IHI[SRDE /H#'1H M97D3"]#6GI6- +W]Z3BU\L7EJ%ODE@WZX$\3I-ZK)KGNE(M;)9YD<> !!0VBI)> *@9EI: M@Z5FP1M:G3Q 8#9G']=&)"<].6#DE/S1RA/%&*Z,E%"E!%38%@P090+XM3(4 M0NDL ")S6S35B-+-F0'-44*39Q G;9D7&2$RPH4P BG*DYU@#%- ,4IM!P.= MQR1E! D5E\!N[:V[#R/4 6E1JYS"16*Z)Q4';1,X;V5VV0L4T(@L^L4J-AS, MD:62;FF,0XPXHA'R&'CD-<\=*<#(/F+J94'U)5O"9YKJ'Y9\>7Z'"O'F C+[ MK+!VDG"KN+=-TC:1>R/W'LN]I1)ZP@36-O52$3(<(6!\EJU#+4%60'Q&[FW0 M8*/\V<;/^/.6#[EYRN6^,[Y\@YE.YJ/Y8CZXGP4PN%Z- L?.H!F>Q^IMVD3K/%#.A$!;--OL^'=(*S8X;?D+IDLW@Z& M80,8)[/L*M?)?;CN*!N@MQGZ;D9_9-VSYLEB\"-\Q.3=].:F@K.79^0)\DXZ M;B]L)WNW=E-W89= @*J.4T- +;(F%.%]ZT'->:@;G MP@*5!%*+!91**&OS'@ >)BGO[U*K_(MF:S6YLUL>C>8WJ<_I52?K,=5&2.+_<> MNL9Z&[7O\(/'V8^SW^?9[Y[$U_DZ;#;^;(><(%Y.B2%'A3("0IXKYA@EQ'KF MH++:+R->RF.,T?.3O5]7D2<_?5K[]V93V*\[_2ZCCM$E\&SDF_;Q#2DJ$0VW MDF.$*8$0*60$A81)XSUAC%A=2>)J.]\TF/D5Y0\CW42Z.8!N&"^U7,2:>,:H M@H8Q18Q!C$D+!'+!VM&^-7132T%4%PBC/^INM6HD=U(+A0M<."J >V <01AQ MBASFW*^:*6JJN*ND(#:'Y/8J)I]$0;VUID1G0T>]YP$!B@H\A9@#BBBFO::0 M*BH1R!P( :VV\(0!BWX(+D<>B#S0&AY 13481D1SAYP02AM'L1/49)8]]41J MP\_. Q?3[*C]IOZE6/29)%[L@KH9OZ38QZU!Q#IBI11*0.Q\P%U^\&"I/.FRL=Y:JS)H/3KVP&EP<"S19 M"1Y)()) 9TA @)(IP) (-H"Q$$CE) 0.9J:\A%H9><+0W@FTC6$O8-R6I-G& M!R J-!R2/!P5&NI0:)"@$&\$1@%ML*0 >*Z%5!;@]?&(HA5ALIHX])1>4(.J M\)):0-<]29J4%$F&LI()*$P%<%A,P$'@ACC\>J"-! MMSE7_O*)\@5UL5JN_4QDJBJ/D[ULF*VM.51&."XX4])0K(4RT@$EN'3>*^YU MN,5?A_FE]],PJ>-A]M;-^?QP?S_.M(6&8STE<*Q MPD/MJ66">0 (1=227 I'> M0$GG*0-]_/3%#?[7X/_['P)!^//@\S]^_?47]W?W\8OZ9:#5+^JC<8//_\NY M+X,/'_VGW_ZNOGSX]#&?KN,)<+"[7DXSND$O++\SB!=-[^ZGDTRY:'HSF&?K M)>W\-;Q?Z@Z-)IF"T? J%1X:3AX#@0\.G(,W_YX*WJ5.R',#8?IXMD_LMT.)FKR;4? M3<(''Z5=-JZ2T?>43U^%.'*,<@@$U)0@AZ12:JUV1; #)8A+[0541&F6GLEI MXL,;&"T;)3!L7XVLH.R:8?^=+H6JWH?-,)FE'V693GV=9$LG'39+'[RG]BI[ZD2%5]BO[I68DWFP/]RULP?)@>%#NAPM2.-^M6/\8= M#R?Y&81@-CYY@[(O*MN*RA(F1QUG18VQMF@('>86-2PX=;:,ASU&H[72(+U= M-J+/)^RJ:M&="$7GRY@^*)YX1+CPW$E!0G()$UYJM,6T Q)321AT2 BCC8=+ M-X:ZX-[(YUY4ODH*+^EOL^E\;M(^ Y-%8QT&X%L)NIVDWRIZ:=.!1V24"V"4 M4OLHRABP% 1J".3@&OUHVL&WY]?1Y\HY:<9(: CWA!**6(($RIECCZ*024_;3VH M?CJSJR&M(K+I[9W7><)779IMT(+9JYM-#Y/P+QE_J,"?9_-6S&;(Z%2TN!W^]\>UCME',-CIYMM&*'&D1;'",$**@QFE; M;P"IQYPN#T*-%(15DHV>'-2JR75V5ENPXL=DT7S<0:#8VS!&+2)Q1N(\-7'R M(J9B@<#>6"FX-D)J*9E0*^*D3%;57(\ASMK"*R 29RO2-LL_9R]:ONUY@D[U ME&WW;,':_*T!!.39$V5?;V=%XL^WY-W763+\_=WP)GS*]\/QC^'C/,TAN9U5 M'W![Q\Q=,H6BFV\V5G#_^>*,D+8 MDW2Z#6W!8DY=S*F+.74QIZX]R^:EG+JX;'9<-MU=%KS%QS$MBZ;IY-MH,DE] MDE5Q5<>3J.H**+8XJ^K D" $K-2H 7NIG$/86@HPEER3U4DS1,( \3PF^)_# M\3(&4H03"E6V^:K*]>5XX%HKX_5K?'F\?RKO5C[<-K/D>K3X93JO3[:YUE/K M]N5OQ;.52&:=)C.!2M%'ZB&0W$HC)4H[T)@5F0%GL:ZDS1Q*9CR2622S[I)9 MRRS74S/=)1[S0@B*ZZ:)"UE@;Y27KJM/A, MN$,)^Q^3Q>#J=CC[ELP'B^D@^>,^FVX M5!(8'D %UKX$H5(WA2SQ5%>T7?MJ>GP3T1K1V@ZTTD+H5S,M@-'<0^(V;O;]9 )9,$%ZIBFT0E9PBCFT#A1F E:B3B;HCQT?V26R2V_9 M!<&"70AS&NGPE7EC9/!#@"Q"!I)4"E./8)=V^QW-E6QUDEVZ%;%_X03+3:Z/ M2SQKI@ZV \> M=YZVM4DKCSU[$-0]/47VAP5;2W0,Q5S=AM+;MBV;R&61RR*7U6"6&S9*OHDN HXD*>5WGBM]U,^"*/G1YM1Y^)UG8O8 MQ^EBHV*QCU/LXQ0U)Z+FQ,6)!_1WV;2YC]-Y8[!^-!G-;Y/KP;?I]'I#>EKM MZ(K=6$Z<7TN0+$K*N"7*:NX82?-N0?C6+YT+J9G2E78L:S\G7RI_2U=*8P++ MDL-8]]K1_)-()!=/)$24SC"PM<89KK0F@#GN'%D1"9'&'TXD]0@..M>MW0N[[)]&"+\&852D M?$CE-2*: NTQ)HAS"ET>0\)";7;]MD"XGLT5@WY#N&N>84P^B\EG3YB(E,I ME60$P^ T Y56;&F9&Q-&V6#[;V2BCTF330(I;ZXLLTTI83WPG"/#])!A6*%' M@[W2F'NMK// 2,D)!#G#,, J#=2W,$Q=W?0@:\[(:1/#Q*33\N+Z?'6;7#^, MDT\WGQ;A5JNFC6H^3Q;S+^D8O9J"JIAWT&-KB$'&>P!I\+Z%HPP :9B6I114 M3#& $$&OA04: T*8#R\-7VCPV:%M3PIJ-A"#J^5(#(;94,1S9[]+_OMA]#TX M2)/G1EZ_>BOTK)7"CFX[+W5.X)(Z+JBA.C@[2@1O!ZP"@\Q2Z2L*3L7B,V&= MJ4GVCRM6FUJ8X6SV&$8EK3W=("I2Q^$%J=6O;^?BC8>/D;@B<96("Q61%TB"C;\^OMP,?J>O!A1ZU-6 M() <(PX2F%5"M&*MKTQ3 N0[2K>&US!X^@3@RVU@SH MP&[?"^10LD:.190KJBB""!%E'!/IT8-W%!#D& *'(Z>F S74B4SVM@02&A^ M7T97R60>;CH(QLUP\BVYVQP2V#VMKX-I>YR34HLQ;RT4G$J+".$&$^,#"(.G MK"16V.0@_#K_X_UZ@,OCV]S&)4[B];9V1^NR8]MO^,FBF,MH98'6WG,JK$/( M.N^R/1"F+I\Z"'X'[G[_2F;3Z^ GIC,GPI[\Y!$0XK&VR*;';]XCHZA&V>Z8 MEBI+6"EUW!^L=2D*M*+-9/MWV O92-M5DA0;+)T_E^"%<=B-S4I=,QT@GHA M6\AA+XP7-OPUF!Y"(@BPQZ^P6=/6AA"UZG7%UD47RVIV\)*0E4PP M8VF@+$Z\@STA>L52SO/I^G4WOP^P^_AH<@(6: M7*??I,%*5&&2D)&22R-(=CG M74(<(J0])9KY4+P=W*>#D27V)_EPO!U,DD4LV(P%FQO>UB?'+A9LQH+-Y8_I MRV/!9BS8C 6;9U\VL6!S8Q)F,.3.7=+3N(*//IY*1-BZ>-EC1((1C+;#B6G'@#-+4 MX5PY31OE024A;P-MU!2AZS9K=,U+U@^C<7K/>18L&MW=SP(5U5'C<;EI">'? M4BZY(\Y0 ;&DB"&!F6CS5Y/I#:33_-ILVV1_D+91UYA"U=E/N MP-[;!P3!4AL"K4W8E(1"UCO# W@\6&F8&RH!J@B$[(N@VH0^8ZN0B\J =<7! MQLW#+,S_PRS)-K&;,+WA^UBD^ (N48%+J EP$',FN()6$*6ES'N]@PW1: MZBBP@1IZR+E:!V,1JVC0F.EDOI@]9-?-&MME8]WLYDA(G6H:VR:VM3MDKS;" M#J-/E-39I'188.TXMF'4&'9LF9\EK,+851JR[H>^FC9#V%SSF1:AKS<>9314 M-P 3@0*8!EM,L9:*$*Z)@9P(GV^+R%7/*#>F9S:[,]*WD-6*SM89JJU"8VMW MRRZB$JH=6CLFMOX M2[">W@^&5U&/6 M'J15%0]2%:-M2X,=OA\GZ3,P^F+S1X>P'6&F1 M1 ,]5@I)+3VCBN/P!R09[ M(7F\D4K?-B<)OC &NQ%>*;,)($( -X@@KQ5U'F'-5JZ#] Y7K).-#-9DAV?T M%IRVPW/[/(M6L5J;\I1/RVI]$#>XV/8OA_(A+N6I(><=X812"0UR%'B@5H%- MZS!QE2SJ/?FPKC0U+IH[\MMG241IA.4E*X7SI:?]Y\-\,;IY;.B!3_\ARH[. M(/GC/IG,D\&/X7R0?[ #W;3_N0VFJ%!6XH!P1I"T-OU& T@PS]48)+45F)8_ M\YO-FA(U' 96L]3R6N)G^-Q[E-+DC8/?7"[(W?O-;QN?6EQJFQ#FT4/#N>7. M2FZ4'O_FG<^\5&W;1=!Y'DX?ATF[)?KU\ MX?./62T[?[/S8]0611QD:O)/GB'[>CO++W,__):\^SI+AK^_&]Z$3_E^./XQ M?)R'F_WU=E9]P&:D\M$\P#0"BBEN3"1)H;\@Z].5 HZ?/5;7+] M,$X^W90$N[ZDIM+K2DG2(L0@"!=F%GF.1>!#X7A <=B'&2PI)7DD(#&.2<6( MDXYZ;U5XJ;"&:>J,;(]24C8"@_$T]6F2V=V+S?>B.E)41_KYE6>\Z//=J(X4 MU9&B.E)41XKJ2!>R;*(ZTJ:%533F'EP-Y[>9XN6J)_>YU4]B!_B6=8!'I*2; M IW03'%H"<.*4H>H!DQ"ZZS"2M!*RXFG'> _3B=7#4NU$]S?3N_QV#,25"\) M2O"BF3?@R#BCL8 T;1RGO>9,(N@U45KQ2H1G#X*J*T5W6Q M<)"6]&;"#J:4 @XXZ2 (AB5D+H 0 &\89M!43^/S\5V>&S:7\0OKW+=B.N]% M[G2=1!\K#LHEDL%6I,@ZAVE (, 69UN@%2#X=97<^QW05U-^J3A)R*G]^^&% M;'L?)M^#S]]SO5Y:THW!4BI!)$9(,JT@9X#B9?H,(AQ"\!Q9I0%L+HQ;:QU> M:W>N/FU0EXP6652H:XFPI@8@1@VA7%"*=8X62W3%"GP=+35I1=0J,-C^G>;2 M/:]?1E?)9)[>SV7#RK1;U^"X:@*RDV\(-1]1;Z;1 7-64PM3]TO@ "-- M5%GN+"8^*Q@I)(1AP- $8 !&<2 MU@1@<78 HWH;3[05P+WQ5*/2R"&YYU%II ZE$5Y*((+6>4LLQLX((3WW7*\[ M[S#*W"OT>8*D8_B6HG9(+K4S[Z]5+-FFQ.3(DI$ECV7)4IH8\10Y@@D!@@ 0 M7$-'5M+6%CB.#F;)>DXI!*&1(]LLP]3,TQTIO*"NKF8/R?4OH^'7T7BT&"4[ MZ"\P+*Q$ C)NG?/84R) +@C!";0E_07HB$(>20Z"2P8%1>'_N<0*H9*T1W]A M-1"YB%147HC*"YO>UK5 <51>B,H+47DA*B]$Y84+639M5EYH/KLG^38<#V;) M/)E]W]12NW8 M=3;B>7*58]=4%IX[$QZ9%,1N%2\4U& %,L5E*E E<+(7X(' M]"WS#7Y;KB_3M)X"/TD3JG;ZY*UBJC;%+2-#=9NA>*$P##&@0@/E*0__I<*4 M:M73V87727X$0]435N3P)(F7[62HKGGZOPX?9]/Q.!-:GB7++GKC(O37WQ($ M(8I,:.64#+!$7BG-D:442)9#DCI>,1K_IWJTMW__)QF M*5K^+2R-]-OYZ#J9U=((MH,E!A(5P,302(=A<(J-9\PPAC7/@:F4K52CZH?Y M:)+,YV9Z]W4TR4;8K$?>E <^Q^QCT[L>C7(,7?6*^PU34N0S:X^IH) I!CWD M&@ I:!ZX@HQ44DUJA6E-P@VXUEZOK<-IUWS#WY*OP?3JL0\H68$_HC1P0GD! ME8+6:.>I9V'?Y( ##="3:MB51;(:OZ9W/R2CS]>QS>R2,2.*/GC80"*0H!P! MA8@G5D(7,(.HHT8QR@[!3$VBL+6FC[=_Q[ET'^\4E:L=M" Q &4T!F_."NF4 M5T(+:HR2N06)A*\(J2R3E2O9H(T[<[Q6;^[026_M/AB]O;YB&=%2%SLB,$$2 M>XN]4Y13#]9!&V,KZ=U[8[F>;9;6Z_%='):[YA&VJ^ZJ(Q54+6"@%QYU-TJB M16$'9\AJ95E8(0@ 20R1>$5)V@I?H:336Q;H+00GK1IMK0W1 5,ATDT/Z885 M.1G4&NP84-89;KA@TD*4>S-28'$,W=048WB+2'.N3)OH)I925FSMU>+:JXH2 M X(4-1YC@(&A+"QFQH23(-Q,B.#)E\6YD0YP8$Y:P@11F$B7OE0[I:V$HCU5 ME,LNUJM2Y\VI9;&<,I93_OS*,W;6;8KEE+&<&I-*ND@!C=%(2Z8 6B+@AGC];]/'X?@4AX-0UMDGOK5;?@=V]EX@AQ:9YQ9JPB1TX:^< M4\P%0&*Y@WEO'=]TTK4#]&EN_=?AG\D\\']\#$]\(A%5U7HE9I( M!+/1:@RY]H1;X9W0.BWZT,B$92^\>@Z];&Q_70YMX]DL["268VMWLBX[K_T& MH"QRUA6 A"*K!=)4* JPDC;;^ZPEQI,# 5B3ZX:Z#<"N>6=UU)!<,*PP+& % M#!0.:N=QFEMBR)"\*6#RQ @JEM0U6HI:8:VF7+!E,1BHJH8W=6;(> MZY#4*_/;,9:,)2^5M5ETM-NKZL4;[Q@*_A+7ADN$@KN$UKW#-"I7O1 6[ QB M D"LH<@;S3C.>X::M:OJ93Q-.2R9W<6ZEUCW$NM>8MU+K'NICE+V\ECW M$NM>8MW+V9=-K^M>1J>I<,%NE1\KESRSN7/MZ2PQH*BPQQ0A7D6B'K M*#3,"21)[E5 IE%%%V^U3CYDRR1+.'BUEW<],4O&ZDQ/;5^R0:O(I4U1QT@G MET G&!7]N[P/M.&U LIB88E#".5T KS9E.B^*YW4U,,+URJ$U3HZZ9HGO4N+ MTSXD,=%21P2) ;%>&0BH1D0P*Q#,@:8QJR195!KEG6#;1BA6E5S&)MP+]#!6 M:C,)/3:<"2*Y(UYK:E2.'AS,X>/04Y."&NP$>GKG0<=.7+M#LM0N@3B*A?>( M*^4=L8P0"')($D\K4@H'M/@YQ98GNVU:M@K$;=TDNPA5!HH$7V0=A A;JQPS M1@6_3J]M3R*JW2SKAFI-^VN]AS+PYBG:#PVMC-B7J<646LWP#[M&'F)2 P MN(( >P1P\ 11 (^%@FJ,(#T*/%%EH(>NX*?[S)X)6]4X& M, :#)5H$1C4RS&BO)7<(,P'!E&1 MUF( D4*8\!?*A(4^_)'F&(1&5W14#\%@3;DMM9X:MA:#O7$E+Z1@]Q2U$BVO MR6V:MEX8@]UXK)0UI!7EA DD#*96$\RQ-;DX@3!@:]GM*?SJMPS7*BUV\)RW MUL#HLNL=.2URV@Z<5LKELE !@!'TT%!GG-#,L%7KW51B^SA.JTEKZJT0[= 3 M.*_!UKQD0/KS,@'K8;@86DD-HU,F^46UK4"=C2_&D_G#[/7)19@&!3-;'#3$#8, M!WM'DUQBP6-B2Q(+GCN%)7=0<2:A,LXZN7PIL9![\&:5W!>\.K78^SYP+X6& MTEK[Y\-\,;IYW&42GG+IQT]?W.##( N0PI\''SZ:3W]W@R_J_[C/NPLQ'/9! M3K4:/E_=)M;8RO(>5!ZF_U&_ MHLAEW>RLAS?GBAQ#>,KLH0:5 ?XK&'I25(>B8,0U!Z MY9::WC+@QW#^%XRC9V&*9)XOQ#>; Q^[A:'G M8:C"[[;$HR$Y2?N>*J(;6QUU86&#V=H>%FS3@5SDP,OFP"T4B L*1,A30SRQ M'%K(!;/*K$+C8>D8P9JE0+$7!;Y6A=;CAM.1Q2*+=9+%MEERM$BF5@0QB'G@ M+N,,L-H*N4RFEL )9U"S-,9KM^0($-&.V]F.ZUH5Q>I(LX=EO"MD@"OZ M*T48E=2&&*LQH-! !QR%.&\)R#VJJ,H=0'_NC\5L&(9I-!G.'C\LDKLL^3^\ MG=_722RJKF)7UA M@;L_[I/)/-'))+D9+79HJ^T)01@Z(H0&7E ()%NWU79 ETKXC,7,6L:\9D!X M[*!QJ_)Q1;& !Q=MUC7"7VZ3P2P9#].ZN*_+YT]!^*3F;I?2N0LJ>HL5;6V_ M6:QHBQ5ML:(MUIC$BK98FA0KVN*R:=>RZ7%%VPL#8I;B5L>NIMZ& CO\X''V MX^SW>?:[E@^^?-#E5Y^D3?7&)[*@6EG8(Z M/YNUB%9:X*SV]]5\5X*EC6:K(]"%3+\>!+$BX$\,^"TU:1"10L%6(>2+4QD%)[)IH M *AFA"--.5:<V^F >2UB M*EULB)GCDA3&;T"B%\9@1240.M6%@'J%2V*=VK3-KGMPG#)(#>J,5+6V(V8/ M E,1A &$K-@!#65XG'Z@P&11!&$)X5A**H M'['*4(D8)EXK!3P!U*[#0,SZBBS2_B"LS39%M+G&JBT"83LCMJV%:0<]2%(* M"'$&'% "*869(,11;M;XM(1MPN>&TK,F#57$3R).W-K-,<+Q4N&X+4 ;OBOV M2V2Y\,% =100F38B7QNMRA$HC\9C_9'9>A5[8F0V KFM0-Z&8U+JE4LD16FS M81O@K06"3.1UT\ K?#R.:S-[J>CVP6>KBG%75>,H+1%O2_YZQYZ[3\\:Y[C[ MS]K+.6YGD.(4]8@VN4F"*7 =BY)B25J<_3C[RAAL?2GYX>[EPS#@+RB MK:4T!K$ %(,4-=H1P'Q^.H2DKP^&]4>E(:HSK!5A&&%XTE@R0P4*O;0> TD M3;O)>LH\=#D*/0&5DO>#45A?*@7O1)>VGD0A8G';;AMCJ2:=6^:(3:5P*=3 M*,F*0E/M6:4;2P[))YGW9[52V]L8M97;9F=]ZL[#>ANJ2^7C5AF&I27( FAE M\#X-H_E&2Q@"-:.ZMO3A;A_@1FCV%9JE@)"4E @5!DI(ZBG2FD&^3N8W>*,- M?" TZ^OWV&EH=CH@V_GNX=L,7@X*V35A@3%.,N^I8I!IK3'.#5YI$-[H@RY' M\9RF+GD;8T$Q%G310"SI'P+$!)"<.N2H!=)!0U&NX*"5J;2..1B(]8=D29U! MH8C"B,(3HY"44,A9\!(QH] Q$;9%1WV>I@^0L*0V%.YGB.XDI%)GY.=R4-C. M6&Y;<;JM>K'603IK \.=T<]D(>]@"9/",VP! I0YI]$Z3L2\<)O0?UXK&(E: M8[['KI"]*..\30MCP#C22%TT(@H:809HX#11QDOG(&"(XO6YKN UT$@#:16L MN8[1D40BB402V1X7#_Y_P2$:4)5&Y 32WCB'07%DA;C:Z(B<(RF$U'I.=>BJ M:''_X[94*9XU@[^)WO*G+^-II$M\"X(E+SSJ;H:/P,5AGA#!Z$' $**@%%H3 MKFW>\1UC5I''.Z_?!.!)&[>W,:3RPJSW--(9N:N/W$4+[B*>6 J #O]*X22D M+NTML>0NH%3E_.6KM1N:*S!69JU7,M8VX>*F61UE%K0D\!:DV5@8[ M:TU !'XT\^EI_WGPWPQNGELZ(&??*;-!OO3M??YZC:Y?A@GGV[K#Q<-B.GL2'%]=.+C,)UYN'7X[#'S=\_ M715'/W7I D^VIE28)+O :!+VU.7/Y3M,4O89/^%T")8,GN%Q<)6,QZN__ML; M\";[.7SRJ_SG%T;ZR^@N/.['Y,?@M^G=L+*1_QA=+V[#M^'15I1T%<9D>#]/ MWN??_/RW1Z_\[; _G>N*?0J5K6=? MM$E.^BH@*YDU8M;\5S*<#5S [O7 )E?)W==D-L#P[5$)'0T,35N7R3E4QZMC M<5B(O<%5E1H:9_/Z]AB-N&S:MFQ$7#9QV>R_;'C/C_@:30B^)*S$B8X3'2?Z MTDC]S;__>99AFE%RO3PP.R.=YN-\P7.'1?J[$/HH+\/M%^!0PO?7# M_5$9(YPP0H@GB-<2UF1(6H&X97$A8CP MB/"(\(,1#DL*G(YP C"4$&H5]FP'N5J>* I#'1*55,EF$%XYX3\M\<1R8SDBBB"A&/1\ M#6XK*GICNX#[9<&C9-ZL9H$J64LUPK-&,!C]U7_ HPO$2X;@EU1Y!6FR/6%$ '?8D6+Q*6F:9 M7XGL&NF9.2A^M0<>]S5Z=RJ?KM7X;27OIT6H;5M0\/-[1#HKR2E9S#0PDDE-G6-A[T5K+]=3>M#.^UMR/US,EM]_ MNED)+[G5'#0>IZZU\*8K/FZKL-^F';N3^!9HC>]@1U/!A/$.2LPQ!F)M65.O MJUW-F\!WK>8UC?".\.XWO&6Q?3L=P.P=<-)R'*"&D4?Y,10FDIX"WC6&J.OU MGCL#[ZY%J)>K, M(KRSTS&3OF<.-("Z.DW%ZE PXP@A3HB2"<"4F9(F@J"(F MM N.GRN>IJ^PH_#&63)9C +NY M".\([Q;;Z"6U?8,AE)BJ5(L) 4&-7"=;*H'A06?,.^*[QM@TK#71\L)@?9R9 M?B'6^&_)/!G.KFX'5[/DNG/9T=L0BTNU#U (RJ4WAGO@,?>,2),CUB)U4'53 M^*7)QG6>CW.SJ2"D5BO[@F 90UL7#$)4E!AB* @P*$ 0($()H4RI'(14'78F MM!,(ZZPJC&<_$807!\)2PP3I)9#<8>L"_*343DJ0QYX8L;HQ$-9HN?86A+V) M(__G+.;K*5'YC#1K[L(8=8I1IZZ#?>O.S8J:0@.Y=-I* M!S%UW*;R'#;?N0'V!^W=(QV'^";20DB?-_I>Q*'-]"X]SQ@>F19RT; NU3AX"IS"V!,, MO2> ,HA%GN)E2+71ZD[%R+?#6:*'\^2Z/-CNCZMD/@]O6'7<^369I;J6)\H+ M 3$7,\;*+@VH!)9J#9E2V"J-O314,J0\=_G^ZXDXJ!CI6* V87/W5DH@ O6" M@8J*'94H9KF'$#E %;!:,IH7_2MNJ3@'4)LPE5&MU<(7!-3>!+X_!@NYR ,: M),M$H"CTL<(\*9(LD0&&&:TDXLXP;CRS:TD?J>5!2_ M3(.CW+#>!Z[59KXP9SA&O2/*4Y272B6DAB MO%;5CXCR:(\!0021Z2!5H.U7"9SASG:!Z*\UC25'A]E M]4?\XQ^3J_#QAZ-,]&-P/UV6/W9-_&,;FDNM)!251!/ A#(:I%!V;%W>R*E? MQ[>_SO_8"DDE*A^&\-C;<3CMO 8+54_&"\9I0I[S240 M MC@+^?;*Z&>-@W(1HH240Q:1U2V#97;0%FNAD <4,"Y= 8J@0UFB.6GP$Y: MU30HZZPD!+WNV=";X/07\Q\JZ[PR"G[4U2'UA%UT9&FI[X/SU%&.C(6062)5 M /;:D0U_0_N".AWQ,.#+\:[9U/U7,IM>#^>WZ=(6"**?H[,:0U+=1O)6H[E4 M7.&XU)YKX!"WQ%"M 2M$\IRL'R!)"C)6>:@(Q M8%APG1\7"Z!PW7"NT;R6]4:A+@S&_0DD?Y@L9L-WJ23C(NU)OAA.OF5)(,,T M/W\0_C:9WR2SK@66M^[)I>8/U#J@5-BE$?'2 $, ]5P02@7!&N^_)X_2$5\. M>#'>V7"O1_M$N=)4\AC/BO&LMH%S&S9+50U&02$,IX!RQA!RE (=L,F\-UH% MW)P&F\!IH_+<(?LB;???%DMUG!K-2^P?NT$HE[)R1F5(5-S^!UMM2!.EK9 MB*OK?S[,%VEZU*G,WGH+&B[,LXT!JL[#>ANJ2XT?/*9(.$8AI$(KQ02$ZV)# MXOQ!8CX[H+K&K&;XD^@OF.,14C\0O76CIL5&C8U& C&ME1.0>Z&ISA5[B.;V MH+3F'2#=1.4AZ',N<_M$.EH%X^GL.IGEGQ[?_S&XGCZD<>O_ ;+_'30 JXNF MKX#ABO/I>'2]OF#36,]^_)%D8_]U.K[>'?REF@;CK(92!7N<>:RTHM*)=:-B M)-1NX#?AHXPF#V%T/MTG&8YK27G>*20M2*TAZ9W7R5[@/VRAU,,,+ZR3&.&. M#/$J0Y3:2"C)%9>(($J)XA J8WQN'D"K=Y3WVI$A&M$-X?6Z[Y$@(D%TG2"V M\ ,'I:I(:J$@1$)-J0K^ ]%JG2%.I'>U\D.-^2I"U!L(Z ,M; GZ_W4Q#$^< M_WY_U_7K[*_/AWXY/Q\?[L);KL(LI#<87"7C\6JP_NT->)/]'-YUE?_\PDV_ MC.Z2^>!C\F/PV_1N./EY4+W[4R_IQ^AZB"4CK9; SDY5F+ W&8BNENMZ MN$;1ES!-GY-QDJVW=\@(#Z#B1F',@=7"Z:4DD!2*2:G>P24(PB62:[78^^WH MZ1H9CR;)N]OEE$($_E2: QD&X2E_D>6C[SZ-,AO'/\._5.>P/ S; !7&[N=Z M!F_;TY<@DT8J1C>/E:?9^_'M0S)83 >+VV0PFER-'^;I9Y_>#"9AZ665M[/I M]U'ZRWGX^R U>=*^1ZG6Y.#K8_:V+_]AU-O!CV1P._R>#&;)U7@XGX]N1N$5 M\^S9!Z-%]_7XVFLX&C\EP-D]OFCW*X,=H<9M=*+WE5;CRM^EL%!9_,D_1 M,YK?A@NM;OTVD-2R#"?];.$UX;/>+-OP#L)%)V$QS ?#R77@VQ>KAW_::::? M<,.>\_%D269HS%XTF@1C8/'^7;9(CYZS%XCGX&5S>.!N._MEOUR^[/F'+'VF M5.DKF?V\^]JO+?8X@( _>X+LZ^TLO\S]\%OR[FM8[[^_&]Z$3_E^./XQ?)RG M#'L[JS[@=@Z EAK-+#0:8<.P\5R3G ,\)G8+@6Y].]J-B10DP>#Q4A/EA#70 M6)A?!C#OWX%CF.C@^?@(XVHX681!N+N?3M)8;,I&TX=9L)F6VLH9I+/L MB"76QZ/AU]$X #SPP7"6)G8&3DC5EN?O=\=(]=.77OT$U. 9IM.?RY>;I";< M^(FQ!,%R:ZK-&GCV:9=[/P3A.58&V%48@.']/'F??_/SV%Y"T[_5+(NGOX-OO(G<-C;FKQ9U]*<7_,2US/,W[S^K$^=@JH%7^L1 MTHKWF[#[548:-KE*[KXFLP&&;X_*^VE@5+:MD-I7Q"&#FKW\_6@11N,JM92# M.17>,TXMJ>I@[VN#"3 \5SA:IVF,T3AS&BLMFZ[(1%Y.Y MV KJ>CI^>5N.P9=@.BX;<[P_=B5>>#)H._)+6A9.C[-_H%DL6OND'R;? R]/ M9X]AD41,L !D3_8^L"&G:ZF MHO&E\U(T+YZA1IR? ^>H.*R%F#&GF:,$24\50@ZL I6(0,O943@7A^'\>;I& MG:>R9\-YW:Y$>PV"U 7XNFPSLCSG"O\LC_ GWP;CZ7QI(EPM.V]O,1/1*B6@GC-H>.*^] %9)#R?L M72;@R'-)&+)2 NE4[A J+D!CP*IGC^L(L/KC+8;%L9@]7"T>9MF-5X'CJ]OA M[-NFN'&?C5 ,8(%5*P6 #F-)H=**" 3A&JM:R(JBQF%8?3)#9CDQS6V,W391 MH^_85]B6U-85)-Q#@AQ"6D -TDK;W'>$$E5*;!N%;4TQVI.4V;=_.[Z47?>7 MT6+T;9F\G/J6][-IVG)NG>G[N.7DM@=&,0:TA%@B83"&+6*I2"04'B*7;[3< M@(K(S6&(79:\?4LF5Z,&=UC(.F$A1]>S&RCC1OIC$@W9*F!E 5CD&&5( M28DX"4"6S).55HQC2GE?#V"W=+^M;V1+JQ_=OOI>RR9GJ7KIFEY[D*]O;7^(6XI)H"TF-+ MAZ#$%D"FB"5K%]-RU4ZJ>-!!9#?H*IY]N MUAVI7^E$7>/6& \\H]/9133*HIV/\5 9A0&Q0C//O;"2Y4ZG\WQ>B6"Q_5'LF",@[('0*P[3\B[!A: !?UQ1O/TDY6_3Z?6/ MT7@<[-=BB)=_:FPGQ&\)J;/O8Q0&($/.5*2F4 M!W![W54ZR)>A2= ^^S%ZB[[PS! M>EPX7*<-V3X(]E)6LPDK\ZQ]%G:%G2Q@%S8\;!TB'EB"A4888IL'413@VPNS M_C:;SAM,GGG+8)V'?.=L=!!=NSZ##D.P!IV6AF(EJ>1&.@HD9B*7P6)85WN9 M[ RZFL*5;R%IH-=9RT#7'P_PEV0^?S_X/AROA.6'J2=/P$(7XJ.8K%- M1&P3$6>_^YEZO\Y2$>C%X]O!_3AM/YC*CB3__3"Z3ZL$^[M?DU(MBA*&.,H% M%U!02I4D&N4>*G;^M=R&$J'F _UK.LQJ!!>MI@]I,LHUG*]@.)2]8BPVF!O M/&$$8(<](-KD9["2DQVW1;N>A 8['T0!DG^,J^(/"8\,0U-;\/_:^ MO+EM),OSJR \L]-V!*7"?53M3@3.*M7Z:DO5%;W_3$ D)*), FR D*S^]/O> MRTP@P4.B1%*B9>[V=%LD""0RWWW\7J@%0OU98,=NQG#W])_LK\'K5?:C'/W$ MU\%B4FE '&N6H8=.DL2F:]I:&.J.2)08KGD?O.O.6&PW.L]['>"N/X[K>-_T M7(15RX?'*0BKN->1"GO,R-?B,/)UVXH2#?ZM>0Y<%AF19[CVAE&>11"?=);/ MF4_?'A%B]>QQ\L&KME:/ON./RJEN-\W2#6/3T6Q3]\PX"@PKL+V8<6JLFK;C M[IU3#["O^O!8]=4YECOIJWZ@AO([YE!;]21$9S723"?4+2^,M,2R \, #O7B MP%"!3\/-.'3'/=;[S(X\=*X'JS!_*+WXBIE/[V9:FJ&MV7:0>'X0QW84F3:" MC"#S.;&GW0NGO@'S':+N.U3F.\RJOH-ESUUNPO?0(6J;DDUKF)836Z9A1([J MN[JI Z>R&0AZH%MKO<^S8EA.LS[K[J^E[%DFLA]F]^B1A8\LO(*%[4[O)HGO MN887FXALXH/>#72OG>[EV&O=T@U9>%>MWNKS()L<)A>_:(/7 9;3?\SF2J^D MGB46E)^4MQ(UKNF6_1'R.[;4".,YD6O%D>=:FJ<&H1.H@2]2J*ZW:0IUGSUD MZG$^PBO3J(?,.@^U33M21"AR[# T[<"UX1^NBAYJBZ2NNNI],Z:?0RWJYBXY M9YG8MCFU@VAX_NXSI)^K;):""8)D"B14@&;EBJ'VH=5I\5R5_5@5>31 M&WVM7"G%C( =M4#5C<0- DOW=-_TNL9L+[!WR)4[]3N(X+]QNR;,BH;+/;=)HOSDL&*%=O\G_O(8TM\ .3#,*,0P9.7H0PF5<[$<)P,D@ M><%0"GOO.LF+[&3,E@8^QO_:DR)@Q/&QF<(OAGURC)B^_>?%TDC5\^$X&S63 M[-/5DJ_C%R.)_"]PRR[@CL&D''Y]0^R&?YYGDXRH\41UC=!T M.(3*9_TD5&#-74/<_RP?+0X/O$LD1.P(RB,/ 9-\%F9B-_OO@Q ML6[B!:8?NU&H8;$PB'3(;X)7P*X24U*'PV4Z01Q-I1YGZ(>\A1_ .TWP!N\6 M@*$>1\S2U3VUJX*(H-W."[ 7V-_R[0H4?I.>H-%49G80PRK#;#+AW_Z?-W#* M^#[/>EV6/L. );Y:$,_M.M]9_I]WSU3VWO.]G^WS8B_KRSVR0 M5N7MRU50/B*N,& ]K)X&)?L(72ZW;S_TTS:/1(16G(O%@!X MQ&X<*FCAZR4+][NII3Z01/5!;LBN:*3;DIPJ)='?6-?-O'.&.=#ZQB=%T!ZB M@T.-G&V8"/ LJXN3^6KD1;H3^K:M&8FJ:@:KQ74CU0WBAR=7?\SF80.?[!/O M\EA.?R!"ZY#B_T![AB)Y7J>96M:%%F1$&HJ?+6J=AUL-V:Z =G-1 &3 M'".=[;="TQP8WNLN8#\HUCQ8L^,ULJ;EM*RI);9M&H[C>G$Y]AM\?3A_O[/8SVLTTC09Y#$V$]NU$]76'%MU75MW>% H" )# MW1"+YADBL]9NL]Q//?:C2W70+M6/R,VF(\T>L$U3=[0D26)'-375,Q)1KI*X M_H:0K<\0Y#7T70X&^?ZX^75EA!^*\DJT=2"F^Z&&:[]G.21-NC6\V/$\SXD= MW8Z5?,A>##KT,F.V&0[V=XC=L_FV&2F;CM';+(C-MEWY+D=Y=M1OFV.36;J MKGW$)MN>+H[89)L)X1XPV$N 8:U8U/,O@J&O/'$(#(;X&6P+4P.&-E!D)(Y' MWVZ@W&;*.!TI?YR>GRI7&=!F.B'[NIZG<\KV*P78Y.4,OICGA.Y5U\HPK:H[ M8,3;M!JQ0G*\< @"(4=P,<0#PP_ %Y[OA*%KFF"K6:83J/ O)M-\R[>3A]N?/HFW?@\O'S:U9;]A=T1X5BBH'_&N+07 8D "%]_CD4L% 9%M)8F9J"!R#,

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

C/#NA/MIBOU^1'M593&9A!SF,F& (PR7($LKW-G!=( MJ_^^'TN#Y9;HR\]>;GY&+<#HSP:B;8:P(]90[H-S:J;=A@2&U=Q3W.@(J!.G M$U-#-U_.29L'AD:HM%^BYO7CO%K."BB03'!&"8* (

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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Supplemental Balance Sheet Information (Tables)
 12 Months Ended
Dec. 31, 2019
Supplemental Balance Sheet Information [Abstract]  
Schedule of Other Assets [Table Text Block]
Other long-term assets
 
As of December 31,
(in millions)
2019
 
2018
Restricted cash equivalents
$
43

 
$
27

Operating lease right-of-use assets
336

 
—

Derivative assets
216

 
183

Investments
458

 
424

Licensing arrangements
332

 
—

Other
144

 
211

 
$
1,529

 
$
845
Trade accounts receivable, net
Trade accounts receivable, net
 
As of December 31,
(in millions)
2019
 
2018
Accounts receivable
$
1,902

 
$
1,676

Allowance for doubtful accounts
(74
)
 
(68
)
 
$
1,828

 
$
1,608
Rollforward of allowances for doubtful accounts

The following is a rollforward of our allowance for doubtful accounts:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Beginning balance
$
68

 
$
68

 
$
73

Net charges to expenses
23

 
19

 
14

Utilization of allowances
(17
)
 
(19
)
 
(18
)
Ending balance
$
74

 
$
68

 
$
68
Inventories
Inventories
 
As of December 31,
(in millions)
2019
 
2018
Finished goods
$
971

 
$
760

Work-in-process
192

 
100

Raw materials
416

 
306

 
$
1,579

 
$
1,166
Schedule of Other Current Assets [Table Text Block]
Other current assets
 
As of December 31,
(in millions)
2019
 
2018
Restricted cash and restricted cash equivalents
$
346

 
$
655

Derivative assets
105

 
122

Licensing arrangements
186

 
—

Taxes receivable
105

 
37

Other
138

 
107

 
$
880

 
$
921
Property, plant and equipment, net
Property, plant and equipment, net
 
As of December 31,
(in millions)
2019
 
2018
Land
$
117

 
$
97

Buildings and improvements
1,198

 
1,100

Equipment, furniture and fixtures
3,411

 
3,224

Capital in progress
442

 
319

 
5,169

 
4,740

Less: accumulated depreciation
3,089

 
2,958

 
$
2,079

 
$
1,782
Accrued expenses
Accrued expenses
 
As of December 31,
(in millions)
2019
 
2018
Legal reserves
$
470

 
$
712

Payroll and related liabilities
708

 
630

Accrued contingent consideration
56

 
138

Rebates
298

 
229

Other
576

 
538

 
$
2,109

 
$
2,246
Other Current Liabilities [Table Text Block]
Other current liabilities
 
As of December 31,
(in millions)
2019
 
2018
Deferred revenue
$
144

 
$
115

Licensing arrangements
197

 
—

Taxes payable
265

 
125

Other
195

 
173

 
$
800

 
$
412
Other long-term liabilities
Other long-term liabilities
 
As of December 31,
(in millions)
2019
 
2018
Accrued income taxes
$
667

 
$
739

Legal reserves
227

 
217

Accrued contingent consideration
299

 
209

Licensing arrangements
374

 
—

Operating lease liabilities
276

 
—

Other
792

 
717

 
$
2,635

 
$
1,882

XML 43 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Schedule II
 12 Months Ended
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]
Description
 
Balance at
Beginning of Year
 
Charges to
Costs and
Expenses (a)
 
Deductions to
Allowances for
Uncollectible
Accounts (b)
 
Charges to
(Deductions from)
Other Accounts (c)
 
Balance at
End of Year
Year Ended December 31, 2019:
 
 
 
 
 
 
 
 
 
 
Allowances for uncollectible accounts (d)
 
$
68

 
23

 
(17
)
 
—

 
$
74

Year Ended December 31, 2018:
 
 
 
 
 
 
 
 
 
 
Allowances for uncollectible accounts (d)
 
$
98

 
19

 
(19
)
 
(30
)
 
$
68

Year Ended December 31, 2017:
 
 
 
 
 
 
 
 
 
 
Allowances for uncollectible accounts and sales returns and allowances
 
$
119

 
14

 
(18
)
 
(17
)
 
$
98


(a) Represents allowances for uncollectible accounts established through selling, general and administrative expenses.
(b) Represents actual write-offs of uncollectible accounts.
(c) Represents net change in allowances for sales returns, recorded as contra-revenue.
(d) Following the adoption of FASB ASC Topic 606 as of January 1, 2018, the allowance for sales returns has been reclassified from Trade accounts receivable, net to Other current liabilities within the consolidated balance sheets and is not included in the ending balance for 2018 above. Prior period balances remain unchanged.
XML 44 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Changes in Other Comprehensive Income
 12 Months Ended
Dec. 31, 2019
Changes in Other Comprehensive Income [Abstract]  
Comprehensive Income (Loss) Note [Text Block]

The following table provides the reclassifications out of Other comprehensive income, net of tax:
(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33

Other comprehensive income (loss) before reclassifications
228

 
116

 
—

 
(22
)
 
322

(Income) loss amounts reclassified from accumulated other comprehensive income
(33
)
 
(54
)
 
—

 
2

 
(86
)
Total other comprehensive income (loss)
195

 
62

 
—

 
(20
)
 
237

Balance as of December 31, 2019
$
142

 
$
173

 
$
—

 
$
(45
)
 
$
270



(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2017
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
—

 
96

 
—

 
(2
)
 
94

(Income) loss amounts reclassified from accumulated other comprehensive income
(21
)
 
14

 
1

 
4

 
(3
)
Total other comprehensive income (loss)
(21
)
 
110

 
—

 
2

 
91

Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33



Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.

As a result of adopting ASC Update No. 2016-01 in the first quarter of 2018, we recorded a cumulative effect adjustment to retained earnings to reclassify unrealized gains and losses from our equity investments previously recorded to Accumulated other comprehensive income (loss), net of tax. These equity investments were classified as available-for-sale securities under the former accounting guidance, and we now refer to these investments as publicly-held equity securities. Refer to Note A – Significant Accounting Policies for additional information.

The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from Accumulated other comprehensive income (loss), net of tax were reduced by immaterial income tax impacts in 2019 and in 2018.
XML 45 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Changes in Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2019
Changes in Other Comprehensive Income [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The following table provides the reclassifications out of Other comprehensive income, net of tax:
(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33

Other comprehensive income (loss) before reclassifications
228

 
116

 
—

 
(22
)
 
322

(Income) loss amounts reclassified from accumulated other comprehensive income
(33
)
 
(54
)
 
—

 
2

 
(86
)
Total other comprehensive income (loss)
195

 
62

 
—

 
(20
)
 
237

Balance as of December 31, 2019
$
142

 
$
173

 
$
—

 
$
(45
)
 
$
270



(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2017
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
—

 
96

 
—

 
(2
)
 
94

(Income) loss amounts reclassified from accumulated other comprehensive income
(21
)
 
14

 
1

 
4

 
(3
)
Total other comprehensive income (loss)
(21
)
 
110

 
—

 
2

 
91

Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33
XML 46 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions and Strategic Investments (Details)
£ / shares in Units, $ / shares in Units, £ in Millions, $ in Millions
 12 Months Ended
Aug. 21, 2019
USD ($)
Aug. 19, 2019
GBP (£)
£ / shares
Aug. 19, 2019
USD ($)
Jun. 11, 2019
USD ($)
Oct. 16, 2018
USD ($)
Aug. 02, 2018
USD ($)
Jul. 05, 2018
USD ($)
Apr. 30, 2018
USD ($)
Apr. 16, 2018
USD ($)
Oct. 10, 2017
USD ($)
May 16, 2017
USD ($)
Dec. 31, 2019
USD ($)
$ / shares
Rate
Dec. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
Aug. 19, 2019
$ / shares
Jan. 29, 2019
USD ($)
Business Acquisition [Line Items]                                
Proceeds from Divestiture of Businesses $ 90                              
Business Acquisition, Pro Forma Revenue                       $ 11,142 $ 10,429      
Revenue from Contract with Customer, Excluding Assessed Tax                       10,735 9,823 $ 9,048    
Goodwill, Purchase Accounting Adjustments                       125 (22)      
Proceeds from secured borrowings relating to royalty arrangements                       256 0 0    
Defined Benefit Plan, Plan Assets, Contributions by Employer                       13 14      
Equity Method Investments                       264 303      
Payments to Acquire Businesses, Net of Cash Acquired                       4,382 1,448 560    
Other Significant Noncash Transaction, Value of Consideration Given                       72        
Business Combination, Contingent Consideration, Asset                       354 347 169    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases                       127 248 94    
Maximum future contingent consideration for acquisitions completed after January 1, 2009                       697        
Goodwill                       10,176 7,911 6,998    
Goodwill, Acquired During Period                       2,218 942      
Acquisitions (Textuals) [Abstract]                                
Contingent consideration expense (benefit)                       (35) (21) (80)    
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred                       (16)        
Contingent payment related to business combination                       68 28      
Cost Method Investments                       171 94      
Notes receivable from portfolio companies                       23 26      
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity                       314        
Deferred Tax Liabilities, Net                       3,601 241      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain                         184      
change in maximum amount of future contingent consideration, increase (decrease)                       176        
Accounts, Notes, Loans and Financing Receivable, Net, Current                       1,828 1,608      
Inventory, Net                       1,579 1,166      
Prepaid Expense and Other Assets, Current                       880 921      
Intangible Assets, Net (Excluding Goodwill)                       7,886 6,372 5,837    
Other Assets, Noncurrent                       1,529 845      
Accrued Liabilities, Current                       (2,109) (2,246)      
Other Liabilities, Noncurrent                       2,635 1,882      
Deferred Tax Liabilities, Net, Noncurrent                       (595) (328)      
Business Acquisition, Pro Forma Net Income (Loss)                       $ 4,585 $ 1,244      
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares                       $ 3.30 $ 0.90      
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares                       $ 3.25 $ 0.89      
2017 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Payments to Acquire Businesses, Net of Cash Acquired                       $ 560        
Goodwill                       287        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                       278        
Indefinite-lived Intangible Assets (Excluding Goodwill)                       186        
Total                       632        
Acquisitions (Textuals) [Abstract]                                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                       44        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                       (61)        
Deferred Tax Liabilities, Net                       102        
2019 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value                       102        
Payments to Acquire Businesses, Net of Cash Acquired                       763        
Fair value of contingent consideration                       127        
Goodwill                       575        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                       220        
Indefinite-lived intangible assets                       240        
Total                       992        
Acquisitions (Textuals) [Abstract]                                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                       24        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                       (12)        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                       (56)        
Intangible Assets Acquired, Finite and Indefinite-lived                       461        
BTG Acquisition [Member]                                
Business Acquisition [Line Items]                                
Revenue from Contract with Customer, Excluding Assessed Tax                       226        
Goodwill, Purchase Accounting Adjustments                       95        
Payments to Acquire Businesses, Net of Cash Acquired                       3,619        
Line of Credit Facility, Maximum Borrowing Capacity                       150        
Cash Acquired from Acquisition     $ 404                          
Goodwill                       1,644        
Acquisitions (Textuals) [Abstract]                                
Intangible Assets Acquired, Finite and Indefinite-lived                       1,785        
Accounts, Notes, Loans and Financing Receivable, Net, Current                       108        
Inventory, Net                       232        
Prepaid Expense and Other Assets, Current                       252        
Intangible Assets, Net (Excluding Goodwill)                       1,785        
Other Assets, Noncurrent                       537        
Accrued Liabilities, Current                       (308)        
Other Liabilities, Noncurrent                       (274)        
Deferred Tax Liabilities, Net, Noncurrent                       (358)        
Vertiflex, Inc. [Member]                                
Acquisitions (Textuals) [Abstract]                                
Payments to Acquire Businesses, Gross       $ 465                        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low       0                        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       $ 100                        
Proposed BTG Acquisition [Member]                                
Business Acquisition [Line Items]                                
Payments to Acquire Businesses, Net of Cash Acquired   £ 3,312 $ 4,023                          
Business Acquisition, Share Price | (per share)   £ 8.40                         $ 10.20  
Millipede [Member]                                
Business Acquisition [Line Items]                                
Total consideration for share purchase                               $ 90
Potential payments based on acheiving certain milestones                               $ 125
Acquisitions (Textuals) [Abstract]                                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage                               20.00%
Closing payment                               $ 325
Augmenix, Inc. [Member]                                
Acquisitions (Textuals) [Abstract]                                
Payments to Acquire Businesses, Gross         $ 500                      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High         $ 100                      
Claret [Member]                                
Acquisitions (Textuals) [Abstract]                                
Payments to Acquire Businesses, Gross           $ 220                    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High           $ 50                    
Cryterion [Member]                                
Acquisitions (Textuals) [Abstract]                                
Payments to Acquire Businesses, Gross             $ 202                  
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage             35.00%                  
NxThera [Member]                                
Acquisitions (Textuals) [Abstract]                                
Payments to Acquire Businesses, Gross               $ 240                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High               $ 85                
nVision [Member]                                
Acquisitions (Textuals) [Abstract]                                
Payments to Acquire Businesses, Gross                 $ 150              
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High                 $ 125              
Other 2018 Acquisitions [Member]                                
Acquisitions (Textuals) [Abstract]                                
Payments to Acquire Businesses, Gross                         $ 158      
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High                         62      
2018 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value                       251        
Payments to Acquire Businesses, Net of Cash Acquired                       1,449        
Fair value of contingent consideration                       248        
Goodwill                       939        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                       939        
Indefinite-lived intangible assets                       213        
Total                       1,948        
Acquisitions (Textuals) [Abstract]                                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                       38        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                       (19)        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                       (162)        
Intangible Assets Acquired, Finite and Indefinite-lived                       $ 1,153        
Apama [Member]                                
Business Acquisition [Line Items]                                
Payments to Acquire Businesses, Net of Cash Acquired                   $ 175            
Potential payments based on acheiving certain milestones                   $ 125            
Symetis [Member]                                
Acquisitions (Textuals) [Abstract]                                
Payments to Acquire Businesses, Gross                     $ 430          
Technology-Based Intangible Assets [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       13 years        
Technology-Based Intangible Assets [Member] | 2017 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 268        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       24.00%        
Technology-Based Intangible Assets [Member] | 2019 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 210        
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       12 years        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       15.00%        
Technology-Based Intangible Assets [Member] | BTG Acquisition [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 1,709        
Technology-Based Intangible Assets [Member] | BTG Acquisition [Member] | Minimum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       10 years        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       11.00%        
Technology-Based Intangible Assets [Member] | BTG Acquisition [Member] | Maximum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       18 years        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       12.00%        
Technology-Based Intangible Assets [Member] | 2018 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 908        
Technology-Based Intangible Assets [Member] | 2018 Acquisitions [Member] | Minimum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       6 years        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       14.00%        
Technology-Based Intangible Assets [Member] | 2018 Acquisitions [Member] | Maximum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       14 years        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       23.00%        
Other Intangible Assets [Member] | Minimum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       2 years        
Other Intangible Assets [Member] | Maximum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       13 years        
Other Intangible Assets [Member] | 2017 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 10        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       24.00%        
Other Intangible Assets [Member] | 2019 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 10        
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       12 years        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       15.00%        
Other Intangible Assets [Member] | BTG Acquisition [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 75        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       11.00%        
Other Intangible Assets [Member] | BTG Acquisition [Member] | Minimum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       2 years        
Other Intangible Assets [Member] | BTG Acquisition [Member] | Maximum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       11 years        
Other Intangible Assets [Member] | 2018 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 31        
Other Intangible Assets [Member] | 2018 Acquisitions [Member] | Minimum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       6 years        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       13.00%        
Other Intangible Assets [Member] | 2018 Acquisitions [Member] | Maximum [Member]                                
Business Acquisition [Line Items]                                
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life                       13 years        
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       15.00%        
In Process Research and Development [Member] | 2017 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       15.00%        
Finite-Lived Intangible Assets [Member]                                
Business Acquisition [Line Items]                                
Finite-lived Intangible Assets Acquired                       $ 464        
In Process Research and Development [Member]                                
Business Acquisition [Line Items]                                
Indefinite-lived Intangible Assets (Excluding Goodwill)                       $ 662 486      
In Process Research and Development [Member] | 2019 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       19.00%        
Acquisitions (Textuals) [Abstract]                                
Indefinite-lived Intangible Assets Acquired                       $ 240        
In Process Research and Development [Member] | 2018 Acquisitions [Member]                                
Business Acquisition [Line Items]                                
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                       15.00%        
Acquisitions (Textuals) [Abstract]                                
Indefinite-lived Intangible Assets Acquired                       $ 213        
Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]                                
Business Acquisition [Line Items]                                
Fair value of contingent consideration                       $ 198        
Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member] | Minimum [Member]                                
Business Acquisition [Line Items]                                
Discount Rate, Fair Value Input                       2.00%        
Additional Acquisitions (Textuals) [Abstract]                                
contingent consideration liability, probability of payment                       40.00%        
Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member] | Maximum [Member]                                
Business Acquisition [Line Items]                                
Discount Rate, Fair Value Input                       3.00%        
Additional Acquisitions (Textuals) [Abstract]                                
contingent consideration liability, probability of payment                       90.00%        
Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member] | Weighted Average [Member]                                
Business Acquisition [Line Items]                                
Discount Rate, Fair Value Input                       3.00%        
Additional Acquisitions (Textuals) [Abstract]                                
contingent consideration liability, probability of payment                       82.00%        
Valuation Technique, Discounted Cash Flow [Member] | Revenue-based payments by valuation technique [Member]                                
Business Acquisition [Line Items]                                
Fair value of contingent consideration                       $ 156        
Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member] | Minimum [Member]                                
Business Acquisition [Line Items]                                
Discount Rate, Fair Value Input                       11.00%        
Additional Acquisitions (Textuals) [Abstract]                                
contingent consideration liability, probability of payment                       60.00%        
Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member] | Maximum [Member]                                
Business Acquisition [Line Items]                                
Discount Rate, Fair Value Input                       15.00%        
Additional Acquisitions (Textuals) [Abstract]                                
contingent consideration liability, probability of payment                       100.00%        
Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member] | Weighted Average [Member]                                
Business Acquisition [Line Items]                                
Discount Rate, Fair Value Input | Rate                       13.00%        
Additional Acquisitions (Textuals) [Abstract]                                
contingent consideration liability, probability of payment                       99.00%        
Cardiovascular [Member]                                
Business Acquisition [Line Items]                                
Revenue from Contract with Customer, Excluding Assessed Tax                       $ 4,208 3,777 3,500    
Goodwill                       5,676 3,925 3,704    
Goodwill, Acquired During Period                       1,712 224      
Cardiovascular [Member] | BTG Acquisition [Member]                                
Business Acquisition [Line Items]                                
Goodwill, Acquired During Period                       1,406        
Other Segments [Member]                                
Business Acquisition [Line Items]                                
Revenue from Contract with Customer, Excluding Assessed Tax                       81        
Goodwill                       247 0 $ 0    
Goodwill, Acquired During Period                       $ 238 $ 0      
divested business due to BTG acquisition [Member]                                
Business Acquisition [Line Items]                                
Fair value of contingent consideration 16                              
Acquisitions (Textuals) [Abstract]                                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 200                              
XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 568 746 1 false 172 0 false 10 false false R1.htm 0002000 - Document - Cover Document Document Sheet http://www.bostonscientific.com/role/CoverDocumentDocument Cover Document Document Cover 1 false false R2.htm 1001000 - Statement - Consolidated Statements of Operations Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 2 false false R3.htm 1002000 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 1003000 - Statement - Consolidated Balance Sheets Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 4 false false R5.htm 1003501 - Statement - Consolidated Balance Sheet Paranthetical Sheet http://www.bostonscientific.com/role/ConsolidatedBalanceSheetParanthetical Consolidated Balance Sheet Paranthetical Statements 5 false false R6.htm 1004000 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bostonscientific.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Significant Accounting Policies Sheet http://www.bostonscientific.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2104100 - Disclosure - Acquisitions and Strategic Investments Sheet http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments Acquisitions and Strategic Investments Notes 9 false false R10.htm 2106100 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 10 false false R11.htm 2107100 - Disclosure - Fair Value Measurements Sheet http://www.bostonscientific.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 2108100 - Disclosure - Borrowings and Credit Arrangements Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements Borrowings and Credit Arrangements Notes 12 false false R13.htm 2109100 - Disclosure - Leases Sheet http://www.bostonscientific.com/role/Leases Leases Notes 13 false false R14.htm 2111100 - Disclosure - Restructuring Related Activities Sheet http://www.bostonscientific.com/role/RestructuringRelatedActivities Restructuring Related Activities Notes 14 false false R15.htm 2112100 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 15 false false R16.htm 2113100 - Disclosure - Income Taxes Sheet http://www.bostonscientific.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2114100 - Disclosure - Commitments and Contingencies Sheet http://www.bostonscientific.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 2115100 - Disclosure - Stockholders' Equity Sheet http://www.bostonscientific.com/role/StockholdersEquity Stockholders' Equity Notes 18 false false R19.htm 2116100 - Disclosure - Stock Inventive and Ownership Plans Sheet http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlans Stock Inventive and Ownership Plans Notes 19 false false R20.htm 2117100 - Disclosure - Weighted Average Shares Outstanding Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding Weighted Average Shares Outstanding Notes 20 false false R21.htm 2118100 - Disclosure - Segment Reporting Sheet http://www.bostonscientific.com/role/SegmentReporting Segment Reporting Notes 21 false false R22.htm 2119100 - Disclosure - Changes in Other Comprehensive Income Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome Changes in Other Comprehensive Income Notes 22 false false R23.htm 2120100 - Disclosure - New Accounting Pronouncements Sheet http://www.bostonscientific.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 23 false false R24.htm 2121100 - Disclosure - Revenue Revenue Sheet http://www.bostonscientific.com/role/RevenueRevenue Revenue Revenue Notes 24 false false R25.htm 2122100 - Disclosure - Employee Retirement Plans (Notes) Notes http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes Employee Retirement Plans (Notes) Notes 25 false false R26.htm 2123100 - Schedule - Schedule II Sheet http://www.bostonscientific.com/role/ScheduleIi Schedule II Uncategorized 26 false false R27.htm 2201201 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Policies) Sheet http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies Significant Accounting Policies Significant Accounting Policies (Policies) Notes 27 false false R28.htm 2203200 - Disclosure - Accounting Policies (Policies) Sheet http://www.bostonscientific.com/role/AccountingPoliciesPolicies Accounting Policies (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 28 false false R29.htm 2220201 - Disclosure - New Accounting Pronouncements New Accounting Pronouncements (Policies) Sheet http://www.bostonscientific.com/role/NewAccountingPronouncementsNewAccountingPronouncementsPolicies New Accounting Pronouncements New Accounting Pronouncements (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 29 false false R30.htm 2222201 - Disclosure - Employee Retirement Plans Employee Retirement Plans (Policies) Sheet http://www.bostonscientific.com/role/EmployeeRetirementPlansEmployeeRetirementPlansPolicies Employee Retirement Plans Employee Retirement Plans (Policies) Policies http://www.bostonscientific.com/role/SignificantAccountingPolicies 30 false false R31.htm 2304301 - Disclosure - Acquisitions and Strategic Investments (Tables) Sheet http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables Acquisitions and Strategic Investments (Tables) Tables http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments 31 false false R32.htm 2306301 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables) Tables 32 false false R33.htm 2307301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.bostonscientific.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.bostonscientific.com/role/FairValueMeasurements 33 false false R34.htm 2308301 - Disclosure - Borrowings and Credit Arrangements (Tables) Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables Borrowings and Credit Arrangements (Tables) Tables http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements 34 false false R35.htm 2309301 - Disclosure - Leases (Tables) Sheet http://www.bostonscientific.com/role/LeasesTables Leases (Tables) Tables http://www.bostonscientific.com/role/Leases 35 false false R36.htm 2311301 - Disclosure - Restructuring Related Activities (Tables) Sheet http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables Restructuring Related Activities (Tables) Tables http://www.bostonscientific.com/role/RestructuringRelatedActivities 36 false false R37.htm 2312301 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation 37 false false R38.htm 2313301 - Disclosure - Income Taxes (Tables) Sheet http://www.bostonscientific.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bostonscientific.com/role/IncomeTaxes 38 false false R39.htm 2316301 - Disclosure - Stock Incentive and Ownership Plans (Tables) Sheet http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables Stock Incentive and Ownership Plans (Tables) Tables 39 false false R40.htm 2316302 - Disclosure - Stock Inventive and Ownership Plans Employee Stock Purchase Plan (Tables) Sheet http://www.bostonscientific.com/role/StockInventiveAndOwnershipPlansEmployeeStockPurchasePlanTables Stock Inventive and Ownership Plans Employee Stock Purchase Plan (Tables) Tables 40 false false R41.htm 2317301 - Disclosure - Weighted Average Shares Outstanding (Tables) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables Weighted Average Shares Outstanding (Tables) Tables http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding 41 false false R42.htm 2318301 - Disclosure - Segment Reporting (Tables) Sheet http://www.bostonscientific.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.bostonscientific.com/role/SegmentReporting 42 false false R43.htm 2319301 - Disclosure - Changes in Other Comprehensive Income (Tables) Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables Changes in Other Comprehensive Income (Tables) Tables http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome 43 false false R44.htm 2321301 - Disclosure - Revenue Revenue (Tables) Sheet http://www.bostonscientific.com/role/RevenueRevenueTables Revenue Revenue (Tables) Tables http://www.bostonscientific.com/role/RevenueRevenue 44 false false R45.htm 2322302 - Disclosure - Employee Retirement Plans (Tables) Sheet http://www.bostonscientific.com/role/EmployeeRetirementPlansTables Employee Retirement Plans (Tables) Tables http://www.bostonscientific.com/role/EmployeeRetirementPlansNotes 45 false false R46.htm 2401403 - Disclosure - Significant Accounting Policies Significant Accounting Policies (Details) Sheet http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesDetails Significant Accounting Policies Significant Accounting Policies (Details) Details http://www.bostonscientific.com/role/SignificantAccountingPoliciesSignificantAccountingPoliciesPolicies 46 false false R47.htm 2404402 - Disclosure - Acquisitions and Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsDetails Acquisitions and Strategic Investments (Details) Details http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsTables 47 false false R48.htm 2404403 - Disclosure - Acquisitions and Strategic Investments Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestmentsStrategicInvestmentsDetails Acquisitions and Strategic Investments Strategic Investments (Details) Details 48 false false R49.htm 2406402 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillAndOtherIntangibleAssetsTables 49 false false R50.htm 2407402 - Disclosure - Fair Value Measurements (Details) Sheet http://www.bostonscientific.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.bostonscientific.com/role/FairValueMeasurementsTables 50 false false R51.htm 2408402 - Disclosure - Borrowings and Credit Arrangements (Details) Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails Borrowings and Credit Arrangements (Details) Details http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables 51 false false R52.htm 2409402 - Disclosure - Leases (Details) Sheet http://www.bostonscientific.com/role/LeasesDetails Leases (Details) Details http://www.bostonscientific.com/role/LeasesTables 52 false false R53.htm 2411402 - Disclosure - Restructuring Related Activities (Details in Narrative) Sheet http://www.bostonscientific.com/role/RestructuringRelatedActivitiesDetailsInNarrative Restructuring Related Activities (Details in Narrative) Details http://www.bostonscientific.com/role/RestructuringRelatedActivitiesTables 53 false false R54.htm 2412402 - Disclosure - Supplemental Balance Sheet Information (Details) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails Supplemental Balance Sheet Information (Details) Details http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables 54 false false R55.htm 2413402 - Disclosure - Income Taxes (Details - Rate Table) Sheet http://www.bostonscientific.com/role/IncomeTaxesDetailsRateTable Income Taxes (Details - Rate Table) Details http://www.bostonscientific.com/role/IncomeTaxesTables 55 false false R56.htm 2413403 - Disclosure - Income Taxes Income Taxes (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesIncomeTaxesDetails Income Taxes Income Taxes (Details) Details 56 false false R57.htm 2414401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.bostonscientific.com/role/CommitmentsAndContingencies 57 false false R58.htm 2415402 - Disclosure - Stockholders' Equity (Details) Sheet http://www.bostonscientific.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.bostonscientific.com/role/StockholdersEquity 58 false false R59.htm 2416403 - Disclosure - Stock Incentive and Ownership Plans (Details) Sheet http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansDetails Stock Incentive and Ownership Plans (Details) Details http://www.bostonscientific.com/role/StockIncentiveAndOwnershipPlansTables 59 false false R60.htm 2417402 - Disclosure - Weighted Average Shares Outstanding (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails Weighted Average Shares Outstanding (Details) Details http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables 60 false false R61.htm 2418402 - Disclosure - Segment Reporting (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.bostonscientific.com/role/SegmentReportingTables 61 false false R62.htm 2419402 - Disclosure - Changes in Other Comprehensive Income (Details) Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails Changes in Other Comprehensive Income (Details) Details http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables 62 false false R63.htm 2421402 - Disclosure - Revenue Revenue (Details) Sheet http://www.bostonscientific.com/role/RevenueRevenueDetails Revenue Revenue (Details) Details http://www.bostonscientific.com/role/RevenueRevenueTables 63 false false R64.htm 2422403 - Disclosure - Employee Retirement Plans (Details) Sheet http://www.bostonscientific.com/role/EmployeeRetirementPlansDetails Employee Retirement Plans (Details) Details http://www.bostonscientific.com/role/EmployeeRetirementPlansTables 64 false false R65.htm 2423401 - Schedule - Schedule II (Details) Sheet http://www.bostonscientific.com/role/ScheduleIiDetails Schedule II (Details) Details 65 false false All Reports Book All Reports a2019form10-k.htm bsx-20191231.xsd bsx-20191231_cal.xml bsx-20191231_def.xml bsx-20191231_lab.xml bsx-20191231_pre.xml exhibit21-listofsubsid.htm exhibit23-2019eyconsent.htm exhibit311-ceo30220191.htm exhibit312-cfo30220191.htm exhibit321-ceo90620191.htm exhibit322-cfo90620191.htm exhibit42-descriptiono.htm totalreturngraph2019.jpg http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/currency/2017-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 48 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Retirement Plans (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Assets for Plan Benefits, Defined Benefit Plan $ 213    
Defined Benefit Plan, Accumulated Benefit Obligation 466 $ 213  
Defined Benefit Plan, Benefit Obligation (488) (232) $ (207)
Defined Benefit Plan, Plan Assets, Amount 332 107 87
Defined Benefit Plan, Plan Assets, Benefits Paid (4)    
Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets 213 16  
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 156 125  
Defined Benefit Plan, Acquired and Established Plan Changes, Plan Assets 216 23  
Defined Benefit Plan, Service Cost 15 14  
Defined Benefit Plan, Interest Cost 5 4  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) 0 (1)  
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment 11 (2)  
pension benefit obligation, benefits paid (10) (10)  
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 19 (3)  
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) 7 (2)  
Defined Benefit Plan, Plan Assets, Contributions by Employer 13 14  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 2 2  
defined benefit plan, plan assets, actuarial gain loss (20) 0  
Defined Benefit Plan, Benefit Obligation, Benefits Paid (10) (10)  
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) $ 19 0  
Executive Retirement Plan Discount Rate 0.40%    
Expense related to matching contributions $ 98 87 $ 79
Executive Retirement Plan Rate of Compensation Increase 3.40%    
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 0.40%    
Defined Benefit Plan, Funded (Unfunded) Status of Plan $ (3)    
Executive retirement plan [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation 50 47  
Defined Benefit Plan, Benefit Obligation (54) (50)  
Defined Benefit Plan, Plan Assets, Amount 0 0  
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 54 50  
International retirement plans [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation 204 166  
Defined Benefit Plan, Benefit Obligation (223) (182)  
Defined Benefit Plan, Plan Assets, Amount 123 107  
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 100 75  
U.K. Plan [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation 212    
Defined Benefit Plan, Benefit Obligation (212)    
Defined Benefit Plan, Plan Assets, Amount 209    
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position 3    
Fair Value, Inputs, Level 3 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Accumulated Benefit Obligation   213  
Defined Benefit Plan, Plan Assets, Amount 207 $ 0  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) (20)    
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 19    
Fair Value, Inputs, Level 2 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 0    
Fair Value, Inputs, Level 1 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 1    
Other Contract [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 207    
Other Contract [Member] | Fair Value, Inputs, Level 3 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 207    
Other Contract [Member] | Fair Value, Inputs, Level 2 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 0    
Other Contract [Member] | Fair Value, Inputs, Level 1 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 0    
Defined Benefit Plan, Cash [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 1    
Defined Benefit Plan, Cash [Member] | Fair Value, Inputs, Level 3 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 0    
Defined Benefit Plan, Cash [Member] | Fair Value, Inputs, Level 2 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 0    
Defined Benefit Plan, Cash [Member] | Fair Value, Inputs, Level 1 [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Plan Assets, Amount 1    
BTG Acquisition [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Defined Benefit Plan, Benefit Obligation $ (216)    
International retirement plans [Member] | Maximum [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate   2.34%  
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return   4.10%  
Executive Retirement Plan Rate of Compensation Increase   6.78%  
International retirement plans [Member] | Minimum [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate   0.50%  
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return   1.90%  
Executive Retirement Plan Rate of Compensation Increase   1.50%  
Other International Plans [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate 0.75%    
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return 2.05%    
Executive Retirement Plan Rate of Compensation Increase 2.65%    
Domestic Plan [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate 2.94%    
Executive Retirement Plan Rate of Compensation Increase 1.50% 3.00%  
Domestic Plan [Member] | Maximum [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate   4.25%  
Domestic Plan [Member] | Minimum [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate   4.00%  
U.K. Plan [Member]      
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]      
Executive Retirement Plan Discount Rate 0.60%    
Defined Benefit Plan, Plan Assets, Assumptions used to Determine Expected Return 0.60%    
Executive Retirement Plan Rate of Compensation Increase 3.00%    
XML 49 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Weighted Average Shares Outstanding (Details) - shares
shares in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Weighted average shares outstanding      
Weighted average shares outstanding - basic 1,391.5 1,381.0 1,370.1
Net effect of common stock equivalents 19.0 20.4 22.6
Weighted average shares outstanding - assuming dilution 1,410.6 1,401.4 1,392.7
XML 50 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accounts Receivable, Net [Abstract]      
Trade accounts receivable, net $ 1,828 $ 1,608  
Accounts receivable 1,902 1,676  
Allowance for doubtful accounts (74) (68)  
Beginning balance 68 98 $ 119
Net (credits) charges to expenses 23 19 14
Utilization of allowances (17) (19) (18)
Ending balance 74 68 98
Inventory, Net [Abstract]      
Finished goods 971 760  
Work-in-process 192 100  
Raw materials 416 306  
Inventory, Net 1,579 1,166  
Other Current Assets [Abstract]      
Restricted Cash and Cash Equivalents, Current 346 655 803
Derivative Asset, Current 105 122  
Licensing arrangements, asset 332 0  
Income Taxes Receivable, Current 105 37  
Other Assets, Miscellaneous, Current 138 107  
Other Assets, Current 880 921  
Property, Plant and Equipment [Abstract]      
Land 117 97  
Buildings and improvements 1,198 1,100  
Equipment, furniture and fixtures 3,411 3,224  
Capital in progress 442 319  
Property, plant and equipment 5,169 4,740  
Less: accumulated depreciation 3,089 2,958  
Property, plant and equipment, net 2,079 1,782 1,697
Depreciation 311 296 279
Other Assets, Noncurrent [Abstract]      
Restricted Cash, Noncurrent 43 27  
Operating Lease, Right-of-Use Asset 336 0 0
Derivative Asset 216 183  
Investments 458 424  
Other Assets, Noncurrent 1,529 845  
Licensing arrangements 186 0  
Accrued Liabilities, Current [Abstract]      
Legal reserves 470 712  
Payroll and related liabilities 708 630  
Accrued contingent consideration 56 138  
Accrued Rebates, Current 298 229  
Other Accrued Liabilities, Current 576 538  
Accrued expenses 2,109 2,246  
Other Liabilities, Current [Abstract]      
Deferred Revenue, Current 144 115  
Licensing arrangements, liability 197 0  
Taxes Payable, Current 265 125  
Other Sundry Liabilities, Current 195 173  
Other Liabilities, Current 800 412  
Other Liabilities, Noncurrent [Abstract]      
Accrued income taxes 667 739  
Legal reserves 227 217  
Accrued contingent consideration 299 209  
Other Liabilities 374 0  
Operating Lease, Liability, Noncurrent 276 0  
Other 792 717  
Other long-term liabilities 2,635 1,882  
SEC Schedule, 12-09, Allowance, Credit Loss [Member]      
Accounts Receivable, Net [Abstract]      
Beginning balance 68 68 73
Net (credits) charges to expenses   19 14
Utilization of allowances   (19) (18)
Ending balance 74 68 $ 68
Other Assets [Member]      
Other Assets, Noncurrent [Abstract]      
Other Assets, Miscellaneous, Noncurrent $ 144 $ 211  
XML 51 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements (Details)
€ in Millions, £ in Millions, $ in Millions
 12 Months Ended
Aug. 19, 2019
GBP (£)
Aug. 19, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2019
GBP (£)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Debt Instrument, Fair Value Disclosure       $ 7,239     $ 11,020  
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax     $ 195 (21) $ 48      
Payments to Acquire Businesses, Net of Cash Acquired     4,382 1,448 560      
Available-for-sale Securities       0     1  
Licensing arrangements, asset       0     332  
Licensing arrangements, liability       0     374  
Notional Amount of Interest Rate Derivatives       12,326     10,218  
Cash       133     165  
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net     34 7        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax     116 96        
Cost of Goods and Services Sold     3,116 2,813 2,593      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax     54 (14)        
Interest Expense     473 241 229      
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax     (33) (21)        
Derivative Asset       183     216  
Derivative Instruments in Hedges, Liabilities, at Fair Value       49     1,009  
Derivative Liability       80     1,037  
Proceeds from secured borrowings relating to royalty arrangements     256 0 0      
Proceeds from Royalties Received     52 0 0      
Derivative, Notional Amount       12,326     10,218  
Net Investment Hedging [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax     95          
Notional Amount of Interest Rate Derivatives             1,950  
Derivative, Notional Amount             1,950  
Fair Value, Inputs, Level 3 [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Licensing arrangements, asset       0     518  
Licensing arrangements, liability             571  
Fair Value, Measurements, Recurring [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Money Market Funds, at Carrying Value       13     50  
Available-for-sale Securities       0     1  
Foreign Currency Contract, Asset, Fair Value Disclosure       304     321  
Licensing arrangements, asset             518  
Assets, Fair Value Disclosure       318     890  
Foreign Currency Contracts, Liability, Fair Value Disclosure       80     1,037  
Accrued Contingent Consideration       347     354  
Licensing arrangements, liability             571  
Liabilities, Fair Value Disclosure       427     1,963  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Money Market Funds, at Carrying Value       13     50  
Available-for-sale Securities       0     1  
Foreign Currency Contract, Asset, Fair Value Disclosure       0     0  
Assets, Fair Value Disclosure       14     51  
Foreign Currency Contracts, Liability, Fair Value Disclosure       0     0  
Accrued Contingent Consideration       0     0  
Liabilities, Fair Value Disclosure       0     0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Money Market Funds, at Carrying Value       0     0  
Available-for-sale Securities       0     0  
Foreign Currency Contract, Asset, Fair Value Disclosure       304     321  
Assets, Fair Value Disclosure       304     321  
Foreign Currency Contracts, Liability, Fair Value Disclosure       80     1,037  
Accrued Contingent Consideration       0     0  
Liabilities, Fair Value Disclosure       80     1,037  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Money Market Funds, at Carrying Value       0     0  
Available-for-sale Securities       0     0  
Foreign Currency Contract, Asset, Fair Value Disclosure       0     0  
Licensing arrangements, asset             518  
Assets, Fair Value Disclosure       0     518  
Foreign Currency Contracts, Liability, Fair Value Disclosure       0     0  
Accrued Contingent Consideration       347     354  
Licensing arrangements, liability       0     571  
Liabilities, Fair Value Disclosure       347     925  
Proposed BTG Acquisition [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Payments to Acquire Businesses, Net of Cash Acquired £ 3,312 $ 4,023            
derivative, notional amount translated             2,550  
BTG Acquisition [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Payments to Acquire Businesses, Net of Cash Acquired     3,619          
BTG Acquisition [Member] | Accounts Payable [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     54          
BTG Acquisition [Member] | Assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     567          
BTG Acquisition [Member] | Other Current Assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     195          
BTG Acquisition [Member] | Other Current Liabilities [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     104          
BTG Acquisition [Member] | Other Noncurrent Liabilities [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     212          
BTG Acquisition [Member] | Other Noncurrent Assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     373          
BTG Acquisition [Member] | Liability [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     $ 370          
Licensing arrangement assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Weighted Average Discount Rate, Percent     19.00%          
Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option     $ 3          
Euro-denominated outstanding debt [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Debt Instrument, Fair Value Disclosure             1,004  
Licensing arrangement liabilities [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Discount Rate, Fair Value Input     19.00%          
Weighted Average Discount Rate, Percent     19.00%          
Minimum [Member] | Licensing arrangement assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Discount Rate, Fair Value Input     11.00%          
Maximum [Member] | Licensing arrangement assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Discount Rate, Fair Value Input     19.00%          
Licensing arrangement liabilities [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     $ 315          
Licensing arrangement assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value of Assets Acquired     567          
Tender Offer [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Long-term Debt             $ 1,000 € 900
December 2027 Notes [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Debt Instrument, Interest Rate, Stated Percentage           0.625% 0.625% 0.625%
Long-term Debt       0     $ 1,011  
Designated as Hedging Instrument [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments in Hedges, Assets, at Fair Value       237     288  
Designated as Hedging Instrument [Member] | Prepaid Expenses and Other Current Assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments in Hedges, Assets, at Fair Value       55     72  
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments in Hedges, Assets, at Fair Value       0     998  
Derivative Instruments in Hedges, Liabilities, at Fair Value       3     8  
Designated as Hedging Instrument [Member] | Other Noncurrent Assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments in Hedges, Assets, at Fair Value       183     216  
Designated as Hedging Instrument [Member] | Forward Contracts [Member] | Other Current Liabilities [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments in Hedges, Liabilities, at Fair Value       2     3  
Designated as Hedging Instrument [Member] | Interest Rate Contract [Member] | Other Current Liabilities [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments in Hedges, Liabilities, at Fair Value       44     0  
Not Designated as Hedging Instrument [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Asset       304     321  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Notional Amount of Interest Rate Derivatives       5,880     4,377  
Derivative, Notional Amount       5,880     4,377  
Not Designated as Hedging Instrument [Member] | Prepaid Expenses and Other Current Assets [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value       67     33  
Not Designated as Hedging Instrument [Member] | Other Current Liabilities [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value       31     29  
Not Designated as Hedging Instrument [Member] | BTG Acquisition [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Cash           £ 3,312 4,303  
Not Designated as Hedging Instrument [Member] | Euro Member Countries, Euro                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative, Loss on Derivative     294          
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Notional Amount of Interest Rate Derivatives       1,483     953  
Derivative, Notional Amount       1,483     953  
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | foreign currency denominated in debt [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Notional Amount of Interest Rate Derivatives       0     997  
Derivative, Notional Amount       0     997  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Notional Amount of Interest Rate Derivatives       3,962     3,891  
Derivative, Notional Amount       3,962     3,891  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Notional Amount of Interest Rate Derivatives       1,000     0  
Derivative, Notional Amount       1,000     0  
Cost of Sales [Member] | Cash Flow Hedging [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months             77  
Cost of Sales [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax     150 167 (101)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax     (34) (38) 37      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax     117 130 (65)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax     (73) 19 (64)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax     16 (4) 23      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax     (56) 15 (41)      
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net     (343) 41 (25)      
Net gain (loss) from foreign currency transaction exposures     (15) (30) 10      
Foreign Currency Transaction Gain (Loss), Realized     (358) 11 (15)      
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | BTG Acquisition [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments     (323) 29        
Interest Expense [Member] | Net Investment Hedging [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net             24  
Interest Expense [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax       (56)        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax       13        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax       (43)        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax       27        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax       6        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax       (21)        
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax     68          
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax     (15)          
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax     53          
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax     (43)          
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax     10          
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax     33          
Interest Expense [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | foreign currency denominated in debt [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax     (14)          
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax     3          
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax     (11)          
Interest Expense [Member] | Cash Flow Hedging [Member] | Interest Rate Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net             $ (5)  
Interest Expense [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax     0 (44) 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax     0 10 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax     0 (34) 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax     (3) (1) 1      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax     (1) 0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax     $ 2 $ (1) $ (1)      
XML 52 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
Dec. 31, 2019
Dec. 31, 2018
Jan. 25, 2013
Stockholders' Equity Attributable to Parent [Abstract]      
Preferred Stock, Shares Authorized 50,000,000 50,000,000  
Common Stock, Shares Authorized 2,000,000,000.000 2,000,000,000  
Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01  
Treasury shares 247,566,270 247,566,270  
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 535    
Stock Repurchase Program, Authorized Amount     $ 1,000
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock Incentive and Ownership Plans (Tables)
 12 Months Ended
Dec. 31, 2019
Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Line Items]  
Free Cash Flow Performance-based DSU Awards, Fair Value Assumptions [Table Text Block]

The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of December 31, 2019:
 
2019 AFCF
 
2018 AFCF
 
2017 AFCF
Fair value, net of forfeitures to date (in millions)
$
8

 
$
11

 
$
6

Achievement of target payout
90
%
 
118
%
 
98
%
Year-end stock price used in determining fair value
$
45.22

 
$
35.34

 
$
24.79
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
The following presents the impact of stock-based compensation on our consolidated statements of operations:
 
Year Ended December 31,
(in millions, except per share data)
2019
 
2018
 
2017
Cost of products sold
$
8

 
$
7

 
$
7

Selling, general and administrative expenses
120

 
109

 
98

Research and development expenses
28

 
24

 
23

 
157

 
140

 
127

Income tax (benefit) expense
(24
)
 
(21
)
 
(32
)
 
$
133

 
$
119

 
$
96

Net impact per common share - basic
$
0.10

 
$
0.09

 
$
0.07

Net impact per common share - assuming dilution
$
0.09

 
$
0.08

 
$
0.07
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Options granted (in thousands)
2,992
 
 
3,491
 
 
4,439
 
Weighted-average exercise price
$
40.20
 
 
$
27.26
 
 
$
24.70
 
Weighted-average grant-date fair value
$
11.76
 
 
$
8.55
 
 
$
7.16
 
Black-Scholes Assumptions
 
 
 
 
 
 
 
 
 
 
 
Expected volatility
24
%
 
26
%
 
25
%
Expected term (in years, weighted)
6.1
 
 
6.0
 
 
6.1
 
Risk-free interest rate
1.38
%
-
2.61%
 
2.61
%
-
3.01%
 
2.03
%
-
2.21%
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Information related to non-vested stock awards is as follows:
 
Non-Vested
Stock Award Units
(in thousands)
 
Weighted Average
Grant-Date
Fair Value
Balance as of December 31, 2016
18,797

 
$
14

Granted
4,798

 
24

Vested (1)
(7,663
)
 
11

Forfeited
(683
)
 
17

Balance as of December 31, 2017
15,250

 
$
18

Granted
4,375

 
28

Vested (1)
(6,194
)
 
16

Forfeited
(748
)
 
22

Balance as of December 31, 2018
12,683

 
$
22

Granted
3,656

 
39

Vested (1)
(4,811
)
 
20

Forfeited
(449
)
 
27

Balance as of December 31, 2019
11,079

 
$
29

(1)
The number of restricted stock units vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]
Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Shares issued or to be issued (in thousands)
2,196
 
 
2,452
 
 
2,491
 
Range of purchase prices
$
29.29

-
$36.47
 
$
21.49

-
$27.91
 
$
18.60

-
$21.07
Expense recognized (in millions)
$
19
 
 
$
17
 
 
$
13
 
Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block]
We expect to recognize the following future expense for awards outstanding as of December 31, 2019:
 
 Unrecognized
 Compensation Cost
(in millions) (1)
 
Weighted Average Remaining
Vesting Period
(in years)
Stock options
$
35

 
 
Non-vested stock awards
169

 
 
 
$
204

 
1.2
(1)
Amounts presented represent compensation cost, net of estimated forfeitures.
Market-based awards, valuation assumptions [Table Text Block]
We determined the fair value of the market-based DSU awards to be approximately $10 million for 2019, $7 million for 2018 and $8 million for 2017. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:
 
2019
 
2018
 
2017
 
Awards
 
Awards
 
Awards
Stock price on date of grant
$
40.12

 
$
27.09

 
$
24.55

Measurement period (in years)
2.9

 
2.9

 
2.8

Risk-free rate
2.48
%
 
2.36
%
 
1.45
%
Share-based Compensation, Stock Options, Activity [Table Text Block]
Information related to stock options under stock incentive plans are as follows:
 
Stock Options
(in thousands)
 
Weighted
Average
Exercise Price
 
Weighted Average
Remaining
Contractual Life 
(in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding as of December 31, 2016
26,644

 
$
11

 
 
 
 
Granted
4,439

 
25

 
 
 
 
Exercised
(3,922
)
 
10

 
 
 
 
Cancelled/forfeited
(445
)
 
17

 
 
 
 
Outstanding as of December 31, 2017
26,716

 
$
13

 
 
 
 
Granted
3,491

 
27

 
 
 
 
Exercised
(4,385
)
 
11

 
 
 
 
Cancelled/forfeited
(519
)
 
22

 
 
 
 
Outstanding as of December 31, 2018
25,304

 
$
16

 
 
 
 
Granted
2,992

 
40

 
 
 
 
Exercised
(4,872
)
 
12

 
 
 
 
Cancelled/forfeited
(359
)
 
24

 
 
 
 
Outstanding as of December 31, 2019
23,065

 
$
19

 
5.5
 
$
594

Exercisable as of December 31, 2019
15,091

 
$
14

 
4.1
 
$
476

Expected to vest as of December 31, 2019
7,617

 
30

 
8.0
 
114

Total vested and expected to vest as of December 31, 2019
22,707

 
$
19

 
5.3
 
$
590
XML 54 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions and Strategic Investments (Tables)
 12 Months Ended
Dec. 31, 2019
Business Acquisition [Line Items]  
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]
Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
 
Balance as of December 31, 2017
$
169

Amounts recorded related to current year acquisitions
248

Purchase price adjustments related to prior year acquisitions
(22
)
Contingent consideration expense (benefit)
(21
)
Contingent consideration payments
(28
)
Balance as of December 31, 2018
$
347

Amounts recorded related to current year acquisitions
127

Contingent consideration arrangements transferred to Varian
(16
)
Contingent consideration expense (benefit)
(35
)
Contingent consideration payments
(68
)
Balance as of December 31, 2019
$
354
Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]
The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
Contingent Consideration Liability
Fair Value as of December 31, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
R&D, Regulatory and Commercialization-based Milestones
$198 million
Discounted Cash Flow
Discount Rate
2
%
-
3%
3%
Probability of Payment
40
%
-
90%
82%
Projected Year of Payment
2020

-
2027
2021
Revenue-based Payments
$156 million
Discounted Cash Flow
Discount Rate
11
%
-
15%
13%
Probability of Payment
60
%
-
100%
99%
Projected Year of Payment
2020

-
2026
2021

(1)
Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Investment [Table Text Block]

The aggregate carrying amount of our strategic investments was comprised of the following:
 
As of December 31,
(in millions)
2019
 
2018
Equity method investments
$
264

 
$
303

Measurement alternative investments(1)
171

 
94

Publicly-held securities(2)
1

 
—

Notes receivable
23

 
26

 
$
458

 
$
424

(1)
Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
(2)
Publicly-held equity securities are measured at fair value with changes in fair value recognized currently in Other, net on our accompanying consolidated statements of operations.
2017 Acquisitions [Member]  
Business Acquisition [Line Items]  
Business Combination, Components of Purchase Price [Table Text Block] The components of the aggregate purchase prices were as follows for our 2017 acquisitions:
(in millions)
 
Payment for acquisitions, net of cash acquired
$
560

Fair value of contingent consideration
72

 
$
632
Business Combination, Purchase Price Allocation Schedule [Table Text Block]
The following summarizes the aggregate purchase price allocations for our 2017 acquisitions:
(in millions)
 
Goodwill
$
287

Amortizable intangible assets
278

Indefinite-lived intangible assets
186

Other assets acquired
44

Liabilities assumed
(61
)
Deferred tax liabilities
(102
)
 
$
632
Business Acquisition, Purchase Price Allocation, Intangible Assets, Description
We allocated a portion of the purchase prices to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
268

 
13
 
24%
Other intangible assets
10

 
2
-
13
 
24%
Indefinite-lived intangible assets
 
 
 
 
 
 
 
In-process research and development
$
186

 
n/a
 
15%
 
$
464

 
 
 
 
 
 
2019 Acquisitions [Member]  
Business Acquisition [Line Items]  
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
We allocated a portion of the preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, to the specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
Technology-related
$
210

 
12
 
15%
Other intangible assets
10

 
12
 
15%
Indefinite-lived intangible assets:
 
 
 
 
 
In-process research and development
240

 
n/a
 
19%
 
$
461

 
 
 
 
Schedule of Business Acquisitions, by Acquisition [Table Text Block] The preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of December 31, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
763

Fair value of contingent consideration
127

Fair value of prior interests
102

 
$
992
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
The preliminary purchase price allocations of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of December 31, 2019:
(in millions)
 
Goodwill
$
575

Amortizable intangible assets
220

Indefinite-lived intangible assets
240

Other assets acquired
24

Liabilities assumed
(12
)
Net deferred tax liabilities
(56
)
 
$
992
BTG Acquisition [Member]  
Business Acquisition [Line Items]  
Business Acquisition, Pro Forma Information [Table Text Block]

 
Year Ended December 31,
(in millions, except per share data) (Unaudited)
2019
 
2018
Net sales
$
11,142

 
$
10,429

Net income (loss)
$
4,585

 
$
1,244

Net income (loss) per common share — basic
$
3.30

 
$
0.90

Net income (loss) per common share — assuming dilution
$
3.25

 
$
0.89
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

We allocated a portion of the preliminary purchase price for our acquisition of BTG to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
1,709

 
10
-
18
 
11
%
-
12%
Other intangible assets
75

 
2
-
11
 
11%
 
$
1,785

 
 
 
 
 
 
 
 
Schedule of Business Acquisitions, by Acquisition [Table Text Block] The preliminary purchase price of BTG, was comprised of the following components as of December 31, 2019:
(in millions)
 
Payment for acquisition, net of cash acquired
$
3,619
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
The following summarizes the preliminary purchase price allocation for our acquisition of BTG as of December 31, 2019:
(in millions)
 
Goodwill
$
1,644

Trade accounts receivable, net
108

Inventories
232

Other current assets
252

Other intangible assets, net
1,785

Other long-term assets
537

Accrued expenses and other current liabilities
(308
)
Other long-term liabilities
(274
)
Deferred tax liability
(358
)
 
$
3,619
2018 Acquisitions [Member]  
Business Acquisition [Line Items]  
Business Combination, Components of Purchase Price [Table Text Block] The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of December 31, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
1,449

Fair value of contingent consideration
248

Fair value of prior interests
251

 
$
1,948
Business Combination, Purchase Price Allocation Schedule [Table Text Block]
The following summarizes the purchase price allocations for our 2018 acquisitions as of December 31, 2019:
(in millions)
 
Goodwill
$
939

Amortizable intangible assets
939

In-process research and development
213

Other assets acquired
38

Liabilities assumed
(19
)
Net deferred tax liabilities
(162
)
 
$
1,948
Business Acquisition, Purchase Price Allocation, Intangible Assets, Description
We allocated a portion of the purchase prices to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets
 
 
 
 
 
 
 
 
 
Technology-related
$
908

 
6
-
14
 
14
%
-
23%
Other intangible assets
31

 
6
-
13
 
13
%
-
15%
Indefinite-lived intangible assets
 
 
 
 
 
 
 
 
 
In-process research and development
213

 
n/a
 
15%
 
$
1,153

 
 
 
 
 
 
 
 
XML 55 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases (Tables)
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Maturities of Lease Liabilities [Table Text Block]
The following table presents the maturities of our operating lease liabilities as of December 31, 2019 (in millions):
Fiscal year
Operating Leases
2020
$
84

2021
71

2022
59

2023
48

2024
41

Thereafter
79

Total future minimum operating lease payments
382

Less: imputed interest
39

Present value of operating lease liabilities
$
343
Supplemental Cash Flow Information Related to Leases [Table Text Block]
The following table presents supplemental cash flow information related to our operating leases:
 
Year Ended
(in millions)
December 31, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
 
Operating cash flows from operating leases
$
77
Lessee Supplemental Balance Sheet Information [Table Text Block]
The following table presents supplemental balance sheet information related to our operating leases:
(in millions)
As of December 31, 2019
Assets
 
Operating lease right-of-use assets in Other long-term assets
$
336

Liabilities
 
Operating lease liabilities in Other current liabilities
67

Operating lease liabilities in Other long-term liabilities
276
Lease, Cost [Table Text Block]
The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
 
As of December 31, 2019
Weighted average remaining lease term
5.8 years
Weighted average discount rate
3.7%
Operating Leases, Rent Expense, Minimum Rentals
Future minimum rental commitments as of December 31, 2018, under all noncancellable lease agreements, including capital leases, were as follows:
Fiscal year
Future Minimum Rental Commitments
2019
$
73

2020
61

2021
47

2022
39

2023
31

Thereafter
111

 
$
362
XML 57 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2016   $ 16 $ (1,717) $ 17,014 $ (8,581) $ 1
Net income (loss) $ 104       104  
Impact of stock-based compensation plans, net of tax       147    
Balance at Dec. 31, 2017   $ 16 (1,717) 17,161 (8,390) (59)
Balance (Shares) at Dec. 31, 2016   1,609,670,817        
Impact of stock-based compensation plans, net of tax (Shares)   11,392,081        
Balance (Shares) at Dec. 31, 2017   1,621,062,898        
Other comprehensive income (loss), net of tax            
Foreign currency translation adjustment 48         48
Net change in derivative financial instruments           (106)
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax 5         5
Defined benefit pensions and other items 6         (6)
Cumulative effect adjustment for ASU Adoptions(1) | Adjustments for New Accounting Pronouncement [Member]         86  
Net income (loss) 1,671       1,671  
Impact of stock-based compensation plans, net of tax       185    
Balance at Dec. 31, 2018 $ 8,726 $ 16 (1,717) 17,346 (6,953) 33
Stock Issued During Period, Value, New Issues          
Impact of stock-based compensation plans, net of tax (Shares)   11,085,132        
Balance (Shares) at Dec. 31, 2018 1,632,148,030 1,632,148,030        
Other comprehensive income (loss), net of tax            
Foreign currency translation adjustment $ (21)         (21)
Net change in derivative financial instruments           110
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax 0          
Defined benefit pensions and other items (2)         2
Cumulative effect adjustment for ASU Adoptions(1) | Accounting Standards Update 2016-09 [Member]         (233)  
Net income (loss) 4,700       4,700  
Impact of stock-based compensation plans, net of tax       215    
Balance at Dec. 31, 2019 $ 13,877 $ 16 $ (1,717) $ 17,561 $ (2,253) 270
Stock Issued During Period, Value, New Issues          
Impact of stock-based compensation plans, net of tax (Shares)   10,340,881        
Balance (Shares) at Dec. 31, 2019 1,642,488,911 1,642,488,911        
Other comprehensive income (loss), net of tax            
Foreign currency translation adjustment $ 195         195
Net change in derivative financial instruments           62
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax 0          
Defined benefit pensions and other items $ 20         $ (20)
XML 58 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE I – INCOME TAXES

Our Income (loss) before income taxes consisted of the following:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Domestic
$
(1,145
)
 
$
35

 
$
(408
)
Foreign
1,832

 
1,387

 
1,341

 
$
687

 
$
1,422

 
$
933



The related benefit for income taxes consisted of the following:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Current
 
 
 
 
 
  Federal
$
120

 
$
(221
)
 
$
320

  State
54

 
(27
)
 
9

  Foreign
101

 
160

 
255

 
275

 
(87
)
 
584

 
 
 
 
 
 
Deferred
 
 
 
 
 
  Federal
(146
)
 
(124
)
 
272

  State
(18
)
 
4

 
1

  Foreign
(4,124
)
 
(42
)
 
(28
)
 
(4,288
)
 
(162
)
 
244

 
$
(4,013
)
 
$
(249
)
 
$
828



The reconciliation of income taxes at the federal statutory rate to the actual benefit for income taxes is as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
(reclassified)(1)
U.S. federal statutory income tax rate
21.0
 %
 
21.0
 %
 
35.0
 %
State income taxes, net of federal benefit
6.7
 %
 
0.4
 %
 
(1.0
)%
Domestic taxes on foreign earnings
21.9
 %
 
0.5
 %
 
0.4
 %
Effect of foreign taxes
(47.6
)%
 
(8.3
)%
 
(38.9
)%
Acquisition-related
12.2
 %
 
2.1
 %
 
(1.7
)%
Research credit
(4.2
)%
 
(2.6
)%
 
(2.6
)%
Valuation allowance
1.1
 %
 
(5.2
)%
 
(4.1
)%
Compensation-related
(0.3
)%
 
(1.0
)%
 
(2.5
)%
Non-deductible expenses
3.3
 %
 
0.3
 %
 
2.2
 %
Uncertain tax positions
1.4
 %
 
(22.0
)%
 
10.7
 %
TCJA net impact
—
 %
 
(4.7
)%
 
91.4
 %
Intra-entity intangible asset transfers
(597.0
)%
 
—
 %
 
—
 %
Other, net
(2.5
)%
 
1.8
 %
 
(0.2
)%
 
(584.0
)%
 
(17.5
)%
 
88.8
 %

(1)
Due to the inclusion of new tax provisions in 2018 created by the TJCA, we have reclassified select items in prior years to align with the new categories established in 2018, domestic taxes on foreign earnings and uncertain tax positions.


Significant components of our deferred tax assets and liabilities are as follows:
 
As of December 31,
 (in millions)
2019
 
2018
 Deferred Tax Assets:
 
 
 
Inventory costs and related reserves
$
—

 
$
18

Tax benefit of net operating loss and credits
545

 
450

Reserves and accruals
258

 
258

Restructuring-related charges
20

 
12

Litigation and product liability reserves
168

 
221

Investment write-down
42

 
28

Compensation related
121

 
106

Federal benefit of uncertain tax positions
10

 
10

Intangible assets
3,447

 
—

Other
—

 
37

 
4,611

 
1,140

Less: valuation allowance
(915
)
 
(344
)
 
3,696

 
796

 Deferred Tax Liabilities:
 
 
 
Property, plant and equipment
16

 
25

Unrealized gains and losses on derivative financial instruments
52

 
44

Intangible assets
—

 
968

Inventory costs and related services
2

 
—

Other
25

 
—

 
95

 
1,037

 Net Deferred Tax Assets / (Liabilities)
3,601

 
(241
)
Prepaid on intercompany profit
195

 
161

 Net Deferred Tax Assets / (Liabilities) and Prepaid on Intercompany Profit
$
3,796

 
$
(80
)


Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit, are included in the following locations within our accompanying consolidated balance sheets (in millions):
 
Location on Consolidated Balance Sheets
As of December 31,
Component
2019
 
2018
Prepaid on intercompany profit
Prepaid income taxes
$
195

 
$
161

Non-current deferred tax asset
Deferred tax assets
4,196

 
87

Deferred Tax Assets and Prepaid on Intercompany Profit
 
4,391

 
249

 
 
 
 
 
Non-current deferred tax liability
Deferred income taxes
595

 
328

Deferred Tax Liabilities
 
595

 
328

 
 
 
 
 
Net Deferred Tax Assets (Liabilities) and Prepaid on Intercompany Profit
$
3,796

 
$
(80
)


As of December 31, 2019, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $449 million. As of December 31, 2018, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was $416 million. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was $105 million as of December 31, 2019, as compared to $42 million as of December 31, 2018. These tax attributes expire periodically beginning in 2020.

During the fourth quarter of 2019, we completed intra-entity asset transfers of certain intellectual property rights among various wholly-owned subsidiaries. These transactions occurred to more closely align the global economic ownership of our intellectual property rights with our current and future business operations. These transactions did not result in a taxable gain in any jurisdiction,
however, some of the transactions did create a step-up in the tax-deductible basis in the transferred intellectual property rights in certain jurisdictions. As a result, we recorded deferred tax assets in the amount of $4.102 billion, which represents the book and tax basis differences measured at applicable statutory tax rates, net of a valuation allowance of $542 million.

After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we established a valuation allowance of $915 million as of December 31, 2019 and $344 million as of December 31, 2018, representing an increase of $571 million. The increase in the valuation allowance as of December 31, 2019, as compared to December 31, 2018, is primarily attributable to an intra-entity transfer of certain intellectual property. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of $13 million in 2019, a charge of $37 million in 2018 and a benefit of $63 million in 2017.

We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100.0 percent exemption from income tax in the first eight years of operations and 50.0 percent exemption in the following four years. This tax incentive resulted in income tax savings of $173 million for 2019, $146 million for 2018 and $127 million for 2017. The tax incentive for 100.0 percent exemption from income tax was renewed during 2019 and is expected to expire in 2027. The impact on per share earnings was $0.12 for 2019 and $0.10 for 2018 and $0.09 for 2017. Additionally, we benefit from tax incentives in Puerto Rico. The income tax savings from Puerto Rico were immaterial for 2019, 2018 and 2017.

As of December 31, 2019, we had $455 million of gross unrecognized tax benefits, of which a net $355 million, if recognized, would affect our effective tax rate. As of December 31, 2018, we had $427 million of gross unrecognized tax benefits, of which a net $332 million, if recognized, would affect our effective tax rate. As of December 31, 2017, we had $1.238 billion of gross unrecognized tax benefits, of which a net $1.150 billion, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Beginning Balance
$
427

 
$
1,238

 
$
1,095

Additions based on positions related to the current year
30

 
79

 
134

Additions based on positions related to prior years
45

 
4

 
16

Reductions for tax positions of prior years
(34
)
 
(433
)
 
(3
)
Settlements with taxing authorities
(4
)
 
(459
)
 
(2
)
Statute of limitation expirations
(9
)
 
(3
)
 
(2
)
Ending Balance
$
455

 
$
427

 
$
1,238


We are subject to U.S. Federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2013, with the exception of select issues in 2011 and substantially all material state and local income tax matters through 2010. We have concluded all foreign income tax matters through 2013, with the exception of issues for Italy, which have concluded through 2002.

In the second quarter of 2018, a decision was entered by the U.S. Tax Court resolving all disputes for Guidant Corporation for its 2001 through 2006 tax years and our 2006 and 2007 tax years as well as the tax issues related to our 2006 transaction with Abbott Laboratories. Additionally, we resolved all issues with the IRS Office of Appeals for our 2008 through 2010 tax years. The final settlement calculation resulted in a final net tax payment of $303 million plus $307 million of estimated interest, which was remitted in the second quarter of 2018. Due to the final settlement of these disputes, we recorded a net tax benefit of $250 million in 2018 to remove a reserve related to these years.

In the fourth quarter of 2018, we received a Revenue Agent Report (RAR) from the IRS for our 2011 through 2013 tax years. We remitted $93 million to the IRS in the fourth quarter of 2018 reflecting the net balance of tax and interest due for these years after consideration of amounts owed to us by the IRS. Due to the resolution of these tax years, we recorded a net tax benefit of $90 million to remove a reserve related to these years.

We recognize interest and penalties related to income taxes as a component of income tax expense. We had $19 million accrued for gross interest and penalties as of December 31, 2019 and $11 million as of December 31, 2018. We recognized a benefit of $643 million of gross interest and penalties in our consolidated statements of operations in 2018 primarily related to reaching settlements with the taxing authorities. We recognized net tax benefit related to interest and penalties of $1 million in 2019, as compared to a net tax benefit of $498 million in 2018 and a net tax expense of $154 million in 2017. The decrease in our net tax benefit related to interest and penalties as of December 31, 2019, as compared to December 31, 2018, is related to reaching settlements with the taxing authorities.

It is reasonably possible that within the next 12 months we will resolve transactional- related issues with foreign and state taxing authorities, in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately $98 million.

During 2018, we completed our analysis and recording of all tax effects related to the Tax Cuts and Jobs Act, as required under SAB 118, and recorded a net benefit of $67 million, exclusive of the one-time transition tax adjustment described below.

For the year ended December 31, 2017, we were required under the Tax Cuts and Jobs Act (TCJA) to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&P) that we previously deferred from U.S. income taxes. As a result of settling our various tax audits, the revised amount of transition tax is approximately $856 million as of December 31, 2018 as compared to the preliminary amount recorded of approximately $1.044 billion as of December 31, 2017. We anticipate offsetting this liability against existing tax attributes reducing the required payment to approximately $499 million, which will be remitted over an eight-year period. We have begun remitting the required installment payments, with a balance remaining of $420 million as of December 31, 2019. In addition, we have provided for U.S. state income taxes of $18 million on all U.S. dollar-denominated E&P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.

We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.
XML 59 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Borrowings and Credit Arrangements
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
BORROWINGS AND CREDIT ARRANGEMENTS
NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS

Borrowings and Credit Arrangements

We had total debt of $10.008 billion as of December 31, 2019 and $7.056 billion as of December 31, 2018. The debt maturity schedule for our long-term debt obligations is presented below:
 
 
Issuance Date
 
Maturity Date
 
As of December 31,
 
Stated Interest Rate
(in millions, except interest rates)
 
 
 
2019
 
2018
 
January 2020 Notes
 
December 2009
 
January 2020
 
$
—

 
$
850

 
6.000%
May 2020 Notes
 
May 2015
 
May 2020
 
—

 
600

 
2.850%
May 2022 Notes
 
May 2015
 
May 2022
 
500

 
500

 
3.375%
August 2022 Term Loan
 
August 2019
 
August 2022
 
1,000

 
—

 
 
October 2023 Notes
 
August 2013
 
October 2023
 
244

 
450

 
4.125%
March 2024 Notes
 
February 2019
 
March 2024
 
850

 
—

 
3.450%
May 2025 Notes
 
May 2015
 
May 2025
 
523

 
750

 
3.850%
March 2026 Notes
 
February 2019
 
March 2026
 
850

 
—

 
3.750%
December 2027 Notes
 
November 2019
 
December 2027
 
1,011

 
—

 
0.625%
March 2028 Notes
 
February 2018
 
March 2028
 
434

 
1,000

 
4.000%
March 2029 Notes
 
February 2019
 
March 2029
 
850

 
—

 
4.000%
November 2035 Notes (1)
 
November 2005
 
November 2035
 
350

 
350

 
7.000%
March 2039 Notes
 
February 2019
 
March 2039
 
750

 
—

 
4.550%
January 2040 Notes
 
December 2009
 
January 2040
 
300

 
300

 
7.375%
March 2049 Notes
 
February 2019
 
March 2049
 
1,000

 
—

 
4.700%
Unamortized Debt Issuance Discount
and Deferred Financing Costs
 
 
 
2020 - 2049
 
(83
)
 
(29
)
 
 
Unamortized Gain on Fair Value Hedges
 
 
 
2020-2023
 
7

 
26

 
 
Finance Lease Obligation (2)
 
 
 
Various
 
6

 
6

 
 
Long-term debt
 
 
 
 
 
$
8,592

 
$
4,803

 
 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)
Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(2)
Effective January 1, 2019, we adopted FASB ASC Topic 842, which requires that we recognize finance lease obligations in our consolidated balance sheets. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with FASB ASC Topic 840. Please refer to Note A – Significant Accounting Policies for additional information.

Revolving Credit Facility

On December 19, 2018, we entered into a $2.750 billion revolving credit facility (the 2018 Facility) with a global syndicate of commercial banks and terminated our previous $2.250 billion revolving credit facility (the 2017 Facility), which was scheduled to mature in August 2022. The 2018 Facility will mature on December 19, 2023 with one-year extension options subject to certain conditions. Eurodollar and multicurrency loans bear interest at the Eurocurrency Rate determined for the interest period plus the applicable margin, based on our corporate credit ratings (1.02 percent as of December 31, 2019). ABR loans bear interest at ABR plus the applicable margin of up to 0.40 percent, based on our corporate credit ratings. Under the credit agreement for the 2018 Facility (the 2018 Credit Agreement), we are required to pay a facility fee (0.11 percent as of December 31, 2019) based on our credit ratings and the total amount of revolving credit commitment, regardless of usage of the 2018 Facility. This facility provides backing for the commercial paper program described below. The 2018 Credit Agreement for the 2018 Facility requires that we comply with certain covenants, including financial covenants as described below. There were no amounts borrowed under our current or prior revolving credit facilities as of December 31, 2019 or December 31, 2018.

Term Loans

On December 5, 2019, we entered into a $700 million term loan credit agreement scheduled to mature on December 3, 2020 (2020 Term Loan). The 2020 Term Loan bears interest at an annual rate of LIBOR plus a margin of 0.65%. In addition, we pay customary expenses. The credit agreement contains covenants, as described below, and also contains customary events of default, which may result in the acceleration of any outstanding commitments. As of December 31, 2019, we had $700 million outstanding under the 2020 Term Loan, which is presented within Current debt obligations on our consolidated balance sheet. We used the proceeds from the 2020 Term Loan to repay a portion of the Two-Year Delayed Draw Term Loan, described below. In January 2020, we repaid $300 million of the outstanding balance of the 2020 Term Loan with proceeds from our commercial paper program.

On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described below, we terminated the $1.000 billion Term Loan Credit Agreement, entered into on August 20, 2018 and amended on December 19, 2018 (August 2019 Term Loan). The August 2019 Term Loan was scheduled to mature on August 19, 2019. As of December 31, 2018, we had $1.000 billion outstanding under our August 2019 Term Loan, which is presented within Current debt obligations on our consolidated balance sheet.

On December 19, 2018, we entered into a $2.000 billion senior unsecured delayed-draw term loan facility consisting of a $1.000 billion two-year delayed draw term loan credit facility maturing in two years from the date of the closing of our acquisition of BTG (Two-Year Delayed Draw Term Loan) and a $1.000 billion three-year delayed draw term loan credit facility maturing in three years from the date of the closing of our acquisition of BTG (Three-Year Delayed Draw Term Loan). In 2019, we used the proceeds from the Two-Year and Three-Year Delayed Draw Term Loan facilities to refinance the Bridge Facility, as described below, and fund a portion of our acquisition of BTG. On November 27, 2019, we repaid $200 million of the Two-Year Delayed Draw Term Loan with proceeds from the sale of the Zytiga-related royalty interests obtained through the acquisition of BTG and extinguished the facility. On December 5, 2019, we repaid the remaining $800 million with proceeds from the 2020 Term Loan and commercial paper and terminated the Two-Year Delayed Draw Term Loan. Borrowings of the Three-Year Delayed Draw Term Loan are available in U.S. dollars and bear interest at LIBOR or a base rate in each case plus an applicable margin based on our public debt ratings (1.13 percent as of December 31, 2019). The facility contains customary events of default, which may result in the acceleration of any outstanding commitments. As of December 31, 2018, we had no amounts borrowed under the Two-Year Delayed Draw Term Loan or the Three-Year Delayed Draw Term Loan. As of December 31, 2019, we had $1.000 billion outstanding under the Three-Year Delayed Draw Term Loan.

Debt Covenants

As of and through December 31, 2019, we were in compliance with all the required covenants related to our debt obligations.

All existing credit arrangements described above require that we maintain certain financial covenants, as follows:
 
Covenant
Requirement as of December 31, 2019
 

Actual as of December 31, 2019
Maximum leverage ratio (1)
4.75 times
 
3.83 times
(1) Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters.

Our covenants require that we maintain a maximum leverage ratio of 3.75 times, provided, however, that for the two consecutive fiscal quarters ended immediately following the consummation of a Qualified Acquisition, as defined by each agreement, the maximum leverage ratio shall be 4.75 times, and then subject to a step-down for each succeeding fiscal quarter end to 4.50 times, 4.25 times, 4.00 times and then back to 3.75 times for each fiscal quarter end thereafter. On August 19, 2019, we announced the closing of our acquisition of BTG, a Qualified Acquisition, and our maximum leverage ratio was 4.75 times as of December 31, 2019. Refer to Note B – Acquisitions and Strategic Investments for more information.

Our covenants provide for an exclusion from the calculation of consolidated EBITDA, as defined by the agreements, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of December 31, 2019, we had $270 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments does not exceed $2.624 billion in the aggregate. As of December 31, 2019, we had $1.199 billion of the litigation exclusion remaining.

Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there
can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper

Our commercial paper program is backed by the 2018 Facility, as discussed above. Outstanding commercial paper directly reduces borrowing capacity under the 2018 Facility.
 
As of December 31,
(in millions, except maturity and yield)
2019
 
2018
Commercial paper outstanding
$
711

 
$
1,248

Maximum borrowing capacity
2,750

 
2,750

Borrowing capacity available
2,039

 
1,502

Weighted average maturity
55 days

 
27 days

Weighted average yield
2.21
%
 
3.04
%


Senior Notes

We had senior notes outstanding of $7.661 billion as of December 31, 2019 and $4.800 billion as of December 31, 2018.

In November 2019, we completed an offering of €900 million (approximately $1.000 billion) in aggregate principal amount of 0.625% senior notes due in 2027. The Euro-denominated debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional entities. Refer to Note D – Hedging Activities and Fair Value Measurements for additional information. We used a portion of the net proceeds from our November 2019 senior notes offering to repay certain outstanding principal amounts of our senior notes including $206 million of our $450 million 4.125% senior notes due 2023, $566 million of our $1.000 billion 4.000% senior notes due 2028 and $227 million of our $750 million 3.850% senior notes due 2025 and pay accrued and unpaid interest, premiums, fees and expenses in connection with the transaction. In 2019, we incurred associated debt extinguishment charges of $86 million presented in Other, net on our consolidated statements of operations.

In February 2019, we completed an offering of $4.300 billion in aggregate principal amount of senior notes comprised of $850 million of 3.450% senior notes due March 2024, $850 million of 3.750% senior notes due March 2026, $850 million of 4.000%
senior notes due March 2029, $750 million of 4.550% senior notes due March 2039 and $1.000 billion of 4.700% senior notes due March 2049. We used a portion of the net proceeds from the offering to repay the $850 million plus accrued interest and premium of our 6.000% senior notes due in January 2020, the $600 million plus accrued interest and premium of our 2.850% senior notes due in May 2020 and the $1.000 billion plus accrued interest of our August 2019 Term Loan. In 2019, the remaining proceeds were used to finance a portion of our acquisition of BTG.

In February 2018, we completed an offering of $1.000 billion in aggregate principal amount of 4.000% senior notes, due March 2028. We used a portion of the net proceeds from the offering to repay the $600 million plus accrued interest of our 2.650% senior notes due in October 2018, which were classified as short-term debt as of December 31, 2017. The remaining proceeds were used to repay a portion of our outstanding commercial paper.

Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below).

Our $7.311 billion of senior notes issued in 2009, 2013, 2015, 2018 and 2019 contain a change-in-control provision, which provides that each holder of the senior notes may require us to repurchase all or a portion of the notes at a price equal to 101 percent of the aggregate repurchased principal, plus accrued and unpaid interest, if a rating event, as defined in the indenture, occurs as a result of a change-in-control, as defined in the indenture. Any other credit rating changes may impact our borrowing cost, but do not require us to repay any borrowings.

Bridge Facility

On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described above, we terminated the Bridge Facility entered into on November 20, 2018. The termination was pursuant to the terms of the Bridge Facility, which required full termination upon the refinancing of the January 2020 Notes and May 2020 Notes discussed above. There were no amounts borrowed under the Bridge Facility as of December 31, 2018.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in the accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
 
As of December 31, 2019
 
As of December 31, 2018
Factoring Arrangements
Amount
De-recognized
 
Weighted Average Interest Rate
 
Amount
De-recognized
 
Weighted Average Interest Rate
Euro denominated
$
171

 
1.4
%
 
$
165

 
2.7
%
Yen denominated
226

 
0.6
%
 
195

 
0.9
%


BTG Revolving Credit Facility

After closing our acquisition of BTG, we terminated BTG's revolving credit facility with a borrowing capacity of £150 million (or approximately $184 million based on the exchange rate at termination on August 27, 2019), which contained an option to increase the facility by £150 million and was scheduled to expire in November 2020. The termination was effective on August 27, 2019, and there were no amounts outstanding at the time of close of the acquisition.
Other Contractual Obligations and Commitments

We had outstanding letters of credit of $105 million as of December 31, 2019 and $111 million as of December 31, 2018, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of December 31, 2019 and December 31, 2018, none of the beneficiaries had drawn upon the letters of credit or guarantees, accordingly, we have not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets as of December 31, 2019 and December 31, 2018.

Future minimum purchase obligations as of December 31, 2019 were as follows (in millions):
Fiscal Year
Unrecorded Purchase Obligations
2020
$
334

2021
20

2022
7

2023
3

2024
1

Thereafter
1

 
$
366



The amounts in the table above with respect to purchase obligations relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business.
XML 60 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net sales $ 10,735 $ 9,823 $ 9,048
Cost of products sold 3,116 2,813 2,593
Gross profit 7,620 7,011 6,455
Operating expenses:      
Selling, general and administrative expenses 3,941 3,569 3,294
Research and development expenses 1,174 1,113 997
Royalty expense 65 70 68
Amortization expense 699 599 565
Intangible asset impairment charges 105 35 4
Contingent consideration expense (benefit) (35) (21) (80)
Restructuring charges (credits) 38 36 37
Litigation-related charges (credits) 115 103 285
Operating expenses 6,102 5,504 5,170
Operating income (loss) 1,518 1,506 1,285
Other income (expense):      
Interest expense (473) (241) (229)
Other, net (358) 156 (124)
Income (loss) before income taxes 687 1,422 933
Income tax (benefit) expense (4,013) (249) 828
Net income (loss) $ 4,700 $ 1,671 $ 104
Net income (loss) per common share — basic $ 3.38 $ 1.21 $ 0.08
Net income (loss) per common share — assuming dilution $ 3.33 $ 1.19 $ 0.08
Weighted-average shares outstanding      
Basic 1,391.5 1,381.0 1,370.1
Assuming dilution 1,410.6 1,401.4 1,392.7
XML 61 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue Revenue
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block]
NOTE O – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
 
Year Ended December 31,
 
2019
 
2018
 
2017
Businesses
U.S.
 
OUS
 
Total
 
U.S.
 
OUS
 
Total
 
U.S.
 
OUS
 
Total
Endoscopy
$
1,080

 
$
814

 
$
1,894

 
$
980

 
$
781

 
$
1,762

 
$
894

 
$
724

 
$
1,619

Urology and Pelvic Health
1,005

 
408

 
1,413

 
864

 
381

 
1,245

 
785

 
339

 
1,124

Cardiac Rhythm Management
1,135

 
804

 
1,939

 
1,159

 
792

 
1,951

 
1,135

 
760

 
1,895

Electrophysiology
148

 
180

 
329

 
150

 
161

 
311

 
136

 
142

 
278

Neuromodulation
695

 
178

 
873

 
624

 
155

 
779

 
517

 
118

 
635

Interventional Cardiology
1,293

 
1,522

 
2,816

 
1,154

 
1,436

 
2,590

 
1,122

 
1,297

 
2,419

Peripheral Interventions
741

 
651

 
1,392

 
608

 
579

 
1,187

 
575

 
506

 
1,081

Specialty Pharmaceuticals
70

 
11

 
81

 
n/a

 
n/a

 
n/a

 
n/a

 
n/a

 
n/a

Net Sales
$
6,167

 
$
4,569

 
$
10,735

 
$
5,538

 
$
4,286

 
$
9,823

 
$
5,162

 
$
3,885

 
$
9,048


 
Year Ended December 31,
Geographic Regions
2019
 
2018
 
2017
U.S.
$
6,097

 
$
5,538

 
$
5,162

EMEA (Europe, Middle East and Africa)
2,264

 
2,176

 
1,940

APAC (Asia-Pacific)
1,898

 
1,727

 
1,587

LACA (Latin America and Canada)
395

 
383

 
358

Medical Devices
10,654

 
9,823

 
9,048

U.S.
70

 
n/a

 
n/a

OUS
11

 
n/a

 
n/a

Specialty Pharmaceuticals
81

 
n/a

 
n/a

Net Sales
$
10,735

 
$
9,823

 
$
9,048

 
 
 
 
 
 
Emerging Markets (1)
$
1,252

 
$
1,097

 
$
931

(1)
We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our deferred revenue balance was $400 million as of December 31, 2019 and $373 million as of December 31, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of $143 million in 2019 that was included in the above December 31, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.
XML 63 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Weighted Average Shares Outstanding
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
NOTE M – WEIGHTED AVERAGE SHARES OUTSTANDING

 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Weighted average shares outstanding - basic
1,391.5

 
1,381.0

 
1,370.1

Net effect of common stock equivalents
19.0

 
20.4

 
22.6

Weighted average shares outstanding - assuming dilution
1,410.6

 
1,401.4

 
1,392.7



The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.
XML 64 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Legal Costs, Policy [Policy Text Block]
Legal and Product Liability Costs

In the normal course of business, we are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue our best estimate of the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related charges (credits) in our consolidated statements of operations; all other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses. See Note J – Commitments and Contingencies for discussion of our individual material legal proceedings.
In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
ASC Topic 820, Fair Value Measurements and Disclosures FASB ASC Topic 815 requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means.
ASC Topic 815, Derivatives and Hedging
Financial Instruments

We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB ASC Topic 815, Derivatives and Hedging, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with FASB ASC Topic 815, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to Note D – Hedging Activities and Fair Value Measurements for more information on our hedging instruments.
XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Changes in Other Comprehensive Income (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax $ 142 $ (53) $ (32)
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax 173 111 1
Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax 0 0 (1)
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax (45) (25) (27)
Accumulated Other Comprehensive Income (Loss), Net of Tax 270 33 (59)
Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) 228 0  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 116 96  
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax 0 0  
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax (22) (2)  
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Recognized in Net Periodic Pension Cost, Net of Tax 2 4  
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax 20 (2) 6
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 322 94  
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax (33) (21)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (86) (3)  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax $ (54) 14  
Compensation and Employee Benefit Plans [Text Block]
NOTE R - EMPLOYEE RETIREMENT PLANS

Defined Benefit Pension Plans

Domestic Retirement Plans

Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan.

We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and division presidents. Participants may retire with benefits once retirement conditions have been satisfied.

U.K. Plan

As a result of our acquisition of BTG, we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom (U.K.) employees (U.K. Plan). The U.K. Plan was closed to new entrants as of June 1, 2004. Prior to the acquisition close date of August 19, 2019, the Trustees of the U.K. Plan executed buy-in arrangements (Buy-in Contracts), which effectively, as structured under the Buy-in Contracts, are intended to provide payments designed to equal all future designated contractual benefit payments to covered participants. The benefit obligation of the pension plan is not transferred to the insurers, and we remain responsible for paying pension benefits. We do not anticipate any additional material contributions or payments to the U.K. Plan or the insurer.

In connection with our preliminary purchase price allocation of BTG, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets as of the August 19, 2019 measurement date:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
U.K. Plan
0.4%
 
0.4%
 
3.4%

As of the measurement date of August 19, 2019, the funded status was as follows:
(in millions)
 
Fair value of plan assets
$
213

Benefit obligation
(216
)
Funded status
$
(3
)


Refer to Note B – Acquisitions and Strategic Investments for additional information on our acquisition of BTG.

Information about the U.K. Plan presented below is as of the December 31, 2019 measurement date.



Other International Retirement Plans

In addition, we maintain retirement plans covering certain international employees.

We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI. As of December 31, 2019 and 2018, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:
 
As of December 31, 2019
(in millions)
Accumulated Benefit Obligation (ABO)
 
Projected
Benefit
Obligation (PBO)
 
Fair value of Plan Assets
 
Unfunded/Underfunded
PBO Recognized
Domestic Retirement Plans
$
50

 
$
54

 
$
—

 
$
54

U.K. Plan
212

 
212

 
209

 
3

Other International Retirement Plans
204

 
223

 
123

 
100

 
$
466

 
$
488

 
$
332

 
$
156



 
As of December 31, 2018
(in millions)
Accumulated Benefit Obligation (ABO)
 
Projected
Benefit
Obligation (PBO)
 
Fair value of Plan Assets
 
Unfunded/Underfunded PBO Recognized
Domestic Retirement Plans
$
47

 
$
50

 
$
—

 
$
50

International Retirement Plans
166

 
182

 
107

 
75

 
$
213

 
$
232

 
$
107

 
$
125



A rollforward of the changes in the PBO for our retirement plans is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
Beginning obligations
$
232

 
$
207

Acquired and established plans(1)
216

 
23

Service costs
15

 
14

Interest costs
5

 
4

Actuarial (gain) loss
—

 
(1
)
Plan amendments and assumption changes
11

 
(2
)
Benefits paid
(10
)
 
(10
)
Impact of foreign currency fluctuations
19

 
(3
)
Ending obligation
$
488

 
$
232

(1)
Plans obtained through acquisition and other increases in connection with our international operations. Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

The critical assumptions associated with our employee retirement plans for 2019 are as follows:
 
Weighted Average Discount Rate
 
Weighted Average Expected Return on Plan
 
Weighted Average Rate of Compensation Increase(1)
 
 
 
Domestic Retirement Plans
2.94%
 
n/a
 
1.50%
U.K. Plan
0.60%
 
0.60%
 
3.00%
Other International Retirement Plans
0.75%
 
2.05%
 
2.65%
(1)
Rates of compensation increase were not weighted by the relative fair value of the instruments. As such, the amount represents the median of the inputs and is not a weighted average.

The critical assumptions associated with our employee retirement plans for 2018 are as follows:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
Domestic Retirement Plans
4.00
%
-
4.25%
 
n/a
 
3.00%
International Retirement Plans
0.50
%
-
2.34%
 
1.90
%
-
4.10%
 
1.50
%
-
6.78%


A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
Beginning fair value
$
107

 
$
87

Acquired and established plans(1)
213

 
16

Actual return on plan assets
7

 
(2
)
Employer contributions
13

 
14

Participant contributions
2

 
2

Actuarial gain (loss)
(20
)
 
—

Benefits paid
(10
)
 
(10
)
Impact of foreign currency fluctuations
19

 
—

Ending fair value
$
332

 
$
107

(1)
Plans obtained through acquisition and other increases in connection with our international operations. Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

For our defined benefit plans excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.

For our U.K. Plan, we utilize the insurance buy-in methodology and base our discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2019. We believe this is a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate is calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assume that all pension increases will continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which will be based on Consumer Price Inflation (CPI). We base our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy is to invest in fully matching assets. This has been achieved through the purchase of two buy-in policies (Buy-in contracts), which provide payments designed to equal all future benefit payments due from the fund. As of December 31, 2019, the Buy-in contracts represented 99% of the total plan assets, as compared to the target percentage of 100%, and are considered Level 3 investments.

The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value as of December 31, 2019:
 
As of
 
December 31, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Buy-in contracts
$
—

 
$
—

 
$
207

 
$
207

Cash
1

 
—

 
—

 
1

Total assets
$
1

 
$
—

 
$
207

 
$
209



Changes in the fair value of the U.K. Plan Level 3 assets were as follows:
(in millions)
Buy-in Contracts
Balance as of December 31, 2018
$
—

Acquired plans(1)
213

Actuarial gain (loss)
(20
)
Benefits paid
(4
)
Impact of foreign currency fluctuations
19

Balance as of December 31, 2019
$
209

(1)
Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

Defined Contribution Plan

We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $98 million in 2019, $87 million in 2018 and $79 million in 2017.
    
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax $ 0 1  
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax 0 0 5
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax 195 (21) 48
Other Comprehensive Income (Loss), Net of Tax $ 237 $ 91 $ (59)
XML 67 a2019form10-k_htm.xml IDEA: XBRL DOCUMENT 0000885725 2019-01-01 2019-12-31 0000885725 bsx:A2019AcquisitionsMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember 2019-01-01 2019-12-31 0000885725 bsx:A2017AcquisitionsMember 2019-01-01 2019-12-31 0000885725 bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 2019-06-28 0000885725 2020-01-31 0000885725 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000885725 bsx:SeniorNotedue2027Member 2019-01-01 2019-12-31 0000885725 2018-01-01 2018-12-31 0000885725 2017-01-01 2017-12-31 0000885725 2018-12-31 0000885725 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000885725 us-gaap:CommonStockMember 2018-12-31 0000885725 us-gaap:CommonStockMember 2017-12-31 0000885725 us-gaap:TreasuryStockMember 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000885725 us-gaap:RetainedEarningsMember 2017-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000885725 us-gaap:TreasuryStockMember 2017-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000885725 us-gaap:CommonStockMember 2016-12-31 0000885725 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2018-12-31 0000885725 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0000885725 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0000885725 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2018-12-31 0000885725 us-gaap:TreasuryStockMember 2019-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000885725 us-gaap:CommonStockMember 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000885725 us-gaap:RetainedEarningsMember 2019-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000885725 us-gaap:NewAccountingPronouncementMember us-gaap:RetainedEarningsMember 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000885725 us-gaap:RetainedEarningsMember 2016-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000885725 us-gaap:TreasuryStockMember 2016-12-31 0000885725 2017-12-31 0000885725 2016-12-31 0000885725 us-gaap:AccountingStandardsUpdate201602Member bsx:OperatingleaserightofuseassetsotherlongtermassetsMember 2019-01-01 2019-01-01 0000885725 us-gaap:ShippingAndHandlingMember 2019-01-01 2019-12-31 0000885725 us-gaap:ShippingAndHandlingMember 2017-01-01 2017-12-31 0000885725 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0000885725 us-gaap:AccountingStandardsUpdate201616Member 2018-03-31 0000885725 us-gaap:AccountingStandardsUpdate201602Member bsx:OperatingleaseliabilityotherlongtermliabilitiesMember 2019-01-01 2019-01-01 0000885725 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-12-31 0000885725 us-gaap:NewAccountingPronouncementMember 2018-01-01 0000885725 bsx:BTGAcquisitionMember 2019-12-31 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000885725 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 us-gaap:FiniteLivedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2017AcquisitionsMember 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2017AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember 2019-12-31 0000885725 bsx:A2019AcquisitionsMember 2019-12-31 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0000885725 bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 bsx:CryterionMember 2018-07-05 2018-07-05 0000885725 bsx:ProposedBTGAcquisitionMember 2019-08-19 2019-08-19 0000885725 bsx:NVisionMember 2018-04-16 0000885725 bsx:Other2018AcquisitionsMember 2018-01-01 2018-12-31 0000885725 bsx:ApamaMember 2017-10-10 2017-10-10 0000885725 bsx:MillipedeMember 2019-01-29 0000885725 bsx:NVisionMember 2018-04-16 2018-04-16 0000885725 bsx:DivestedbusinessduetoBTGacquisitionMember 2019-08-21 0000885725 bsx:VertiflexInc.Member 2019-06-11 0000885725 bsx:ClaretMember 2018-08-02 0000885725 bsx:Other2018AcquisitionsMember 2018-12-31 0000885725 bsx:BTGAcquisitionMember 2019-08-19 2019-08-19 0000885725 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-12-31 0000885725 bsx:CryterionMember 2018-07-05 0000885725 bsx:NxTheraMember 2018-04-30 2018-04-30 0000885725 bsx:ClaretMember 2018-08-02 2018-08-02 0000885725 bsx:ProposedBTGAcquisitionMember 2019-08-19 0000885725 bsx:ApamaMember 2017-10-10 0000885725 bsx:BTGAcquisitionMember bsx:CardiovascularMember 2019-01-01 2019-12-31 0000885725 bsx:VertiflexInc.Member 2019-06-11 2019-06-11 0000885725 bsx:AugmenixInc.Member 2018-10-16 0000885725 bsx:AugmenixInc.Member 2018-10-16 2018-10-16 0000885725 bsx:SymetisMember 2017-05-16 2017-05-16 0000885725 2019-08-21 2019-08-21 0000885725 bsx:NxTheraMember 2018-04-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 bsx:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 bsx:RevenuebasedpaymentsbyvaluationtechniqueMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-12-31 0000885725 us-gaap:PatentsMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:PatentsMember 2019-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0000885725 us-gaap:OtherIntangibleAssetsMember 2018-12-31 0000885725 bsx:CardiovascularMember 2019-01-01 2019-12-31 0000885725 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-12-31 0000885725 bsx:RhythmandNeuroMember 2019-12-31 0000885725 us-gaap:AllOtherSegmentsMember 2019-12-31 0000885725 bsx:RhythmandNeuroMember 2018-01-01 2018-12-31 0000885725 bsx:CardiovascularMember 2018-01-01 2018-12-31 0000885725 bsx:RhythmandNeuroMember 2019-01-01 2019-12-31 0000885725 bsx:CardiovascularMember 2017-12-31 0000885725 us-gaap:AllOtherSegmentsMember 2018-12-31 0000885725 us-gaap:AllOtherSegmentsMember 2017-12-31 0000885725 bsx:MedsurgMember 2018-01-01 2018-12-31 0000885725 bsx:RhythmandNeuroMember 2017-12-31 0000885725 bsx:MedsurgMember 2017-12-31 0000885725 bsx:CardiovascularMember 2019-12-31 0000885725 bsx:MedsurgMember 2019-01-01 2019-12-31 0000885725 bsx:RhythmandNeuroMember 2018-12-31 0000885725 bsx:CardiovascularMember 2018-12-31 0000885725 bsx:MedsurgMember 2018-12-31 0000885725 bsx:MedsurgMember 2019-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885725 bsx:LicensingarrangementassetsMember 2019-01-01 2019-12-31 0000885725 bsx:LicensingarrangementassetsMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2019-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-12-31 0000885725 srt:MinimumMember bsx:LicensingarrangementassetsMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:LicensingarrangementassetsMember 2019-01-01 2019-12-31 0000885725 bsx:LicensingarrangementliabilitiesMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForwardContractsMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2017-01-01 2017-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0000885725 bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherNoncurrentAssetsMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0000885725 us-gaap:LiabilityMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000885725 bsx:TenderOfferMember 2019-12-31 0000885725 bsx:ProposedBTGAcquisitionMember 2019-12-31 0000885725 us-gaap:NetInvestmentHedgingMember 2019-12-31 0000885725 bsx:BTGAcquisitionMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 bsx:December2027NotesMember 2019-12-31 0000885725 us-gaap:AccountsPayableMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherCurrentAssetsMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 currency:EUR us-gaap:NondesignatedMember 2019-01-01 2019-12-31 0000885725 bsx:EurodenominatedoutstandingdebtMember 2019-12-31 0000885725 us-gaap:AssetsMember bsx:BTGAcquisitionMember 2019-01-01 2019-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 bsx:ForeigncurrencydenominatedindebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000885725 bsx:LicensingarrangementliabilitiesMember 2019-01-01 2019-12-31 0000885725 bsx:ActualCovenantMember 2019-12-31 0000885725 bsx:CurrentRequirementMember 2019-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2019-01-01 2019-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2018-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2019-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2019-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2018-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2018-01-01 2018-12-31 0000885725 bsx:January2020NotesMember 2019-12-31 0000885725 bsx:March2039NotesMember 2019-12-31 0000885725 bsx:August2022TermLoanMember 2018-12-31 0000885725 bsx:May2025NotesMember 2018-12-31 0000885725 bsx:November2035NotesMember 2018-12-31 0000885725 bsx:March2028NotesMember 2019-12-31 0000885725 bsx:December2027NotesMember 2018-12-31 0000885725 bsx:March2024NotesMember 2018-12-31 0000885725 bsx:March2039NotesMember 2018-12-31 0000885725 us-gaap:SeniorNotesMember 2019-12-31 0000885725 us-gaap:SeniorNotesMember 2018-12-31 0000885725 bsx:October2023NotesMember 2019-12-31 0000885725 bsx:March2026NotesMember 2019-12-31 0000885725 bsx:March2029NotesMember 2019-12-31 0000885725 bsx:May2025NotesMember 2019-12-31 0000885725 bsx:January2020NotesMember 2018-12-31 0000885725 bsx:November2035NotesMember 2019-12-31 0000885725 bsx:May2020NotesMember 2018-12-31 0000885725 bsx:March2029NotesMember 2018-12-31 0000885725 bsx:October2023NotesMember 2018-12-31 0000885725 bsx:March2028NotesMember 2018-12-31 0000885725 bsx:March2026NotesMember 2018-12-31 0000885725 bsx:March2024NotesMember 2019-12-31 0000885725 bsx:May2022NotesMember 2018-12-31 0000885725 bsx:May2022NotesMember 2019-12-31 0000885725 bsx:March2049NotesMember 2019-12-31 0000885725 bsx:January2040NotesMember 2019-12-31 0000885725 bsx:March2049NotesMember 2018-12-31 0000885725 us-gaap:InterestRateSwapMember 2019-12-31 0000885725 bsx:May2020NotesMember 2019-12-31 0000885725 bsx:January2040NotesMember 2018-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000885725 bsx:August2022TermLoanMember 2019-12-31 0000885725 us-gaap:InterestRateSwapMember 2018-12-31 0000885725 bsx:A2020TermLoanMember us-gaap:SubsequentEventMember 2020-01-09 2020-01-09 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember 2019-01-01 2019-12-31 0000885725 bsx:August2019TermLoanMember 2019-12-31 0000885725 bsx:RequirementfourthquarterfollowingqualifiedacquisitionMember 2019-12-31 0000885725 2019-11-27 2019-11-27 0000885725 bsx:March2028NotesMember 2019-01-01 2019-12-31 0000885725 bsx:February2019AggregateOfferingMember 2019-02-25 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2018-12-19 0000885725 bsx:January2020NotesMember 2019-01-01 2019-12-31 0000885725 bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember 2019-12-31 0000885725 bsx:The2018facilityMember 2019-01-01 2019-12-31 0000885725 bsx:October2018NotesMember 2018-01-01 2018-12-31 0000885725 bsx:May2020NotesMember 2019-01-01 2019-12-31 0000885725 bsx:August2019TermLoanMember 2019-01-01 2019-12-31 0000885725 bsx:May2025NotesMember 2019-01-01 2019-12-31 0000885725 bsx:October2023NotesMember 2019-01-01 2019-12-31 0000885725 bsx:RequirementsixthquarterandthereafterfollowingqualifiedacquisitionMember 2019-12-31 0000885725 bsx:CovenantRequirementDomain 2019-12-31 0000885725 bsx:The2017FacilityMember 2017-08-04 0000885725 us-gaap:CommercialPaperMember 2018-12-19 0000885725 bsx:RequirementthirdquarterfollowingqualifiedacquisitionMember 2019-12-31 0000885725 bsx:TwoYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2018-12-19 0000885725 bsx:RequirementfirsttwoquartersfollowingqualifiedacquisitionMember 2019-12-31 0000885725 bsx:TwoYearDelayedDrawTermLoanMember bsx:AggregateSeniorUnsecuredDelayedDrawTermLoanMember 2018-12-19 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2019-12-31 0000885725 bsx:A2020TermLoanMember 2019-12-05 0000885725 bsx:October2018NotesMember 2018-12-31 0000885725 2019-12-05 2019-12-05 0000885725 bsx:A2020TermLoanMember 2019-12-31 0000885725 us-gaap:BorrowingsMember 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2019-01-01 2019-12-31 0000885725 us-gaap:CommercialPaperMember 2019-12-31 0000885725 us-gaap:CommercialPaperMember 2018-01-01 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2019-12-31 0000885725 us-gaap:BorrowingsMember 2019-12-31 0000885725 srt:MaximumMember 2019-12-31 0000885725 srt:MaximumMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000885725 bsx:TransferCostsMember 2019-01-01 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 bsx:TransferCostsMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 bsx:TransferCostsMember bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember bsx:TransferCostsMember 2019-01-01 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember bsx:TransferCostsMember 2019-01-01 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0000885725 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 us-gaap:OtherRestructuringMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000885725 us-gaap:EmployeeSeveranceMember 2017-01-01 2017-12-31 0000885725 bsx:TransferCostsMember 2017-01-01 2017-12-31 0000885725 us-gaap:OtherRestructuringMember us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 us-gaap:OtherRestructuringMember 2017-01-01 2017-12-31 0000885725 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000885725 bsx:TransferCostsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000885725 us-gaap:EmployeeSeveranceMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000885725 bsx:TransferCostsMember us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 bsx:TransferCostsMember 2016-06-06 2019-12-31 0000885725 2016-06-06 2019-12-31 0000885725 bsx:A2019RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember 2016-06-06 2019-12-31 0000885725 bsx:A2016RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 bsx:TransferCostsMember bsx:A2019RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 bsx:A2016RestructuringPlanMember 2019-12-31 0000885725 us-gaap:OtherRestructuringMember 2016-06-06 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2019RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 bsx:TransferCostsMember bsx:A2016RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember 2016-06-06 2019-12-31 0000885725 srt:MinimumMember us-gaap:EmployeeSeveranceMember bsx:A2016RestructuringPlanMember bsx:RestructuringPlanMember 2019-12-31 0000885725 srt:MinimumMember us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember bsx:RestructuringPlanMember 2019-12-31 0000885725 srt:MinimumMember us-gaap:OtherRestructuringMember bsx:A2016RestructuringPlanMember bsx:RestructuringRelatedToPlanMember 2019-12-31 0000885725 srt:MinimumMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember bsx:A2019RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember bsx:A2016RestructuringPlanMember 2019-01-01 2019-12-31 0000885725 srt:MaximumMember us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember bsx:RestructuringRelatedToPlanMember 2019-12-31 0000885725 srt:MinimumMember us-gaap:EmployeeSeveranceMember bsx:A2019RestructuringPlanMember bsx:RestructuringPlanMember 2019-12-31 0000885725 srt:MinimumMember us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember bsx:RestructuringRelatedToPlanMember 2019-12-31 0000885725 srt:MinimumMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 srt:MaximumMember bsx:A2019RestructuringPlanMember 2019-12-31 0000885725 srt:MaximumMember us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember bsx:RestructuringPlanMember 2019-12-31 0000885725 srt:MaximumMember us-gaap:EmployeeSeveranceMember bsx:A2019RestructuringPlanMember bsx:RestructuringPlanMember 2019-12-31 0000885725 srt:MinimumMember us-gaap:OtherRestructuringMember bsx:A2019RestructuringPlanMember bsx:RestructuringPlanMember 2019-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-12-31 0000885725 bsx:TransferCostsMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember bsx:TransferCostsMember 2018-01-01 2018-12-31 0000885725 us-gaap:EmployeeSeveranceMember 2018-01-01 2018-12-31 0000885725 us-gaap:OtherRestructuringMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember bsx:TransferCostsMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember 2018-01-01 2018-12-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-12-31 0000885725 us-gaap:OtherAssetsMember 2019-12-31 0000885725 us-gaap:OtherAssetsMember 2018-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2019-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000885725 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0000885725 us-gaap:SubsequentEventMember 2020-01-01 2020-12-31 0000885725 2018-06-30 0000885725 2018-10-01 2018-12-31 0000885725 2018-04-01 2018-06-30 0000885725 2019-07-01 2019-09-30 0000885725 2017-11-10 2017-11-10 0000885725 us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2020-01-29 0000885725 us-gaap:SubsequentEventMember 2020-01-29 0000885725 2019-01-01 2019-03-31 0000885725 2019-04-01 2019-06-30 0000885725 2019-10-01 2019-12-31 0000885725 2019-01-15 0000885725 2013-01-25 0000885725 srt:MaximumMember 2018-01-01 2018-12-31 0000885725 srt:MinimumMember 2017-01-01 2017-12-31 0000885725 srt:MinimumMember 2019-01-01 2019-12-31 0000885725 srt:MinimumMember 2018-01-01 2018-12-31 0000885725 srt:MaximumMember 2017-01-01 2017-12-31 0000885725 bsx:A2011LtipPlanMember 2011-05-31 0000885725 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000885725 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0000885725 us-gaap:CostOfSalesMember 2017-01-01 2017-12-31 0000885725 2017-02-28 0000885725 2019-02-21 0000885725 2018-02-15 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2017-01-01 2017-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2019-01-01 2019-12-31 0000885725 bsx:BTGSpecPharmaMember 2019-01-01 2019-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2019-01-01 2019-12-31 0000885725 bsx:SpecialChargesMember 2017-01-01 2017-12-31 0000885725 bsx:SpecialChargesMember 2019-01-01 2019-12-31 0000885725 bsx:SpecialChargesMember 2018-01-01 2018-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2018-01-01 2018-12-31 0000885725 bsx:MedsurgMember 2017-01-01 2017-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2018-01-01 2018-12-31 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2017-01-01 2017-12-31 0000885725 bsx:CardiovascularMember 2017-01-01 2017-12-31 0000885725 bsx:RhythmandNeuroMember 2017-01-01 2017-12-31 0000885725 country:US 2017-12-31 0000885725 country:IE 2017-12-31 0000885725 country:US 2018-12-31 0000885725 bsx:OtherCountriesMember 2017-12-31 0000885725 bsx:OtherCountriesMember 2018-12-31 0000885725 bsx:OtherCountriesMember 2019-12-31 0000885725 country:IE 2019-12-31 0000885725 country:IE 2018-12-31 0000885725 country:US 2019-12-31 0000885725 bsx:BSXReportableSegmentsMember 2019-01-01 2019-12-31 0000885725 bsx:BSXReportableSegmentsMember 2018-01-01 2018-12-31 0000885725 bsx:BSXReportableSegmentsMember 2017-01-01 2017-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2018-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2018-12-31 0000885725 bsx:BTGSpecPharmaMember 2019-12-31 0000885725 bsx:BTGSpecPharmaMember 2018-12-31 0000885725 bsx:TotalAllocatedToReportableSegmentsMember 2019-12-31 0000885725 us-gaap:CorporateNonSegmentMember 2019-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2017-01-01 2017-12-31 0000885725 country:US 2017-01-01 2017-12-31 0000885725 bsx:EmergingMarketsMember 2018-01-01 2018-12-31 0000885725 srt:AsiaPacificMember 2018-01-01 2018-12-31 0000885725 srt:AsiaPacificMember 2017-01-01 2017-12-31 0000885725 country:US 2018-01-01 2018-12-31 0000885725 country:US bsx:BSXReportableSegmentsMember 2019-01-01 2019-12-31 0000885725 bsx:EmergingMarketsMember 2017-01-01 2017-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2018-01-01 2018-12-31 0000885725 bsx:EmergingMarketsMember 2019-01-01 2019-12-31 0000885725 us-gaap:EMEAMember 2019-01-01 2019-12-31 0000885725 us-gaap:EMEAMember 2017-01-01 2017-12-31 0000885725 srt:AsiaPacificMember 2019-01-01 2019-12-31 0000885725 bsx:LatinAmericaandCanadaMember 2019-01-01 2019-12-31 0000885725 bsx:BTGSpecPharmaMember country:US 2019-01-01 2019-12-31 0000885725 us-gaap:EMEAMember 2018-01-01 2018-12-31 0000885725 bsx:BTGSpecPharmaMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalCrmReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2018-01-01 2018-12-31 0000885725 us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2017-01-01 2017-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-12-31 0000885725 us-gaap:NonUsMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalCrmReportingUnitMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2018-01-01 2018-12-31 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2018-01-01 2018-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2019-01-01 2019-12-31 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2017-01-01 2017-12-31 0000885725 bsx:GlobalCrmReportingUnitMember 2019-01-01 2019-12-31 0000885725 bsx:InternationalRetirementPlansMember 2019-12-31 0000885725 bsx:U.K.PlanMember 2019-12-31 0000885725 bsx:ExecutiveRetirementPlanMember 2019-12-31 0000885725 bsx:BTGAcquisitionDomain 2019-12-31 0000885725 us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-12-31 0000885725 bsx:U.K.PlanMember 2019-12-31 0000885725 bsx:OtherInternationalPlansMember 2019-12-31 0000885725 us-gaap:DomesticPlanMember 2019-12-31 0000885725 bsx:ExecutiveRetirementPlanMember 2018-12-31 0000885725 bsx:InternationalRetirementPlansMember 2018-12-31 0000885725 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000885725 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000885725 us-gaap:DefinedBenefitPlanCashMember 2019-12-31 0000885725 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000885725 us-gaap:OtherContractMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000885725 us-gaap:FairValueInputsLevel1Member 2019-12-31 0000885725 us-gaap:OtherContractMember 2019-12-31 0000885725 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000885725 srt:MinimumMember us-gaap:DomesticPlanMember 2018-12-31 0000885725 srt:MinimumMember bsx:InternationalRetirementPlansMember 2018-12-31 0000885725 srt:MaximumMember bsx:InternationalRetirementPlansMember 2018-12-31 0000885725 srt:MaximumMember us-gaap:DomesticPlanMember 2018-12-31 0000885725 us-gaap:DomesticPlanMember 2018-12-31 iso4217:GBP pure iso4217:USD iso4217:GBP shares iso4217:USD shares utreg:Rate shares iso4217:EUR bsx:claims bsx:reportablesegments false --12-31 FY 2019 0000885725 0.01 2000000000 1632148030 1642488911 1384581760 1394922641 0 0 0 0.01 0.01 50000000 0 0 0 0 248000000 247566270 247566270 10-K true 2019-12-31 false 1-11083 BOSTON SCIENTIFIC CORPORATION DE 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 Common Stock, $0.01 par value BSX NYSE 0.625% Senior Notes due 2027 BSX27 NYSE Yes No Yes Yes Large Accelerated Filer false false false 53100000000 0.01 1396195349 10735000000 9823000000 9048000000 3116000000 2813000000 2593000000 7620000000 7011000000 6455000000 3941000000 3569000000 3294000000 1174000000 1113000000 997000000 65000000 70000000 68000000 699000000 599000000 565000000 105000000 35000000 4000000 -35000000 -21000000 -80000000 38000000 36000000 37000000 115000000 103000000 285000000 6102000000 5504000000 5170000000 1518000000 1506000000 1285000000 473000000 241000000 229000000 -358000000 156000000 -124000000 687000000 1422000000 933000000 -4013000000 -249000000 828000000 4700000000 1671000000 104000000 3.38 1.21 0.08 3.33 1.19 0.08 1391500000 1381000000.0 1370100000 1410600000 1401400000 1392700000 4700000000 1671000000 104000000 195000000 -21000000 48000000 62000000 110000000 -106000000 0 0 5000000 20000000 -2000000 6000000 237000000 91000000 -59000000 4937000000 1761000000 45000000 217000000 146000000 1828000000 1608000000 1579000000 1166000000 195000000 161000000 880000000 921000000 4699000000 4003000000 2079000000 1782000000 10176000000 7911000000 7886000000 6372000000 4196000000 87000000 1529000000 845000000 30565000000 20999000000 1416000000 2253000000 542000000 349000000 2109000000 2246000000 800000000 412000000 4866000000 5260000000 8592000000 4803000000 595000000 328000000 2635000000 1882000000 16000000 16000000 1717000000 1717000000 17561000000 17346000000 -2253000000 -6953000000 142000000 -53000000 173000000 111000000 45000000 25000000 13877000000 8726000000 30565000000 20999000000 1609670817 16000000 -1717000000 17014000000 -8581000000 1000000 104000000 86000000 48000000 -106000000 5000000 -6000000 11392081 147000000 1621062898 16000000 -1717000000 17161000000 -8390000000 -59000000 1671000000 -233000000 -21000000 110000000 2000000 11085132 185000000 1632148030 16000000 -1717000000 17346000000 -6953000000 33000000 4700000000 195000000 62000000 -20000000 10340881 215000000 1642488911 16000000 -1717000000 17561000000 -2253000000 270000000 4700000000 1671000000 104000000 8000000 0 0 1011000000 894000000 844000000 -4301000000 -87000000 245000000 157000000 140000000 127000000 105000000 35000000 4000000 -30000000 155000000 -92000000 -35000000 -21000000 -80000000 6000000 9000000 14000000 46000000 6000000 10000000 -358000000 11000000 -15000000 63000000 8000000 13000000 130000000 110000000 30000000 290000000 83000000 107000000 -45000000 172000000 20000000 111000000 -631000000 195000000 -18000000 -1164000000 28000000 1836000000 310000000 1426000000 461000000 316000000 319000000 7000000 14000000 0 4382000000 1448000000 560000000 90000000 0 0 52000000 0 0 199000000 0 0 149000000 172000000 131000000 -5041000000 -1921000000 -1010000000 135000000 19000000 33000000 256000000 0 0 700000000 999000000 0 -575000000 21000000 1183000000 0 569000000 2156000000 0 569000000 2216000000 1000000000 0 0 3560000000 602000000 1000000000 7229000000 987000000 0 65000000 56000000 65000000 123000000 101000000 85000000 2973000000 1432000000 110000000 10000000 -8000000 4000000 -222000000 -188000000 530000000 829000000 1017000000 487000000 607000000 829000000 1017000000 242000000 1037000000 42000000 449000000 262000000 235000000 127000000 248000000 94000000 217000000 146000000 188000000 346000000 655000000 803000000 43000000 27000000 26000000 607000000 829000000 1017000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-weight:bold;">NOTE A – SIGNIFICANT ACCOUNTING POLICIES<br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> include the accounts of Boston Scientific Corporation and our wholly-owned subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest in a VIE. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reportable Segments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. </span><span style="font-family:inherit;font-size:10pt;">Following our acquisition of BTG plc (BTG), which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subsequent Events</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. We did not identify any material subsequent events requiring adjustment to our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> have been disclosed accordingly. Refer to </span><span style="font-style:italic;">Note E – Contractual Obligations and Commitments</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-style:italic;">Note J – Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for further details.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To prepare our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Critical Accounting Estimates</span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:inherit;font-size:10pt;"> of this Annual Report for further discussion.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider to be cash equivalents all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets </span><span style="font-family:inherit;font-size:10pt;">caption on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us as servicer of previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash Equivalents</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets </span><span style="font-family:inherit;font-size:10pt;">caption on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets </span><span style="font-family:inherit;font-size:10pt;">caption on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> are related to deferred compensation plans. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral. We record our accounts receivable in our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> at net realizable value. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses, based on historical information and management's best estimates. We write-off amounts determined to be uncollectible against this reserve. Write-offs of uncollectible accounts receivable were immaterial in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers in Southern Europe are subject to an increased number of days outstanding prior to payment relative to other countries. Historically, receivable balances with certain publicly-owned hospitals in these countries accumulated over a period of time and are then subsequently settled as large lump sum payments, sometimes at large discounts. While we believe our allowance for doubtful accounts in these countries is adequate as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts receivable may increase. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued </span><span>FASB ASC Topic 606, </span><span style="font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">(Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;">. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in </span><span>FASB ASC Topic 605, </span><span style="font-style:italic;">Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to the adoption of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;">, we recorded a net reduction to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$177 million</span></span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2018, primarily related to the cost of providing non-contractual post-implant support to certain customers, which we historically deemed immaterial in the context of the arrangement. Upon the adoption of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;">, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Selling, general and administrative expenses </span><span style="font-family:inherit;font-size:10pt;">and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> resulted in </span><span style="font-family:inherit;font-size:10pt;">an increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$59 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$205 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2018, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in </span><span style="font-family:inherit;font-size:10pt;">an increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">a reduction</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred income taxes</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$41 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2018. The remaining impact of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> was not material to our financial position or results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a contract with a customer that creates enforceable rights and obligations,</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Promised products or services are identified,</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price, or the amount we expect to receive, is determinable and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have transferred control of the promised items to the customer.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities are classified within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> on our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Consideration</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Capitalized Contract Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Post-Implant Services</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. Following our modified retrospective adoption of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2018, because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warranty Obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our Cardiac Rhythm Management business, which include implantable defibrillator and pacemaker systems. Our Cardiac Rhythm Management products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We state inventories at the lower of first-in, first-out cost or net realizable value. We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>32 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of our finished goods inventory as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>40 percent</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was at customer locations pursuant to consignment arrangements or held by sales representatives.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Plant and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of </span><span style="font-family:inherit;font-size:10pt;">40</span><span style="font-family:inherit;font-size:10pt;"> years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASC Update No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (</span><span>FASB ASC Topic 842, </span><span style="font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">). We adopted the standard as of January 1, 2019, using the modified retrospective approach and the transition method provided by ASC Update No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">. Under this method, we applied the new leasing rules on the date of adoption and recognized the cumulative effect of initially applying the standard as an adjustment to our January 1, 2019 opening balance sheet, rather than at the earliest comparative period presented in the financial statements. Prior periods presented are in accordance with the previous lease guidance under </span><span>FASB ASC Topic 840, </span><span style="font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 840</span><span style="font-family:inherit;font-size:10pt;">). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we applied the package of practical expedients permitted under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> transition guidance to our entire lease portfolio at January 1, 2019. As a result, we were not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases and (iii) the treatment of initial direct costs for any existing leases. Furthermore, we elected not to separate lease and non-lease components for the majority of our leases. Instead, for all applicable classes of underlying assets, we accounted for each separate lease component and the non-lease components associated with that lease component, as a single lease component.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2019, we recognized right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$271 million</span></span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$278 million</span></span><span style="font-family:inherit;font-size:10pt;"> for our existing operating lease portfolio on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheet</span><span style="font-family:inherit;font-size:10pt;">. Operating lease right-of-use assets are presented within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities are presented within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Finance leases are immaterial to our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note E – Contractual Obligations and Commitments</span><span style="font-family:inherit;font-size:10pt;"> for additional information. There was no material impact to our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of cash flows</span><span style="font-family:inherit;font-size:10pt;"> as a result of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">. Please refer to </span><span style="font-style:italic;">Note F – Leases</span><span style="font-family:inherit;font-size:10pt;"> for information regarding our lease portfolio as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> as accounted for under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To meet the reporting and disclosure requirements of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">, we implemented a new lease administration and lease accounting system in 2018 that tracks all of our material leasing arrangements. In addition, we designed and implemented new processes and internal controls during the first quarter of 2019 to ensure the completeness and accuracy of the transition adjustment and subsequent financial reporting under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">. We have also established monitoring controls to ensure we have appropriate mechanisms in place to identify material leases in a timely manner, particularly contracts that may contain embedded lease features.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation of Business Combinations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In those circumstances where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent consideration expense (benefit)</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones.</span><span style="font-family:inherit;font-size:10pt;"> Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indefinite-lived Intangibles, including IPR&amp;D</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which is foundational to our ongoing operations within the Cardiovascular market and other markets within interventional medicine and IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with </span><span>FASB ASC Topic 350, </span><span style="font-style:italic;">Intangibles - Goodwill and Other</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="font-style:italic;">Note C – Goodwill and Other Intangible Assets</span><span style="font-family:inherit;font-size:10pt;"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Amortization and Impairment of Intangible Assets</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">20</span><span style="font-family:inherit;font-size:10pt;"> years; amortizable technology-related and customer relationships, </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">25</span><span style="font-family:inherit;font-size:10pt;"> years; other intangible assets, various.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="font-style:italic;">Note C – Goodwill and Other Intangible Assets</span><span style="font-family:inherit;font-size:10pt;"> for more information related to impairments of intangible assets.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill Valuation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> annual impairment assessment, we identified the following reporting units: Interventional Cardiology, Peripheral Interventions (including the Interventional Medicine business acquired with BTG), Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health and Neuromodulation. In addition, following the BTG acquisition in the third quarter of 2019, we added Specialty Pharmaceuticals as an additional reporting unit. We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based on the criteria prescribed in </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 350</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In performing the goodwill impairment assessments for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we utilized both the optional qualitative assessment and the quantitative approach prescribed under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 350</span><span style="font-family:inherit;font-size:10pt;">. The qualitative assessment was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent. All other reporting units were tested using the quantitative approach described below. The qualitative assessment requires an evaluation of whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount based on an assessment of relevant events including macroeconomic factors, industry and market conditions, cost factors, overall financial performance and other entity-specific factors. After assessing the totality of events, if it is determined that it is more likely than not that the fair value of the reporting unit exceeds its carrying value, no further steps are required. If it is determined that impairment is more likely than not, then we perform the quantitative impairment test. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When allocating goodwill from business combinations to our reporting units, we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition. In addition, for purposes of performing our goodwill impairment tests, assets and liabilities, including corporate assets, which relate to a reporting unit’s operations, and would be considered in determining its fair value, are allocated to the individual reporting units. We allocate assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> annual impairment assessments, for those reporting units for which a quantitative test was performed, we used only the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets. We have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technology-based assets within our reporting units for application of the cost approach. Therefore, we believe that the income approach represents the most appropriate valuation technique for which sufficient data are available to determine the fair value of our reporting units. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In applying the income approach to our accounting for goodwill, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk-adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note C – Goodwill and Other Intangible Assets</span><span style="font-family:inherit;font-size:10pt;"> to our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> for additional details related to our goodwill balances.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments in Publicly Traded and Privately Held Entities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASC Update No. 2016-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall </span><span style="font-family:inherit;font-size:10pt;">(Subtopic 825-10)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Recognition and Measurement of Financial Assets and Financial Liabilities. </span><span style="font-family:inherit;font-size:10pt;">The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;">. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> were reclassified to retained earnings,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">and all future fair value changes will be recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net income (loss)</span><span style="font-family:inherit;font-size:10pt;">. For privately-held securities of investee companies over which we do not have the ability to exercise significant influence, we elected the measurement alternative approach for our existing investments, which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, we accounted for our publicly traded investments as available-for-sale securities based on the quoted market price at the end of the reporting period. Unrealized holding gains or losses during the period, net of tax, were recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">. We computed realized gains and losses on sales of available-for-sale securities at fair value, adjusted for any other-than-temporary declines in fair value. We accounted for investments in privately-held entities in which we had less than a 20 percent ownership interest under the cost method of accounting if we did not have the ability to exercise significant influence over the investee in accordance with </span><span>FASB ASC Topic 325</span><span style="font-style:italic;">,</span><span> </span><span style="font-style:italic;">Investments - Other</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for investments in entities over which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with </span><span>FASB ASC Topic 323, </span><span style="font-style:italic;">Investments - Equity Method and Joint Ventures</span><span style="font-family:inherit;font-size:10pt;">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. Lastly, we have notes receivable from certain companies that we account for in accordance with </span><span>FASB ASC Topic 320</span><span style="font-style:italic;">, Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for additional details on our investment balances.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. If the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value if accounted for under measurement alternative. For our equity method investments, an impairment loss is recorded if we determine the impairment is other-than-temporary. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. For other-than-temporary impairments, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. Impairment losses on our investments are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net </span><span style="font-family:inherit;font-size:10pt;">in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASC Update No. 2018-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement - Reporting Comprehensive Income </span><span style="font-family:inherit;font-size:10pt;">(Topic 220):</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.</span><span style="font-family:inherit;font-size:10pt;"> The purpose of Update No. 2018-02 is to allow an entity to reclassify the income tax effects of the Tax Cut and Jobs Act of 2017 (TCJA) on items within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax (AOCI)</span><span style="font-family:inherit;font-size:10pt;"> to retained earnings. Update No. 2018-02 is effective for all entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We adopted Update No. 2018-02 in the first quarter of 2019 and have not elected to reclassify the income tax effects of the TCJA from AOCI to retained earnings.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASC Update No. 2016-16,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> (Topic 740): </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</span><span style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$55 million</span></span><span style="font-family:inherit;font-size:10pt;"> for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income tax expense (benefit)</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the TCJA, we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and will be reported as a part of continuing operations. See </span><span style="font-style:italic;">Note I – Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal and Product Liability Costs </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the normal course of business, we are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue our best estimate of the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation-related charges (credits)</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">; all other legal and product liability charges, credits and costs are recorded within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">. See </span><span style="font-style:italic;">Note J – Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;"> for discussion of our individual material legal proceedings.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs Associated with Exit Activities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record employee termination costs in accordance with </span><span>FASB ASC Topic 712</span><span style="font-style:italic;">,</span><span> </span><span style="font-style:italic;">Compensation - Nonretirement and Postemployment Benefits</span><span style="font-family:inherit;font-size:10pt;">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with </span><span>FASB</span><span style="font-style:italic;"> </span><span>ASC Topic 420</span><span style="font-style:italic;">,</span><span> </span><span style="font-style:italic;">Exit or Disposal Cost Obligation</span><span>s</span><span style="font-family:inherit;font-size:10pt;">. We record such costs into expense over the employee’s future service period, if any. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 420</span><span style="font-family:inherit;font-size:10pt;"> and are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring charges (credits)</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities and are included within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Costs of products sold</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Impairment of right of use lease assets and lease terminations directly related to our active restructuring initiatives are expensed in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> and included within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Costs of products sold</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. See </span><span style="font-style:italic;">Note G – Restructuring-related Activities</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for further information and discussion of our restructuring plans.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Translation of Foreign Currency</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate and translate revenues and expenses at the average exchange rates in effect during the year. We show the net effect of these translation adjustments in our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">. For any significant foreign subsidiaries located in highly inflationary economies, we would re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency transaction gains and losses are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net </span><span style="font-family:inherit;font-size:10pt;">in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">, net of losses and gains from any related derivative financial instruments. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize all derivative financial instruments in our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> at fair value in accordance with </span><span>FASB ASC Topic 815</span><span style="font-style:italic;">, Derivatives and Hedging</span><span style="font-family:inherit;font-size:10pt;">, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;">, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="font-style:italic;">Note D – Hedging Activities and Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> for more information on our hedging instruments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shipping and Handling Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generally do not bill customers for shipping and handling of our products. We treat shipping and handling costs incurred after a customer obtains control of the good as a fulfillment cost and record in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses </span><span style="font-family:inherit;font-size:10pt;">in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Shipping and handling costs were </span><span style="font-family:inherit;font-size:10pt;"><span>$144 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$124 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$110 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expense research and development costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Indefinite-lived Intangibles,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">including</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In-Process Research and Development</span><span style="font-family:inherit;font-size:10pt;"> above for our policy regarding IPR&amp;D acquired in connection with our business combinations and asset purchases.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Income (Loss) per Common Share</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We base </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net income (loss) per common share</span><span style="font-family:inherit;font-size:10pt;"> upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options and stock awards whose effect would be anti-dilutive from the calculation.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> include the accounts of Boston Scientific Corporation and our wholly-owned subsidiaries, after the elimination of intercompany transactions. When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">For any VIEs, we perform an analysis to determine whether our variable interests give us a controlling financial interest in a VIE. The analysis identifies the primary beneficiary of a VIE as the enterprise that has both 1) the power to direct activities of a VIE that most significantly impact the entity’s economic performance and 2) the obligation to absorb losses of the entity or the right to receive benefits from the entity. Based on our assessments under the applicable guidance, we did not have controlling financial interests in any VIEs and, therefore, did not consolidate any VIEs for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-K and Regulation S-X.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reportable Segments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. </span><span style="font-family:inherit;font-size:10pt;">Following our acquisition of BTG plc (BTG), which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subsequent Events</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We evaluate events occurring after the date of our accompanying consolidated balance sheets for potential recognition or disclosure in our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. We did not identify any material subsequent events requiring adjustment to our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> (recognized subsequent events). Those items requiring disclosure (unrecognized subsequent events) in the </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> have been disclosed accordingly. Refer to </span><span style="font-style:italic;">Note E – Contractual Obligations and Commitments</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-style:italic;">Note J – Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for further details.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To prepare our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> in accordance with U.S. GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> and the reported amounts of our revenues and expenses during the reporting period. Our actual results may differ from these estimates. Refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Critical Accounting Estimates</span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:inherit;font-size:10pt;"> of this Annual Report for further discussion.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> at cost, which approximates fair value. Our policy is to invest excess cash in short-term marketable securities earning a market rate of interest without assuming undue risk of loss of principal amounts invested and we limit our direct exposure to securities in any one industry or issuer. We consider to be cash equivalents all short-term marketable securities with remaining days to maturity of 90 days or less from the purchase date that can be readily converted to cash.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts included in restricted cash represent cash on hand required to be set aside by a contractual agreement related to receivable factoring arrangements and deferred compensation plans and are included in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets </span><span style="font-family:inherit;font-size:10pt;">caption on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Generally, the restrictions related to the factoring arrangements lapse at the time we remit the customer payments collected by us as servicer of previously sold customer receivables to the purchaser. Restrictions for deferred compensation lapse when amounts are paid to the employee. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash Equivalents</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash equivalents primarily represent amounts paid into various qualified settlement funds related to our ongoing transvaginal surgical mesh litigation and current amounts related to our non-qualified pension plan and are included in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets </span><span style="font-family:inherit;font-size:10pt;">caption on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. The restrictions related to the various qualified settlement funds will lapse as we approve amounts payable to claimants, at which time we no longer have rights to a return of the amounts paid into the various qualified settlement funds. Restricted cash equivalents included in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets </span><span style="font-family:inherit;font-size:10pt;">caption on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> are related to deferred compensation plans. </span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, derivative financial instruments and accounts and notes receivable. Our investment policy limits exposure to concentrations of credit risk and changes in market conditions. Counterparties to financial instruments expose us to credit-related losses in the event of nonperformance. We transact our financial instruments with a diversified group of major financial institutions with investment grade credit ratings and actively monitor their credit ratings and our outstanding positions to limit our credit exposure. In the normal course, our payment terms with customers, including hospitals, healthcare agencies, clinics, doctors' offices and other private and governmental institutions, are typically 30 days in the U.S. but may be longer in international markets and generally do not require collateral. We record our accounts receivable in our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> at net realizable value. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses, based on historical information and management's best estimates. We write-off amounts determined to be uncollectible against this reserve. Write-offs of uncollectible accounts receivable were immaterial in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. We are not dependent on any single institution, and no single customer accounted for more than ten percent of our net sales in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">; however, large group purchasing organizations, hospital networks, international distributors and dealers and other buying groups have become increasingly important to our business and represent a substantial portion of our net sales.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We closely monitor outstanding receivables for potential collection risks, including those that may arise from economic conditions, in both the U.S. and international economies. Our European sales to government-owned or supported customers in Southern Europe are subject to an increased number of days outstanding prior to payment relative to other countries. Historically, receivable balances with certain publicly-owned hospitals in these countries accumulated over a period of time and are then subsequently settled as large lump sum payments, sometimes at large discounts. While we believe our allowance for doubtful accounts in these countries is adequate as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, if significant changes were to occur in the payment practices of these European governments or if government funding becomes unavailable, we may not be able to collect on receivables due to us from these customers, and our write-offs of uncollectible accounts receivable may increase. </span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued </span><span>FASB ASC Topic 606, </span><span style="font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">(Topic 606), which was subsequently updated. We adopted the standard as of January 1, 2018, using the modified retrospective method. Under this method, we applied </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> to contracts that were not complete as of January 1, 2018 and recognized the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. Results for reporting periods beginning after January 1, 2018 are presented in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;">. Prior period amounts are not adjusted and are reported in accordance with legacy GAAP requirements in </span><span>FASB ASC Topic 605, </span><span style="font-style:italic;">Revenue Recognition</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to the adoption of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;">, we recorded a net reduction to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$177 million</span></span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2018, primarily related to the cost of providing non-contractual post-implant support to certain customers, which we historically deemed immaterial in the context of the arrangement. Upon the adoption of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;">, when we sell a device with an implied non-contractual post-implant support obligation, we forward accrue the cost of the service within</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Selling, general and administrative expenses </span><span style="font-family:inherit;font-size:10pt;">and recognize it at the point in time the associated revenue is earned. We release the accrual over the related service period. These costs were previously expensed as incurred due to such service obligation being non-contractual. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> resulted in </span><span style="font-family:inherit;font-size:10pt;">an increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$59 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">an increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$205 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2018, as a result of accruing for our post-implant support obligation. We also recorded deferred tax assets primarily related to post-implant support, resulting in </span><span style="font-family:inherit;font-size:10pt;">an increase</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets </span><span style="font-family:inherit;font-size:10pt;">of </span><span style="font-family:inherit;font-size:10pt;"><span>$12 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">a reduction</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred income taxes</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$41 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2018. The remaining impact of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> was not material to our financial position or results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We sell our products primarily through a direct sales force. In certain international markets, we sell our products through independent distributors or dealers. We consider revenue to be earned when all of the following criteria are met:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a contract with a customer that creates enforceable rights and obligations,</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Promised products or services are identified,</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price, or the amount we expect to receive, is determinable and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have transferred control of the promised items to the customer.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional services. We treat shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and record these costs as a selling expense when incurred. We recognize revenue from consignment arrangements based on product usage, or implant, which indicates that the sale is complete. We recognize a receivable at the point in time we have an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment is received or due in advance of our performance. When we sell a device with a future service obligation, we defer revenue on the unfulfilled performance obligation and recognize this revenue over the related service period. Many of our Cardiac Rhythm Management product offerings combine the sale of a device with our LATITUDE™ Patient Management System, which represents a future service obligation. Generally, we do not have observable evidence of the standalone selling price related to our future service obligations; therefore, we estimate the selling price using an expected cost plus a margin approach. We allocate the transaction price using the relative standalone selling price method. The use of alternative estimates could result in a different amount of revenue deferral.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities are classified within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> on our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Consideration</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit. We base our estimate for sales returns upon historical trends and record the amount as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to sales returns and could cause actual returns to differ from these estimates.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. We estimate rebates for products where there is sufficient historical information available to predict the volume of expected future rebates. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Capitalized Contract Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We capitalize commission fees related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE Remote Monitoring Service. These fulfillment costs are amortized over the average service period. Our total capitalized contract costs are immaterial to our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Post-Implant Services</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We provide non-contractual services to customers to ensure the safe and effective use of certain implanted devices. Following our modified retrospective adoption of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2018, because the revenue related to the immaterial services is recognized before they are delivered, we forward accrue the costs to provide these services at the time the devices are sold. We record these costs to</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">. We estimate the amount of time spent by our representatives performing these services and their compensation throughout the device life to determine the service cost. Changes to our business practice or the use of alternative estimates could result in a different amount of accrued cost.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 177000000 59000000 205000000 12000000 -41000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warranty Obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our Cardiac Rhythm Management business, which include implantable defibrillator and pacemaker systems. Our Cardiac Rhythm Management products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We assess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We state inventories at the lower of first-in, first-out cost or net realizable value. We base our provisions for excess, expired and obsolete inventory primarily on our estimates of forecasted net sales. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional provisions for excess, expired and obsolete inventory in the future. Further, the industry in which we participate is characterized by rapid product development and frequent new product introductions. Uncertain timing of next-generation product approvals, variability in product launch strategies, product recalls and variation in product utilization all affect our estimates related to excess, expired and obsolete inventory. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>32 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of our finished goods inventory as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>40 percent</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was at customer locations pursuant to consignment arrangements or held by sales representatives.</span></div> 0.32 0.40 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Plant and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We state property, plant, equipment and leasehold improvements at historical cost. We charge expenditures for maintenance and repairs to expense and capitalize additions and improvements that extend the life of the underlying asset. We provide for depreciation using the straight-line method at rates that approximate the estimated useful lives of the assets. We depreciate buildings over a maximum life of </span><span style="font-family:inherit;font-size:10pt;">40</span><span style="font-family:inherit;font-size:10pt;"> years; building improvements over the remaining useful life of the building structure; equipment, furniture and fixtures over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> year life; and leasehold improvements over the shorter of the useful life of the improvement or the term of the related lease.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASC Update No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (</span><span>FASB ASC Topic 842, </span><span style="font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">). We adopted the standard as of January 1, 2019, using the modified retrospective approach and the transition method provided by ASC Update No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">. Under this method, we applied the new leasing rules on the date of adoption and recognized the cumulative effect of initially applying the standard as an adjustment to our January 1, 2019 opening balance sheet, rather than at the earliest comparative period presented in the financial statements. Prior periods presented are in accordance with the previous lease guidance under </span><span>FASB ASC Topic 840, </span><span style="font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 840</span><span style="font-family:inherit;font-size:10pt;">). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we applied the package of practical expedients permitted under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> transition guidance to our entire lease portfolio at January 1, 2019. As a result, we were not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases and (iii) the treatment of initial direct costs for any existing leases. Furthermore, we elected not to separate lease and non-lease components for the majority of our leases. Instead, for all applicable classes of underlying assets, we accounted for each separate lease component and the non-lease components associated with that lease component, as a single lease component.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2019, we recognized right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$271 million</span></span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$278 million</span></span><span style="font-family:inherit;font-size:10pt;"> for our existing operating lease portfolio on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheet</span><span style="font-family:inherit;font-size:10pt;">. Operating lease right-of-use assets are presented within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities are presented within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Finance leases are immaterial to our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note E – Contractual Obligations and Commitments</span><span style="font-family:inherit;font-size:10pt;"> for additional information. There was no material impact to our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of cash flows</span><span style="font-family:inherit;font-size:10pt;"> as a result of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">. Please refer to </span><span style="font-style:italic;">Note F – Leases</span><span style="font-family:inherit;font-size:10pt;"> for information regarding our lease portfolio as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> as accounted for under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To meet the reporting and disclosure requirements of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">, we implemented a new lease administration and lease accounting system in 2018 that tracks all of our material leasing arrangements. In addition, we designed and implemented new processes and internal controls during the first quarter of 2019 to ensure the completeness and accuracy of the transition adjustment and subsequent financial reporting under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">. We have also established monitoring controls to ensure we have appropriate mechanisms in place to identify material leases in a timely manner, particularly contracts that may contain embedded lease features.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 271000000 278000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Valuation of Business Combinations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocate the amounts we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the date of acquisition, including identifiable intangible assets and in-process research and development (IPR&amp;D), which either arise from a contractual or legal right or are separable from goodwill. We base the fair value of identifiable intangible assets acquired in a business combination, including IPR&amp;D, on detailed valuations that use information and assumptions provided by management, which consider management’s best estimates of inputs and assumptions that a market participant would use. We allocate to goodwill any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Transaction costs associated with these acquisitions are expensed as incurred through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In those circumstances where an acquisition involves a contingent consideration arrangement, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent consideration expense (benefit)</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving regulatory, revenue or commercialization-based milestones.</span><span style="font-family:inherit;font-size:10pt;"> Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones after the acquisition date, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indefinite-lived Intangibles, including IPR&amp;D</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our indefinite-lived intangible assets, which are not subject to amortization, include acquired balloon and other technology, which is foundational to our ongoing operations within the Cardiovascular market and other markets within interventional medicine and IPR&amp;D intangible assets acquired in a business combination. Our IPR&amp;D represents intangible assets that are used in research and development activities but have not yet reached technological feasibility, regardless of whether they have alternative future use. The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region. We classify IPR&amp;D as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. Upon completion of the associated research and development efforts, we will determine the useful life of the technology and begin amortizing the assets to reflect their use over their remaining lives. Upon permanent abandonment, we write-off the remaining carrying amount of the associated IPR&amp;D intangible asset. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We test our indefinite-lived intangible assets at least annually during the third quarter for impairment and reassess their classification as indefinite-lived assets. In addition, we review our indefinite-lived intangible assets for classification and impairment more frequently if impairment indicators exist. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with </span><span>FASB ASC Topic 350, </span><span style="font-style:italic;">Intangibles - Goodwill and Other</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">If the carrying value exceeds the fair value of the indefinite-lived intangible asset, we write the carrying value down to the fair value.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use the income approach to determine the fair values of our IPR&amp;D. We base our revenue assumptions on estimates of relevant market sizes, expected market growth rates, expected trends in technology and expected levels of market share. In arriving at the value of the in-process projects, we consider, among other factors, the in-process projects’ stage of completion, the complexity of the work completed as of the acquisition date, the costs already incurred, the projected costs to complete, the contribution of other acquired assets, the expected regulatory path and introduction dates by region and the estimated useful life of the technology. See </span><span style="font-style:italic;">Note C – Goodwill and Other Intangible Assets</span><span style="font-family:inherit;font-size:10pt;"> for more information related to indefinite-lived intangibles, including IPR&amp;D.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For asset purchases outside of business combinations, we expense any purchased research and development assets as of the acquisition date. </span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Amortization and Impairment of Intangible Assets</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record definite-lived intangible assets at historical cost and amortize them over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows: patents and licenses, </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">20</span><span style="font-family:inherit;font-size:10pt;"> years; amortizable technology-related and customer relationships, </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">25</span><span style="font-family:inherit;font-size:10pt;"> years; other intangible assets, various.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Conditions that may indicate impairment include, but are not limited to, a significant adverse change in legal factors or business climate that could affect the value of an asset, a product recall or an adverse action or assessment by a regulator. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. For purposes of the recoverability test, we group our amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We calculate fair value of our intangible assets as the present value of estimated future cash flows we expect to generate from the asset. In determining our estimated future cash flows associated with our intangible assets, we use estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset or asset group. See </span><span style="font-style:italic;">Note C – Goodwill and Other Intangible Assets</span><span style="font-family:inherit;font-size:10pt;"> for more information related to impairments of intangible assets.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For patents developed internally, we capitalize costs incurred to obtain patents, including attorney fees, registration fees, consulting fees and other expenditures directly related to securing the patent. </span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill Valuation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination to goodwill. We test our goodwill balances during the second quarter of each year for impairment or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> annual impairment assessment, we identified the following reporting units: Interventional Cardiology, Peripheral Interventions (including the Interventional Medicine business acquired with BTG), Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health and Neuromodulation. In addition, following the BTG acquisition in the third quarter of 2019, we added Specialty Pharmaceuticals as an additional reporting unit. We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based on the criteria prescribed in </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 350</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In performing the goodwill impairment assessments for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we utilized both the optional qualitative assessment and the quantitative approach prescribed under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 350</span><span style="font-family:inherit;font-size:10pt;">. The qualitative assessment was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent. All other reporting units were tested using the quantitative approach described below. The qualitative assessment requires an evaluation of whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount based on an assessment of relevant events including macroeconomic factors, industry and market conditions, cost factors, overall financial performance and other entity-specific factors. After assessing the totality of events, if it is determined that it is more likely than not that the fair value of the reporting unit exceeds its carrying value, no further steps are required. If it is determined that impairment is more likely than not, then we perform the quantitative impairment test. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When allocating goodwill from business combinations to our reporting units, we assign goodwill to the reporting units that we expect to benefit from the respective business combination at the time of acquisition. In addition, for purposes of performing our goodwill impairment tests, assets and liabilities, including corporate assets, which relate to a reporting unit’s operations, and would be considered in determining its fair value, are allocated to the individual reporting units. We allocate assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> annual impairment assessments, for those reporting units for which a quantitative test was performed, we used only the income approach, specifically the Discounted Cash Flow method, to derive the fair value of each of our reporting units in preparing our goodwill impairment assessments. We selected this method as being the most meaningful in preparing our goodwill assessments because we believe the income approach most appropriately measures our income producing assets. We have considered using the market approach and cost approach but concluded they are not appropriate in valuing our reporting units given the lack of relevant market comparisons available for application of the market approach and the inability to replicate the value of the specific technology-based assets within our reporting units for application of the cost approach. Therefore, we believe that the income approach represents the most appropriate valuation technique for which sufficient data are available to determine the fair value of our reporting units. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In applying the income approach to our accounting for goodwill, we make assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within our Discounted Cash Flow analysis is based on our most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate reflects our best estimates for stable, perpetual growth of our reporting units. We use estimates of market-participant risk-adjusted weighted average cost of capital as a basis for determining the discount rates to apply to our reporting units’ future expected cash flows. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note C – Goodwill and Other Intangible Assets</span><span style="font-family:inherit;font-size:10pt;"> to our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> for additional details related to our goodwill balances.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments in Publicly Traded and Privately Held Entities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASC Update No. 2016-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Overall </span><span style="font-family:inherit;font-size:10pt;">(Subtopic 825-10)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Recognition and Measurement of Financial Assets and Financial Liabilities. </span><span style="font-family:inherit;font-size:10pt;">The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;">. We adopted Update No. 2016-01 in the first quarter of 2018, using both the modified retrospective and prospective methods. For publicly-held securities, we used the modified retrospective approach. Unrealized gains and losses previously recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> were reclassified to retained earnings,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">and all future fair value changes will be recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net income (loss)</span><span style="font-family:inherit;font-size:10pt;">. For privately-held securities of investee companies over which we do not have the ability to exercise significant influence, we elected the measurement alternative approach for our existing investments, which is applied prospectively upon adoption. This approach requires entities to measure their investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The adoption of the standard did not have a material impact on our financial position or results of operations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2017, we accounted for our publicly traded investments as available-for-sale securities based on the quoted market price at the end of the reporting period. Unrealized holding gains or losses during the period, net of tax, were recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">. We computed realized gains and losses on sales of available-for-sale securities at fair value, adjusted for any other-than-temporary declines in fair value. We accounted for investments in privately-held entities in which we had less than a 20 percent ownership interest under the cost method of accounting if we did not have the ability to exercise significant influence over the investee in accordance with </span><span>FASB ASC Topic 325</span><span style="font-style:italic;">,</span><span> </span><span style="font-style:italic;">Investments - Other</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We account for investments in entities over which we have the ability to exercise significant influence under the equity method if we hold 50 percent or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary in accordance with </span><span>FASB ASC Topic 323, </span><span style="font-style:italic;">Investments - Equity Method and Joint Ventures</span><span style="font-family:inherit;font-size:10pt;">. We record these investments initially at cost and adjust the carrying amount to reflect our share of the earnings or losses of the investee, including all adjustments similar to those made in preparing </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. Lastly, we have notes receivable from certain companies that we account for in accordance with </span><span>FASB ASC Topic 320</span><span style="font-style:italic;">, Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for additional details on our investment balances.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each reporting period, we evaluate our investments to determine if there are any events or circumstances that are likely to have a significant adverse effect on the fair value of the investment. Examples of such impairment indicators include, but are not limited to, a significant deterioration in earnings performance, recent financing rounds at reduced valuations, a significant adverse change in the regulatory, economic or technological environment of an investee or a significant doubt about an investee’s ability to continue as a going concern. If we identify an impairment indicator, we will estimate the fair value of the investment and compare it to its carrying value. Our estimation of fair value considers financial information related to the investee available to us, including valuations based on recent third-party equity investments in the investee. If the fair value of the investment is less than its carrying value, the investment is impaired and we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value if accounted for under measurement alternative. For our equity method investments, an impairment loss is recorded if we determine the impairment is other-than-temporary. We deem an impairment to be other-than-temporary unless available evidence indicates that the valuation is more likely than not to recover up to the carrying value of the investment in a reasonable period of time, and we have both the ability and intent to hold the investment for at least the period of time needed to recover the value. For other-than-temporary impairments, we recognize an impairment loss equal to the difference between an investment’s carrying value and its fair value. Impairment losses on our investments are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net </span><span style="font-family:inherit;font-size:10pt;">in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASC Update No. 2018-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement - Reporting Comprehensive Income </span><span style="font-family:inherit;font-size:10pt;">(Topic 220):</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.</span><span style="font-family:inherit;font-size:10pt;"> The purpose of Update No. 2018-02 is to allow an entity to reclassify the income tax effects of the Tax Cut and Jobs Act of 2017 (TCJA) on items within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax (AOCI)</span><span style="font-family:inherit;font-size:10pt;"> to retained earnings. Update No. 2018-02 is effective for all entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods. We adopted Update No. 2018-02 in the first quarter of 2019 and have not elected to reclassify the income tax effects of the TCJA from AOCI to retained earnings.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2016, the FASB issued ASC Update No. 2016-16,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> (Topic 740): </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intra-Entity Transfers of Assets Other Than Inventory</span><span style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 was effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. We adopted Update No. 2016-16 prospectively in the first quarter of 2018 and recognized a net reduction to retained earnings of </span><span style="font-family:inherit;font-size:10pt;"><span>$55 million</span></span><span style="font-family:inherit;font-size:10pt;"> for income tax consequences not previously recognized for intra-entity transfers of assets other than inventories. All future income tax consequences of intra-entity transfers of assets other than inventories will be recognized through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income tax expense (benefit)</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">We utilize the asset and liability method of accounting for income taxes. Under this method, we determine deferred tax assets and liabilities based on differences between the financial reporting and tax bases of our assets and liabilities. We measure deferred tax assets and liabilities using the enacted tax rates and laws that will be in effect when we expect the differences to reverse. We reduce our deferred tax assets by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will not realize some portion or all of the deferred tax assets. We consider relevant evidence, both positive and negative, to determine the need for a valuation allowance. Information evaluated includes our financial position and results of operations for the current and preceding years, the availability of deferred tax liabilities and tax carrybacks, as well as estimates of the impact of future taxable income and available prudent and feasible tax-planning strategies. We recognize interest and penalties related to income taxes as a component of income tax expense. As part of the TCJA, we are subject to a territorial tax system in which we are required to establish an accounting policy in providing for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a period cost and will be reported as a part of continuing operations. See </span><span style="font-style:italic;">Note I – Income Taxes</span> for further information and discussion of our income tax provision and balances including a discussion of the impacts of the TCJA 55000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal and Product Liability Costs </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the normal course of business, we are involved in various legal and regulatory proceedings, including intellectual property, breach of contract, securities litigation and product liability suits. In some cases, the claimants seek damages, as well as other relief, which, if granted, could require significant expenditures or impact our ability to sell our products. We are also the subject of certain governmental investigations, which could result in substantial fines, penalties and administrative remedies. We maintain an insurance policy providing limited coverage against securities claims, and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. We accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue our best estimate of the minimum amount of the range. We analyze litigation settlements to identify each element of the arrangement. We allocate arrangement consideration to patent licenses received based on estimates of fair value and capitalize these amounts as assets if the license will provide an ongoing future benefit. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation-related charges (credits)</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">; all other legal and product liability charges, credits and costs are recorded within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">. See </span><span style="font-style:italic;">Note J – Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;"> for discussion of our individual material legal proceedings.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with </span><span>FASB ASC Topic 450, </span><span style="font-style:italic;">Contingencies</span><span style="font-family:inherit;font-size:10pt;">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs Associated with Exit Activities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record employee termination costs in accordance with </span><span>FASB ASC Topic 712</span><span style="font-style:italic;">,</span><span> </span><span style="font-style:italic;">Compensation - Nonretirement and Postemployment Benefits</span><span style="font-family:inherit;font-size:10pt;">, if we pay the benefits as part of an ongoing benefit arrangement, which includes benefits provided as part of our established severance policies or that we provide in accordance with international statutory requirements. We accrue employee termination costs associated with an ongoing benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and we can reasonably estimate the liability. We account for involuntary employee termination benefits that represent a one-time benefit in accordance with </span><span>FASB</span><span style="font-style:italic;"> </span><span>ASC Topic 420</span><span style="font-style:italic;">,</span><span> </span><span style="font-style:italic;">Exit or Disposal Cost Obligation</span><span>s</span><span style="font-family:inherit;font-size:10pt;">. We record such costs into expense over the employee’s future service period, if any. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other costs associated with exit activities may include contract termination costs and consulting fees, which are expensed in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 420</span><span style="font-family:inherit;font-size:10pt;"> and are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring charges (credits)</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Additionally, costs directly related to our active restructuring initiatives, including program management costs, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities and are included within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Costs of products sold</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Impairment of right of use lease assets and lease terminations directly related to our active restructuring initiatives are expensed in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> and included within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Costs of products sold</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. See </span><span style="font-style:italic;">Note G – Restructuring-related Activities</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for further information and discussion of our restructuring plans.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Translation of Foreign Currency</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We translate all assets and liabilities of foreign subsidiaries from the functional currency, which is generally the local currency, into U.S. dollars using the year-end exchange rate and translate revenues and expenses at the average exchange rates in effect during the year. We show the net effect of these translation adjustments in our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">. For any significant foreign subsidiaries located in highly inflationary economies, we would re-measure their financial statements as if the functional currency were the U.S. dollar. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency transaction gains and losses are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net </span><span style="font-family:inherit;font-size:10pt;">in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">, net of losses and gains from any related derivative financial instruments. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize all derivative financial instruments in our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> at fair value in accordance with </span><span>FASB ASC Topic 815</span><span style="font-style:italic;">, Derivatives and Hedging</span><span style="font-family:inherit;font-size:10pt;">, and we present assets and liabilities associated with our derivative financial instruments on a gross basis in our financial statements. In accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;">, for those derivative instruments that are designated and qualify as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The accounting for changes in the fair value of a derivative instrument depends on whether it qualifies for, and has been designated as part of a hedging relationship, as well as on the type of hedging relationship. Our derivative instruments do not subject our earnings to material risk, as gains and losses on these derivatives generally offset gains and losses on the item being hedged, and we do not enter into derivative transactions for speculative purposes. Refer to </span><span style="font-style:italic;">Note D – Hedging Activities and Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> for more information on our hedging instruments.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shipping and Handling Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">We generally do not bill customers for shipping and handling of our products. We treat shipping and handling costs incurred after a customer obtains control of the good as a fulfillment cost and record in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses </span><span style="font-family:inherit;font-size:10pt;">in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Shipping and handling costs were </span><span style="font-family:inherit;font-size:10pt;"><span>$144 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$124 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$110 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span> 144000000 124000000 110000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expense research and development costs, including new product development programs, regulatory compliance and clinical research as incurred. Refer to</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Indefinite-lived Intangibles,</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">including</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">In-Process Research and Development</span><span style="font-family:inherit;font-size:10pt;"> above for our policy regarding IPR&amp;D acquired in connection with our business combinations and asset purchases.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Income (Loss) per Common Share</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We base </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net income (loss) per common share</span><span style="font-family:inherit;font-size:10pt;"> upon the weighted-average number of common shares and common stock equivalents outstanding during each year. Potential common stock equivalents are determined using the treasury stock method. We exclude stock options and stock awards whose effect would be anti-dilutive from the calculation.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-weight:bold;">NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS<br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> include the operating results for acquired entities from the respective dates of acquisition. With the exception of the acquisition of BTG, which was completed on August 19, 2019, we have not presented supplemental pro forma financial information for acquisitions given their results are not material to our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. Transaction costs for all acquisitions in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were immaterial to our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> and were expensed as incurred. In </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> of purchase price adjustments, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$95 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to BTG.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2019 Acquisitions</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">BTG plc</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 19, 2019, we announced the closing of our acquisition of BTG, a public company organized under the laws of England and Wales. BTG had three key portfolios, the largest of which is its interventional medicine portfolio (Interventional Medicine) that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. Following the closing of the acquisition, we began to integrate BTG's Interventional Medicine business into our Peripheral Interventions division. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the Interventional Medicine product lines, the BTG portfolio also included a specialty pharmaceutical business (Specialty Pharmaceuticals) comprised of acute care antidotes to treat overexposure to certain medications and toxins and a licensing portfolio (Licensing arrangements) that generates net royalties related to BTG intellectual property and product license agreements. In connection with the acquisition, we acquired rights to future royalties associated with the Zytiga™ drug used to treat certain forms of prostate cancer. In the fourth quarter of 2019, we sold our rights to these royalties for </span><span style="font-family:inherit;font-size:10pt;"><span>$256 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, included in </span><span style="font-size:10pt;font-style:italic;">Proceeds from royalty rights transfer</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note D – Hedging Activities and Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> for additional information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price consisted of upfront cash in the aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>£3.312 billion</span></span><span style="font-family:inherit;font-size:10pt;"> (or </span><span style="font-family:inherit;font-size:10pt;"><span>$4.023 billion</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate at closing on August 19, 2019) for the entire issued ordinary share capital of BTG, whereby BTG stockholders received </span><span style="font-family:inherit;font-size:10pt;"><span>840 pence</span></span><span style="font-family:inherit;font-size:10pt;"> (or </span><span style="font-family:inherit;font-size:10pt;"><span>$10.20</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate at closing) in cash for each BTG share. The transaction price included </span><span style="font-family:inherit;font-size:10pt;"><span>$404 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents acquired. We implemented our acquisition of BTG by way of a court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Price Allocation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accounted for our acquisition of BTG as a business combination, and in accordance with </span><span>FASB ASC Topic 805</span><span style="font-style:italic;">, Business Combinations</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">), we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed from the acquisition. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the valuation studies necessary to determine the fair market value of the assets acquired and liabilities assumed are preliminary, including the projection of the underlying cash flows used to determine the fair value of the identified tangible, intangible and financial assets and liabilities. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accounted for BTG as a business combination, and in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary purchase price of BTG, was comprised of the following components as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment for acquisition, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the preliminary purchase price allocation for our acquisition of BTG as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,785</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(308</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(274</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of our acquisition of BTG, we recognized goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.644 billion</span></span><span style="font-family:inherit;font-size:10pt;">, which is attributable to the synergies expected to arise from the acquisition and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have allocated </span><span style="font-family:inherit;font-size:10pt;"><span>$1.406 billion</span></span><span style="font-family:inherit;font-size:10pt;"> to our Peripheral Interventions reporting unit and </span><span style="font-family:inherit;font-size:10pt;"><span>$238 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Specialty Pharmaceuticals reporting unit. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the preliminary purchase price for our acquisition of BTG to specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,785</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Pro Forma Financial Information (unaudited)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BTG contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$226 million</span></span><span style="font-family:inherit;font-size:10pt;"> to our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net sales</span><span style="font-family:inherit;font-size:10pt;"> and had an immaterial impact to our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net income (loss)</span><span style="font-family:inherit;font-size:10pt;"> for the period post acquisition through </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited estimated pro forma results presented below include the effects of our acquisition of BTG as if it was consummated on January 1, 2018. In 2019, we incurred nonrecurring charges that we attributed to our acquisition of BTG, which are presented in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> for this period. These charges include acquisition-related costs, stock-based compensation expenses as a result of the change in control and retention bonuses and severance payments, adjusted for the related tax effects. We have reflected these nonrecurring charges as adjustments to the pro forma earnings presented below for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, these pro forma amounts have been calculated after applying our accounting policies and adjusting the results of BTG to reflect the additional costs associated with fair value adjustments relating to inventories, property, plant, and equipment, and intangible assets as if the acquisition had occurred on January 1, 2018, with the consequential tax effects. Additionally, the pro forma amounts have been adjusted to reflect the amortization of deferred financing costs and interest expense associated with additional financing entered into as part of the acquisition. The pro forma results exclude BTG’s historical licensing revenue and related cost of sales, as these arrangements are accounted for as part of the acquisition as a financial asset and liability and are not accounted for within the scope of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The supplemental pro forma information presented below is for informational purposes only and should be read in conjunction with our historical financial statements. The pro forma results do not include any anticipated synergies or other expected benefits of the acquisition. Accordingly, the unaudited estimated pro forma financial information below is not necessarily indicative of what the actual results of operations of the combined companies would have been had the acquisition of BTG occurred as of January 1, 2018, nor are they indicative of future results of operations. We believe that the pro forma assumptions and adjustments are reasonable and appropriate under the circumstances and are factually supported based on information currently available.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except per share data) (Unaudited)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per common share — basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per common share — assuming dilution</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction with Varian Medical Systems, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 21, 2019, we completed the sale of our drug-eluting and bland embolic microsphere portfolio to Varian Medical Systems, Inc. (Varian) in connection with our acquisition of BTG. The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;">, a portion of which is allocated to the fair value of the services to be rendered under the Transition Services Agreement and Transition Manufacturing Agreement entered into with Varian as part of this transaction. Additionally, we transferred certain contingent consideration arrangements arising from our initial acquisition of the portfolio to Varian and agreed to indemnify Varian for any payments ultimately arising under the terms of the contingent consideration arrangement. Accordingly, as part of the disposal, we recorded a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:10pt;"> to recognize the fair value of this guarantee based on our potential obligation resulting from the indemnifications. The maximum amount payable under this guarantee is </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accordance with </span><span>FASB ASC Topic 460, </span><span style="font-style:italic;">Guarantees</span><span style="font-family:inherit;font-size:10pt;">, which is consistent with the contingent consideration arrangement executed with our initial acquisition of the portfolio in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Vertiflex, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 11, 2019, we announced the closing of our acquisition of Vertiflex, Inc. (Vertiflex), a privately-held company which has developed and commercialized the Superion™ Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$465 million</span></span><span style="font-family:inherit;font-size:10pt;"> and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. We estimate the sales-based contingent payments to be in a range of </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;">; however, the payments are uncapped over the three year earn-out period. Following the closing of the acquisition, we have integrated the Vertiflex business into our Neuromodulation division.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Millipede, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 29, 2019, we announced the closing of our acquisition of Millipede, Inc. (Millipede)</span><span style="font-family:inherit;font-size:10pt;">, a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. We had previously been an investor in Millipede since the first quarter of 2018 as part of an investment and acquisition option agreement, whereby we purchased a portion of the outstanding shares of Millipede, along with newly issued shares of the company, for an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;">. In the fourth quarter of 2018, upon the successful completion of a first-in-human clinical study, we exercised our option to acquire the remaining shares of Millipede. We held an interest of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>20 percent</span></span><span style="font-family:inherit;font-size:10pt;"> immediately prior to the acquisition date. We remeasured the fair value of our previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. </span><span style="font-family:inherit;font-size:10pt;">The transaction price for the remaining stake consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$325 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> of future payments upon achievement of a commercial milestone. Following the closing of the acquisition, we have integrated the Millipede business into our Interventional Cardiology division.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Price Allocation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accounted for our 2019 acquisitions of Vertiflex and Millipede as business combinations, and in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of prior interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preliminary purchase price allocations of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, to the specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>461</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2018 Acquisitions</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Augmenix, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 16, 2018, we announced the closing of our acquisition of Augmenix, Inc. (Augmenix), a privately-held company that developed and commercialized the SpaceOAR™ Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer. The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$500 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments contingent upon achieving certain revenue-based milestones. Following the closing of the acquisition, we have integrated the Augmenix business into our Urology and Pelvic Health division.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Claret Medical, Inc.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 2, 2018, we announced the closing of our acquisition of Claret Medical, Inc. (Claret), a privately-held company that has developed and commercialized the Sentinel™ Cerebral Embolic Protection System. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter aortic valve replacement (TAVR). The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$220 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> payment for achieving a reimbursement-based milestone that was achieved in the third quarter of 2018. Following the closing of the acquisition, we have integrated the Claret business into our Interventional Cardiology division.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Cryterion Medical, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 5, 2018, we announced the closing of our acquisition of Cryterion Medical, Inc. (Cryterion), a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation. We had been an investor in Cryterion since 2016 and held an interest of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>35 percent</span></span><span style="font-family:inherit;font-size:10pt;"> immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$202 million</span></span><span style="font-family:inherit;font-size:10pt;">. Following the closing of the acquisition, we have integrated the Cryterion business into our Electrophysiology division.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">NxThera, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company that developed the Rezūm™ System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). We held a minority interest immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$240 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$85 million</span></span><span style="font-family:inherit;font-size:10pt;"> in future potential payments contingent upon achieving commercial milestones over the four years following the date of acquisition. Following the closing of the acquisition, we have integrated the NxThera business into our Urology and Pelvic Health division.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">nVision Medical Corporation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> in future potential payments contingent upon achieving certain clinical and commercial milestones over the four years following the date of acquisition. Following the closing of the acquisition, we have integrated the nVision business into our Urology and Pelvic Health division.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Other Acquisitions</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we completed other individually immaterial acquisitions in 2018 for total consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$158 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash at closing plus aggregate future potential contingent consideration of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$184 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2018 within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> based on the difference between the book values and the fair values of our previously-held investments immediately prior to the acquisition dates. The aggregate fair value of our previously-held investments immediately prior to the acquisition dates was </span><span style="font-family:inherit;font-size:10pt;"><span>$251 million</span></span><span style="font-family:inherit;font-size:10pt;">. We remeasured the fair value of each previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Price Allocation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accounted for these acquisitions as business combinations, and in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,449</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of prior interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the purchase price allocations for our 2018 acquisitions as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>939</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>939</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the purchase prices to specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 Acquisitions</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Apama Medical Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 11, 2017, we announced the closing of our acquisition of Apama Medical Inc. (Apama), a privately-held company developing the Apama™ Radiofrequency single-shot Balloon Catheter System for the treatment of atrial fibrillation. The transaction price consisted of an upfront cash payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$175 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> in future potential payments contingent upon achieving certain clinical and regulatory milestones. Following the closing of the acquisition, we have integrated the Apama business into our Electrophysiology division.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Symetis SA</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 16, 2017, we announced the closing of our acquisition of Symetis SA (Symetis), a privately-held Swiss structural heart company focused on minimally-invasive TAVR devices, having developed the ACURATE </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">neo</span><span style="font-family:inherit;font-size:10pt;">™</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Aortic Valve. The transaction price consisted of an upfront cash payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$430 million</span></span><span style="font-family:inherit;font-size:10pt;">. Following the closing of the acquisition, we have integrated the Symetis business into our Interventional Cardiology division.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Price Allocation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accounted for these acquisitions as business combinations and, in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices were as follows for our 2017 acquisitions:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the aggregate purchase price allocations for our 2017 acquisitions:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(102</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the purchase prices to specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>464</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations as well as revenue and cash flow projections associated with future technologies and has been allocated to our reportable segments based on the relative expected benefit. Based on preliminary estimates updated for applicable regulatory changes, the goodwill recorded relating to our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> acquisitions is not deductible for tax purposes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contingent Consideration</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of our contingent consideration liability were as follows:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded related to current year acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase price adjustments related to prior year acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded related to current year acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration arrangements transferred to Varian</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was </span><span style="font-family:inherit;font-size:10pt;"><span>$697 million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes our estimate of maximum contingent payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the Vertiflex acquisition described above. The maximum decreased </span><span style="font-family:inherit;font-size:10pt;"><span>$176 million</span></span><span style="font-family:inherit;font-size:10pt;"> compared to the amount as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> due to the contingent consideration arrangement which is now accounted for as a guarantee in connection with our transaction with Varian as discussed in the BTG section above. In addition, the aggregated maximum decreased as a result of the expiration or full payment of certain contingent consideration arrangements in 2019, partially offset by the Millipede and Vertiflex arrangements entered into in 2019.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:21%;"/><td style="width:17%;"/><td style="width:10%;"/><td style="width:24%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average (1)</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">R&amp;D, Regulatory and Commercialization-based Milestones</span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$198 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue-based Payments</span></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$156 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of Payment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2026</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected contingent payment amounts related to some of our R&amp;D, commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Strategic Investments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Measurement alternative investments</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Publicly-held securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>458</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Publicly-held equity securities are measured at fair value with changes in fair value recognized currently in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other, net</span><span style="font-family:inherit;font-size:9pt;"> on our accompanying </span><span style="font-family:inherit;font-size:9pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:9pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These investments are classified as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span><span style="font-family:inherit;font-size:10pt;"> within our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, in accordance with U.S. GAAP and our accounting policies.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by </span><span style="font-family:inherit;font-size:10pt;"><span>$314 million</span></span><span style="font-family:inherit;font-size:10pt;">, which represents amortizable intangible assets, IPR&amp;D, goodwill and deferred tax liabilities.</span></div> 125000000 95000000 256000000 3312000000 4023000000.000 8.40 10.20 404000000 The preliminary purchase price of BTG, was comprised of the following components as of <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment for acquisition, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3619000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the preliminary purchase price allocation for our acquisition of BTG as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,785</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(308</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(274</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1644000000 108000000 232000000 252000000 1785000000 537000000 308000000 -274000000 358000000 3619000000 1644000000 1406000000 238000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the preliminary purchase price for our acquisition of BTG to specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,709</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,785</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1709000000 P10Y P18Y 0.11 0.12 75000000 P2Y P11Y 0.11 1785000000 226000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except per share data) (Unaudited)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,244</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per common share — basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per common share — assuming dilution</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11142000000 10429000000 4585000000 1244000000 3.30 0.90 3.25 0.89 90000000 16000000 200000000 465000000 0 100000000 90000000 0.20 325000000 125000000 The preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of prior interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 763000000 127000000 102000000 992000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preliminary purchase price allocations of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 575000000 220000000 240000000 24000000 12000000 56000000 992000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, to the specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>461</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 210000000 P12Y 0.15 10000000 P12Y 0.15 240000000 0.19 461000000 500000000 100000000 220000000 50000000 0.35 202000000 240000000 85000000 150000000 125000000 158000000 62000000 184000000 251000000 The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of <span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,449</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of prior interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1449000000 248000000 251000000 1948000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the purchase price allocations for our 2018 acquisitions as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>939</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>939</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 939000000 939000000 213000000 38000000 19000000 162000000 1948000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the purchase prices to specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 908000000 P6Y P14Y 0.14 0.23 31000000 P6Y P13Y 0.13 0.15 213000000 0.15 1153000000 175000000 125000000 430000000 The components of the aggregate purchase prices were as follows for our 2017 acquisitions:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 560000000 72000000 632000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the aggregate purchase price allocations for our 2017 acquisitions:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(102</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 287000000 278000000 186000000 44000000 61000000 102000000 632000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the purchase prices to specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>464</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 268000000 P13Y 0.24 10000000 P2Y P13Y 0.24 186000000 0.15 464000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of our contingent consideration liability were as follows:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded related to current year acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase price adjustments related to prior year acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded related to current year acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration arrangements transferred to Varian</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 169000000 248000000 -22000000 -21000000 28000000 347000000 127000000 -16000000 -35000000 68000000 354000000 697000000 100000000 176000000 <div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:21%;"/><td style="width:17%;"/><td style="width:10%;"/><td style="width:24%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average (1)</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">R&amp;D, Regulatory and Commercialization-based Milestones</span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$198 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue-based Payments</span></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$156 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of Payment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2026</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 198000000 0.02 0.03 0.03 0.40 0.90 0.82 156000000 0.11 0.15 0.13 0.60 1 0.99 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate carrying amount of our strategic investments was comprised of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Measurement alternative investments</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Publicly-held securities</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>458</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Publicly-held equity securities are measured at fair value with changes in fair value recognized currently in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Other, net</span><span style="font-family:inherit;font-size:9pt;"> on our accompanying </span><span style="font-family:inherit;font-size:9pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:9pt;">.</span></div> 264000000 303000000 171000000 94000000 1000000 0 23000000 26000000 458000000 424000000 314000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization/Write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization/Write-offs</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,020</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,706</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,266</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(393</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,081</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(958</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(7,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(6,617</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,076</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development (IPR&amp;D)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>20,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>18,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the third quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we performed our annual impairment test of all IPR&amp;D projects and our indefinite-lived core technology assets and determined that the assets were not impaired. In addition, we verified the classification as indefinite-lived assets continues to be appropriate.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset impairment charges were </span><span style="font-family:inherit;font-size:10pt;"><span>$105 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$35 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note A - Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> for a discussion of key assumptions used in our goodwill and intangible asset impairment testing. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we reclassified our Neuromodulation operating segment and associated goodwill balance from our MedSurg reportable segment to our Rhythm and Neuro reportable segment. This change did not impact our total goodwill carrying value. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. </span><span style="font-family:inherit;font-size:10pt;">Following our acquisition of BTG, which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents our goodwill balance by global reportable segment and our separately reported Specialty Pharmaceuticals operating segment:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rhythm and Neuro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiovascular</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Specialty Pharmaceuticals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>417</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>6,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reportable segment revisions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,379</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency fluctuations and other changes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,924</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency fluctuations and other changes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,218</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill divested</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,061</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5,676</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>247</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not have any goodwill impairments in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization expense</span><span style="font-family:inherit;font-size:10pt;"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>722</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization/Write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization/Write-offs</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,020</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,706</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,266</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(393</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,081</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(958</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(7,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(6,617</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,076</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development (IPR&amp;D)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>20,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>18,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 12020000000 5706000000 10197000000 5266000000 525000000 408000000 520000000 393000000 1754000000 1081000000 1666000000 958000000 14299000000 7195000000 12383000000 6617000000 20076000000 9900000000 17811000000 9900000000 662000000 486000000 120000000 0 120000000 0 20858000000 9900000000 18417000000 9900000000 105000000 35000000 4000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents our goodwill balance by global reportable segment and our separately reported Specialty Pharmaceuticals operating segment:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rhythm and Neuro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiovascular</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Specialty Pharmaceuticals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,877</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>417</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,704</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>6,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reportable segment revisions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,379</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,379</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency fluctuations and other changes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,063</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,924</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency fluctuations and other changes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,218</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill divested</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,061</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5,676</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>247</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2877000000 417000000 3704000000 0 6998000000 -1379000000 1379000000 -3000000 -22000000 -3000000 0 -29000000 568000000 150000000 224000000 0 942000000 2063000000 1924000000 3925000000 0 7911000000 -1000000 0 58000000 9000000 66000000 0 268000000 1712000000 238000000 2218000000 -19000000 0 19000000 2061000000 2192000000 5676000000 247000000 10176000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Estimated </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Amortization expense</span><span style="font-family:inherit;font-size:10pt;"> for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>722</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 787000000 750000000 722000000 708000000 672000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Currency Hedging Instruments</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Management Strategy</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions, net investments in certain subsidiaries and the purchase price of any acquisition that is denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative and nonderivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in Euro, Japanese yen, Chinese renminbi and British pound sterling. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hedge Designations and Relationships</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our currency derivative instruments are designated as cash flow hedges under </span><span>FASB ASC Topic 815</span><span style="font-style:italic;">, Derivatives and Hedging</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;">), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net change in derivative financial instruments</span><span style="font-family:inherit;font-size:10pt;"> component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss), net of tax (OCI)</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of products sold</span><span style="font-family:inherit;font-size:10pt;"> caption of our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to earnings at that time.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro, Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. We elected to use the spot method to assess effectiveness for our derivatives that are designated as net investment hedges. Under the spot method, the change in fair value attributable to changes in the spot rate is recorded in the</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Foreign currency translation adjustment (CTA)</span><span style="font-family:inherit;font-size:10pt;"> component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">. We have elected to exclude the spot-forward difference from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. Amortization of the spot-forward difference is then reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to current period earnings as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. In November 2019, we terminated and settled all of our outstanding forward currency contracts designated as net investment hedges in our entities with Euro-denominated functional currencies and recognized a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$95 million</span></span><span style="font-family:inherit;font-size:10pt;"> presented in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">CTA</span><span style="font-family:inherit;font-size:10pt;"> component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI </span><span style="font-family:inherit;font-size:10pt;">on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also completed an offering of </span><span style="font-family:inherit;font-size:10pt;"><span>€900 million</span></span><span style="font-family:inherit;font-size:10pt;"> (approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;">)</span><span style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>0.625%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due in 2027.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">The Euro-denominated debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional entities.</span><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the notional value of our outstanding net investment hedges was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.950 billion</span></span><span style="font-family:inherit;font-size:10pt;">, which includes our derivative and nonderivative instruments designated as net investment hedges.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also use forward currency contracts that are not part of designated hedging relationships under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net</span><span style="font-family:inherit;font-size:10pt;"> caption of our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the GBP-denominated purchase price of BTG.</span><span style="font-family:inherit;font-size:10pt;"> In 2019, we settled all outstanding contracts</span><span style="font-family:inherit;font-size:10pt;">, resulting in a cumulative loss on the contracts of </span><span style="font-family:inherit;font-size:10pt;"><span>$294 million</span></span><span style="font-family:inherit;font-size:10pt;"> that was recognized over time in earnings as we adjusted for changes in fair value until the final fair value was determined at maturity.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">As of December 31, 2018, the notional value of the contracts was </span><span style="font-family:inherit;font-size:10pt;"><span>$2.550 billion</span></span><span style="font-family:inherit;font-size:10pt;">, and we entered into additional contracts in 2019.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">Upon settlement in 2019, we received </span><span style="font-family:inherit;font-size:10pt;"><span>£3.312 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash to fund our acquisition of BTG, which translated into </span><span style="font-family:inherit;font-size:10pt;"><span>$4.303 billion</span></span><span style="font-family:inherit;font-size:10pt;"> based on hedged currency exchange rates. </span><span style="font-family:inherit;font-size:10pt;">We recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$323 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in 2019 and a </span><span style="font-family:inherit;font-size:10pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:10pt;"> gain in 2018</span><span> within </span><span style="font-style:italic;">Other, net</span><span style="font-family:inherit;font-size:10pt;"> due to changes in fair value of the contracts.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interest Rate Hedging Instruments</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Management Strategy</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to mitigate the risk to our earnings and cash flows associated with exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Hedge Designations and Relationships</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had no interest rate derivative instruments designated as cash flow hedges outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, which were intended to manage our earnings and cash flow exposure to changes in the benchmark interest rate in connection with the forecasted issuance of fixed-rate debt. For outstanding designated cash flow hedges, we record the changes in the fair value of the derivatives within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> until the underlying hedged transaction occurs, at which time we recognize the gain or loss within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> over the same period that the hedged items affect earnings, so long as the hedge relationship remains effective. If we determine the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the amount of gains or losses from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to earnings at that time.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2018, we entered into interest rate derivative contracts designated as cash flow hedges having a notional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> to hedge interest rate risk. In the first quarter of 2019, we terminated these instruments in connection with our senior notes issuance in the same period as discussed in </span><span style="font-style:italic;">Note E – Contractual Obligations and Commitments</span><span style="font-family:inherit;font-size:10pt;">. We recognized an immaterial loss within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and are reclassifying the amortization of the loss from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> into earnings as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> over the same period that the hedged item affects earnings, so long as the hedge relationship remains effective. We are also continuing to reclassify in a similar manner the amortization of the gains or losses of our other previously terminated interest rate derivative instruments that were designated as cash flow hedges. The balance of the deferred amounts on our terminated cash flow hedges within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> was a </span><span style="font-family:inherit;font-size:10pt;"><span>$34 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>$7 million</span></span><span style="font-family:inherit;font-size:10pt;"> gain </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. We recognized immaterial gains and losses in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> relating to the amortization of our terminated cash flow hedges in the current and prior periods.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had no interest rate derivative instruments designated as fair value hedges outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Prior to 2018, we terminated interest rate derivative instruments that were designated as fair value hedges and are continuing to recognize the amortization of the gains or losses originally recorded within the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span><span style="font-family:inherit;font-size:10pt;"> caption on our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> into earnings as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> over the same period that the discount or premium associated with the hedged items affects earnings. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;">, which generally offset. The balance of the deferred gains on our terminated fair value hedges within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span><span style="font-family:inherit;font-size:10pt;"> was immaterial as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. We recognized immaterial gains in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> relating to the amortization of the terminated fair value hedges in the current and prior periods. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the contractual amounts of our hedging instruments outstanding:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency-denominated debt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>997</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-designated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Notional Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The </span><span style="font-family:inherit;font-size:9pt;"><span>€900 million</span></span><span style="font-family:inherit;font-size:9pt;"> (approximately </span><span style="font-family:inherit;font-size:9pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:9pt;">) debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional subsidiaries.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The remaining time to maturity as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is within </span><span style="font-family:inherit;font-size:10pt;">60</span><span style="font-family:inherit;font-size:10pt;"> months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts. The Euro-denominated debt principal designated as a net investment hedge has a contractual maturity of December 1, 2027.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> on our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note P – Changes in Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;"> for the total amounts relating to derivative and nonderivative instruments presented within the </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:12%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="24" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Recognized in OCI on Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Reclassified from AOCI into Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Tax Gain (Loss)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax Benefit (Expense)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain (Loss) Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Amount Reclassified</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Amount of Line Item Presented</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Tax (Gain) Loss</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax (Benefit) Expense</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Gain) Loss Net of Tax</span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign currency-denominated debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:9pt;"> to earnings represent the effect of the hedging relationships on earnings. All other amounts included in earnings related to hedging relationships were immaterial.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:9pt;"> to earnings as a reduction of </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:9pt;">. In the current period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> that may be reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Designated Hedging Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency hedge contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency transaction exposures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net currency exchange gain (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(358</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the GBP-denominated purchase price of BTG.</span><span style="font-family:inherit;font-size:10pt;"> In 2019, we settled all outstanding contracts</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">We recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$323 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in 2019 and a </span><span style="font-family:inherit;font-size:10pt;"><span>$29 million</span></span><span style="font-family:inherit;font-size:10pt;"> gain in 2018</span><span style="font-family:inherit;font-size:10pt;"> within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net gain (loss) on currency hedge contracts</span><span style="font-family:inherit;font-size:10pt;"> due to changes in fair value of the contracts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by </span><span>FASB ASC Topic 820, </span><span style="font-style:italic;">Fair Value Measurements and Disclosures</span><span style="font-family:inherit;font-size:10pt;">, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Consolidated Balance Sheets </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative and Nonderivative Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Hedging Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Hedging Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative and Nonderivative Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative and Nonderivative Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Hedging Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency-denominated debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Hedging Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative and Nonderivative Liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Recurring Fair Value Measurements</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 820</span><span style="font-family:inherit;font-size:10pt;"> establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market and government funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Publicly-held securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedging instruments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>890</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>571</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>571</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>925</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,963</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span><span style="font-family:inherit;font-size:10pt;"> within our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, in accordance with U.S. GAAP and our accounting policies. In addition to </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> invested in money market and government funds as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$165 million</span></span><span style="font-family:inherit;font-size:10pt;"> in interest bearing and non-interest-bearing bank accounts. In addition to </span><span style="font-family:inherit;font-size:10pt;"><span>$13 million</span></span><span style="font-family:inherit;font-size:10pt;"> invested in money market and government funds as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$133 million</span></span><span style="font-family:inherit;font-size:10pt;"> in interest bearing and non-interest bearing bank accounts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our recurring fair value measurements using Level 3 inputs relates to our contingent consideration liability. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for a discussion of the changes in the fair value of our contingent consideration liability.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our recurring fair value measurements using Level 3 inputs relate to our licensing arrangements. In connection with our acquisition of BTG, we acquired intellectual property and related licensing arrangements, principally relating to Zytiga™, as a result of our acquisition of BTG that provides the contractual right to receive future royalty payments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2019, we entered into a royalty purchase agreement with the Ontario Municipal Employees Retirement System (OMERS), whereby we sold to OMERS our remaining </span><span style="font-family:inherit;font-size:10pt;">50 percent</span><span style="font-family:inherit;font-size:10pt;"> of the future Zytiga™ royalty stream. The purchase price for these royalty interests consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$256 million</span></span><span style="font-family:inherit;font-size:10pt;">. Prior to our acquisition of BTG, BTG agreed to pay </span><span style="font-family:inherit;font-size:10pt;">50 percent</span><span style="font-family:inherit;font-size:10pt;"> of the Zytiga™ royalty stream, net of certain offsets, to the inventors associated with the intellectual property. As such, we do not expect to receive any future cash benefit from Zytiga™ royalties subsequent to our transaction with OMERS. In accordance with </span><span>FASB ASC Topic 860, </span><span style="font-style:italic;">Transfers and Servicing</span><span style="font-family:inherit;font-size:10pt;">, we are accounting for the transfer as a secured borrowing and continue to recognize the financial asset and financial liability in our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have elected the fair value option to account for the licensing arrangements' financial asset and financial liability in accordance with </span><span>FASB ASC Topic 825, </span><span style="font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">. </span><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have recorded the fair values of the financial asset and financial liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our preliminary purchase price allocation of BTG as of the acquisition date, the amount recognized for the financial asset was </span><span style="font-family:inherit;font-size:10pt;"><span>$567 million</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate, comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$195 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$373 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span><span style="font-family:inherit;font-size:10pt;">. The amount recognized for the financial liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$370 million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$54 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts payable</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$104 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in O</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ther current liabilities </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;"><span>$212 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">. The amounts above were valued using the fair value option with the exception of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts payable</span><span style="font-family:inherit;font-size:10pt;">, which was settled in the third quarter. During the fourth quarter, we also recorded the </span><span style="font-family:inherit;font-size:10pt;"><span>$256 million</span></span><span style="font-family:inherit;font-size:10pt;"> proceeds received from the sale of the Zytiga royalty stream as an increase in the fair value of the financial liability now accounted for as a secured borrowing, as discussed above. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for further information on the preliminary purchase price allocation of BTG.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> include the following significant unobservable inputs:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:20%;"/><td style="width:18%;"/><td style="width:10%;"/><td style="width:23%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensing Arrangements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average (1)</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Asset</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$518 million</span></span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2028</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Liability</span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$571 million</span></span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td colspan="4" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements' financial asset and liability as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. However, increases or decreases in the financial asset would be substantially offset by increases or decreases in the financial liability, as such our earnings are not subject to material gains or losses from the licensing arrangement.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of our licensing arrangements' financial asset was as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded related to current year acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from royalty rights</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value adjustment (expense) benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of our licensing arrangements' financial liability was as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded related to current year acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from secured borrowings relating to royalty arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Recurring Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for a discussion of our strategic investments. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note C – Goodwill and Other Intangible Assets</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for a discussion of the fair values.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of our outstanding debt obligations as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$11.020 billion</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$1.004 billion</span></span><span style="font-family:inherit;font-size:10pt;"> relates to the Euro-denominated </span><span style="font-family:inherit;font-size:10pt;">December 2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, and as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$7.239 billion</span></span><span style="font-family:inherit;font-size:10pt;">. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, and face value for commercial paper, term loans and credit facility borrowings outstanding. Refer to </span><span style="font-style:italic;">Note E – Contractual Obligations and Commitments</span><span style="font-family:inherit;font-size:10pt;"> for a discussion of our debt obligations.</span></div> 95000000 900000000 1000000000.000 0.00625 1950000000 294000000 2550000000 3312000000 4303000000 -323000000 29000000 1000000000.000 1000000000.000 34000000 7000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the contractual amounts of our hedging instruments outstanding:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,891</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency-denominated debt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>997</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-designated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,377</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,880</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Notional Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The </span><span style="font-family:inherit;font-size:9pt;"><span>€900 million</span></span><span style="font-family:inherit;font-size:9pt;"> (approximately </span><span style="font-family:inherit;font-size:9pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:9pt;">) debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional subsidiaries.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3891000000 3962000000 953000000 1483000000 997000000 0 4377000000 5880000000 0 1000000000 10218000000 12326000000 900000000 1000000000.000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the effect of our derivative and nonderivative instruments designated as cash flow and net investment hedges under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> on our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note P – Changes in Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;"> for the total amounts relating to derivative and nonderivative instruments presented within the </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:12%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="24" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Recognized in OCI on Hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Reclassified from AOCI into Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Tax Gain (Loss)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax Benefit (Expense)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain (Loss) Net of Tax</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Amount Reclassified</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Amount of Line Item Presented</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Tax (Gain) Loss</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax (Benefit) Expense</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Gain) Loss Net of Tax</span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign currency-denominated debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:9pt;"> to earnings represent the effect of the hedging relationships on earnings. All other amounts included in earnings related to hedging relationships were immaterial.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For our outstanding forward currency contracts designated as net investment hedges, the net gain or loss reclassified from </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:9pt;"> to earnings as a reduction of </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:9pt;">. In the current period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in earnings.</span></div> 150000000 -34000000 117000000 3116000000 -73000000 16000000 -56000000 68000000 -15000000 53000000 473000000 -43000000 10000000 33000000 -14000000 3000000 -11000000 473000000 0 0 0 473000000 -3000000 -1000000 2000000 167000000 -38000000 130000000 2813000000 19000000 -4000000 15000000 -56000000 13000000 -43000000 241000000 27000000 6000000 -21000000 -44000000 10000000 -34000000 241000000 -1000000 0 -1000000 -101000000 37000000 -65000000 2593000000 -64000000 23000000 -41000000 0 0 0 229000000 1000000 0 -1000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> that may be reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Designated Hedging Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 77000000 24000000 -5000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency hedge contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency transaction exposures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net currency exchange gain (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(358</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -343000000 41000000 -25000000 -15000000 -30000000 10000000 -358000000 11000000 -15000000 -323000000 29000000 <span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> requires all derivative and nonderivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative and nonderivative instruments using the framework prescribed by </span><span>FASB ASC Topic 820, </span><span style="font-style:italic;">Fair Value Measurements and Disclosures</span>, and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date with respect to current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative and nonderivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Consolidated Balance Sheets </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative and Nonderivative Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Hedging Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Hedging Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative and Nonderivative Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative and Nonderivative Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Hedging Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency-denominated debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>998</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Hedging Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative and Nonderivative Liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.</span></div> 72000000 55000000 216000000 183000000 288000000 237000000 33000000 67000000 321000000 304000000 3000000 2000000 8000000 3000000 998000000 0 0 44000000 1009000000 49000000 29000000 31000000 1037000000 80000000 50000000 0 0 50000000 13000000 0 0 13000000 1000000 0 0 1000000 0 0 0 0 0 321000000 0 321000000 0 304000000 0 304000000 518000000 518000000 51000000 321000000 518000000 890000000 14000000 304000000 0 318000000 0 1037000000 0 1037000000 0 80000000 0 80000000 0 0 354000000 354000000 0 0 347000000 347000000 571000000 571000000 0 1037000000 925000000 1963000000 0 80000000 347000000 427000000 50000000 165000000 13000000 133000000 256000000 567000000 195000000 373000000 370000000 54000000 104000000 212000000 256000000 518000000 0.11 0.19 0.19 571000000 0.19 0.19 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of our licensing arrangements' financial asset was as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded related to current year acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>567</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from royalty rights</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value adjustment (expense) benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of our licensing arrangements' financial liability was as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recorded related to current year acquisition</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from secured borrowings relating to royalty arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our licensing arrangements recognized in our </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> include the following significant unobservable inputs:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:20%;"/><td style="width:18%;"/><td style="width:10%;"/><td style="width:23%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensing Arrangements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average (1)</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Asset</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$518 million</span></span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2028</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Liability</span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$571 million</span></span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td colspan="4" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market and government funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Publicly-held securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedging instruments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>890</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hedging instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>571</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>571</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>925</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,963</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 567000000 52000000 3000000 518000000 0 315000000 256000000 571000000 11020000000.000 1004000000.000 7239000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-weight:bold;">NOTE E – CONTRACTUAL OBLIGATIONS AND COMMITMENTS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Borrowings and Credit Arrangements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had total debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.008 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.056 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The debt maturity schedule for our long-term debt obligations is presented below: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuance Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stated Interest Rate</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except interest rates)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2020 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2009</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2020 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.850%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2022 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.375%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2022 Term Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2023 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2013</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.125%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2024 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.450%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2025 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.850%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.750%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2027 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2027</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.625%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2028 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2029 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2029</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2035 Notes (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2005</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2035</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2039 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2039</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.550%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2040 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2009</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.375%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2049 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2049</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.700%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized Debt Issuance Discount<br/>and Deferred Financing Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2049</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized Gain on Fair Value Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020-2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance Lease Obligation (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>8,592</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Note:</span><span style="font-family:inherit;font-size:9pt;"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective January 1, 2019, we adopted </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:9pt;">, which requires that we recognize finance lease obligations in our </span><span style="font-family:inherit;font-size:9pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:9pt;">. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 840</span><span style="font-family:inherit;font-size:9pt;">. Please refer to </span><span style="font-size:9pt;font-style:italic;">Note A – Significant Accounting Policies</span><span style="font-family:inherit;font-size:9pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Credit Facility </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 19, 2018, we entered into a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.750 billion</span></span><span style="font-family:inherit;font-size:10pt;"> revolving credit facility (the 2018 Facility) with a global syndicate of commercial banks and terminated our previous </span><span style="font-family:inherit;font-size:10pt;"><span>$2.250 billion</span></span><span style="font-family:inherit;font-size:10pt;"> revolving credit facility (the 2017 Facility), which was scheduled to mature in August 2022. The 2018 Facility will mature on December 19, 2023 with one-year extension options subject to certain conditions. Eurodollar and multicurrency loans bear interest at the Eurocurrency Rate determined for the interest period plus the applicable margin, based on our corporate credit ratings (</span><span style="font-family:inherit;font-size:10pt;"><span>1.02 percent</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">). ABR loans bear interest at ABR plus the applicable margin of up to </span><span style="font-family:inherit;font-size:10pt;"><span>0.40 percent</span></span><span style="font-family:inherit;font-size:10pt;">, based on our corporate credit ratings. Under the credit agreement for the 2018 Facility (the 2018 Credit Agreement), we are required to pay a facility fee (</span><span style="font-family:inherit;font-size:10pt;"><span>0.11 percent</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">) based on our credit ratings and the total amount of revolving credit commitment, regardless of usage of the 2018 Facility. This facility provides backing for the commercial paper program described below. The 2018 Credit Agreement for the 2018 Facility requires that we comply with certain covenants, including financial covenants as described below. There were no amounts borrowed under our current or prior revolving credit facilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Term Loans </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 5, 2019, we entered into a </span><span style="font-family:inherit;font-size:10pt;"><span>$700 million</span></span><span style="font-family:inherit;font-size:10pt;"> term loan credit agreement scheduled to mature on December 3, 2020 (2020 Term Loan).</span><span style="font-family:inherit;font-size:10pt;"> The 2020 Term Loan bears interest at an annual rate of LIBOR plus a margin of </span><span style="font-family:inherit;font-size:10pt;"><span>0.65%</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, we pay customary expenses. The credit agreement contains covenants, as described below, and also contains customary events of default, which may result in the acceleration of any outstanding commitments. </span><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$700 million</span></span><span> outstanding under the 2020 Term Loan, which is presented within</span><span style="font-style:italic;"> Current debt obligations</span><span> on our consolidated balance sheet.</span><span style="font-family:inherit;font-size:10pt;"> We used the proceeds from the 2020 Term Loan to repay a portion of the Two-Year Delayed Draw Term Loan, described below. In January 2020, we repaid </span><span style="font-family:inherit;font-size:10pt;"><span>$300 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding balance of the 2020 Term Loan with proceeds from our commercial paper program.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.300 billion</span></span><span style="font-family:inherit;font-size:10pt;"> described below, we terminated the </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> Term Loan Credit Agreement, entered into on August 20, 2018 and amended on December 19, 2018 (August 2019 Term Loan). The August 2019 Term Loan was scheduled to mature on August 19, 2019. As of December 31, 2018, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding under our August 2019 Term Loan, which is presented within</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Current debt obligations</span><span style="font-family:inherit;font-size:10pt;"> on our consolidated balance sheet.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 19, 2018, we entered into a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> senior unsecured delayed-draw term loan facility consisting of a </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> two-year delayed draw term loan credit facility maturing in two years from the date of the closing of our acquisition of BTG (Two-Year Delayed Draw Term Loan) and a </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> three-year delayed draw term loan credit facility maturing in three years from the date of the closing of our acquisition of BTG (Three-Year Delayed Draw Term Loan). In 2019, we used the proceeds from the Two-Year and Three-Year Delayed Draw Term Loan facilities to refinance the Bridge Facility, as described below, and fund a portion of our acquisition of BTG. On November 27, 2019, we repaid </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Two-Year Delayed Draw Term Loan with proceeds from the sale of the Zytiga-related royalty interests obtained through the acquisition of BTG and extinguished the facility. On December 5, 2019, we repaid the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$800 million</span></span><span style="font-family:inherit;font-size:10pt;"> with proceeds from the 2020 Term Loan and commercial paper and terminated the Two-Year Delayed Draw Term Loan.</span><span style="font-family:inherit;font-size:10pt;"> Borrowings of the Three-Year Delayed Draw Term Loan are available in U.S. dollars and bear interest at LIBOR or a base rate in each case plus an applicable margin based on our public debt ratings (</span><span style="font-family:inherit;font-size:10pt;"><span>1.13 percent</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">). The facility contains customary events of default, which may result in the acceleration of any outstanding commitments. </span><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had no amounts borrowed under the Two-Year Delayed Draw Term Loan or the Three-Year Delayed Draw Term Loan.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding under the Three-Year Delayed Draw Term Loan</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt Covenants</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of and through </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we were in compliance with all the required covenants related to our debt obligations.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All existing credit arrangements described above require that we maintain certain financial covenants, as follows: </span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:29%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:35%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Covenant</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Requirement as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actual as of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum leverage ratio (1)</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.75 times</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.83 times</span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1) Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our covenants require that we maintain a maximum leverage ratio of </span><span style="font-family:inherit;font-size:10pt;"><span>3.75 times</span></span><span style="font-family:inherit;font-size:10pt;">, provided, however, that for the two consecutive fiscal quarters ended immediately following the consummation of a Qualified Acquisition, as defined by each agreement, the maximum leverage ratio shall be </span><span style="font-family:inherit;font-size:10pt;"><span>4.75 times</span></span><span style="font-family:inherit;font-size:10pt;">, and then subject to a step-down for each succeeding fiscal quarter end to </span><span style="font-family:inherit;font-size:10pt;"><span>4.50 times</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>4.25 times</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>4.00 times</span></span><span style="font-family:inherit;font-size:10pt;"> and then back to </span><span style="font-family:inherit;font-size:10pt;"><span>3.75 times</span></span><span style="font-family:inherit;font-size:10pt;"> for each fiscal quarter end thereafter. On August 19, 2019, we announced the closing of our acquisition of BTG, a Qualified Acquisition, and our maximum leverage ratio was </span><span style="font-family:inherit;font-size:10pt;"><span>4.75 times</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for more information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our covenants provide for an exclusion from the calculation of consolidated EBITDA, as defined by the agreements, through maturity, of any non-cash charges and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$500 million</span></span><span style="font-family:inherit;font-size:10pt;"> in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$270 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments does not exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$2.624 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$1.199 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of the litigation exclusion remaining.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable</span><span style="font-family:inherit;font-size:10pt;color:#4f81bd;">.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-style:italic;">Commercial Paper</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial paper program is backed by the 2018 Facility, as discussed above. Outstanding commercial paper directly reduces borrowing capacity under the 2018 Facility.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except maturity and yield)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>711</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum borrowing capacity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Borrowing capacity available</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,502</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average maturity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55 days</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27 days</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average yield</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Senior Notes </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had senior notes outstanding of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.661 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.800 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2019, we completed an offering of </span><span style="font-family:inherit;font-size:10pt;"><span>€900 million</span></span><span style="font-family:inherit;font-size:10pt;"> (approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;">)</span><span style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>0.625%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due in 2027.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">The Euro-denominated debt principal is a nonderivative instrument designated as a net investment hedge of our net investments in certain of our Euro functional entities.</span><span style="font-family:inherit;font-size:10pt;"> Refer to </span><span style="font-style:italic;">Note D – Hedging Activities and Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> for additional information. </span><span style="font-family:inherit;font-size:10pt;">We used a portion of the net proceeds from our November 2019 senior notes offering to repay certain outstanding principal amounts of our senior notes including </span><span style="font-family:inherit;font-size:10pt;"><span>$206 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our </span><span style="font-family:inherit;font-size:10pt;"><span>$450 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>4.125%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due 2023, </span><span style="font-family:inherit;font-size:10pt;"><span>$566 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due 2028 and </span><span style="font-family:inherit;font-size:10pt;"><span>$227 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>3.850%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due 2025 and pay accrued and unpaid interest, premiums, fees and expenses in connection with the transaction.</span><span style="font-family:inherit;font-size:10pt;"> In 2019, we incurred associated debt extinguishment charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$86 million</span></span><span> presented in </span><span style="font-style:italic;">Other, net</span><span> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we completed an offering of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.300 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of senior notes</span><span style="font-family:inherit;font-size:10pt;"> comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$850 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>3.450%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due March 2024, </span><span style="font-family:inherit;font-size:10pt;"><span>$850 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>3.750%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due March 2026, </span><span style="font-family:inherit;font-size:10pt;"><span>$850 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">senior notes due March 2029, </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>4.550%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due March 2039 and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>4.700%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due March 2049. </span><span style="font-family:inherit;font-size:10pt;">We used a portion of the net proceeds from the offering to repay the </span><span style="font-family:inherit;font-size:10pt;"><span>$850 million</span></span><span style="font-family:inherit;font-size:10pt;"> plus accrued interest and premium of our </span><span style="font-family:inherit;font-size:10pt;"><span>6.000%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due in January 2020</span><span style="font-family:inherit;font-size:10pt;">, the </span><span style="font-family:inherit;font-size:10pt;"><span>$600 million</span></span><span style="font-family:inherit;font-size:10pt;"> plus accrued interest and premium of our </span><span style="font-family:inherit;font-size:10pt;"><span>2.850%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due in May 2020</span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> plus accrued interest of our August 2019 Term Loan. In 2019, the remaining proceeds were used to finance a portion of our acquisition of BTG.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2018, we completed an offering of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes, due March 2028. We used a portion of the net proceeds from the offering to repay the </span><span style="font-family:inherit;font-size:10pt;"><span>$600 million</span></span><span style="font-family:inherit;font-size:10pt;"> plus accrued interest of our </span><span style="font-family:inherit;font-size:10pt;"><span>2.650%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due in October 2018, which were classified as short-term debt as of December 31, 2017. The remaining proceeds were used to repay a portion of our outstanding commercial paper.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Other Arrangements</span><span style="font-family:inherit;font-size:10pt;"> below). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;"><span>$7.311 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of senior notes issued in 2009, 2013, 2015, 2018 and 2019 contain a change-in-control provision, which provides that each holder of the senior notes may require us to repurchase all or a portion of the notes at a price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>101 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate repurchased principal, plus accrued and unpaid interest, if a rating event, as defined in the indenture, occurs as a result of a change-in-control, as defined in the indenture. Any other credit rating changes may impact our borrowing cost, but do not require us to repay any borrowings.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridge Facility </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.300 billion</span></span><span style="font-family:inherit;font-size:10pt;"> described above, we terminated the Bridge Facility entered into on November 20, 2018.</span><span style="font-family:inherit;font-size:10pt;"> The termination was pursuant to the terms of the Bridge Facility, which required full termination upon the refinancing of the January 2020 Notes and May 2020 Notes discussed above. There were no amounts borrowed under the Bridge Facility as of December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Arrangements </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accounts receivable factoring programs in certain European countries and with commercial banks in Japan which include promissory notes discounting programs. We account for our factoring programs as sales under </span><span>FASB ASC Topic 860, </span><span style="font-style:italic;">Transfers and Servicing</span><span style="font-family:inherit;font-size:10pt;">. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, net </span><span style="font-family:inherit;font-size:10pt;">in the accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, are aggregated by contract denominated currency below (in millions): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Factoring Arrangements</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br/>De-recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br/>De-recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Interest Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Euro denominated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Yen denominated</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">BTG Revolving Credit Facility</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After closing our acquisition of BTG, we terminated BTG's revolving credit facility with a borrowing capacity of </span><span style="font-family:inherit;font-size:10pt;"><span>£150 million</span></span><span style="font-family:inherit;font-size:10pt;"> (or approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$184 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate at termination on August 27, 2019), which contained an option to increase the facility by </span><span style="font-family:inherit;font-size:10pt;"><span>£150 million</span></span><span style="font-family:inherit;font-size:10pt;"> and was scheduled to expire in November 2020. The termination was effective on August 27, 2019, and there were no amounts outstanding at the time of close of the acquisition.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Contractual Obligations and Commitments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had outstanding letters of credit of </span><span style="font-family:inherit;font-size:10pt;"><span>$105 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$111 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, which consisted primarily of bank guarantees and collateral for workers' compensation insurance arrangements. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, none of the beneficiaries had drawn upon the letters of credit or guarantees, accordingly, we have not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum purchase obligations as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrecorded Purchase Obligations</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>366</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The amounts in the table above with respect to purchase obligations relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business.</span></div> 10008000000.000 7056000000.000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuance Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stated Interest Rate</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except interest rates)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2020 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2009</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2020 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.850%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2022 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.375%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2022 Term Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2023 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2013</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.125%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2024 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.450%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2025 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2025</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.850%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.750%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2027 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2027</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.625%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2028 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2029 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2029</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2035 Notes (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2005</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2035</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2039 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2039</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.550%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2040 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2009</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.375%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2049 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2049</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.700%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized Debt Issuance Discount<br/>and Deferred Financing Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2049</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized Gain on Fair Value Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020-2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance Lease Obligation (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>8,592</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Note:</span><span style="font-family:inherit;font-size:9pt;"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective January 1, 2019, we adopted </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:9pt;">, which requires that we recognize finance lease obligations in our </span><span style="font-family:inherit;font-size:9pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:9pt;">. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 840</span><span style="font-family:inherit;font-size:9pt;">. Please refer to </span><span style="font-size:9pt;font-style:italic;">Note A – Significant Accounting Policies</span><span style="font-family:inherit;font-size:9pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 850000000 0.06000 0 600000000 0.02850 500000000 500000000 0.03375 1000000000 0 244000000 450000000 0.04125 850000000 0 0.03450 523000000 750000000 0.03850 850000000 0 0.03750 1011000000 0 0.00625 434000000 1000000000 0.04000 850000000 0 0.04000 350000000 350000000 0.07000 750000000 0 0.04550 300000000 300000000 0.07375 1000000000 0 0.04700 -83000000 -29000000 7000000 26000000 6000000 6000000 8592000000 4803000000 2750000000 2250000000 0.0102 0.0040 0.0011 700000000 0.0065 700000000 300000000 4300000000 1000000000.000 1000000000.000 2000000000.000 1000000000.000 1000000000.000 200000000 800000000 0.0113 1000000000.000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All existing credit arrangements described above require that we maintain certain financial covenants, as follows: </span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:29%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:35%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Covenant</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Requirement as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actual as of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum leverage ratio (1)</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.75 times</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.83 times</span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1) Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters. </span></div> 4.75 3.83 3.75 4.75 4.50 4.25 4.00 3.75 4.75 500000000 270000000 2624000000 1199000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-style:italic;">Commercial Paper</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial paper program is backed by the 2018 Facility, as discussed above. Outstanding commercial paper directly reduces borrowing capacity under the 2018 Facility.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except maturity and yield)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>711</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum borrowing capacity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Borrowing capacity available</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,502</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average maturity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55 days</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27 days</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average yield</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 711000000 1248000000 2750000000 2750000000 2039000000 1502000000 P55D P27D 0.0221 0.0304 7661000000 4800000000 900000000 1000000000.000 0.00625 206000000 450000000 0.04125 566000000 1000000000.000 0.04000 227000000 750000000 0.03850 86000000 4300000000 850000000 0.03450 850000000 0.03750 850000000 0.04000 750000000 0.04550 1000000000.000 0.04700 850000000 0.06000 600000000 0.02850 1000000000.000 1000000000.000 0.04000 600000000 0.02650 7311000000 1.01 4300000000 Amounts de-recognized for accounts and notes receivable, which are excluded from <span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, net </span><span style="font-family:inherit;font-size:10pt;">in the accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, are aggregated by contract denominated currency below (in millions): </span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Factoring Arrangements</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br/>De-recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount<br/>De-recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Interest Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Euro denominated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Yen denominated</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 171000000 0.014 165000000 0.027 226000000 0.006 195000000 0.009 150000000 184000000 150000000 105000000 111000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum purchase obligations as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrecorded Purchase Obligations</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>366</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 334000000 20000000 7000000 3000000 1000000 1000000 366000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE F – LEASES</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. Effective January 1, 2019, we adopted </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> as discussed in </span><span style="font-style:italic;">Note A – Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;">. Beginning in 2019, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than </span><span style="font-family:inherit;font-size:10pt;"><span>1 year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>60 years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to our operating leases:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:78%;"/><td style="width:22%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.8 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operating lease cost under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$80 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Rent expense under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 840</span><span style="font-family:inherit;font-size:10pt;"> amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$92 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$88 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease obligations were </span><span style="font-family:inherit;font-size:10pt;"><span>$137 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the maturities of our operating lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in millions):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>343</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have additional leases for office space and warehouse space, that have not yet commenced, of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:10pt;">. These leases will commence in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, with lease terms of up to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum rental commitments as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, under all noncancellable lease agreements, including capital leases, were as follows: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Future Minimum Rental Commitments</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P1Y P60Y P10Y <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to our operating leases:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 336000000 67000000 276000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:78%;"/><td style="width:22%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.8 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P5Y9M18D 0.037 80000000 92000000 88000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental cash flow information related to our operating leases:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 77000000 137000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the maturities of our operating lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in millions):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:78%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>343</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 84000000 71000000 59000000 48000000 41000000 79000000 382000000 39000000 343000000 70000000 P15Y <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Future minimum rental commitments as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, under all noncancellable lease agreements, including capital leases, were as follows: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Future Minimum Rental Commitments</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 73000000 61000000 47000000 39000000 31000000 111000000 362000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE G – RESTRUCTURING-RELATED ACTIVITIES</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Restructuring Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 15, 2018, the Board of Directors approved, and we committed to a new global restructuring program (the 2019 Restructuring Plan). The 2019 Restructuring Plan is </span><span style="font-family:inherit;font-size:10pt;">intended to support our effort to improve operating performance and meet anticipated market demands by ensuring that we are appropriately structured and resourced to deliver sustainable value to patients and customers.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">Key activities under the 2019 Restructuring Plan include supply chain network optimization intended to maximize our global manufacturing and distribution network capacity and building functional capabilities that support business growth.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">These activities were initiated in 2019, with the majority of activity expected to be complete by the end of 2021.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a summary of our estimates of total pre-tax charges associated with the 2019 Restructuring Plan by major type of cost:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Type of Cost</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Estimated Amount Expected to be Incurred</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> to</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> to</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> to</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>$200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> million</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> to</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>$300 million</span></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consists primarily of consulting fees and costs associated with contractual cancellations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$280 million</span></span><span style="font-family:inherit;font-size:10pt;"> of these charges are expected to result in cash outlays. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Restructuring Plan </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 6, 2016, our Board of Directors approved, and we committed to a restructuring initiative (the 2016 Restructuring Plan). The 2016 Restructuring Plan was </span><span style="font-family:inherit;font-size:10pt;">intended to develop global commercialization, technology and manufacturing capabilities in key growth markets, build on our Plant Network Optimization (PNO) strategy which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expand operational efficiencies in support of our operating income margin goals.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">Key activities under the 2016 Restructuring Plan included strengthening global infrastructure through evolving global real estate assets and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our PNO strategy.</span><span style="font-family:inherit;font-size:10pt;"> These activities were initiated </span><span style="font-family:inherit;font-size:10pt;">in the second quarter of 2016 and substantially completed in 2019.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a summary of total pre-tax charges associated with the 2016 Restructuring Plan by major type of cost:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Type of cost</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Amount Incurred</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (1)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>271</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> million</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consists primarily of consulting fees and costs associated with contract cancellations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$255 million</span></span><span style="font-family:inherit;font-size:10pt;"> of these charges are expected to result in cash outlays; the majority of which were completed as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the restructuring and restructuring-related charges (credits) by major type and line item within our accompanying consolidated statements of operations (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>59</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>96</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents cumulative restructuring and restructuring-related charges incurred as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, related to our Restructuring Plans by major type:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016 Restructuring Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019 Restructuring Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (1)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transfer costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related charges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>271</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consists primarily of consulting fees and costs associated with contract cancellations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprised of other costs directly related to our Restructuring Plans, including program management, accelerated depreciation, and fixed asset write-offs.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash payments associated with our Restructuring Plans were made using cash generated from operations and are comprised of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016 Restructuring Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019 Restructuring Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transfer costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a summary of our estimates of total pre-tax charges associated with the 2019 Restructuring Plan by major type of cost:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:12%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Type of Cost</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Estimated Amount Expected to be Incurred</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> to</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> to</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> to</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>$200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> million</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> to</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>$300 million</span></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consists primarily of consulting fees and costs associated with contractual cancellations.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprised of other costs directly related to the restructuring program, including program management, accelerated depreciation, fixed asset write-offs, and costs to transfer product lines among facilities.</span></div> 75000000 100000000 25000000 50000000 100000000 150000000 200000000 300000000 180000000 280000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a summary of total pre-tax charges associated with the 2016 Restructuring Plan by major type of cost:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Type of cost</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Amount Incurred</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (1)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> million</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>271</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> million</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consists primarily of consulting fees and costs associated with contract cancellations.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation, fixed asset write-offs and costs to transfer product lines among facilities.</span></div> 86000000 21000000 164000000 271000000 255000000 <div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the restructuring and restructuring-related charges (credits) by major type and line item within our accompanying consolidated statements of operations (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>59</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>96</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2017</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Termination</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transfer Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 38000000 0 0 38000000 0 32000000 0 32000000 0 0 13000000 13000000 0 32000000 13000000 44000000 38000000 32000000 13000000 82000000 32000000 0 4000000 36000000 0 47000000 0 47000000 0 0 12000000 12000000 0 47000000 12000000 59000000 32000000 47000000 16000000 96000000 25000000 0 12000000 37000000 0 45000000 0 45000000 0 0 13000000 13000000 0 45000000 13000000 58000000 25000000 45000000 25000000 95000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents cumulative restructuring and restructuring-related charges incurred as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, related to our Restructuring Plans by major type:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016 Restructuring Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019 Restructuring Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (1)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transfer costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (2)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring-related charges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>271</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consists primarily of consulting fees and costs associated with contract cancellations.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprised of other costs directly related to our Restructuring Plans, including program management, accelerated depreciation, and fixed asset write-offs.</span></div> 86000000 30000000 115000000 21000000 2000000 23000000 106000000 32000000 138000000 126000000 13000000 139000000 39000000 2000000 41000000 164000000 15000000 180000000 271000000 47000000 318000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash payments associated with our Restructuring Plans were made using cash generated from operations and are comprised of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:32%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2016 Restructuring Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019 Restructuring Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Transfer costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 13000000 6000000 18000000 18000000 13000000 32000000 10000000 4000000 14000000 41000000 23000000 64000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE H – SUPPLEMENTAL BALANCE SHEET INFORMATION</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of selected captions in our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trade accounts receivable, net</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a rollforward of our allowance for doubtful accounts:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net charges to expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization of allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Inventories</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>416</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,166</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other current assets</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash and restricted cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>655</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Property, plant and equipment, net</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment, furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,958</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,782</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$311 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$296 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$279 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other long-term assets</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>458</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>424</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>845</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Accrued expenses</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and related liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other current liabilities</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>800</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>412</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other long-term liabilities</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>667</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>717</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trade accounts receivable, net</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1902000000 1676000000 74000000 68000000 1828000000 1608000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a rollforward of our allowance for doubtful accounts:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net charges to expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization of allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 68000000 68000000 73000000 23000000 19000000 14000000 17000000 19000000 18000000 74000000 68000000 68000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Inventories</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>971</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>416</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,166</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 971000000 760000000 192000000 100000000 416000000 306000000 1579000000 1166000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other current assets</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash and restricted cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>655</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 346000000 655000000 105000000 122000000 186000000 0 105000000 37000000 138000000 107000000 880000000 921000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Property, plant and equipment, net</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment, furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,411</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,958</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,782</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 117000000 97000000 1198000000 1100000000 3411000000 3224000000 442000000 319000000 5169000000 4740000000 3089000000 2958000000 2079000000 1782000000 311000000 296000000 279000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other long-term assets</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>458</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>424</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>845</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 43000000 27000000 336000000 0 216000000 183000000 458000000 424000000 332000000 0 144000000 211000000 1529000000 845000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Accrued expenses</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and related liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>708</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 470000000 712000000 708000000 630000000 56000000 138000000 298000000 229000000 576000000 538000000 2109000000 2246000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other current liabilities</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>800</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>412</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 144000000 115000000 197000000 0 265000000 125000000 195000000 173000000 800000000 412000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other long-term liabilities</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>667</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>717</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 667000000 739000000 227000000 217000000 299000000 209000000 374000000 0 276000000 0 792000000 717000000 2635000000 1882000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE I – INCOME TAXES</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income (loss) before income taxes</span><span style="font-family:inherit;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,832</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>687</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The related benefit for income taxes consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(221</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(146</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,124</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(4,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The reconciliation of income taxes at the federal statutory rate to the actual benefit for income taxes is as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(reclassified)</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal statutory income tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State income taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of foreign taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-deductible expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax positions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TCJA net impact</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intra-entity intangible asset transfers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(597.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(584.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>88.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Due to the inclusion of new tax provisions in 2018 created by the TJCA, we have reclassified select items in prior years to align with the new categories established in 2018, domestic taxes on foreign earnings and uncertain tax positions.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred Tax Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory costs and related reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax benefit of net operating loss and credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>545</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserves and accruals</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring-related charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation and product liability reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment write-down</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal benefit of uncertain tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,611</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(915</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(344</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>796</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gains and losses on derivative financial instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>968</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory costs and related services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Deferred Tax Assets / (Liabilities)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(241</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid on intercompany profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> Net Deferred Tax Assets / (Liabilities) and Prepaid on Intercompany Profit</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit, are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:50%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Consolidated Balance Sheets</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Component</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid on intercompany profit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current deferred tax asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred Tax Assets and Prepaid on Intercompany Profit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current deferred tax liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>595</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred Tax Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>595</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Deferred Tax Assets (Liabilities) and Prepaid on Intercompany Profit</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was </span><span style="font-family:inherit;font-size:10pt;"><span>$449 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had U.S. federal and state tax net operating loss carryforwards and tax credits, the tax effect of which was </span><span style="font-family:inherit;font-size:10pt;"><span>$416 million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, we had foreign tax net operating loss carryforwards and tax credits, the tax effect of which was </span><span style="font-family:inherit;font-size:10pt;"><span>$105 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, as compared to </span><span style="font-family:inherit;font-size:10pt;"><span>$42 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. These tax attributes expire periodically beginning in 2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2019, we completed intra-entity asset transfers of certain intellectual property rights among various wholly-owned subsidiaries. These transactions occurred to more closely align the global economic ownership of our intellectual property rights with our current and future business operations. These transactions did not result in a taxable gain in any jurisdiction, </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">however, some of the transactions did create a step-up in the tax-deductible basis in the transferred intellectual property rights in certain jurisdictions. As a result, we recorded deferred tax assets in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.102 billion</span></span><span style="font-family:inherit;font-size:10pt;">, which represents the book and tax basis differences measured at applicable statutory tax rates, net of a valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$542 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After consideration of all positive and negative evidence, we believe that it is more likely than not that a portion of our deferred tax assets will not be realized. As a result, we established a valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$915 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$344 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, representing an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$571 million</span></span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in the valuation allowance as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, as compared to </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, is primarily attributable to an intra-entity transfer of certain intellectual property. The income tax impact of the unrealized gain or loss component of other comprehensive income and stockholders' equity was a charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$13 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, a charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$37 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$63 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We obtain tax incentives through Free Trade Zone Regime offered in Costa Rica which allows 100.0 percent exemption from income tax in the first eight years of operations and 50.0 percent exemption in the following four years. This tax incentive resulted in income tax savings of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$173 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$146 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>$127 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The tax incentive for 100.0 percent exemption from income tax was renewed during 2019 and is expected to expire in 2027. The impact on per share earnings was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.12</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.10</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.09</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. Additionally, we benefit from tax incentives in Puerto Rico. The income tax savings from Puerto Rico were immaterial for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$455 million</span></span><span style="font-family:inherit;font-size:10pt;"> of gross unrecognized tax benefits, of which a net </span><span style="font-family:inherit;font-size:10pt;"><span>$355 million</span></span><span style="font-family:inherit;font-size:10pt;">, if recognized, would affect our effective tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$427 million</span></span><span style="font-family:inherit;font-size:10pt;"> of gross unrecognized tax benefits, of which a net </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$332 million</span></span><span style="font-family:inherit;font-size:10pt;">, if recognized, would affect our effective tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$1.238 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of gross unrecognized tax benefits, of which a net </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$1.150 billion</span></span><span style="font-family:inherit;font-size:10pt;">, if recognized, would affect our effective tax rate. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning Balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions based on positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions based on positions related to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions for tax positions of prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(433</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements with taxing authorities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statute of limitation expirations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending Balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,238</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to U.S. Federal income tax as well as income tax of multiple state and foreign jurisdictions. We have concluded all U.S. federal income tax matters through 2013, with the exception of select issues in 2011 and substantially all material state and local income tax matters through 2010. We have concluded all foreign income tax matters through 2013, with the exception of issues for Italy, which have concluded through 2002.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2018, a decision was entered by the U.S. Tax Court resolving all disputes for Guidant Corporation for its 2001 through 2006 tax years and our 2006 and 2007 tax years as well as the tax issues related to our 2006 transaction with Abbott Laboratories. Additionally, we resolved all issues with the IRS Office of Appeals for our 2008 through 2010 tax years. The final settlement calculation resulted in a final net tax payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$303 million</span></span><span style="font-family:inherit;font-size:10pt;"> plus </span><span style="font-family:inherit;font-size:10pt;"><span>$307 million</span></span><span style="font-family:inherit;font-size:10pt;"> of estimated interest, which was remitted in the second quarter of 2018. Due to the final settlement of these disputes, we recorded a net tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2018 to remove a reserve related to these years.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2018, we received a Revenue Agent Report (RAR) from the IRS for our 2011 through 2013 tax years. We remitted </span><span style="font-family:inherit;font-size:10pt;"><span>$93 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the IRS in the fourth quarter of 2018 reflecting the net balance of tax and interest due for these years after consideration of amounts owed to us by the IRS. Due to the resolution of these tax years, we recorded a net tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> to remove a reserve related to these years. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize interest and penalties related to income taxes as a component of income tax expense. We had </span><span style="font-family:inherit;font-size:10pt;"><span>$19 million</span></span><span style="font-family:inherit;font-size:10pt;"> accrued for gross interest and penalties as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$11 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. We recognized a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$643 million</span></span><span style="font-family:inherit;font-size:10pt;"> of gross interest and penalties in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> primarily related to reaching settlements with the taxing authorities. We recognized net tax benefit related to interest and penalties of </span><span style="font-family:inherit;font-size:10pt;"><span>$1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, as compared to a net tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$498 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and a net tax expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$154 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The decrease in our net tax benefit related to interest and penalties as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, as compared to </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, is related to reaching settlements with the taxing authorities.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is reasonably possible that within the next 12 months we will resolve transactional- related issues with foreign and state taxing authorities, in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$98 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During 2018, we completed our analysis and recording of all tax effects related to the Tax Cuts and Jobs Act, as required under SAB 118, and recorded a net benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$67 million</span></span><span style="font-family:inherit;font-size:10pt;">, exclusive of the one-time transition tax adjustment described below.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended December 31, 2017, we were required under the Tax Cuts and Jobs Act (TCJA) to calculate a one-time transition tax based on our total post-1986 foreign subsidiaries' earnings and profits (E&amp;P) that we previously deferred from U.S. income taxes. As a result of settling our various tax audits, the revised amount of transition tax is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$856 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2018 as compared to the preliminary amount recorded of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.044 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2017. We anticipate offsetting this liability against existing tax attributes reducing the required payment to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$499 million</span></span><span style="font-family:inherit;font-size:10pt;">, which will be remitted over an eight-year period. We have begun remitting the required installment payments, with a balance remaining of </span><span style="font-family:inherit;font-size:10pt;"><span>$420 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. In addition, we have provided for U.S. state income taxes of </span><span style="font-family:inherit;font-size:10pt;"><span>$18 million</span></span><span style="font-family:inherit;font-size:10pt;"> on all U.S. dollar-denominated E&amp;P accumulated through December 31, 2017, which constitutes the preponderance of our foreign subsidiaries' accumulated E&amp;P through December 31, 2017. We intend to indefinitely reinvest the unremitted foreign earnings of all other subsidiaries as of December 31, 2017, as well as all subsequent earnings generated by all of our foreign subsidiaries. Determining the amount of unrecognized deferred tax liability related to any remaining undistributed foreign earnings and additional outside basis difference in these entities is not practicable.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>We are subject to a territorial tax system under the TCJA, in which we are required to provide for tax on Global Intangible Low Taxed Income (GILTI) earned by certain foreign subsidiaries. We have established an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income (loss) before income taxes</span><span style="font-family:inherit;font-size:10pt;"> consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(408</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,832</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>687</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -1145000000 35000000 -408000000 1832000000 1387000000 1341000000 687000000 1422000000 933000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The related benefit for income taxes consisted of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(221</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>275</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>584</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(146</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  State</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,124</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(4,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 120000000 -221000000 320000000 54000000 -27000000 9000000 101000000 160000000 255000000 275000000 -87000000 584000000 -146000000 -124000000 272000000 -18000000 4000000 1000000 -4124000000 -42000000 -28000000 -4288000000 -162000000 244000000 -4013000000 -249000000 828000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The reconciliation of income taxes at the federal statutory rate to the actual benefit for income taxes is as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:59%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(reclassified)</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. federal statutory income tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State income taxes, net of federal benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic taxes on foreign earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of foreign taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research credit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-deductible expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Uncertain tax positions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TCJA net impact</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intra-entity intangible asset transfers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(597.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(584.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>88.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Due to the inclusion of new tax provisions in 2018 created by the TJCA, we have reclassified select items in prior years to align with the new categories established in 2018, domestic taxes on foreign earnings and uncertain tax positions.</span></div> 0.210 0.210 0.350 0.067 0.004 -0.010 0.219 0.005 0.004 -0.476 -0.083 -0.389 -0.122 -0.021 0.017 0.042 0.026 0.026 0.011 -0.052 -0.041 -0.003 -0.010 -0.025 0.033 0.003 0.022 0.014 -0.220 0.107 0 -0.047 0.914 -5.970 0 0 -0.025 0.018 -0.002 -5.840 -0.175 0.888 0 18000000 545000000 450000000 258000000 258000000 20000000 12000000 168000000 221000000 42000000 28000000 121000000 106000000 10000000 10000000 3447000000 0 0 37000000 4611000000 1140000000 915000000 344000000 3696000000 796000000 16000000 25000000 52000000 44000000 0 968000000 2000000 0 25000000 0 95000000 1037000000 3601000000 241000000 195000000 161000000 3796000000 -80000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit, are included in the following locations within our accompanying consolidated balance sheets (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:50%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Consolidated Balance Sheets</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Component</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid on intercompany profit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current deferred tax asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred Tax Assets and Prepaid on Intercompany Profit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current deferred tax liability</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>595</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred Tax Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>595</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Deferred Tax Assets (Liabilities) and Prepaid on Intercompany Profit</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred Tax Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory costs and related reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax benefit of net operating loss and credits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>545</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reserves and accruals</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring-related charges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation and product liability reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investment write-down</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal benefit of uncertain tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,611</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(915</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(344</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>796</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred Tax Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gains and losses on derivative financial instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>968</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory costs and related services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Deferred Tax Assets / (Liabilities)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(241</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid on intercompany profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> Net Deferred Tax Assets / (Liabilities) and Prepaid on Intercompany Profit</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 195000000 161000000 4196000000 87000000 4391000000 249000000 595000000 328000000 595000000 328000000 3796000000 -80000000 449000000 416000000 105000000 42000000 4102000000 542000000 915000000 344000000 571000000 13000000 37000000 63000000 173000000 146000000 127000000 0.12 0.10 0.09 455000000 355000000 427000000 332000000 1238000000 1150000000 A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning Balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>427</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,095</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions based on positions related to the current year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions based on positions related to prior years</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions for tax positions of prior years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(433</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements with taxing authorities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statute of limitation expirations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending Balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>455</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,238</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 427000000 1238000000 1095000000 30000000 79000000 134000000 45000000 4000000 16000000 34000000 433000000 3000000 4000000 459000000 2000000 9000000 3000000 2000000 455000000 427000000 1238000000 303000000 307000000 250000000 93000000 90000000 19000000 11000000 -643000000 -1000000 -498000000 154000000 98000000 67000000 856000000 1044000000.000 499000000 420000000 18000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE J – COMMITMENTS AND CONTINGENCIES</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with </span><span>FASB ASC Topic 450, </span><span style="font-style:italic;">Contingencies</span><span style="font-family:inherit;font-size:10pt;">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our accrual for legal matters that are probable and estimable was </span><span style="font-family:inherit;font-size:10pt;"><span>$697 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$929 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and includes certain estimated costs of settlement, damages and defense. The decrease in our legal accrual was mainly due to settlement payments associated with product liability cases or claims related to transvaginal surgical mesh products. A portion of our legal accrual is already funded through our qualified settlement fund (QSF), which is included in our restricted cash and restricted cash equivalent balances in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>$346 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$655 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, as discussed in </span><span style="font-style:italic;">Note A – Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded litigation-related net charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$115 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$103 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$285 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. These included litigation-related net charges included a net charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$223 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fourth quarter of 2019, primarily related to litigation with Channel Medsystems, Inc., net charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the third quarter of 2019 and </span><span style="font-family:inherit;font-size:10pt;"><span>$15 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the second quarter of 2019, primarily related to transvaginal surgical mesh product liability litigation, and a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$148 million</span></span><span style="font-family:inherit;font-size:10pt;"> recorded in the first quarter of 2019, which represents a portion of the total </span><span style="font-family:inherit;font-size:10pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:10pt;"> one-time settlement payment received from Edwards Lifesciences Corporation (Edwards) in January 2019. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation-related net charges (credits)</span><span style="font-family:inherit;font-size:10pt;"> in our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. All other legal and product liability charges, credits and costs are recorded within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">. As such, a portion of the related gain from the Edwards settlement was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Patent Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 28, 2015, BSC filed suit against Cook Group Limited and Cook Medical LLC (collectively, “Cook”) in the District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct Endoscopic Hemoclip. The case was transferred to the District Court for the S.D. Indiana. Cook filed seven Inter Partes Review (“IPR”) requests with the U.S. Patent and Trademark Office against the four asserted patents. All IPRs have concluded with claims confirmed in each patent. Cook and Boston Scientific have both appealed the Patent Office’s IPR decisions to the Federal Circuit Court of Appeals. The district court had stayed the case pending the appeals court decision on the IPRs.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 29, 2016 Nevro Corp. (Nevro) filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Neuromodulation Corporation, in the U.S. District Court for the Northern District of California alleging that six U.S. patents (Alataris) owned by Nevro are infringed by our spinal cord stimulation systems. On June 29, 2017, Nevro amended the complaint to add an additional patent (Fang). On July 24, 2018, summary judgment was entered in favor of the Company and on July 31, 2018, we received final judgment and dismissal of the action. On July 31, 2018, Nevro filed an appeal.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro in U.S. District Court for the District of Delaware alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro’s Senza™ Spinal Cord Stimulation System.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen. Inc., served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in U.S. District Court for the District of Delaware, and </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro’s Senza™ I and Senza™ II Spinal Cord Stimulation Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our Spinal Cord Stimulation systems infringe 5 Nevro patents. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 30, 2019, Tissue Anchor Innovations filed a complaint for patent infringement in the United States District Court Central District of California against Fountain Valley Regional Hospital and Medical Center, Los Alamitos Medical Center and us. The complaint alleges that the Solyx™ Sling System infringes US Patent 6,506,190. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Liability Litigation</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">January 29, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>54,000</span></span><span style="font-family:inherit;font-size:10pt;"> product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. As of </span><span style="font-family:inherit;font-size:10pt;">January 29, 2020</span><span style="font-family:inherit;font-size:10pt;">, we have entered into master settlement agreements in principle or are in the final stages of entering one with certain plaintiffs' counsel to resolve an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>52,000</span></span><span style="font-family:inherit;font-size:10pt;"> cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately </span><span style="font-family:inherit;font-size:10pt;"><span>52,000</span></span><span style="font-family:inherit;font-size:10pt;"> cases and claims, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>46,000</span></span><span style="font-family:inherit;font-size:10pt;"> have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered that all manufacturers of surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse stop selling and distributing their products in the United States immediately, stemming from the FDA’s 2016 reclassification of these devices to class III (high risk) devices, and as a result, the Company ceased global sales and distribution of surgical mesh products indicated for transvaginal pelvic organ prolapse. The pending cases are in various federal and state courts in the U.S. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over </span><span style="font-family:inherit;font-size:10pt;"><span>3,100</span></span><span style="font-family:inherit;font-size:10pt;"> of the cases were specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the U.S. District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. On December 12, 2019 the Mississippi Attorney General filed suit against BSC in State Court alleging violations of the Mississippi Consumer Protection Act which the Company plans to vigorously defend. There were also fewer than </span><span style="font-family:inherit;font-size:10pt;"><span>25</span></span><span style="font-family:inherit;font-size:10pt;"> cases in Canada, inclusive of </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> certified class action and fewer than </span><span style="font-family:inherit;font-size:10pt;"><span>25</span></span><span style="font-family:inherit;font-size:10pt;"> claims in the United Kingdom. We have reached an agreement to settle the Canadian class action pending Court approval. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us, that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Governmental Investigations and Qui Tam Matters</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 5, 2014, we were served with a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General. The subpoena seeks information relating to the launch of the Cognis™ and Teligen™ line of devices in 2008, the performance of those devices from 2007 to 2009 and the operation of the Physician Guided Learning Program. We are cooperating with this request. On May 6, 2016, a qui tam lawsuit in this matter was unsealed in the U.S. District Court for the District of Minnesota. At the same time, we learned that the U.S. government and the State of California had earlier declined to intervene in that lawsuit on April 15, 2016. The complaint was served on us on July 21, 2016. On October 7, 2016, the plaintiff/relator served an amended complaint that dropped the allegations relating to the Physician Guided Learning Program. We filed a motion to dismiss the amended complaint on December 7, 2016 and the court heard our motion to dismiss on April 5, 2017. On August 29, 2017, the Court granted the motion to dismiss, without prejudice and on September 19, 2017, the relator filed a Second Amended Complaint.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">We filed a motion to dismiss the Second Amended Complaint on October 10, 2017 and the Court denied that motion on December 13, 2017. On July 31, 2018, the relator filed a motion seeking leave to file a Third Amended Complaint. The Court denied the motion on October 30, 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 23, 2015, a judge for the Court of Modena (Italy) ordered a trial for Boston Scientific and three of its employees, as well as numerous other defendants charged in criminal proceedings. The charges arise from allegations that the defendants made improper donations to certain healthcare providers and other employees of the Hospital of Modena in order to induce them to conduct unauthorized clinical trials, as well as related government fraud in relation to the financing of such clinical trials. A trial began on February 24, 2016. On November 10, 2017, the Court issued a ruling that convicted one Boston Scientific employee but acquitted two others and levied a fine of </span><span style="font-family:inherit;font-size:10pt;"><span>€245 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> against us and imposed joint and several civil damages of </span><span style="font-family:inherit;font-size:10pt;"><span>€620 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> on all defendants. We continue to deny these allegations, timely appealed the decision on May 10, 2018 and intend to continue to defend ourselves vigorously.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda., as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. We deny the allegations and intend to defend ourselves vigorously.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Proceedings</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments are due pursuant a transaction agreement regarding Labcoat Limited.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 6, 2019, Boston Scientific Corporation, Boston Scientific Scimed, Inc., and Fortis Advisors, LLC, as a Securityholder Representative for the former Securityholders of nVision Medical Corp. filed a declaratory judgment action against BioCardia, Inc. in the United States District Court for the Northern District of California to address threats and allegations by BioCardia challenging inventorship and ownership of various patents that Boston Scientific Corporation acquired through an April 13, 2018 merger with nVision as well as related threats and allegations by BioCardia of trade secret misappropriation and unjust enrichment. On December 11, 2019, BioCardia filed an amended answer and counterclaims.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 18, 2019, Blue Cross &amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp; Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia. The complaint alleges that the defendants violated the Sherman Act and the antitrust and consumer protections laws of several states by pursuing patent litigation relating to ZYTIGA™ in order to delay generic entry. On June 21, 2019, the case was transferred to the United States District Court for the District of New Jersey and has been consolidated with similar complaints. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam </span><span style="font-family:inherit;font-size:10pt;">complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note I – Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> for information regarding our tax litigation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Matters Concluded Since December 31, 2018</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 15, 2019, we announced that we reached an agreement with Edwards Lifesciences Corporation (Edwards) to settle all outstanding patent disputes between us and Edwards in all venues around the world. All pending cases or appeals in courts and patent offices between the two companies will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices, and left atrial appendage closure devices. Any injunctions currently in place will be lifted. Under the terms of the agreement, Edwards made a one-time payment to us of </span><span style="font-family:inherit;font-size:10pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:10pt;">. No further royalties will be owed by either party under the agreement. All other terms remain confidential. The previously disclosed matters that have been resolved as a result of this settlement include:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 30, 2015, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation and Edwards Lifesciences Services GmbH in Düsseldorf District Court in Germany for patent infringement. We allege that Edwards’ </span></div></td></tr></table><div style="line-height:120%;padding-left:48px;text-align:justify;"><span style="font-family:inherit;font-size:10pt;">SAPIEN 3™ Heart Valve infringes our patent related to adaptive sealing technology. On February 25, 2016, we extended the action to allege infringement of a second patent related to adaptive sealing technology. The trial began on February 7, 2017. On March 9, 2017, the court found that Edwards infringed both patents and Edwards appealed.</span></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 23, 2015, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '672) owned by Edwards is infringed by our Lotus™ Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we did not infringe the Spenser '672 patent. Edwards filed an appeal.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 23, 2015, Edwards Lifesciences Corporation filed a patent infringement action against us and Boston Scientific Medizintechnik GmbH in the District Court of Düsseldorf, Germany alleging an European patent (Bourang) owned by Edwards is infringed by our Lotus Valve System. The trial began on February 7, 2017. On March 28, 2017, the European Patent Office revoked the Bourang patent and on April 3, 2017, the court suspended the infringement action pending Edwards' appeal of the revocation of the patent at the European Patent Office.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation (Edwards) in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards’ SAPIEN 3™ Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus™ Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found our patent invalid. The Company filed an appeal before the United States Court of Appeals for the Federal Circuit on May 24, 2018.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the Central District of California for patent infringement. We allege that Edwards’ aortic valve delivery systems infringe eight of our catheter related patents. On October 13, 2016, Edwards filed a petition for inter partes review of one asserted patent with the USPTO, Patent Trial and Appeal Board. On April 21, 2017, the USPTO denied the petition. On April 19 and 20, 2017, Edwards filed multiple inter partes review petitions against the patents in suit. On September 8, 2017, the court granted a stay of the action pending an inter partes review of the patents in suit.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus™ Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 27, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific, LTD, in the Federal Court of Canada alleging that three Canadian patents (Spenser) owned by Edwards are infringed by our Lotus Transcatheter Heart Valve System.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 1, 2018, the Company filed a patent infringement action on the merits in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3™ Device and Sapien 3 Ultra Device infringed a patent owned by the Company.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 3, 2018, the Company filed a preliminary injunction request in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3 Ultra Device infringed a patent owned by the Company. On October 23, 2018, the court found that the Sapien 3 Ultra Device infringed the patent. Edwards had the right to appeal.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 22, 2018, Edwards Lifesciences LLC filed a patent infringement action against Boston Scientific Corporation, in the U. S. District Court of Delaware, alleging that two U.S. patents (Schweich) owned by them are infringed by our Watchman™ Left Atrial Appendage Closure Device, Watchman Delivery System and Watchman Access System.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 14, 2016, we learned that the Associacao Brasileira de Medicina de Grupo d/b/a ABRAMGE filed a complaint against us, Arthrex and Zimmer Biomet Holdings, in the U.S. District Court for the District of Delaware. This complaint, which ABRAMGE never served against us, alleges that the defendants or their agents paid kickbacks to health care providers in order to increase sales and prices and are liable under a variety of common law theories. On February 6, 2017, ABRAMGE filed and served an amended complaint on us and the other defendants. The amended complaint does not contain any material changes in the allegations against us. Subsequently, on March 2, 2017, ABRAMGE filed a motion to consolidate this lawsuit with two other similar suits that it had brought against Stryker and Abbott Laboratories, in a multidistrict litigation proceeding. On April 13, 2017, we filed a motion to dismiss the amended complaint, as well as a separate opposition to the multidistrict litigation motion and on May 31, 2017, the Joint Panel on Multi-District Litigation denied ABRAMGE’s motion for the multidistrict litigation. On September 1, 2017, ABRAMGE filed a motion for leave to file a Second Amended Complaint, while our motion to dismiss the Amended Complaint remained pending. On September 15, 2017, we filed an opposition to the motion seeking leave to amend. On November 8, 2018, the Court granted ABRAMGE’s motion for leave to file a Second Amended Complaint, while also granting us leave to renew our motion to dismiss. We filed our motion to dismiss the Second Amended Complaint on January 18, 2019. On February 28, 2019, ABRAMGE dismissed its Second Amended Complaint, concluding the lawsuit.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or about January 12, 2016, Teresa L. Stevens filed a claim against us and three other defendants asserting, for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Southern District of West Virginia, before the same Court that is hearing the mesh MDL. The complaint, which alleges Racketeer Influenced and Corrupt Organizations Act (RICO) violations, fraud, misrepresentation, deceptive trade practices and unjust enrichment, seeks both equitable relief and damages under state and federal law. On January 26, 2016, the Court issued an order staying the case and directing the plaintiff to submit information to allow the FDA to issue a determination with respect to her allegations. In addition, we were in contact with the U.S. Attorney’s Office for the Southern District of West Virginia and responded voluntarily to their requests in connection with that office’s review of the allegations concerning the use of mesh resin in the complaint. We reached a settlement on this matter and this case was dismissed on May 13, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 27, 2017, Carolyn Turner filed a complaint against us and five other defendants asserting for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Middle District of Florida, Orlando Division and alleges violations of the RICO, negligence, strict liability, breach of an express or implied warranty, intentional and negligent misrepresentation, fraud and unjust enrichment. Ms. Turner served this complaint against us on April 7, 2017. As of April 27, 2017, this case was stayed, pending resolution of the transfer petition to the mesh multidistrict litigation. We reached a settlement on this matter and this case was dismissed on February 25, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 24, 2019, a class action complaint was filed in the U.S. District Court for the Southern District of New York against Boston Scientific Corporation, Michael F. Mahoney, our Chief Executive Officer, and Daniel J. Brennan, our Chief Financial Officer. The complaint alleges violations of federal securities laws based on false and/or misleading statements and failure to disclose facts related to the Company’s transvaginal surgical mesh products. On September 20, 2019, the case was dismissed with prejudice.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 10, 2017, Imran Niazi filed a patent infringement action against us in the U.S. District Court for the Western District of Wisconsin alleging that a U.S. patent owned by him is infringed by our Acuity™ Lead Delivery System. On June 30, 2017, we filed a motion to dismiss for improper venue and on November 7, 2017 the Wisconsin Court granted the motion to dismiss. On November 13, 2017 Niazi refiled the same action in the U.S. District of Minnesota. We reached a confidential settlement on this matter on February 3, 2020 pursuant to which we anticipate the court will dismiss the pending action.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 3, 2012, we were served with a qui tam complaint that had previously been filed under seal against Boston Scientific Neuromodulation Corporation in the U.S. District Court for the District of New Jersey on March 2, 2011. On August 8, 2012, we learned that the federal government had previously declined to intervene in this matter. The relators’ complaint, now unsealed, alleges that Boston Scientific Neuromodulation Corporation violated the federal and various states' false claims acts through </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">submission of fraudulent bills for implanted devices, under-reporting of certain adverse events and promotion of off-label uses. On September 10, 2012, the relators filed an amended complaint revising and restating certain of the claims in the original complaint. Our motion to dismiss, filed subsequently, was denied on May 31, 2013 and on June 28, 2013, we answered the amended complaint and brought certain counterclaims arising from relators’ unauthorized removal of documents from the business during their employments, which the relators moved to dismiss on July 22, 2013. The Court denied relators’ motion to dismiss the counterclaims on September 4, 2014. Following the completion of fact and expert discovery, we filed a motion for summary judgment against all claims on January 27, 2017, relators filed their own motion for summary judgment against our counterclaims that same date. On December 15, 2017, the Court denied both motions for summary judgment. The parties reached a settlement on May 2, 2019, and the Court subsequently ordered the case dismissed, except for any claim by relators to recover attorneys’ fees.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 1, 2017, we entered into a definitive agreement with Channel Medsystems, Inc. (Channel) pursuant to which we could have been obligated to pay </span><span style="font-family:inherit;font-size:10pt;">$145 million</span><span style="font-family:inherit;font-size:10pt;"> in cash up-front and a maximum of </span><span style="font-family:inherit;font-size:10pt;">$130 million</span><span style="font-family:inherit;font-size:10pt;"> in contingent payments to acquire Channel. The agreement contained a provision allowing Channel to sell the remaining equity interests of Channel to us upon achievement of a regulatory milestone and an option allowing us to acquire the remaining equity interests. We sent a notice of termination of that agreement to Channel in the second quarter of 2018. On September 12, 2018, Channel filed a complaint in Delaware Chancery Court against us for alleged breach of the agreement. Channel alleged that we breached the agreement by terminating it. We have answered the complaint, denied the claims by Channel and counterclaimed to recover part of our investment in Channel, alleging fraud in the inducement. On April 2, 2019, Channel announced its receipt of FDA approval of the Cerene™ Cryotherapy Device. Trial testimony was taken in April 2019, and the post-trial briefing and hearing have been completed. During the third quarter of 2019, Channel notified us that they were exercising their option to sell the remaining equity interests in Channel to us. We responded to the notification that we did not intend to purchase Channel since the previous agreement had been terminated. On December 18, 2019, the Chancery Court ruled that Boston Scientific was in breach of the agreement and granted Channel's request for specific performance to require the Company to complete the purchase. On January 10, 2020, we filed a Notice of Appeal of the Chancery Court’s decision to the Delaware Supreme Court. On February 4, 2020, the Company settled the dispute with Channel resulting in termination of the agreement, payment by the Company of an undisclosed sum and surrender of the Company's equity interest in Channel.</span></div> 697000000 929000000 346000000 655000000 115000000 103000000 285000000 223000000 25000000 15000000 148000000 180000000 54000 52000 52000 46000 3100 25 1 25 245000 620000 180000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE K – STOCKHOLDERS' EQUITY</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are authorized to issue </span><span style="font-family:inherit;font-size:10pt;"><span>50 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our stockholders. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, we had no shares of preferred stock issued or outstanding.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are authorized to issue </span><span style="font-family:inherit;font-size:10pt;"><span>2.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> par value per share. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors and to share ratably in our assets legally available for distribution to our stockholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption, or conversion rights. The holders of common stock do not have cumulative voting rights. The holders of a majority of the shares of common stock can elect all of the directors and can control our management and affairs.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 25, 2013, our Board of Directors approved a stock repurchase program authorizing the repurchase of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of our common stock. Repurchased shares are available for reissuance under our equity incentive plans and for general corporate purposes, including acquisitions. We did not repurchase any shares of our common stock during </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$535 million</span></span><span style="font-family:inherit;font-size:10pt;"> authorized under our 2013 share repurchase program. There were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>248 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares in treasury as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 50000000 2000000000.000 0.01 1000000000.000 535000000 248000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE L – STOCK INCENTIVE AND OWNERSHIP PLANS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee and Director Stock Incentive Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2011, our Board of Directors and stockholders approved our 2011 Long-Term Incentive Plan (the 2011 LTIP), authorizing for issuance up to </span><span style="font-family:inherit;font-size:10pt;"><span>146 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock. The 2011 LTIP covers officers, directors, employees and consultants and provides for the grant of restricted or unrestricted common stock, deferred stock units (DSU), options to acquire our common stock, stock appreciation rights, performance awards (market-based and performance-based DSUs) and other stock and non-stock awards. Shares reserved under our current and former stock incentive plans totaled approximately </span><span style="font-family:inherit;font-size:10pt;"><span>124 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Executive Compensation and Human Resources Committee (the Committee) of the Board of Directors, consisting of independent, non-employee directors may authorize the issuance of common stock and cash awards under the 2011 LTIP in recognition of the achievement of long-term performance objectives established by the Committee.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-qualified options issued to employees are generally granted with an exercise price equal to the market price of our stock on the grant date, vest over a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year service period and have a </span><span style="font-family:inherit;font-size:10pt;">ten</span><span style="font-family:inherit;font-size:10pt;">-year contractual life. In the case of qualified options, if the recipient owns more than </span><span style="font-family:inherit;font-size:10pt;"><span>ten percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the voting power of all classes of stock, the option granted will be at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>110 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of our common stock on the date of grant and will expire over a period not to exceed </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> years. Non-vested stock awards, including restricted stock awards and DSUs, issued to employees are generally granted with an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> and typically vest in four or five equal annual installments. These awards represent our commitment to issue shares to recipients after the vesting period. Upon each vesting date, such awards are no longer subject to risk of forfeiture and we issue shares of our common stock to the recipient.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the impact of stock-based compensation on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>119</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>96</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net impact per common share - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net impact per common share - assuming dilution</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options granted </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,992</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average exercise price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.20</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.26</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.70</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Black-Scholes Assumptions</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years, weighted)</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.61%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.01%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.21%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expected Volatility</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use our historical volatility and implied volatility as a basis to estimate expected volatility in our valuation of stock options.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expected Term</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate the expected term of options using historical exercise and forfeiture data. We believe that this historical data provides the best estimate of the expected term of new option grants.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Risk-Free Interest Rate</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use yield rates on U.S. Treasury securities for a period approximating the expected term of the award to estimate the risk-free interest rate in our grant-date fair value assessment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expected Dividend Yield</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not historically paid cash dividends to our stockholders and currently do not intend to pay cash dividends. Therefore, we have assumed an expected dividend yield of zero in our grant-date fair value assessment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information related to stock options under stock incentive plans are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Life</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>26,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cancelled/forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(445</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>26,716</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,385</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cancelled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(519</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25,304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cancelled/forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>23,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,617</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total vested and expected to vest as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>22,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total intrinsic value of stock options exercised was </span><span style="font-family:inherit;font-size:10pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$64 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Vested Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We value restricted stock awards and DSUs based on the closing trading value of our shares on the date of grant. Information related to non-vested stock awards is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:63%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Vested</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Award Units</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant-Date </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>18,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,798</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(683</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>15,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(748</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,683</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,656</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(449</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>11,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">The number of restricted stock units vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total vesting date fair value of stock award units that vested was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$193 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$170 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$190 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Market-based DSU Awards</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we granted market-based DSU awards to certain members of our senior management team. The number of shares ultimately issued to the recipient is based on the total stockholder return (TSR) of our common stock as compared to the TSR of the common stock of the other companies in the S&amp;P 500 Healthcare Index over a three-year performance period. The number of DSUs ultimately granted under this program range from </span><span style="font-family:inherit;font-size:10pt;"><span>0 percent</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>200 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the target number of performance-based DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, award recipients must remain employed by us throughout the three-year performance period to attain the full amount of the market-based DSUs that satisfied the market performance criteria.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined the fair value of the market-based DSU awards to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Awards</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock price on date of grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Measurement period</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize the expense on these awards in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> on a straight-line basis over the three-year measurement period.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Free Cash Flow Performance-based DSU Awards</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, we granted free cash flow performance-based DSU awards to certain members of our senior management team. The attainment of these performance-based DSUs is based on our adjusted free cash flow (AFCF) measured against our internal annual financial plan performance for AFCF. AFCF is measured over a one-year performance period beginning January 1st</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></span><span style="font-family:inherit;font-size:10pt;">of each year and ending December 31st. The number of DSUs ultimately granted under this program range from </span><span style="font-family:inherit;font-size:10pt;"><span>0 percent</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>150 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the target number of performance-based DSUs awarded to the participant as determined by achievement of the performance criteria of the program. In addition, award recipients must remain employed by us throughout a three-year service period (inclusive of the one-year performance period) to attain the full amount of the performance-based DSUs that satisfied the performance criteria.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019 AFCF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018 AFCF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017 AFCF</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value, net of forfeitures to date </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Achievement of target payout</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year-end stock price used in determining fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize the expense on these awards in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> over the vesting period which is three years after the date of grant.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expense Attribution</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize compensation expense for our stock incentive plan using a straight-line method over the substantive vesting period. Most of our stock awards provide for immediate vesting upon death or disability of the participant. In addition, our stock grants to employees provide for accelerated vesting of our stock-based awards, other than performance-based and market-based awards, upon retirement, if the stock award has been held for at least one year by the recipient. In accordance with the terms of our stock grants, for employees who will become retirement eligible prior to the vest date we expense stock-based awards, other than performance-based and market-based awards, over the greater of one year or the period between grant date and retirement-eligibility. The performance-based and market-based awards discussed above do not contain provisions that would accelerate the full vesting of the awards upon retirement-eligibility.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize stock-based compensation expense for the value of the portion of awards that are ultimately expected to vest. </span><span>FASB ASC Topic 718, </span><span style="font-style:italic;">Compensation – Stock Compensation</span><span style="font-family:inherit;font-size:10pt;"> allows forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock-based award. We have applied, based on an analysis of our historical forfeitures, a weighted-average annual forfeiture rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>six percent</span></span><span style="font-family:inherit;font-size:10pt;"> to all unvested stock-based awards as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which represents the portion that we expect will be forfeited each year over the vesting period. We re-evaluate this analysis annually or more frequently if there are significant changes in circumstances and adjust the forfeiture rate as necessary. Ultimately, we will only recognize expense for those shares that vest.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrecognized Compensation Cost</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to recognize the following future expense for awards outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrecognized</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Compensation Cost</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions) </span><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Vesting Period</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested stock awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>204</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1.2</span></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee Stock Purchase Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our global employee stock purchase plan provides for the granting of options to purchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>50 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock to all eligible employees. Under the global employee stock purchase plan, we grant each eligible employee, at the beginning of each six-month offering period, an option to purchase shares of our common stock equal to not more than </span><span style="font-family:inherit;font-size:10pt;"><span>ten percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the employee’s eligible compensation or the statutory limit under the U.S. Internal Revenue Code. Such options may be exercised only to the extent of accumulated payroll deductions at the end of the offering period, at a purchase price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>85 percent</span></span><span style="font-family:inherit;font-size:10pt;"> of the fair market value of our common stock at the beginning or end of each offering period, whichever is less. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were approximately </span><span style="font-family:inherit;font-size:10pt;"><span>8 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares available for future issuance under the employee stock purchase plan.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares issued or to be issued </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Range of purchase prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$36.47</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$27.91</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$21.07</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expense recognized </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of shares issued under the employee stock purchase plan. We recognize expense related to shares purchased through the employee stock purchase plan ratably over the offering period.</span></div> 146000000 124000000 0.10 1.10 0 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the impact of stock-based compensation on our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax (benefit) expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>119</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>96</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net impact per common share - basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net impact per common share - assuming dilution</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8000000 7000000 7000000 120000000 109000000 98000000 28000000 24000000 23000000 157000000 140000000 127000000 24000000 21000000 32000000 133000000 119000000 96000000 0.10 0.09 0.07 0.09 0.08 0.07 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use the Black-Scholes option-pricing model to calculate the grant-date fair value of stock options granted to employees under our stock incentive plans. We calculated the fair value for options granted using the following estimated weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options granted </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,992</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average exercise price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.20</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.26</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.70</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Black-Scholes Assumptions</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years, weighted)</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.1</span></span></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.61%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.61</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.01%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.21%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2992000 3491000 4439000 40.20 27.26 24.70 11.76 8.55 7.16 0.24 0.26 0.25 P6Y1M6D P6Y P6Y1M6D 0.0138 0.0261 0.0261 0.0301 0.0203 0.0221 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information related to stock options under stock incentive plans are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Life</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>26,644</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cancelled/forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(445</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>26,716</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,385</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cancelled/forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(519</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25,304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cancelled/forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(359</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>23,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>594</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,617</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total vested and expected to vest as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>22,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 26644000 11 4439000 25 3922000 10 445000 17 26716000 13 3491000 27 4385000 11 519000 22 25304000 16 2992000 40 4872000 12 359000 24 23065000 19 P5Y6M 594000000 15091000 14 P4Y1M6D 476000000 7617000 30 P8Y 114000000 22707000 19 P5Y3M18D 590000000 140000000 90000000 64000000 Information related to non-vested stock awards is as follows:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:63%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Vested</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Award Units</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant-Date </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>18,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,798</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(683</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>15,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(748</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,683</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,656</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(449</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>11,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">The number of restricted stock units vested includes shares withheld on behalf of employees to satisfy statutory tax withholding requirements.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 18797000 14 4798000 24 7663000 11 683000 17 15250000 18 4375000 28 6194000 16 748000 22 12683000 22 3656000 39 4811000 20 449000 27 11079000 29 193000000 170000000 190000000 0 2 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined the fair value of the market-based DSU awards to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$10 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$7 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8 million</span></span><span style="font-family:inherit;font-size:10pt;"> for </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. We determined these fair values based on Monte Carlo simulations as of the date of grant, utilizing the following assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Awards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Awards</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock price on date of grant</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Measurement period</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10000000 7000000 8000000 40.12 27.09 24.55 P2Y10M24D P2Y10M24D P2Y9M18D 0.0248 0.0236 0.0145 0 1.50 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents our assumptions used in determining the fair value of our AFCF awards currently expected to vest as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019 AFCF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018 AFCF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017 AFCF</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value, net of forfeitures to date </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Achievement of target payout</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year-end stock price used in determining fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45.22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8000000 11000000 6000000 0.90 1.18 0.98 45.22 35.34 24.79 0.06 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to recognize the following future expense for awards outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrecognized</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Compensation Cost</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in millions) </span><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Vesting Period</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">(in years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested stock awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>204</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1.2</span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amounts presented represent compensation cost, net of estimated forfeitures.</span></div> 35000000 169000000 204000000 P1Y2M12D 50000000 0.10 0.85 8000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares issued or to be issued </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in thousands)</span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Range of purchase prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$36.47</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$27.91</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$21.07</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expense recognized </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2196000 2452000 2491000 29.29 36.47 21.49 27.91 18.60 21.07 19000000 17000000 13000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE M – WEIGHTED AVERAGE SHARES OUTSTANDING</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,391.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,381.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,370.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net effect of common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average shares outstanding - assuming dilution</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,410.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,401.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,392.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.</span></div> <div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,391.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,381.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,370.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net effect of common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average shares outstanding - assuming dilution</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,410.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,401.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,392.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1391500000 1381000000.0 1370100000 19000000.0 20400000 22600000 1410600000 1401400000 1392700000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE N – SEGMENT REPORTING</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices. </span><span style="font-family:inherit;font-size:10pt;">We measure and evaluate our reportable segments based on net sales of reportable segments, operating income of reportable segments, excluding intersegment profits, and operating income of reportable segments as a percentage of net sales of reportable segments. Operating income of reportable segments as a percentage of net sales of reportable segments is defined as operating income of reportable segments divided by net sales of reportable segments. </span><span>We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition/divestitures-related items, restructuring and restructuring-related items, medical device regulation charges and litigation-related charges/(credits). Although we exclude these amounts from operating income of reportable segments, they are included in reported </span><span style="font-style:italic;">Income (loss) before income taxes</span><span> on the </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> and are included in the reconciliation below.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. </span><span style="font-family:inherit;font-size:10pt;">Following our acquisition of BTG, which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in millions, except percentages):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,307</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,007</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,808</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,777</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales of reportable segments </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,823</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other (Specialty Pharmaceuticals)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Depreciation expense</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total depreciation expense of reportable segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other (Specialty Pharmaceuticals)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated depreciation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating income of reportable segments </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,007</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,875</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,509</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other (Specialty Pharmaceuticals)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unallocated amounts:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate expenses, including hedging activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(372</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and EU MDR implementation costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(582</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(398</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(407</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(699</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(565</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(831</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(353</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>687</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating income of reportable segments as a percentage of net sales of reportable segments</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,803</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets of reportable segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,497</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other (Specialty Pharmaceuticals)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,911</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,886</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,372</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other corporate assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>30,565</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>20,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-lived assets</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,061</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ireland</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,079</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,782</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,697</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,372</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,837</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>20,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>16,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in millions, except percentages):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,307</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,007</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,742</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,808</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,208</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,777</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net sales of reportable segments </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,823</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other (Specialty Pharmaceuticals)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated net sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3307000000 3007000000 2742000000 3140000000 3041000000 2808000000 4208000000 3777000000 3500000000 10654000000 9048000000 81000000 10735000000 9823000000 9048000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Depreciation expense</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total depreciation expense of reportable segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other (Specialty Pharmaceuticals)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated depreciation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>279</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 75000000 72000000 68000000 92000000 91000000 91000000 138000000 133000000 120000000 306000000 296000000 279000000 6000000 311000000 296000000 279000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,204</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>984</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>666</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>537</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>988</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating income of reportable segments </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,007</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,875</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,509</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other (Specialty Pharmaceuticals)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unallocated amounts:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate expenses, including hedging activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(372</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and EU MDR implementation costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(582</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(398</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(407</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(699</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(599</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(565</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,518</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(831</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(353</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>687</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1204000000 1102000000 984000000 666000000 655000000 537000000 1137000000 1117000000 988000000 3007000000 2875000000 2509000000 56000000 -264000000 -372000000 -252000000 -582000000 -398000000 -407000000 699000000 599000000 565000000 1518000000 1506000000 1285000000 -831000000 -85000000 -353000000 687000000 1422000000 933000000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating income of reportable segments as a percentage of net sales of reportable segments</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.364 0.367 0.359 0.212 0.215 0.191 0.270 0.296 0.282 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,803</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,873</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets of reportable segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,211</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,497</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other (Specialty Pharmaceuticals)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,911</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,886</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,372</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All other corporate assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>30,565</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>20,999</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1803000000 1846000000 1873000000 1696000000 2535000000 1954000000 6211000000 5497000000 211000000 0 10176000000 7911000000 7886000000 6372000000 6082000000 1219000000 30565000000 20999000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-lived assets</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,061</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ireland</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other countries</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,079</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,782</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,697</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,998</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,372</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,837</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>20,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>16,064</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1148000000 1061000000 1065000000 327000000 242000000 210000000 604000000 478000000 422000000 2079000000 1782000000 1697000000 10176000000 7911000000 6998000000 7886000000 6372000000 5837000000 336000000 0 0 20477000000 16064000000 14531000000 <div style="line-height:120%;font-size:10pt;"><span style="font-weight:bold;">NOTE O – REVENUE</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our </span><span style="font-family:inherit;font-size:10pt;">consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="35" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Businesses</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OUS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OUS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OUS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Endoscopy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,080</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,894</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>781</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>894</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>724</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Urology and Pelvic Health</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>785</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiac Rhythm Management</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>804</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,939</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,159</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,951</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Electrophysiology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neuromodulation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>624</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional Cardiology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,816</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,436</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,590</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peripheral Interventions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>579</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>506</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Specialty Pharmaceuticals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>6,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5,538</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5,162</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic Regions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EMEA (Europe, Middle East and Africa)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,940</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">APAC (Asia-Pacific)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,587</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LACA (Latin America and Canada)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,654</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">OUS</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Specialty Pharmaceuticals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. </span><span style="font-family:inherit;font-size:9pt;">Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam.</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;">We have revised prior year amounts to the current year’s presentation. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities are classified within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> on our accompanying </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Our deferred revenue balance was </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$373 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$143 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> that was included in the above </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Refer to </span><span style="font-style:italic;">Note A – Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> for additional information on our accounting policies relating to revenue recognition.</span></div> The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions): <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="35" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Businesses</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OUS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OUS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">OUS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Endoscopy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,080</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,894</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>781</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>894</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>724</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Urology and Pelvic Health</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>381</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>785</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiac Rhythm Management</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>804</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,939</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,159</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,951</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Electrophysiology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>278</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neuromodulation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>873</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>624</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>517</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional Cardiology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,522</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,816</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,436</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,590</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peripheral Interventions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,392</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>579</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>506</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Specialty Pharmaceuticals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>6,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5,538</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,286</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>5,162</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic Regions</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,538</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EMEA (Europe, Middle East and Africa)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,940</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">APAC (Asia-Pacific)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,727</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,587</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LACA (Latin America and Canada)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Medical Devices</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,654</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">OUS</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Specialty Pharmaceuticals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,735</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. </span><span style="font-family:inherit;font-size:9pt;">Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam.</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;">We have revised prior year amounts to the current year’s presentation. </span></div> 1080000000 814000000 1894000000 980000000 781000000 1762000000 894000000 724000000 1619000000 1005000000 408000000 1413000000 864000000 381000000 1245000000 785000000 339000000 1124000000 1135000000 804000000 1939000000 1159000000 792000000 1951000000 1135000000 760000000 1895000000 148000000 180000000 329000000 150000000 161000000 311000000 136000000 142000000 278000000 695000000 178000000 873000000 624000000 155000000 779000000 517000000 118000000 635000000 1293000000 1522000000 2816000000 1154000000 1436000000 2590000000 1122000000 1297000000 2419000000 741000000 651000000 1392000000 608000000 579000000 1187000000 575000000 506000000 1081000000 70000000 11000000 81000000 6167000000 4569000000 10735000000 5538000000 4286000000 9823000000 5162000000 3885000000 9048000000 6097000000 5538000000 5162000000 2264000000 2176000000 1940000000 1898000000 1727000000 1587000000 395000000 383000000 358000000 10654000000 9823000000 9048000000 70000000 11000000 81000000 10735000000 9823000000 9048000000 1252000000 1097000000 931000000 400000000 373000000 143000000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the reclassifications out of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income, net of tax</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>322</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(86</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>270</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>111</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note D – Hedging Activities and Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> for further detail on our net investment hedges recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign currency translation adjustments</span><span style="font-family:inherit;font-size:10pt;"> and our cash flow hedges recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net change in derivative financial instruments</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of adopting ASC Update No. 2016-01 in the first quarter of 2018, we recorded a cumulative effect adjustment to retained earnings to reclassify unrealized gains and losses from our equity investments previously recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">. These equity investments were classified as available-for-sale securities under the former accounting guidance, and we now refer to these investments as publicly-held equity securities. Refer to </span><span style="font-style:italic;">Note A – Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The gains and losses on defined benefit and pension items before reclassifications and gains and losses on defined benefit and pension items reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;"> were reduced by immaterial income tax impacts in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and in </span><span style="font-family:inherit;font-size:10pt;">2018</span>. <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the reclassifications out of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income, net of tax</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>322</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(86</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>270</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>111</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -53000000 111000000 0 25000000 33000000 228000000 116000000 0 -22000000 322000000 -33000000 54000000 0 2000000 -86000000 195000000 62000000 0 20000000 237000000 142000000 173000000 0 45000000 270000000 -32000000 1000000 -1000000 27000000 -59000000 0 96000000 0 -2000000 94000000 -21000000 -14000000 1000000 4000000 -3000000 -21000000 110000000 0 -2000000 91000000 -53000000 111000000 0 25000000 33000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE Q – NEW ACCOUNTING PRONOUNCEMENTS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Standards to be Implemented</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-13</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASC Update No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses </span><span style="font-family:inherit;font-size:10pt;">(Topic 326)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. We expect the adoption will have an immaterial impact on our financial position and results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2018-15</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASC Update No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2018-18</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASC Update No. 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying The Interaction Between Topic 808 and Topic 606. </span><span style="font-family:inherit;font-size:10pt;">The purpose of Update No. 2018-18 is to clarify the interaction between </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 808</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> as </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 808</span><span style="font-family:inherit;font-size:10pt;"> did not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements was often based on an analogy to other accounting literature or an accounting policy election. Update No. 2018-18 is effective for annual periods beginning after December 15, 2019. We plan to adopt Update No. 2018-18 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No other new accounting pronouncements, issued or effective, during the period had, or is expected to have, a material impact on our </span><span style="font-family:inherit;font-size:10pt;">consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-13</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASC Update No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses </span><span style="font-family:inherit;font-size:10pt;">(Topic 326)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. We expect the adoption will have an immaterial impact on our financial position and results of operations.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2018-15</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASC Update No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2018-18</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASC Update No. 2018-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying The Interaction Between Topic 808 and Topic 606. </span><span style="font-family:inherit;font-size:10pt;">The purpose of Update No. 2018-18 is to clarify the interaction between </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 808</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 606</span><span style="font-family:inherit;font-size:10pt;"> as </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 808</span><span style="font-family:inherit;font-size:10pt;"> did not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements was often based on an analogy to other accounting literature or an accounting policy election. Update No. 2018-18 is effective for annual periods beginning after December 15, 2019. We plan to adopt Update No. 2018-18 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-weight:bold;">NOTE R - EMPLOYEE RETIREMENT PLANS</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Defined Benefit Pension Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Domestic Retirement Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and division presidents. Participants may retire with benefits once retirement conditions have been satisfied. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.K. Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of our acquisition of BTG, we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom (U.K.) employees (U.K. Plan). The U.K. Plan was closed to new entrants as of June 1, 2004. Prior to the acquisition close date of August 19, 2019, the Trustees of the U.K. Plan executed buy-in arrangements (Buy-in Contracts), which effectively, as structured under the Buy-in Contracts, are intended to provide payments designed to equal all future designated contractual benefit payments to covered participants. The benefit obligation of the pension plan is not transferred to the insurers, and we remain responsible for paying pension benefits. We do not anticipate any additional material contributions or payments to the U.K. Plan or the insurer. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with our preliminary purchase price allocation of BTG, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets as of the August 19, 2019 measurement date:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:20%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:26%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Return on Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate of Compensation Increase</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.K. Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4%</span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the measurement date of August 19, 2019, the funded status was as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Funded status</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for additional information on our acquisition of BTG.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information about the U.K. Plan presented below is as of the December 31, 2019 measurement date.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other International Retirement Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we maintain retirement plans covering certain international employees. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, recognizing changes primarily through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">. As of December 31, 2019 and 2018, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Benefit Obligation (ABO)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Projected<br/>Benefit<br/>Obligation (PBO)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value of Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unfunded/Underfunded<br/>PBO Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic Retirement Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.K. Plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other International Retirement Plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>488</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>332</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>156</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Benefit Obligation (ABO)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Projected<br/>Benefit<br/>Obligation (PBO)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value of Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unfunded/Underfunded PBO Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic Retirement Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International Retirement Plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A rollforward of the changes in the PBO for our retirement plans is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired and established plans</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan amendments and assumption changes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefits paid</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>488</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans obtained through acquisition and other increases in connection with our international operations. Refer to </span><span style="font-size:9pt;font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:9pt;"> for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical assumptions associated with our employee retirement plans for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:47%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Expected Return on Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Rate of Compensation Increase</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic Retirement Plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.94%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.50%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.K. Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.60%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.60%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.00%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other International Retirement Plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.75%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.05%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.65%</span></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Rates of compensation increase were not weighted by the relative fair value of the instruments. As such, the amount represents the median of the inputs and is not a weighted average.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical assumptions associated with our employee retirement plans for </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:44%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Return on Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate of Compensation Increase</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic Retirement Plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.25%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.00%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International Retirement Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.34%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.10%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.78%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired and established plans</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employer contributions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Participant contributions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefits paid</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>332</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans obtained through acquisition and other increases in connection with our international operations. Refer to </span><span style="font-size:9pt;font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:9pt;"> for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our defined benefit plans excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our U.K. Plan, we utilize the insurance buy-in methodology and base our discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We believe this is a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate is calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assume that all pension increases will continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which will be based on Consumer Price Inflation (CPI). We base our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy is to invest in fully matching assets. This has been achieved through the purchase of two buy-in policies (Buy-in contracts), which provide payments designed to equal all future benefit payments due from the fund. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Buy-in contracts represented 99% of the total plan assets, as compared to the target percentage of 100%, and are considered Level 3 investments. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buy-in contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of the U.K. Plan Level 3 assets were as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Buy-in Contracts</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired plans</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefits paid</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Refer to </span><span style="font-size:9pt;font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:9pt;"> for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Defined Contribution Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was </span><span style="font-family:inherit;font-size:10pt;"><span>$98 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$87 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$79 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div> 0.004 0.004 0.034 213000000 216000000 -3000000 <span style="font-family:inherit;font-size:10pt;">We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the </span><span style="font-family:inherit;font-size:10pt;">consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, recognizing changes primarily through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span>. The outstanding obligation is as follows:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Benefit Obligation (ABO)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Projected<br/>Benefit<br/>Obligation (PBO)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value of Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unfunded/Underfunded<br/>PBO Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic Retirement Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.K. Plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other International Retirement Plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>488</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>332</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>156</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Benefit Obligation (ABO)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Projected<br/>Benefit<br/>Obligation (PBO)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value of Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unfunded/Underfunded PBO Recognized</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic Retirement Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International Retirement Plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 50000000 54000000 0 54000000 212000000 212000000 209000000 3000000 204000000 223000000 123000000 100000000 466000000 488000000 332000000 156000000 47000000 50000000 0 50000000 166000000 182000000 107000000 75000000 213000000 232000000 107000000 125000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A rollforward of the changes in the PBO for our retirement plans is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired and established plans</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial (gain) loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan amendments and assumption changes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefits paid</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>488</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans obtained through acquisition and other increases in connection with our international operations. Refer to </span><span style="font-size:9pt;font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:9pt;"> for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 232000000 207000000 216000000 23000000 15000000 14000000 5000000 4000000 0 -1000000 11000000 -2000000 10000000 10000000 19000000 -3000000 488000000 232000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical assumptions associated with our employee retirement plans for </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:47%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Expected Return on Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Rate of Compensation Increase</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic Retirement Plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.94%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.50%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.K. Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.60%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.60%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.00%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other International Retirement Plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.75%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.05%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.65%</span></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Rates of compensation increase were not weighted by the relative fair value of the instruments. As such, the amount represents the median of the inputs and is not a weighted average.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical assumptions associated with our employee retirement plans for </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> are as follows: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:44%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Return on Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate of Compensation Increase</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic Retirement Plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.00</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.25%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.00%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International Retirement Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.34%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.10%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.78%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets as of the August 19, 2019 measurement date:<div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:20%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:26%;"/><td style="width:1%;"/><td style="width:26%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Return on Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate of Compensation Increase</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.K. Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4%</span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the measurement date of August 19, 2019, the funded status was as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Funded status</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.0294 0.0150 0.0060 0.0060 0.0300 0.0075 0.0205 0.0265 0.0400 0.0425 0.0300 0.0050 0.0234 0.0190 0.0410 0.0150 0.0678 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning fair value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired and established plans</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employer contributions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Participant contributions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefits paid</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>332</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Plans obtained through acquisition and other increases in connection with our international operations. Refer to </span><span style="font-size:9pt;font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:9pt;"> for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of the U.K. Plan Level 3 assets were as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Buy-in Contracts</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired plans</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial gain (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefits paid</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Refer to </span><span style="font-size:9pt;font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:9pt;"> for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.</span></div> 107000000 87000000 213000000 16000000 7000000 -2000000 13000000 14000000 2000000 2000000 -20000000 0 10000000 10000000 19000000 0 332000000 107000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buy-in contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 207000000 207000000 1000000 0 0 1000000 1000000 0 207000000 209000000 0 213000000 -20000000 4000000 19000000 209000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was </span><span style="font-family:inherit;font-size:10pt;"><span>$98 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$87 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$79 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our defined benefit plans excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">For our U.K. Plan, we utilize the insurance buy-in methodology and base our discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. We believe this is a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate is calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assume that all pension increases will continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which will be based on Consumer Price Inflation (CPI). We base our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy is to invest in fully matching assets. This has been achieved through the purchase of two buy-in policies (Buy-in contracts), which provide payments designed to equal all future benefit payments due from the fund. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span>, the Buy-in contracts represented 99% of the total plan assets, as compared to the target percentage of 100%, and are considered Level 3 investments. 98000000 87000000 79000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Balance at<br/> Beginning of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Charges to<br/>Costs and</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Expenses (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Deductions to<br/>Allowances for<br/>Uncollectible</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accounts (b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Charges to<br/>(Deductions from)<br/>Other Accounts (c)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">End of Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Year Ended December 31, 2019:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Allowances for uncollectible accounts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Year Ended December 31, 2018:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Allowances for uncollectible accounts (d)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Year Ended December 31, 2017:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Allowances for uncollectible accounts and sales returns and allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:26px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Represents allowances for uncollectible accounts established through selling, general and administrative expenses.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(b) Represents actual write-offs of uncollectible accounts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(c) Represents net change in allowances for sales returns, recorded as contra-revenue.</span></div><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:-18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(d) Following the adoption of FASB ASC Topic 606 as of January 1, 2018, the allowance for sales returns has been reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, net</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> within the consolidated balance sheets and is not included in the ending balance for 2018 above. Prior period balances remain unchanged.</span></div> 68000000 23000000 17000000 0 74000000 98000000 19000000 19000000 -30000000 68000000 119000000 14000000 18000000 -17000000 98000000 XML 68 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Other Intangible Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Goodwill [Line Items]      
Impairment of Intangible Assets (Excluding Goodwill) $ 105,000,000 $ 35,000,000 $ 4,000,000
Goodwill 10,176,000,000 7,911,000,000 6,998,000,000
Goodwill, Translation and Purchase Accounting Adjustments 66,000,000 (29,000,000)  
Finite-Lived Intangible Assets, Gross 14,299,000,000 12,383,000,000  
Finite-Lived Intangible Assets, Accumulated Amortization (7,195,000,000) (6,617,000,000)  
Goodwill, Impaired, Accumulated Impairment Loss (9,900,000,000) (9,900,000,000)  
Goodwill (Textuals) [Abstract]      
Intangible Assets, Net (Excluding Goodwill) 7,886,000,000 6,372,000,000 5,837,000,000
Goodwill, Acquired During Period 2,218,000,000 942,000,000  
Other Intangible Assets (Textuals) [Abstract]      
Other intangible asset charges (19,000,000)    
Goodwill, Gross 20,076,000,000 17,811,000,000  
Indefinite-lived intangible assets, accumulated write-offs (9,900,000,000) (9,900,000,000)  
Indefinite-lived intangible assets, including goodwill 20,858,000,000 18,417,000,000  
Future Amortization Expense, Year One 787,000,000    
Future Amortization Expense, Year Two 750,000,000    
Future Amortization Expense, Year Three 722,000,000    
Future Amortization Expense, Year Four 708,000,000    
Future Amortization Expense, Year Five 672,000,000    
Revenue from Contract with Customer, Excluding Assessed Tax 10,735,000,000 9,823,000,000 9,048,000,000
Cardiovascular [Member]      
Goodwill [Line Items]      
Goodwill 5,676,000,000 3,925,000,000 3,704,000,000
Goodwill, Translation and Purchase Accounting Adjustments 58,000,000 (3,000,000)  
Goodwill (Textuals) [Abstract]      
Goodwill, Acquired During Period 1,712,000,000 224,000,000  
Other Intangible Assets (Textuals) [Abstract]      
Other intangible asset charges 19,000,000    
Revenue from Contract with Customer, Excluding Assessed Tax 4,208,000,000 3,777,000,000 3,500,000,000
BSX Reportable Segments [Member]      
Other Intangible Assets (Textuals) [Abstract]      
Revenue from Contract with Customer, Excluding Assessed Tax 10,654,000,000 9,823,000,000 9,048,000,000
Other Segments [Member]      
Goodwill [Line Items]      
Goodwill 247,000,000 0 0
Goodwill, Translation and Purchase Accounting Adjustments 9,000,000 0  
Goodwill (Textuals) [Abstract]      
Goodwill, Acquired During Period 238,000,000 0  
Other Intangible Assets (Textuals) [Abstract]      
Other intangible asset charges 0    
Revenue from Contract with Customer, Excluding Assessed Tax 81,000,000    
MedSurg [Member]      
Goodwill [Line Items]      
Goodwill 2,061,000,000 2,063,000,000 2,877,000,000
Goodwill, Period Increase (Decrease)   (1,379,000,000)  
Goodwill, Translation and Purchase Accounting Adjustments (1,000,000) (3,000,000)  
Goodwill (Textuals) [Abstract]      
Goodwill, Acquired During Period 0 568,000,000  
Other Intangible Assets (Textuals) [Abstract]      
Revenue from Contract with Customer, Excluding Assessed Tax 3,307,000,000 3,007,000,000 2,742,000,000
Rhythm and Neuro [Member]      
Goodwill [Line Items]      
Goodwill 2,192,000,000 1,924,000,000 417,000,000
Goodwill, Period Increase (Decrease)   1,379,000,000  
Goodwill, Translation and Purchase Accounting Adjustments 0 (22,000,000)  
Goodwill (Textuals) [Abstract]      
Goodwill, Acquired During Period 268,000,000 150,000,000  
Other Intangible Assets (Textuals) [Abstract]      
Revenue from Contract with Customer, Excluding Assessed Tax 3,140,000,000 3,041,000,000 $ 2,808,000,000
Technology-Based Intangible Assets [Member]      
Goodwill [Line Items]      
Finite-Lived Intangible Assets, Gross 12,020,000,000 10,197,000,000  
Finite-Lived Intangible Assets, Accumulated Amortization (5,706,000,000) (5,266,000,000)  
Patents [Member]      
Goodwill [Line Items]      
Finite-Lived Intangible Assets, Gross 525,000,000 520,000,000  
Finite-Lived Intangible Assets, Accumulated Amortization (408,000,000) (393,000,000)  
Other Intangible Assets [Member]      
Goodwill [Line Items]      
Finite-Lived Intangible Assets, Gross 1,754,000,000 1,666,000,000  
Finite-Lived Intangible Assets, Accumulated Amortization (1,081,000,000) (958,000,000)  
In Process Research and Development [Member]      
Other Intangible Assets (Textuals) [Abstract]      
Indefinite-lived Intangible Assets (Excluding Goodwill) 662,000,000 486,000,000  
Technology-Based Intangible Assets [Member]      
Other Intangible Assets (Textuals) [Abstract]      
Indefinite-lived Intangible Assets (Excluding Goodwill) 120,000,000 120,000,000  
Indefinite-lived intangible assets, accumulated write-offs $ 0 $ 0  
XML 69 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Weighted Average Shares Outstanding (Tables)
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Weighted average shares outstanding
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Weighted average shares outstanding - basic
1,391.5

 
1,381.0

 
1,370.1

Net effect of common stock equivalents
19.0

 
20.4

 
22.6

Weighted average shares outstanding - assuming dilution
1,410.6

 
1,401.4

 
1,392.7
XML 70 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Retirement Plans (Tables)
 12 Months Ended
Dec. 31, 2019
Retirement Benefits [Abstract]  
Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI.
Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] The outstanding obligation is as follows:
 
As of December 31, 2019
(in millions)
Accumulated Benefit Obligation (ABO)
 
Projected
Benefit
Obligation (PBO)
 
Fair value of Plan Assets
 
Unfunded/Underfunded
PBO Recognized
Domestic Retirement Plans
$
50

 
$
54

 
$
—

 
$
54

U.K. Plan
212

 
212

 
209

 
3

Other International Retirement Plans
204

 
223

 
123

 
100

 
$
466

 
$
488

 
$
332

 
$
156



 
As of December 31, 2018
(in millions)
Accumulated Benefit Obligation (ABO)
 
Projected
Benefit
Obligation (PBO)
 
Fair value of Plan Assets
 
Unfunded/Underfunded PBO Recognized
Domestic Retirement Plans
$
47

 
$
50

 
$
—

 
$
50

International Retirement Plans
166

 
182

 
107

 
75

 
$
213

 
$
232

 
$
107

 
$
125
Schedule of Changes in Projected Benefit Obligations [Table Text Block]
A rollforward of the changes in the PBO for our retirement plans is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
Beginning obligations
$
232

 
$
207

Acquired and established plans(1)
216

 
23

Service costs
15

 
14

Interest costs
5

 
4

Actuarial (gain) loss
—

 
(1
)
Plan amendments and assumption changes
11

 
(2
)
Benefits paid
(10
)
 
(10
)
Impact of foreign currency fluctuations
19

 
(3
)
Ending obligation
$
488

 
$
232

(1)
Plans obtained through acquisition and other increases in connection with our international operations. Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.
Schedule of Defined Benefit Plans Disclosures [Table Text Block]
The critical assumptions associated with our employee retirement plans for 2019 are as follows:
 
Weighted Average Discount Rate
 
Weighted Average Expected Return on Plan
 
Weighted Average Rate of Compensation Increase(1)
 
 
 
Domestic Retirement Plans
2.94%
 
n/a
 
1.50%
U.K. Plan
0.60%
 
0.60%
 
3.00%
Other International Retirement Plans
0.75%
 
2.05%
 
2.65%
(1)
Rates of compensation increase were not weighted by the relative fair value of the instruments. As such, the amount represents the median of the inputs and is not a weighted average.

The critical assumptions associated with our employee retirement plans for 2018 are as follows:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
Domestic Retirement Plans
4.00
%
-
4.25%
 
n/a
 
3.00%
International Retirement Plans
0.50
%
-
2.34%
 
1.90
%
-
4.10%
 
1.50
%
-
6.78%

The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets as of the August 19, 2019 measurement date:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
U.K. Plan
0.4%
 
0.4%
 
3.4%

As of the measurement date of August 19, 2019, the funded status was as follows:
(in millions)
 
Fair value of plan assets
$
213

Benefit obligation
(216
)
Funded status
$
(3
)
Pension and Other Postretirement Plans, Policy [Policy Text Block]
We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $98 million in 2019, $87 million in 2018 and $79 million in 2017.
For our defined benefit plans excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.

For our U.K. Plan, we utilize the insurance buy-in methodology and base our discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2019. We believe this is a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate is calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assume that all pension increases will continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which will be based on Consumer Price Inflation (CPI). We base our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy is to invest in fully matching assets. This has been achieved through the purchase of two buy-in policies (Buy-in contracts), which provide payments designed to equal all future benefit payments due from the fund. As of December 31, 2019, the Buy-in contracts represented 99% of the total plan assets, as compared to the target percentage of 100%, and are considered Level 3 investments.
Schedule of Changes in Fair Value of Plan Assets [Table Text Block]
A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
Beginning fair value
$
107

 
$
87

Acquired and established plans(1)
213

 
16

Actual return on plan assets
7

 
(2
)
Employer contributions
13

 
14

Participant contributions
2

 
2

Actuarial gain (loss)
(20
)
 
—

Benefits paid
(10
)
 
(10
)
Impact of foreign currency fluctuations
19

 
—

Ending fair value
$
332

 
$
107

(1)
Plans obtained through acquisition and other increases in connection with our international operations. Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.
Changes in the fair value of the U.K. Plan Level 3 assets were as follows:
(in millions)
Buy-in Contracts
Balance as of December 31, 2018
$
—

Acquired plans(1)
213

Actuarial gain (loss)
(20
)
Benefits paid
(4
)
Impact of foreign currency fluctuations
19

Balance as of December 31, 2019
$
209

(1)
Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.
Schedule of Allocation of Plan Assets [Table Text Block]
The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value as of December 31, 2019:
 
As of
 
December 31, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Buy-in contracts
$
—

 
$
—

 
$
207

 
$
207

Cash
1

 
—

 
—

 
1

Total assets
$
1

 
$
—

 
$
207

 
$
209
XML 71 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
New Accounting Pronouncements New Accounting Pronouncements (Policies)
 12 Months Ended
Dec. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
NOTE Q – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our consolidated financial statements.

Standards to be Implemented

ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. We expect the adoption will have an immaterial impact on our financial position and results of operations.

ASC Update No. 2018-15

In August 2018, the FASB issued ASC Update No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.

ASC Update No. 2018-18

In November 2018, the FASB issued ASC Update No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying The Interaction Between Topic 808 and Topic 606. The purpose of Update No. 2018-18 is to clarify the interaction between FASB ASC Topic 808 and FASB ASC Topic 606 as FASB ASC Topic 808 did not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements was often based on an analogy to other accounting literature or an accounting policy election. Update No. 2018-18 is effective for annual periods beginning after December 15, 2019. We plan to adopt Update No. 2018-18 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.

No other new accounting pronouncements, issued or effective, during the period had, or is expected to have, a material impact on our consolidated financial statements.
ASC Update No. 2016-13 [Policy Text Block]
ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. We expect the adoption will have an immaterial impact on our financial position and results of operations.
ASC Update No. 2018-15, Internal-Use Software [Policy Text Block]
ASC Update No. 2018-15

In August 2018, the FASB issued ASC Update No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.

ASC Update No. 2016-02, Leases (Topic 842) [Policy Text Block]
ASC Update No. 2018-18

In November 2018, the FASB issued ASC Update No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying The Interaction Between Topic 808 and Topic 606. The purpose of Update No. 2018-18 is to clarify the interaction between FASB ASC Topic 808 and FASB ASC Topic 606 as FASB ASC Topic 808 did not provide comprehensive recognition or measurement guidance for collaborative arrangements, and the accounting for those arrangements was often based on an analogy to other accounting literature or an accounting policy election. Update No. 2018-18 is effective for annual periods beginning after December 15, 2019. We plan to adopt Update No. 2018-18 in the first quarter of 2020. We expect the adoption will have an immaterial impact on our financial position and results of operations.
XML 72 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Retirement Plans (Notes)
 12 Months Ended
Dec. 31, 2019
Retirement Benefits [Abstract]  
Compensation and Employee Benefit Plans [Text Block]
NOTE R - EMPLOYEE RETIREMENT PLANS

Defined Benefit Pension Plans

Domestic Retirement Plans

Following our 2006 acquisition of Guidant, we assumed the Guidant Supplemental Retirement Plan, a frozen, non-qualified defined benefit plan for certain former officers and employees of Guidant. The Guidant Supplemental Retirement Plan was partially funded through a Rabbi Trust that contains segregated company assets within restricted cash used to pay the benefit obligations related to the plan.

We also maintain an Executive Retirement Plan, a defined benefit plan covering executive officers and division presidents. Participants may retire with benefits once retirement conditions have been satisfied.

U.K. Plan

As a result of our acquisition of BTG, we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom (U.K.) employees (U.K. Plan). The U.K. Plan was closed to new entrants as of June 1, 2004. Prior to the acquisition close date of August 19, 2019, the Trustees of the U.K. Plan executed buy-in arrangements (Buy-in Contracts), which effectively, as structured under the Buy-in Contracts, are intended to provide payments designed to equal all future designated contractual benefit payments to covered participants. The benefit obligation of the pension plan is not transferred to the insurers, and we remain responsible for paying pension benefits. We do not anticipate any additional material contributions or payments to the U.K. Plan or the insurer.

In connection with our preliminary purchase price allocation of BTG, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets as of the August 19, 2019 measurement date:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
U.K. Plan
0.4%
 
0.4%
 
3.4%

As of the measurement date of August 19, 2019, the funded status was as follows:
(in millions)
 
Fair value of plan assets
$
213

Benefit obligation
(216
)
Funded status
$
(3
)


Refer to Note B – Acquisitions and Strategic Investments for additional information on our acquisition of BTG.

Information about the U.K. Plan presented below is as of the December 31, 2019 measurement date.



Other International Retirement Plans

In addition, we maintain retirement plans covering certain international employees.

We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI. As of December 31, 2019 and 2018, the funded status of our plans were unfunded or underfunded in aggregate. The outstanding obligation is as follows:
 
As of December 31, 2019
(in millions)
Accumulated Benefit Obligation (ABO)
 
Projected
Benefit
Obligation (PBO)
 
Fair value of Plan Assets
 
Unfunded/Underfunded
PBO Recognized
Domestic Retirement Plans
$
50

 
$
54

 
$
—

 
$
54

U.K. Plan
212

 
212

 
209

 
3

Other International Retirement Plans
204

 
223

 
123

 
100

 
$
466

 
$
488

 
$
332

 
$
156



 
As of December 31, 2018
(in millions)
Accumulated Benefit Obligation (ABO)
 
Projected
Benefit
Obligation (PBO)
 
Fair value of Plan Assets
 
Unfunded/Underfunded PBO Recognized
Domestic Retirement Plans
$
47

 
$
50

 
$
—

 
$
50

International Retirement Plans
166

 
182

 
107

 
75

 
$
213

 
$
232

 
$
107

 
$
125



A rollforward of the changes in the PBO for our retirement plans is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
Beginning obligations
$
232

 
$
207

Acquired and established plans(1)
216

 
23

Service costs
15

 
14

Interest costs
5

 
4

Actuarial (gain) loss
—

 
(1
)
Plan amendments and assumption changes
11

 
(2
)
Benefits paid
(10
)
 
(10
)
Impact of foreign currency fluctuations
19

 
(3
)
Ending obligation
$
488

 
$
232

(1)
Plans obtained through acquisition and other increases in connection with our international operations. Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

The critical assumptions associated with our employee retirement plans for 2019 are as follows:
 
Weighted Average Discount Rate
 
Weighted Average Expected Return on Plan
 
Weighted Average Rate of Compensation Increase(1)
 
 
 
Domestic Retirement Plans
2.94%
 
n/a
 
1.50%
U.K. Plan
0.60%
 
0.60%
 
3.00%
Other International Retirement Plans
0.75%
 
2.05%
 
2.65%
(1)
Rates of compensation increase were not weighted by the relative fair value of the instruments. As such, the amount represents the median of the inputs and is not a weighted average.

The critical assumptions associated with our employee retirement plans for 2018 are as follows:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
Domestic Retirement Plans
4.00
%
-
4.25%
 
n/a
 
3.00%
International Retirement Plans
0.50
%
-
2.34%
 
1.90
%
-
4.10%
 
1.50
%
-
6.78%


A rollforward of the changes in the fair value of plan assets for our funded retirement plans is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
Beginning fair value
$
107

 
$
87

Acquired and established plans(1)
213

 
16

Actual return on plan assets
7

 
(2
)
Employer contributions
13

 
14

Participant contributions
2

 
2

Actuarial gain (loss)
(20
)
 
—

Benefits paid
(10
)
 
(10
)
Impact of foreign currency fluctuations
19

 
—

Ending fair value
$
332

 
$
107

(1)
Plans obtained through acquisition and other increases in connection with our international operations. Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

For our defined benefit plans excluding our U.K. Plan, we base our discount rate on the rates of return available on high-quality bonds with maturities approximating the expected period over which benefits will be paid. The rate of compensation increase is based on historical and expected rate increases. We base our rate of expected return on plan assets on historical experience, our investment guidelines and expectations for long-term rates of return. Our assets are invested in a variety of securities, primarily equity securities and government bonds. These securities are considered Level 1 and Level 2 investments.

For our U.K. Plan, we utilize the insurance buy-in methodology and base our discount rate on a yield curve reflective of the market pricing obtained in the most recent buy-in transaction, which occurred prior to the acquisition of BTG, and movements in market-observed buy-in pricing as of December 31, 2019. We believe this is a reasonable proxy for an effective settlement rate of the buy-in assets. The discount rate is calculated as the single equivalent assumption that gives the same value of the liabilities as if the figures were calculated using the full yield curve. We assume that all pension increases will continue to be linked to the Retail Price Inflation (RPI), both before and after retirement, for all members, with the exception of post-88 Guaranteed Minimum Pensions (GMP), which will be based on Consumer Price Inflation (CPI). We base our rate of expected return on plan assets as equal to the discount rate used to value the buy-in assets. The U.K. Plan assets' investment policy is to invest in fully matching assets. This has been achieved through the purchase of two buy-in policies (Buy-in contracts), which provide payments designed to equal all future benefit payments due from the fund. As of December 31, 2019, the Buy-in contracts represented 99% of the total plan assets, as compared to the target percentage of 100%, and are considered Level 3 investments.

The following table presents the fair value hierarchy of the U.K. Plan assets measured at fair value as of December 31, 2019:
 
As of
 
December 31, 2019
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
Buy-in contracts
$
—

 
$
—

 
$
207

 
$
207

Cash
1

 
—

 
—

 
1

Total assets
$
1

 
$
—

 
$
207

 
$
209



Changes in the fair value of the U.K. Plan Level 3 assets were as follows:
(in millions)
Buy-in Contracts
Balance as of December 31, 2018
$
—

Acquired plans(1)
213

Actuarial gain (loss)
(20
)
Benefits paid
(4
)
Impact of foreign currency fluctuations
19

Balance as of December 31, 2019
$
209

(1)
Refer to Note B – Acquisitions and Strategic Investments for additional information regarding the U.K. Plan we acquired with BTG on August 19, 2019.

Defined Contribution Plan

We also sponsor a voluntary 401(k) Retirement Savings Plan for eligible employees. We match 200 percent of employee elective deferrals for the first two percent of employee eligible compensation and 50 percent of employee elective deferrals greater than two percent, but not exceeding six percent, of employee eligible compensation. Total expense for our matching contributions to the plan was $98 million in 2019, $87 million in 2018 and $79 million in 2017.
XML 73 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Reporting
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
SEGMENT REPORTING
NOTE N – SEGMENT REPORTING

We have three reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices. We measure and evaluate our reportable segments based on net sales of reportable segments, operating income of reportable segments, excluding intersegment profits, and operating income of reportable segments as a percentage of net sales of reportable segments. Operating income of reportable segments as a percentage of net sales of reportable segments is defined as operating income of reportable segments divided by net sales of reportable segments. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker (CODM) considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition/divestitures-related items, restructuring and restructuring-related items, medical device regulation charges and litigation-related charges/(credits). Although we exclude these amounts from operating income of reportable segments, they are included in reported Income (loss) before income taxes on the consolidated statements of operations and are included in the reconciliation below.

Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG, which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments.


A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying consolidated statements of operations is as follows (in millions, except percentages):
 
Year Ended December 31,
Net sales
2019
 
2018
 
2017
MedSurg
$
3,307

 
$
3,007

 
$
2,742

Rhythm and Neuro
3,140

 
3,041

 
2,808

Cardiovascular
4,208

 
3,777

 
3,500

Total net sales of reportable segments
10,654

 
9,823

 
9,048

All other (Specialty Pharmaceuticals)
81

 
n/a

 
n/a

Consolidated net sales
$
10,735

 
$
9,823

 
$
9,048



 
Year Ended December 31,
Depreciation expense
2019
 
2018
 
2017
MedSurg
$
75

 
$
72

 
$
68

Rhythm and Neuro
92

 
91

 
91

Cardiovascular
138

 
133

 
120

Total depreciation expense of reportable segments
306

 
296

 
279

All other (Specialty Pharmaceuticals)
6

 
n/a

 
n/a

Consolidated depreciation expense
$
311

 
$
296

 
$
279


 
Year Ended December 31,
Income (loss) before income taxes
2019
 
2018
 
2017
MedSurg
$
1,204

 
$
1,102

 
$
984

Rhythm and Neuro
666

 
655

 
537

Cardiovascular
1,137

 
1,117

 
988

Total operating income of reportable segments
3,007

 
2,875

 
2,509

All other (Specialty Pharmaceuticals)
56

 
n/a

 
n/a

Unallocated amounts:
 
 
 
 
 
Corporate expenses, including hedging activities
(264
)
 
(372
)
 
(252
)
Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and EU MDR implementation costs
(582
)
 
(398
)
 
(407
)
Amortization expense
(699
)
 
(599
)
 
(565
)
Operating income (loss)
1,518

 
1,506

 
1,285

Other expense, net
(831
)
 
(85
)
 
(353
)
Income (loss) before income taxes
$
687

 
$
1,422

 
$
933


Operating income of reportable segments as a percentage of net sales of reportable segments
Year Ended December 31,
2019
 
2018
 
2017
MedSurg
36.4
%
 
36.7
%
 
35.9
%
Rhythm and Neuro
21.2
%
 
21.5
%
 
19.1
%
Cardiovascular
27.0
%
 
29.6
%
 
28.2
%

 
As of December 31,
Total assets
2019
 
2018
MedSurg
$
1,803

 
$
1,846

Rhythm and Neuro
1,873

 
1,696

Cardiovascular
2,535

 
1,954

Total assets of reportable segments
6,211

 
5,497

All other (Specialty Pharmaceuticals)
211

 
—

Goodwill
10,176

 
7,911

Other intangible assets, net
7,886

 
6,372

All other corporate assets
6,082

 
1,219

 
$
30,565

 
$
20,999



 
As of December 31,
Long-lived assets
2019
 
2018
 
2017
U.S.
$
1,148

 
$
1,061

 
$
1,065

Ireland
327

 
242

 
210

Other countries
604

 
478

 
422

Property, plant and equipment, net
2,079

 
1,782

 
1,697

Goodwill
10,176

 
7,911

 
6,998

Other intangible assets, net
7,886

 
6,372

 
5,837

Operating lease right-of-use assets in Other long-term assets
336

 
—

 
—

 
$
20,477

 
$
16,064

 
$
14,531
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue Revenue (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]      
Contract with Customer, Liability $ 400 $ 373  
Revenue from Contract with Customer, Excluding Assessed Tax 10,735 9,823 $ 9,048
Contract with Customer, Liability, Revenue Recognized 143    
EMEA [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,264 2,176 1,940
UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 6,167 5,538 5,162
Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 4,569 4,286 3,885
Asia Pacific [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,898 1,727 1,587
Latin America and Canada [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 395 383 358
Emerging Markets [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,252 1,097 931
Global Endoscopy (Endo) Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,894 1,762 1,619
Global Endoscopy (Endo) Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,080 980 894
Global Endoscopy (Endo) Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 814 781 724
Global Urology and Pelvic Health Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,413 1,245 1,124
Global Urology and Pelvic Health Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,005 864 785
Global Urology and Pelvic Health Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 408 381 339
Global CRM Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,939 1,951 1,895
Global CRM Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,135 1,159 1,135
Global CRM Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 804 792 760
Global Electrophysiology (EP) Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 329 311 278
Global Electrophysiology (EP) Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 148 150 136
Global Electrophysiology (EP) Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 180 161 142
Global Neuromodulation (NM) Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 873 779 635
Global Neuromodulation (NM) Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 695 624 517
Global Neuromodulation (NM) Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 178 155 118
Global Interventional Cardiology (IC) Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 2,816 2,590 2,419
Global Interventional Cardiology (IC) Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,293 1,154 1,122
Global Interventional Cardiology (IC) Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,522 1,436 1,297
Global Peripheral Interventions (PI) Reporting Unit [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 1,392 1,187 1,081
Global Peripheral Interventions (PI) Reporting Unit [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 741 608 575
Global Peripheral Interventions (PI) Reporting Unit [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 651 579 506
BTG Spec Pharma [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 81    
BTG Spec Pharma [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 70    
BTG Spec Pharma [Member] | Non-US [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 11    
BSX Reportable Segments [Member]      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax 10,654 $ 9,823 $ 9,048
BSX Reportable Segments [Member] | UNITED STATES      
Disaggregation of Revenue [Line Items]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 6,097    
XML 75 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock Inventive and Ownership Plans Employee Stock Purchase Plan (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]
Information related to shares issued or to be issued in connection with the employee stock purchase plan based on employee contributions and the range of purchase prices is as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
Shares issued or to be issued (in thousands)
2,196
 
 
2,452
 
 
2,491
 
Range of purchase prices
$
29.29

-
$36.47
 
$
21.49

-
$27.91
 
$
18.60

-
$21.07
Expense recognized (in millions)
$
19
 
 
$
17
 
 
$
13
 
XML 76 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue Revenue (Tables)
 12 Months Ended
Dec. 31, 2019
Disaggregation of Revenue [Abstract]  
Disaggregation of Revenue [Table Text Block] The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
 
Year Ended December 31,
 
2019
 
2018
 
2017
Businesses
U.S.
 
OUS
 
Total
 
U.S.
 
OUS
 
Total
 
U.S.
 
OUS
 
Total
Endoscopy
$
1,080

 
$
814

 
$
1,894

 
$
980

 
$
781

 
$
1,762

 
$
894

 
$
724

 
$
1,619

Urology and Pelvic Health
1,005

 
408

 
1,413

 
864

 
381

 
1,245

 
785

 
339

 
1,124

Cardiac Rhythm Management
1,135

 
804

 
1,939

 
1,159

 
792

 
1,951

 
1,135

 
760

 
1,895

Electrophysiology
148

 
180

 
329

 
150

 
161

 
311

 
136

 
142

 
278

Neuromodulation
695

 
178

 
873

 
624

 
155

 
779

 
517

 
118

 
635

Interventional Cardiology
1,293

 
1,522

 
2,816

 
1,154

 
1,436

 
2,590

 
1,122

 
1,297

 
2,419

Peripheral Interventions
741

 
651

 
1,392

 
608

 
579

 
1,187

 
575

 
506

 
1,081

Specialty Pharmaceuticals
70

 
11

 
81

 
n/a

 
n/a

 
n/a

 
n/a

 
n/a

 
n/a

Net Sales
$
6,167

 
$
4,569

 
$
10,735

 
$
5,538

 
$
4,286

 
$
9,823

 
$
5,162

 
$
3,885

 
$
9,048


 
Year Ended December 31,
Geographic Regions
2019
 
2018
 
2017
U.S.
$
6,097

 
$
5,538

 
$
5,162

EMEA (Europe, Middle East and Africa)
2,264

 
2,176

 
1,940

APAC (Asia-Pacific)
1,898

 
1,727

 
1,587

LACA (Latin America and Canada)
395

 
383

 
358

Medical Devices
10,654

 
9,823

 
9,048

U.S.
70

 
n/a

 
n/a

OUS
11

 
n/a

 
n/a

Specialty Pharmaceuticals
81

 
n/a

 
n/a

Net Sales
$
10,735

 
$
9,823

 
$
9,048

 
 
 
 
 
 
Emerging Markets (1)
$
1,252

 
$
1,097

 
$
931

(1)
We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation.
EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 78 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions and Strategic Investments Strategic Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]    
Equity Method Investments $ 264 $ 303
Cost Method Investments 171 94
Available-for-sale Securities 1 0
Notes Receivable From Portfolio Companies 23 26
Investments 458 $ 424
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity $ 314  

XML 79 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock Incentive and Ownership Plans (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Feb. 21, 2019
Feb. 15, 2018
Feb. 28, 2017
Dec. 31, 2016
May 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Fair value of market based awards $ 10 $ 7 $ 8          
Share Price $ 45.22 $ 35.34 $ 24.79 $ 40.12 $ 27.09 $ 24.55    
Unrecognized Compensation Cost - Stock Options $ 35              
Stock Issued During Period, Shares, Employee Stock Purchase Plans 2,196,000 2,452,000 2,491,000          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 11,079,000 12,683,000 15,250,000       18,797,000  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $ 29 $ 22 $ 18       $ 14  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3,656,000 4,375,000 4,798,000          
Measurement period - market based awards 2 years 10 months 24 days 2 years 10 months 24 days 2 years 9 months 18 days          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 2.48% 2.36% 1.45%          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value $ 39 $ 28 $ 24          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (4,811,000) (6,194,000) (7,663,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value $ 20 $ 16 $ 11          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (449,000) (748,000) (683,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Date Fair Value $ 27 $ 22 $ 17          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 23,065,000 25,304,000 26,716,000       26,644,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 2,992,000 3,491,000 4,439,000          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (4,872,000) (4,385,000) (3,922,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 12 $ 11 $ 10          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period (359,000) (519,000) (445,000)          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price $ 24 $ 22 $ 17          
Stock-based compensation expense $ 157 $ 140 $ 127          
Common Stock, Shares Authorized 2,000,000,000.000 2,000,000,000            
Common Stock, Capital Shares Reserved for Future Issuance 124,000,000              
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense $ (24) $ (21) (32)          
Share-based compensation, net of tax benefit $ 133 $ 119 $ 96          
compensation expense, per share - basic $ 0.10 $ 0.09 $ 0.07          
compensation expense, per share - diluted 0.09 0.08 0.07          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 40.20 27.26 24.70          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 11.76 $ 8.55 $ 7.16          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 24.00% 26.00% 25.00%          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 6 years 1 month 6 days 6 years 6 years 1 month 6 days          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value $ 140 $ 90 $ 64          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $ 19 $ 16 $ 13       $ 11  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 5 years 6 months              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $ 594              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 15,091,000              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $ 14              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 4 years 1 month 6 days              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value $ 476              
Options expected to vest 7,617,000              
Options expected to vest, weighted average exercise price $ 30              
Options expected to vest, weighted average remaining contractual life 8 years              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 114              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number 22,707,000              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $ 19              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 5 years 3 months 18 days              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $ 590              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Total Fair Value $ 193 $ 170 $ 190          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 50,000,000              
Amount of employees total compensation eligible for GESOP purchase 10.00%              
Global Employee Stock Purchase Plan - Exercise Amount equivalent to 85% of Fair Market Value of Common Stock at beginning or end of each offering period (whichever is less) 85.00%              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 8,000,000              
Unrecognized Compensation Cost - Non-vested stock awards $ 169              
Unrecognized Compensation Cost $ 204              
weighted average remaining vesting period 1 year 2 months 12 days              
annualweightedaverageforfeiturerate 6.00%              
voting power of all classes of stock 10.00%              
Exercise price of the fair market value of our common stock on the date of grant 110.00%              
Qualified options exercise price $ 0              
Fair value of the Free Cash Flow (FCF) performance awards $ 8 $ 11 $ 6          
Target payout of Free Cash Flows (FCF) performance awards 90.00% 118.00% 98.00%          
Employee Stock Ownership Plan (ESOP), Compensation Expense $ 19 $ 17 $ 13          
High end of range [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Range of the target number of performance-based DSUs awarded 150.00%              
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased $ 36.47 $ 27.91 $ 21.07          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 2.61% 3.01% 2.21%          
Range of the target number of market-based DSUs awarded 200.00%              
Minimum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Range of the target number of performance-based DSUs awarded 0.00%              
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased $ 29.29 $ 21.49 $ 18.60          
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 1.38% 2.61% 2.03%          
Range of the target number of market-based DSUs awarded 0.00%              
2011 LTIP Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common Stock, Shares Authorized               146,000,000
Cost of Sales [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense $ 8 $ 7 $ 7          
Selling, General and Administrative Expenses [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense 120 109 98          
Research and Development Expense [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense $ 28 $ 24 $ 23          
XML 80 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Details - Rate Table)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Schedule of Income Tax Rate Reconciliation [Line Items]      
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent 21.90% 0.50% 0.40%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses 3.30% 0.30% 2.20%
effective income tax reconciliation, compensation-related (0.30%) (1.00%) (2.50%)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate 21.00% 21.00% 35.00%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes 6.70% 0.40% (1.00%)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential (47.60%) (8.30%) (38.90%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense 12.20% 2.10% (1.70%)
Effective Income Tax Rate Reconciliation, Tax Credits, Research (4.20%) (2.60%) (2.60%)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance 1.10% (5.20%) (4.10%)
Effective Income Tax Rate Reconciliation, Uncertain Domestic Tax Positions 1.40% (22.00%) 10.70%
Effective Income Tax Rate Reconciliation, TCJA net impact 0.00% (4.70%) 91.40%
Effective Income Tax Rate Reconciliation, intra entity intangible asset transfers (597.00%) 0.00% 0.00%
Effective Income Tax Rate Reconciliation, Other Adjustments (2.50%) 1.80% (0.20%)
Reported tax rate (584.00%) (17.50%) 88.80%
XML 81 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Borrowings and Credit Arrangements (Details)
€ in Millions, £ in Millions
 12 Months Ended
Jan. 09, 2020
USD ($)
Dec. 05, 2019
USD ($)
Nov. 27, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2019
GBP (£)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
EUR (€)
Feb. 25, 2019
USD ($)
Dec. 19, 2018
USD ($)
Aug. 04, 2017
USD ($)
Debt Instrument [Line Items]                        
Purchase Obligation, Due in Next Twelve Months               $ 334,000,000        
Recorded Unconditional Purchase Obligation Due in Next Twelve Months               1,000,000        
Recorded Unconditional Purchase Obligation Due in Second Year               20,000,000        
Purchase Obligation, Due in Third Year               7,000,000        
Purchase Obligation, Due in Fourth Year               3,000,000        
Purchase Obligation, Due in Fifth Year               1,000,000        
Repurchase Agreement Counterparty, Amount at Risk               1.01        
Senior notes issued               7,311,000,000        
Schedule of debt maturities                        
Long-term Debt and Capital Lease Obligations         $ 4,803,000,000     8,592,000,000        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Total debt         7,056,000,000.000     10,008,000,000.000        
Debt, Current         2,253,000,000     1,416,000,000        
Amount of exclusions from EBITDA related to existing restructuring plans               500,000,000        
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA               270,000,000        
Amount of exclusions from EBITDA related to future litigation charges and payments               2,624,000,000        
Legal payments remaining to be excluded from calculation of consolidated EBITDA               1,199,000,000        
Gain (Loss) on Extinguishment of Debt       $ 86,000,000                
Repayments of Debt   $ 800,000,000 $ 200,000,000                  
Interest Expense       $ 473,000,000 241,000,000 $ 229,000,000            
Purchase Obligation               366,000,000        
Letters of Credit Outstanding, Amount         111,000,000     105,000,000        
Borrowings [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Commercial Paper         $ 1,248,000,000     $ 711,000,000        
Commercial Paper [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Weighted Average Maturity, Days       55 days 27 days              
Maximum Commercial Paper Outstanding with 2018 Facility         $ 2,750,000,000           $ 2,750,000,000  
Short-term Debt, Weighted Average Interest Rate, at Point in Time         3.04%   2.21% 2.21% 2.21%      
August 2019 Term Loan [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Short-term Debt               $ 1,000,000,000.000        
Covenant Requirement [Domain]                        
Summary of compliance with debt covenants                        
Maximum Leverage Ratio             3.75 3.75 3.75      
Covenant Requirement [Member]                        
Summary of compliance with debt covenants                        
Maximum Leverage Ratio             4.75 4.75 4.75      
Actual, Covenant [Member]                        
Summary of compliance with debt covenants                        
Maximum Leverage Ratio             3.83 3.83 3.83      
Requirement, first two quarters following qualified acquisition [Member]                        
Summary of compliance with debt covenants                        
Maximum Leverage Ratio             4.75 4.75 4.75      
Requirement, third quarter following qualified acquisition [Member]                        
Summary of compliance with debt covenants                        
Maximum Leverage Ratio             4.50 4.50 4.50      
Requirement, fourth quarter following qualified acquisition [Member]                        
Summary of compliance with debt covenants                        
Maximum Leverage Ratio             4.25 4.25 4.25      
Requirement, fifth quarter following qualified acquisition [Member]                        
Summary of compliance with debt covenants                        
Maximum Leverage Ratio             4.00 4.00 4.00      
Requirement, sixth quarter and thereafter following qualified acquisition [Member]                        
Summary of compliance with debt covenants                        
Maximum Leverage Ratio             3.75 3.75 3.75      
Commercial Paper [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Revolving credit facility         $ 1,502,000,000     $ 2,039,000,000        
the 2017 Facility [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Line of Credit Facility, Maximum Borrowing Capacity                       $ 2,250,000,000
the 2018 facility [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Current interest rate on revolving credit facility       1.02%                
Line of Credit Facility, Description       0.40%                
Commitment fee percentage       0.11%                
Tender Offer [Member]                        
Schedule of debt maturities                        
Payments due, Total               (1,000,000,000.000) € (900)      
February2019AggregateOffering [Member]                        
Schedule of debt maturities                        
Payments due, Total                   $ (4,300,000,000)    
March 2039 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         $ 0     $ (750,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (4.55%) (4.55%) (4.55%)      
October 2018 Notes [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage         (2.65%)              
Repayments of Debt         $ 600,000,000              
January 2020 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         (850,000,000)     $ 0        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (6.00%) (6.00%) (6.00%)      
Repayments of Debt       $ 850,000,000                
May 2020 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         (600,000,000)     $ 0        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (2.85%) (2.85%) (2.85%)      
Repayments of Debt       600,000,000                
August 2019 Term Loan [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Repayments of Debt       1,000,000,000.000                
May 2022 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         (500,000,000)     $ (500,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (3.375%) (3.375%) (3.375%)      
August 2022 Term Loan [Member]                        
Schedule of debt maturities                        
Payments due, Total         0     $ (1,000,000,000)        
October 2023 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         (450,000,000)     $ (244,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (4.125%) (4.125%) (4.125%)      
Repayments of Debt       206,000,000                
March 2024 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         0     $ (850,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (3.45%) (3.45%) (3.45%)      
May 2025 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         (750,000,000)     $ (523,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (3.85%) (3.85%) (3.85%)      
Repayments of Debt       227,000,000                
March 2026 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         0     $ (850,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (3.75%) (3.75%) (3.75%)      
December 2027 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         0     $ (1,011,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (0.625%) (0.625%) (0.625%)      
March 2028 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         $ (1,000,000,000)     $ (434,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage         (4.00%)   (4.00%) (4.00%) (4.00%)      
Repayments of Debt       $ 566,000,000                
March 2029 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         $ 0     $ (850,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (4.00%) (4.00%) (4.00%)      
November 2035 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         (350,000,000)     $ (350,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (7.00%) (7.00%) (7.00%)      
January 2040 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         (300,000,000)     $ (300,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (7.375%) (7.375%) (7.375%)      
March 2049 Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         0     $ (1,000,000,000.000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate, Stated Percentage             (4.70%) (4.70%) (4.70%)      
Interest Rate Swap [Member]                        
Schedule of debt maturities                        
Payments due, Total         (26,000,000)     $ (7,000,000)        
Capital Lease Obligations [Member]                        
Schedule of debt maturities                        
Payments due, Total         (6,000,000)     (6,000,000)        
Senior Notes [Member]                        
Schedule of debt maturities                        
Payments due, Total         (4,800,000,000)     (7,661,000,000)        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net         (29,000,000)     (83,000,000)        
2020 Term Loan [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Short-term Debt   $ 700,000,000           $ 700,000,000        
Debt Instrument, Interest Rate, Stated Percentage             (0.65%) (0.65%) (0.65%)      
2020 Term Loan [Member] | Subsequent Event [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Repayments of Debt $ 300,000,000                      
Two-Year Delayed Draw Term Loan [Member] | Aggregate Senior Unsecured Delayed Draw Term Loan [Member]                        
Schedule of debt maturities                        
Payments due, Total                     (2,000,000,000.000)  
Two-Year Delayed Draw Term Loan [Member] | Debt Instrument, Redemption, Period Two [Member]                        
Schedule of debt maturities                        
Payments due, Total                     (1,000,000,000.000)  
Euro Denominated Factoring Arrangements [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
De-recognized receivables         $ 165,000,000     $ 171,000,000        
Average interest rate of de-recognized receivables       1.40% 2.70%              
Yen Denominated Factoring Arrangements [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
De-recognized receivables         $ 195,000,000     $ 226,000,000        
Average discounted rates of notes receivables         0.90%   0.60% 0.60% 0.60%      
Three-Year Delayed Draw Term Loan [Member]                        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Debt Instrument, Interest Rate During Period       1.13%                
Three-Year Delayed Draw Term Loan [Member] | Debt Instrument, Redemption, Period Three [Member]                        
Schedule of debt maturities                        
Payments due, Total                     $ (1,000,000,000.000)  
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Long-term Line of Credit               $ 1,000,000,000.000        
BTG Acquisition [Member]                        
Debt Instrument [Line Items]                        
Termination Loans             £ 150 184,000,000        
Borrowings and Credit Arrangements (Textuals) [Abstract]                        
Line of Credit Facility, Maximum Borrowing Capacity               $ 150,000,000        
XML 82 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Employee Retirement Plans Employee Retirement Plans (Policies)
 12 Months Ended
Dec. 31, 2019
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]  
Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] We use a December 31 measurement date for these plans and record the net unfunded and underfunded portion as a liability within non-current liabilities, with the current portion within accrued expenses, on the consolidated balance sheets, recognizing changes primarily through OCI.
XML 83 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Borrowings and Credit Arrangements (Tables)
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Schedule of Short-term Debt [Table Text Block]
Commercial Paper

Our commercial paper program is backed by the 2018 Facility, as discussed above. Outstanding commercial paper directly reduces borrowing capacity under the 2018 Facility.
 
As of December 31,
(in millions, except maturity and yield)
2019
 
2018
Commercial paper outstanding
$
711

 
$
1,248

Maximum borrowing capacity
2,750

 
2,750

Borrowing capacity available
2,039

 
1,502

Weighted average maturity
55 days

 
27 days

Weighted average yield
2.21
%
 
3.04
%
Long-term Purchase Commitment [Table Text Block]
Future minimum purchase obligations as of December 31, 2019 were as follows (in millions):
Fiscal Year
Unrecorded Purchase Obligations
2020
$
334

2021
20

2022
7

2023
3

2024
1

Thereafter
1

 
$
366
Schedule of debt maturities
 
 
Issuance Date
 
Maturity Date
 
As of December 31,
 
Stated Interest Rate
(in millions, except interest rates)
 
 
 
2019
 
2018
 
January 2020 Notes
 
December 2009
 
January 2020
 
$
—

 
$
850

 
6.000%
May 2020 Notes
 
May 2015
 
May 2020
 
—

 
600

 
2.850%
May 2022 Notes
 
May 2015
 
May 2022
 
500

 
500

 
3.375%
August 2022 Term Loan
 
August 2019
 
August 2022
 
1,000

 
—

 
 
October 2023 Notes
 
August 2013
 
October 2023
 
244

 
450

 
4.125%
March 2024 Notes
 
February 2019
 
March 2024
 
850

 
—

 
3.450%
May 2025 Notes
 
May 2015
 
May 2025
 
523

 
750

 
3.850%
March 2026 Notes
 
February 2019
 
March 2026
 
850

 
—

 
3.750%
December 2027 Notes
 
November 2019
 
December 2027
 
1,011

 
—

 
0.625%
March 2028 Notes
 
February 2018
 
March 2028
 
434

 
1,000

 
4.000%
March 2029 Notes
 
February 2019
 
March 2029
 
850

 
—

 
4.000%
November 2035 Notes (1)
 
November 2005
 
November 2035
 
350

 
350

 
7.000%
March 2039 Notes
 
February 2019
 
March 2039
 
750

 
—

 
4.550%
January 2040 Notes
 
December 2009
 
January 2040
 
300

 
300

 
7.375%
March 2049 Notes
 
February 2019
 
March 2049
 
1,000

 
—

 
4.700%
Unamortized Debt Issuance Discount
and Deferred Financing Costs
 
 
 
2020 - 2049
 
(83
)
 
(29
)
 
 
Unamortized Gain on Fair Value Hedges
 
 
 
2020-2023
 
7

 
26

 
 
Finance Lease Obligation (2)
 
 
 
Various
 
6

 
6

 
 
Long-term debt
 
 
 
 
 
$
8,592

 
$
4,803

 
 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)
Corporate credit rating improvements may result in a decrease in the adjusted interest rate on our November 2035 Notes to the extent that our lowest credit rating is above BBB- or Baa3. The interest rates on our November 2035 Notes will be permanently reinstated to the issuance rate if the lowest credit ratings assigned to these senior notes is either A- or A3 or higher.
(2)
Effective January 1, 2019, we adopted FASB ASC Topic 842, which requires that we recognize finance lease obligations in our consolidated balance sheets. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with FASB ASC Topic 840. Please refer to Note A – Significant Accounting Policies for additional information.
Summary of term loan and revolving credit facility agreement compliance with debt covenants
All existing credit arrangements described above require that we maintain certain financial covenants, as follows:
 
Covenant
Requirement as of December 31, 2019
 

Actual as of December 31, 2019
Maximum leverage ratio (1)
4.75 times
 
3.83 times
(1) Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters.
Transfer of Financial Assets Accounted for as Sales [Table Text Block] Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in the accompanying consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
 
As of December 31, 2019
 
As of December 31, 2018
Factoring Arrangements
Amount
De-recognized
 
Weighted Average Interest Rate
 
Amount
De-recognized
 
Weighted Average Interest Rate
Euro denominated
$
171

 
1.4
%
 
$
165

 
2.7
%
Yen denominated
226

 
0.6
%
 
195

 
0.9
%
XML 84 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Tax rate
The reconciliation of income taxes at the federal statutory rate to the actual benefit for income taxes is as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
(reclassified)(1)
U.S. federal statutory income tax rate
21.0
 %
 
21.0
 %
 
35.0
 %
State income taxes, net of federal benefit
6.7
 %
 
0.4
 %
 
(1.0
)%
Domestic taxes on foreign earnings
21.9
 %
 
0.5
 %
 
0.4
 %
Effect of foreign taxes
(47.6
)%
 
(8.3
)%
 
(38.9
)%
Acquisition-related
12.2
 %
 
2.1
 %
 
(1.7
)%
Research credit
(4.2
)%
 
(2.6
)%
 
(2.6
)%
Valuation allowance
1.1
 %
 
(5.2
)%
 
(4.1
)%
Compensation-related
(0.3
)%
 
(1.0
)%
 
(2.5
)%
Non-deductible expenses
3.3
 %
 
0.3
 %
 
2.2
 %
Uncertain tax positions
1.4
 %
 
(22.0
)%
 
10.7
 %
TCJA net impact
—
 %
 
(4.7
)%
 
91.4
 %
Intra-entity intangible asset transfers
(597.0
)%
 
—
 %
 
—
 %
Other, net
(2.5
)%
 
1.8
 %
 
(0.2
)%
 
(584.0
)%
 
(17.5
)%
 
88.8
 %

(1)
Due to the inclusion of new tax provisions in 2018 created by the TJCA, we have reclassified select items in prior years to align with the new categories established in 2018, domestic taxes on foreign earnings and uncertain tax positions.
Summary of Income Tax Contingencies [Table Text Block] A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Beginning Balance
$
427

 
$
1,238

 
$
1,095

Additions based on positions related to the current year
30

 
79

 
134

Additions based on positions related to prior years
45

 
4

 
16

Reductions for tax positions of prior years
(34
)
 
(433
)
 
(3
)
Settlements with taxing authorities
(4
)
 
(459
)
 
(2
)
Statute of limitation expirations
(9
)
 
(3
)
 
(2
)
Ending Balance
$
455

 
$
427

 
$
1,238
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
Our Income (loss) before income taxes consisted of the following:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Domestic
$
(1,145
)
 
$
35

 
$
(408
)
Foreign
1,832

 
1,387

 
1,341

 
$
687

 
$
1,422

 
$
933
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Our deferred tax assets, deferred tax liabilities and prepaid on intercompany profit, are included in the following locations within our accompanying consolidated balance sheets (in millions):
 
Location on Consolidated Balance Sheets
As of December 31,
Component
2019
 
2018
Prepaid on intercompany profit
Prepaid income taxes
$
195

 
$
161

Non-current deferred tax asset
Deferred tax assets
4,196

 
87

Deferred Tax Assets and Prepaid on Intercompany Profit
 
4,391

 
249

 
 
 
 
 
Non-current deferred tax liability
Deferred income taxes
595

 
328

Deferred Tax Liabilities
 
595

 
328

 
 
 
 
 
Net Deferred Tax Assets (Liabilities) and Prepaid on Intercompany Profit
$
3,796

 
$
(80
)

Significant components of our deferred tax assets and liabilities are as follows:
 
As of December 31,
 (in millions)
2019
 
2018
 Deferred Tax Assets:
 
 
 
Inventory costs and related reserves
$
—

 
$
18

Tax benefit of net operating loss and credits
545

 
450

Reserves and accruals
258

 
258

Restructuring-related charges
20

 
12

Litigation and product liability reserves
168

 
221

Investment write-down
42

 
28

Compensation related
121

 
106

Federal benefit of uncertain tax positions
10

 
10

Intangible assets
3,447

 
—

Other
—

 
37

 
4,611

 
1,140

Less: valuation allowance
(915
)
 
(344
)
 
3,696

 
796

 Deferred Tax Liabilities:
 
 
 
Property, plant and equipment
16

 
25

Unrealized gains and losses on derivative financial instruments
52

 
44

Intangible assets
—

 
968

Inventory costs and related services
2

 
—

Other
25

 
—

 
95

 
1,037

 Net Deferred Tax Assets / (Liabilities)
3,601

 
(241
)
Prepaid on intercompany profit
195

 
161

 Net Deferred Tax Assets / (Liabilities) and Prepaid on Intercompany Profit
$
3,796

 
$
(80
)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
The related benefit for income taxes consisted of the following:
 
Year Ended December 31,
(in millions)
2019
 
2018
 
2017
Current
 
 
 
 
 
  Federal
$
120

 
$
(221
)
 
$
320

  State
54

 
(27
)
 
9

  Foreign
101

 
160

 
255

 
275

 
(87
)
 
584

 
 
 
 
 
 
Deferred
 
 
 
 
 
  Federal
(146
)
 
(124
)
 
272

  State
(18
)
 
4

 
1

  Foreign
(4,124
)
 
(42
)
 
(28
)
 
(4,288
)
 
(162
)
 
244

 
$
(4,013
)
 
$
(249
)
 
$
828
XML 85 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE J – COMMITMENTS AND CONTINGENCIES

The medical device market in which we participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Our accrual for legal matters that are probable and estimable was $697 million as of December 31, 2019 and $929 million as of December 31, 2018 and includes certain estimated costs of settlement, damages and defense. The decrease in our legal accrual was mainly due to settlement payments associated with product liability cases or claims related to transvaginal surgical mesh products. A portion of our legal accrual is already funded through our qualified settlement fund (QSF), which is included in our restricted cash and restricted cash equivalent balances in Other current assets of $346 million as of December 31, 2019 and $655 million as of December 31, 2018, as discussed in Note A – Significant Accounting Policies.

We recorded litigation-related net charges of $115 million in 2019, $103 million in 2018 and $285 million in 2017. These included litigation-related net charges included a net charge of $223 million in the fourth quarter of 2019, primarily related to litigation with Channel Medsystems, Inc., net charges of $25 million in the third quarter of 2019 and $15 million in the second quarter of 2019, primarily related to transvaginal surgical mesh product liability litigation, and a gain of $148 million recorded in the first quarter of 2019, which represents a portion of the total $180 million one-time settlement payment received from Edwards Lifesciences Corporation (Edwards) in January 2019. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) in our consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses. As such, a portion of the related gain from the Edwards settlement was recorded in Selling, general and administrative expenses on our consolidated statements of operations. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.

In management's opinion, we are not currently involved in any legal proceedings other than those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.

Patent Litigation

On October 28, 2015, BSC filed suit against Cook Group Limited and Cook Medical LLC (collectively, “Cook”) in the District Court for the District of Delaware (1:15-cv-00980) alleging infringement of certain Company patents regarding Cook’s Instinct Endoscopic Hemoclip. The case was transferred to the District Court for the S.D. Indiana. Cook filed seven Inter Partes Review (“IPR”) requests with the U.S. Patent and Trademark Office against the four asserted patents. All IPRs have concluded with claims confirmed in each patent. Cook and Boston Scientific have both appealed the Patent Office’s IPR decisions to the Federal Circuit Court of Appeals. The district court had stayed the case pending the appeals court decision on the IPRs. 

On November 29, 2016 Nevro Corp. (Nevro) filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Neuromodulation Corporation, in the U.S. District Court for the Northern District of California alleging that six U.S. patents (Alataris) owned by Nevro are infringed by our spinal cord stimulation systems. On June 29, 2017, Nevro amended the complaint to add an additional patent (Fang). On July 24, 2018, summary judgment was entered in favor of the Company and on July 31, 2018, we received final judgment and dismissal of the action. On July 31, 2018, Nevro filed an appeal.

On December 9, 2016, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement action against Nevro in U.S. District Court for the District of Delaware alleging that ten U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro’s Senza™ Spinal Cord Stimulation System.

On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen. Inc., served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas.

On April 21, 2018, the Company and Boston Scientific Neuromodulation Corporation filed a patent infringement, theft of trade secrets and tortious interference with a contract action against Nevro in U.S. District Court for the District of Delaware, and
amended the complaint on July 18, 2018, alleging that nine U.S. patents owned by Boston Scientific Neuromodulation Corporation are infringed by Nevro’s Senza™ I and Senza™ II Spinal Cord Stimulation Systems. On December 9, 2019, Nevro filed an answer and counterclaims, in which it alleged that our Spinal Cord Stimulation systems infringe 5 Nevro patents.

On April 30, 2019, Tissue Anchor Innovations filed a complaint for patent infringement in the United States District Court Central District of California against Fountain Valley Regional Hospital and Medical Center, Los Alamitos Medical Center and us. The complaint alleges that the Solyx™ Sling System infringes US Patent 6,506,190.

Product Liability Litigation

As of January 29, 2020, approximately 54,000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. As of January 29, 2020, we have entered into master settlement agreements in principle or are in the final stages of entering one with certain plaintiffs' counsel to resolve an aggregate of approximately 52,000 cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately 52,000 cases and claims, approximately 46,000 have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered that all manufacturers of surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse stop selling and distributing their products in the United States immediately, stemming from the FDA’s 2016 reclassification of these devices to class III (high risk) devices, and as a result, the Company ceased global sales and distribution of surgical mesh products indicated for transvaginal pelvic organ prolapse. The pending cases are in various federal and state courts in the U.S. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over 3,100 of the cases were specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the U.S. District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. On December 12, 2019 the Mississippi Attorney General filed suit against BSC in State Court alleging violations of the Mississippi Consumer Protection Act which the Company plans to vigorously defend. There were also fewer than 25 cases in Canada, inclusive of one certified class action and fewer than 25 claims in the United Kingdom. We have reached an agreement to settle the Canadian class action pending Court approval.

We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us, that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Governmental Investigations and Qui Tam Matters

On May 5, 2014, we were served with a subpoena from the U.S. Department of Health and Human Services, Office of the Inspector General. The subpoena seeks information relating to the launch of the Cognis™ and Teligen™ line of devices in 2008, the performance of those devices from 2007 to 2009 and the operation of the Physician Guided Learning Program. We are cooperating with this request. On May 6, 2016, a qui tam lawsuit in this matter was unsealed in the U.S. District Court for the District of Minnesota. At the same time, we learned that the U.S. government and the State of California had earlier declined to intervene in that lawsuit on April 15, 2016. The complaint was served on us on July 21, 2016. On October 7, 2016, the plaintiff/relator served an amended complaint that dropped the allegations relating to the Physician Guided Learning Program. We filed a motion to dismiss the amended complaint on December 7, 2016 and the court heard our motion to dismiss on April 5, 2017. On August 29, 2017, the Court granted the motion to dismiss, without prejudice and on September 19, 2017, the relator filed a Second Amended Complaint. We filed a motion to dismiss the Second Amended Complaint on October 10, 2017 and the Court denied that motion on December 13, 2017. On July 31, 2018, the relator filed a motion seeking leave to file a Third Amended Complaint. The Court denied the motion on October 30, 2018.

On February 23, 2015, a judge for the Court of Modena (Italy) ordered a trial for Boston Scientific and three of its employees, as well as numerous other defendants charged in criminal proceedings. The charges arise from allegations that the defendants made improper donations to certain healthcare providers and other employees of the Hospital of Modena in order to induce them to conduct unauthorized clinical trials, as well as related government fraud in relation to the financing of such clinical trials. A trial began on February 24, 2016. On November 10, 2017, the Court issued a ruling that convicted one Boston Scientific employee but acquitted two others and levied a fine of €245 thousand against us and imposed joint and several civil damages of €620 thousand on all defendants. We continue to deny these allegations, timely appealed the decision on May 10, 2018 and intend to continue to defend ourselves vigorously.

On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda., as well as against the Brazilian operations of Medtronic, Biotronik and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO and 29 individuals for alleged anti-competitive behavior. We deny the allegations and intend to defend ourselves vigorously.

Other Proceedings

On May 16, 2018, Arthur Rosenthal et al., filed a plenary summons against Boston Scientific Corporation and Boston Scientific Limited with the High Court of Ireland alleging that payments are due pursuant a transaction agreement regarding Labcoat Limited.

On September 6, 2019, Boston Scientific Corporation, Boston Scientific Scimed, Inc., and Fortis Advisors, LLC, as a Securityholder Representative for the former Securityholders of nVision Medical Corp. filed a declaratory judgment action against BioCardia, Inc. in the United States District Court for the Northern District of California to address threats and allegations by BioCardia challenging inventorship and ownership of various patents that Boston Scientific Corporation acquired through an April 13, 2018 merger with nVision as well as related threats and allegations by BioCardia of trade secret misappropriation and unjust enrichment. On December 11, 2019, BioCardia filed an amended answer and counterclaims.

On April 18, 2019, Blue Cross & Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research & Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia. The complaint alleges that the defendants violated the Sherman Act and the antitrust and consumer protections laws of several states by pursuing patent litigation relating to ZYTIGA™ in order to delay generic entry. On June 21, 2019, the case was transferred to the United States District Court for the District of New Jersey and has been consolidated with similar complaints.

On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research & Development, LLC, and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint filed on behalf of the United States, 28 states, and the District of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant.

Refer to Note I – Income Taxes for information regarding our tax litigation.

Matters Concluded Since December 31, 2018

On January 15, 2019, we announced that we reached an agreement with Edwards Lifesciences Corporation (Edwards) to settle all outstanding patent disputes between us and Edwards in all venues around the world. All pending cases or appeals in courts and patent offices between the two companies will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices, and left atrial appendage closure devices. Any injunctions currently in place will be lifted. Under the terms of the agreement, Edwards made a one-time payment to us of $180 million. No further royalties will be owed by either party under the agreement. All other terms remain confidential. The previously disclosed matters that have been resolved as a result of this settlement include:

•
On October 30, 2015, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation and Edwards Lifesciences Services GmbH in Düsseldorf District Court in Germany for patent infringement. We allege that Edwards’
SAPIEN 3™ Heart Valve infringes our patent related to adaptive sealing technology. On February 25, 2016, we extended the action to allege infringement of a second patent related to adaptive sealing technology. The trial began on February 7, 2017. On March 9, 2017, the court found that Edwards infringed both patents and Edwards appealed.

•
On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.

•
On November 23, 2015, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '672) owned by Edwards is infringed by our Lotus™ Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we did not infringe the Spenser '672 patent. Edwards filed an appeal.

•
On November 23, 2015, Edwards Lifesciences Corporation filed a patent infringement action against us and Boston Scientific Medizintechnik GmbH in the District Court of Düsseldorf, Germany alleging an European patent (Bourang) owned by Edwards is infringed by our Lotus Valve System. The trial began on February 7, 2017. On March 28, 2017, the European Patent Office revoked the Bourang patent and on April 3, 2017, the court suspended the infringement action pending Edwards' appeal of the revocation of the patent at the European Patent Office.

•
On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation (Edwards) in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards’ SAPIEN 3™ Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus™ Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found our patent invalid. The Company filed an appeal before the United States Court of Appeals for the Federal Circuit on May 24, 2018.

•
On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the Central District of California for patent infringement. We allege that Edwards’ aortic valve delivery systems infringe eight of our catheter related patents. On October 13, 2016, Edwards filed a petition for inter partes review of one asserted patent with the USPTO, Patent Trial and Appeal Board. On April 21, 2017, the USPTO denied the petition. On April 19 and 20, 2017, Edwards filed multiple inter partes review petitions against the patents in suit. On September 8, 2017, the court granted a stay of the action pending an inter partes review of the patents in suit.

•
On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus™ Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

•
On October 27, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific, LTD, in the Federal Court of Canada alleging that three Canadian patents (Spenser) owned by Edwards are infringed by our Lotus Transcatheter Heart Valve System.

•
On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

•
On August 1, 2018, the Company filed a patent infringement action on the merits in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3™ Device and Sapien 3 Ultra Device infringed a patent owned by the Company.

•
On August 3, 2018, the Company filed a preliminary injunction request in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3 Ultra Device infringed a patent owned by the Company. On October 23, 2018, the court found that the Sapien 3 Ultra Device infringed the patent. Edwards had the right to appeal.

•
On August 22, 2018, Edwards Lifesciences LLC filed a patent infringement action against Boston Scientific Corporation, in the U. S. District Court of Delaware, alleging that two U.S. patents (Schweich) owned by them are infringed by our Watchman™ Left Atrial Appendage Closure Device, Watchman Delivery System and Watchman Access System.

On December 14, 2016, we learned that the Associacao Brasileira de Medicina de Grupo d/b/a ABRAMGE filed a complaint against us, Arthrex and Zimmer Biomet Holdings, in the U.S. District Court for the District of Delaware. This complaint, which ABRAMGE never served against us, alleges that the defendants or their agents paid kickbacks to health care providers in order to increase sales and prices and are liable under a variety of common law theories. On February 6, 2017, ABRAMGE filed and served an amended complaint on us and the other defendants. The amended complaint does not contain any material changes in the allegations against us. Subsequently, on March 2, 2017, ABRAMGE filed a motion to consolidate this lawsuit with two other similar suits that it had brought against Stryker and Abbott Laboratories, in a multidistrict litigation proceeding. On April 13, 2017, we filed a motion to dismiss the amended complaint, as well as a separate opposition to the multidistrict litigation motion and on May 31, 2017, the Joint Panel on Multi-District Litigation denied ABRAMGE’s motion for the multidistrict litigation. On September 1, 2017, ABRAMGE filed a motion for leave to file a Second Amended Complaint, while our motion to dismiss the Amended Complaint remained pending. On September 15, 2017, we filed an opposition to the motion seeking leave to amend. On November 8, 2018, the Court granted ABRAMGE’s motion for leave to file a Second Amended Complaint, while also granting us leave to renew our motion to dismiss. We filed our motion to dismiss the Second Amended Complaint on January 18, 2019. On February 28, 2019, ABRAMGE dismissed its Second Amended Complaint, concluding the lawsuit.

On or about January 12, 2016, Teresa L. Stevens filed a claim against us and three other defendants asserting, for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Southern District of West Virginia, before the same Court that is hearing the mesh MDL. The complaint, which alleges Racketeer Influenced and Corrupt Organizations Act (RICO) violations, fraud, misrepresentation, deceptive trade practices and unjust enrichment, seeks both equitable relief and damages under state and federal law. On January 26, 2016, the Court issued an order staying the case and directing the plaintiff to submit information to allow the FDA to issue a determination with respect to her allegations. In addition, we were in contact with the U.S. Attorney’s Office for the Southern District of West Virginia and responded voluntarily to their requests in connection with that office’s review of the allegations concerning the use of mesh resin in the complaint. We reached a settlement on this matter and this case was dismissed on May 13, 2019.

On February 27, 2017, Carolyn Turner filed a complaint against us and five other defendants asserting for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Middle District of Florida, Orlando Division and alleges violations of the RICO, negligence, strict liability, breach of an express or implied warranty, intentional and negligent misrepresentation, fraud and unjust enrichment. Ms. Turner served this complaint against us on April 7, 2017. As of April 27, 2017, this case was stayed, pending resolution of the transfer petition to the mesh multidistrict litigation. We reached a settlement on this matter and this case was dismissed on February 25, 2019.

On April 24, 2019, a class action complaint was filed in the U.S. District Court for the Southern District of New York against Boston Scientific Corporation, Michael F. Mahoney, our Chief Executive Officer, and Daniel J. Brennan, our Chief Financial Officer. The complaint alleges violations of federal securities laws based on false and/or misleading statements and failure to disclose facts related to the Company’s transvaginal surgical mesh products. On September 20, 2019, the case was dismissed with prejudice.

On March 10, 2017, Imran Niazi filed a patent infringement action against us in the U.S. District Court for the Western District of Wisconsin alleging that a U.S. patent owned by him is infringed by our Acuity™ Lead Delivery System. On June 30, 2017, we filed a motion to dismiss for improper venue and on November 7, 2017 the Wisconsin Court granted the motion to dismiss. On November 13, 2017 Niazi refiled the same action in the U.S. District of Minnesota. We reached a confidential settlement on this matter on February 3, 2020 pursuant to which we anticipate the court will dismiss the pending action.

On August 3, 2012, we were served with a qui tam complaint that had previously been filed under seal against Boston Scientific Neuromodulation Corporation in the U.S. District Court for the District of New Jersey on March 2, 2011. On August 8, 2012, we learned that the federal government had previously declined to intervene in this matter. The relators’ complaint, now unsealed, alleges that Boston Scientific Neuromodulation Corporation violated the federal and various states' false claims acts through
submission of fraudulent bills for implanted devices, under-reporting of certain adverse events and promotion of off-label uses. On September 10, 2012, the relators filed an amended complaint revising and restating certain of the claims in the original complaint. Our motion to dismiss, filed subsequently, was denied on May 31, 2013 and on June 28, 2013, we answered the amended complaint and brought certain counterclaims arising from relators’ unauthorized removal of documents from the business during their employments, which the relators moved to dismiss on July 22, 2013. The Court denied relators’ motion to dismiss the counterclaims on September 4, 2014. Following the completion of fact and expert discovery, we filed a motion for summary judgment against all claims on January 27, 2017, relators filed their own motion for summary judgment against our counterclaims that same date. On December 15, 2017, the Court denied both motions for summary judgment. The parties reached a settlement on May 2, 2019, and the Court subsequently ordered the case dismissed, except for any claim by relators to recover attorneys’ fees.

On November 1, 2017, we entered into a definitive agreement with Channel Medsystems, Inc. (Channel) pursuant to which we could have been obligated to pay $145 million in cash up-front and a maximum of $130 million in contingent payments to acquire Channel. The agreement contained a provision allowing Channel to sell the remaining equity interests of Channel to us upon achievement of a regulatory milestone and an option allowing us to acquire the remaining equity interests. We sent a notice of termination of that agreement to Channel in the second quarter of 2018. On September 12, 2018, Channel filed a complaint in Delaware Chancery Court against us for alleged breach of the agreement. Channel alleged that we breached the agreement by terminating it. We have answered the complaint, denied the claims by Channel and counterclaimed to recover part of our investment in Channel, alleging fraud in the inducement. On April 2, 2019, Channel announced its receipt of FDA approval of the Cerene™ Cryotherapy Device. Trial testimony was taken in April 2019, and the post-trial briefing and hearing have been completed. During the third quarter of 2019, Channel notified us that they were exercising their option to sell the remaining equity interests in Channel to us. We responded to the notification that we did not intend to purchase Channel since the previous agreement had been terminated. On December 18, 2019, the Chancery Court ruled that Boston Scientific was in breach of the agreement and granted Channel's request for specific performance to require the Company to complete the purchase. On January 10, 2020, we filed a Notice of Appeal of the Chancery Court’s decision to the Delaware Supreme Court. On February 4, 2020, the Company settled the dispute with Channel resulting in termination of the agreement, payment by the Company of an undisclosed sum and surrender of the Company's equity interest in Channel.
XML 86 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net income (loss) $ 4,700,000,000 $ 1,671,000,000 $ 104,000,000
Adjustments to reconcile net income (loss) to cash provided by operating activities      
Gain on sale of businesses (8,000,000) 0 0
Depreciation and amortization 1,011,000,000 894,000,000 844,000,000
Deferred and prepaid income taxes (4,301,000,000) (87,000,000) 245,000,000
Stock-based compensation expense 157,000,000 140,000,000 127,000,000
Intangible asset impairment charges 105,000,000 35,000,000 4,000,000
Net loss (gain) on investments and notes receivable 30,000,000 (155,000,000) 92,000,000
Contingent consideration expense (benefit) (35,000,000) (21,000,000) (80,000,000)
Payment of contingent consideration in excess of amount recognized at acquisition (6,000,000) (9,000,000) (14,000,000)
Inventory step-up amortization 46,000,000 6,000,000 10,000,000
Exchange (gain) loss 358,000,000 (11,000,000) 15,000,000
Other, net 63,000,000 8,000,000 13,000,000
Increase (decrease) in operating assets and liabilities, net of acquisitions:      
Trade accounts receivable (130,000,000) (110,000,000) (30,000,000)
Inventories (290,000,000) (83,000,000) (107,000,000)
Other assets 45,000,000 (172,000,000) (20,000,000)
Accounts payable and accrued expenses 111,000,000 (631,000,000) 195,000,000
Other liabilities (18,000,000) (1,164,000,000) 28,000,000
Cash provided by (used for) operating activities 1,836,000,000 310,000,000 1,426,000,000
Investing Activities      
Purchases of property, plant and equipment (461,000,000) (316,000,000) (319,000,000)
Proceeds on disposals of property, plant and equipment 7,000,000 14,000,000 0
Payments for acquisitions of businesses, net of cash acquired (4,382,000,000) (1,448,000,000) (560,000,000)
Proceeds from divestiture of certain businesses 90,000,000 0 0
Proceeds from royalty rights 52,000,000 0 0
Payments for settlements of hedge contracts (199,000,000) 0 0
Payments for investments and acquisitions of certain technologies (149,000,000) (172,000,000) (131,000,000)
Cash provided by (used for) investing activities (5,041,000,000) (1,921,000,000) (1,010,000,000)
Financing Activities      
Payment of contingent consideration and royalty rights previously established in purchase accounting (135,000,000) (19,000,000) (33,000,000)
Proceeds from royalty rights transfer 256,000,000 0 0
Proceeds from short-term borrowings, net of debt issuance costs 700,000,000 999,000,000 0
Net increase (decrease) in commercial paper (575,000,000) 21,000,000 1,183,000,000
Proceeds from borrowings on credit facilities 0 569,000,000 2,156,000,000
Payments on borrowings from credit facilities 0 (569,000,000) (2,216,000,000)
Payments on short-term borrowings (1,000,000,000) 0 0
Payments on long-term borrowings and debt extinguishment costs (3,560,000,000) (602,000,000) (1,000,000,000)
Proceeds from long-term borrowings, net of debt issuance costs 7,229,000,000 987,000,000 0
Cash used to net share settle employee equity awards (65,000,000) (56,000,000) (65,000,000)
Proceeds from issuances of shares of common stock 123,000,000 101,000,000 85,000,000
Cash provided by (used for) financing activities 2,973,000,000 1,432,000,000 110,000,000
Effect of foreign exchange rates on cash 10,000,000 (8,000,000) 4,000,000
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (222,000,000) (188,000,000) 530,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 829,000,000 1,017,000,000 487,000,000
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 607,000,000 829,000,000 1,017,000,000
Supplemental Information      
Cash (received) paid for income taxes, net 242,000,000 1,037,000,000  
Income Taxes Paid     (42,000,000)
Cash paid for interest 449,000,000 262,000,000 235,000,000
Fair value of contingent consideration recorded in purchase accounting 127,000,000 248,000,000 94,000,000
Cash and cash equivalents 217,000,000 146,000,000 188,000,000
Restricted cash and restricted cash equivalents included in Other current assets 346,000,000 655,000,000 803,000,000
Restricted cash equivalents included in Other long-term assets $ 43,000,000 $ 27,000,000 $ 26,000,000
XML 87 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net income (loss) $ 4,700 $ 1,671 $ 104
Foreign currency translation adjustment 195 (21) 48
Net change in derivative financial instruments 62 110 (106)
Net change in available-for-sale securities 0 0 5
Net change in defined benefit pensions and other items (20) 2 (6)
Total other comprehensive income (loss) 237 91 (59)
Total comprehensive income (loss) $ 4,937 $ 1,761 $ 45
XML 88 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases of Lessee Disclosure [Text Block]
NOTE F – LEASES

We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term and, as a result, the remaining lease term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. Effective January 1, 2019, we adopted FASB ASC Topic 842 as discussed in Note A – Significant Accounting Policies. Beginning in 2019, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 60 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.

We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The following table presents supplemental balance sheet information related to our operating leases:
(in millions)
As of December 31, 2019
Assets
 
Operating lease right-of-use assets in Other long-term assets
$
336

Liabilities
 
Operating lease liabilities in Other current liabilities
67

Operating lease liabilities in Other long-term liabilities
276



The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
 
As of December 31, 2019
Weighted average remaining lease term
5.8 years
Weighted average discount rate
3.7%


Our operating lease cost under FASB ASC Topic 842 was $80 million in 2019. Rent expense under FASB ASC Topic 840 amounted to $92 million in 2018 and $88 million in 2017.

The following table presents supplemental cash flow information related to our operating leases:
 
Year Ended
(in millions)
December 31, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
 
Operating cash flows from operating leases
$
77



Right-of-use assets obtained in exchange for operating lease obligations were $137 million as of December 31, 2019.

The following table presents the maturities of our operating lease liabilities as of December 31, 2019 (in millions):
Fiscal year
Operating Leases
2020
$
84

2021
71

2022
59

2023
48

2024
41

Thereafter
79

Total future minimum operating lease payments
382

Less: imputed interest
39

Present value of operating lease liabilities
$
343



As of December 31, 2019, we have additional leases for office space and warehouse space, that have not yet commenced, of approximately $70 million. These leases will commence in 2020, with lease terms of up to 15 years.

Future minimum rental commitments as of December 31, 2018, under all noncancellable lease agreements, including capital leases, were as follows:
Fiscal year
Future Minimum Rental Commitments
2019
$
73

2020
61

2021
47

2022
39

2023
31

Thereafter
111

 
$
362

'+]1AN7$+ H3!.@=GE!D_ N1.R:?R:-,/9TA&7^[OZ)U^[K>7"-#Q) M_K.YFOH8IF%PA9+UW#S+X3-,]6S#8"K^*]R 6[C+Q'H4DFO_#(I>&RDF%9N* M8&_CVK1^'2;].PTGT(E 5P0R&OG,/S+#\DS)(5#CW7?,?>+H0.W=%"[HK\*_ ML\EK&[WE211GY.:$)LQIQ- %)IH1Q*K/%A2S.-%W=(K38S3#V-/C)3W>X0() M*I!X@>2?$I-5B1AFBYML49,M(K!;F6"8/6ZR0TUVB$"Z,L$P'W"3/6JR?R] M-RL3#/.??R)%35)$@*Y,,$R\,B&+_UR JGR'ZZ"0?>NGRR(Z#Y%'ZOOD+WR< M0-^8JII6!Q=I;+?YGBBE-&!3V3S83U?;H3&PO=V]R:W-H965T M[^?I+L>I['OE@B=7@.*9G,!JE>=0U@R)O@K3X&M3'=@5)=U""8OI,= MM/:DE$HP8TU54=TI8%@>=:Q"KZ#^=&=E;7HS')M!+2ZD2U14!Z#^_!P2AW> UX: M&/1B3UPE%RE?G?'E>@PV+B'@4!C'P.QR@P?@W!'9-'Y-G,$LZ0*7^W?V)U^[ MK>7"-#Q(_K.YFOH8I &Y0LEZ;I[E\!FF>K8!F8K_"C?@%NXRL1J%Y-I_2=%K M(\7$8E,1[&UX[YIXX M/$3V;@KG]%?ASVSRVGIO>1(E&;TYH@ES&C'1 A/."&K99XD(DSA%_X5'>'B, M9AC[\'@9GFQP@@0E2#Q!\D^)VU6)&&:'BVQ1D2U"L%^)8)@4%]FA(CN$X--* M!,'$'US7'A79(P3A2@3#?/"H*2J2(@3Q2@3#)"L1NOC/!:C*=[@FA>Q;/UT6 MWGF(W/O&HG_AXP3ZQE35M)IT%_)-50#:>^>L49E?:=UN M"5%%!9RJ)]%"8]ZF>@E3^)%2BY6:,3L!TPTPX03@ACUR2+"+/;1 M?_0(I\=HAK&CQQ\R7.(""2J0.('D@\#JID0,L\9-%JC) A'8W)@@F"3 39:H MR1(1"&],,,R=_5ZA)BM$(,8%UJC ^O$#VZ "FP<.#,$D"6X2!OB7'R 2BSL2 M=RY/^'BI(7HY=F'T0+$8*+GU(;,KST&>7;-37B&ZQG7:671JJ#O73\D_^-"- MOU-YKAOE'84VC<>UAY,0&DPNP9/YBBOS Y@6#$[:3E=F+H&PO=V]R:W-H965T ML+V>G=DUWG762?6F2\Y-\%Z+1N_"TIAVBY N2EXS_21; MWMB=BU0U,W:IKDBWBK.S=ZH%(E&4H)I539AGWG94>29O1E0-/ZI W^J:J3\' M+F2W"W'X87BIKJ5Q!I1G+;OR']S\;(_*KM#(AW4"_G(/S'#\DS)+E#] MX;?,_6.\)?9L"F?T1^'W;/#:6N\YI>L,W1W1@#GT&#+!X!&!+/LH02") UFX M$]A]!4:X\NZKJ3M-80(*$E!/0/]+,9VE"&$VL$@,BL0+ AS%,Y$EAL81+)* M(@E @&:]!D36023(366)HO()%4E D!0CH3 3"Q+#(!A39+#/!T4QD MB:%Q HO@"*Z@")#9S$MH":+Q^H'.@TK% ,7\'H.@!Q<9@^6ZQV29#YG_&P!$ MD_E=1I,F5'-U]>U7!X6\-;[W3ZQCB]_[KH?^P?OWX3M3UZK1P4D:VPI]P[I( M:;B-)7JR=57:)VE<"'XQ;KJV<]7WY7YA9#N\.6A\^/*_4$L#!!0 ( #N' M65#-\M&PO=V]R:W-H965TFK@G,H_)V!BS/V=_^9X;NM&6P[?[XZGU.(=X&<+HUKM/5O)18@7:WRYYGY@ M$P(&I;8,U"PW> #&+)%)X_?,Z2^2-G"]?V-_E!9]93"J"."81)<)$%%$H0@W8A@F$^X M2(J*I!\)DF C@F&V/QY9_><<9.TZ7'FE&#HW75;>98C&UL=55A;YLP$/TKB!]0 R$)B0A2TZG:I$V*.FW[[) +H-J8VB9T_WZV M(8S2XPNVCW?OW?GL<]H)^:I* .V]P)47D)G*H'T4!M_ER%Y%2; MI2R(:B30BW/BC$1!L"&<5K6?I!+L M3W71Y<%/?.\"5]HR_2*ZKS DM/:](?OO< -FX#82HY$+IMS7RUNE!1]83"B< MOO=C5;NQ&_CO;KA#-#A$,P?2"[G(OU!-LU2*SI/]YC?4UCC<1V9O"5L=ZR>!NEY&:)!LRQQT033#@BB&$?)2),XAA],B:U1DC1!L9B(89HN+;%"1#4*0S$0PS X7V:(BV\\$ M23 3P3 +9R)!11*$8'[L,,Q"X7>HR XAF!<>PRP4/@SP&Q0@%//2HZ"%VH<+ M-S5$*.;51T'S\I-)<^ @"]<6E9>+MG8]>6(=6^]CY)K+?WC?MW]0652U\LY" MFQ;E&LE5" TFEN#!G/?2/!7C@L%5V^G6S&7?+_N%%LWP%I#Q0&R"Y/6,TT61SQO-S%P9HKF6P+QHD<78R109#D[)#DZ&V$%K87X=0>&8TQV]!IYDT[H0 M8$76BP:^@?O>GXSWV,)220V=E=@1 W5.'W:'8QKR8\*SA-&N;!(Z.2.^!.=S ME=,D" (%I0L,PA\7> 2E I&7\7/FI$O) %S;5_:/L7??RUE8>$3U0U:NS>D] M)1748E#N"<=/,/?SAI*Y^2]P >73@Q)?HT1EXY>4@W6H9Q8O18O7Z91=/,>9 M_PK;!O 9P&\ ;"H4E7\03A29P9&8:?:]"%>\.W _FS($XRCB/R_>^NBE2-\G M&;L$HCGG..7P5?2G!MTH<^3]PO@W?;RK<1_C^+X7_J9]N$J21(%T3 MW/.;%K=R]C=%V&JF&DP3M\F2$H[\"K7^@2V.@MH%\YVWS;1FD^.PGU\06YYQ\1M02P,$% @ M.X=94)ES0X*W 0 T@, !D !X;"]W;W)K&UL M;5/;;MP@$/T5Q >$7=9)MRO;4C91U$JMM$K5YIFUQS8*>!S Z_3O"]AQG<0O MP SGG+DPI .:9]L ./*J56LSVCC7'1BS10-:V"OLH/4W%1HMG#=-S6QG0)21 MI!7CF\T-TT*V-$^C[V3R%'NG9 LG0VROM3!_CZ!PR.B6OCD>9=VXX&!YVHD: M?H'[W9V,M]BL4DH-K978$@-51F^WAV,2\!'P1\)@%V<2*CDC/@?C>YG134@( M%!0N* B_7> .E I"/HV729/.(0-Q>7Y3?XBU^UK.PL(=JB=9NB:C>TI*J$2O MW",.WV"JYYJ2J?@?< 'EX2$3'Z- 9>-*BMXZU).*3T6+UW&7;=R'\2:YGFCK M!#X1^$S8QSAL#!0SOQ=.Y*G!@9BQ]YT(3[P]<-^;(CAC*^*=3]YZ[R5/OO*4 M78+0A#F.&+[ ;&<$\^IS"+X6XL@_T?DZ?;>:X2[2=TOZS7Y=(%D52*) \J[$ MW8<2US#)AR!LT5,-IH[39$F!?1LG>>&=!_:6QS?Y#Q^G_:8_;HZG@\4[P$L+@UKL/=O)18A7&WPM,S^P M!0�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